<SEC-DOCUMENT>0001367644-20-000047.txt : 20200501
<SEC-HEADER>0001367644-20-000047.hdr.sgml : 20200501
<ACCEPTANCE-DATETIME>20200430181634
ACCESSION NUMBER:		0001367644-20-000047
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		85
CONFORMED PERIOD OF REPORT:	20200331
FILED AS OF DATE:		20200501
DATE AS OF CHANGE:		20200430

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Emergent BioSolutions Inc.
		CENTRAL INDEX KEY:			0001367644
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				141902018
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33137
		FILM NUMBER:		20837512

	BUSINESS ADDRESS:	
		STREET 1:		400 PROFESSIONAL DR, SUITE 400
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20879
		BUSINESS PHONE:		240-631-3200

	MAIL ADDRESS:	
		STREET 1:		400 PROFESSIONAL DR, SUITE 400
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20879
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ebs-20200331x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:0A29663FDA8B5D4DB724CE0356008492,x:07654e74da1b411ca158de6eae55e396-->
<!-- Document created using Wdesk  -->
<!-- Copyright 2020 Workiva -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:schedoi-fednote="http://fasb.org/dis/schedoi-fednote/2019-01-31" xmlns:fs-interest="http://fasb.org/dis/fs-interest/2019-01-31" xmlns:sfp-ibo="http://fasb.org/stm/sfp-ibo/2019-01-31" xmlns:sfp-sbo="http://fasb.org/stm/sfp-sbo/2019-01-31" xmlns:sic-std="http://xbrl.sec.gov/sic-std/2011-01-31" xmlns:stpr-std="http://xbrl.sec.gov/stpr-std-std-std/2018-01-31" xmlns:currency-ent-std="http://xbrl.sec.gov/currency-ent-std/2019-01-31" xmlns:lea="http://fasb.org/dis/lea/2019-01-31" xmlns:ctbl="http://fasb.org/dis/ctbl/2019-01-31" xmlns:guar="http://fasb.org/dis/guar/2019-01-31" xmlns:ru="http://fasb.org/dis/ru/2019-01-31" xmlns:stpr-all="http://xbrl.sec.gov/stpr-all-all-all/2018-01-31" xmlns:leas="http://fasb.org/dis/leas/2019-01-31" xmlns:sfp-clreo="http://fasb.org/stm/sfp-clreo/2019-01-31" xmlns:iaoi="http://fasb.org/dis/iaoi/2019-01-31" xmlns:soi-ins="http://fasb.org/stm/soi-ins/2019-01-31" xmlns:country-ent-std="http://xbrl.sec.gov/country-ent-std/2017-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:fs-insa="http://fasb.org/dis/fs-insa/2019-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:cce="http://fasb.org/dis/cce/2019-01-31" xmlns:inv="http://fasb.org/dis/inv/2019-01-31" xmlns:naics-ent-std="http://xbrl.sec.gov/naics-ent-std/2017-01-31" xmlns:srt-std="http://fasb.org/srt-std/2019-01-31" xmlns:stpr-ent-all="http://xbrl.sec.gov/stpr-ent-all-all-all/2018-01-31" xmlns:stpr-ent-std="http://xbrl.sec.gov/stpr-ent-std-std-std/2018-01-31" xmlns:schedoi-iiaa="http://fasb.org/dis/schedoi-iiaa/2019-01-31" xmlns:us-arcroles="http://fasb.org/us-arcroles/2019-01-31" xmlns:dccpoa="http://fasb.org/dis/dccpoa/2019-01-31" xmlns:soi-sbi="http://fasb.org/stm/soi-sbi/2019-01-31" xmlns:ebs="http://emergentbiosolutions.com/20200331" xmlns:us-gaap-all="http://fasb.org/us-gaap-all/2019-01-31" xmlns:scf-sd="http://fasb.org/stm/scf-sd/2019-01-31" xmlns:ceclcalc3l="http://fasb.org/dis/ceclcalc3l/2019-01-31" xmlns:dei-ent-all="http://xbrl.sec.gov/dei-ent-all/2019-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:naics-all="http://xbrl.sec.gov/naics-all/2017-01-31" xmlns:re="http://fasb.org/dis/re/2019-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:reorg="http://fasb.org/dis/reorg/2019-01-31" xmlns:invco="http://fasb.org/dis/invco/2019-01-31" xmlns:currency-ent-all="http://xbrl.sec.gov/currency-ent-all/2019-01-31" xmlns:currency-std="http://xbrl.sec.gov/currency-std/2019-01-31" xmlns:currency-ent-dep="http://xbrl.sec.gov/currency-ent-dep/2019-01-31" xmlns:aro="http://fasb.org/dis/aro/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:ocpfs="http://fasb.org/dis/ocpfs/2019-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:naics-std="http://xbrl.sec.gov/naics-std/2017-01-31" xmlns:srt-all="http://fasb.org/srt-all/2019-01-31" xmlns:codification-part="http://fasb.org/codification-part/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:deprecated1="http://www.xbrl.org/2009/role/deprecated" xmlns:sec-re="http://fasb.org/dis/sec-re/2019-01-31" xmlns:soi-int="http://fasb.org/stm/soi-int/2019-01-31" xmlns:emjv="http://fasb.org/dis/emjv/2019-01-31" xmlns:sec-suppc="http://fasb.org/dis/sec-suppc/2019-01-31" xmlns:equity="http://fasb.org/dis/equity/2019-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:se="http://fasb.org/dis/se/2019-01-31" xmlns:crcrb="http://fasb.org/dis/crcrb/2019-01-31" xmlns:edco="http://fasb.org/dis/edco/2019-01-31" xmlns:te="http://fasb.org/dis/te/2019-01-31" xmlns:dei-all="http://xbrl.sec.gov/dei-all/2019-01-31" xmlns:fs-bd="http://fasb.org/dis/fs-bd/2019-01-31" xmlns:hco="http://fasb.org/dis/hco/2019-01-31" xmlns:fs-bt="http://fasb.org/dis/fs-bt/2019-01-31" xmlns:us-roles="http://fasb.org/us-roles/2019-01-31" xmlns:dr="http://fasb.org/dis/dr/2019-01-31" xmlns:ero="http://fasb.org/dis/ero/2019-01-31" xmlns:country-ent-all="http://xbrl.sec.gov/country-ent-all/2017-01-31" xmlns:schedoi-oocw="http://fasb.org/dis/schedoi-oocw/2019-01-31" xmlns:cecl="http://fasb.org/dis/cecl/2019-01-31" xmlns:rpd="http://fasb.org/dis/rpd/2019-01-31" xmlns:schedoi-sumhold="http://fasb.org/dis/schedoi-sumhold/2019-01-31" xmlns:ceclcalc2="http://fasb.org/dis/ceclcalc2/2019-01-31" xmlns:othliab="http://fasb.org/dis/othliab/2019-01-31" xmlns:soi-egm="http://fasb.org/stm/soi-egm/2019-01-31" xmlns:schedoi-shorthold="http://fasb.org/dis/schedoi-shorthold/2019-01-31" xmlns:soi="http://fasb.org/stm/soi/2019-01-31" xmlns:diha="http://fasb.org/dis/diha/2019-01-31" xmlns:debt="http://fasb.org/dis/debt/2019-01-31" xmlns:schedoi-hold="http://fasb.org/dis/schedoi-hold/2019-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap-ent-std="http://fasb.org/us-gaap-ent-std/2019-01-31" xmlns:bc="http://fasb.org/dis/bc/2019-01-31" xmlns:sic-ent-all="http://xbrl.sec.gov/sic-ent-all/2011-01-31" xmlns:exch-ent-std="http://xbrl.sec.gov/exch-ent-std/2019-01-31" xmlns:rcc="http://fasb.org/dis/rcc/2019-01-31" xmlns:rd="http://fasb.org/dis/rd/2019-01-31" xmlns:sfp-ucreo="http://fasb.org/stm/sfp-ucreo/2019-01-31" xmlns:eui="http://fasb.org/dis/eui/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:ap="http://fasb.org/dis/ap/2019-01-31" xmlns:soi-reit="http://fasb.org/stm/soi-reit/2019-01-31" xmlns:fs-mort="http://fasb.org/dis/fs-mort/2019-01-31" xmlns:sec-reins="http://fasb.org/dis/sec-reins/2019-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sec-cndfir="http://fasb.org/dis/sec-cndfir/2019-01-31" xmlns:sr="http://fasb.org/dis/sr/2019-01-31" xmlns:currency-all="http://xbrl.sec.gov/currency-all/2019-01-31" xmlns:scf-dbo="http://fasb.org/stm/scf-dbo/2019-01-31" xmlns:fs-fhlb="http://fasb.org/dis/fs-fhlb/2019-01-31" xmlns:crcpb="http://fasb.org/dis/crcpb/2019-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:scf-inv="http://fasb.org/stm/scf-inv/2019-01-31" xmlns:scf-indira="http://fasb.org/stm/scf-indira/2019-01-31" xmlns:bsoff="http://fasb.org/dis/bsoff/2019-01-31" xmlns:exch-ent-all="http://xbrl.sec.gov/exch-ent-all/2019-01-31" xmlns:oi="http://fasb.org/dis/oi/2019-01-31" xmlns:soi-indira="http://fasb.org/stm/soi-indira/2019-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:schedoi-otsh="http://fasb.org/dis/schedoi-otsh/2019-01-31" xmlns:sfp-dbo="http://fasb.org/stm/sfp-dbo/2019-01-31" xmlns:cc="http://fasb.org/dis/cc/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:crcsbp="http://fasb.org/dis/crcsbp/2019-01-31" xmlns:disops="http://fasb.org/dis/disops/2019-01-31" xmlns:reference="http://www.xbrl.org/2009/role/reference" xmlns:cn-part="http://fasb.org/cn-part/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2019-01-31" xmlns:country-std="http://xbrl.sec.gov/country-std/2017-01-31" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:scf-indir="http://fasb.org/stm/scf-indir/2019-01-31" xmlns:rlnro="http://fasb.org/dis/rlnro/2019-01-31" xmlns:ts="http://fasb.org/dis/ts/2019-01-31" xmlns:us-gaap-std="http://fasb.org/us-gaap-std/2019-01-31" xmlns:naics-ent-all="http://xbrl.sec.gov/naics-ent-all/2017-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:scf-dir="http://fasb.org/stm/scf-dir/2019-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2019-01-31" xmlns:ni="http://fasb.org/dis/ni/2019-01-31" xmlns:sec-mort="http://fasb.org/dis/sec-mort/2019-01-31" xmlns:fifvd="http://fasb.org/dis/fifvd/2019-01-31" xmlns:otherexp="http://fasb.org/dis/otherexp/2019-01-31" xmlns:scf-re="http://fasb.org/stm/scf-re/2019-01-31" xmlns:sec-vq="http://fasb.org/dis/sec-vq/2019-01-31" xmlns:sec-sum="http://fasb.org/dis/sec-sum/2019-01-31" xmlns:exch-std="http://xbrl.sec.gov/exch-std/2019-01-31" xmlns:ir="http://fasb.org/dis/ir/2019-01-31" xmlns:sheci="http://fasb.org/stm/sheci/2019-01-31" xmlns:foct="http://fasb.org/dis/foct/2019-01-31" xmlns:soc="http://fasb.org/stm/soc/2019-01-31" xmlns:scf-sbo="http://fasb.org/stm/scf-sbo/2019-01-31" xmlns:inctax="http://fasb.org/dis/inctax/2019-01-31" xmlns:ppe="http://fasb.org/dis/ppe/2019-01-31" xmlns:country-all="http://xbrl.sec.gov/country-all/2017-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:con="http://fasb.org/dis/con/2019-01-31" xmlns:sic-ent-std="http://xbrl.sec.gov/sic-ent-std/2011-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:fs-ins="http://fasb.org/dis/fs-ins/2019-01-31" xmlns:eps="http://fasb.org/dis/eps/2019-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:iago="http://fasb.org/dis/iago/2019-01-31" xmlns:pay="http://fasb.org/dis/pay/2019-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:tin-part="http://fasb.org/tin-part/2019-01-31" xmlns:acec="http://fasb.org/dis/acec/2019-01-31" xmlns:us-gaap-entryPoint-all="http://fasb.org/us-gaap-entryPoint-all/2019-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:nt="http://fasb.org/dis/nt/2019-01-31" xmlns:spc="http://fasb.org/stm/spc/2019-01-31" xmlns:exch-all="http://xbrl.sec.gov/exch-all/2019-01-31" xmlns:ides="http://fasb.org/dis/ides/2019-01-31" xmlns:sec-supins="http://fasb.org/dis/sec-supins/2019-01-31" xmlns:sic-all="http://xbrl.sec.gov/sic-all/2011-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:regop="http://fasb.org/dis/regop/2019-01-31" xmlns:sfp-cls="http://fasb.org/stm/sfp-cls/2019-01-31" xmlns:com="http://fasb.org/stm/com/2019-01-31" xmlns:soi-re="http://fasb.org/stm/soi-re/2019-01-31" xmlns:crcgen="http://fasb.org/dis/crcgen/2019-01-31" xmlns:exch-ent-dep="http://xbrl.sec.gov/exch-ent-dep/2019-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:ei="http://fasb.org/dis/ei/2019-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
	<head>
		<meta http-equiv="Content-Type" content="text/html" />
		<title>Document</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="FD2020Q1YTD" name="dei:AmendmentFlag" id="Fact-0E48C724DA10C59FE81950AC63A01A52-wk-Fact-0E48C724DA10C59FE81950AC63A01A52" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q1YTD" name="dei:CurrentFiscalYearEndDate" id="Fact-4396D86F1A3FDBC19A9250AC639F06D1-wk-Fact-4396D86F1A3FDBC19A9250AC639F06D1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q1YTD" name="dei:DocumentFiscalPeriodFocus" id="Fact-37BE7E72F9D1211F809B50AC639BECEB-wk-Fact-37BE7E72F9D1211F809B50AC639BECEB">Q1</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q1YTD" name="dei:DocumentFiscalYearFocus" id="Fact-63014366F6CAC9253AF550AC63A32998-wk-Fact-63014366F6CAC9253AF550AC63A32998">2020</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q1YTD" name="dei:EntityCentralIndexKey" id="Fact-DFB26AB808743B9170D950AC639BC443-wk-Fact-DFB26AB808743B9170D950AC639BC443">0001367644</ix:nonNumeric><ix:nonNumeric contextRef="D2019Q2Jun01-Jun30" name="ebs:DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod" id="Fact-792A9376BDBEDC53AE2D9EA600438185-wk-Fact-792A9376BDBEDC53AE2D9EA600438185">P12M</ix:nonNumeric><ix:nonNumeric contextRef="D2019Q2Jun01-Jun30" name="ebs:DebtInstrumentCovenantNetLeverageRatioRollingPeriod" id="Fact-74840B652875D67B158E9EA59E38C0FF-wk-Fact-74840B652875D67B158E9EA59E38C0FF">P12M</ix:nonNumeric><ix:nonFraction decimals="-5" unitRef="usd" contextRef="FI2019Q4" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" id="Fact-82AE42CE832629C215EE9EB3C093C1EE-wk-Fact-82AE42CE832629C215EE9EB3C093C1EE">0</ix:nonFraction><ix:nonFraction decimals="3" unitRef="number" contextRef="FI2020Q1_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MeasurementInputTypeAxis_ebs_MeasurementInputProbabilityofPaymentMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueDiscountedCashFlowMember" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" id="Fact-4AC65DC8B32E9F044ABAB80AFA1983C3-wk-Fact-4AC65DC8B32E9F044ABAB80AFA1983C3">0.400</ix:nonFraction><ix:nonFraction decimals="3" unitRef="number" contextRef="FI2020Q1_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueDiscountedCashFlowMember" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" id="Fact-F9E0045F8ADC836B1187B80AEF872CAC-wk-Fact-F9E0045F8ADC836B1187B80AEF872CAC">0.086</ix:nonFraction><ix:nonFraction decimals="3" unitRef="number" contextRef="FI2020Q1_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MeasurementInputTypeAxis_ebs_MeasurementInputProbabilityofPaymentMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueDiscountedCashFlowMember" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" id="Fact-EC21897CE200076E02EDB80AF4DF7B99-wk-Fact-EC21897CE200076E02EDB80AF4DF7B99">0.100</ix:nonFraction><ix:nonFraction decimals="3" unitRef="number" contextRef="FI2020Q1_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueDiscountedCashFlowMember" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" id="Fact-3A474463AF0A5360DB6FB80AE7975568-wk-Fact-3A474463AF0A5360DB6FB80AE7975568">0.025</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2019Q1" name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact-E20634217EA5EC624B867A3947029C47-wk-Fact-E20634217EA5EC624B867A3947029C47">0.001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2019Q4" name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact-C15AF22F31B6D3BF653950AC63BB4FC0-wk-Fact-C15AF22F31B6D3BF653950AC63BB4FC0">0.001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2020Q1" name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact-B24104F24953598727B350AC63E51183-wk-Fact-B24104F24953598727B350AC63E51183">0.001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:CommonStockSharesAuthorized" id="Fact-0B47661E1FC500879DBB50AC63C4AD59-wk-Fact-0B47661E1FC500879DBB50AC63C4AD59">200000000.0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2020Q1" name="us-gaap:CommonStockSharesAuthorized" id="Fact-2452C7B85C317F8FC40D50AC63C5FEFB-wk-Fact-2452C7B85C317F8FC40D50AC63C5FEFB">200000000.0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:CommonStockSharesIssued" id="Fact-CDEF45159D132E885F0450AC63E5B191-wk-Fact-CDEF45159D132E885F0450AC63E5B191">53000000.0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2020Q1" name="us-gaap:CommonStockSharesIssued" id="Fact-F77B42B38EF53C877AD350AC63C4FA21-wk-Fact-F77B42B38EF53C877AD350AC63C4FA21">53500000.0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:CommonStockSharesOutstanding" id="Fact-C0616B95FA5D9DB05DB650AC63A5719F-wk-Fact-C0616B95FA5D9DB05DB650AC63A5719F">51700000.0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2020Q1" name="us-gaap:CommonStockSharesOutstanding" id="Fact-2FF701A5C07CD02712E150AC63C50455-wk-Fact-2FF701A5C07CD02712E150AC63C50455">52300000.0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FI2020Q1_us-gaap_DebtInstrumentAxis_ebs_ConvertibleSeniorNotesDue2021Member" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact-1907CAB695D6B50981DABEB6F29AC3C9-wk-Fact-1907CAB695D6B50981DABEB6F29AC3C9">0.02875</ix:nonFraction><ix:nonNumeric contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="Fact-1F31B62DEACA9ADAC6EC50AC63C0B1EE-wk-Fact-1F31B62DEACA9ADAC6EC50AC63C0B1EE">P22Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="Fact-9118AECFCECBCE5D09D450AC63BBDBA6-wk-Fact-9118AECFCECBCE5D09D450AC63BBDBA6">P9Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q1YTD_srt_RangeAxis_srt_MaximumMember" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="Fact-EEA09AA570F17F620DD950AC63C1A001-wk-Fact-EEA09AA570F17F620DD950AC63C1A001">P22Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q1YTD_srt_RangeAxis_srt_MinimumMember" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="Fact-0F5CD76F0FFA7669CAF950AC63C2BA6E-wk-Fact-0F5CD76F0FFA7669CAF950AC63C2BA6E">P9Y</ix:nonNumeric><ix:nonFraction decimals="-3" unitRef="usd" contextRef="FD2019Q1QTD" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax" id="Fact-28F10BE3DBDE7DD4EAFA9E5DEE964BB1-wk-Fact-28F10BE3DBDE7DD4EAFA9E5DEE964BB1">0</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="usd" contextRef="FD2020Q1YTD" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax" id="Fact-AF6392AD8B7C3AD1740A9E5DEE76C01F-wk-Fact-AF6392AD8B7C3AD1740A9E5DEE76C01F">0</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="usd" contextRef="FD2019Q1QTD" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" id="Fact-3C07EDBFB2D5AB6707819E5670607F3B-wk-Fact-3C07EDBFB2D5AB6707819E5670607F3B">0</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="usd" contextRef="FD2020Q1YTD" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" id="Fact-36580CA52809B6FD14519E56708A55E7-wk-Fact-36580CA52809B6FD14519E56708A55E7">2800000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2019Q4" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact-20991F85DEBD2590A10650AC63DCC0A7-wk-Fact-20991F85DEBD2590A10650AC63DCC0A7">0.001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2020Q1" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact-77D0BDC6D97591104E4050AC63E41A4B-wk-Fact-77D0BDC6D97591104E4050AC63E41A4B">0.001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:PreferredStockSharesAuthorized" id="Fact-33550EF448D84030613750AC63DA3B99-wk-Fact-33550EF448D84030613750AC63DA3B99">15000000.0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2020Q1" name="us-gaap:PreferredStockSharesAuthorized" id="Fact-118A608FFA82F495C94350AC63C52749-wk-Fact-118A608FFA82F495C94350AC63C52749">15000000.0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:PreferredStockSharesIssued" id="Fact-0E13776D0F7E27792D6150AC63E382AD-wk-Fact-0E13776D0F7E27792D6150AC63E382AD">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2020Q1" name="us-gaap:PreferredStockSharesIssued" id="Fact-2894DAC3673B5A9A48E350AC63C38BBF-wk-Fact-2894DAC3673B5A9A48E350AC63C38BBF">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:PreferredStockSharesOutstanding" id="Fact-C9170C6983974D800D9D50AC63C461C9-wk-Fact-C9170C6983974D800D9D50AC63C461C9">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2020Q1" name="us-gaap:PreferredStockSharesOutstanding" id="Fact-E1800D4F844FEA794D6850AC63C3EA20-wk-Fact-E1800D4F844FEA794D6850AC63C3EA20">0</ix:nonFraction><ix:nonNumeric contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Fact-73263950C1D92479FFBC50AC63A0B4FB-wk-Fact-73263950C1D92479FFBC50AC63A0B4FB">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Fact-35C4F50EB8FE20CCFE9850AC63A95FC9-wk-Fact-35C4F50EB8FE20CCFE9850AC63A95FC9">P3Y</ix:nonNumeric><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Fact-32682A7A94DB39055A1150AC63A82951-wk-Fact-32682A7A94DB39055A1150AC63A82951">0.3333</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Fact-24001A6C353632BC400250AC639F2C8E-wk-Fact-24001A6C353632BC400250AC639F2C8E">0.3333</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Fact-96495D4C6A2EA38905D650AC63A97826-wk-Fact-96495D4C6A2EA38905D650AC63A97826">0.3333</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Fact-9D796BDE9BDFD0C3E1E650AC639A9634-wk-Fact-9D796BDE9BDFD0C3E1E650AC639A9634">0.3333</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Fact-66B837E236D2CE25D4DA50AC639F5AF2-wk-Fact-66B837E236D2CE25D4DA50AC639F5AF2">0.3333</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Fact-771F2C6D94BC83AFEF9F50AC63992869-wk-Fact-771F2C6D94BC83AFEF9F50AC63992869">0.3333</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:TreasuryStockShares" id="Fact-D73F2FB29977991040EC50AC63C68599-wk-Fact-D73F2FB29977991040EC50AC63C68599">1200000.0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2020Q1" name="us-gaap:TreasuryStockShares" id="Fact-D2F73C42A3180429E09050AC63D780E1-wk-Fact-D2F73C42A3180429E09050AC63D780E1">1200000.0</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:href="ebs-20200331.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="FD2020Q1YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2020Q2Apr24">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-04-24</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractManufacturingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractManufacturingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandAndLandImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandAndLandImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerSoftwareIntangibleAssetMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerSoftwareIntangibleAssetMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_srt_RangeAxis_srt_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_srt_RangeAxis_srt_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_BusinessAcquisitionAxis_ebs_RaxibacumabMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:RaxibacumabMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ebs_ContractManufacturingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:ContractManufacturingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ebs_ContractManufacturingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:ContractManufacturingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ebs_ContractManufacturingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:ContractManufacturingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ebs_ContractManufacturingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:ContractManufacturingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_srt_RangeAxis_srt_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_srt_RangeAxis_srt_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueDiscountedCashFlowMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueDiscountedCashFlowMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MeasurementInputTypeAxis_ebs_MeasurementInputProbabilityofPaymentMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueDiscountedCashFlowMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ebs:MeasurementInputProbabilityofPaymentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MeasurementInputTypeAxis_ebs_MeasurementInputProbabilityofPaymentMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueDiscountedCashFlowMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ebs:MeasurementInputProbabilityofPaymentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueDiscountedCashFlowMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MeasurementInputTypeAxis_ebs_MeasurementInputProbabilityofPaymentMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueDiscountedCashFlowMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ebs:MeasurementInputProbabilityofPaymentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueDiscountedCashFlowMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_InterestExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_InterestExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Oct15-Oct15_us-gaap_CreditFacilityAxis_ebs_TermLoanFacilityMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ebs:TermLoanFacilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-15</xbrli:startDate>
			<xbrli:endDate>2018-10-15</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Oct15-Oct15_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-15</xbrli:startDate>
			<xbrli:endDate>2018-10-15</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Oct15-Oct15_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_EurodollarMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-15</xbrli:startDate>
			<xbrli:endDate>2018-10-15</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Oct15-Oct15_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_BaseRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-15</xbrli:startDate>
			<xbrli:endDate>2018-10-15</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q4Oct31_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_DebtInstrumentAxis_ebs_CreditAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:CreditAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-10-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q4Oct31_us-gaap_CreditFacilityAxis_ebs_TermLoanFacilityMember_us-gaap_DebtInstrumentAxis_ebs_CreditAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ebs:TermLoanFacilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:CreditAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-10-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2014Q1Jan29_us-gaap_DebtInstrumentAxis_ebs_ConvertibleSeniorNotesDue2021Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:ConvertibleSeniorNotesDue2021Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-01-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_DebtInstrumentAxis_ebs_CreditAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:CreditAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_DebtInstrumentAxis_ebs_CreditAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:CreditAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Oct15-Oct15_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_EurodollarMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-15</xbrli:startDate>
			<xbrli:endDate>2018-10-15</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Oct15-Oct15_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_BaseRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-15</xbrli:startDate>
			<xbrli:endDate>2018-10-15</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Oct15-Oct15_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_EurodollarMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-15</xbrli:startDate>
			<xbrli:endDate>2018-10-15</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Oct15-Oct15_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_FederalFundsEffectiveSwapRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-15</xbrli:startDate>
			<xbrli:endDate>2018-10-15</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Oct15-Oct15_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-15</xbrli:startDate>
			<xbrli:endDate>2018-10-15</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_DebtInstrumentAxis_ebs_ConvertibleSeniorNotesDue2021Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:ConvertibleSeniorNotesDue2021Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DebtInstrumentAxis_ebs_OtherLongTermDebtFacilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:OtherLongTermDebtFacilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_CreditFacilityAxis_ebs_TermLoanFacilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ebs:TermLoanFacilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_CreditFacilityAxis_ebs_TermLoanFacilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ebs:TermLoanFacilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DebtInstrumentAxis_ebs_ConvertibleSeniorNotesDue2021Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:ConvertibleSeniorNotesDue2021Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_DebtInstrumentAxis_ebs_OtherLongTermDebtFacilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:OtherLongTermDebtFacilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q2Jun01-Jun30">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-06-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2020-04-01">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
					<us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2020-04-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
				</xbrldi:typedMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractManufacturingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractManufacturingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractManufacturingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractManufacturingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:unit id="category">
		<xbrli:measure>ebs:category</xbrli:measure>
	</xbrli:unit><xbrli:unit id="instrument">
		<xbrli:measure>ebs:instrument</xbrli:measure>
	</xbrli:unit><xbrli:unit id="segment">
		<xbrli:measure>ebs:segment</xbrli:measure>
	</xbrli:unit><xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit><xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit><xbrli:unit id="product">
		<xbrli:measure>ebs:product</xbrli:measure>
	</xbrli:unit><xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit><xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit></ix:resources></ix:header></div><div><a id="s0B747E012AC7529A9DFB288D2EB54AFC"></a></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:14pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:14pt;color:#00497f;font-weight:bold;">UNITED STATES SECURITIES AND EXCHANGE COMMISSION</span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#00497f;font-weight:bold;">Washington, D.C. 20549</span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:14pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:14pt;color:#00497f;font-weight:bold;">Form </span><span><ix:nonNumeric id="d17795988e571-wk-Fact-6DEAE98BF4E4CC5B31BA50AC639B4FB7" name="dei:DocumentType" contextRef="FD2020Q1YTD"><span style="color:#00497f;font-family:Franklin Gothic Book,sans-serif;font-size:14pt;font-weight:bold;">10-Q</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:14pt;color:#00497f;font-weight:bold;"> </span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:6%;"></td><td style="width:38%;"></td><td style="width:56%;"></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(Mark One)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial Unicode MS;font-size:10pt;"><span><ix:nonNumeric id="d17795988e606-wk-Fact-BD771E682C415565483D50AC63DBB692" name="dei:DocumentQuarterlyReport" contextRef="FD2020Q1YTD" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></span></span></div></td><td colspan="2" style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">For the quarterly period ended</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;"><span><span style="white-space:nowrap"><ix:nonNumeric id="d17795988e648-wk-Fact-16AE0F0436DAC9FA373050AC63DA7BAF" name="dei:DocumentPeriodEndDate" contextRef="FD2020Q1YTD" format="ixt:datemonthdayyearen">March 31, 2020</ix:nonNumeric></span></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;font-weight:bold;">OR</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial Unicode MS;font-size:10pt;"><span><ix:nonNumeric id="d17795988e686-wk-Fact-C9BBC1529E1A700AB13C50AC63DC9A1C" name="dei:DocumentTransitionReport" contextRef="FD2020Q1YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;font-weight:bold;">For the transition period from&#160;to</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:24px;font-size:7pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#2c2c2c;font-weight:bold;">Commission file number: </span><span><ix:nonNumeric id="d17795988e733-wk-Fact-6530F33A47CA90654E8950AC63A56A04" name="dei:EntityFileNumber" contextRef="FD2020Q1YTD"><span style="color:#2c2c2c;font-family:Franklin Gothic Book,sans-serif;font-size:7pt;font-weight:bold;">001-33137</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#2c2c2c;font-weight:bold;"> </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:24px;font-size:10pt;"><span style="font-family:;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:24px;"><img src="emergentlogo01.jpg" alt="emergentlogo01.jpg" style="height:88px;width:208px;"></img></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:24px;font-size:14pt;"><span><ix:nonNumeric id="d17795988e743-wk-Fact-2C31B79B1C72985B4E3350AC63C30708" name="dei:EntityRegistrantName" contextRef="FD2020Q1YTD"><span style="color:#2c2c2c;font-family:Franklin Gothic Book,sans-serif;font-size:14pt;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:14pt;color:#2c2c2c;font-weight:bold;"> </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:24px;font-size:7pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#2c2c2c;font-style:italic;font-weight:bold;">(Exact Name of Registrant as Specified in Its Charter)</span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.09864603481626%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:46%;"></td><td style="width:9%;"></td><td style="width:45%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;"><span><ix:nonNumeric id="d17795988e765-wk-Fact-983C045558B233D9139A50AC63DD24AD" name="dei:EntityIncorporationStateCountryCode" contextRef="FD2020Q1YTD" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;"><span><ix:nonNumeric id="d17795988e775-wk-Fact-14E0D6B5959DBE5529F150AC63C6583E" name="dei:EntityTaxIdentificationNumber" contextRef="FD2020Q1YTD">14-1902018</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;font-style:italic;">(State or Other Jurisdiction of</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;font-style:italic;">Incorporation or Organization)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;font-style:italic;">(I.R.S. Employer</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;font-style:italic;">Identification No.)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;"><span><ix:nonNumeric id="d17795988e818-wk-Fact-414452901DD31FEF35CA50AC63C419A9" name="dei:EntityAddressAddressLine1" contextRef="FD2020Q1YTD">400 Professional Drive Suite 400</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;"><span><ix:nonNumeric id="d17795988e834-wk-Fact-E6DD8063A830283A1B5750AC63C561C8" name="dei:EntityAddressCityOrTown" contextRef="FD2020Q1YTD">Gaithersburg,  </ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;"><span><ix:nonNumeric id="d17795988e839-wk-Fact-4E8A16F433DB7295520550AC63E34572" name="dei:EntityAddressStateOrProvince" contextRef="FD2020Q1YTD" format="ixt-sec:stateprovnameen">Maryland</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;"><span><ix:nonNumeric id="d17795988e844-wk-Fact-F338C7B98F99E81C248F50AC63E5996A" name="dei:EntityAddressPostalZipCode" contextRef="FD2020Q1YTD">20879</ix:nonNumeric></span></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;font-style:italic;">(Address and zip code of Principal Executive Offices)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2c2c2c;font-weight:bold;">(</span><span><ix:nonNumeric id="d17795988e865-wk-Fact-FA62D83AA4734DB7F0ED50AC63A7BB86" name="dei:CityAreaCode" contextRef="FD2020Q1YTD"><span style="color:#2c2c2c;font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">240</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2c2c2c;font-weight:bold;">) </span><span><ix:nonNumeric id="d17795988e870-wk-Fact-D6BA8FA29828958E4C0050AC639BD7A1" name="dei:LocalPhoneNumber" contextRef="FD2020Q1YTD"><span style="color:#2c2c2c;font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">631-3200</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2c2c2c;font-weight:bold;"> </span></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#2c2c2c;font-style:italic;font-weight:normal;">(Registrant's Telephone Number, Including Area Code)</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:36%;"></td><td style="width:27%;"></td><td style="width:37%;"></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">Securities registered pursuant to Section 12(b) of the Act</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-style:italic;">Title of each class</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-style:italic;">Trading Symbol(s)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-style:italic;">Name of each exchange on which registered</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonNumeric id="d17795988e924-wk-Fact-6A5D973F6182836FB76E50AC63BBBB05" name="dei:Security12bTitle" contextRef="FD2020Q1YTD">Common Stock, Par Value $0.001 per share</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonNumeric id="d17795988e929-wk-Fact-2E5E75E50F5188B99E5050AC63BB66DE" name="dei:TradingSymbol" contextRef="FD2020Q1YTD">EBS</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonNumeric id="d17795988e934-wk-Fact-767C979097CD02FB009E50AC63BA91AE" name="dei:SecurityExchangeName" contextRef="FD2020Q1YTD" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric></span></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2c2c2c;font-weight:normal;">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. </span><span style="font-family:Arial Unicode MS;font-size:9pt;color:#2c2c2c;font-weight:normal;">&#9746;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#2c2c2c;font-weight:normal;"> </span><span><ix:nonNumeric id="d17795988e943-wk-Fact-1D83F2C7E0A581507F4150AC63A28A97" name="dei:EntityCurrentReportingStatus" contextRef="FD2020Q1YTD"><span style="color:#2c2c2c;font-family:Franklin Gothic Book,sans-serif;font-size:7pt;font-weight:normal;">Yes</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#2c2c2c;font-weight:normal;"> </span><span style="font-family:Arial Unicode MS;font-size:7pt;color:#2c2c2c;font-weight:normal;">&#9744;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#2c2c2c;font-weight:bold;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#2c2c2c;font-weight:normal;">No</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2c2c2c;font-weight:normal;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). </span><span style="font-family:Arial Unicode MS;font-size:9pt;color:#2c2c2c;font-weight:normal;">&#9746;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#2c2c2c;font-weight:normal;"> </span><span><ix:nonNumeric id="d17795988e961-wk-Fact-B7AD05D5E90AF678F6D850AC63A43E62" name="dei:EntityInteractiveDataCurrent" contextRef="FD2020Q1YTD"><span style="color:#2c2c2c;font-family:Franklin Gothic Book,sans-serif;font-size:7pt;font-weight:normal;">Yes</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#2c2c2c;font-weight:normal;"> </span><span style="font-family:Arial Unicode MS;font-size:7pt;color:#2c2c2c;font-weight:normal;">&#9744;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#2c2c2c;font-weight:bold;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#2c2c2c;font-weight:normal;">No</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2c2c2c;font-weight:normal;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):</span></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:97.48549323017409%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:32%;"></td><td style="width:6%;"></td><td style="width:31%;"></td><td style="width:31%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonNumeric id="d17795988e991-wk-Fact-AA24FAEAD7693C489D8150AC63C92EC8" name="dei:EntityFilerCategory" contextRef="FD2020Q1YTD" format="ixt-sec:entityfilercategoryen">Large accelerated filer</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial Unicode MS;font-size:9pt;">&#9746;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Accelerated filer</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial Unicode MS;font-size:9pt;">&#9744;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Non-accelerated filer </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial Unicode MS;font-size:9pt;">&#9744;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Smaller reporting company</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial Unicode MS;font-size:9pt;"><span><ix:nonNumeric id="d17795988e1027-wk-Fact-69D6192B18F0B2A7E52550AC63CECAB2" name="dei:EntitySmallBusiness" contextRef="FD2020Q1YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br/></span></div><div style="font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Emerging growth company</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial Unicode MS;font-size:9pt;"><span><ix:nonNumeric id="d17795988e1049-wk-Fact-BBFF384C1B0AA61E44E250AC63CC5A7E" name="dei:EntityEmergingGrowthCompany" contextRef="FD2020Q1YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2c2c2c;font-weight:normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to section 13(a) of the Exchange Act. </span><span style="font-family:Arial Unicode MS;font-size:9pt;color:#2c2c2c;font-weight:normal;">&#9744;</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2c2c2c;font-weight:normal;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#2c2c2c;font-weight:normal;">Yes </span><span><ix:nonNumeric id="d17795988e1061-wk-Fact-AF90944F6872DFE82A8050AC63A01975" name="dei:EntityShellCompany" contextRef="FD2020Q1YTD" format="ixt-sec:boolballotbox"><span style="color:#2c2c2c;font-family:Arial Unicode MS;font-size:7pt;font-weight:normal;">&#9744;</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#2c2c2c;font-weight:normal;"> No</span><span style="font-family:Wingdings;font-size:7pt;color:#2c2c2c;font-weight:normal;"> </span><span style="font-family:Arial Unicode MS;font-size:7pt;color:#2c2c2c;font-weight:normal;">&#9746;</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2c2c2c;font-weight:normal;">As of April 24, 2020, the registrant had </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2c2c2c;font-weight:normal;"><span><ix:nonFraction id="d17795988e1073-wk-Fact-BE9BF63A9DC7E53BA14950AC63A0C27D" name="dei:EntityCommonStockSharesOutstanding" contextRef="I2020Q2Apr24" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">52,427,756</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2c2c2c;font-weight:normal;"> shares of common stock outstanding.</span></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">1</span></div></div><hr style="page-break-after:always"></hr><div><a id="s9849D1EB0C56579BA67E871E09E76708"></a></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Emergent BioSolutions Inc.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Index to Form 10-Q</span></div><div style="line-height:120%;padding-bottom:12px;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:16%;"></td><td style="width:75%;"></td><td style="width:9%;"></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;color:#000000;" href="#s3E8EF16D34E25C02A8107F4ED7EA997F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;color:#000000;">Part I. Financial Information</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Page No.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;" href="#sBC31F4C3A0755CE5B2A93CAD25BEBF30"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;">Item 1.</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sBC31F4C3A0755CE5B2A93CAD25BEBF30"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financial Statements</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:none;" href="#sBC31F4C3A0755CE5B2A93CAD25BEBF30">5</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s2733B17D3F585BB4A23423774B556764"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Condensed Consolidated Balance Sheets</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:none;" href="#s2733B17D3F585BB4A23423774B556764">5</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sA94E90EF9CFB5E1EA187AB94AD342267"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Condensed Consolidated Statements of Operations</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:none;" href="#sA94E90EF9CFB5E1EA187AB94AD342267">6</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s1C90156C7DC2502D8654AC8C2AB720B2"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Condensed Consolidated Statements of Comprehensive Income</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:none;" href="#s1C90156C7DC2502D8654AC8C2AB720B2">7</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s20968007722D5EE6BEF725CADE7CC4F7"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Condensed Consolidated Statements of Cash Flows</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:none;" href="#s20968007722D5EE6BEF725CADE7CC4F7">8</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s9E7BB9E21BC7561B8EAB5C00C4ED0A71"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Condensed Consolidated Statements of Changes in Stockholders' Equity</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:none;" href="#s9E7BB9E21BC7561B8EAB5C00C4ED0A71">9</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sBF91395DF12C51EBB4EC3EB02EB18CFD"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes to Condensed Consolidated Financial Statements</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:none;" href="#sBF91395DF12C51EBB4EC3EB02EB18CFD">10</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;" href="#sB65FDA24BFAF57AD957C6207B513CC20"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;">Item 2.</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sB65FDA24BFAF57AD957C6207B513CC20"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Management's Discussion and Analysis of Financial Condition and Results of Operations</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:none;" href="#sB65FDA24BFAF57AD957C6207B513CC20">22</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;" href="#sC8FFA27C6DC45406AC5E7F54768122AB"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;">Item 3.</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sC8FFA27C6DC45406AC5E7F54768122AB"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Quantitative and Qualitative Disclosures About Market Risk</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:none;" href="#sC8FFA27C6DC45406AC5E7F54768122AB">31</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;" href="#sD8BEE3C57C715AA3A431AA571A78A702"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;">Item 4.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sD8BEE3C57C715AA3A431AA571A78A702"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Controls and Procedures</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:none;" href="#sD8BEE3C57C715AA3A431AA571A78A702">32</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;color:#000000;" href="#sE60158D0294F5C2C95A226DD865A3C17"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;color:#000000;">Part II. Other Information</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;" href="#s70DB988F33235785836815FA375A774C"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;">Item 1.</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s70DB988F33235785836815FA375A774C"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Legal Proceedings</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:none;" href="#s70DB988F33235785836815FA375A774C">32</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;" href="#s0EBFB2C1798D5256809447832BBAB468"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;">Item 1A.</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s0EBFB2C1798D5256809447832BBAB468"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Risk Factors</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:none;" href="#s0EBFB2C1798D5256809447832BBAB468">33</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;" href="#sC900B480A8A95BB28329FE51859FA8AD"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;">Item 2.</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sC900B480A8A95BB28329FE51859FA8AD"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:none;" href="#sC900B480A8A95BB28329FE51859FA8AD">64</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;" href="#s0A7588C115F15148AAFBC3D1EC5BF00E"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;">Item 3.</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s0A7588C115F15148AAFBC3D1EC5BF00E"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Defaults Upon Senior Securities</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:none;" href="#s0A7588C115F15148AAFBC3D1EC5BF00E">64</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;" href="#sDA16D97534245CADBFB543ED448673F3"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;">Item 4.</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sDA16D97534245CADBFB543ED448673F3"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mine Safety Disclosures</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:none;" href="#sDA16D97534245CADBFB543ED448673F3">64</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;" href="#s5C6B594F885850C68B12EBD9E1DEB744"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;">Item 5.</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s5C6B594F885850C68B12EBD9E1DEB744"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other Information</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:none;" href="#s5C6B594F885850C68B12EBD9E1DEB744">64</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;" href="#s3996B53194875C5AA0337F9819FE4FA5"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;">Item 6.</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s3996B53194875C5AA0337F9819FE4FA5"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Exhibits</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:none;" href="#s3996B53194875C5AA0337F9819FE4FA5">64</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s196640A4BC2750B590A7789B53F8315E"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Signatures</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:none;" href="#s196640A4BC2750B590A7789B53F8315E">66</a></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:0px;font-size:7pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">2</span></div></div><hr style="page-break-after:always"></hr><div><a id="s3E8EF16D34E25C02A8107F4ED7EA997F"></a></div><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">PART I. FINANCIAL INFORMATION</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">This quarterly report on Form 10-Q </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">and the documents we incorporate by reference include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">All statements, other than statements of historical fact, including statements regarding the future earnings and performance of Emergent BioSolutions Inc. or any of our businesses, our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management and the expected impact of the COVID-19 pandemic, are forward-looking statements. We generally identify forward-looking statements by using words like "will," "believes," "expects," "anticipates," "intends," "plans," "forecasts," "estimates" and similar expressions in conjunction with, among other things, discussions of financial performance or financial condition, growth strategy, product sales, manufacturing capabilities, product development, regulatory approvals or expenditures. These forward-looking statements are based on our current intentions, beliefs and expectations regarding future events. We cannot guarantee that any forward-looking statement will be accurate. You should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. You are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date on which such statement is made, and, except as required by law, we do not undertake to update any forward-looking statement to reflect new information, events or circumstances.</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">There are a number of important factors that could cause our actual results to differ materially from those indicated by such forward-looking statements, including, among others:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#9642;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">the impact of global economic conditions and public health crises and epidemics, such as the novel strain of coronavirus (SARS-CoV-2) causing COVID-19 disease, on our markets, operations and employees as well as those of our customers and suppliers;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">&#9642;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">the availability of U.S. government (USG) funding for procurement of our products; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#9642;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">our ability to perform under our contracts with the USG including the timing of and specifications relating to deliveries;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#9642;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">the continued exercise of discretion by the&#160;Biomedical Advanced Research and Development Authority (BARDA)&#160;to procure additional doses of AV7909 (anthrax vaccine adsorbed with adjuvant) prior to approval by the&#160;U.S. Food and Drug Administration (FDA);</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#9642;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">the exercise of all options under our recently executed contract for the procurement of ACAM2000&#174; (Smallpox (Vaccinia) Vaccine, Live);</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#9642;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">our ability to secure licensure of AV7909 from the FDA within the anticipated timeframe, if at all;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#9642;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">our ability to secure follow-on procurement contracts for our public health threat (PHT) products that are under procurement contracts that have expired or will be expiring;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#9642;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">our ability and the ability of our collaborators to enforce patents related to NARCAN Nasal Spray against potential generic entrants;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#9642;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">our ability to identify and acquire companies, businesses, products or product candidates that satisfy our selection criteria;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#9642;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">our ability and the ability of our contractors and suppliers to maintain compliance with current good manufacturing practices and other regulatory obligations;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#9642;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">our ability to comply with the operating and financial covenants required by our Senior Secured Credit Facilities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#9642;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">our ability to obtain and maintain regulatory approvals for our product candidates and the timing of any such approvals;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#9642;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">the procurement of products by USG entities under regulatory exemptions prior to approval by the FDA and corresponding procurement by government entities outside of the United States under regulatory exemptions prior to approval by the corresponding regulatory authorities in the applicable country;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#9642;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">the success of our commercialization, marketing and manufacturing capabilities and strategy; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#9642;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">the accuracy of our estimates regarding future revenues, expenses, capital requirements and needs for additional financing.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-left:48px;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. New factors emerge from time to time and it is not possible for management to predict all such factors, nor can it assess the impact of any such factor on the business or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. You should consider this cautionary statement, the risk factors identified in the section entitled "Risk Factors" in this quarterly </span></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">3</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">report on Form 10-Q and the risk factors identified in our other periodic reports filed with the Securities and Exchange Commission (SEC) when evaluating our forward-looking statements.</span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTE REGARDING COMPANY REFERENCES</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">References in this report to &#8220;Emergent,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Emergent BioSolutions Inc. and its consolidated subsidiaries.</span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTE REGARDING TRADENAMES</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">BioThrax&#174; (Anthrax Vaccine Adsorbed), RSDL&#174; (Reactive Skin Decontamination Lotion Kit), BAT&#174; (Botulism Antitoxin Heptavalent (A,B,C,D,E,F,G)-(Equine)), Anthrasil&#174; (Anthrax Immune Globulin Intravenous (Human)), VIGIV (Vaccinia Immune Globulin Intravenous (Human)), Trobigard&#174; (atropine sulfate, obidoxime chloride), ACAM2000&#174; (Smallpox (Vaccinia) Vaccine, Live), Vivotif&#174; (Typhoid Vaccine Live Oral Ty21a), Vaxchora&#174; (Cholera Vaccine, Live, Oral), NARCAN&#174; (naloxone HCI) Nasal Spray and any and all Emergent brands, products, services and feature names, logos and slogans are trademarks or registered trademarks of Emergent or its subsidiaries in the United States or other countries. All other brands, products, services and feature names or trademarks are the property of their respective owners.</span></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">4</span></div></div><hr style="page-break-after:always"></hr><div><a id="sBC31F4C3A0755CE5B2A93CAD25BEBF30"></a></div><div><br/></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM 1. FINANCIAL STATEMENTS</span></div><div><a id="s2733B17D3F585BB4A23423774B556764"></a></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">Emergent BioSolutions Inc. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#000000;font-weight:bold;">Condensed Consolidated Balance Sheets</span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#000000;font-weight:bold;">(unaudited, in millions, except per share amounts)</span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:61%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:middle;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#ffffff;">March&#160;31, 2020</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#ffffff;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ASSETS</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current assets:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#ededed;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17799691e723-wk-Fact-73115F8A6D878C47A0EB50AC63D25B5C" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">181.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17799691e741-wk-Fact-E7531639DF62C4543F8750AC63E073A0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">167.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restricted cash</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17799691e756-wk-Fact-9C3A03D295A31EBA495650AC63AEC122" name="us-gaap:RestrictedCashCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17799691e774-wk-Fact-A58135F386AA24C78D2950AC63D6C50B" name="us-gaap:RestrictedCashCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts receivable, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17799691e794-wk-Fact-33FB468D40ED33E2CA7E50AC63CE721D" name="us-gaap:AccountsReceivableNetCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">162.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17799691e812-wk-Fact-BF3721EEB20B5C10A7E650AC63C709EB" name="us-gaap:AccountsReceivableNetCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">270.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventories</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17799691e832-wk-Fact-F091EAB5DDEA37D108C650AC63DA852F" name="us-gaap:InventoryNet" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">248.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17799691e850-wk-Fact-ED5377811E6E36E4601D50AC63CE5708" name="us-gaap:InventoryNet" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">222.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax receivable, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17799691e870-wk-Fact-54837CD9CFA375A403F350AC63DCFB89" name="us-gaap:IncomeTaxesReceivable" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17799691e888-wk-Fact-4FB79AF7A858A2341DA950AC63D4374E" name="us-gaap:IncomeTaxesReceivable" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17799691e908-wk-Fact-4721DEFE865038E6CADF79E1416AFA2A" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">24.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17799691e926-wk-Fact-0759214C7B45FD29009B50AC63AE075A" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">20.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total current assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17799691e946-wk-Fact-FE7B86C0506DA35877F150AC63A5334C" name="us-gaap:AssetsCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">626.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17799691e965-wk-Fact-A81A28E49D8C32EC9A2550AC63BBA07D" name="us-gaap:AssetsCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">686.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17799691e1027-wk-Fact-99ED5AE3E83E32B0A84150AC63E1866C" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">549.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17799691e1045-wk-Fact-1C28759FD7611ABEF76950AC6399C4F9" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">542.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17799691e1065-wk-Fact-B49A570526091681767C50AC63B1DD0D" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">708.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17799691e1083-wk-Fact-72A979EF03E562242D1450AC63AB4C9C" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">712.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17799691e1103-wk-Fact-4D5C23166D2307F0819050AC63ACCEE2" name="ebs:InProcessResearchAndDevelopment" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">29.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17799691e1121-wk-Fact-DB0D64C1BA6FEF98588750AC63AC530A" name="ebs:InProcessResearchAndDevelopment" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">29.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17799691e1141-wk-Fact-F9685A10CF0BB5F123BD9E6E56E0368A" name="us-gaap:Goodwill" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">266.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17799691e1159-wk-Fact-4537F01ABBB58F8704CB9E6E57053B1F" name="us-gaap:Goodwill" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">266.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred tax assets, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17799691e1179-wk-Fact-3FD72E9203D87B35604950AC63A38852" name="us-gaap:DeferredIncomeTaxAssetsNet" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">17.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17799691e1197-wk-Fact-66C2214084B3C924149F50AC63DD3211" name="us-gaap:DeferredIncomeTaxAssetsNet" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17799691e1217-wk-Fact-68E09D3467BF5A071DDC50AC63A841FE" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">81.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17799691e1235-wk-Fact-70D0BD6868EF8CFCB83750AC63E2E56D" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">76.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total assets</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17799691e1260-wk-Fact-8289105D534674239F6D50AC63E0297E" name="us-gaap:Assets" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,278.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17799691e1279-wk-Fact-B9A72825751718913BFC50AC63A12F40" name="us-gaap:Assets" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,327.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">LIABILITIES AND STOCKHOLDERS' EQUITY</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#ededed;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17799691e1422-wk-Fact-5192F8833539EFE2FB2150AC63B30B21" name="us-gaap:AccountsPayableCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">84.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17799691e1440-wk-Fact-80EABBBC6372D24F543050AC63A7397A" name="us-gaap:AccountsPayableCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">94.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17799691e1456-wk-Fact-C32DE5D5524B841DAD5850AC63E3C74F" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">41.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17799691e1474-wk-Fact-64582B022E3416FE1E3150AC63D4C29F" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">39.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued compensation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17799691e1494-wk-Fact-131921BFC22FDD16BE0650AC63B32091" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">47.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17799691e1512-wk-Fact-F58E7639F289FFBAA84050AC63A6D5C3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">62.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Debt, current portion</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17799691e1532-wk-Fact-EDFB84F5BCBDDB3725A550AC63DD854B" name="us-gaap:NotesPayableCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">26.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17799691e1550-wk-Fact-8E23349626858D270DF850AC63A9DADA" name="us-gaap:NotesPayableCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17799691e1570-wk-Fact-891ECA6D8F117B66CDC150AC63A369E8" name="us-gaap:OtherLiabilitiesCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17799691e1588-wk-Fact-662DC37D9D46F2A55FA950AC63AEB68B" name="us-gaap:OtherLiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17799691e1608-wk-Fact-D2060A248A724782B40150AC63D7BDB7" name="us-gaap:LiabilitiesCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">207.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17799691e1627-wk-Fact-F83E9C8D0A81971D54C450AC63ACF606" name="us-gaap:LiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">216.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration, net of current portion</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17799691e1688-wk-Fact-3525AFAA6E6B6428C6C779E141549F48" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">26.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17799691e1706-wk-Fact-9675E09614563F7AB24050AC63D6EE1D" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">26.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Debt, net of current portion</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17799691e1726-wk-Fact-71761EF4F2817FB54EF079E14164F9D7" name="us-gaap:LongTermDebtNoncurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">762.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17799691e1744-wk-Fact-64FB9723C0B0F0E7FB3A50AC639B2838" name="us-gaap:LongTermDebtNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">798.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred tax liability</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17799691e1764-wk-Fact-AF42ABBED13CCD4BEA3A79E1415FD331" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">63.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17799691e1782-wk-Fact-AF95766366587A01D21E50AC639B65EA" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">63.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contract liabilities, net of current portion</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17799691e1802-wk-Fact-E83B41BBD8F6FA973F4A79E14170DCE4" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">85.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17799691e1820-wk-Fact-97288A5C7A024691416E50AC63BB628B" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">85.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17799691e1840-wk-Fact-16A4886E2C7D095CD6E379E141762975" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">58.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17799691e1858-wk-Fact-24CF32C26102222BC0DC50AC63C4DC4F" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">48.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17799691e1884-wk-Fact-A3E6250EB4CC9585AC7C50AC63DD6486" name="us-gaap:Liabilities" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,203.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17799691e1903-wk-Fact-FAFC0EBAE0F639F0D4DC50AC63E475E8" name="us-gaap:Liabilities" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,238.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stockholders' equity:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Preferred stock, $0.001 par value; 15.0 shares authorized, no shares issued or outstanding</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17799691e1995-wk-Fact-6E0CE4CF2FF543719D2550AC63BB49B1" name="us-gaap:PreferredStockValue" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17799691e2013-wk-Fact-06458A77AC6860E6C17750AC63D9EDE3" name="us-gaap:PreferredStockValue" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Common stock, $0.001 par value; 200.0 shares authorized, 53.5 and 53.0 shares issued; 52.3  and 51.7 shares outstanding, respectively</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17799691e2033-wk-Fact-0DD964487A8EED7993AB50AC63BB9605" name="us-gaap:CommonStockValue" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17799691e2051-wk-Fact-2991BD9296A4754091F950AC63C80B24" name="us-gaap:CommonStockValue" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Treasury stock, at cost, 1.2 common shares</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d17799691e2071-wk-Fact-B1AA53C2F1975AECAF0C50AC63DC1B9E" name="us-gaap:TreasuryStockValue" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">39.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d17799691e2090-wk-Fact-339985F5A48334107D9A50AC63BBF1A5" name="us-gaap:TreasuryStockValue" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">39.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additional paid-in capital</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17799691e2111-wk-Fact-B09F55E52E0C2B00D7E150AC63D9E7EE" name="us-gaap:AdditionalPaidInCapital" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">726.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17799691e2129-wk-Fact-FD222C34C01EB0E1DF9550AC639FFF95" name="us-gaap:AdditionalPaidInCapital" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">716.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accumulated other comprehensive loss, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d17799691e2149-wk-Fact-75D07BE3D88B6FE7C68450AC63DC6586" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">21.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d17799691e2168-wk-Fact-D974F7E588DC56BC76D650AC63A42F69" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">9.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Retained earnings</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17799691e2189-wk-Fact-8D2C5E2E86A0799FBE1F50AC63B36413" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">409.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17799691e2207-wk-Fact-E4D7E53D3B0CEBC5BD9350AC63BBCB15" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">421.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total stockholders' equity</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17799691e2227-wk-Fact-D7815A59ED29A9FB7CCF50AC63D5C63B" name="us-gaap:StockholdersEquity" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,074.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17799691e2245-wk-Fact-F4507548E8C1AB00D3DA50AC63B454D8" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,088.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total liabilities and stockholders' equity</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ededed;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17799691e2270-wk-Fact-A70AE53866C3EB44BA6150AC63C7EEA9" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,278.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17799691e2288-wk-Fact-192D80C3CBA4B307C85250AC63D2B93D" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,327.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;">See accompanying notes.</span></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">5</span></div></div><hr style="page-break-after:always"></hr><div><a id="sA94E90EF9CFB5E1EA187AB94AD342267"></a></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">Emergent BioSolutions Inc. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#000000;font-weight:bold;">Condensed Consolidated Statements of Operations</span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#000000;font-weight:bold;">(unaudited, in millions, except per share amounts)</span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:63%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:middle;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Three Months Ended March&#160;31,</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2020</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product sales, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17799136e723-wk-Fact-15F576BF23B68ED3410550AC63B6D635" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">148.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17799136e741-wk-Fact-100EA167C32CD4E7BF7F50AC63C22D94" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">153.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contract development and manufacturing services</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17799136e756-wk-Fact-C945A823FC8AB77DBA5A50AC63C78AD8" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">21.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17799136e774-wk-Fact-86B8A67AE3A5069C980750AC63B51F29" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contracts and grants</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17799136e794-wk-Fact-3612644390F14B60C4B550AC63CA1285" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">22.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17799136e812-wk-Fact-8EAC98B280127C3147AA50AC63C5A1FF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">21.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17799136e832-wk-Fact-EE62D36AAC76E41DE0BE50AC63C826F6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">192.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17799136e851-wk-Fact-4783103E7C9579FDD76750AC63CB769E" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">190.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost of product sales and contract development and manufacturing services</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17799136e952-wk-Fact-BA336E685E86F57C6D0D50AC63B4634B" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">76.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17799136e970-wk-Fact-0BC613ED4D26B153FA5650AC63BA8BFC" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">91.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17799136e990-wk-Fact-2B8E60DC76A9801A1FE950AC63B1087D" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">42.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17799136e1008-wk-Fact-7BEDB621BDB5A994783B50AC63BA77D6" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">46.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17799136e1029-wk-Fact-4600FDC44E9E0418798B50AC63BB32E0" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">69.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17799136e1047-wk-Fact-78C0CF404ADD5B797E5650AC63C1B641" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">65.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization of intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17799136e1067-wk-Fact-20A4A30F776CD2C76C8050AC63AE3F61" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17799136e1085-wk-Fact-BCD7D8B56A51DBB9F81E50AC63C5640D" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total operating expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17799136e1105-wk-Fact-90E0AEBB8A82E78B6F5A50AC63C007FD" name="us-gaap:OperatingCostsAndExpenses" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">204.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17799136e1124-wk-Fact-BBD73BF964A9A45FC8CF50AC63C21AA2" name="us-gaap:OperatingCostsAndExpenses" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">217.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Loss from operations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d17799136e1184-wk-Fact-104EC02A9D5162DADE0950AC63C8F1B3" name="us-gaap:OperatingIncomeLoss" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">11.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d17799136e1203-wk-Fact-2DCE31345877D0C7E09E50AC63CA3397" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">27.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other (expense) income:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d17799136e1305-wk-Fact-C924066F66385D680AF19E4630872773" name="us-gaap:InterestExpense" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d17799136e1324-wk-Fact-75106F69A5C39D9D72E750AC63BB0DE2" name="us-gaap:InterestExpense" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other expense, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d17799136e1345-wk-Fact-4E3D23064239778474469E4630A5BC2F" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">1.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d17799136e1364-wk-Fact-A68B5F700B16A2E9A41850AC63AD7A24" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">1.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other expense, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d17799136e1385-wk-Fact-D76206CE7E7977D824CD9E4630A15853" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">9.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d17799136e1405-wk-Fact-600160C34CC7B2DF82189E46309AF484" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">10.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Loss before provision for income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d17799136e1467-wk-Fact-550E5D1D072394C5C60050AC63AF1195" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">21.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d17799136e1486-wk-Fact-7EC256BDE4B0C851EC3350AC63C6FFB9" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">37.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17799136e1507-wk-Fact-3112495982BCF3C558E450AC63AAAA8E" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">8.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17799136e1525-wk-Fact-DD6E636C0FAA0013733950AC63AAA28D" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">11.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d17799136e1550-wk-Fact-2BE66961830A83F48E5050AC63AB2A6D" name="us-gaap:NetIncomeLoss" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">12.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d17799136e1570-wk-Fact-68AB7F5A194EFA0424DB50AC63CA9408" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">26.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net loss per common share</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d17799136e1673-wk-Fact-92317C4056EAA9BE7F9C50AC63C0B75A" name="us-gaap:EarningsPerShareBasic" contextRef="FD2020Q1YTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.24</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d17799136e1693-wk-Fact-398962EC77284B56EAE350AC63CB3AD7" name="us-gaap:EarningsPerShareBasic" contextRef="FD2019Q1QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.51</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d17799136e1714-wk-Fact-F4635BF4F58F1DABA08450AC63C76B0E" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2020Q1YTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.24</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d17799136e1734-wk-Fact-3F3AD90A570B8318774450AC63B12D21" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2019Q1QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.51</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares used in computing loss per share</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17799136e1791-wk-Fact-86AA0904084337CA20DD50AC63BB987B" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2020Q1YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">52.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17799136e1809-wk-Fact-E5106EB7EC5DD52FFE1750AC63AAA0C9" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2019Q1QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">51.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17799136e1829-wk-Fact-FE0D54A71F3B22F2C1A650AC63BB0266" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2020Q1YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">52.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17799136e1847-wk-Fact-025C9BBD3873347BD04350AC63AAE1F5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2019Q1QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">51.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;">See accompanying notes.</span></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">6</span></div></div><hr style="page-break-after:always"></hr><div><a id="s1C90156C7DC2502D8654AC8C2AB720B2"></a></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">Emergent BioSolutions Inc. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#000000;font-weight:bold;">Condensed Consolidated Statements of Comprehensive Income</span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#000000;font-weight:bold;">(unaudited, in millions)</span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:0%;"></td><td style="width:63%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td><span>&#160;</span></td><td style="vertical-align:middle;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Three Months Ended March&#160;31,</span></div></td></tr><tr><td><span>&#160;</span></td><td style="vertical-align:middle;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2020</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2019</span></div></td></tr><tr><td><span>&#160;</span></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d17800287e681-wk-Fact-2BE66961830A83F48E5050AC63AB2A6D" name="us-gaap:NetIncomeLoss" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">12.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d17800287e701-wk-Fact-68AB7F5A194EFA0424DB50AC63CA9408" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">26.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td><span>&#160;</span></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive (loss) income, net of tax:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td><span>&#160;</span></td><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign currency translation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d17800287e756-wk-Fact-A53862397182309EA63A50AC63E001ED" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17800287e776-wk-Fact-96B2693D63C32DF527C850AC63C28C3C" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td><span>&#160;</span></td><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized losses on hedging activities, net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d17800287e796-wk-Fact-BFD2CECA667105B62EBC50AC63C41C07" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">11.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17800287e816-wk-Fact-15377C4CBC8E47785A2150AC63C79933" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td><span>&#160;</span></td><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized losses on pension benefit obligation, net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17800287e836-wk-Fact-86FFD151DC1F2E6E0C2C50AC63C33BCA" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d17800287e855-wk-Fact-F5F2648BC2AD1B5A0A9B50AC63BB0174" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td><span>&#160;</span></td><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other comprehensive (loss) income, net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d17800287e876-wk-Fact-2AF3E574CF6A3F51147E50AC63C7A17E" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">11.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17800287e896-wk-Fact-EF2F7C8B369F4438E69250AC63D50C89" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td><span>&#160;</span></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Comprehensive loss</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d17800287e921-wk-Fact-E321E1C6CE0BC0C66B0350AC63DD188F" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">23.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d17800287e941-wk-Fact-8EC54BB1C591FEA38E0E50AC63E5F501" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">25.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td><span>&#160;</span></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td><span>&#160;</span></td><td colspan="8" rowspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the three months ended March 31, 2020, there were tax benefits related to unrealized losses on hedging activities of $2.8 million and tax losses related to foreign currency translations that were de minimus. During the three months ended March 31, 2019, the tax effects of the amounts presented were de minimus. </span></div></td></tr><tr><td><span>&#160;</span></td></tr><tr><td><span>&#160;</span></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;">See accompanying notes.</span></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">7</span></div></div><hr style="page-break-after:always"></hr><div><a id="s20968007722D5EE6BEF725CADE7CC4F7"></a></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">Emergent BioSolutions Inc. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#000000;font-weight:bold;">Condensed Consolidated Statements of Cash Flows</span></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#000000;font-weight:bold;">(unaudited, in millions)</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:63%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:middle;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;</span></div></td><td colspan="7" style="vertical-align:middle;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2020</span></div></td><td style="vertical-align:middle;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:middle;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash flows provided by operating activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d17802373e721-wk-Fact-2BE66961830A83F48E5050AC63AB2A6D" name="us-gaap:NetIncomeLoss" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">12.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d17802373e741-wk-Fact-68AB7F5A194EFA0424DB50AC63CA9408" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">26.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments to reconcile net loss to net cash provided by operating activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17802373e798-wk-Fact-739507C483111AB19B8B50AC639F00E6" name="us-gaap:ShareBasedCompensation" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17802373e817-wk-Fact-72D70E05B77F63E1B16550AC63DC057D" name="us-gaap:ShareBasedCompensation" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17802373e837-wk-Fact-1DE51309ACCFE8B283B250AC63E3A642" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">28.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17802373e856-wk-Fact-F57F9DA62263F8628FC750AC63E235DA" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">26.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization of deferred financing costs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17802373e876-wk-Fact-60091772919504C1FC7250AC63A1DE52" name="us-gaap:AmortizationOfFinancingCosts" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17802373e895-wk-Fact-6362222B217449806E6850AC63DAEF07" name="us-gaap:AmortizationOfFinancingCosts" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d17802373e915-wk-Fact-3F6E0290413999EC3F1850AC63DD34AE" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">4.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d17802373e935-wk-Fact-32531DA821298C43466C50AC63DD51B3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">11.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Change in fair value of contingent consideration, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17802373e956-wk-Fact-6EBBCA15A2A26C796ACD50AC63E0DD30" name="ebs:ChangeInFairValueOfContingentConsideration" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17802373e975-wk-Fact-179F8013B589BE02F28C50AC63A6022B" name="ebs:ChangeInFairValueOfContingentConsideration" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17802373e995-wk-Fact-980561FB9B0682BC55F850AC639BFCB7" name="us-gaap:OtherNoncashIncomeExpense" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d17802373e1014-wk-Fact-76F4B60F1C885A21A34A50AC63DB0B22" name="us-gaap:OtherNoncashIncomeExpense" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in operating assets and liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts receivable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17802373e1077-wk-Fact-9459167624DEEA3EF92F50AC63E60698" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">108.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17802373e1096-wk-Fact-D0F9804277606C7DB99C50AC63A37980" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">141.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventories</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d17802373e1116-wk-Fact-11A15607E213184500C750AC63DB4BBF" name="us-gaap:IncreaseDecreaseInInventories" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">25.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d17802373e1136-wk-Fact-0A4207CA36C06EE1370750AC63DDC92C" name="us-gaap:IncreaseDecreaseInInventories" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Prepaid expenses and other assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d17802373e1157-wk-Fact-9CF3C0B60DCFCBD3A03E50AC639B2D9C" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d17802373e1177-wk-Fact-F92A9D5670BB1F6AD5A250AC63E4AABE" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts payable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d17802373e1198-wk-Fact-4A4823A9A2368E86DA7C50AC63A75481" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">15.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17802373e1218-wk-Fact-668FD98B48F825D37C1050AC63A5CF39" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17802373e1238-wk-Fact-F8D4040486E74D0F56D850AC63E10862" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17802373e1257-wk-Fact-C1CFA3CA308F03407DB850AC63DDE506" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued compensation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d17802373e1277-wk-Fact-985655A1E0A46438DFF450AC63E005F7" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">14.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d17802373e1297-wk-Fact-56288A6590BC4AAD092C50AC63A50B76" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">21.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contract liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17802373e1318-wk-Fact-4074E36C6BD07D24A66D50AC639B577A" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17802373e1337-wk-Fact-5A15EA545F7122AA207B50AC63DA2EBE" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash provided by operating activities:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;font-weight:bold;"><span><ix:nonFraction id="d17802373e1357-wk-Fact-12CB37B34743CE077A9650AC63A50D41" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">57.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17802373e1376-wk-Fact-908BC741591EB58CAC9C50AC639BE65F" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">104.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash flows used in investing activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchases of property, plant and equipment and other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d17802373e1437-wk-Fact-C4AFBE1D5DFF313E0CD750AC63A01EB8" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">24.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d17802373e1457-wk-Fact-732CB60DEDF9689506C150AC639F2F30" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">21.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:48px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash used in investing activities:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d17802373e1479-wk-Fact-EBD36A64FC50C88B684750AC63A38736" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">24.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d17802373e1499-wk-Fact-E8A65B1CE6618CD6331350AC63DA4D9A" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">21.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash flows used in financing activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from revolving credit facility</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17802373e1561-wk-Fact-036411553056CA6996B350AC63DDEC95" name="us-gaap:ProceedsFromLinesOfCredit" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17802373e1580-wk-Fact-71CF40DA3FB2333B635A50AC63E302FE" name="us-gaap:ProceedsFromLinesOfCredit" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">30.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Principal payments on revolving credit facility</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d17802373e1600-wk-Fact-84D8CAE601269854BDBC50AC63DBE614" name="us-gaap:RepaymentsOfLinesOfCredit" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">20.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d17802373e1620-wk-Fact-2367615F6A83A7B4F98450AC63E25A92" name="us-gaap:RepaymentsOfLinesOfCredit" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">80.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Principal payments on term loan facility</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d17802373e1641-wk-Fact-54AE99CC8E559401E7A550AC63DDA262" name="us-gaap:RepaymentsOfMediumTermNotes" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d17802373e1661-wk-Fact-B31B4A9B1A704D1DBBA550AC639B9EA3" name="us-gaap:RepaymentsOfMediumTermNotes" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from issuance of common stock upon exercise of stock options</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17802373e1682-wk-Fact-34DA41A6E4F450796D1550AC63E0A588" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17802373e1701-wk-Fact-7F56B3B8D7B35376C44850AC63E0029D" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Taxes paid on behalf of employees for equity activity</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d17802373e1721-wk-Fact-AC2FA75F6595AFA8434250AC63A2187F" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d17802373e1741-wk-Fact-44DD65CE9AD52BB3136450AC63DD6DDA" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration payments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d17802373e1762-wk-Fact-BA3A647EC1AE184FBD8F50AC63A1AD11" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d17802373e1782-wk-Fact-A4EB44574B1685CD5E4D50AC63DDDD9F" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash used in financing activities:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d17802373e1803-wk-Fact-F3B22C6688A93B448A1F50AC63E2BACD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">20.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d17802373e1823-wk-Fact-7A9AC0C6101EB8EF9C9E50AC639AA02D" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">58.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effect of exchange rate changes on cash, cash equivalents and restricted cash</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17802373e1844-wk-Fact-ECB7C97F0886EE5A70A350AC63DC0249" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17802373e1863-wk-Fact-A872686DD763EFA2AA8250AC63DACEAB" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net increase in cash, cash equivalents and restricted cash</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17802373e1883-wk-Fact-AE7424ECD1DE706F27AD50AC63E4FF53" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17802373e1902-wk-Fact-137055F36063B1BBA4BE50AC639BB8DC" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">25.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash, cash equivalents and restricted cash at beginning of period</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17802373e1923-wk-Fact-1482B415680B1E1FEDA650AC63A4C847" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">168.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17802373e1942-wk-Fact-A16160C5AF27529784EF50AC639F139D" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">112.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash, cash equivalents and restricted cash at end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17802373e1967-wk-Fact-2F58183E8D39BA6B17BC79D8CF0E2E3F" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">181.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17802373e1986-wk-Fact-84DDE874EEA34BD29B9F50AC63A4C53B" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2019Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">137.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Supplemental disclosure of cash flow information: </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash paid during the period for interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17802373e2047-wk-Fact-245A8E2E59D47D8CB64979D69CA6EE92" name="us-gaap:InterestPaidNet" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17802373e2066-wk-Fact-5780A12AEABD58AC2D5379D69C94248F" name="us-gaap:InterestPaidNet" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash paid during the period for income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17802373e2086-wk-Fact-899CD2D46D2D60EAD1DA79D6D6FD0EB6" name="us-gaap:IncomeTaxesPaid" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17802373e2105-wk-Fact-F434AB870E0433BA6EF279D6D71DEB1D" name="us-gaap:IncomeTaxesPaid" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Supplemental information on non-cash investing and financing activities: </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchases of property, plant and equipment unpaid at period end</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17802373e2166-wk-Fact-4B5741A19C409247ACD979D742C8A374" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17802373e2185-wk-Fact-98754DB7C539952D509079D742D0F656" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reconciliation of cash and cash equivalent and restricted cash at March 31, 2020 and December 31, 2019:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17802373e2246-wk-Fact-73115F8A6D878C47A0EB50AC63D25B5C" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">181.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17802373e2265-wk-Fact-E7531639DF62C4543F8750AC63E073A0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">167.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restricted cash</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17802373e2285-wk-Fact-9C3A03D295A31EBA495650AC63AEC122" name="us-gaap:RestrictedCashCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17802373e2299-wk-Fact-A58135F386AA24C78D2950AC63D6C50B" name="us-gaap:RestrictedCashCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17802373e2324-wk-Fact-2F58183E8D39BA6B17BC79D8CF0E2E3F" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">181.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17802373e2343-wk-Fact-1482B415680B1E1FEDA650AC63A4C847" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">168.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;">See accompanying notes.</span></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">8</span></div></div><hr style="page-break-after:always"></hr><div><a id="s9E7BB9E21BC7561B8EAB5C00C4ED0A71"></a></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">Emergent BioSolutions Inc. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#000000;font-weight:bold;">Condensed Consolidated Statements of Changes in Stockholders' Equity</span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#000000;font-weight:bold;">(unaudited, in millions)</span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="31"></td></tr><tr><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">$0.001 Par Value Common Stock</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Additional Paid-In Capital</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Treasury Stock</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Accumulated Other Comprehensive Loss</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Retained Earnings</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Total Stockholders' Equity</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Shares</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Amount</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Shares</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Amount</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance at December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17805435e1098-wk-Fact-ABE00B4C79A85CA4568250AC63D83265" name="us-gaap:CommonStockSharesIssued" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="6" format="ixt:numdotdecimal">53.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17805435e1117-wk-Fact-CC8EE6D21DBA8ED50E3CB9BCA88E58F1" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17805435e1136-wk-Fact-E168E6F27F6A8A384EFB50AC63E0E4E5" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">716.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d17805435e1151-wk-Fact-D92478E35B9CF94EF99750AC63CEA000" name="us-gaap:CommonStockSharesIssued" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="INF" scale="6" format="ixt:numdotdecimal">1.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d17805435e1171-wk-Fact-8227D790086ECFD37B1150AC639BBC63" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">39.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d17805435e1191-wk-Fact-846F395BCB065E297E2750AC639BFA1D" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">9.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17805435e1212-wk-Fact-242D143308EE9EC0D8E250AC63A8B267" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">421.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17805435e1231-wk-Fact-F4507548E8C1AB00D3DA50AC63B454D8" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,088.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee equity plans activity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17805435e1251-wk-Fact-9F33978D20311C8C656150AC63BB5368" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17805435e1284-wk-Fact-F1D2E901C655DBA2EBD5B9BCA87645AA" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17805435e1318-wk-Fact-9ADC20BDFC008F7984EB50AC63BBE3E0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17805435e1376-wk-Fact-CBD9A0543FD6D6FC32DEB9BCA8834E58" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d17805435e1507-wk-Fact-FA2798FC4BC99383B7DE50AC63AC5038" name="us-gaap:NetIncomeLoss" contextRef="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">12.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d17805435e1527-wk-Fact-2BE66961830A83F48E5050AC63AB2A6D" name="us-gaap:NetIncomeLoss" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">12.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d17805435e1639-wk-Fact-80DDB522CA293FEF2FC2B9BCA893D055" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">11.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d17805435e1679-wk-Fact-2AF3E574CF6A3F51147E50AC63C7A17E" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">11.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance at March&#160;31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17805435e1705-wk-Fact-273068F1982C62A6992D50AC63CDCC26" name="us-gaap:CommonStockSharesIssued" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="6" format="ixt:numdotdecimal">53.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17805435e1724-wk-Fact-10BE38BE28444D67433350AC63CBBBA2" name="us-gaap:StockholdersEquity" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17805435e1743-wk-Fact-D6CFBD9DCC5476F28C80B9BCA898DBCD" name="us-gaap:StockholdersEquity" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">726.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d17805435e1758-wk-Fact-74862663C92A269A7B9E50AC63CB06EA" name="us-gaap:CommonStockSharesIssued" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="INF" scale="6" format="ixt:numdotdecimal">1.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d17805435e1778-wk-Fact-04596E6BA9E26B10608E50AC639B3101" name="us-gaap:StockholdersEquity" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">39.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d17805435e1798-wk-Fact-E1F20C5A2968660CACE7B9BCA8A8AB58" name="us-gaap:StockholdersEquity" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">21.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17805435e1819-wk-Fact-6FB7700C7B0F47E7FC2A50AC63CB7872" name="us-gaap:StockholdersEquity" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">409.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17805435e1838-wk-Fact-D7815A59ED29A9FB7CCF50AC63D5C63B" name="us-gaap:StockholdersEquity" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,074.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance at December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17805435e2174-wk-Fact-5D2567B870B3DA58A16A50AC63CD56F7" name="us-gaap:CommonStockSharesIssued" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="6" format="ixt:numdotdecimal">52.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17805435e2193-wk-Fact-4C034EF0D3338A29366350AC63AA4678" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17805435e2212-wk-Fact-E02D12257B0932DBBCCE50AC63D95918" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">688.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d17805435e2227-wk-Fact-95DC7D1CC9CC6FE5E13E50AC63E2B78D" name="us-gaap:CommonStockSharesIssued" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="INF" scale="6" format="ixt:numdotdecimal">1.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d17805435e2247-wk-Fact-1A1ABC6942C3B10BE9C350AC63BB7E36" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">39.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d17805435e2267-wk-Fact-40639A081310045BBA2850AC63A37C99" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">5.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17805435e2288-wk-Fact-4E9C2D54D4F142CDEC4C50AC63E4DF55" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">367.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17805435e2307-wk-Fact-E97D7327996A8B104B2A50AC63D0AD3F" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,010.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee equity plans activity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17805435e2328-wk-Fact-DED4E400BF9308F35F8650AC63E10BBB" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17805435e2359-wk-Fact-A7BEF91734CC07C8AA8B50AC639BA350" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17805435e2391-wk-Fact-9309807C000204E3979D50AC63A06930" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17805435e2446-wk-Fact-5DA03859615691BD457F50AC63D2BC44" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d17805435e2571-wk-Fact-480139014EC63EE487AB50AC63C9CB39" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">26.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d17805435e2590-wk-Fact-68AB7F5A194EFA0424DB50AC63CA9408" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">26.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17805435e2697-wk-Fact-81CDEC6B9B9234EFDE0B50AC63AEA6DD" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17805435e2734-wk-Fact-EF2F7C8B369F4438E69250AC63D50C89" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance at March&#160;31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17805435e2759-wk-Fact-214DBE4CBE85DBC2E60A50AC63B1A751" name="us-gaap:CommonStockSharesIssued" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="6" format="ixt:numdotdecimal">52.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17805435e2777-wk-Fact-F936351DECCF51FC1CC750AC63CF5F4E" name="us-gaap:StockholdersEquity" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17805435e2795-wk-Fact-8C4C79E98FB5423C622850AC63A2FF79" name="us-gaap:StockholdersEquity" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">690.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d17805435e2809-wk-Fact-CBACD24C8F887A547D0350AC63CD6A0F" name="us-gaap:CommonStockSharesIssued" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="INF" scale="6" format="ixt:numdotdecimal">1.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d17805435e2828-wk-Fact-F615E3A3E6D641BAE4A450AC63ABFEEB" name="us-gaap:StockholdersEquity" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">39.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d17805435e2847-wk-Fact-6F53647C31426785422050AC63A27CFB" name="us-gaap:StockholdersEquity" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">4.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17805435e2867-wk-Fact-98F004FB159337762E5B50AC63DD6FA9" name="us-gaap:StockholdersEquity" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">341.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17805435e2885-wk-Fact-BB6829A3D98510B088A450AC63D6C3F0" name="us-gaap:StockholdersEquity" contextRef="FI2019Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">987.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:normal;">See accompanying notes.</span></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">9</span></div></div><hr style="page-break-after:always"></hr><div><a id="sBF91395DF12C51EBB4EC3EB02EB18CFD"></a></div><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">(unaudited, in millions, except share and per share amounts)</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;"><br/></span></div><div><a id="sEEACD257584A5872ABD475DB5A8C15D8"></a></div><div style="line-height:120%;padding-bottom:12px;font-size:11pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="TextSelection-83848454B326B83E353750AC63F1EC2C-0-wk-Fact-246B6739011B3AABBCCE50AC63D4F9BF" continuedAt="TextSelection-83848454B326B83E353750AC63F1EC2C-1" escape="true">Business</ix:nonNumeric></span></div><ix:continuation id="TextSelection-83848454B326B83E353750AC63F1EC2C-1" continuedAt="TextSelection-83848454B326B83E353750AC63F1EC2C-2"><div style="line-height:120%;padding-bottom:12px;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Organization and business</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">Emergent BioSolutions Inc. (the "Company" or "Emergent") is a global life sciences company focused on providing civilian and military populations a portfolio of innovative preparedness and response products and solutions that address accidental, deliberate and naturally occurring public health threats ("PHTs," each a &#8220;PHT&#8221;).</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">The Company is focused on the following </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"><span><ix:nonFraction id="d17805584e579-wk-Fact-A0A2BDF6C42B23FF549850AC63D1E890" name="ebs:NumberOfCategoriesOfPublicHealthThreats" contextRef="FD2020Q1YTD" unitRef="category" decimals="INF" scale="0" format="ixt-sec:numwordsen">six</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> distinct PHT categories: Chemical, Biological, Radiological, Nuclear and Explosives ("CBRNE"); emerging infectious diseases ("EID"); travel health; </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">emerging health crises; acute/emergency care, and contract development and manufacturing ("CDMO")</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">. The Company has a product portfolio of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"><span><ix:nonFraction id="d17805584e587-wk-Fact-09821EF7F9824557603FB7E29D9BB39D" name="ebs:NumberOfRevenueGeneratingProducts" contextRef="FD2020Q1YTD" unitRef="product" decimals="INF" scale="0" format="ixt-sec:numwordsen">ten</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> products and product candidates (vaccines, therapeutics, and drug-device combination products) that contribute a substantial portion of our revenue. The Company also has two product candidates that are procured under special circumstances by certain government agencies, although they are not approved by the FDA or any health agency. The U.S. government (the "USG') is the Company's largest customer and provides the Company with substantial funding for the development of a number of it</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">s product candidates.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">The Company's product portfolio includes:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;font-style:italic;text-decoration:underline;">Vaccines</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:5px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">&#9642;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">ACAM2000</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> (Smallpox (Vaccinia) Vaccine, Live), the only single-dose smallpox vaccine licensed by the FDA for active immunization against smallpox disease for persons determined to be at high risk for smallpox infection;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:5px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">&#9642;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">BioThrax</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> (Anthrax Vaccine Adsorbed), the only vaccine licensed by the U.S. Food and Drug Administration ("FDA"), for the general use prophylaxis and post-exposure prophylaxis of anthrax disease;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:5px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">&#9642;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">Vaxchora&#174; (Cholera Vaccine, Live, Oral), the only FDA-licensed vaccine for the prevention of cholera; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">&#9642;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">Vivotif&#174; (Typhoid Vaccine Live Oral Ty21a), the only oral vaccine licensed by the FDA for the prevention of typhoid fever.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;font-style:italic;text-decoration:underline;">Devices</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:5px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">&#9642;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">NARCAN&#174; (naloxone HCl) Nasal Spray, the first needle-free formulation of naloxone approved by the FDA and Health Canada, for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:5px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">&#9642;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">RSDL</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> (Reactive Skin Decontamination Lotion Kit), the only medical device cleared by the FDA to remove or neutralize the following chemical warfare agents from the skin: tabun, sarin, soman, cyclohexyl sarin, VR, VX, mustard gas and T-2 toxin; </span></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;font-style:italic;text-decoration:underline;">Therapeutics</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:5px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">&#9642;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">raxibacumab (Anthrax Monoclonal), the first fully human monoclonal antibody therapeutic licensed by the FDA for the treatment and prophylaxis of inhalational anthrax;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:5px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">&#9642;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">Anthrasil</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> (Anthrax Immune Globulin Intravenous (Human)), the only polyclonal antibody therapeutic licensed by the FDA and Health Canada for the treatment of inhalational anthrax;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:5px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">&#9642;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">BAT&#174; (Botulism Antitoxin Heptavalent (A,B,C,D,E,F,G)-(Equine)), the only heptavalent antibody therapeutic licensed by the FDA and Health Canada for the treatment of botulism; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">&#9642;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">VIGIV (Vaccinia Immune Globulin Intravenous (Human)), the only polyclonal antibody therapeutic licensed by the FDA and Health Canada to address certain complications from smallpox vaccination.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;font-style:italic;text-decoration:underline;">Product Candidates</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">&#9642;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">AV7909</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;  </sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">(Anthrax Vaccine Absorbed with Adjuvant), is a product candidate being developed as a next generation anthrax vaccine for post-exposure prophylaxis of disease resulting from suspected or confirmed Bacillus anthracis exposure. The USG has started procuring AV7909 for the Strategic National Stockpile (SNS) prior to its approval by the FDA and has been reducing its purchases of BioThrax as a result; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">&#9642;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">Trobigard&#174; is a combination drug-device auto-injector product candidate that contains atropine sulfate and obidoxime chloride. It has not been approved by the FDA or any similar health regulatory body, but it is procured </span></div></td></tr></table></ix:continuation><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">10</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">(unaudited, in millions, except share and per share amounts)</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-83848454B326B83E353750AC63F1EC2C-2"><div style="line-height:120%;padding-left:48px;padding-bottom:12px;text-align:justify;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">by certain authorized government buyers under special circumstances for potential use as a nerve agent countermeasure. </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">The Company also generates revenue from contract development and manufacturing services on a clinical and commercial (small and large) scale by providing such services to the pharmaceutical and biotechnology industry.&#160; These services include process development and bulk drug substance and drug product manufacturing of biologics, fill/finish formulation and analytical development services for injectable and other sterile products, inclusive of process design, technical transfer, manufacturing validations, aseptic filling, lyophilization, final packaging and stability studies, as well as manufacturing of vial and pre-filled syringe formats across bacterial, viral and mammalian therapy technology platforms. </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">The Company operates as </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"><span><ix:nonFraction id="d17805584e727-wk-Fact-D886683251CE85E78A9A50AC63D47DF7" name="us-gaap:NumberOfOperatingSegments" contextRef="FD2020Q1YTD" unitRef="segment" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">operating segment.</span></div></ix:continuation><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div><a id="s962865A52C745592B7A54E081898CE33"></a></div><div style="line-height:120%;padding-bottom:12px;font-size:11pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="TextSelection-511022022D53AA8F23A050AC63F111EC-0-wk-Fact-CA65C04E0271363D324F50AC63CD4C54" continuedAt="TextSelection-511022022D53AA8F23A050AC63F111EC-1" escape="true">Basis of Presentation and Principles of Consolidation</ix:nonNumeric></span></div><ix:continuation id="TextSelection-511022022D53AA8F23A050AC63F111EC-1" continuedAt="TextSelection-511022022D53AA8F23A050AC63F111EC-2"><div style="line-height:120%;padding-bottom:8px;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Basis of presentation </span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ConsolidationPolicyTextBlock" id="TextSelection-397B6AAF0A92F463659450AC63F1B2B9-0-wk-Fact-14E6AF8434DB2E74C66050AC63D07EA0" escape="true"><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">The accompanying unaudited condensed consolidated financial statements include the accounts of Emergent and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements included herein have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X issued by the SEC. Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">, as filed with the SEC.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">All adjustments contained in the accompanying unaudited condensed consolidated financial statements are of a normal recurring nature and are necessary to present fairly the financial position of the Company as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">. Interim results are not necessarily indicative of results that may be expected for any other interim period or for an entire year.</span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-style:normal;text-decoration:none;">Significant accounting policies</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">During the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">three months ended March 31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">, there have been no significant changes to the Company's summary of significant accounting policies contained in the Company's Annual Report on Form 10-K for the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">, as filed with the SEC.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-style:normal;text-decoration:none;">Fair value measurements</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="TextSelection-11330CC0B52BE73E273550AC63F1AEB2-0-wk-Fact-F7F57C61B75A989915CA50AC63D8FA1B" escape="true">Separate disclosure is required for assets and liabilities measured at fair value on a recurring basis from those measured at fair value on a non-recurring basis. The Company has cash held in money market accounts (level 1), contingent purchase consideration (level 3) and interest rate swaps arrangements (level 2) that are measured at fair value on a recurring basis (Note 7 and Note 8).</ix:nonNumeric> As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">, the Company held cash in money market accounts of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"><span>$<ix:nonFraction id="d17805776e629-wk-Fact-ACF0E9E8BC6FAA9A25355CEE99E0CA2B" name="us-gaap:MoneyMarketFundsAtCarryingValue" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">90.7</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"><span>$<ix:nonFraction id="d17805776e633-wk-Fact-C75BE7655975F3CD729DB7E3EF8F4D15" name="us-gaap:MoneyMarketFundsAtCarryingValue" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">52.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">, respectively. The Company also records the assets and liabilities of acquisitions at fair value. On a non-recurring basis, the Company measures its IPR&amp;D assets (level 3) using fair value measurements. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">, the Company had </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">no</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> other significant assets or liabilities that were measured at fair value. </span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">11</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">(unaudited, in millions, except share and per share amounts)</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-511022022D53AA8F23A050AC63F111EC-2" continuedAt="TextSelection-511022022D53AA8F23A050AC63F111EC-3"><div style="line-height:120%;padding-bottom:8px;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Recently issued accounting standards</span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="TextSelection-94C351BABA3BFD27A0F250AC63F11BF5-0-wk-Fact-CDC5C92C1FB553F0A1E750AC639B3E08" continuedAt="TextSelection-94C351BABA3BFD27A0F250AC63F11BF5-1" escape="true"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#0094ff;font-style:italic;text-decoration:underline;">Recently Adopted</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;">ASU 2016-13,&#160;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&#160;("ASU 2016-13")</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">In June 2016, the FASB issued ASU 2016-13. ASU 2016-13 provides guidance on measurement of credit losses on financial instruments that changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, held-to-maturity debt securities and loans, and that requires entities to use a new, forward-looking &#8220;expected loss&#8221; model that is expected to generally result in the earlier recognition of allowances for losses. The guidance&#160;became effective for annual periods beginning after December 15, 2019, including interim periods within those years. The Company adopted the standard as of January 1, 2020 and has evaluated the effects of this standard and determined that the adoption did not have a material impact on the Company's consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;">ASU 2018-13,&#160;Fair Value Measurement - Disclosure Framework (Topic 820)&#160;("ASU 2018-13")</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">In August 2018, the FASB issued ASU 2018-13. ASU 2018-13 improves the disclosure requirements on fair value measurements. The updated guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Early adoption is permitted for any removed or modified disclosures. The Company adopted the standard as of January 1, 2020 which has resulted in expanded disclosures around the Company's recurring level 3 fair value measurements. The disclosures are included in note 7 of the condensed consolidated financial statements. </span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;">ASU 2018-15,&#160;Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract ("ASU 2018-15")</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">In August 2018, the FASB issued ASU 2018-15. ASU 2018-15 clarifies the accounting for implementation costs in cloud computing arrangements. ASU 2018-15 is effective for all entities for fiscal years beginning after December 15, 2019. The Company adopted the standard as of January 1, 2020 and has evaluated the effects of this standard and determined that the adoption did not have a material impact on the Company's consolidated financial statements. </span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;">ASU 2017-4,&#160;Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment ("ASU 2017-4")</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">In January 2017, the FASB issued ASU 2017-4. ASU 2017-4 simplifies the subsequent measurement of goodwill and eliminates Step 2 from the goodwill impairment test. ASU 2017-4 is effective for annual and interim goodwill tests beginning after December 15, 2019. The Company's measurement period is September 30. The Company adopted the standard as of January 1, 2020 and has evaluated the effects of this standard and determined that the adoption will not have a material impact on the Company's consolidation financial statements. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#0094ff;font-style:italic;text-decoration:underline;">Not Yet Adopted</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;">ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">In March 2020, the FASB issued Topic 848. Topic 848 provides relief for impacted areas as it relates to impending reference rate reform. ASC 848 contains optional expedients and exceptions for applying US GAAP to debt arrangements, contracts, hedging relationships, and other areas or transactions that are impacted by reference rate reform. This guidance is effective for upon issuance for all entities and elections of certain optional expedients are required to apply the provisions of the guidance. The Company continues to assess all potential impacts of the standard and will disclose the nature and reason for any elections that the Company makes. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;">ASU 2018-14,&#160;Compensation -&#160;Retirement Benefits - Defined Benefit Plans - General (Topic 715-20):&#160;Disclosure Framework - Changes to the Disclosure Requirements for Defined Benefit Plans&#160;("ASU 2018-14")</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">In August 2018, the FASB issued ASU 2018-14. ASU 2018-14 modifies the disclosure requirements for defined benefit pension plans and other post-retirement plans. ASU 2018-14 is effective for all entities for fiscal years ending after December 15, 2020, and earlier adoption is permitted. The Company is currently evaluating the impact of adopting ASU 2018-14 on its consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">12</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">(unaudited, in millions, except share and per share amounts)</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-94C351BABA3BFD27A0F250AC63F11BF5-1"><ix:continuation id="TextSelection-511022022D53AA8F23A050AC63F111EC-3" continuedAt="TextSelection-511022022D53AA8F23A050AC63F111EC-4"><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;">ASU 2019-12, Simplifications to Accounting for Income Taxes ("ASU 2019-12")</span></div></ix:continuation><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"><ix:continuation id="TextSelection-511022022D53AA8F23A050AC63F111EC-4"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">In December 2019, the FASB issued ASU 2019-12. ASU 2019-12 removes certain exceptions for recognizing deferred taxes for investments, performing intra-period allocation and calculating income taxes in interim periods. The ASU also adds guidance to reduce complexity in certain areas, including deferred taxes for goodwill and allocating taxes for members of a consolidated group. ASU 2019-12 is effective for all entities for fiscal years beginning after December 15, 2020, and earlier adoption is permitted. The Company is currently evaluating the impact of adopting ASU 2019-12 on its consolidated financial statements.</span></ix:continuation><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> </span></div></ix:continuation><div><a id="s31293095C1F6549B8520893B124F18D3"></a></div><div style="line-height:120%;padding-bottom:12px;font-size:11pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:InventoryDisclosureTextBlock" id="TextSelection-AA6FECD7E6169A78688350AC63F27313-0-wk-Fact-D634668AFEE6A66A0D5750AC63D87F8B" continuedAt="TextSelection-AA6FECD7E6169A78688350AC63F27313-1" escape="true">Inventories</ix:nonNumeric></span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="TextSelection-1656B389C79112900FF450AC63F2CC23-0-wk-Fact-8BE5756A0EC972C7A3A950AC63D8B41F" escape="true"><ix:continuation id="TextSelection-AA6FECD7E6169A78688350AC63F27313-1"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">The components of inventory are as follows:</span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:61%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">March&#160;31, 2020</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Raw materials and supplies</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17806105e646-wk-Fact-058BB9D5B1E9C3059D6850AC63C01902" name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">77.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17806105e665-wk-Fact-AED6E5912C9A8A64084550AC63E6756D" name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">70.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Work-in-process</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17806105e680-wk-Fact-1D02B4370A92BA0DA2F650AC63C84CE7" name="us-gaap:InventoryWorkInProcessNetOfReserves" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">114.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17806105e699-wk-Fact-5FF461D0DBC0E6B9D77C50AC63E44B2F" name="us-gaap:InventoryWorkInProcessNetOfReserves" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">89.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Finished goods</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17806105e719-wk-Fact-36287B9BAFB1D8F6105A50AC63E3545E" name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">56.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17806105e738-wk-Fact-55AA2C10F441AA2AB7E550AC63E39FC4" name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">62.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventories</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17806105e763-wk-Fact-F091EAB5DDEA37D108C650AC63DA852F" name="us-gaap:InventoryNet" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">248.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17806105e782-wk-Fact-ED5377811E6E36E4601D50AC63CE5708" name="us-gaap:InventoryNet" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">222.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div></ix:continuation></ix:nonNumeric><div><a id="sC91EE2CCF29758DE8AB96FAFFE7E7523"></a></div><div style="line-height:120%;padding-bottom:12px;font-size:11pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="TextSelection-2075361569F8414EBE1C50AC63F22303-0-wk-Fact-E6C851553EAE049A2F2850AC63DA6421" continuedAt="TextSelection-2075361569F8414EBE1C50AC63F22303-1" escape="true">Property, plant and equipment</ix:nonNumeric></span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="TextSelection-28D8F4359059EE96455850AC63F253EE-0-wk-Fact-36098905452BF3C6323B50AC63DB590C" escape="true"><ix:continuation id="TextSelection-2075361569F8414EBE1C50AC63F22303-1"><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Property, plant and equipment consisted of the following:</span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:63%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">March&#160;31, 2020</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Land and improvements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17806698e646-wk-Fact-036CD9AE33310F76039950AC63CC5FFE" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2020Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandAndLandImprovementsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">46.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17806698e665-wk-Fact-7C945696B7199C4DF21D50AC63CB9A58" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandAndLandImprovementsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">46.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Buildings, building improvements and leasehold improvements</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17806698e680-wk-Fact-899A8B7428DCA941D07750AC639B11CE" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2020Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">242.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17806698e699-wk-Fact-1BC7EB05CEDF5E833B0450AC63CAA3E5" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">234.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Furniture and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17806698e719-wk-Fact-70E036CB4A200219E47250AC639A7907" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2020Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">340.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17806698e738-wk-Fact-C15EE064807EB17F347650AC63CE70D3" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">334.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Software</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17806698e758-wk-Fact-0270F0B3C67F0C61F39150AC63C6A3A3" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2020Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerSoftwareIntangibleAssetMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">55.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17806698e777-wk-Fact-09C32717A638DE0F32B650AC63D3005F" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerSoftwareIntangibleAssetMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">55.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Construction-in-progress</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17806698e797-wk-Fact-883FCB6A9EA4B6D5F4FB50AC63E28D68" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2020Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">86.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17806698e816-wk-Fact-BF86A09B6F07C6F6F1AC50AC63CAD2B4" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">81.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment, gross</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17806698e836-wk-Fact-8D9DD118FF47BE674B1950AC63D172EB" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">771.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17806698e855-wk-Fact-8712D1FDDA51130E554050AC63D7AE36" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">752.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accumulated depreciation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d17806698e875-wk-Fact-1C90626E08734D429EB250AC63D16D4F" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">221.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d17806698e895-wk-Fact-563733EFDFD672AA08D050AC63DD8913" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">210.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total property, plant and equipment, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17806698e921-wk-Fact-99ED5AE3E83E32B0A84150AC63E1866C" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">549.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17806698e940-wk-Fact-1C28759FD7611ABEF76950AC6399C4F9" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">542.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div></ix:continuation></ix:nonNumeric><div><a id="s02A1A04C7E225852A41CB2AC30A8C821"></a></div><div style="line-height:120%;padding-bottom:12px;font-size:11pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:LesseeOperatingLeasesTextBlock" id="TextSelection-6F7C699D521F1DE32BFD50AC63F24F35-0-wk-Fact-D5AC0C17BFBEA57BC2F350AC63DDBE52" continuedAt="TextSelection-6F7C699D521F1DE32BFD50AC63F24F35-1" escape="true"><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:LesseeFinanceLeasesTextBlock" id="TextSelection-11B2EBE071C4262D916150AC63F29E7E-0-wk-Fact-68A32D7FDF7707B2516050AC63DD4A28" continuedAt="TextSelection-11B2EBE071C4262D916150AC63F29E7E-1" escape="true">Leases</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="TextSelection-6F7C699D521F1DE32BFD50AC63F24F35-1" continuedAt="TextSelection-6F7C699D521F1DE32BFD50AC63F24F35-2"><ix:continuation id="TextSelection-11B2EBE071C4262D916150AC63F29E7E-1" continuedAt="TextSelection-11B2EBE071C4262D916150AC63F29E7E-2"><div style="line-height:120%;padding-bottom:10px;padding-top:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">The Company has operating leases for corporate offices, research and development facilities and manufacturing facilities. We determine if an arrangement is a lease at inception. Operating leases are included in right-of-use (ROU) assets and liabilities. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">ROU assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of the Company's leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company uses an implicit rate when readily determinable. At the beginning of a lease, the operating lease ROU asset also includes any concentrated lease payments expected to be paid and excludes lease incentives. The Company's lease ROU asset may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise those options. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company has lease agreements with lease and non-lease components, which are accounted for separately. The Company's leases have remaining lease terms of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><span><ix:nonNumeric id="d17807561e581-wk-Fact-37AFB2B597B23076BF8850AC63DDB758" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="FI2020Q1_srt_RangeAxis_srt_MinimumMember" format="ixt-sec:duryear">1</ix:nonNumeric></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> year to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><span><ix:nonNumeric id="d17807561e585-wk-Fact-BA815A211DCE01E4D68C50AC63E11119" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="FI2020Q1_srt_RangeAxis_srt_MaximumMember" format="ixt-sec:duryear">15</ix:nonNumeric></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> years, some of which include options to extend the leases for up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><span><ix:nonNumeric id="d17807561e589-wk-Fact-4A2E4922E67FD236BC0F50AC63DD7859" name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="FI2020Q1" format="ixt-sec:duryear">5</ix:nonNumeric></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> years, and some of which include options to terminate the leases within </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><span><ix:nonNumeric id="d17807561e593-wk-Fact-EE2A0389DE88D9E4260150AC639AFDDA" name="ebs:LesseeOperatingLeaseTerminationPeriod" contextRef="FD2020Q1YTD" format="ixt-sec:duryear">1</ix:nonNumeric></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> year.</span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:LeaseCostTableTextBlock" id="TextSelection-0BE95110EF79AEF77C4050AC63F25AFD-0-wk-Fact-85CF60AD7B65262EDC2D50AC63DD6741" continuedAt="TextSelection-0BE95110EF79AEF77C4050AC63F25AFD-1" escape="true"><div style="line-height:120%;padding-bottom:10px;padding-top:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">The components of lease expense were as follows:&#160;</span></div></ix:nonNumeric></ix:continuation></ix:continuation><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">13</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">(unaudited, in millions, except share and per share amounts)</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-6F7C699D521F1DE32BFD50AC63F24F35-2"><ix:continuation id="TextSelection-11B2EBE071C4262D916150AC63F29E7E-2"><ix:continuation id="TextSelection-0BE95110EF79AEF77C4050AC63F25AFD-1"><div style="line-height:120%;padding-bottom:10px;padding-top:12px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:61%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Three months ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2020</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease cost:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization of right-of-use assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17807561e755-wk-Fact-6F92BB4D0468AAC50E749E68D01BC951" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17807561e774-wk-Fact-0E98739DC2F88922908250AC63DDFEDA" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest on lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17807561e789-wk-Fact-7246D8D2CEBCAAA65EE49E68D02F2798" name="us-gaap:FinanceLeaseInterestExpense" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17807561e808-wk-Fact-D8173FCEA1502854BB6050AC63E6C8E7" name="us-gaap:FinanceLeaseInterestExpense" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total operating lease cost</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17807561e833-wk-Fact-E8BD74F647013E68DB8550AC63E5EE6C" name="us-gaap:LeaseCost" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17807561e852-wk-Fact-046FE3D5F4CBA2C8F46750AC63E54FDD" name="us-gaap:LeaseCost" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div></ix:continuation><ix:nonNumeric contextRef="FD2020Q1YTD" name="ebs:ScheduleOfLeasesSupplementalBalanceSheetsTableTextBlock" id="TextSelection-3E2F3FC0FE360F562DA050AC63F211C9-0-wk-Fact-4110D577A7CAAD85E63250AC63DDB272" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">Supplemental balance sheet information related to leases was as follows:</span></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td style="width:39%;"></td><td style="width:21%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;font-style:italic;">(In millions, except lease term and discount rate)</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Balance Sheet location</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">March&#160;31, 2020</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease right-of-use assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17807561e962-wk-Fact-BA9D48416DE5C4C80B2550AC63A4901D" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">25.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17807561e981-wk-Fact-9B3E274FAFB5587C9D0F50AC63D0EE16" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">24.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease liabilities, current portion</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17807561e1057-wk-Fact-1641FA87C6F4270E2C5C50AC63AEAD79" name="ebs:OperatingLeaseOtherLiabilityCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17807561e1076-wk-Fact-C28D8134C0E5A1E1C72A50AC63CFCB90" name="ebs:OperatingLeaseOtherLiabilityCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17807561e1106-wk-Fact-9AE154B09F03A838808D50AC63B0A673" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">22.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17807561e1125-wk-Fact-BE1C9CBC7E9DCF0006B150AC63C0F998" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">22.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17807561e1160-wk-Fact-C680541510192003638F50AC63AB0772" name="us-gaap:OperatingLeaseLiability" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">26.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17807561e1179-wk-Fact-7D685955C9AB481E48C550AC63E0AC0A" name="us-gaap:OperatingLeaseLiability" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">25.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating leases:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average remaining lease term (years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonNumeric id="d17807561e1306-wk-Fact-F82C9BE408331B0DF4A050AC63AD3E35" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="FI2020Q1" format="ixt-sec:duryear">7.7</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d17807561e1325-wk-Fact-73755A5FA4D527DAB82A50AC63CF7D92" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="FI2019Q4" format="ixt-sec:duryear">8.0</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average discount rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17807561e1355-wk-Fact-EACB9698BADF4861C87050AC63AFBB8B" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="FI2020Q1" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">4.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17807561e1375-wk-Fact-CCAA4DF7F94F88577E4F50AC63DB69AD" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="FI2019Q4" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">4.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation></ix:continuation><div><a id="s42E7B968E65B5D91BF37B150E8D9FEA0"></a></div><div style="line-height:120%;padding-bottom:12px;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="TextSelection-A4073591F8B0BD050E5650AC63F2672D-0-wk-Fact-3F77C3AF40CA270213F250AC63CC1B80" continuedAt="TextSelection-A4073591F8B0BD050E5650AC63F2672D-1" escape="true">Intangible assets</ix:nonNumeric></span></div><ix:continuation id="TextSelection-A4073591F8B0BD050E5650AC63F2672D-1" continuedAt="TextSelection-A4073591F8B0BD050E5650AC63F2672D-2"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">The Company's intangible as</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">sets consist of products acquired via business combinations or asset acquisitions. <ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="TextSelection-1DFD16A835B068C441F350AC63F39308-0-wk-Fact-661D276D2D726CC9F65650AC63CD61F7" continuedAt="TextSelection-1DFD16A835B068C441F350AC63F39308-1" escape="true">The following tables summarize the Company's intangible assets for the periods ended </ix:nonNumeric></span><ix:continuation id="TextSelection-1DFD16A835B068C441F350AC63F39308-1" continuedAt="TextSelection-1DFD16A835B068C441F350AC63F39308-2"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> and December 31, 2019:</span></ix:continuation></div><ix:continuation id="TextSelection-1DFD16A835B068C441F350AC63F39308-2"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:30%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="12" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">March 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">(in millions)&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Estimated Life</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Cost</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Additions</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Accumulated Amortization</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Net</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Products</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9-22 years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;">$</span></div></td><td style="vertical-align:bottom;background-color:#ededed;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"><span><ix:nonFraction id="d17808642e785-wk-Fact-36C9590F29070154342C50AC63A9C422" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2020Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">788.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ededed;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;">$</span></div></td><td style="vertical-align:bottom;background-color:#ededed;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"><span><ix:nonFraction id="d17808642e799-wk-Fact-0E96CC0D766AAC2738D379EAF5925F4A" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" contextRef="FD2020Q1YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ededed;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;">$</span></div></td><td style="vertical-align:bottom;background-color:#ededed;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"><span><ix:nonFraction id="d17808642e813-wk-Fact-8B53B38D19F00F8A42A179EAF57D9293" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2020Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">96.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;">$</span></div></td><td style="vertical-align:bottom;background-color:#ededed;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"><span><ix:nonFraction id="d17808642e828-wk-Fact-5B8E5447046B50A8018C79EAF57916A2" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2020Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">702.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Customer relationships</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d17808642e843-wk-Fact-36EF03DA5E9225B8FB4A50AC639B00E3" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="FD2020Q1YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember" format="ixt-sec:duryear">8</ix:nonNumeric> years</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"><span><ix:nonFraction id="d17808642e853-wk-Fact-D745B685D5307788E0C650AC63CF39F6" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2020Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">28.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"><span><ix:nonFraction id="d17808642e881-wk-Fact-F18D11E6A3CC33122EF779EAF570145B" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2020Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">23.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"><span><ix:nonFraction id="d17808642e896-wk-Fact-7E433BF71C4E95601CB179EAF5815BCD" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2020Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contract development and manufacturing</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d17808642e916-wk-Fact-F0F63A1B976F7DDFD61250AC63A510E2" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="FD2020Q1YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ebs_ContractManufacturingMember" format="ixt-sec:duryear">8</ix:nonNumeric> years</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"><span><ix:nonFraction id="d17808642e926-wk-Fact-B4421EAFAE32CD50B53050AC63A806A2" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2020Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ebs_ContractManufacturingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"><span><ix:nonFraction id="d17808642e954-wk-Fact-591542D989A32E9AB63679EAF56818DB" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2020Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ebs_ContractManufacturingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"><span><ix:nonFraction id="d17808642e969-wk-Fact-C897C42DCD82C12D57E579EAF597BE4C" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2020Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ebs_ContractManufacturingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;Total intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ededed;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ededed;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"><span><ix:nonFraction id="d17808642e1004-wk-Fact-B14E76E52D795D865E4E50AC63C2500D" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">822.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ededed;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ededed;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ededed;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"><span><ix:nonFraction id="d17808642e1018-wk-Fact-DF0E47FD6ADFFDD935F279EAF56DFF8C" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ededed;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ededed;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ededed;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"><span><ix:nonFraction id="d17808642e1032-wk-Fact-3B3E23D20D069491370679EAF575E3CE" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">124.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ededed;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ededed;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ededed;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"><span><ix:nonFraction id="d17808642e1047-wk-Fact-CDEA88DDC95DCF2AE6A679EAF55DCE3A" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">708.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ededed;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:43%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">(in millions)&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Estimated Life</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Cost</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Accumulated Amortization</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Net</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Products</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9-22 years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17808642e1222-wk-Fact-C816DFD13FF187EAD27350AC639B6821" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">788.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17808642e1236-wk-Fact-2B75A1D3DDFB9991F63250AC63D37501" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">82.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17808642e1250-wk-Fact-775D6009C0C6B9D7783A50AC63D871E6" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">705.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Customer relationships</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d17808642e1266-wk-Fact-F4C912DAA2326785CB7350AC639BC0B8" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="FD2019Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember" format="ixt-sec:duryear">8</ix:nonNumeric> years</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17808642e1276-wk-Fact-9E0B09D1255E64FE262050AC63B448D6" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">28.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17808642e1290-wk-Fact-6AF214D5E14C156B257150AC63C2770C" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">23.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17808642e1309-wk-Fact-FEEF896011F0C19A36BE50AC63D3E54A" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contract development and manufacturing</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d17808642e1325-wk-Fact-6FC82488CF8A2E03D00150AC63CF99EF" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="FD2019Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ebs_ContractManufacturingMember" format="ixt-sec:duryear">8</ix:nonNumeric> years</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17808642e1335-wk-Fact-A1BBA71C4EF9D74A0CD150AC63BB3188" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ebs_ContractManufacturingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17808642e1349-wk-Fact-4CDB900EBB638C1CE87E50AC63A376BB" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ebs_ContractManufacturingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17808642e1368-wk-Fact-2CE4EDEF8AC86507F5FB50AC639B54B3" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ebs_ContractManufacturingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;Total intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17808642e1399-wk-Fact-A3265C341A80D9326B9750AC63BB80DB" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">822.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17808642e1413-wk-Fact-0BEC1D62904B20F63A4050AC63B4DA1E" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">109.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17808642e1427-wk-Fact-0003C74888027F58C28D50AC63D2FA1A" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">712.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">During the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">three months ended March 31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">, the Company achieved a sales milestone that resulted in a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"><span>$<ix:nonFraction id="d17808642e1445-wk-Fact-E6045948A32349B227F39E6ED8CFD926" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="FD2020Q1YTD_us-gaap_BusinessAcquisitionAxis_ebs_RaxibacumabMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> obligation related to the Company's asset acquisition of raxibacumab in October 2017. The achievement of the milestone resulted in an increase to intangible assets with a corresponding increase in accounts payable. As of March 31, 2020 there are no remaining contractual obligations for sales milestones related to the raxibacumab acquisition. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">During the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">three months ended March 31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">, the Company recorded amortization expense for intangible assets of $</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"><span><ix:nonFraction id="d17808642e1466-wk-Fact-20A4A30F776CD2C76C8050AC63AE3F61" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14.8</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> million and $</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"><span><ix:nonFraction id="d17808642e1470-wk-Fact-BCD7D8B56A51DBB9F81E50AC63C5640D" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14.5</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> million, respectively. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">, the weighted average amortization period remaining for intangible assets was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"><span><ix:nonNumeric id="d17808642e1479-wk-Fact-A07D313F8ABC2C8A3B8C50AC63CD96A5" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" contextRef="FD2020Q1YTD" format="ixt-sec:duryear">13.3</ix:nonNumeric></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> years. </span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">14</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">(unaudited, in millions, except share and per share amounts)</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-A4073591F8B0BD050E5650AC63F2672D-2" continuedAt="TextSelection-A4073591F8B0BD050E5650AC63F2672D-3"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">In-process research and development (IPR&amp;D) assets are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. There were no changes to the Company's IPR&amp;D assets during the three months ended March 31, 2020. </span></div></ix:continuation><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><ix:continuation id="TextSelection-A4073591F8B0BD050E5650AC63F2672D-3" continuedAt="TextSelection-A4073591F8B0BD050E5650AC63F2672D-4"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Goodwill was $</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"><span><ix:nonFraction id="d17808642e1492-wk-Fact-F9685A10CF0BB5F123BD9E6E56E0368A" name="us-gaap:Goodwill" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">266.4</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> and $</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"><span><ix:nonFraction id="d17808642e1496-wk-Fact-4537F01ABBB58F8704CB9E6E57053B1F" name="us-gaap:Goodwill" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">266.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> for the periods ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">December&#160;31, 2019</span></ix:continuation><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"><ix:continuation id="TextSelection-A4073591F8B0BD050E5650AC63F2672D-4">, respectively. The change in the balance during the period was due to foreign currency translation adjustments.</ix:continuation> </span></div><div><a id="s046F1D3EC7E45FC689E54EF48C715088"></a></div><div style="line-height:120%;padding-bottom:12px;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:FairValueDisclosuresTextBlock" id="TextSelection-921F791BE5207262715350AC63F3A0A9-0-wk-Fact-C951550142015FE5B17050AC63B28878" continuedAt="TextSelection-921F791BE5207262715350AC63F3A0A9-1" escape="true">Contingent consideration</ix:nonNumeric></span></div><ix:continuation id="TextSelection-921F791BE5207262715350AC63F3A0A9-1"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Contingent consideration liabilities associated with business combinations are fair value measurement items. These liabilities represent an obligation of the Company to transfer additional assets to the selling shareholders and owners if future events occur or conditions are met. These liabilities associated with business combinations are measured at fair value at inception and at each subsequent reporting date. The changes in the fair value are primarily due to the expected amount and timing of future net sales, which are inputs that have no observable market (Level 3). </span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="TextSelection-0CE743F93AE8E8D9864E50AC63F3A7AA-0-wk-Fact-1832F6C861CC9745C9B950AC63AF5197" escape="true"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">The following table is a reconciliation of the beginning and ending balance of contingent considerations and is based on level 3 significant unobservable inputs. </span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:82%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;">Balance at December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17809027e627-wk-Fact-80A163A46A9DA636DA7850AC63D05493" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">29.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Change in fair value</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17809027e642-wk-Fact-7CCC53B493852DD12C3450AC63D2A9E1" name="ebs:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Settlements</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d17809027e662-wk-Fact-4BC29C5E69D6EB3FBB9850AC63D6FCFA" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;">Balance at March&#160;31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17809027e688-wk-Fact-B6DD2ABD01E91975F17450AC63CFB353" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">29.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="TextSelection-978BE19EDB8D9A08D318BEB4161E5BB0-0-wk-Fact-89654CF6B360AE1E2C95BEB5236F4B19" escape="true"><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">The recurring Level 3 fair value measurements the Company's contingent consideration liability include the following significant unobservable inputs: </span></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:15%;"></td><td style="width:17%;"></td><td style="width:17%;"></td><td style="width:17%;"></td><td style="width:17%;"></td><td style="width:17%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Contingent Consideration Liability</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Fair Value as of March 31, 2020</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Valuation Technique</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Unobservable Input</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Range</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Weighted Average </span></div></td></tr><tr><td rowspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue milestone and royalty based</span></div></td><td rowspan="3" style="vertical-align:middle;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>$<ix:nonFraction id="d17809027e755-wk-Fact-915F481F91904C5D032EB7FC4F749A15" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueDiscountedCashFlowMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">29.1</ix:nonFraction> million</span></span></div></td><td rowspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Discounted cash flow</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Discount rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.5% - 8.6%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17809027e775-wk-Fact-36C5A15C332CBCAA6870B8028149D1CF" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" contextRef="FI2020Q1_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueDiscountedCashFlowMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">4.3</ix:nonFraction>%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Probability of payment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.0% - 40.0%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17809027e806-wk-Fact-E504EC77D17715E9D5E0B8028158BD7A" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" contextRef="FI2020Q1_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MeasurementInputTypeAxis_ebs_MeasurementInputProbabilityofPaymentMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueDiscountedCashFlowMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">20.9</ix:nonFraction>%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Projected year of payment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020 - 2028</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022</span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div><a id="s82A9413828725966B272E11B6727C03C"></a></div><div style="line-height:120%;padding-bottom:12px;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="TextSelection-1546BBF1977DE3D5DE9E50AC63F38885-0-wk-Fact-97B0473CC686F4FAD1B650AC63D0CAEA" continuedAt="TextSelection-1546BBF1977DE3D5DE9E50AC63F38885-1" escape="true">Derivative instruments and hedging activities</ix:nonNumeric></span></div><ix:continuation id="TextSelection-1546BBF1977DE3D5DE9E50AC63F38885-1" continuedAt="TextSelection-1546BBF1977DE3D5DE9E50AC63F38885-2"><div style="line-height:120%;padding-bottom:12px;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Risk management objective of using derivatives</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">The Company is exposed to certain risk arising from both its business operations and economic conditions. The Company principally manages its exposures to a wide variety of business and operational risks through management of its core business activities. The Company manages economic risks, including interest rate, liquidity, and credit risk primarily by managing the amount, sources, and duration of its assets and liabilities and the use of derivative financial instruments. Specifically, the Company has entered into interest rate swaps to manage exposures that arise from the Company's senior secured credit agreement's payments of variable interest rate debt.</span></div><div style="line-height:120%;padding-bottom:12px;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Accounting policy for derivative instruments and hedging activities</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">The Company entered into interest rate swaps in June 2019. The Company's interest rate swaps qualify for hedge accounting as cash flow hedges. All derivatives are recorded on the balance sheet at fair value.&#160;Hedge accounting provides for the matching of the timing of gain or loss recognition on these interest rate swaps with the recognition of the changes in interest expense on the Company's variable rate debt. For derivatives designated as cash flow hedges of interest rate risk, the gain or loss on the derivative is recorded in accumulated other comprehensive income and subsequently reclassified into interest expense in the same period during which the hedged transaction affects earnings. Amounts reported in accumulated other comprehensive income related to derivatives will be reclassified to interest </span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">15</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">(unaudited, in millions, except share and per share amounts)</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-1546BBF1977DE3D5DE9E50AC63F38885-2"><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">expense as interest payments are made on the Company&#8217;s variable-rate debt. The cash flows from the designated interest rate swaps are classified as a component of operating cash flows, similar to interest expense.&#160;If current fair values of designated interest rate swaps&#160;re</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">mained static over the next&#160;twelve&#160;months, the Company would reclassify&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"><span>$<ix:nonFraction id="d17810139e587-wk-Fact-8F6C0BDCA4D514F2C1F650AC63D3D1F3" name="us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" contextRef="FD2020Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">&#160;of net deferred losses from&#160;accumulated other comprehensive loss&#160;to the statement of operations over the next&#160;twelve&#160;month period. All outstanding cash flow hedges mature in October 2023.</span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ScheduleOfDerivativeInstrumentsTextBlock" id="TextSelection-F14FB17FB63549E0C71150AC63F3BCCE-0-wk-Fact-11DC88E0ECE24805BC9850AC63CE7769" escape="true"><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">, the Company had the following outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk: </span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:61%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Number of Instruments</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Notional</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest rate swaps</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17810139e653-wk-Fact-62569FB6033E64FC40EB50AC63AA54AE" name="us-gaap:NumberOfInterestRateDerivativesHeld" contextRef="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="instrument" decimals="INF" scale="0" format="ixt:numdotdecimal">7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17810139e668-wk-Fact-307065E3EB369D30581A50AC63AD2129" name="ebs:DerivativeNotionalAmount1" contextRef="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">350.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="TextSelection-05F838EF9AA27860505450AC63F3C48C-0-wk-Fact-3F4CF8F35375703CEB0F50AC63D2B71C" escape="true"><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">The table below presents the fair value of the Company&#8217;s derivative financial instruments designated as hedges as well as their classification on the balance sheet.</span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td style="width:11%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td colspan="9" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Asset Derivatives</span></div></td><td colspan="9" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Liability Derivatives</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;</span></div></td><td colspan="4" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">March&#160;31, 2020</span></div></td><td colspan="4" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">December&#160;31, 2019</span></div></td><td colspan="4" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">March&#160;31, 2020</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;</span></div></td><td style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Balance Sheet Location</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Fair Value</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Balance Sheet Location</span></div></td><td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Fair Value</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Balance Sheet Location</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Fair Value</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Balance Sheet Location</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Fair Value</span></div></td></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest Rate Swaps</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">Other Current Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17810139e1003-wk-Fact-0C614DAF7903E264A50E50AC63BBBA6C" name="us-gaap:DerivativeFairValueOfDerivativeAsset" contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other Current Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17810139e1022-wk-Fact-81535FF0AE52A5ED3C0650AC63BB1401" name="us-gaap:DerivativeFairValueOfDerivativeAsset" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">Other Current Liabilities </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17810139e1042-wk-Fact-218EFC9D09A094D2512650AC63BB9C1C" name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other Current Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17810139e1066-wk-Fact-453E7082B4615A2F3A999E771F45C181" name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">Other Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17810139e1091-wk-Fact-B85ACD00501E1A46D4B69E77785BC5F6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:;font-size:10pt;"><span><ix:nonFraction id="d17810139e1110-wk-Fact-1C3CC075FBEC951196B79E7780CC38CE" name="us-gaap:DerivativeFairValueOfDerivativeAsset" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">Other Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17810139e1130-wk-Fact-FE62A6A0E35D50E1C11B9E7789F7E6D7" name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17810139e1154-wk-Fact-3A6359E6546F2C48391A50AC63BB96C2" name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">The valuation of the interest rate swaps is determined using widely accepted valuation techniques, including discounted cash flow analysis on the expected cash flows of each interest rate swap. This analysis reflects the contractual terms of the interest rate swaps, including the period to maturity, and uses observable market-based inputs, including interest rate curves and implied volatilities. The fair values of interest rate swaps are determined using the market standard methodology of netting the discounted future fixed cash payments (or receipts) and the discounted expected variable cash receipts (or payments). The variable cash payments (or receipts) are based on an expectation of future interest rates (forward curves) derived from observable market interest rate curves. To comply with the provisions of ASC 820, Fair Value Measurement, we incorporate credit valuation adjustments in the fair value measurements to appropriately reflect both our own nonperformance risk and the respective counterparty&#8217;s nonperformance risk. These credit valuation adjustments were concluded to not be significant inputs for the fair value calculations for the periods presented. In adjusting the fair value of our derivative contracts for the effect of nonperformance risk, we have considered the impact of netting and any applicable credit enhancements, such as the posting of collateral, thresholds, mutual puts and guarantees. The valuation of interest rate swaps fall into Level 2 in the fair value hierarchy.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> <ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="TextSelection-FA5CF837AAD03124170650AC63F3A957-0-wk-Fact-A256EAFD8C0B9A64447C50AC63D13D67" continuedAt="TextSelection-FA5CF837AAD03124170650AC63F3A957-1" escape="true">The table below presents the effect of cash flow hedge accounting on accumulated other comprehensive income.</ix:nonNumeric></span></div><ix:continuation id="TextSelection-FA5CF837AAD03124170650AC63F3A957-1"><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:32%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:23%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Hedging derivatives</span></div></td><td colspan="6" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Cumulative Amount of Gain/(Loss) Recognized in OCI on Derivative</span></div></td><td rowspan="2" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Location of Gain or (Loss) Reclassified from Accumulated OCI into Income </span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Amount of Gain/(Loss) Reclassified from Accumulated OCI into Income</span></div></td></tr><tr><td colspan="6" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">March 31,</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Three months ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2020</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2019</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2020</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2019</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest Rate Swaps</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d17810139e1437-wk-Fact-F5994A5369014879B6A850AC63A77C82" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" contextRef="FD2020Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">16.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17810139e1452-wk-Fact-48C48B58498F43869E1E50AC63A809D2" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" contextRef="FD2019Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest expense</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17810139e1476-wk-Fact-C9A43DC2B370047B4DB150AC63AE2650" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" contextRef="FD2020Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_InterestExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17810139e1491-wk-Fact-8AB5B04CCCE4C903B56150AC63A1392B" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" contextRef="FD2019Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_InterestExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div></ix:continuation></ix:continuation><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">16</span></div></div><hr style="page-break-after:always"></hr><div><a id="sBF08B09946595D698A368263AFCF8C31"></a></div><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">(unaudited, in millions, except share and per share amounts)</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:12px;font-size:11pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:DebtDisclosureTextBlock" id="TextSelection-CB78BC4A13F7DC05894350AC63F32806-0-wk-Fact-B4CFFE235F9BC3D32AC250AC63BAA09C" continuedAt="TextSelection-CB78BC4A13F7DC05894350AC63F32806-1" escape="true">Debt</ix:nonNumeric></span></div><ix:continuation id="TextSelection-CB78BC4A13F7DC05894350AC63F32806-1" continuedAt="TextSelection-CB78BC4A13F7DC05894350AC63F32806-2"><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ScheduleOfDebtTableTextBlock" id="TextSelection-23EEF1BB71CA99E2EDE650AC63F324DA-0-wk-Fact-7B6B75C1DACBFDAA2A8150AC63BA8FA7" escape="true"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">The components of debt are as follows:</span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:21%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:21%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">March&#160;31, 2020</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Senior secured credit agreement - Term loan due 2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17810719e644-wk-Fact-5912A89482277888C8BC50AC63D460B0" name="us-gaap:LongTermDebt" contextRef="FI2020Q1_us-gaap_CreditFacilityAxis_ebs_TermLoanFacilityMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">433.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17810719e663-wk-Fact-1107387FB4C7ED1C455950AC63D467EC" name="us-gaap:LongTermDebt" contextRef="FI2019Q4_us-gaap_CreditFacilityAxis_ebs_TermLoanFacilityMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">435.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Senior secured credit agreement - Revolver loan due 2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17810719e678-wk-Fact-DA178281F2D0D4209BAA50AC63D3A74F" name="us-gaap:LongTermDebt" contextRef="FI2020Q1_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">353.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17810719e697-wk-Fact-4B5BB9AC92A701600B3650AC63D55EC0" name="us-gaap:LongTermDebt" contextRef="FI2019Q4_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">373.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.875% Convertible Senior Notes due 2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17810719e717-wk-Fact-71C7D35E4932DC6BCEB350AC63D68F79" name="us-gaap:LongTermDebt" contextRef="FI2020Q1_us-gaap_DebtInstrumentAxis_ebs_ConvertibleSeniorNotesDue2021Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17810719e736-wk-Fact-95BA10BC61B0B2387ACE50AC63D21BD4" name="us-gaap:LongTermDebt" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ebs_ConvertibleSeniorNotesDue2021Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17810719e756-wk-Fact-AF6DA030B535C2F9DEFF50AC63D8000B" name="us-gaap:LongTermDebt" contextRef="FI2020Q1_us-gaap_DebtInstrumentAxis_ebs_OtherLongTermDebtFacilityMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17810719e775-wk-Fact-D18D0B8B2B4BB80F62D250AC63D53DBF" name="us-gaap:LongTermDebt" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ebs_OtherLongTermDebtFacilityMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total debt</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17810719e795-wk-Fact-DC952A83F128CB61556B50AC63D0E0E6" name="us-gaap:LongTermDebt" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">799.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17810719e814-wk-Fact-CB38FA676D3DB1E6166550AC63D39BCD" name="us-gaap:LongTermDebt" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">822.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of long-term debt, net of debt issuance costs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d17810719e834-wk-Fact-F3A5DC4CD600BAC73D4750AC63D5E58E" name="us-gaap:LongTermDebtCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">26.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d17810719e854-wk-Fact-7483437E94B0458F855C50AC63D59F31" name="us-gaap:LongTermDebtCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unamortized debt issuance costs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d17810719e875-wk-Fact-DBB6BB16D4F19C6DA67450AC63D79F3C" name="us-gaap:DeferredFinanceCostsNoncurrentNet" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d17810719e895-wk-Fact-289325CD3BAC1EE0BDF150AC63D59787" name="us-gaap:DeferredFinanceCostsNoncurrentNet" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current portion of debt</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17810719e921-wk-Fact-71761EF4F2817FB54EF079E14164F9D7" name="us-gaap:LongTermDebtNoncurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">762.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17810719e940-wk-Fact-64FB9723C0B0F0E7FB3A50AC639B2838" name="us-gaap:LongTermDebtNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">798.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:24px;font-size:11pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:11pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Senior secured credit agreement</span></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">In October 2018, the Company entered into a senior secured credit agreement with multiple lending institutions (the "Credit Agreement"). The terms of the credit agreement include (i) a revolving credit facility (the "Revolving Credit Facility") of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><span>$<ix:nonFraction id="d17810719e959-wk-Fact-50746D18D2B78C63A2DC9E7D72FCB41B" name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" contextRef="I2018Q4Oct31_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_DebtInstrumentAxis_ebs_CreditAgreementMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">600</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> with a maturity date of October 13, 2023, and (ii) a term loan with a principal amount of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><span>$<ix:nonFraction id="d17810719e963-wk-Fact-2F476AE96F1BC3B0CF5C9E7D73137444" name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" contextRef="I2018Q4Oct31_us-gaap_CreditFacilityAxis_ebs_TermLoanFacilityMember_us-gaap_DebtInstrumentAxis_ebs_CreditAgreementMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">450</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> (the "Term Loan Facility," and together with the Revolving Credit Facility, the "Senior Secured Credit Facilities"). The Company may request incremental term loan facilities or increases in the Revolving Credit Facility (each an "Incremental Loan") as long as requirements relating to net leverage ratio will be maintained on a pro forma basis.  </span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">Borrowings under the Revolving Credit Facility and the Term Loan Facility will bear interest at a rate per annum equal to (a) a eurocurrency rate plus a margin ranging from </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><span><ix:nonFraction id="d17810719e972-wk-Fact-B1A80DA1D8F5FB012B8B50AC63AF5B88" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="D2018Q4Oct15-Oct15_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_EurodollarMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">1.25</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><span><ix:nonFraction id="d17810719e976-wk-Fact-878D5849BAB352173FFE50AC63C58FC1" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="D2018Q4Oct15-Oct15_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_EurodollarMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">2.00</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> per annum, depending on the Company's consolidated net leverage ratio or (b) a base rate (which is the highest of the prime rate, the federal funds rate plus </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><span><ix:nonFraction id="d17810719e980-wk-Fact-A418242498E2814D5FFA50AC63B06811" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="D2018Q4Oct15-Oct15_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_FederalFundsEffectiveSwapRateMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">0.50</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">, and a eurocurrency rate for an interest period of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">one month</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> plus </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><span><ix:nonFraction id="d17810719e988-wk-Fact-CD0508352A7FAC75A1A150AC63B22FA3" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="D2018Q4Oct15-Oct15_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_EurodollarMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> plus a margin ranging from </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><span><ix:nonFraction id="d17810719e993-wk-Fact-896F0DAEABA13A14AD1950AC63A9AF1D" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="D2018Q4Oct15-Oct15_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_BaseRateMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">0.25</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><span><ix:nonFraction id="d17810719e997-wk-Fact-228202233B737C2A39B450AC63C346A1" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="D2018Q4Oct15-Oct15_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_BaseRateMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">1.00</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">, depending on the Company's consolidated net leverage ratio. The Company is required to make quarterly payments under the Credit Agreement for accrued and unpaid interest on the outstanding principal balance, based on the above interest rates. In addition, the Company is required to pay commitment fees ranging from </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><span><ix:nonFraction id="d17810719e1001-wk-Fact-CBAEA79B790E3AD038DA50AC63B3CA1F" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" contextRef="D2018Q4Oct15-Oct15_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">0.15</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><span><ix:nonFraction id="d17810719e1005-wk-Fact-63691A5BF31915F9DC5D50AC63B0CF2F" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" contextRef="D2018Q4Oct15-Oct15_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">0.30</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> per annum, depending on the Company's consolidated net leverage ratio, in respect of the average daily unused commitments under the Revolving Credit Facility. The Company is to repay the outstanding principal amount of the Term Loan Facility in quarterly installments based on an annual percentage equal to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><span><ix:nonFraction id="d17810719e1009-wk-Fact-3C4436228CA8E397623050AC63B52670" name="ebs:PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears" contextRef="D2018Q4Oct15-Oct15_us-gaap_CreditFacilityAxis_ebs_TermLoanFacilityMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">2.5</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> of the original principal amount of the Term Loan Facility during each of the first two years of the Term Loan Facility, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><span><ix:nonFraction id="d17810719e1013-wk-Fact-B8D1E50E35A3C0559D3A50AC63B44CC5" name="ebs:PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear" contextRef="D2018Q4Oct15-Oct15_us-gaap_CreditFacilityAxis_ebs_TermLoanFacilityMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> of the original principal amount of the Term Loan Facility during the third year of the Term Loan Facility and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><span><ix:nonFraction id="d17810719e1018-wk-Fact-77E137CB099E0D4C65FE50AC63BB5176" name="ebs:PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears" contextRef="D2018Q4Oct15-Oct15_us-gaap_CreditFacilityAxis_ebs_TermLoanFacilityMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">7.5</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> of the original principal amount of the Term Loan Facility during each year of the remainder of the term of the Term Loan Facility until the maturity date of the Term Loan Facility, at which time the entire unpaid principal balance of the Term Loan Facility will be due and payable. The Company has the right to prepay the Term Loan Facility without premium or penalty. The Revolving Credit Facility and the Term Loan Facility mature (unless earlier terminated) on </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">October&#160;13, 2023</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">The Credit Agreement also requires mandatory prepayments of the Term Loan Facility in the event the Company or its Subsidiaries (a) incur indebtedness not otherwise permitted under the Credit Agreement or (b) receive cash proceeds in excess of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><span>$<ix:nonFraction id="d17810719e1031-wk-Fact-E39DC5B95C2CE85BF13A50AC63BB99AD" name="ebs:CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight" contextRef="D2018Q4Oct15-Oct15_us-gaap_CreditFacilityAxis_ebs_TermLoanFacilityMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">100</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> during the term of the Credit Agreement from certain dispositions of property or from casualty events involving their property, subject to certain reinvestment rights.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">The financial covenants under the Credit Agreement currently require the quarterly presentation of a minimum consolidated 12-month rolling debt service coverage ratio of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><span><ix:nonFraction id="d17810719e1041-wk-Fact-29ADE7BCD4B7A915FD159E95B7A3F9E9" name="ebs:DebtInstrumentCovenantDebtServiceCoverageRatio" contextRef="FD2020Q1YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_DebtInstrumentAxis_ebs_CreditAgreementMember" unitRef="number" decimals="INF" scale="0" format="ixt:numdotdecimal">2.50</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> to 1.00, and a maximum consolidated net leverage ratio of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><span><ix:nonFraction id="d17810719e1045-wk-Fact-99F61511D402C6FE82B89E9C4A3F4D9E" name="ebs:DebtInstrumentCovenantNetLeverageRatioOne" contextRef="FD2020Q1YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_DebtInstrumentAxis_ebs_CreditAgreementMember" unitRef="number" decimals="INF" scale="0" format="ixt:numdotdecimal">3.75</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> to 1.00 for the quarterly filing periods from October&#160;1, 2019 through September&#160;29, 2020 and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><span><ix:nonFraction id="d17810719e1049-wk-Fact-028CAEC85C3F221400FD9E9E055AA24E" name="ebs:DebtInstrumentCovenantNetLeverageRatioTwo" contextRef="FD2020Q1YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_DebtInstrumentAxis_ebs_CreditAgreementMember" unitRef="number" decimals="INF" scale="0" format="ixt:numdotdecimal">3.50</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> to 1.0, thereafter, which may be adjusted to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><span><ix:nonFraction id="d17810719e1053-wk-Fact-55A77288C06E069BE0299E9EC93B07AD" name="ebs:DebtInstrumentCovenantNetLeverageRatioThree" contextRef="FD2020Q1YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_DebtInstrumentAxis_ebs_CreditAgreementMember" unitRef="number" decimals="INF" scale="0" format="ixt:numdotdecimal">4.00</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> to 1.00 for a four quarter period in connection with a material permitted acquisition. Negative covenants in the Credit Agreement, among other things, limit the ability of the Company to incur indebtedness and liens, dispose of assets, make investments, enter into certain merger or consolidation transactions and make restricted payments. As of the date of these financial statements, the Company is in compliance with all affirmative and negative covenants.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">17</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">(unaudited, in millions, except share and per share amounts)</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-CB78BC4A13F7DC05894350AC63F32806-2"><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;"><span><ix:nonFraction id="d17810719e1060-wk-Fact-1042AA2FA58C9790C9A650AC63BB086A" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="I2014Q1Jan29_us-gaap_DebtInstrumentAxis_ebs_ConvertibleSeniorNotesDue2021Member" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">2.875</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;"> Convertible senior notes due 2021</span></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">On </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">January&#160;29, 2014</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">, the Company issued </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><span><ix:nonFraction id="d17810719e1073-wk-Fact-1042AA2FA58C9790C9A650AC63BB086A" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="I2014Q1Jan29_us-gaap_DebtInstrumentAxis_ebs_ConvertibleSeniorNotesDue2021Member" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">2.875</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> convertible senior notes due </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">2021</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> (the "Notes"). The Notes bear interest at a rate of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><span><ix:nonFraction id="d17810719e1081-wk-Fact-1042AA2FA58C9790C9A650AC63BB086A" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="I2014Q1Jan29_us-gaap_DebtInstrumentAxis_ebs_ConvertibleSeniorNotesDue2021Member" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">2.875</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> per year, payable semi-annually in arrears on </span><span style="color:#000000;font-family:Franklin Gothic Book,sans-serif;font-weight:normal;">January 15</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> and </span><span style="color:#000000;font-family:Franklin Gothic Book,sans-serif;font-weight:normal;">July 15</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> of each year. The Notes mature on </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">January&#160;15, 2021</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">.</span></div></ix:continuation><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div><a id="s140F650306E35E889F4F560C0614C5BD"></a></div><div style="line-height:120%;padding-bottom:12px;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">10.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="TextSelection-99D291FDAE3D0D01DBB150AC63F48BDF-0-wk-Fact-72C8F716405B707F875850AC63A6567C" continuedAt="TextSelection-99D291FDAE3D0D01DBB150AC63F48BDF-1" escape="true">Revenue recognition</ix:nonNumeric></span></div><ix:continuation id="TextSelection-99D291FDAE3D0D01DBB150AC63F48BDF-1" continuedAt="TextSelection-99D291FDAE3D0D01DBB150AC63F48BDF-2"><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">The Company operates as </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"><span><ix:nonFraction id="d17812012e573-wk-Fact-D886683251CE85E78A9A50AC63D47DF7" name="us-gaap:NumberOfOperatingSegments" contextRef="FD2020Q1YTD" unitRef="segment" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> operating segment. Therefore, results of its operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. <ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="TextSelection-922B7CF6048D1330F90750AC63F45D4C-0-wk-Fact-62D8960ED38210AE73BD50AC63DD289E" continuedAt="TextSelection-922B7CF6048D1330F90750AC63F45D4C-1" escape="true">The Company's revenues disaggregated by the major sources were as follows:</ix:nonNumeric></span></div><ix:continuation id="TextSelection-922B7CF6048D1330F90750AC63F45D4C-1" continuedAt="TextSelection-922B7CF6048D1330F90750AC63F45D4C-2"><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"></td></tr><tr><td style="width:23%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Three Months Ended March 31, 2020</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Three Months Ended March 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">U.S.<br/>Government</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Non-U.S.<br/>Government</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;Total</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">U.S.<br/>Government</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Non-U.S.<br/>Government</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product sales, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17812012e872-wk-Fact-2A93D1427337E33F1B6050AC63DB9F11" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">63.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17812012e891-wk-Fact-1EE7DFA9170F861423F050AC63D42746" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">84.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17812012e910-wk-Fact-15F576BF23B68ED3410550AC63B6D635" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">148.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17812012e930-wk-Fact-C7031B5C198114569AF050AC63D93005" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">73.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17812012e949-wk-Fact-92A0061DAA2D0330A1AB50AC63D5326C" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">79.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17812012e969-wk-Fact-100EA167C32CD4E7BF7F50AC63C22D94" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">153.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contract development and manufacturing services</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17812012e984-wk-Fact-F4349E3C85239E59E8A250AC63D7435B" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17812012e1003-wk-Fact-769A3058C6CC8C9A649F50AC63D68A2A" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">21.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17812012e1022-wk-Fact-C945A823FC8AB77DBA5A50AC63C78AD8" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">21.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17812012e1042-wk-Fact-28537BD2C023A388A37450AC63DBB7D3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17812012e1061-wk-Fact-E5ADF2BE4811BE814F1B50AC63D7E7EA" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17812012e1080-wk-Fact-86B8A67AE3A5069C980750AC63B51F29" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contracts and grants</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17812012e1101-wk-Fact-F039F0D08AECABA0FA8150AC639BCA23" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">22.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17812012e1120-wk-Fact-9566621BC3B9309DF83950AC63D722BF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17812012e1139-wk-Fact-3612644390F14B60C4B550AC63CA1285" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">22.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17812012e1159-wk-Fact-929341516385840F8F8F50AC63DD8C5F" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">20.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17812012e1178-wk-Fact-54AA0CDA9D852730D97450AC63D8DBDE" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17812012e1197-wk-Fact-8EAC98B280127C3147AA50AC63C5A1FF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">21.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17812012e1223-wk-Fact-52DE0AEEB0FA0D4A73AA50AC63DC63D9" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q1QTD_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">85.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17812012e1242-wk-Fact-786F364755748F812B4A50AC63D5E39F" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q1QTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">106.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17812012e1261-wk-Fact-EE62D36AAC76E41DE0BE50AC63C826F6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">192.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17812012e1281-wk-Fact-46F83D518EFEE9F25DD450AC63D7C496" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q1QTD_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">93.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17812012e1300-wk-Fact-E06C4BDB953AACFA5A2050AC63D6FC74" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q1QTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">96.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17812012e1320-wk-Fact-4783103E7C9579FDD76750AC63CB769E" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">190.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div></ix:continuation><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:0px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;"><ix:continuation id="TextSelection-922B7CF6048D1330F90750AC63F45D4C-2"></ix:continuation>Contract liabilities </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">When performance obligations are not transferred to a customer at the end of a reporting period, cash received associated with amounts allocated to those performance obligations is reflected as contract liabilities on the consolidated balance sheets and is deferred until control of these performance obligations is transferred to the customer. <ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="TextSelection-01C8180CDD07E035067750AC63F45E5C-0-wk-Fact-DC3FA048B09E76E489F650AC63E28098" continuedAt="TextSelection-01C8180CDD07E035067750AC63F45E5C-1" escape="true">The following table presents the rollforward of the contract liability balances: </ix:nonNumeric></span></div><ix:continuation id="TextSelection-01C8180CDD07E035067750AC63F45E5C-1"><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:82%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><span><ix:nonFraction id="d17812012e1385-wk-Fact-D3C32C2B142F48414D5D50AC639BDA42" name="us-gaap:ContractWithCustomerLiability" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">88.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferral of revenue</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17812012e1400-wk-Fact-732738E8070B28506D9050AC639BF380" name="ebs:ContractWithCustomerLiabilityAdditions" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue recognized</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d17812012e1420-wk-Fact-834C4BA8995E517FB93950AC63A6C2B3" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">March&#160;31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;font-weight:bold;"><span><ix:nonFraction id="d17812012e1446-wk-Fact-93C997EAFBF67C12919D50AC63E3E7CE" name="us-gaap:ContractWithCustomerLiability" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">89.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:0px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Transaction price allocated to remaining performance obligations</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;"> </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">, the Company expects future revenues of approximately $</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><span><ix:nonFraction id="d17812012e1468-wk-Fact-3E73BA1550B73B2C3FBF50AC63A0FB58" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">555.9</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> million associated with performance obligations that have not been satisfied. The Company expects to recognize a majority of these revenues within the next </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><span><ix:nonNumeric id="d17812012e1472-wk-Fact-CDF5120DAD5156EB949350AC63DDF1EC" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" contextRef="FI2020Q1_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2020-04-01" format="ixt-sec:durmonth">24</ix:nonNumeric></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> months, with the remainder recognized thereafter. However, the amount and timing of revenue recognition for unsatisfied performance obligations can materially change due to timing of funding appropriations from the USG and the overall success of the Company's development activities associated with its PHT product candidates that are then receiving development funding support from the USG under development contracts. In addition, the amount of future revenues associated with unsatisfied performance obligations excludes the value associated with unexercised option periods in the Company's contracts. </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:0px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Contract assets</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;"> </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">The Company considers unbilled accounts receivables and deferred costs associated with revenue generating contracts, which are not included in inventory or property, plant and equipment, as contract assets. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">, the Company had contract assets associated with deferred costs of $</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><span><ix:nonFraction id="d17812012e1492-wk-Fact-F47655CB25005B5ED86D50AC63E0A89C" name="us-gaap:DeferredCostsCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">36.3</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> million and $</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><span><ix:nonFraction id="d17812012e1496-wk-Fact-879509E4A94B4F6CD9E050AC63A7AF0C" name="us-gaap:DeferredCostsCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">34.0</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> million, respectively, which is reflected as a component of prepaid expenses and other current assets on the Company's consolidated balance sheets. </span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">18</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">(unaudited, in millions, except share and per share amounts)</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-99D291FDAE3D0D01DBB150AC63F48BDF-2"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:0px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Accounts receivable</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;"> </span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="ebs:ScheduleofAccountsReceivableNetTableTextBlock" id="TextSelection-E45B9451E6D6C6BE981750AC63F49E02-0-wk-Fact-65ECEC1253F8FB2BE9AF50AC639A51E4" escape="true"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">Accounts receivable, including unbilled accounts receivable contract assets, consist of the following:</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> </span></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">March&#160;31, 2020</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Billed, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17812012e1595-wk-Fact-E6453855F10A6EAADAA450AC63B5CFF1" name="us-gaap:BilledContractReceivables" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">119.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17812012e1614-wk-Fact-9795B9FE625975243C8A50AC63B65C49" name="us-gaap:BilledContractReceivables" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">227.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unbilled</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17812012e1634-wk-Fact-E6A4AEF951DA651FEE0050AC63B6C764" name="us-gaap:UnbilledContractsReceivable" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">43.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17812012e1653-wk-Fact-6D73FC7678536E63D51850AC63C2848D" name="us-gaap:UnbilledContractsReceivable" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">43.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17812012e1683-wk-Fact-33FB468D40ED33E2CA7E50AC63CE721D" name="us-gaap:AccountsReceivableNetCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">162.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17812012e1702-wk-Fact-BF3721EEB20B5C10A7E650AC63C709EB" name="us-gaap:AccountsReceivableNetCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">270.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">, allowances for doubtful accounts were </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><span>$<ix:nonFraction id="d17812012e1723-wk-Fact-7A190FC9A634E8B263029EB23545D3C8" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> and de minimis, respectively.</span></div></ix:continuation><div><a id="s565754CC1A7158A9B51DC88ED532AD65"></a></div><div style="line-height:120%;padding-bottom:12px;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">11.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:IncomeTaxDisclosureTextBlock" id="TextSelection-14155CAAEACBBB4231D250AC63F4BFCE-0-wk-Fact-9A96D2CB2BB3CB25595D50AC63A3E678" continuedAt="TextSelection-14155CAAEACBBB4231D250AC63F4BFCE-1" escape="true">Income taxes </ix:nonNumeric></span></div><ix:continuation id="TextSelection-14155CAAEACBBB4231D250AC63F4BFCE-1" continuedAt="TextSelection-14155CAAEACBBB4231D250AC63F4BFCE-2"><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">On</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> March</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> 27, 2020, the President of the United States signed into law the Coronavirus Aid, Relief and Economic Security Act (the &#8220;CARES Act&#8221;). The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">credit</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> refunds, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property. The Company is currently assessing the impact of the CARES Act, but we do not expect there to be a material impact to our consolidated financial statements. </span></div></ix:continuation><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><ix:continuation id="TextSelection-14155CAAEACBBB4231D250AC63F4BFCE-2" continuedAt="TextSelection-14155CAAEACBBB4231D250AC63F4BFCE-3"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">The estimated effective annual tax rate for the Company, which excludes discrete adjustments, was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"><span><ix:nonFraction id="d17812107e584-wk-Fact-EC78297E612D9138B54350AC63A0790B" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="FD2020Q1YTD" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">26</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"><span><ix:nonFraction id="d17812107e588-wk-Fact-4351A20008D9B1C533E950AC63C48AD1" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="FD2019Q1QTD" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">27</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">. </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">three months ended March 31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">, the Company recorded a discrete tax benefit of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"><span>$<ix:nonFraction id="d17812107e615-wk-Fact-CE29E8253C15A84470C850AC63A2E7C6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> and $</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"><span><ix:nonFraction id="d17812107e619-wk-Fact-0F418074BB2057CAC47A50AC63DC4159" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.8</ix:nonFraction></span></span></ix:continuation><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"><ix:continuation id="TextSelection-14155CAAEACBBB4231D250AC63F4BFCE-3"> million, respectively, primarily due to activity associated with equity awards.</ix:continuation> </span></div><div><a id="sC686026AAE7A5837A4F25D7E30F4D407"></a></div><div style="line-height:120%;padding-bottom:12px;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">12.&#160;&#160;&#160;&#160;Net l<ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:EarningsPerShareTextBlock" id="TextSelection-522A55D0E383DFBA2F0F50AC63F4D88B-0-wk-Fact-DF277C57F669222753D450AC63A43613" continuedAt="TextSelection-522A55D0E383DFBA2F0F50AC63F4D88B-1" escape="true">oss per share</ix:nonNumeric></span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="TextSelection-417C8ABF4BDB3191B94150AC63F4078E-0-wk-Fact-C69B5F4D810A67B6A26F50AC639A9121" escape="true"><ix:continuation id="TextSelection-522A55D0E383DFBA2F0F50AC63F4D88B-1" continuedAt="TextSelection-522A55D0E383DFBA2F0F50AC63F4D88B-2"><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:24px;text-indent:0px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">The following table presents the calculation of basic and diluted net loss per share:</span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:63%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Three Months Ended March 31,</span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2020</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Numerator:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d17812781e727-wk-Fact-2BE66961830A83F48E5050AC63AB2A6D" name="us-gaap:NetIncomeLoss" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">12.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d17812781e747-wk-Fact-68AB7F5A194EFA0424DB50AC63CA9408" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">26.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Denominator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average number of shares&#8212;basic</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17812781e845-wk-Fact-86AA0904084337CA20DD50AC63BB987B" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2020Q1YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">52.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17812781e864-wk-Fact-E5106EB7EC5DD52FFE1750AC63AAA0C9" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2019Q1QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">51.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dilutive securities&#8212;equity awards</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17812781e884-wk-Fact-0A00A9B05AB5AB9D115A50AC639B4F55" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2020Q1YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17812781e903-wk-Fact-8D71A32FA17F83B1654250AC63A1FDB2" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2019Q1QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average number of shares&#8212;diluted</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d17812781e923-wk-Fact-FE0D54A71F3B22F2C1A650AC63BB0266" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2020Q1YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">52.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d17812781e942-wk-Fact-025C9BBD3873347BD04350AC63AAE1F5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2019Q1QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">51.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net loss per share - basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d17812781e1008-wk-Fact-92317C4056EAA9BE7F9C50AC63C0B75A" name="us-gaap:EarningsPerShareBasic" contextRef="FD2020Q1YTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.24</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d17812781e1028-wk-Fact-398962EC77284B56EAE350AC63CB3AD7" name="us-gaap:EarningsPerShareBasic" contextRef="FD2019Q1QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.51</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net loss per share - diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d17812781e1050-wk-Fact-F4635BF4F58F1DABA08450AC63C76B0E" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2020Q1YTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.24</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d17812781e1070-wk-Fact-3F3AD90A570B8318774450AC63B12D21" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2019Q1QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.51</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div></ix:continuation></ix:nonNumeric><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><ix:continuation id="TextSelection-522A55D0E383DFBA2F0F50AC63F4D88B-2" continuedAt="TextSelection-522A55D0E383DFBA2F0F50AC63F4D88B-3"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Basic earnings (loss) per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted earnings (loss) per share is computed using the treasury method by dividing net loss by the weighted average number of shares of common stock outstanding during the period, adjusted for the potential dilutive effect of other securities if such securities were converted or exercised and are not anti-dilutive. </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">three months ended March 31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">, approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"><span><ix:nonFraction id="d17812781e1094-wk-Fact-728594F63012A7BB858C50AC63DDB0E0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2020Q1YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> million and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"><span><ix:nonFraction id="d17812781e1098-wk-Fact-1D426725D1AA06B6D6E850AC63B66EC7" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2019Q1QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">3.1</ix:nonFraction></span></span></ix:continuation><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"><ix:continuation id="TextSelection-522A55D0E383DFBA2F0F50AC63F4D88B-3"> million stock options are not considered in the diluted net loss per share calculation because the exercise price of these options is greater than the average per share closing price during the three month period and their effect would be anti-dilutive.</ix:continuation> </span></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">19</span></div></div><hr style="page-break-after:always"></hr><div><a id="s389EE56CB6855143B6A72A8500209FD0"></a></div><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">(unaudited, in millions, except share and per share amounts)</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:12px;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">13.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="TextSelection-D082AF06F0D24143945550AC63F4BA32-0-wk-Fact-B1C5473C851FE57ECBB950AC63A69D46" continuedAt="TextSelection-D082AF06F0D24143945550AC63F4BA32-1" escape="true">Share-based compensation</ix:nonNumeric></span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><ix:continuation id="TextSelection-D082AF06F0D24143945550AC63F4BA32-1" continuedAt="TextSelection-D082AF06F0D24143945550AC63F4BA32-2"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">During the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">three months ended March 31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">, the Company granted stock options to purchase </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"><span><ix:nonFraction id="d17812973e577-wk-Fact-A877B4DBC52134A5685650AC63AB1C97" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> shares of common stock and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"><span><ix:nonFraction id="d17812973e581-wk-Fact-FC2EDDF5201D7D3F7C5550AC63A8CC9D" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> restricted and performance stock units under the Emergent BioSolutions Inc. Stock Incentive Plan. The stock option and restricted stock unit grants vest over </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">three</span></ix:continuation><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"><ix:continuation id="TextSelection-D082AF06F0D24143945550AC63F4BA32-2"> equal annual installments beginning on the day prior to the anniversary of the grant date. The performance stock units settle in stock at the end of the three-year performance period based on the Company's results compared to the performance criteria.</ix:continuation> </span></div><div><a id="s67FA98AB2BEC53539DDC83A808B36728"></a></div><div style="line-height:120%;padding-bottom:12px;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">14. <ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="TextSelection-C9C19D679C31075BC25350AC63F52EFA-0-wk-Fact-62DA777D0B5F6E19DFAA50AC63C92BA2" continuedAt="TextSelection-C9C19D679C31075BC25350AC63F52EFA-1" escape="true">Commitments and contingencies </ix:nonNumeric></span></div><ix:continuation id="TextSelection-C9C19D679C31075BC25350AC63F52EFA-1" continuedAt="TextSelection-C9C19D679C31075BC25350AC63F52EFA-2"><div style="line-height:120%;padding-bottom:12px;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">ANDA Litigation - Perrigo 4mg</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">On September 14, 2018,  Adapt Pharma Inc.,  Adapt Pharma Operations Limited and Adapt Pharma Ltd. (collectively, "Adapt Pharma"), and Opiant Pharmaceuticals, Inc. ("Opiant"), received notice from Perrigo UK FINCO Limited Partnership ("Perrigo"), that Perrigo had filed an Abbreviated New Drug Application ("ANDA"), with the United States Food and Drug Administration seeking regulatory approval to market a generic version of NARCAN&#174;(naloxone hydrochloride) Nasal Spray 4mg/spray before the expiration of U.S. Patent Nos. 9,211,253, (the "&#8216;253 Patent"), 9,468,747 (the "&#8216;747 Patent"), 9,561,177, (the "&#8216;177 Patent"), 9,629,965, (the "&#8216;965 Patent") and 9,775,838 (the "&#8216;838 Patent"). On or about October 25, 2018, Perrigo sent a subsequent notice letter relating to U.S. Patent No. 10,085,937 (the "937 Patent"). Perrigo&#8217;s notice letters assert that its generic product will not infringe any valid and enforceable claim of these patents.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">On October 25, 2018, Emergent BioSolutions&#8217; Adapt Pharma subsidiaries and Opiant, (collectively, the "Plaintiffs"), filed a complaint for patent infringement of the &#8216;253, &#8216;747, &#8216;177, &#8216;965, and the &#8216;838 Patents against Perrigo in the United States District Court for the District of New Jersey arising from Perrigo&#8217;s ANDA filing with the FDA. Plaintiffs filed a second complaint against Perrigo on December 7, 2018, for the infringement of the &#8216;937 Patent. On February 12, 2020, Adapt Pharma and Perrigo entered into a settlement agreement to resolve the ongoing litigation.  Under the terms of the settlement, Perrigo has received a non-exclusive license under Adapt Pharma's patents to make, have made and market its generic naloxone hydrochloride nasal spray under its own ANDA. Perrigo&#8217;s license will be effective as of January 5, 2033 or earlier under certain circumstances including circumstances related to the outcome of the current litigation against Teva (as defined below) or litigation against future ANDA filers.  The Perrigo settlement agreement is subject to review by the U.S. Department of Justice and the Federal Trade Commission, and entry of an order dismissing the litigation by the U.S. District Court for the District of New Jersey.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">ANDA Litigation - Teva 2mg</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">On or about February 27, 2018, Adapt Pharma Inc. and Adapt Pharma Operations Limited and Opiant received notice from Teva Pharmaceuticals Industries Ltd. and Teva Pharmaceuticals USA, Inc. (collectively "Teva"), that Teva had filed an ANDA with the FDA seeking regulatory approval to market a generic version of NARCAN&#174; (naloxone hydrochloride) Nasal Spray 2 mg/spray before the expiration of U.S. Patent No. 9,480,644, (the "&#8216;644 Patent"), and U.S. Patent No. 9,707,226, (the "'226 Patent"). Teva's notice letter asserts that the commercial manufacture, use or sale of its generic drug product described in its ANDA will not infringe the '644 Patent or the '226 Patent, or that the '644 Patent and '226 Patent are invalid or unenforceable. Adapt Pharma Inc. and Adapt Pharma Operations Limited and Opiant filed a complaint for patent infringement against Teva in the United States District Court for the District of New Jersey.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">ANDA Litigation - Teva 4mg</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">On or about September 13, 2016, Adapt Pharma Inc. and Adapt Pharma Operations Limited and Opiant received notice from Teva that Teva had filed an ANDA with the FDA seeking regulatory approval to market a generic version of NARCAN&#174; (naloxone hydrochloride) Nasal Spray 4 mg/spray before the expiration of U.S. Patent No. 9,211,253 (the "'253 Patent"). Adapt Pharma Inc. and Adapt Pharma Operations Limited and Opiant received additional notices from Teva relating to the '747, the '177, the '965, the '838, and the &#8216;937 Patents. Teva's notice letters assert that the commercial manufacture, use or sale of its generic drug product described in its ANDA will not infringe the '253, the '747, the '177, the '965, the '838, or the &#8216;937 Patent, or that the '253, the '747, the '177, the '965, the '838, and the &#8216;937 Patents are invalid or unenforceable. Adapt Pharma Inc. and Adapt Pharma Operations Limited and Opiant filed a complaint for patent infringement against Teva in the United States District Court for the District of New Jersey with respect to the '253 Patent. Adapt Pharma Inc. and Adapt Pharma Operations Limited and Opiant also filed complaints for patent infringement against Teva in the United States District Court for the District of New Jersey with respect to the '747, the '177, the '965, and the '838 Patents. All five proceedings have been consolidated. As of the date of this filing, Adapt Pharma Inc., Adapt Pharma Operations Limited, and Opiant, have not filed a complaint related to the &#8216;937 Patent. Closing arguments took place on February 26, 2020. </span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">20</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">(unaudited, in millions, except share and per share amounts)</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-C9C19D679C31075BC25350AC63F52EFA-2" continuedAt="TextSelection-C9C19D679C31075BC25350AC63F52EFA-3"><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">In the complaints described in the paragraphs above, the Plaintiffs seek, among other relief, orders that the effective date of FDA approvals of the Teva ANDA products and the Perrigo ANDA product be a date not earlier than the expiration of the patents listed for each product, equitable relief enjoining Teva and Perrigo from making, using, offering to sell, selling, or importing the products that are the subject of Teva and Perrigo&#8217;s respective ANDAs, until after the expiration of the patents listed for each product, and monetary relief or other relief as deemed just and proper by the court.</span></div></ix:continuation><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"><ix:continuation id="TextSelection-C9C19D679C31075BC25350AC63F52EFA-3">Nalox-1 Pharmaceuticals, a non-practicing entity, filed petitions with the United States Patent and Trademark Office Patent Trial and Appeal Board (the "PTAB") requesting inter parties review ("IPR") of five of the six patents listed in the Orange Book related to NARCAN&#174; Nasal Spray 4mg/spray. In a series of decisions, the PTAB agreed to institute a review of the '253 Patent, the '747 Patent and the '965 Patent but denied review of the '177 Patent and the '838 Patent. Nalox-1 did not request review of the '937 Patent.</ix:continuation> </span></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">21</span></div></div><hr style="page-break-after:always"></hr><div><a id="sB65FDA24BFAF57AD957C6207B513CC20"></a></div><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">(unaudited, amounts in millions, except share and per share amounts)</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:12px;font-size:11pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and accompanying notes and other financial information included elsewhere in this quarterly report on Form 10-Q and our audited consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">. Some of the information contained in this discussion and analysis or set forth elsewhere in this quarterly report on Form 10-Q, includes information with respect to our plans and strategy for our business and financing, as well as forward-looking statements that involve risks and uncertainties. You should carefully review the "Special Note Regarding Forward-Looking Statements" and "Risk Factors" sections of this quarterly report on Form 10-Q for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">.</span></div><div><a id="sAC37B3B6296E5C97897C2C3BE98965E4"></a></div><div style="line-height:120%;padding-bottom:12px;padding-left:24px;text-indent:-18px;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Business Overview</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">We a</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">re a global life scienc</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">es company focused on providing to civilian and military populations a portfolio of innovative preparedness and response products and solutions that address accidental, deliberate and naturally occurring PHTs.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">We are currently focused on the following six distinct PHT categories: CBRNE; EID; travel health; emerging health crises; acute/emergency care; and CDMO. We have a product portfolio of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">ten</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> products (vaccines, therapeutics, and drug-device combination products) </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">that contribute a substantial portion of our revenue. We also have two product candidates that are procured under special circumstances by certain government agencies,  although they are not approved by the FDA or any other health agency. Additionally, we have a development pipeline consisting of a diversified mix of both pre-clinical and clinical stage product candidates (vaccines, therapeutics, devices and combination products). Finally,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">we have a fully-integrated portfolio of contract development and manufacturing services. We continue to pursue acquiring and developing products and solutions that provide an opportunity to serve both government and commercial (non-government) customers globally. The majority of revenue comes from the following products and product candidates:</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Vaccines</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Anthrax Vaccines, including our AV7909 (Anthrax Vaccine Adsorbed with Adjuvant) product candidate being developed as a next-generation anthrax vaccine for post-exposure prophylaxis and BioThrax&#174; (Anthrax Vaccine Adsorbed), the only vaccine licensed by the FDA for the general use prophylaxis and post-exposure prophylaxis of anthrax disease;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">ACAM2000&#174; (Smallpox (Vaccinia) Vaccine, Live), the only single-dose smallpox vaccine licensed by the FDA for active immunization against smallpox disease for persons determined to be at high risk for smallpox infection;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Vivotif&#174; (Typhoid Vaccine Live Oral Ty21a), the only oral vaccine licensed by the FDA for the prevention of typhoid fever; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Vaxchora&#174; (Cholera Vaccine, Live, Oral), the only FDA-licensed vaccine for the prevention of cholera.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Devices</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">NARCAN&#174; (naloxone HCl) Nasal Spray, the first needle-free formulation of naloxone approved by the FDA and Health Canada, for the emergency treatment&#160;of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">RSDL&#174; (Reactive Skin Decontamination Lotion Kit), the only medical device cleared by the FDA to remove or neutralize the following chemical warfare agents from the skin: tabun, sarin, soman, cyclohexyl sarin, VR, VX, mustard gas and T-2 toxin; and</span></div></td></tr></table></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">22</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">(unaudited, amounts in millions, except share and per share amounts)</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Trobigard&#174;, a combination drug-device auto-injector product candidate that contains atropine sulfate and obidoxime chloride. It has not been approved by the FDA or any similar health regulatory body, but is procured by certain authorized government buyers under special circumstances for potential use as a nerve agent countermeasure.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Therapeutics</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">raxibacumab (Anthrax Monoclonal), the first fully human monoclonal antibody therapeutic licensed by the FDA for the treatment and prophylaxis of inhalational anthrax;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Anthrasil&#174; (Anthrax Immune Globulin Intravenous (Human)), the only polyclonal antibody therapeutic licensed by the FDA and Health Canada for the treatment of inhalational anthrax;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">BAT&#174; (Botulism Antitoxin Heptavalent (A,B,C,D,E,F,G)-(Equine)), the only heptavalent antibody therapeutic licensed by the FDA, as well as the governing bodies in Canada, Singapore and Ukraine for the treatment of botulism;&#160;and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">VIGIV (Vaccinia Immune Globulin Intravenous (Human)), the only polyclonal antibody therapeutic licensed by the FDA and Health Canada to address certain complications from smallpox vaccination.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Contract Development and Manufacturing Services</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:24px;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">We compete for CDMO service business with a number of biopharmaceutical product development organizations, contract manufacturers of biopharmaceutical products and university research laboratories. We also compete with in-house research, development and support service departments of other biopharmaceutical companies.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#0094ff;font-style:normal;text-decoration:none;">Highlights and Business Accomplishments for 2020</span></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:5px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">On January 13, 2020, received agreement from the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) on the company&#8217;s proposed development plan to use Serum Neutralizing Antibodies (SNA) as surrogate endpoint to predict likely clinical benefit of CHIKV VLP, the company&#8217;s chikungunya virus virus-like particle (VLP) vaccine candidate, in a Phase 3 safety and immunogenicity study anticipated in late 2020. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:5px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">On January 31, 2020, received positive opinion and subsequent approval from EMA of Vaxchora</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> (Cholera Vaccine, Live, Oral), the company&#8217;s </span></div></td></tr></table></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-left:48px;padding-bottom:5px;padding-top:0px;text-align:justify;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">cholera vaccine, making it the only single-dose oral vaccine indicated for active immunization against disease caused by </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:normal;">Vibrio cholerae</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> serogroup 01 in adults and children from 6 years of age across all 27 member states of the European Union and the European Economic Area countries. </span></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">On March 10, 2020, signed a development and manufacturing agreement with Novavax, Inc. for an experimental vaccine candidate for COVID-19.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">On March 11, 2020, initiated development of two investigational plasma-derived therapies. COVID-Human Immune Globulin (COVID-HIG) is being developed as a human plasma-derived therapy candidate for potential treatment of COVID-19 in severe hospitalized and high-risk patients, and COVID-Equine Immune Globulin (COVID-EIG) is being developed as an equine plasma-derived therapy candidate for potential treatment of severe disease in humans.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">On March 18, 2020, signed a development and manufacturing agreement with Vaxart, Inc. to produce its experimental oral vaccine candidate for COVID-19.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">On March 31, 2020, signed an agreement with Novavax, Inc. to manufacture NanoFlu</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">, its seasonal influenza vaccine candidate.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">On April 2, 2020, announced HHS funding valued at $14.5 million to support the development of COVID-Human Immune Globulin (COVID-HIG), which will be included in one of the studies of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, evaluating potential treatments for COVID-19.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">On April 23, 2002, announced an agreement, valued at $135 million, to be U.S. manufacturing partner of Johnson &amp; Johnson for its lead vaccine candidate for COVID-19.</span></div></td></tr></table><div><a id="sE84F2F1336F05E1D809E6CDFC45F2207"></a></div><div style="line-height:120%;padding-bottom:12px;padding-left:24px;text-indent:-24px;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#0094ff;font-weight:bold;">Financial Operations Overview</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-style:italic;text-decoration:underline;">Revenues</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">W</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:normal;text-decoration:none;">e generate revenues from the sale of our marketed products and product candidates which include vaccines, therapeutics and devices which have been described above. Additionally, revenue is generated from the performance of CDMO services, and our performance of research and development services under contracts and grants. The USG is the largest purchaser of our CBRNE products and primarily purchases our products for the SNS, a national repository of medical countermeasures </span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">23</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">(unaudited, amounts in millions, except share and per share amounts)</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:normal;text-decoration:none;">including critical antibiotics, vaccines, chemical antidotes, antitoxins, and other critical medical supplies. The USG primarily purchases our products under long-term, firm fixed-price procurement contracts.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:normal;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Our opioid overdose reversal product, NARCAN&#174; Nasal Spray and our travel health products, comprising Vivotif and Vaxchora, are sold commercially through wholesalers and distributors, physician-directed or standing order prescriptions at retail pharmacies, as well as to other state and local community healthcare agencies, practitioners and hospitals.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">We also generate revenue from the performance of CDMO services for third-parties. Our services include fill/finish activities as well as the production of bulk drug substances on behalf of our customers.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">We have received contracts and grants funding from the USG and other non-governmental organizations to perform research and development activities, particularly related to programs addressing certain CBRNE threats and EIDs.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Our revenue, operating results and profitability have varied, and we expect that they will continue to vary on a quarterly basis.</span></div><div><a id="s9F85A646EAE6586D8305C3FE86955F06"></a></div><div style="line-height:120%;padding-bottom:12px;padding-left:24px;text-indent:-24px;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#0094ff;font-weight:bold;">Critical Accounting Policies and Estimates</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">During the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">three months ended March 31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">, there have been no significant changes to our critical accounting policies and estimates contained in our Annual Report on Form 10-K for the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">, as filed with the SEC, (see Note 2 to the accompanying condensed consolidated financial statements).</span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">24</span></div></div><hr style="page-break-after:always"></hr><div><a id="sCB9169F4B9FC5F48867E604EB80E7CCC"></a></div><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">(unaudited, amounts in millions, except share and per share amounts)</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Results of Operations</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="14" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2020</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2019</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">$ Change</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">% Change</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product sales net:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NARCAN Nasal Spray</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">72.2</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65.5</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.7</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ACAM2000</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">45.6</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(45.6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(100</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Anthrax vaccines</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">51.9</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.7</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40.2</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NM</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">24.1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30.2</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(20</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total product sales, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">148.2</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">153.0</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.8</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contract development and manufacturing services</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">21.7</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.9</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.8</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">36</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contracts and grants</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">22.6</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21.7</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.9</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">192.5</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">190.6</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.9</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost of product sales and contract development and manufacturing services</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">76.9</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">91.8</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(14.9</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(16</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">42.7</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">46.1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.4</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(7</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">69.7</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65.4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.3</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization of intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">14.8</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14.5</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">204.1</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">217.8</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(13.7</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Loss from operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">(11.6</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(27.2</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.6</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(57</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other (expense) income:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">(8.6</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(9.6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.0</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other expense, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">(1.1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.0</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other expense, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">(9.7</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.9</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(8</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Loss before provision for income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">(21.3</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(37.8</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.5</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(44</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">8.8</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.8</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.0</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(25</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">(12.5</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(26.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.5</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(52</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%)</span></div></td></tr></table></div></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">NM - Not meaningful </span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">25</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">(unaudited, amounts in millions, except share and per share amounts)</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:12px;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Total Revenues</span></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:24px;"><img src="chart-937e1a19d8725011b0d.jpg" alt="chart-937e1a19d8725011b0d.jpg" style="height:320px;width:324px;"></img></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.47325102880659%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:4%;"></td><td style="width:43%;"></td><td style="width:5%;"></td><td style="width:48%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#006ebf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NARCAN Nasal Spray</span></div></td><td style="vertical-align:bottom;background-color:#abcde5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other product sales</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ACAM2000</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#a0a0a0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contracts development and manufacturing services</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Anthrax vaccines</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#656565;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contracts and Grants</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Product Sales, net</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#0094ff;font-style:italic;text-decoration:underline;">NARCAN Nasal Spray </span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">The </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">increase</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> in NARCAN Nasal Spray sales for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">three months ended March 31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> was primarily due to an increase in sales to the U.S. public interest markets slightly offset by a decrease in sales to the U.S. commercial markets. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#0094ff;font-style:italic;text-decoration:underline;">ACAM2000</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">The </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">decrease</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> in ACAM2000 sales for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">three months ended March 31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> was due to timing of deliveries to the SNS between the two periods. ACAM2000 product sales are made under a long-term procurement contract. The fluctuations in ACAM2000 revenue are dictated by the timing of orders from the USG. </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#0094ff;font-style:italic;text-decoration:underline;">Anthrax Vaccines </span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">The </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">increase</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> in anthrax vaccine sales for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">three months ended March 31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> was primarily due to the transition of SNS deliveries from BioThrax to a consistent cadence of deliveries of AV7909.  There were limited sales of BioThrax during the three months ended March 31, 2019 in anticipation of the USG's transition from BioThrax to AV7909. Deliveries of AV7909 began in September of 2019.</span><span style="font-family:Times New Roman;font-size:12pt;color:#000000;font-weight:normal;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">   </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#0094ff;font-style:italic;text-decoration:underline;">Other Product Sales </span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">The </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">decrease</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> in the Company's other product sales during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">three months ended March 31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> was primarily due to a decline in sales of raxibacumab, Vaxchora and Vivotif offset by an increase in sales of BAT. </span></div><div style="line-height:120%;padding-bottom:12px;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Contract Manufacturing</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">The </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">increase</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> in contract manufacturing revenue for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">three months ended March 31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> is largely due to increased volumes at our Camden and Winnipeg facilities partially offset by decreases at our Bayview facility.  </span></div><div style="line-height:120%;padding-bottom:12px;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Contracts and Grants</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Contracts and grants revenue for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">three months ended March 31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> was consistent with the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">three months ended March 31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-style:normal;text-decoration:none;">Cost of Product Sales and Contract Development and Manufacturing Services</span></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:24px;"><img src="chart-f886e6c0564f5edb9d1.jpg" alt="chart-f886e6c0564f5edb9d1.jpg" style="height:233px;width:298px;"></img></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#006ebf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost of Product Sales and Contract Manufacturing</span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Wingdings;font-size:10pt;">l</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gross profit margin for product sales and contract manufacturing</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Cost of product sales and contract development and manufacturing services </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">decreased</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">three months ended March 31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> primarily due to decreases in </span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">26</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">(unaudited, amounts in millions, except share and per share amounts)</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">sales of ACAM2000 and raxibacumab which have lower gross margins. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;text-indent:0px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-style:normal;text-decoration:none;">Research and Development Expenses (Gross and Net)</span><img src="chart-7be1608b6ea75fd5aa6.jpg" alt="chart-7be1608b6ea75fd5aa6.jpg" style="height:266px;width:298px;"></img><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:92.5925925925926%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#006ebf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and Development expense</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Wingdings;font-size:10pt;">l</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and Development expense, net of contracts and grants revenue</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">The </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">decrease</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> in research and development expenses  during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">three months ended March 31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> is consistent with the decline of contract and grant revenue  following completion of developmental activities associated with our AV7909 product candidate. </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-style:normal;text-decoration:none;">Selling, General and Administrative Expenses </span></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:24px;"><img src="chart-93d7bf203aab502f964.jpg" alt="chart-93d7bf203aab502f964.jpg" style="height:233px;width:298px;"></img></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:24px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.76954732510289%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:7%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#006ebf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, General and Administrative</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Wingdings;font-size:10pt;">l</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SG&amp;A as a percentage of total revenue</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Selling, general and administrative expenses </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">increased</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">three months ended March 31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> primarily due to professional services and staffing costs to support the Company's growth. </span></div><div style="line-height:120%;padding-bottom:12px;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Amortization of Intangible Assets</span></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:24px;"><img src="chart-45f5bcfaac85917cb05.jpg" alt="chart-45f5bcfaac85917cb05.jpg" style="height:233px;width:300px;"></img></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Amortization of intangible assets for the  </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">three months ended March 31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> was consistent with the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">three months ended March 31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">. </span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">27</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">(unaudited, amounts in millions, except share and per share amounts)</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-style:normal;text-decoration:none;">Other Expense, Net</span></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:24px;"><img src="chart-ade9397b4ccf58cca64.jpg" alt="chart-ade9397b4ccf58cca64.jpg" style="height:233px;width:298px;"></img></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:84.36213991769547%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:7%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#006ebf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest expense</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Total other income (expense), net decreased by $</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">0.9</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> million for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">three months ended March 31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> due primarily to a decrease in interest expense due to a decline in interest rates period over period. </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-style:normal;text-decoration:none;">Income Tax Benefit</span></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:24px;"><img src="chart-aeca25847b2a5d44978.jpg" alt="chart-aeca25847b2a5d44978.jpg" style="height:228px;width:298px;"></img></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:24px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.5925925925926%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:7%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#006ebf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Wingdings;font-size:10pt;">l</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effective tax rate</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">During the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">three months ended March 31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> and 2019, the estimated effective tax rate was 26% and 27%, respectively. The actual effective tax rate includes the effects of discrete tax benefits of $3.2 million and $1.8 million during the three months ended March 31, 2020 and 2019. </span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">28</span></div></div><hr style="page-break-after:always"></hr><div><a id="s17110117F517591DBEFDE820B2231A3C"></a></div><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">(unaudited, amounts in millions, except share and per share amounts)</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:12px;padding-left:24px;text-indent:-24px;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#0094ff;font-weight:bold;">Liquidity and Capital Resources</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-style:italic;text-decoration:underline;">Sources of Liquidity</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">We have historically financed our operating and capital expenditures through cash on hand, cash from operations, debt financing and development funding. We also obtain financing from the sale of our common stock upon exercise of stock options. We have operated profitably for each of the last five years through the period ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">, we had unrestricted cash and cash equivalents of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">$181.5 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> and capacity under our revolving credit facility of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">$244.8 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">, we believe that we have sufficient liquidity to fund our operations over the next 12 months. </span></div><div style="line-height:120%;padding-bottom:12px;padding-left:24px;text-indent:-24px;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#0094ff;font-weight:bold;">Cash Flows</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">The following table provides information regarding our cash flows for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">three months ended March 31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:69%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2020</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2019</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash provided by (used in):</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">57.8</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">104.8</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investing activities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">(24.2</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(21.4</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financing activities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">(20.0</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(58.4</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effect of exchange rate changes on cash, cash equivalents and restricted cash</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">0.1</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Net increase in cash, cash equivalents and restricted cash</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">13.7</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;"><br/></span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;"><br/></span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">29</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">(unaudited, amounts in millions, except share and per share amounts)</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-style:normal;text-decoration:none;">Operating Activities</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Net cash provided by operating activities of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">$57.8</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> million for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">three months ended March 31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> was due to net income excluding non-cash items of $</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">19.4</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> million and working capital changes of $</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">38.4</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> million, made up of decreases in accounts receivable offset by various other items. </span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Net cash provided by operating activities of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">$104.8</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> million for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">three months ended March 31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> was due to net losses excluding non-cash items of $</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">1.7</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> million and working capital changes of $</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">106.5</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> million.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">The cash flows from operating activities </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">decreased</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">three months ended March 31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> largely due to a decline in cash collections on accounts receivables and an increase in spend for inventory.  </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-style:normal;text-decoration:none;">Investing Activities</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Net cash used in investing activities was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">$24.2</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> million and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">$21.4</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">three months ended March 31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> and 2019, respectively. The cash used in investing activities increased during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">three months ended March 31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> due to an increase in infrastructure and equipment investments.  </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-style:normal;text-decoration:none;">Financing Activities</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Net cash used in financing activities of $</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">20.0</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> million for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">three months ended March 31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> was primarily due to $</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">22.8</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> million of principal payments on the term loan and credit facility, primarily offset by cash provided by employee share-based compensation activity of $</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">3.5</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> million.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Net cash used in financing activities of $</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">58.4</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> million for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">three months ended March 31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> was primarily due to net $52.8 million of payments on the term loan and credit facility, primarily offset by cash provided by employee share-based compensation activity of $5.1 million. </span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">The cash flows used in financing activities </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">decreased</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">   $</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">38.4</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> million during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">three months ended March 31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> due to a decrease in net payments on the term loan and revolving credit facility of $</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">30.0</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> million and an increase in cash provided by net employee share-based compensation activity of $</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">8.6</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> million. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-style:normal;text-decoration:none;">Funding Requirements</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">We expect to continue to fund our anticipated operating expenses, capital expenditures, debt service </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">requirements and any future repurchase of our common stock from the following sources:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:5px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">&#9642;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">existing cash and cash equivalents;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:5px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">&#9642;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">net proceeds from the sale of our products and contract development and manufacturing services;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:5px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">&#9642;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">development contracts and grants funding; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">&#9642;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">our Senior Secured Credit Facilities and any other lines of credit we may establish from time to time.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">There are numerous risks and uncertainties associated with product sales and with the development and commercialization of our product candidates. We may seek additional external financing to provide additional financial flexibility. Our future capital requirements will depend on many factors, including (but not limited to):</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:5px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">&#9642;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">the level, timing and cost of product sales and contract development and manufacturing services;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">&#9642;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">the extent to which we acquire or invest in and integrate companies, businesses, products or technologies;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">&#9642;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">the acquisition of new facilities and capital improvements to new or existing facilities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">&#9642;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">the payment obligations under our indebtedness;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">&#9642;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">the scope, progress, results and costs of our development activities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">&#9642;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">our ability to obtain funding from collaborative partners, government entities and non-governmental organizations for our development programs;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">&#9642;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">the extent to which we adopt a share repurchase program and repurchase shares of our common stock and;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">&#9642;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">the costs of commercialization activities, including product marketing, sales and distribution.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">If our capital resources are insufficient to meet our future capital requirements, we will need to finance our cash needs through public or private equity or debt offerings, bank loans or collaboration and licensing arrangements.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">If we raise funds by issuing equity securities, our stockholders may experience dilution. Public or bank debt financing, if available, may involve agreements that include covenants, like those contained in our Senior Secured Credit Facilities, which could limit or restrict our ability to take specific actions, such as incurring additional debt, making capital expenditures, pursuing acquisition opportunities, buying back shares or </span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">30</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">(unaudited, amounts in millions, except share and per share amounts)</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">declaring dividends. If we raise funds through collaboration and licensing arrangements with third parties, it may be necessary to relinquish valuable rights to our technologies or product candidates or grant licenses on terms that may not be favorable to us.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">We are not restricted under the terms of the indenture governing our 2.875% Convertible Senior Notes due 2021 from incurring additional debt, securing existing or future debt, recapitalizing our debt or taking a number of other actions that are not limited by the terms of the indenture governing our notes that could have the effect of diminishing our ability to make payments on our indebtedness. However, our Senior Secured Credit Facilities restricts our ability to incur additional indebtedness, including secured indebtedness.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Economic conditions, including market volatility and adverse impacts on financial markets as a result of the COVID-19 pandemic, may make it more difficult to obtain financing on attractive terms, or at all. If financing is unavailable or lost, our business, operating results, financial condition and cash flows would be adversely affected, and we could be forced to delay, reduce the scope of or eliminate many of our planned activities.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;font-style:italic;text-decoration:underline;">Unused Credit Capacity</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Available room under the revolving credit facility for the periods ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">March&#160;31, 2020</span><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:normal;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">and</span><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:normal;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> was: </span></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td style="width:1%;"></td><td style="width:21%;"></td><td style="width:1%;"></td><td style="width:25%;"></td><td style="width:1%;"></td><td style="width:26%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:22%;"></td><td style="width:1%;"></td></tr><tr><td colspan="5" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">(in millions)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Total Capacity</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Outstanding Letters of Credit</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Outstanding Indebtedness on Revolving Credit Facility</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Unused Capacity</span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">March 31, 2020</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ededed;border-left:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;">$</span></div></td><td style="vertical-align:bottom;background-color:#ededed;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;">600.0</span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;">2.2</span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;">353.0</span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;">$</span></div></td><td style="vertical-align:bottom;background-color:#ededed;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;">244.8</span></div></td><td style="vertical-align:bottom;background-color:#ededed;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">December 31, 2019</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">600.0</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.2</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">373.0</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">224.8</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#0094ff;font-weight:normal;">Share Repurchase Program</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">There were no repurchases of common stock that were made through open market transactions during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">three months ended March 31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">. The Company previously had a share repurchase program, which expired as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">.</span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div><a id="sC8FFA27C6DC45406AC5E7F54768122AB"></a></div><div style="line-height:120%;padding-bottom:12px;font-size:11pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET&#160;RISK</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">For a discussion of additional risks arising from our operations, see &#8220;Item&#160;1A-Risk Factors&#8221; in this&#160;quarterly report.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Market Risk</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">We have interest rate and foreign currency market risk. We manage our interest rate risk in part by entering into interest rate swaps to swap a portion of our indebtedness that is based on variable interest rates to a fixed rate. We currently do not hedge our foreign currency exchange exposure, and the movement of foreign currency exchange rates could have an adverse or positive impact on our results of operations. We have not used derivative financial instruments for speculation or trading purposes. Because of the short-term maturities of our cash and cash equivalents, we believe that an increase in market rates would likely not have a significant impact on the realized value of our investments, but any increase in market rates would likely increase the interest expense associated with our debt.</span></div><div style="line-height:120%;padding-bottom:12px;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Interest Rate Risk</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">We have debt with a mix of fixed and variable rates of interest. Floating rate debt carries interest based generally on the eurocurrency, as defined in our Amended Credit Agreement, plus an applicable margin. We manage the impact of interest rate changes on our variable debt through derivative instruments such as interest rate swap arrangements. For debt that we have not hedged through our interest rate swap arrangements increases in interest rates could therefore increase the associated interest payments that we are required to make on this debt. </span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">We have assessed our exposure to changes in interest rates by analyzing the sensitivity to our operating results assuming various changes in market interest rates. A hypothetical increase of one percentage point in the eurocurrency rate as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> would increase our interest expense by approximately $4.5 million annually.</span></div><div style="line-height:120%;padding-bottom:12px;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Foreign Currency Exchange Rate Risk</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">We have exposure to foreign currency exchange rate fluctuations worldwide and primarily with respect to the Euro, Canadian dollar, Swiss franc and British pound. We manage our foreign currency exchange rate risk primarily by incurring, to the extent practicable, operating and financing expenses in the local currency in the countries in which we operate. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">31</span></div></div><hr style="page-break-after:always"></hr><div><a id="sD8BEE3C57C715AA3A431AA571A78A702"></a></div><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:12px;font-size:11pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">ITEM 4. CONTROLS AND PROCEDURES</span></div><div style="line-height:120%;padding-bottom:12px;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Evaluation of Disclosure Controls and Procedures</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Our management, with the participation of our chief executive officer and chief financial officer, evaluated the effectiveness of our disclosure controls and procedures as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">. The term "disclosure controls and procedures," as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the Exchange Act), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company's management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">, our chief executive officer and chief financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Changes in Internal Control Over Financial Reporting</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">There have been no changes in our internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act that occurred during the quarter ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div><a id="sE60158D0294F5C2C95A226DD865A3C17"></a></div><div style="line-height:120%;padding-bottom:12px;font-size:11pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">PART II. OTHER INFORMATION</span></div><div><a id="s70DB988F33235785836815FA375A774C"></a></div><div style="line-height:120%;padding-bottom:12px;font-size:11pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">ITEM 1. LEGAL PROCEEDINGS</span></div><div style="line-height:120%;padding-bottom:12px;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">ANDA Litigation - Perrigo 4mg</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">On September 14, 2018,  Adapt Pharma Inc.,  Adapt Pharma Operations Limited and Adapt Pharma Ltd., (collectively, Adapt Pharma), and Opiant Pharmaceuticals, Inc. (Opiant), received notice from Perrigo UK FINCO Limited Partnership (Perrigo), that Perrigo had filed an Abbreviated New Drug Application, (ANDA), with the United States Food and Drug Administration, seeking regulatory approval to market a generic version of NARCAN&#174;(naloxone hydrochloride) </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Nasal Spray 4mg/spray before the expiration of U.S. Patent Nos. 9,211,253, (the '253 Patent), 9,468,747 (the &#8216;747 Patent), 9,561,177, (the &#8216;177 Patent), 9,629,965, (the &#8216;965 Patent) and 9,775,838 (the &#8216;838 Patent). On or about October 25, 2018, Perrigo sent a subsequent notice letter relating to U.S. Patent No. 10,085,937 (the 937 Patent). Perrigo&#8217;s notice letters assert that its generic product will not infringe any valid and enforceable claim of these patents.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">On October 25, 2018, Emergent BioSolutions&#8217; Adapt Pharma subsidiaries and Opiant (collectively, Plaintiffs) filed a complaint for patent infringement of the &#8216;253, &#8216;747, &#8216;177, &#8216;965, and the &#8216;838 Patents against Perrigo in the United States District Court for the District of New Jersey arising from Perrigo&#8217;s ANDA filing with the FDA. Plaintiffs filed a second complaint against Perrigo on December 7, 2018, for the infringement of the &#8216;937 Patent.&#160; On February 12, 2020, Adapt Pharma and Perrigo entered into a settlement agreement to resolve  the ongoing litigation. Under the terms of the settlement, Perrigo has received a non-exclusive license under Adapt Pharma's patents to make, have made, and market its generic naloxone hydrochloride nasal spray under its own ANDA.  Perrigo's license will be effective as of January 5, 2033 or earlier under certain circumstances including circumstances related to the outcome of the current litigation against Teva (as defined below) or litigation against future ANDA filers. The Perrigo settlement agreement is subject to review by the U.S. Department of Justice and the Federal Trade Commission, and entry of an order dismissing the litigation by the U.S. District Court for the District of New Jersey.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">ANDA Litigation - Teva 2mg</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">On or about February 27, 2018, Adapt Pharma Inc. and Adapt Pharma Operations Limited and Opiant received notice from Teva Pharmaceuticals Industries Ltd. and Teva Pharmaceuticals USA, Inc. (collectively, Teva) that Teva had filed an ANDA with the FDA seeking regulatory approval to market a generic version of NARCAN&#174; (naloxone hydrochloride) Nasal Spray 2 mg/spray before the expiration of U.S. Patent No. 9,480,644, (the '644 Patent) and U.S. Patent No. 9,707,226, (the '226 Patent). Teva's notice letter asserts that the commercial manufacture, use or sale of its generic drug product described in its ANDA will not infringe the '644 Patent or the '226 Patent, or that the '644 Patent and '226 Patent are invalid or unenforceable. Adapt Pharma Inc. and Adapt Pharma Operations Limited and Opiant filed a complaint for patent infringement against Teva in the United States District Court for the District of New Jersey.</span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">32</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">ANDA Litigation - Teva 4mg</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">On or about September 13, 2016, Adapt Pharma Inc. and Adapt Pharma Operations Limited and Opiant received notice from Teva that Teva had filed an ANDA with the FDA seeking regulatory approval to market a generic version of NARCAN&#174; (naloxone hydrochloride) Nasal Spray 4 mg/spray before the expiration the '253 Patent. Adapt Pharma Inc. and Adapt Pharma Operations Limited and Opiant received additional notices from Teva relating to the '747, the '177, the '965, the '838, and the &#8216;937 Patents. Teva's notice letters assert that the commercial manufacture, use or sale of its generic drug product described in its ANDA will not infringe the '253, the '747, the '177, the '965, the '838, or the &#8216;937 Patent, or that the '253, the '747, the '177, the '965, the '838, and the &#8216;937 Patents are invalid or unenforceable. Adapt Pharma Inc. and Adapt Pharma Operations Limited and Opiant filed a complaint for patent infringement against Teva in the United States District Court for the District of New Jersey with respect to the '253 Patent. Adapt Pharma Inc. and Adapt Pharma Operations Limited and Opiant also filed complaints for patent infringement against Teva in the United States District Court for the District of New Jersey with respect to the '747, the '177, the '965, and the '838 Patents. All five proceedings have been consolidated. As of the date of this filing, Adapt Pharma Inc., Adapt Pharma Operations Limited, and Opiant, have not filed a complaint related to the &#8216;937 Patent. Closing arguments  took place on February 26, 2020.  </span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">In the complaints described in the paragraphs above, the Plaintiffs seek, among other relief, orders that the effective date of FDA approvals of the Teva ANDA products and the Perrigo ANDA product be a date not earlier than the expiration of the patents listed for each product,&#160; equitable relief enjoining Teva and Perrigo from making, using, offering to sell, selling, or importing the products that are the subject of Teva and Perrigo&#8217;s respective ANDAs, until after the expiration of the patents listed for each product, and monetary relief or other relief as deemed just and proper by the court.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Nalox-1 Pharmaceuticals, a non-practicing entity, filed petitions with the United States Patent and Trademark Office Patent Trial and Appeal Board ("PTAB") requesting inter parties review (IPR) of five of the six patents listed in the Orange Book related to NARCAN&#174; Nasal Spray 4mg/spray. In a series of decisions, the PTAB agreed to institute a review of the '253 Patent, the '747 Patent and the '965 Patent but denied review of the '177 Patent and the '838 Patent. Nalox-1 did not request review of the '937 Patent. </span></div><div><a id="s0EBFB2C1798D5256809447832BBAB468"></a></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:0px;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">ITEM 1A. RISK FACTORS</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">You should carefully consider the following risk factors in addition to the other information in this Quarterly Report on Form 10-Q when evaluating our </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">business because these risk factors may have a significant impact on our business, financial condition, operating results or cash flows. If any of the risks described below or in subsequent reports we file with the SEC actually occur, they may materially harm our business, financial condition, operating results or cash flows. Additional risks and uncertainties that we have not yet identified or that we presently consider to be immaterial may also materially harm our business, financial condition, operating results or cash flows. Discussion of these factors is incorporated by reference into and considered an integral part of Part&#160;I,&#160;Item 2, &#8220;Management&#8217;s Discussion and Analysis of Financial Conditions and Results of Operations.&#8221;</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GLOBAL PANDEMIC RISK</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:normal;">The COVID-19 coronavirus pandemic could adversely impact our business, results of operations and financial performance.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">In December 2019, a novel strain of coronavirus, SARS-CoV-2, was reported to have surfaced. Since then, the SARS-CoV-2 virus has been determined to cause the disease COVID-19. COVID-19 has spread worldwide, including in United States, Canada and several European countries.&#160; The World Health Organization declared the COVID-19 coronavirus outbreak as a global pandemic on March 11, 2020. The pandemic has caused various governments, including in the United States at Federal and state levels, to impose restrictions on people and businesses, such as quarantines, closures, cancellations and travel restrictions. Depending upon the severity of the COVID-19 pandemic in the United States and elsewhere where we sell our products, we may experience significant disruptions that could severely impact our business and operations, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">diversion of government funding away from our primary procured products and product candidates resulting from changes in government priorities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">limitation of company operations, including reduced productivity resulting from remote work and prolonged office closures as well as a potential adverse impact on our manufacturing operations if a significant number of our manufacturing employees contract the disease;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">potential delays or difficulties in receiving raw and other materials from third party suppliers to manufacture our products and product candidates as the pandemic has resulted in the extended shutdown of certain businesses which may in turn result in disruptions or delays to our supply chain;</span></div></td></tr></table></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">33</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">potential delays delivering products to our customers which may lead to decline in sales of our government or commercially procured products that may consequently negatively impact our revenues;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">decline to our revenues from the sales of our vaccine products that target travelers due to the significant reduction to international travel caused by the COVID-19 pandemic;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">potential delays or disruptions in our key clinical trials; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">limitations in employee resources that would otherwise be focused on our business.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">The global pandemic caused by COVID-19 continues to rapidly evolve. The extent to which the COVID-19 pandemic will impact our business, results of operations and our financial condition will depend on future developments, which are highly uncertain and cannot be predicted or reasonably estimated with confidence at this time, such as the duration of the pandemic, travel restrictions and social distancing policies and requirements in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to mitigate and treat the disease.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Due to the widespread impact of the pandemic, it is possible that our consolidated financial results for future fiscal quarters and for 2020 may be negatively impacted, including as a result of increased government regulation and introduction of mitigation and prevention measures. In addition, the COVID-19 pandemic has adversely affected, and is expected to continue to adversely affect the United States and the global economy, possibly resulting in an economic downturn and recession that could impact demand for our products. Such events that are generally outside of our control could have a material adverse impact on our business, operating results and financial conditions.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GOVERNMENT CONTRACTING RISKS</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:bold;">   </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:normal;">We currently derive a substantial portion of our revenue from USG procurement of AV7909, BioThrax and ACAM2000. If the USG&#8217;s demand for and/or funding for procurement of AV7909, BioThrax or ACAM2000 is substantially reduced, our business, financial condition, operating results and cash flows would be materially harmed.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">   We derive a substantial portion of our current and expected future revenues from USG procurement of AV7909 and BioThrax. As AV7909 is a product development candidate, there is a higher level of risk that we may encounter challenges causing delays or </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">an inability to deliver AV7909 than with BioThrax, which may have a material effect on our ability to generate and recognize revenue.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> The success of our business and our future operating results are significantly dependent on anticipated funding for the procurement of our anthrax vaccines and the terms of our BioThrax and AV7909 sales to the USG, including the price per dose, the number of doses and the timing of deliveries.  We have no certainty that funding will be made available for the procurement of these vaccines. If priorities for the SNS change generally or  with respect to our anthrax vaccines, funding to procure future doses of BioThrax or AV7909 may be delayed, limited or not available, BARDA may never complete the anticipated full transition to stockpiling AV7909 in support of anthrax preparedness, and our future business, financial condition, operating results and cash flows could be materially harmed.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">In addition, we currently derive a substantial portion of our revenues from sales of ACAM2000 to the USG. If priorities for the SNS change with respect to ACAM2000 or the USG decides not to exercise options under our ACAM2000 contract our future business, financial condition, operating results and cash flows could be materially harmed. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">   </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:normal;">  Although a pre-EUA submission package related to AV7909 has been submitted to the FDA, we may not receive an EUA and eventual FDA licensure in a timely manner or at all. Delays in our ability to achieve a favorable outcome from the FDA could prevent us from realizing the full potential value of our BARDA contract for the advanced development and procurement of AV7909.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">In collaboration with us, the CDC filed with the FDA a pre-EUA submission package related to AV7909, which enables FDA review of data in anticipation of a request for an EUA. This submission triggered BARDA to exercise its first contract option (valued at $261 million) in July 2019 to procure 10 million doses of AV7909 for inclusion into the SNS in support of anthrax preparedness.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Notwithstanding, the FDA may decide that our data are insufficient and require additional pre-clinical, clinical or other studies. If we are unsuccessful in obtaining an EUA and, ultimately, FDA licensure, in a timely manner or at all, we may not be able to realize the full potential value of the contract, which could have a material adverse effect on our future business, financial condition, operating results and cash flows. Furthermore, prior to FDA licensure, if we obtain an EUA, the EUA could be terminated if the emergency determination underlying the EUA terminates.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:normal;">Our USG procurement and development contracts require ongoing funding decisions by the USG. Simultaneous reduction or discontinuation of funding </span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">34</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:normal;">of these contracts could cause our business, financial condition, operating results and cash flows to suffer materially.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">The USG is the principal customer for our PHT-focused MCMs and is the primary source of funds for the development of most of our product candidates in our development pipeline, most notably our AV7909 product candidate. We anticipate that the USG will also be a principal customer for those MCMs that we successfully develop within our existing product development pipeline, as well as those we acquire in the future. Additionally, a significant portion of our revenue comes from USG development contracts and grants. Over its lifetime, a USG procurement or development program may be implemented through the award of many different individual contracts and subcontracts. The funding for such government programs is subject to Congressional appropriations, generally made on a fiscal year basis, even for programs designed to continue for several years. For example, sales of BioThrax to be supplied under our procurement contract with the CDC are subject to the availability of funding, mostly from annual appropriations. These appropriations can be subject to political considerations, changes in priorities due to global pandemics and stringent budgetary constraints.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Additionally, our government-funded development contracts typically give the USG the right, exercisable in its sole discretion, to extend these contracts for successive option periods following a base period of performance. The value of the services to be performed during these option periods may constitute the majority of the total value of the underlying contract. For example, the September 2016 contract award from BARDA for the development and delivery to the SNS of AV7909 for post-exposure prophylaxis of anthrax disease consists of a five-year base period of performance valued at approximately $200 million. The contract award also includes options for the delivery of additional doses of AV7909 to the SNS and options for an additional clinical study and post-marketing commitments, which, if both were to be exercised in full, would increase the total contract value to up to $1.5 billion. If levels of government expenditures and authorizations for public health countermeasure preparedness decrease or shift to programs in areas where we do not offer products or are not developing product candidates, or if the USG otherwise declines to exercise its options under our existing contracts, our revenues would suffer, as well as our business, financial condition, operating results and cash flows.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:normal;">There can be no assurance that we will be able to secure follow-on procurement contracts with the USG upon the expiration of any of our current product procurement contracts.</span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">The majority of our revenue is substantially dependent upon product procurement contracts with the USG and foreign governments for our PHT products. Upon the expiration of a procurement contract, we may not be able to negotiate a follow-on procurement contract for the particular product for a similar product volume, period of performance, pricing or other terms, or at all. The inability to secure a similar or increased procurement contract could materially affect our revenues and our business, financial condition, operating results and cash flows could be harmed. For example, the BARDA procurement contract for raxibacumab that we acquired in our acquisition of raxibacumab from Human Genome Sciences, Inc. and GlaxoSmithKline LLC (collectively referred to as GSK), expired in November 2019. We intend to negotiate follow-on procurement contracts for most of our PHT products upon the expiration of a related procurement contract, including our procurement contract for raxibacumab, but there can be no assurance that we will be successful obtaining any follow-on contracts. Even if we are successful in negotiating a follow-on procurement contract, it may be for a lower product volume, over a shorter period of performance or be on less favorable pricing or other terms. An inability to secure follow-on procurement contracts for our products could materially and adversely affect our revenues, and our business, financial condition, operating results and cash flows could be harmed.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:normal;">The government contracting process is typically a competitive bidding process and involves unique risks and requirements.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Our business involves government contracts and grants, which may be awarded through competitive bidding. Competitive bidding for government contracts presents many risks and requirements, including:</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">the possibility that we may be ineligible to respond to a request for proposal issued by the government;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">the commitment of substantial time and attention of management and key employees to the preparation of bids and proposals for contracts that may not be awarded to us;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">the need to accurately estimate the resources and cost structure that will be required to perform any contract that we might be awarded;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">the submission by third parties of protests to our responses to requests for proposal that could result in delays or withdrawals of those requests for proposal; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">in the event our competitors protest or challenge contract or grant awards made to </span></div></td></tr></table></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">35</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-left:48px;padding-bottom:12px;text-align:justify;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">us pursuant to competitive bidding, the potential that we may incur expenses or delays, and that any such protest or challenge could result in the resubmission of bids based on modified specifications, or in the termination, reduction or modification of the awarded contract.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">The USG may choose not to award us future contracts for either the development of our new product candidates or for the procurement of our existing products addressing PHTs and may instead award such contracts to our competitors. If we are unable to secure particular contracts, we may not be able to operate in the market for products that are provided under those contracts. Additionally, if we are unable to consistently win new contract awards over an extended period, or if we fail to anticipate all of the costs or resources that we will be required to secure and, if applicable, perform under such contract awards, our growth strategy and our business, financial condition and operating results and cash flows could be materially and adversely affected.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:normal;">There are a number of laws and regulations that pertain to government contracts and compliance with those laws and regulations require significant time and cost, which could have a material adverse effect on our business, financial condition, operating results and cash flows.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">As a manufacturer and supplier of MCMs to the USG addressing PHTs, we must comply with numerous laws and regulations relating to the procurement, formation, administration and performance of government contracts. These laws and regulations govern how we transact business with our government clients and, in some instances, impose additional costs and related obligations on our business operations. Among the most significant government contracting regulations that affect our business are:</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">the Federal Acquisition Regulation (FAR), and agency-specific regulations supplemental to FAR, which comprehensively regulate the award, formation, administration and performance of government contracts;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">the Defense Federal Acquisition Regulations (DFARs), and agency-specific regulations supplemental to DFARs, which comprehensively regulate the award, formation, administration and performance of U.S. Department of Defense (DoD) government contracts;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">the Department of State Acquisition Regulation (DOSAR), which regulates the relationship between a Department of State organization and a contractor or potential contractor;</span></div></td></tr></table></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">business ethics and public integrity obligations, which govern conflicts of interest and the hiring of former government employees, restrict the granting of gratuities and funding of lobbying activities and incorporate other requirements such as the Anti-Kickback Act, the Procurement Integrity Act, the False Claims Act and the Foreign Corrupt Practices Act;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">trade controls, including export and import control laws, International Traffic in Arms Regulations (ITAR), U.S. sanctions programs, and anti-boycott laws and regulations; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">laws, regulations and executive orders restricting the use and dissemination of information classified for national security purposes and the exportation of certain products and technical data.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">We may be subject to government investigations of business practices and compliance with government acquisition regulations. USG agencies routinely audit and investigate government contractors for compliance with applicable laws and standards. Even though we take significant precautions to identify, prevent and deter fraud, misconduct and non-compliance, we face the risk that our personnel or outside partners may engage in misconduct, fraud or improper activities. If we are audited or investigated and such audit or investigation were to uncover improper or illegal activities, we could be subject to civil and criminal fines and penalties, administrative sanctions, including suspension or debarment from government contracting, and suffer significant reputational harm. The loss of our status as an eligible government contractor or significant fines or penalties associated with contract non-compliance or resulting from investigations could have a material adverse effect on our business.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:normal;">The amount we are paid under our fixed price government procurement contracts is based on estimates we have made of the time, resources and expenses required for us to perform under those contracts. If our actual costs exceed our estimates, we may not be able to earn an adequate return or may incur a loss under these contracts, which could harm our operating results and materially reduce our net income.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Our current procurement contracts with HHS and the DoD are generally fixed price contracts. We expect that future procurement contracts we successfully secure with the USG would also be fixed price contracts. Under a fixed price contract, we are required to deliver our products at a fixed price regardless of the actual costs we incur. Estimating costs that are related to performance in accordance with contract </span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">36</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">specifications is difficult, particularly where the period of performance is over several years. Our failure to anticipate technical problems, estimate costs accurately or control costs during performance of a fixed price contract could reduce the profitability of such a contract or cause a loss, which could harm our operating results and materially reduce our net income.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:normal;">Unfavorable provisions in government contracts, some of which may be customary, may subject our business to material limitations, restrictions and uncertainties and may have a material adverse impact on our business, financial condition, operating results and cash flows.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Government contracts customarily contain provisions that give the USG substantial rights and remedies, many of which are not typically found in commercial contracts, including provisions that allow the USG to:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">terminate existing contracts, in whole or in part, for any reason or no reason;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">unilaterally reduce or modify contracts or subcontracts, including by imposing equitable price adjustments;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">cancel multi-year contracts and related orders, if funds for contract performance for any subsequent year become unavailable;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">decline, in whole or in part, to exercise an option to purchase product under a procurement contract or to fund additional development under a development contract;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">decline to renew a procurement contract;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">claim rights to facilities or to products, including intellectual property, developed under the contract;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">require repayment of contract funds spent on construction of facilities in the event of contract default;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">take actions that result in a longer development timeline than expected;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">direct the course of a development program in a manner not chosen by the government contractor;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">suspend or debar the contractor from doing business with the government or a specific government agency;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">pursue civil or criminal remedies under acts such as the False Claims Act and False Statements Act; and</span></div></td></tr></table></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">control or prohibit the export of products.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Generally, government contracts contain provisions permitting unilateral termination or modification, in whole or in part, at the USG&#8217;s convenience. Under general principles of government contracting law, if the USG terminates a contract for convenience, the government contractor may recover only its incurred or committed costs, settlement expenses and profit on work completed prior to the termination. If the USG terminates a contract for default, the government contractor is entitled to recover costs incurred and associated profits on accepted items only and may be liable for excess costs incurred by the government in procuring undelivered items from another source. All of our contracts, both development and procurement, with the USG, are terminable at the USG&#8217;s convenience with these potential consequences.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">In addition, our USG contracts grant the USG the right to use technologies developed by us under the government contract or the right to share data related to our technologies, for or on behalf of the USG. Under our USG contracts, we might not be able to prohibit third parties, including our competitors, from accessing such technology or data, including intellectual property, in providing products and services to the USG.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">REGULATORY AND COMPLIANCE RISKS</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:normal;">Our long-term success depends, in part, upon our ability to develop, receive regulatory approval for and commercialize product candidates we develop or acquire and, if we are not successful, our business, financial condition, operating results and cash flows may suffer.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Our product candidates and the activities associated with them are subject to extensive FDA regulation and oversight, as well as oversight by other regulatory agencies in the United States and by comparable authorities in other countries. This includes, but is not limited to, laws and regulations governing product development, including testing, manufacturing, record keeping, storage and approval, as well as advertising and promotion. In limited circumstances, governments may procure products that have not obtained regulatory approval.  In all other circumstances, failure to obtain regulatory approval for a product candidate will prevent us from selling and commercializing the product candidate.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">In the United States, to obtain approval from the FDA to market any of our future drug, biologic, or vaccine products, we will be required to submit a new drug application (NDA) or biologics license application (BLA) to the FDA. Ordinarily, the FDA requires a company to support an NDA or BLA with substantial evidence of the product candidate&#8217;s effectiveness, </span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">37</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">safety, purity and potency in treating the targeted indication based on data derived from adequate and well-controlled clinical trials, including Phase 3 trials conducted in patients with the disease or condition being targeted. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">However, many of our MCM product candidates, for example, may take advantage of a different regulatory approval pathway under the FDA&#8217;s &#8220;Animal Rule.&#8221; The Animal Rule provides a regulatory pathway for drug and biologic products targeting indications for which human efficacy studies are not feasible or would be unethical. Instead, efficacy must be demonstrated, in part, by utilizing animal models rather than testing in humans. We cannot guarantee that the FDA will permit us to proceed with licensure of any of our PHT MCM candidates under the Animal Rule. Even if we are able to proceed pursuant to the Animal Rule, it can be a very long process, and the FDA may decide that our data are insufficient to support approval and require additional preclinical, clinical or other studies, refuse to approve our products, or place restrictions on our ability to commercialize those products. Furthermore, products approved under the Animal Rule are subject to certain additional post-marketing requirements. For example, to the extent feasible and ethical, manufacturers of products approved pursuant to the Animal Rule must conduct post-marketing studies, such as field studies, to verify and describe the product candidate's clinical benefit and to assess its safety when used as indicated. We cannot guarantee that we will be able to meet this regulatory requirement even if one or more of our product candidates are approved under the Animal Rule.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">The process of obtaining these regulatory approvals is expensive, often takes many years if approval is obtained at all, and can vary substantially based upon the type, complexity and novelty of the product candidate involved. Changes in the regulatory approval process during the development period, changes in or the enactment of additional statutes or regulations, or changes in the regulatory review process generally may cause delays in the approval or rejection of an application. There is a high rate of failure inherent in this process, and potential products that appear promising at early stages of development may fail for a number of reasons, and positive results from preclinical studies may not be predictive of similar results in human clinical trials. Similarly, promising results from earlier clinical trials of a product candidate may not be replicated in later clinical trials.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">There are many other difficulties and uncertainties inherent in pharmaceutical research and development that could significantly delay or otherwise materially delay our ability to develop future product candidates.  These include, but are not limited to: </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Conditions imposed by regulators, ethics committees, or IRBs for preclinical testing and clinical trials relating to the scope or design of our clinical trials;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Restrictions placed upon, or other difficulties with respect to, clinical trials and clinical trial sites, such as clinical holds or suspension or termination of clinical trials due to, among other things, potential safety or ethical concerns or noncompliance with regulatory requirements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Delayed or reduced enrollment in clinical trials, or high discontinuation rates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Failure by third-party contractors, contract research organizations (CROs), clinical investigators, clinical laboratories, or suppliers to comply with regulatory requirements or meet their contractual obligations in a timely manner;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Greater than anticipated cost of or time required to complete our clinical trials; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Insufficient product supply or inadequate product quality.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Failure to successfully develop future product candidates for any of these or other reasons may materially adversely affect our business, financial condition, operating results and cash flows.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Once an NDA or BLA is submitted, the FDA has substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient to support approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent regulatory approval of a product candidate.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Unapproved and investigational products are also subject to FDA's laws and regulations governing advertising and promotion, which prohibit the promotion of both unapproved products and unapproved uses of approved products. &#160;There is some risk that the FDA could conclude that our communications relating to unapproved products or unapproved uses of approved products constitute the promotion of an unapproved product or product use in violation of FDA laws and regulations.&#160; There is also a risk that a regulatory authority in another country could take a similar position under that country's laws and regulations and conclude that we have violated the laws and regulations related to product development, approval, or promotion in that country.&#160; Therefore, there is a risk that we could be subject to </span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">38</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">enforcement actions if found to be in violation of such laws or regulations.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:normal;">Even if we or our collaborators obtain marketing approvals for our product candidates, the terms of approvals and ongoing regulation of our products may limit how we manufacture and market our products, which could materially impair our ability to generate revenue.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Once approval has been granted, an approved product and its manufacturer and marketer remain subject to ongoing review and extensive regulation. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">We and our collaborators must therefore comply with requirements concerning advertising and promotion for any of our product candidates for which we obtain marketing approval. Promotional communications with respect to FDA-regulated products are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#8217;s approved labeling. Thus, we will not be able to promote any products we develop for indications or uses for which they are not approved.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">In addition, manufacturers of approved products and those manufacturers&#8217; facilities are required to comply with extensive FDA requirements, including ensuring that quality control and manufacturing procedures conform to cGMPs, which include requirements relating to quality control and quality assurance as well as the corresponding maintenance of records and documentation and reporting requirements. We and our collaborators and our contract manufacturers could be subject to periodic unannounced inspections by the FDA to monitor and ensure compliance with cGMPs.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Accordingly, were we to receive marketing approval for one or more of our product candidates, we would continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production, product surveillance and quality control.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">If we and our collaborators are not able to comply with post-approval regulatory requirements, we could have the marketing approvals for our products withdrawn by regulatory authorities and our ability to market any products could be limited, which could adversely affect our ability to achieve or sustain profitability. Further, the cost of compliance with post-approval regulations may have a negative effect on our operating results and financial condition.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:normal;">Any product candidate for which we or our collaborators obtain marketing approval could be subject to restrictions or withdrawal from the market and we may be subject to substantial penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our product candidates, when and if any of them are approved.</span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Any product candidate for which we or our collaborators obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, advertising and promotional activities for such product, will be subject to continual requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, cGMP requirements relating to quality control and manufacturing, quality assurance and corresponding maintenance of records and documents, and requirements regarding the distribution of samples to physicians and recordkeeping. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the medicine, including the requirement to implement a risk evaluation and mitigation strategy.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Certain of our products are subject to postmarketing requirements (PMRs), which we are required to conduct, and postmarketing commitments (PMCs), which we have agreed to conduct. The FDA has the authority to take action against sponsors who fail to meet the obligations of a PMR, including civil monetary penalties and/or misbranding charges.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">The FDA and other agencies, including the U.S. Department of Justice (DOJ) and the HHS Office of Inspector General (OIG), closely regulate and monitor the pre-approval and post-approval marketing and promotion of products to ensure that they are marketed and distributed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA, DOJ, and OIG impose stringent restrictions on manufacturers&#8217; communications regarding unapproved products and unapproved uses of approved products and if we market unapproved products or market our approved products for unapproved indications, we may be subject to enforcement action for marketing of unapproved products or unapproved uses of approved products. Violations of the Federal Food, Drug, and Cosmetic Act (FDCA) and other statutes, including the False Claims Act, relating to the promotion and advertising of prescription products may lead to investigations and enforcement actions alleging violations of federal and state health care fraud and abuse laws, as well as state consumer protection laws.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">In addition, later discovery of previously unknown adverse events or other problems with our products, manufacturing partners or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including:</span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">39</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">restrictions on such products, manufacturing partners or manufacturing processes;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">restrictions on the labeling or marketing of a product;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">restrictions on distribution or use of a product;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">requirements to conduct post-marketing studies or clinical trials;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">warning letters or untitled letters;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">withdrawal of the products from the market;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">refusal to approve pending applications or supplements to approved applications that we submit;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">recall of products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">damage to relationships with collaborators;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">unfavorable press coverage and damage to our reputation;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">fines, restitution or disgorgement of profits or revenues;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">suspension or withdrawal of marketing approvals;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">refusal to permit the import or export of our products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">product seizure;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">injunctions or the imposition of civil or criminal penalties; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">litigation involving patients using our products.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Non-compliance with EU requirements regarding safety monitoring or pharmacovigilance, and with requirements related to the development of products for the pediatric population, can also result in significant financial penalties. Similarly, failure to comply with the EU and other legal and regulatory requirements regarding the protection of personal information can also lead to significant penalties and sanctions.  Non-compliance with similar requirements in other jurisdictions can also result in enforcement actions and significant penalties.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:normal;">Current and future legislation may increase the difficulty and cost for us and any collaborators to obtain marketing approval of and commercialize our product candidates and affect the prices we, or they, may obtain.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">In the United States and foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the health care system that could prevent or delay marketing </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product candidates for which we obtain marketing approval. We expect that current laws, as well as other health care reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we, or any collaborators, may receive for any approved products.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act (collectively, the ACA), passed in 2010, contains the following provisions of potential importance to our business and our product candidates:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">an annual, non-deductible fee on any entity that manufactures or imports specified branded prescription products and biologic agents;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for products that are inhaled, infused, instilled, implanted or injected;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">expansion of health care fraud and abuse laws, including the civil False Claims Act and the federal Anti-Kickback Statute, new government investigative powers and enhanced penalties for noncompliance;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts off negotiated prices of applicable brand products to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient products to be covered under Medicare Part D;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">extension of manufacturers&#8217; Medicaid rebate liability to individuals enrolled in Medicaid managed care organizations;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">expansion of eligibility criteria for Medicaid programs;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">new requirements to report certain financial arrangements with physicians and teaching hospitals;</span></div></td></tr></table></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">40</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">a new requirement to annually report product samples that manufacturers and distributors provide to physicians;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">a new Independent Payment Advisory Board (IPAB), which has authority to recommend certain changes to the Medicare program to reduce expenditures by the program that could result in reduced payments for prescription products; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">established the Center for Medicare and Medicaid Innovation within the Centers for Medicare &amp; Medicaid Services (CMS) to test innovative payment and service delivery models.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. These changes included aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect in April 2013 and will remain in effect through 2024 unless additional Congressional action is taken. The American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in additional reductions in Medicare and other health care funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Since enactment of the ACA, there have been numerous legal challenges and Congressional actions to repeal and replace provisions of the law. For example, with enactment of the Tax Cuts and Jobs Act of 2017, which was signed by the President on December 22, 2017, Congress repealed the &#8220;individual mandate.&#8221; The repeal of this provision, which required most Americans to carry a minimal level of health insurance, became effective on January 1, 2019. In addition, Congress will likely consider other </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">legislation to replace elements of the ACA, during the next Congressional session. It is possible that such initiatives, if enacted into law, could ultimately result in fewer individuals having health insurance coverage or in individuals having insurance coverage with less generous benefits. We will continue to evaluate the effect that the ACA and its possible repeal and replacement could have on our business.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">There have been executive actions to challenge or delay implementation of the ACA. Since January 2017, there have been two Executive Orders issued designed to delay the implementation of certain provisions of the ACA or otherwise circumvent some of the requirements for health insurance mandated by the ACA. One Executive Order directs federal agencies with authorities and responsibilities under the ACA to waive, defer, grant exemptions from, or delay the implementation of any provision of the ACA that would impose a fiscal or regulatory burden on states, individuals, health care providers, health insurers, or manufacturers of pharmaceuticals or medical devices. The second Executive Order terminates the cost-sharing subsidies that reimburse insurers under the ACA. In addition, the CMS has proposed regulations that would give states greater flexibility in setting benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the ACA for plans sold through such marketplaces. On May 16, 2019, CMS finalized a rule that amends the Medicare Advantage and Medicare Part D prescription drug benefit regulations to reduce out of pocket costs for plan enrollees and allow Medicare plans to negotiate lower rates for certain drugs. Among other things, the rule changes allow Medicare Advantage plans to use preauthorization (PA) and step therapy (ST) for six protected classes of drugs and, with certain exceptions, permit plans to implement PA and ST in Medicare Part B drugs.  The first change took effect in January 2020, while the second change will take effect in January 2021. Litigation and legislation over the ACA are likely to continue, with unpredictable and uncertain results.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">The costs of prescription pharmaceuticals have also been the subject of considerable discussion in the United States, and members of legislative and executive branches have stated that they will address such costs through new legislative and administrative measures. While any proposed measures will require authorization through additional legislation to become effective, there may be new legislative and/or administrative measures to control drug costs. At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency </span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">41</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional health care authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing. We expect that additional state and federal health care reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for health care products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:normal;">If we fail to comply with foreign, federal, state and local health care laws, including fraud and abuse and health information privacy and security laws, and antitrust laws, we could face substantial&#160;penalties and our business, results of operations, financial condition and prospects could be adversely affected.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">In the United States, certain of our products are reimbursed under federal and state health care programs such as Medicaid, Medicare, TriCare, and/or state pharmaceutical assistance programs. Many foreign countries have similar laws. Federal and state laws designed to prevent fraud and abuse under these programs prohibit pharmaceutical companies from offering valuable items or services to customers or potential customers to induce them to buy, prescribe, or recommend our product (the so-called &#8220;anti-kickback&#8221; laws). Exceptions are provided for discounts and certain other arrangements if specified requirements are met. Other federal and state laws, and similar foreign laws, not only prohibit us from submitting any false information to government reimbursement programs but also prohibit us, our employees, or any third party acting on our behalf from doing anything to cause, assist, or encourage our customers to submit false claims for payment to these programs. We are also subject to various federal, state and foreign antitrust and competition laws that prohibit certain activities that may have an impact against potential competitors. Violations of the various fraud and abuse and antitrust laws may result in severe penalties against the responsible employees and us, including jail sentences, large </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">fines, and the exclusion of our products from reimbursement under federal and state programs. Some of the laws that may affect our ability to operate include:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">the federal Anti-Kickback Statute makes it illegal for any person or entity, including a prescription drug manufacturer (or a party acting on its behalf) to knowingly and willfully solicit, receive, offer or pay remuneration, directly or indirectly, overtly or covertly, to induce, or in return for, either the referral of an individual, or the purchase, lease, prescribing or recommendation of an item, good, facility or service reimbursable by a federally funded health care program, such as the Medicare or Medicaid program. The term &#8220;remuneration&#8221; has been interpreted broadly and may constrain our marketing practices, educational programs, pricing policies and relationships with health care providers or other entities, among other activities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">the federal False Claims Act imposes criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, false or fraudulent claims for payment by a federal health care program or making a false statement or record material to payment of a false claim or avoiding, decreasing or concealing an obligation to pay money to the federal government, with potential liability including mandatory treble damages and significant per-claim penalties, currently set at $11,181 to $22,363 per false claim;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">the U.S. federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any health care benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any health care benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statement, in connection with the delivery of, or payment for, health care benefits, items or services. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge </span></div></td></tr></table></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">42</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-left:48px;padding-bottom:12px;text-align:justify;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">of the statute or specific intent to violate it in order to have committed a violation;</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (HITECH), and their respective implementing regulations mandates, among other things, the adoption of uniform standards for the electronic exchange of information in common health care transactions, as well as standards relating to the privacy, security and transmission of individually identifiable health information, which require the adoption of administrative, physical and technical safeguards to protect such information. Among other things, HITECH makes HIPAA's security standards directly applicable to &#8220;business associates,&#8221; or independent contractors or agents of covered entities that create, receive or obtain protected health information in connection with providing a service for or on behalf of a covered entity;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">the Physician Payments Sunshine Act and its implementing regulations, which require certain manufacturers of drugs, biologics, medical devices and medical supplies for which payment is available under Medicare, Medicaid or the Centers for Medicare&#160;&amp; Medicaid Services (CMS), certain payments and transfers of value made to U.S. physicians and teaching hospitals, and ownership or investment interests held by physicians and their immediate family members. Beginning in 2022, applicable manufacturers will also be required to report information regarding payments and transfers of value provided to U.S. physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, and certified nurse-midwives; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws, which may apply to items or services reimbursed by any third-party payor, including commercial insurers; state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts; state, local and foreign laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, obtain </span></div></td></tr></table></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-left:48px;padding-bottom:12px;text-align:justify;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">pharmaceutical agent licensure, and/or otherwise restrict payments that may be made to health care providers and entities; and state, local and foreign laws that require drug manufacturers to report information related to payments and other transfers of value to health care providers or entities, or marketing expenditures.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available under the federal Anti-Kickback Statute, it is possible that some of our business activities could be subject to challenges under one or more of such laws. Moreover, recent health care reform legislation has strengthened these laws. For example, the ACA, among other things, amends the intent requirement of the federal Anti-Kickback Statute and criminal health care fraud statutes, so that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it. In addition, the ACA provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">If our operations are found to be in violation of any of the laws described above or any governmental regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, individual imprisonment, integrity obligations, exclusion from funded health care programs and the curtailment or restructuring of our operations. Any such penalties could adversely affect our financial results. We continue to improve our corporate compliance program designed to ensure that our development, marketing, and sales of existing and future products and product candidates are in compliance with all applicable laws and regulations, but we cannot guarantee that this program will protect us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Efforts to ensure that our business arrangements with third parties will comply with applicable health care laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other health care laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may </span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">43</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">be subject to significant civil, criminal and administrative penalties, damages, fines, individual imprisonment, integrity obligations, exclusion from government funded health care programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any of the physicians or other health care providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusion from government funded health care programs. If a third party fails to comply with applicable laws and regulations while acting on our behalf, we may also be subject to criminal, civil, and administrative penalties, including those listed above.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">We are committed to conducting the development, sale and marketing of our applicable products and product candidates and all our activities in compliance with all applicable laws and regulations, but certain applicable laws and regulations may impose liability even in the absence of specific intent to defraud. Furthermore, should there be ambiguity, a governmental authority may take a position contrary to a position we have taken, or should an employee or third party acting on our behalf violate these laws without our knowledge, a governmental authority may impose civil and/or criminal sanctions.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">The United States government, state governments and private payors regularly investigate the pricing and competitive practices of pharmaceutical companies and biotechnology companies, and many file actions alleging that inaccurate reporting of prices has improperly inflated reimbursement rates. We may also be subject to investigations related to our pricing practices. Regardless of merit or eventual outcome, these types of investigations and related litigation can result in:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Diversion of management time and attention;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Expenditure of large amounts of cash on legal fees, costs and payment of damages or penalties;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Limitations on our ability to continue some of our operations;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Decreased demand for our products; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Injury to our reputation.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Moreover, an adverse outcome, or the imposition of penalties or sanctions for failing to comply with the fraud and abuse and antitrust laws, could adversely affect us and may have a material adverse effect on our business, results of operations, financial condition and cash flows.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:normal;">If we fail to comply with our obligations under U.S. governmental pricing programs, we could&#160;be required </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:normal;">to reimburse government programs for underpayments and could pay penalties, sanctions and fines.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">The issuance of regulations and coverage expansion by various governmental agencies relating to the Medicaid rebate program will continue to increase our costs and the complexity of compliance and will be time-consuming. Changes to the definition of &#8220;average manufacturer price&#8221; (AMP), and the Medicaid rebate amount under the ACA and CMS and the issuance of final regulations implementing those changes has affected and could further affect our 340B &#8220;ceiling price&#8221; calculations. Because we participate in the Medicaid rebate program, we are required to report &#8220;average sales price&#8221; (ASP), information to CMS for certain categories of drugs that are paid for under Part B of the Medicare program. Future statutory or regulatory changes or CMS binding guidance could affect the ASP calculations for our products and the resulting Medicare payment rate and could negatively impact our results of operations.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Pricing and rebate calculations vary among products and programs, involve complex calculations and are often subject to interpretation by us, governmental or regulatory agencies and the courts. The Medicaid rebate amount is computed each quarter based on our submission to CMS of our current AMP and &#8220;best price&#8221; for the quarter. If we become aware that our reporting for a prior quarter was incorrect, or has changed as a result of recalculation of the pricing data, we are obligated to resubmit the corrected data for a period not to exceed twelve quarters from the quarter in which the data originally were due. Any such revisions could have the impact of increasing or decreasing our rebate liability for prior quarters, depending on the direction of the revision. Such restatements and recalculations increase our costs for complying with the laws and regulations governing the Medicaid rebate program. Price recalculations also may affect the &#8220;ceiling price&#8221; at which we are required to offer our products to certain covered entities, such as safety-net providers, under the 340B/Public Health Service (PHS) drug pricing program.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">In addition to retroactive rebate liability and the potential for 340B program refunds, if we are found to have made a misrepresentation in the reporting of ASP, we are subject to civil monetary penalties for each such price misrepresentation and for each day in which such price misrepresentation was applied. If we are found to have knowingly submitted false AMP or &#8220;best price&#8221; information to the government, we may be liable for civil monetary penalties per item of false information. Any refusal of a request for information or knowing provision of false information in connection with an AMP survey verification also would subject us to civil monetary penalties. In addition, our failure to submit monthly/quarterly AMP or &#8220;best price&#8221; </span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">44</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">information on a timely basis could result in a civil monetary penalty per day for each day the information is late beyond the due date. Such failure also could be grounds for CMS to terminate our Medicaid drug rebate agreement, pursuant to which we participate in the Medicaid program. In the event that CMS terminates our rebate agreement, no federal payments would be available under Medicaid or Medicare Part B for our covered outpatient drugs. Governmental agencies may also make changes in program interpretations, requirements or conditions of participation, some of which may have implications for amounts previously estimated or paid. We cannot assure that our submissions will not be found by CMS to be incomplete or incorrect.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">In order for our products to be reimbursed by the primary federal governmental programs, we must report certain pricing data to the USG. Compliance with reporting and other requirements of these federal programs is a pre-condition to: (i)&#160;the availability of federal funds to pay for our products under Medicaid and Medicare Part B; and (ii)&#160;procurement of our products by the Department of Veterans Affairs (DVA), and by covered entities under the 340B/PHS program. The pricing data reported are used as the basis for establishing Federal Supply Schedule (FSS), and 340B/PHS program contract pricing and payment and rebate rates under the Medicare Part B and Medicaid programs, respectively. Pharmaceutical companies have been prosecuted under federal and state false claims laws for submitting inaccurate and/or incomplete pricing information to the government that resulted in increased payments made by these programs. The rules governing the calculation of certain reported prices are highly complex. Although we maintain and follow strict procedures to ensure the maximum possible integrity for our federal pricing calculations, the process for making the required calculations involves some subjective judgments and the risk of errors always exists, which creates the potential for exposure under the false claims laws. If we become subject to investigations or other inquiries concerning our compliance with price reporting laws and regulations, and our methodologies for calculating federal prices are found to include flaws or to have been incorrectly applied, we could be required to pay or be subject to additional reimbursements, penalties, sanctions or fines, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">To be eligible to have our products paid for with federal funds under the Medicaid and Medicare Part B programs as well as to be purchased by certain federal agencies and certain federal grantees, we also must participate in the DVA FSS pricing program. To participate, we are required to enter into an&#160;FSS contract with the DVA, under which we must make our innovator &#8220;covered drugs&#8221; available to the &#8220;Big Four&#8221; </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">federal agencies-the DVA, the DoD, the Public Health Service (including the Indian Health Service), and the Coast Guard-at pricing that is capped pursuant to a statutory federal ceiling price (FCP), formula set forth in Section&#160;603 of the Veterans Health Care Act of 1992 (VHCA). The FCP is based on a weighted average wholesale price known as the Non-Federal Average Manufacturer Price (Non-FAMP), which manufacturers are required to report on a quarterly and annual basis to the DVA. Pursuant to the VHCA, knowing provision of false information in connection with a Non-FAMP filing can subject us to significant penalties for each item of false information. If we overcharge the government in connection with our FSS contract or Section&#160;703 Agreement, whether due to a misstated FCP or otherwise, we are required to disclose the error and refund the difference to the government. The failure to make necessary disclosures and/or to identify contract overcharges can result in allegations against us under the False Claims Act and other laws and regulations. Unexpected refunds to the government, and responding to a government&#160;investigation or enforcement action, can be expensive and time-consuming, and could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:normal;">Under certain circumstances, we might sell unapproved MCMs to government entities. While this is permissible in some cases, the extent to which we may be able to lawfully market and sell unapproved products in many jurisdictions may be unclear or ambiguous. Such sales could subject us to regulatory enforcement action, product liability and reputational risk.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Under certain circumstances, MCMs may be procured by government entities prior to approval by the FDA or other regulatory authorities, a practice which we follow in connection with AV7909 and Trobigard. In the United States, the Project BioShield Act of 2004 (Project BioShield) permits the Secretary of HHS to contract to purchase MCMs for the SNS prior to FDA approval of the countermeasure in specified circumstances. Project BioShield and the Pandemic and All-Hazards Preparedness Reauthorization Act of 2013 also allow the FDA Commissioner to authorize the emergency use of medical products that have not yet been approved by the FDA under an EUA. An EUA terminates when the emergency determination underlying the EUA terminates. An EUA is not a long-term alternative to obtaining FDA approval, licensure, or clearance for a product. Absent an applicable exception, our MCM product candidates generally will have to be approved by the FDA or other regulatory authorities in the relevant country through traditional pathways before we can sell those products to governments. Additionally, the laws in certain jurisdictions regarding the ability of government entities to purchase unapproved product candidates are ambiguous, and </span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">45</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">the permissibility of exporting unapproved products from the United States and importing them to foreign countries may be unclear. Nevertheless, government bodies, such as U.S. federal entities other than HHS, state and local governments within the United States, and foreign governments, may seek to procure our MCM product candidates that are not yet approved. If so, we would expect to assess the permissibility and liability implications of supplying our product candidates to such entities on a case-by-case basis, which presents certain challenges, both in the case of U.S. and foreign governments, and particularly under emergency conditions. In addition, agencies or branches of one country&#8217;s government may take different positions regarding the permissibility of such sales than another country&#8217;s government or even other agencies or branches of the same government. If we determine that we believe such activities are permissible, local enforcement authorities could disagree with our conclusion and take enforcement action against us.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">In addition, the sale of unapproved products also could give rise to product liability claims for which we may not be able to obtain indemnification or insurance coverage. For example, liability protections applicable to claims arising under U.S. law and resulting from the use of certain unlicensed products, such as a declaration issued under the Public Readiness and Emergency Preparedness Act (the PREP Act) do not cover claims arising under non-U.S. law.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Regardless of the permissibility and liability risks, in the event a user of one or more of our products suffers an adverse event, we may be subject to additional reputational risk if the product has not been approved by the FDA or the corresponding regulatory authority of another country, particularly because we will not have approved labeling regarding the safety or efficacy of those products. In addition, legislatures and other governmental bodies that have oversight responsibility for procuring agencies may raise concerns after the fact, even if procurement was permissible at the time, which could result in negative publicity, reputational risk and harm to our business prospects.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">There is also a risk that our communications with governments about our unapproved products, such as in the procurement context, could be considered promotion of an unapproved product or unapproved use of an approved product. Therefore, there is a risk that we could be subject to enforcement actions if found to be in violation of such laws or regulations.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:normal;">Even after regulatory approval is received, if we fail to comply with regulatory requirements, or if we experience unanticipated problems with our approved products, they could be subject to restrictions, penalties or withdrawal from the market.</span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">In addition to the requirements and uncertainties related to pre-approval activities discussed previously, any vaccine, therapeutic product or medical device for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, advertising and promotional activities for such product, will be subject to continual requirements of and review by the FDA and other regulatory bodies. Our approved products are subject to these requirements and ongoing review. These requirements include submissions of safety and other post-marketing information and reports, plasma donor testing, registration requirements, cGMP, requirements relating to potency and stability, quality control, quality assurance, restrictions on advertising and promotion, import and export restrictions and recordkeeping requirements. In addition, various state laws require that companies that manufacture and/or distribute drug products within the state obtain and maintain a manufacturer or distributor license, as appropriate. Because of the breadth of these laws, it is possible that some of our business activities could be subject to challenge under one or more of such laws.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Government regulators enforce cGMP and other requirements through periodic unannounced inspections of manufacturing facilities. The FDA is authorized to inspect domestic and foreign manufacturing facilities without prior notice at reasonable times and in a reasonable manner. Health Canada may conduct similar inspections of our domestic and foreign facilities where Canadian marketed products are produced, or related formulation and filling operations are conducted. The FDA, Health Canada, and other foreign regulatory agencies conduct periodic inspections of our facilities. Following several of these inspections, regulatory authorities have issued inspectional observations, some of which were significant, but all of which are being, or have been, addressed through corrective actions. If, in connection with any future inspection, regulatory authorities find that we are not in substantial compliance with all applicable requirements, or if they are not satisfied with the corrective actions we take, our regulators may undertake enforcement action against us, which may include:</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">warning letters and other communications;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">product seizure or withdrawal of the product from the market;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">restrictions on the marketing or manufacturing of a product;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">suspension or withdrawal of regulatory approvals or refusal to approve pending </span></div></td></tr></table></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">46</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-left:48px;padding-bottom:12px;text-align:justify;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">applications or supplements to approved applications;</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">fines or disgorgement of profits or revenue; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">injunctions or the imposition of civil or criminal penalties.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Similar action may be taken against us should we fail to comply with regulatory requirements, or later discover previously unknown problems with our products or manufacturing processes. For instance, our products are tested regularly to determine if they satisfy potency and stability requirements for their required shelf lives. Failure to meet potency, stability or other specification requirements could result in delays in distributions, recalls or other consequences.  Even if regulatory approval of a product is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval. Regulatory approval may also contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the product. If we experience any of these post-approval events, our business, financial condition, operating results and cash flows could be materially and adversely affected.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Additionally, companies may not promote unapproved products or unapproved uses of approved products (i.e. &#8220;off-label&#8221; uses or uses that are not described in the product&#8217;s approved labeling and that differ from the uses approved by the applicable regulatory agencies). A company that is found to have improperly promoted an unapproved product or unapproved use of an approved product may be subject to significant liability, including civil and administrative remedies (such as entering into corporate integrity agreements with the USG), as well as criminal sanctions. If our employees or agents engage in marketing of an unapproved product or the unapproved use of an approved product, we could be subject to civil or criminal investigations and monetary and injunctive penalties, which could adversely impact our ability to conduct business in certain markets, negatively affect our business, financial condition, operating results and cash flows, and damage our reputation.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:normal;">Failure to obtain or maintain regulatory approval in international jurisdictions could prevent us from marketing our products abroad and could limit the growth of our business.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">We intend to sell certain of our products, outside the United States and received market authorization under the mutual recognition procedure to sell BioThrax in France, Italy, the Netherlands, Poland, and the United Kingdom. To market our products in foreign jurisdictions under normal circumstances, we </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">generally need to obtain separate regulatory approvals and comply with numerous and varying requirements or use alternative &#8220;emergency use&#8221; or other exemptions from general approval and import requirements. Approval by the FDA in the United States or the mutual recognition procedure in the European member states does not ensure approval by all foreign regulatory authorities. The approval procedures in foreign jurisdictions can vary widely and can involve additional clinical trials and data review beyond that required by the FDA or under the mutual recognition procedure. There is also a risk that a regulatory authority in another country could conclude that we have violated the rules and regulations related to product development, approval or promotion in that country.  Therefore, there is a risk that we could be subject to a foreign enforcement action if found to be in violation of such laws and regulations.  We and our collaborators may not be able to obtain foreign regulatory approvals on a timely basis, if at all, and we may be unable to successfully commercialize our products internationally if no alternate procurement pathway is identified for authorized government customers in a particular jurisdiction. We have limited experience in preparing, filing and prosecuting the applications necessary to gain foreign regulatory approvals and expect to rely on third-party contract research organizations and consultants to assist us in this process. Our reliance on third parties can introduce additional uncertainty into the process.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">On January 31, 2020, the United Kingdom formally withdrew from the European Union and entered into a transition period through December 31, 2020 pursuant to a Withdrawal Agreement. Since a significant proportion of the regulatory framework in the United Kingdom is derived from European Union directives and regulations, Brexit could materially impact the regulatory regime with respect to the approval of our products or product candidates in the United Kingdom or the European Union. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, would prevent us from commercializing product candidates in the United Kingdom and/or the European Union and could restrict our ability to generate revenue and achieve and sustain profitability. Therefore, there is a risk that we could be subject to an enforcement action if found to be in violation of such laws or regulations.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:normal;">Laws and regulations governing international operations may preclude us from developing, manufacturing and selling certain products outside of the United States and require us to develop and implement costly compliance programs.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">As we continue to expand our commercialization activities outside of the United States, we are subject to an increased risk of, and must dedicate additional resources towards avoiding inadvertently conducting </span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">47</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">activities in a manner that violates the U.S. Foreign Corrupt Practices Act (FCPA), the U.K. Bribery Act, Canada's Corruption of Foreign Public Officials Act, and other similar foreign laws, which prohibit corporations and individuals from paying, offering to pay, or authorizing the payment of anything of value to any foreign government official, government staff member, political party, or political candidate in an attempt to obtain or retain business or to otherwise influence a person working in an official capacity. The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations.  Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Many countries, including the United States, also have various lobbying laws and regulations governing the conduct of individuals and companies who interact with government officials. These laws and regulations typically include certain restrictions and disclosure obligations. If we, our employees, or third parties acting on our behalf do not comply with these laws and regulations, we may be subject to civil and criminal penalties.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Many countries, including the United States, restrict the export or import of products to or from certain countries through, for example, bans, sanction programs, and boycotts. Such restrictions may preclude us from supplying products in certain countries, which could limit our growth potential. Furthermore, if we, or third parties acting on our behalf, do not comply with these restrictions, we may be subject to civil and criminal penalties. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Various laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain non-U.S. nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. If we continue to expand our presence outside of the United States, it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">selling certain products and product candidates outside of the United States, which could limit our growth potential and increase our development costs.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">The failure to comply with laws governing international business practices may result in substantial civil and criminal penalties and suspension or debarment from government contracting. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#8217;s accounting provisions.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">MANUFACTURING RISKS</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:normal;">Disruption at, damage to or destruction of our manufacturing facilities could impede our ability to manufacture AV7909, BioThrax, ACAM2000 or our other products, as well as deliver our contract development and manufacturing services, which would harm our business, financial condition, operating results and cash flows.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">An interruption in our manufacturing operations could result in our inability to produce our products for delivery to satisfy the product demands of our customers in a timely manner, which would reduce our revenues and materially harm our business, financial condition, operating results and cash flows. A number of factors could cause interruptions, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">equipment malfunctions or failures;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">technology malfunctions;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">cyber-attacks;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">work stoppages or slowdowns;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">protests, including by animal rights activists;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">injunctions;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">damage to or destruction of the facility; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">product contamination or tampering.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Providers of PHT countermeasures could be subject to an increased risk of terrorist activities. The USG has designated both our Lansing, Michigan and our Bayview bulk manufacturing facility in Baltimore, Maryland as facilities requiring additional security. Although we continually evaluate and update security measures, there can be no assurance that any additional security measures would protect these facilities from terrorist efforts determined to disrupt our manufacturing activities.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">The factors listed above could also cause disruptions at our other facilities, including our manufacturing facilities in Winnipeg, Manitoba, Canada; other Baltimore, Maryland facilities in Camden; facilities in Canton, Massachusetts; Rockville, Maryland, Bern, Switzerland; and </span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">48</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Hattiesburg, Mississippi. We do not have any redundant manufacturing facilities for any of our marketed products. Accordingly, any disruption, damage, or destruction of these facilities could impede our ability to manufacture our marketed products, our product candidates and our ability to produce products for external customers, result in losses and delays, including delay in the performance of our contractual obligations or delay in our clinical trials, any of which could be costly to us and materially harm our business, financial condition, operating results and cash flows.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:normal;">We may not be able to utilize the full manufacturing capacity of our manufacturing facilities, which could impact our future revenues and materially harm our business, financial condition, operating results and cash flows.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Despite our ongoing efforts to optimize the utilization of our manufacturing infrastructure (including bulk, fill/finish, support, aseptic filling, lyophilization, final packaging), we may not be able to realize full utilization, which could adversely affect our future revenues, financial condition, operating results and cash flows.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:normal;">Problems may arise during the production of our marketed products and product candidates due to the complexity of the processes involved in their manufacturing and shipment. Significant delays in product manufacturing or development could cause delays in revenues, which would harm our business, financial condition, operating results and cash flows.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Several of our products, including BioThrax and ACAM2000 and many of our current product candidates, including AV7909, are biologics. Manufacturing biologic products, especially in large quantities, is complex. The products must be made consistently and in compliance with a clearly defined manufacturing process. Problems during manufacturing may arise for a variety of reasons, including problems with raw materials, equipment malfunction and failure to follow specific protocols and procedures. In addition, slight deviations anywhere in the manufacturing process, including obtaining materials, maintaining master seed or cell banks and preventing genetic drift, seed or cell growth, fermentation, contamination including from particulates among other things, filtration, filling, labeling, packaging, storage and shipping, potency and stability issues and other quality control testing, may result in lot failures or manufacturing shut-downs, delays in the release of lots, product recalls, spoilage or regulatory action. Such deviations may require us to revise manufacturing processes or change manufacturers. Additionally, as our equipment ages, it will need to be replaced. Replacement of equipment has the potential to introduce variations in the manufacturing process that may result in lot failures </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">or manufacturing shut-downs, delay in the release of lots, product recalls, spoilage or regulatory action. Success rates can also vary dramatically at different stages of the manufacturing process, which can reduce yields and increase costs. From time to time, we may experience deviations in the manufacturing process that may take significant time and resources to resolve and, if unresolved, may affect manufacturing output and could cause us to fail to satisfy customer orders or contractual commitments, lead to a termination of one or more of our contracts, lead to delays in our clinical trials, result in litigation or regulatory action against us, including warning letters and other restrictions on the marketing or manufacturing of a product, or cause the FDA to cease releasing product until the deviations are explained and corrected, any of which could be costly to us, damage our reputation and negatively impact our business.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Additionally, if changes are made to the manufacturing process, we may be required to provide the FDA with pre-clinical and clinical data showing the comparable identity, strength, quality, purity or potency of any impacted products before and after the changes.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">We are contractually required to ship our biologic products at a prescribed temperature range and variations from that temperature range could result in loss of product and could significantly and adversely impact our revenues, which would harm our business, financial condition, operating results and cash flows.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Manufacturing delays, lot failures, shipping deviations, spoilage or other loss during shipping could cause us to fail to satisfy customer orders or contractual commitments, lead to a termination of one or more of our contracts, lead to delays in potential clinical trials or result in litigation or regulatory action against us, any of which could be costly to us and otherwise harm our business.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:normal;">Our products and product candidates procured by the USG and other customers require us to perform tests for and meet certain potency and lot release standards prescribed by the FDA and other agencies, which may not be met on a timely basis or at all.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Our products and product candidates procured by the USG and other customers require us to perform tests for and meet certain potency and lot release standards prescribed by the FDA and other agencies, which may not be met on a timely basis or at all. We are unable to sell any products and product candidates that fail to satisfy such testing specifications. For example, we must provide the FDA with the results of certain tests, including potency tests, before certain lots are released for sale. Potency testing of each applicable lot is performed against qualified control lots that we maintain. We continually monitor the </span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">49</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">status of such reference lots for FDA compliance and periodically produce and qualify a new reference lot to replace the existing reference lot. If we are unable to satisfy USG requirements for the release of our products or product candidates, our ability to supply such products and product candidates to authorized buyers would be impaired until such time as we become able to meet such requirements, which could materially harm our future business, financial condition, operating results and cash flows.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:normal;">Our operations, including our use of hazardous materials, chemicals, bacteria and viruses, require us to comply with regulatory requirements and expose us to significant potential liabilities.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Our operations involve the use of hazardous materials, including chemicals, bacteria and viruses, and may produce dangerous waste products. Accordingly, we, along with the third parties that conduct clinical trials and manufacture our products and product candidates on our behalf, are subject to federal, state, local and foreign laws and regulations that govern the use, manufacture, distribution, storage, handling, exposure, disposal and recordkeeping with respect to these materials. Under the Federal Select Agent Program, pursuant to the Public Health Security and Bioterrorism Preparedness and Response Act, we are required to register with and be inspected by the Centers for Disease Control (CDC) and the Animal and Plant Health Inspection Service if we have in our possession, or if we use or transfer, select biological agents or toxins that could pose a threat to public health and safety, to animal or plant health or to animal or plant products. This legislation requires stringent safeguards and security measures for these select agents and toxins, including controlled access and the screening of entities and personnel and establishes a comprehensive national database of registered entities. We are also subject to a variety of environmental and occupational health and safety laws. Compliance with current or future laws and regulations can require significant costs and we could be subject to substantial fines and penalties in the event of noncompliance. In addition, the risk of contamination or injury from these materials cannot be completely eliminated. In such event, we could be held liable for substantial civil damages or costs associated with the cleanup of hazardous materials. From time to time, we have been involved in remediation activities and may be so involved in the future. Any related cost or liability might not be fully covered by insurance, could exceed our resources and could have a material adverse effect on our business, financial condition, operating results and cash flows. In addition to complying with environmental and occupational health and safety laws, we must comply with special regulations relating to biosafety administered by the CDC, HHS, U.S. Department of </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Agriculture and the DoD, as well as regulatory authorities in Canada.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">RELIANCE ON THIRD PARTIES</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:normal;">The loss of any of our non-exclusive, sole-source or single source suppliers or an increase in the price of inventory supplied to us could have an adverse effect on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">We purchase certain supplies used in our manufacturing processes from non-exclusive, or single sources due to quality considerations, costs or constraints resulting from regulatory requirements, including key components for NARCAN&#174; Nasal Spray. Where a particular single-source supply relationship is terminated, we may not be able to establish additional or replacement suppliers for certain components or materials quickly. This is largely due to the FDA approval system, which mandates validation of materials prior to use in our products, and the complex nature of manufacturing processes. In addition, we may lose a sole-source supplier due to, among other things, the acquisition of such a supplier by a competitor (which may cause the supplier to stop selling its products to us) or the bankruptcy of such a supplier, which may cause the supplier to cease operations. Any reduction or interruption by a sole-source supplier of the supply of materials or key components used in the manufacturing of our products or an increase in the price of those materials or components could adversely affect our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Additionally, any failure by us to forecast demand for, or our suppliers to maintain an adequate supply of, the raw material and finished product for producing NARCAN&#174; Nasal Spray could result in an interruption in the supply of NARCAN&#174; Nasal Spray and a decline in sales of the product.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:normal;">If we are unable to obtain supplies for the manufacture of our products and product candidates in sufficient quantities, at an acceptable cost and in acceptable quality, our ability to manufacture or to develop and commercialize our products and product candidates could be impaired, which could materially harm our revenues, lead to a termination of one or more of our contracts, lead to delays in clinical trials or otherwise materially harm our business.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">We depend on certain single-source suppliers for key materials and services necessary for the manufacture of AV7909, BioThrax, ACAM2000, NARCAN Nasal Spray and our other products and product candidates. For example, we rely on a single-source supplier to provide us with Alhydrogel in sufficient quantities to meet our needs to manufacture BioThrax and AV7909. We also rely on single-source suppliers for the specialty plasma in our hyperimmune </span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">50</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">specialty plasma products and certain ingredients for ACAM2000. A disruption in the availability of such materials or services from these suppliers or in the quality of the material provided by such suppliers could require us to qualify and validate alternative suppliers. If we are unable to locate or establish alternative suppliers, our ability to manufacture our products and product candidates could be adversely affected and could harm our revenues, cause us to fail to satisfy contractual commitments, lead to a termination of one or more of our contracts or lead to delays in our clinical trials, any of which could be costly to us and otherwise materially harm our business, financial condition, operating results and cash flows.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:normal;">We depend on third parties to conduct many of our clinical and non-clinical trials. If these third parties do not perform as contractually required or as we expect, we may not be able to obtain regulatory approval for or commercialize our product candidates and, as a result, our business, financial condition, operating results and cash flows may suffer.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">We depend on third parties, such as independent clinical investigators, contract research organizations and other third-party service providers to conduct the clinical and non-clinical trials of our product candidates and expect to continue to do so. We rely heavily on these third parties for successful execution of our clinical and non-clinical trials, but do not exercise day-to-day control over their activities. Our reliance on these service providers does not relieve us of our regulatory responsibilities, including ensuring that our trials are conducted in accordance with good clinical practice regulations and the plan and protocols contained in the relevant regulatory application. In addition, these organizations may not complete these activities on our anticipated or desired timeframe. We also may experience unexpected cost increases that are beyond our control. Problems with the timeliness or quality of the work of a contract research organization may lead us to seek to terminate the relationship and use an alternative service provider, which may prove difficult, costly and result in a delay of our trials. Any delay in or inability to complete our trials could delay or prevent the development, approval and commercialization of our product candidates.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">In certain cases, government entities and non-government organizations conduct studies of our product candidates, and we may seek to rely on these studies in applying for marketing approval for certain of our product candidates. These government entities and non-government organizations have no obligation or commitment to us to conduct or complete any of these studies or clinical trials and may choose to discontinue these development efforts at any time. Furthermore, government entities depend on annual </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Congressional appropriations to fund their development efforts, which may not be approved.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">If we are unable to obtain any necessary third-party services on acceptable terms or if these service providers do not successfully carry out their contractual duties or meet expected deadlines, our efforts to obtain regulatory approvals for our product candidates may be delayed or prevented.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">RISKS RELATED TO STRATEGIC ACQUISITIONS AND COLLABORATIONS</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:normal;">Our strategy of generating growth through acquisitions may not be successful.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Our business strategy includes growing our business through acquisition and in-licensing transactions. We may not be successful in identifying, effectively evaluating, structuring, acquiring or in-licensing, and developing and commercializing additional products on favorable terms, or at all. Competition for attractive product opportunities is intense and may require us to devote substantial resources, both managerial and financial, to an acquisition opportunity. A number of more established companies are also pursuing strategies to acquire or in-license products in the biopharmaceutical field. These companies may have a competitive advantage over us due to their size, cash resources, cost of capital, effective tax rate and greater clinical development and commercialization capabilities.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Acquisition efforts can consume significant management attention and require substantial expenditures, which could detract from our other programs. In addition, we may devote significant resources to potential acquisitions that are never completed. Even if we are successful in acquiring a company or product, it may not result in a successfully developed or commercialized product or, even if an acquired product is commercialized, competing products or technologies could render a product noncompetitive, uneconomical or obsolete. Moreover, the cost of acquiring other companies or in-licensing products could be substantial, and in order to acquire companies or new products, we may need to incur substantial debt or issue dilutive securities.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">If we are unsuccessful in our efforts to acquire other companies or in-license and develop additional products, or if we acquire or in-license unproductive assets, it could have a material adverse effect on the growth of our business, and we could be compelled to record significant impairment charges to write-down the carrying value of our acquired intangible assets, which could materially harm our business, financial condition, operating results and cash flows.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:normal;">Our failure to successfully integrate acquired businesses and/or assets into our operations could </span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">51</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:normal;">adversely affect our ability to realize the benefits of such acquisitions and, therefore, to grow our business.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">We may not be able to integrate any acquired business successfully or operate any acquired business profitably, including our acquisitions of Adapt and PaxVax. In addition, cost synergies, if achieved at all, may be less than we expect, or may take greater time to achieve than we anticipate.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Issues that could delay or prevent successful integration or cost synergies of an acquired business or products include, among others:</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">retaining existing customers and attracting new customers;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">retaining key employees;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">diversion of management attention and resources;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">conforming internal controls, policies and procedures, business cultures and compensation programs;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">consolidating corporate and administrative infrastructures;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">successfully executing technology transfers and obtaining required regulatory approvals;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">consolidating sales and marketing operations;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">identifying and eliminating redundant and underperforming operations and assets;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">assumption of known and unknown liabilities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">coordinating geographically dispersed organizations; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">managing tax costs or inefficiencies associated with integrating operations.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">If we are unable to successfully integrate pending and future acquisitions with our existing businesses, or operate any acquired business profitably, we may not obtain the advantages that the acquisitions were intended to create, which may materially adversely affect the growth of our business, financial condition, operating results and cash flows.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">COMPETITIVE AND POLITICAL RISKS</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:normal;">We face substantial competition, which may result in others developing or commercializing products before or more successfully than we do.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">The development and commercialization of new biopharmaceutical and medical technology products is highly competitive and subject to rapid technological advances. We may face future competition from other </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">companies and governments, universities and other non-profit research organizations in respect to our products, any products that we acquire, our current product candidates and any products we may seek to develop or commercialize in the future. Our competitors may develop products that are safer, more effective, more convenient or less costly than any products that we may develop or market. Our competitors may have greater resources to devote to marketing or selling their products, adapt more quickly to new technologies, scientific advances or patient preferences and needs, initiate or withstand substantial price competition more successfully than we can, or more effectively negotiate third-party licensing and collaborative arrangements.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">There are a number of companies with products or product candidates addressing PHT preparedness that are competing with us for both USG procurement and development resources. Many of our competitors have greater financial, technical and marketing resources than we do. Our competitors may receive patent protection that dominates, blocks or adversely affects our products or product candidates.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Any reduction in demand for our products or reduction or loss of development funding for our products or product candidates in favor of a competing product could lead to a loss of market share for our products and cause reduced revenues, margins and levels of profitability for us, which could adversely affect our business, financial condition, operating results and cash flows.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:normal;">Our Biologic Products may face risks of competition from biosimilar manufacturers.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Competition for BioThrax, ACAM2000, and our other biological products and product candidates, including AV7909, otherwise referred to as our &#8220;Biologic Products,&#8221; may be affected by follow-on biologics, or &#8220;biosimilars,&#8221; in the United States and other jurisdictions. Regulatory and legislative activity in the United States and other countries may make it easier for generic drug manufacturers to manufacture and sell biological drugs similar or identical to our Biologic Products, which might affect the profitability or commercial viability of our Biologic Products. Under the Biologics Price Competition and Innovation Act of 2010, the FDA cannot approve a biosimilar application until the 12-year exclusivity period for the innovator biologic has expired. Regulators in the European Union and in other foreign jurisdictions have already approved biosimilars. The specific regulatory framework for this biosimilar approval path and the extent to which an approved biosimilar would be substituted for the innovator biologic are not yet clear and will depend on many factors. If a biosimilar version of one of our Biologic Products were approved, it could have a material adverse effect on the sales and gross profits of the affected Biologic Product and could </span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">52</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">adversely affect our business, financial condition, operating results and cash flows.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:normal;">We expect our NARCAN&#174; Nasal Spray marketed product to face future competition from other treatments.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Our marketed product NARCAN&#174; Nasal Spray faces potentially substantial competition from other treatments, including injectable naloxone, auto-injectors, nasal sprays or improvised nasal spray kits. In addition, other entrants may seek approval to market generic versions of NARCAN&#174; Nasal Spray before the underlying patents expire. For example, in 2016 Teva filed, and in 2018 Perrigo filed, Abbreviated new Drug Applications with the FDA (ANDAs) which sought regulatory approval to market generic versions of NARCAN&#174; Nasal Spray before the expiration of certain underlying patents and in April 2019, Teva received FDA approval to market its generic version of NARCAN&#174; Nasal Spray. Perrigo recently entered into a settlement agreement with us. However, Teva may decide to sell its approved generic product in the market, although we have sued Teva and the litigation has not yet been resolved, so any market launch could subject Teva to the risk of damages for patent infringement. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Additionally, we are aware that other companies are developing other product candidates containing naloxone that, if successful, would compete with NARCAN Nasal Spray and reduce our market share. In January 2019, the FDA released new proposed template Drug Facts Labels to assist sponsors of investigational naloxone nasal sprays and auto-injectors seeking approval from the FDA for over-the-counter naloxone products. Any reduction in demand for NARCAN&#174; Nasal Spray in favor of a competing product, or unsuccessful efforts to defend underlying patents from infringement by generic entrants, could lead to a loss of market share and cause reduced revenues, margins and levels of profitability for us, which could adversely affect our business, financial condition, operating results and cash flows.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:normal;">Political or social factors may delay or impair our ability to market our products and may require us to spend significant management time and financial resources to address these issues.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Products developed to counter the potential impact of PHTs are subject to changing political and social environments. The political responses and social awareness of the risks of these threats on military personnel or civilians may vary over time. If the threat of terrorism were to decline, then the public perception of the risk on public health and safety may be reduced. This perception, as well as political or social pressures, could delay or cause resistance to bringing our products in development to market or limit pricing or purchases of our products, any of which </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">could negatively affect our revenues and our business, financial condition, operating results and cash flows.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">In addition, substantial delays or cancellations of purchases could result from protests or challenges from third parties. Lawsuits brought against us by third parties or activists, even if not successful, could require us to spend significant management time and financial resources defending the related litigation and could potentially damage the public's perception of us and our products. Any publicity campaigns or other negative publicity may adversely affect the degree of market acceptance of our PHT countermeasures and thereby limit the demand for our products, which would adversely affect our business, financial condition, operating results and cash flows.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">PRODUCT DEVELOPMENT AND COMMERCIALIZATION RISKS</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:normal;">Our growth depends on our success in developing and commercializing our product candidates. If we are unable to commercialize these product candidates, or experience significant delays or unanticipated costs in doing so, our business would be materially and adversely affected.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">We have invested significant effort and financial resources in the development of our vaccines, therapeutics and medical device product candidates and the acquisition of additional product candidates. In addition to our product sales, our ability to generate revenue is dependent on a number of factors, including the success of our development programs, the USG's interest in providing development funding for or procuring certain of our product candidates, and the commercial viability of our acquired or developed product candidates. The commercial success of our product candidates will depend on many factors, including accomplishing the following in an economical manner:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">successful development, formulation and cGMP scale-up of manufacturing that meets FDA or other foreign regulatory requirements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">successful program partnering;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">successful completion of clinical or non-clinical development, including toxicology studies and studies in approved animal models;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">receipt of marketing approvals from the FDA and equivalent foreign regulatory authorities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">establishment of commercial manufacturing processes and product supply arrangements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">training of a commercial sales force for the product, whether alone or in collaboration with others;</span></div></td></tr></table></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">53</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">successful registration and maintenance of relevant patent and/or other proprietary protection; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">acceptance of the product by potential government and other customers.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;">The COVID-19 product candidates we are working on may not be safe or effective and, even if they are, we may not be able to manufacture sufficient quantities to meet demand.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">We are developing two product candidates for the possible prophylaxis or treatment of COVID-19 and we are also providing contract development and manufacturing services for the development and/or manufacture of three vaccine product candidates for customers. There can be no assurance that any of these product candidates will be safe or effective. There can be no assurance that any of these product candidates will receive approval or be authorized for emergency use by the FDA or any other health regulatory authority. Even if these product candidates are safe and/or effective and receive approval or authorization by a health regulatory authority, the manufacturing process for these programs are under development and will be complex. As a result, there can be no assurance that we will be able to produce any significant quantity of these products or a timely basis or at all.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:normal;">Clinical trials of product candidates are expensive and time-consuming, and their outcome is uncertain. We must invest substantial amounts of time and financial resources in these trials, which may not yield viable products. Failure to obtain regulatory approval for product candidates, particularly in the United States, could materially and adversely affect our financial resources, which would adversely affect our business, financial condition, operating results and cash flows.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Before obtaining regulatory approval for the marketing of our product candidates, we and our collaborative partners, where applicable, must conduct preclinical studies and clinical trials to establish proof of concept and demonstrate the safety and efficacy of our product candidates. Preclinical and clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome. Success in preclinical testing and early clinical trials does not ensure that later clinical trials or animal efficacy studies will be successful, and interim results of a clinical trial or animal efficacy study do not necessarily predict final results. An unexpected result in one or more of our clinical trials can occur at any stage of testing.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Preclinical and clinical testing for certain of our product candidates addressing CBRNE threats may face additional difficulties and uncertainties because </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">they cannot ethically or feasibly be tested in human subjects. We therefore expect to rely on the Animal Rule to obtain regulatory approval. The Animal Rule permits, in certain limited circumstances, the use of animal efficacy studies, together with human clinical safety and immunogenicity trials, to support an application for marketing approval. For a product approved under the Animal Rule, certain additional post-marketing requirements apply. For example, to the extent feasible and ethical, applicants must conduct post-marketing studies, such as field studies, to verify and describe the drug's clinical benefit and to assess its safety when used as indicated. We have limited experience in the application of these rules to the product candidates that we are developing. It is possible that results from these animal efficacy studies may not be predictive of the actual efficacy of our product candidates in humans.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Under Project BioShield, the Secretary of HHS can contract to purchase MCMs for the SNS prior to FDA approval of the countermeasure in specified circumstances. Project BioShield also allows the FDA commissioner to authorize the emergency use of medical products that have not yet been approved by the FDA under an EUA. If our product candidates are not selected under this Project BioShield authority, they generally will have to be approved by the FDA through traditional regulatory mechanisms for distribution in the United States.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">We may experience unforeseen events or issues during, or as a result of, preclinical testing, clinical trials or animal efficacy studies. These issues and events, which could delay or prevent our ability to receive regulatory approval for a product candidate, include, among others:</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#160;&#160;&#160;&#160;</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">our inability to manufacture sufficient quantities of materials for use in trials;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">the unavailability or variability in the number and types of subjects for each study;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">safety issues or inconclusive or incomplete testing, trial or study results;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">drug immunogenicity;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">lack of efficacy of product candidates during the trials;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">government or regulatory restrictions or delays; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">greater than anticipated costs of trials.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:normal;">We may fail to select or capitalize on the most scientifically, clinically or commercially promising or profitable product candidates.</span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">54</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">We continue to evaluate our product development strategy and, as a result, may modify our strategy in the future. In this regard, we may, from time to time, focus our product development efforts on different product candidates or may delay or halt the development of various product candidates. We may change or refocus our existing product development, commercialization and manufacturing activities based on government funding decisions. This could require changes in our facilities and our personnel. Any product development changes that we implement may not be successful. In particular, we may fail to select or capitalize on the most scientifically, clinically or commercially promising or profitable product candidates or choose candidates for which government development funds are not available. Our decisions to allocate our research and development, management and financial resources toward particular product candidates or therapeutic areas may not lead to the development of viable commercial products and may divert resources from better business opportunities. Similarly, our decisions to delay or terminate product development programs may also prove to be incorrect and could cause us to miss valuable opportunities.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">INTELLECTUAL PROPERTY RISKS</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:normal;">If we are unable to protect our proprietary rights, our business, financial condition, operating results, and cash flows could be materially harmed.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Our success will depend, in large part, on our ability to obtain and maintain protection in the United States and other countries for the intellectual property incorporated into or covering our technology, products, and product candidates. Obtaining and maintaining protection of our intellectual property is very costly. The patentability of technology in the biopharmaceutical field generally is highly uncertain and involves complex legal and scientific questions.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">We may not be able to obtain additional issued patents relating to our technology or products. Even if issued, patents may inadvertently lapse or be challenged, narrowed, invalidated, or circumvented, and such happenings could limit our ability to stop competitors from marketing similar products or limit the duration of patent protection we may have for our products. In the past, we have abandoned the prosecution and/or maintenance of patent applications related to patent families in the ordinary course of business. In the future we may choose to abandon such prosecution and/or maintenance in a similar fashion. If these patent rights are later determined to be valuable or necessary to our business, our competitive position may be adversely affected. Changes in patent laws or administrative patent office rules or changes in interpretations of patent laws in the United States and in other countries </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">may diminish the value of our intellectual property, narrow the scope of our patent protection, or result in costly defensive measures. In addition, some countries do not grant patent claims directed to methods of treating humans and, in these countries, patent protection may not be available at all to protect our products or product candidates.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Changes to the U.S. patent system under the Leahy-Smith America Invents Act (the America Invents Act), affected the way patent applications are filed, prosecuted and litigated. For example, the America Invents Act enacted proceedings involving post-issuance patent review procedures, such as inter parties review (IPR) post-grant review (PGR) and covered business methods review (CBM). These proceedings are conducted before the Patent Trial and Appeal Board (the PTAB) of the U.S. Patent and Trademark Office. Each proceeding has different eligibility criteria and different patentability challenges that can be raised. In this regard, the IPR process permits any person (except a party who has been litigating the patent for more than a year) to challenge the validity of some patents on the grounds that it was anticipated or made obvious by prior art. As a result, non-practicing entities associated with hedge funds, pharmaceutical companies who may be our competitors and others have challenged certain valuable pharmaceutical U.S. patents based on prior art through the IPR process. A decision in such a proceeding adverse to our interests could result in the loss of valuable patent rights which would have a material adverse effect on our business, financial condition, results of operations and growth prospects. The America Invents Act and any other potential future changes to the U.S. patent system could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">The cost of litigation to uphold the validity of patents to prevent or stop infringement or to otherwise protect or enforce our proprietary rights could be substantial and, from time to time, our patents may be subjected to opposition proceedings or validity challenges. Some of our competitors may choose to or be better able to sustain the costs of complex patent litigation. Intellectual property lawsuits are expensive and unpredictable and consume management's time and attention and other resources, even if the outcome is successful. In addition, there is a risk that a court could decide that our patents are not valid, are unenforceable, or are not infringed by a competitor product. There is also a risk that, even if the validity of a patent is upheld, a court could refuse to stop the other party from using the invention(s), including on the grounds that its </span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">55</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">activities do not infringe the patent. If any of these events occur, our business, financial condition, operating results and cash flows could be materially and adversely affected.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Our collaborators and licensors may not adequately protect our intellectual property rights. These third parties may have the first right to maintain or defend intellectual property rights in which we have an interest and, although we may have the right to assume the maintenance and defense of such intellectual property rights if these third parties do not do so, our ability to maintain and defend such intellectual property rights may be compromised by the acts or omissions of these third parties. For example, we license from Opiant Pharmaceuticals, Inc. formulations of naloxone used in our NARCAN&#174; Nasal Spray.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">We also will rely on current and future trademarks to establish and maintain recognized brands. If we fail to acquire and protect such trademarks, our ability to market and sell our products, and therefore our business, financial condition, operating results, and cash flows could be materially and adversely affected.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:normal;">Third parties may choose to file patent infringement claims against us; defending ourselves from such allegations could be costly, time-consuming, distracting to management, and could materially and adversely affect our business, financial condition, operating results, and cash flows.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Our development and commercialization activities, as well as any product candidates or products resulting from these activities, may infringe or be claimed to infringe patents and other intellectual property rights of third parties for which we do not hold sufficient licenses or other rights. Additionally, third parties may be successful in obtaining patent protection for technologies that cover development and commercialization activities in which we are already engaged. Third parties may own or control these patents and intellectual property rights in the United States and abroad. These third parties could bring claims against us that could cause us to incur substantial expenses to defend against these claims and, if successful against us, could cause us to pay substantial damages. Further, if a patent infringement or other similar suit is brought against us, we could be forced to stop or delay development, manufacturing, or sales of the product or product candidate that is the subject of the suit. Intellectual property litigation in the biopharmaceutical industry is common, and we expect this trend to continue.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">As a result of patent infringement or other similar claims, or to avoid potential claims, we may choose or be required to seek a license from a third party and be required to pay license fees or royalties or both. These licenses may not be available on acceptable </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">terms, or at all. Even if we are able to obtain a license, the rights may be non-exclusive, which could result in our competitors gaining access to the same intellectual property. Ultimately, we could be prevented from commercializing a product, or be forced to cease some aspect of our business operations. If, as a result of actual or threatened patent infringement claims, we are unable to enter into licenses on acceptable terms, if at all, or if an injunction is granted against us, these could materially harm our business, financial condition, operating results, and cash flows.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:normal;">If we fail to comply with our obligations in our intellectual property licenses with third parties, we could lose license rights that are important to our business.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">We are a party to a number of license agreements and expect to enter into additional license agreements in the future. Our existing licenses impose, and we expect future licenses will impose, various diligence, milestone payment, royalty, insurance, and other obligations on us. If we fail to comply with these obligations, the licensor may have the right to terminate the license and/or sue us for breach, which could cause us to not be able to market any product that is covered by the license and subject us to damages, which may be material.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:normal;">If we are unable to protect the confidentiality of our proprietary information and know-how, the value of our technology and products could be adversely affected.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">We also rely upon unpatented proprietary technology, processes, and know-how, particularly as to our proprietary manufacturing processes. Because we do not have patent protection for all of our current products, our only other intellectual property protection for products, other than trademarks, is confidentiality regarding our manufacturing capability and specialty know-how, such as techniques, processes, and unique starting materials. However, these types of confidential information and trade secrets can be difficult to protect. We seek to protect this confidential information, in part, through agreements with our employees, consultants, and third parties, as well as confidentiality policies and audits, although these may not be successful in protecting our trade secrets and confidential information.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">These agreements may be breached, and we may not have adequate remedies for any such breach. In addition, our trade secrets may otherwise become known, including through a potential cyber security breach, or may be independently developed by competitors. If we are unable to protect the confidentiality of our proprietary information and know-how, or if others independently develop our proprietary information or processes, competitors may be able to use this information to develop products that compete </span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">56</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">with our products, which could materially and adversely impact our business.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:normal;">One or more of our products could be subject to early competition from generic drugs and biosimilars.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">One or more of our products is approved as a drug product under the provisions of the U.S. Food, Drug and Cosmetic Act (FDCA), which renders it susceptible to potential competition from generic manufacturers via the Hatch-Waxman Act and ANDA process. Generic manufacturers pursuing ANDA approval are not required to conduct costly and time-consuming clinical trials to establish the safety and efficacy of their products; rather, they are permitted to rely on the innovator&#8217;s data regarding safety and efficacy. Additionally, generic drug companies generally do not expend significant sums on sales and marketing activities, instead relying on pharmacists or payers to substitute the generic form of a drug for the branded form. Thus, generic manufacturers can sell their products at prices much lower than those charged by the innovative pharmaceutical or biotechnology companies who have incurred substantial expenses associated with the research and development of the drug product and who must spend significant sums marketing a new drug.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">The ANDA procedure includes provisions allowing generic manufacturers to challenge the innovator&#8217;s patent protection by submitting &#8220;Paragraph IV&#8221; certifications to the FDA in which the generic manufacturer claims that the innovator&#8217;s patents are invalid, unenforceable, and/or will not be infringed by the manufacture, use, or sale of the generic product. A patent owner who receives a Paragraph IV certification may choose to sue the generic applicant for patent infringement. If the patent owner files suit within 45 days of receiving notice from an ANDA filer, the patent owner is entitled to receive a 30 month stay on the FDA&#8217;s ability to give final approval for the generic product that is the subject of the ANDA.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">In recent years, generic manufacturers have used Paragraph IV certifications extensively to challenge the validity of patents listed in the FDA&#8217;s Approved Drug Products List with Therapeutic Equivalence Evaluations, commonly referred to as the Orange Book, on a wide array of innovative therapeutic products. We expect this trend to continue and to affect drug products with even relatively modest revenues.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Although we intend to vigorously enforce our intellectual property rights, there can be no assurance that we will prevail in our enforcement or defense of our patent rights. Our existing patents could be invalidated, found unenforceable, or found not to cover a generic form of our product.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Further, the 2010 Patient Protection and Affordable Care Act, which was signed into law on </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">March 23, 2010, included a subtitle called the Biologics Price Competition and Innovation Act of 2009 (BPCIA). That Act established a regulatory scheme authorizing the FDA to approve biosimilars and interchangeable biosimilars. As of January 15, 2020, the FDA has approved thirty six biosimilar products for use in the United States. No interchangeable biosimilars, have been approved. The FDA has issued several guidance documents outlining approaches for review and approval of biosimilars. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Under the Act, a manufacturer may apply for licensure of a biologic product that is &#8220;biosimilar to&#8221; or &#8220;interchangeable with&#8221; a previously approved biological product or &#8220;reference product.&#8221; In order for the FDA to approve a biosimilar product, it must find that there are no clinically meaningful differences between the reference product and proposed biosimilar product in terms of safety, purity and potency. For the FDA to approve a biosimilar product as interchangeable with a reference product, the agency must find that the biosimilar product can be expected to produce the same clinical results as the reference product, and (for products administered multiple times) that the biologic and the reference biologic may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date of approval of the reference product. The FDA may not approve a biosimilar product until 12 years from the date on which the reference product was approved. Even if a product is considered to be a reference product eligible for exclusivity, another company could market a competing version of that product if the FDA approves a full BLA for such product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it is unclear whether products deemed &#8220;interchangeable&#8221; by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">FINANCIAL RISKS</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:normal;">We have incurred significant indebtedness in connection with our acquisitions and servicing our debt requires a significant amount of cash. We may not have sufficient cash flow from our operations to pay our substantial debt.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Our ability to make scheduled payments of the principal of, to pay interest on or to refinance our indebtedness depends on our future performance, which is subject to economic, financial, competitive </span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">57</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">and other factors beyond our control. We may also seek additional debt financing to support our ongoing activities or to provide additional financial flexibility. Debt financing could have significant adverse consequences for our business, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">requiring us to dedicate a substantial portion of any cash flow from operations to payment on our debt, which would reduce the amounts available to fund other corporate initiatives;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">increasing the amount of interest that we have to pay on debt with variable interest rates, if market rates of interest increase, to the extent we are unable to offset the risk of such increases through our hedging instruments;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">subjecting us, as under our Senior Secured Credit Facilities, to restrictive covenants that may reduce our ability to take certain corporate actions, acquire companies, products or technology, or obtain further debt financing; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">requiring us to pledge our assets as collateral, which could limit our ability to obtain additional debt financing; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">limiting our flexibility in planning for, or reacting to, general adverse economic and industry conditions; and </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">placing us at a competitive disadvantage compared to our competitors that have less debt, better debt servicing options or stronger debt servicing capacity.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">We may not have sufficient funds or be able to obtain additional financing to pay the amounts due under our indebtedness. In addition, failure to comply with the covenants under our Senior Secured Credit Facilities and other debt agreements could result in an event of default under those agreements. An event of default could result in the acceleration of amounts due under a particular debt agreement and a cross default and acceleration under other debt agreements, and we may not have sufficient funds to pay or be able to obtain additional financing to make any accelerated payments. Under these circumstances, our lenders could seek to enforce security interests in our assets securing our indebtedness.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:normal;">Our current indebtedness and any additional debt financing may restrict the operation of our business and limit the cash available for investment in our&#160;business operations.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">In connection with the acquisition of Adapt, we entered into an amendment and restatement of our 2017 credit agreement to provide for new five-year syndicated Senior Secured Credit Facilities that </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">replaced our existing facility. The Senior Secured Credit Facilities include a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">$450 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> Term Loan and the ability to borrow up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">$600 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> with a revolving credit facility, of which we had outstanding borrowings of approximately $433 million and $353 million, respectively, as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">. We may also seek additional debt financing to support our ongoing activities or to provide additional financial flexibility. Debt financing could have significant adverse consequences for our business, including:</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">the level, timing and cost of product sales  and contract development and manufacturing services;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">the extent to which we acquire or invest in and integrate companies, businesses, products or technologies;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">the acquisition of new facilities and capital improvements to new or existing facilities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">the payment obligations under our indebtedness;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">the scope, progress, results and costs of our development activities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">our ability to obtain funding from collaborative partners, government entities and non-governmental organizations for our development programs;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">the extent to which we repurchase additional common stock under any future share repurchase program; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">the costs of commercialization activities, including product marketing, sales and distribution.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">We may not have sufficient funds or be able to obtain additional financing to pay the amounts due under our indebtedness. In addition, failure to comply with the covenants under our debt agreements could result in an event of default under those instruments. An event of default could result in the acceleration of amounts due under a particular debt agreement and a cross default and acceleration under other debt agreements, and we may not have sufficient funds or be able to obtain additional financing to make any accelerated payments. Under these circumstances, our lenders could seek to enforce security interests in our assets securing our indebtedness.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:normal;">hedging </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">program is subject to counterparty default risk.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">We manage our interest rate risk in part by entering into interest rate swaps with a number of counterparties to swap a portion of our indebtedness </span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">58</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">that is based on variable interest rates to a fixed rate. As a result, we are subject to the risk that the counterparty to one or more of these contracts defaults on its performance under the contract. During an economic downturn, the counterparty's financial condition may deteriorate rapidly and with little notice and we may be unable to take action to protect our exposure. In the event of a counterparty default, we could incur losses, which may harm our business and financial condition. In the event that one or more of our counterparties becomes insolvent or files for bankruptcy, our ability to eventually recover any losses suffered as a result of that counterparty's default may be limited by the liquidity of the counterparty.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:normal;">We may require significant additional funding and may be unable to raise capital when&#160;needed or on acceptable terms, which would harm our ability to grow our business, and our results of operations and financial condition.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">If our capital resources are insufficient to meet our future capital requirements, we will need to finance our cash needs through public or private equity or debt offerings, bank loans or collaboration and licensing arrangements. In August 2018, we filed an automatic shelf registration statement, which immediately became effective under SEC rules. For so long as we continue to satisfy the requirements to be deemed a &#8220;well-known seasoned issuer&#8221; under SEC rules (which include, among other things, the timely filing of our reports under the Exchange Act and maintenance of at least $700 million of public float or issuing an aggregate amount of $1 billion of non-convertible securities, other than common stock, in registered offerings for cash during the past three years), this shelf registration statement, effective until August 8, 2021, allows us to issue an unrestricted amount of equity, debt and certain other types of securities through one or more future primary or secondary offerings. If we do not file a new shelf registration statement prior to August 8, 2021, the existing shelf registration statement will expire, and we will not be able to publicly raise capital or issue debt until a new registration statement is filed and becomes effective. There can be no assurance that we will be eligible to file an automatically effective shelf registration statement at a future date when we may need to raise funds publicly.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">If we raise funds by issuing equity securities, our stockholders may experience dilution. Public or bank debt financing, if available, may involve agreements that include covenants, like those contained in our Senior Secured Credit Facilities, limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, pursuing acquisition opportunities or declaring dividends. If we raise funds through collaboration and licensing arrangements with third parties, it may be necessary </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">to relinquish valuable rights to our technologies or product candidates or grant licenses on terms that may not be favorable to us. We are not restricted under the terms of the indenture governing our 2.875% Convertible Senior Notes due 2021 (Senior Convertible Notes) from incurring additional debt, securing existing or future debt, recapitalizing our debt or taking a number of other actions that could have the effect of diminishing our ability to make payments on our indebtedness. However, our senior secured credit facilities restrict our ability to incur additional indebtedness, including secured indebtedness.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Economic conditions may make it difficult to obtain financing on attractive terms, or at all. If financing is unavailable or lost, our business, operating results, financial condition and cash flows would be adversely affected, and we could be forced to delay, reduce the scope of or eliminate many of our planned activities.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:normal;">We may not maintain profitability in future periods or on a consistent basis.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Although we have been profitable for each of the last five fiscal years, we have not been profitable for every quarter during that time. Our profitability has been substantially dependent on product sales, which historically have fluctuated significantly from quarter to quarter, and we expect that they will continue to fluctuate significantly based primarily on the timing of our fulfillment of orders from the USG. We may not be able to achieve consistent profitability on a quarterly basis or sustain or increase profitability on an annual basis.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:normal;">The expansion of our international operations increases our risk of exposure to credit losses.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">As we continue to expand our business activities with foreign governments in certain countries that have experienced deterioration in credit and economic conditions or otherwise, our exposure to uncollectible accounts will rise. Global economic conditions and liquidity issues in certain countries have resulted and may continue to result in delays in the collection of accounts receivable and may result in credit losses. Future governmental actions and customer specific actions may require us to re-evaluate the collectability of our accounts receivable and we may potentially incur credit losses that materially impact our operating results.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">OTHER BUSINESS RISKS</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:normal;">We face product liability exposure, which could cause us to incur substantial liabilities and negatively affect our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">We face an inherent risk of product liability exposure related to the sale of our products, any other </span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">59</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">products that we successfully acquire or develop and the testing of our product candidates in clinical trials.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">One measure of protection against such lawsuits is coverage under the PREP Act, which was signed into law in December 2005. The PREP Act creates liability protection for manufacturers of biodefense countermeasures when the Secretary of HHS issues a declaration for their manufacture, administration or use. A PREP Act declaration is meant to provide liability protection from all claims under federal or state law for loss arising out of the administration or use of a covered countermeasure under a government contract. The Secretary of HHS has issued PREP Act declarations identifying certain of our products, namely BioThrax, ACAM2000, raxibacumab, Anthrasil, BAT and VIGIV, as covered countermeasures. These declarations expire in 2022. Manufacturers are not entitled to protection under the PREP Act in cases of willful misconduct or for cases brought in non-U.S. tribunals or under non-U.S. law. We cannot predict whether the Secretary of HHS will renew the declarations when they expire, whether Congress will fund the relevant PREP Act compensation programs, or whether the necessary prerequisites for immunity would be triggered with respect to our products or product candidates.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Additionally, certain of our products, namely BioThrax and RSDL, are certified anti-terrorism products covered under the protections of the Support Anti-Terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). The SAFETY Act creates product liability limitations for qualifying anti-terrorism technologies for claims arising from or related to an act of terrorism. Although we are entitled to the benefits of the SAFETY Act for BioThrax and RSDL, the SAFETY Act may not provide adequate protection from claims made against us.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">If we cannot successfully defend ourselves against future claims that our products or product candidates caused injuries and if we are not entitled to indemnity by the USG, or the USG does not honor its obligations to us under the PREP Act or SAFETY Act, or if the liability protections under the PREP Act and SAFETY Act are not adequate to cover all claims, we may incur substantial liabilities. Regardless of merit or eventual outcome, product liability claims may result in:</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">decreased demand or withdrawal of a product;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">injury to our reputation;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">withdrawal of clinical trial participants;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">costs to defend the related litigation;</span></div></td></tr></table></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">substantial monetary awards to trial participants or patients;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">loss of revenue; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">an inability to commercialize products that we may develop.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">The amount of insurance that we currently hold may not be adequate to cover all liabilities that we may incur. Further product liability insurance may be difficult and expensive to obtain. We may not be able to maintain insurance coverage at a reasonable cost and we may not be able to obtain insurance coverage that will be adequate to satisfy all potential liabilities. For example, we may not have sufficient insurance against potential liabilities associated with a possible large-scale deployment of BioThrax as a countermeasure to a bioterrorism threat. We rely on PREP Act protection for BioThrax, raxibacumab, ACAM2000, Anthrasil, BAT and VIGIV, and SAFETY Act protection for BioThrax and RSDL in addition to our insurance coverage to help mitigate our product liability exposure for these products. Additionally, potential product liability claims related to our commercial products, including NARCAN&#174; Nasal Spray, Vivotif and Vaxchora, may be made by patients, health care providers or others who sell or consume these products. Such claims may be made even with respect to those products that possess regulatory approval for commercial sale. Claims or losses in excess of our product liability insurance coverage could have a material adverse effect on our business, financial condition, operating results and cash flows.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:normal;">The accuracy of our financial reporting depends on the effectiveness of our internal control over financial reporting. A material weakness in our internal control over financial reporting could have an adverse effect on our business and financial results and our ability to meet our reporting obligations could be negatively affected, each of which could negatively affect the trading price of our common stock.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Internal control over financial reporting can provide only reasonable assurance with respect to the preparation and fair presentation of financial statements and may not prevent or detect misstatements. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. Failure to maintain effective internal control over financial reporting, or lapses in disclosure controls and procedures, could impact our financial information and disclosures, require significant resources to remediate, and expose us to legal or regulatory proceedings.</span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">60</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">We regularly review and update our internal controls and disclosure controls and procedures. In addition, we are required under the Sarbanes-Oxley Act of 2002 to report annually on our internal control over financial reporting. Our system of internal controls, however well-designed, can provide only reasonable, not absolute, assurances that the objectives of the system are met. If we, or our independent registered public accounting firm, determine that our internal controls over financial reporting, or the internal controls of other companies we may acquire, are not effective, or we discover areas that need improvement in the future, these shortcomings could have an adverse effect on our business and financial reporting, and the trading price of our common stock could be negatively affected.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:normal;">We rely significantly on information technology systems and any failure, inadequacy, interruption or security lapse of that technology, including any cyber security incidents, could harm our ability to operate our business effectively or result in data leakage of proprietary and confidential business and employee information.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Our business is increasingly dependent on critical, complex and interdependent information technology systems, including Internet-based systems, to support business processes as well as internal and external communications. The size and complexity of our computer systems make them potentially vulnerable to interruption, invasion, computer viruses, destruction, malicious intrusion and additional related disruptions, which may result in the impairment of production and key business processes.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">In addition, our systems are potentially vulnerable to data security breaches-whether by employee error, malfeasance or other disruption-which may expose sensitive data to unauthorized persons. Such data security breaches could lead to the loss of trade secrets or other intellectual property or could lead to the public exposure of personal information, including sensitive personal information, of our employees, clinical trial patients, customers and others.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">A significant business disruption or a breach in security resulting in misappropriation, theft or sabotage with respect to our proprietary and confidential business and employee information could result in financial, legal, business or reputational harm to us, any of which could materially and adversely affect our business, financial condition and operating results.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:normal;">Our success is dependent on our continued ability to attract, motivate and retain key personnel, and any failure to attract or retain key personnel may negatively affect our business.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Because of the specialized scientific nature of our business, our ability to develop products and to </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">compete with our current and future competitors largely depends upon our ability to attract, retain and motivate highly qualified managerial and key scientific and technical personnel. If we are unable to retain the services of one or more of the principal members of senior management or other key employees, our ability to implement our business strategy could be materially harmed. We face intense competition for qualified employees from biopharmaceutical companies, research organizations and academic institutions. Attracting, retaining or replacing these personnel on acceptable terms may be difficult and time-consuming given the high demand in our industry for similar personnel. We believe part of being able to attract, motivate and retain personnel is our ability to offer a competitive compensation package, including equity incentive awards.  If we cannot offer a competitive compensation package to attract and retain the qualified personnel necessary for the continued development of our business, we may not be able to maintain our operations or grow our business.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">RISKS RELATED TO OWNERSHIP OF OUR COMMON STOCK</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:normal;">Fuad El-Hibri, executive chairman of our Board of Directors, has significant influence over us through his substantial beneficial ownership of our common stock, including an ability to influence the election of the members of our Board of Directors, or delay or prevent a change of control of us.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Mr. El-Hibri has the ability to significantly influence the election of the members of our Board of Directors due to his substantial beneficial ownership of our common stock. As of March 31, 2020, Mr. El-Hibri was the beneficial owner of approximately 11% of our outstanding common stock. As a result, Mr. El-Hibri could exercise substantial influence over all corporate actions requiring board or stockholder approval, including a change of control, or any amendment of our certificate of incorporation or by-laws. The control by Mr. El-Hibri may prevent other stockholders from influencing significant corporate decisions. In addition, Mr. El-Hibri's significant beneficial ownership of our shares could present the potential for a conflict of interest.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:normal;">Provisions in our certificate of incorporation and by-laws and under Delaware law may discourage acquisition proposals, delay a change in control or prevent transactions that stockholders may consider favorable.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Provisions in our certificate of incorporation and by-laws may discourage, delay or prevent a merger, acquisition or other changes in control that stockholders may consider favorable, including transactions in which stockholders might otherwise receive a premium for their shares. These provisions </span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">61</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">may also prevent or frustrate attempts by our stockholders to replace or remove our management.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">These provisions include:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">the classification of our directors;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">limitations on changing the number of directors then in office;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">limitations on the removal of directors;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">limitations on filling vacancies on the board;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">advance notice requirements for stockholder nominations of candidates for election to the Board of Directors and other proposals;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">the inability of stockholders to act by written consent;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">the inability of stockholders to call special meetings; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">the ability of our Board of Directors to designate the terms of and issue a new series of preferred stock without stockholder approval.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">The affirmative vote of holders of our capital stock representing at least 75% of the voting power of all outstanding stock entitled to vote is required to amend or repeal the above provisions of our certificate of incorporation. The affirmative vote of either a majority of the directors present at a meeting of our Board of Directors or holders of our capital stock representing at least 75% of the voting power of all outstanding stock entitled to vote is required to amend or repeal our by-laws.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">In addition, we are subject to Section 203 of the Delaware General Corporation Law (Section 203). In general and subject to certain exceptions, Section 203 prohibits a publicly-held corporation from engaging in a business combination with an interested stockholder, generally a person which, together with its affiliates, owns or within the last three years has owned 15% or more of the corporation's voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner. Accordingly, Section 203 may discourage, delay or prevent a change in control of us.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:normal;">Our Board of Directors may implement a new stockholder rights plan without stockholder approval, which could prevent a change in control of us in instances in which some stockholders may believe a change in control is in their best interests.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Our Board of Directors may implement a stockholder rights plan without stockholder approval. We previously implemented a stockholder rights plan, </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">which expired on November 14, 2016. Under our prior stockholder rights plan, we issued to each of our stockholders one preferred stock purchase right for each outstanding share of our common stock. Each right, when exercisable, would have entitled its holder to purchase from us a unit consisting of one one-thousandth of a share of series A junior participating preferred stock at a purchase price of $150 in cash, subject to adjustments. Our stockholder rights plan was intended to protect stockholders in the event of an unfair or coercive offer to acquire us and to provide our Board of Directors with adequate time to evaluate unsolicited offers.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Our Board of Directors may implement a new stockholder rights plan, which may have anti-takeover effects, potentially preventing a change in control of us in instances in which some stockholders may believe a change in control is in their best interests. This could cause substantial dilution to a person or group that attempts to acquire us on terms that our Board of Directors does not believe are in our best interests or those of our stockholders and may discourage, delay or prevent a merger or acquisition that stockholders may consider favorable, including transactions in which stockholders might otherwise receive a premium for their shares.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:normal;">Our stock price is volatile, and purchasers of our common stock could incur substantial losses.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Our stock price has been, and is likely to continue to be, volatile. The market price of our common stock could fluctuate significantly for many reasons, including in response to the risks described in this &#8220;Risk Factors&#8221; section, or for reasons unrelated to our operations, such as reports by industry analysts, investor perceptions or negative announcements by our customers, competitors or suppliers regarding their own performance, as well as industry conditions and general financial, economic and political instability. From November 15, 2006, when our common stock first began trading on the New York Stock Exchange, through April 27, 2020, our common stock has traded as high as $83.01 per share and as low as $4.17 per share. Due to fears associated with COVID-19, the stock market has recently experienced extreme volatility and the market for biopharmaceutical companies has generally experienced extreme volatility that has often been unrelated to the operating performance of particular companies. The market price of our common stock may be influenced by many factors, including, among others:</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">contracts, decisions and procurement policies by the USG affecting BioThrax and our other products and product candidates;</span></div></td></tr></table></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">62</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">the success of competitive products or technologies;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">results of clinical and non-clinical trials of our product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">announcements of acquisitions, financings or other transactions by us;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">litigation or legal proceedings;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">public concern as to the safety of our products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">termination or delay of a development program;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">the recruitment or departure of key personnel;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">variations in our product revenue and profitability; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">the other factors described in this &#8220;Risk Factors&#8221; section.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:normal;">Because we currently do not pay dividends, investors will benefit from an investment in our common stock only if it appreciates in value.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">We currently do not pay dividends on our common stock. Our Senior Secured Credit Facilities limit and any future debt agreements that we enter into may limit our ability to pay dividends. As a result, capital appreciation, if any, of our common stock will be the sole source of gain for our stockholders for the foreseeable future.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:normal;">A significant portion of our shares may be sold into the market at any time. This could cause the market price of our common stock to drop significantly.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales or the perception in the market that the holders of a large number of shares intend to sell shares could reduce the market price of our common stock. Moreover, holders of an aggregate of approximately 6 million shares of our common stock outstanding as of March 31, 2020, have the right to require us to register these shares of common stock under specified circumstances.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;text-indent:0px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">63</span></div></div><hr style="page-break-after:always"></hr><div><a id="sC900B480A8A95BB28329FE51859FA8AD"></a></div><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:12px;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="line-height:120%;padding-bottom:12px;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Recent Sales of Unregistered Securities</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Not applicable.</span></div><div style="line-height:120%;padding-bottom:12px;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Use of Proceeds</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Not applicable.</span></div><div style="line-height:120%;padding-bottom:12px;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Purchases of Equity Securities</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Not applicable.</span></div><div><a id="s0A7588C115F15148AAFBC3D1EC5BF00E"></a></div><div style="line-height:120%;padding-bottom:12px;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">ITEM 3. DEFAULTS UPON SENIOR SECURITIES</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Not applicable.</span></div><div><a id="sDA16D97534245CADBFB543ED448673F3"></a></div><div style="line-height:120%;padding-bottom:12px;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">ITEM 4. MINE SAFETY DISCLOSURES</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Not applicable.</span></div><div><a id="s5C6B594F885850C68B12EBD9E1DEB744"></a></div><div style="line-height:120%;padding-bottom:12px;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">ITEM 5. OTHER INFORMATION</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">Not applicable.</span></div><div><a id="s3996B53194875C5AA0337F9819FE4FA5"></a></div><div style="line-height:120%;padding-bottom:12px;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">ITEM 6. EXHIBITS</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">The exhibits required to be filed by Item 601 of Regulation S-K are listed in the Exhibit Index immediately preceding the exhibits hereto.</span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">64</span></div></div><hr style="page-break-after:always"></hr><div><a id="sFE304DF407B2582286CAE79F4705849D"></a></div><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:12px;text-align:center;-sec-extract:summary;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#00497f;font-weight:bold;">Exhibit Index</span></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:9%;"></td><td style="width:91%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;font-weight:bold;">Exhibit</span></div><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;font-weight:bold;">Number</span></div></td><td style="vertical-align:middle;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;font-weight:bold;">&#160;</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;font-weight:bold;">Description</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.1#&#8224;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="a101-bardaav7909mod4.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Modification #No. 4, effective March 3, 2020, to the Award/Contract, effective September 30, 2016, from the BioMedical Advanced Research and Development Authority to Emergent Product Development Gaithersburg Inc. (the BARDA AV7909 Contract).</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.2#&#8224;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="a102-bardaav7909mod5.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Modification #No. 5, effective April 10, 2020, to the BARDA AV7909 Contract.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.1 #</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="a311-kramercertificati.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certification of the Chief Executive Officer pursuant to Exchange Act Rule 13a-14(a).</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.2 #</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="a312-lindhalcertificat.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certification of the Chief Financial Officer pursuant to Exchange Act Rule 13a-14(a).</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">32.1 #</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="a321-kramercertificati.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">32.2 #</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="a322-lindhalcertificat.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">101 #</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following financial information related to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, formatted in iXBRL (Inline Extensible Business Reporting Language): (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Operations, (iii) the Condensed Consolidated Statements of Comprehensive Income, (iv) the Condensed Consolidated Statements of Cash Flows, (v) the Condensed Consolidated Statement of Changes in Stockholders' Equity; and (vi) the related Notes to the Condensed Consolidated Financial Statements.</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">104 #</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cover Page Interactive Data File, formatted in iXBRL and contained in Exhibit 101.</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">#</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Filed herewith.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8224;    Certain confidential portions of this exhibit were omitted by means of marking such portions with asterisks because the identified confidential portions (i) are not material and (ii) would be competitively harmful if publicly disclosed.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:48px;text-indent:-24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;padding-left:48px;text-indent:-24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">65</span></div></div><hr style="page-break-after:always"></hr><div><a id="s196640A4BC2750B590A7789B53F8315E"></a></div><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#00497f;font-weight:bold;">SIGNATURES</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:24px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:60.3515625%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">EMERGENT BIOSOLUTIONS INC.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">By: </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">/s/ROBERT G. KRAMER, SR.</span></div><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Robert G. Kramer, Sr.</span></div><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">President, Chief Executive Officer and Director</span></div><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(Principal Executive Officer)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Date: April&#160;30, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">By: </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">/s/RICHARD S. LINDAHL</span></div><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Richard S. Lindahl</span></div><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President, Chief Financial Officer and Treasurer</span></div><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(Principal Financial and Accounting Officer)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Date: April&#160;30, 2020</span></div></td></tr></table></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">66</span></div></div>	</div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>a101-bardaav7909mod4.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s283D8231F1C23D878042C798909BDE80"></a></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">Certain identified information has been marked in the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:5%;"></td><td style="width:19%;"></td><td style="width:6%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:3%;"></td><td style="width:10%;"></td><td style="width:6%;"></td><td style="width:2%;"></td><td style="width:14%;"></td></tr><tr><td colspan="9" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:2px solid #000000;"><div style="padding-top:6px;text-align:center;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT</font></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:2px solid #000000;"><div style="font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">1. CONTRACT ID CODE</font></div><div style="padding-top:2px;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">PAGE    OF   PAGES</font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:7pt;">&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">1</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">3</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">2. AMENDMENT/MODIFICATION NO.</font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">P0004</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">3.  EFFECTIVE DATE</font></div><div style="padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">See Block 16C</font></div></td><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">4.  REQUISITION/PURCHASE REQ. NO.</font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">5. PROJECT NO. </font><font style="font-family:Arial;font-size:7pt;font-style:italic;">(If applicable)</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">6. ISSUED BY</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">CODE</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">ASPR-BARDA</font></div></td><td colspan="5" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">7.  ADMINISTERED BY </font><font style="font-family:Arial;font-size:7pt;font-style:italic;">(If other than Item 6)</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">CODE</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">ASPR-BARDA</font></div></td></tr><tr><td colspan="6" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="padding-top:1px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">ASPR-BARDA</font></div><div style="padding-top:1px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">200 Independence Ave., S.W.</font></div><div style="padding-top:1px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Room 640-G</font></div><div style="padding-top:1px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Washington DC 20201</font></div></td><td colspan="8" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:1px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">ASPR-BARDA</font></div><div style="padding-top:1px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">200 Independence Ave., S.W.</font></div><div style="padding-top:1px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Room 638-G</font></div><div style="padding-top:1px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Washington DC 20201</font></div></td></tr><tr><td colspan="9" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">8.  NAME AND ADDRESS OF CONTRACTOR</font><font style="font-family:Arial;font-size:7pt;font-style:italic;">&#160;(No., street, county, State and ZIP Code)</font><font style="font-family:Arial;font-size:7pt;">&#160;&#160;&#160;</font></div><div style="padding-top:1px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.</font></div><div style="padding-top:1px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">EMERGENT PRODUCT DEVLOPMENT GAITHE</font></div><div style="padding-top:1px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">300 PROFESSIONAL DR # 100</font></div><div style="padding-top:1px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">GAITHERSBURG MD 208793419</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">X</font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">X</font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">9A. AMENDMENT OF SOLICITATION NO.</font></div><div style="padding-top:12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="padding-top:10px;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">9B.  DATED </font><font style="font-family:Arial;font-size:7pt;font-style:italic;">(See Item 11)</font></div><div style="padding-top:4px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="padding-top:6px;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">10A. MODIFICATION OF CONTRACT/ORDER NO.</font></div><div style="padding-top:12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">HHSO100201600030C</font></div><div style="padding-top:10px;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">10B. DATED </font><font style="font-family:Arial;font-size:7pt;font-style:italic;">(See Item 13)</font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div></td></tr><tr><td colspan="4" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="padding-top:1px;font-size:9pt;"><font style="font-family:Arial;font-size:7pt;">CODE     </font><font style="font-family:inherit;font-size:9pt;">1365869</font></div></td><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">FACILITY CODE</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">09/30/2016</font></div></td></tr><tr><td colspan="14" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS</font></div></td></tr><tr><td colspan="14" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:5px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#160;&#160;&#160;&#160;&#160;&#160;The  above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offers          is extended,        is not extended.</font></div><div style="padding-top:1px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended, by one of the following methods:</font></div><div style="padding-top:5px;font-size:9pt;"><font style="font-family:Arial;font-size:8pt;">(a) By completing Items 8 and 15, and returning </font><font style="font-family:inherit;font-size:9pt;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:8pt;">&#160;copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer</font></div><div style="padding-top:1px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">submitted; or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEGMENT </font></div><div style="padding-top:1px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT</font></div><div style="padding-top:1px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">IN  REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram or letter,</font></div><div style="padding-top:1px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.</font></div></td></tr><tr><td colspan="14" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">12. ACCOUNTING AND APPROPRIATION DATA </font><font style="font-family:Arial;font-size:7pt;font-style:italic;">(If required)</font></div><div style="padding-top:2px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">See Schedule</font></div></td></tr><tr><td colspan="14" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:1px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACTS/ORDERS,</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:5pt;"><font style="font-family:Arial;font-size:5pt;">CHECK ONE</font></div></td><td colspan="13" rowspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">A.   THIS CHANGE ORDER IS ISSUED PURSUANT TO: </font><font style="font-family:Arial;font-size:7pt;font-style:italic;">(Specify authority)</font><font style="font-family:Arial;font-size:7pt;">&#160;&#160;THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="13" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:4px;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">B.   THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES </font><font style="font-family:Arial;font-size:7pt;font-style:italic;">(such as changes in paying office, appropriation date, etc.)</font><font style="font-family:Arial;font-size:7pt;">&#160;SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b).     </font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="13" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">C.   THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:</font></div><div style="padding-top:2px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:8px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">X</font></div></td><td colspan="13" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">D.   OTHER </font><font style="font-family:Arial;font-size:7pt;font-style:italic;">(Specify type of modification and authority)</font></div><div style="padding-top:2px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">FAR 52.243-2 &#8211; Changes - Cost Reimbursement</font></div></td></tr><tr><td colspan="14" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-top:8px;font-size:8.5pt;"><font style="font-family:Arial;font-size:8.5pt;">E. IMPORTANT:  Contractor       is not,    x   is required to sign this document and return </font><font style="font-family:Arial;font-size:8.5pt;text-decoration:underline;">&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:8.5pt;text-decoration:underline;">2</font><font style="font-family:Arial;font-size:8.5pt;text-decoration:underline;">&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:8.5pt;">&#160;copies to the issuing office.</font></div></td></tr><tr><td colspan="14" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">14. DESCRIPTION OF AMENDMENT/MODIFICATION </font><font style="font-family:Arial;font-size:7pt;font-style:italic;">(Organized by UCF section headings, including solicitation/contract subject matter where feasible.)</font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Tax ID Number: [**]</font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">DUNS Number: [**]</font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">The purpose of this modification is to modify ARTICLES B.5. ADVANCE UNDERSTANDINGS and G.3. KEY PERSONNEL.</font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Funds Obligated Prior to this Modification: $464,692,203</font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Funds Obligated with Mod #4: $0</font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total Funds Obligated to Date: $464,692,203</font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Expiration Date: September 29, 2021 (unchanged)</font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Period of Performance: 09/30/2016 to 09/29/2021</font></div></td></tr><tr><td colspan="14" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect.</font></div></td></tr><tr><td colspan="8" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">15A.  NAME AND TITLE OF SIGNER </font><font style="font-family:Arial;font-size:7pt;font-style:italic;">(Type or print)</font></div><div style="padding-top:4px;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">Abigail Jenkins    SVP Business Unit Head, Vaccines</font></div></td><td colspan="6" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">16A.  NAME OF CONTRACTING OFFICER</font></div><div style="padding-top:4px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">CHRISTOPHER SCOTT</font></div></td></tr><tr><td colspan="5" style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">15B. CONTRACTOR/OFFEROR</font></div><div style="padding-top:1px;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;"><br></font></div><div style="font-size:7pt;"><font style="font-family:Arial;font-size:7pt;text-decoration:underline;">/s/ Abigail Jenkins   </font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-style:italic;">(Signature of person authorized to sign)</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">15C.  DATE SIGNED</font></div><div style="font-size:7pt;"><font style="font-family:Arial;font-size:7pt;"><br></font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Mar 2, 2020</font></div></td><td colspan="5" style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">16B.  UNITED STATES OF AMERICA</font></div><div style="padding-top:1px;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;"><br></font></div><div style="font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">BY  </font><font style="font-family:Arial;font-size:7pt;text-decoration:underline;">/s/ Christopher Scott</font><font style="font-family:Arial;font-size:7pt;">&#160;&#160;&#160;</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:7pt;font-style:italic;">&#160;(Signature of Contracting Officer)</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">16C.  DATE SIGNED</font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3/3/20</font></div></td></tr></table></div></div><div style="line-height:100%;padding-top:1px;text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#32;&#32;&#32;NSN 7540-01-152-8070&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;STANDARD FORM 30 (REV. 10-83)</font></div><div style="line-height:100%;text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#32;&#32;&#32;Previous Edition Unusable&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Prescribed by GSA</font></div><div style="line-height:100%;text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">FAR (48 CFR) 53.243</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><a name="s59ED27C608E51F9ADEF0C79890CDCB24"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE B.5. ADVANCE UNDERSTANDINGS is hereby modified as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">m.  Shipment to the Strategic National Stockpile and Storage</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:78px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Emergent shall develop a delivery schedule that is in agreement with BARDA. Delivery estimates are dependent on product release. Shipping will be FOB destination.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:78px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">At least [**] before each scheduled shipment by the Contractor, the Contractor shall provide the following to the Contracting Officer and COR:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:168px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:144px;"><font style="font-family:inherit;font-size:12pt;">i.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Packing Slip</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:168px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:144px;"><font style="font-family:inherit;font-size:12pt;">ii.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Certificate(s) of Analysis</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:168px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:144px;"><font style="font-family:inherit;font-size:12pt;">iii.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Confirm the number of pallets, vials and doses to be loaded</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:168px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:144px;"><font style="font-family:inherit;font-size:12pt;">iv.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Diagram of product shipment pallet (how many vials per box, per pallet)</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:78px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The Contractor will assume responsibility for the cost of shipping and transport of finished product to the SNS for long-term storage once usable product requirements have been met. The USG will assume responsibility for long-term storage of the finished product, and emergency distribution of the finished product. The USG shall incur only the storage costs while the product is held within the USG&#8217;s control. The product shall be stored in compliance with cGMP at the Contractor&#8217;s facility until the delivery of finished product to the SNS.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:78px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The Contractor shall ensure that vaccine delivery follows cGMPs to maintain the integrity of the product en route. The Contractor shall file the necessary documentation to the FDA/CBER for the safe movement of the product to include any protocol deviations en route.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:78px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The Contractor shall be responsible for the secure and segregated storage of held intermediates and the FDP prior to lot release and subsequent arrival at the SNS. The Contractor will agree upon a delivery schedule. [**] advance notice is required prior to shipment to the SNS. However, while the product is in long-term storage with the USG (i.e., in the SNS), the Contractor shall continue to be responsible for all quality control/quality assurance monitoring and subsequent reporting necessary to insure appropriate storage conditions of the product until said product is licensed.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:78px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The Contractor, via this contract with the USG, will be expected to comply with a written Quality Agreement (attached) as to the manner in which the product will be stored within the specific USG stockpile facility (ies) that have been identified post contract award. In addition, this Quality Agreement will outline the responsibilities of both the Contractor and the USG (i.e., SNS- Quality Control). These documents shall be drafted and signed by both parties prior to the transport and storage of the product.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:78px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">BARDA will not accept considerations for stability failures/reduced shelf-life. Any lots deemed non-conforming will be placed in quarantine and must be replaced by Emergent. If there is an indication of trending stability issues then an investigation will need to be opened and deliveries suspended until resolved. </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Notwithstanding anything to the contrary herein, until the Contractor receives concurrence by the FDA, the USG may accept any lots produced following Contractor&#8217;s implementation of new spore dose challenge levels in [**] as part of potency release testing. Should the FDA not concur that the new spore dose challenge levels are acceptable to release and use of the material under either Emergency Use Authorization or licensure, Contractor will be responsible for replacing any such lots with new lots, acceptable to the FDA, at no cost to the USG.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE G.3. KEY PERSONNEL is hereby modified as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The key personnel specified in this contract are considered to be essential to work performance. At least [**] prior to diverting any of the specified individuals to other programs or contracts (or as soon as possible, if an individual must be replaced, for example, as a result of leaving the employ of the Contractor), the Contractor shall notify the Contracting Officer and shall submit comprehensive justification for the diversion or replacement request (including proposed substitutions for key personnel) to permit evaluation by the Government of the impact on performance under this contract. The Contractor shall not divert or otherwise replace any key personnel without the written consent of the Contracting Officer. The Government may modify the contract to add or delete key personnel at the request of the Contractor or Government.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The following individuals are considered to be essential to the work being performed hereunder:</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:58%;"></td><td style="width:42%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Name</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Position</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">[**]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">[**]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">[**]</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">[**]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">[**]</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">*Bold indicated changes in this modification</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">All other terms and conditions of this contract remain unchanged.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">End of Modification #4</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>a102-bardaav7909mod5.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s912ED337ACDB8D0703F7C7A42DBDDA38"></a></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">Certain identified information has been marked in the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:5%;"></td><td style="width:19%;"></td><td style="width:6%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:3%;"></td><td style="width:10%;"></td><td style="width:6%;"></td><td style="width:2%;"></td><td style="width:14%;"></td></tr><tr><td colspan="9" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:2px solid #000000;"><div style="padding-top:6px;text-align:center;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT</font></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:2px solid #000000;"><div style="font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">1. CONTRACT ID CODE</font></div><div style="padding-top:2px;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">PAGE    OF   PAGES</font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:7pt;">&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">1</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;3</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">2. AMENDMENT/MODIFICATION NO.</font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">P00005</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">3.  EFFECTIVE DATE</font></div><div style="padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">See Block 16C</font></div></td><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">4.  REQUISITION/PURCHASE REQ. NO.</font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">5. PROJECT NO. </font><font style="font-family:Arial;font-size:7pt;font-style:italic;">(If applicable)</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">6. ISSUED BY</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">CODE</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">ASPR-BARDA</font></div></td><td colspan="5" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">7.  ADMINISTERED BY </font><font style="font-family:Arial;font-size:7pt;font-style:italic;">(If other than Item 6)</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">CODE</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">ASPR-BARDA</font></div></td></tr><tr><td colspan="6" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="padding-top:1px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">ASPR-BARDA</font></div><div style="padding-top:1px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">200 Independence Ave., S.W.</font></div><div style="padding-top:1px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Room 640-G</font></div><div style="padding-top:1px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Washington DC 20201</font></div></td><td colspan="8" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:1px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">ASPR-BARDA</font></div><div style="padding-top:1px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">200 Independence Ave., S.W.</font></div><div style="padding-top:1px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Room 638-G</font></div><div style="padding-top:1px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Washington DC 20201</font></div></td></tr><tr><td colspan="9" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">8.  NAME AND ADDRESS OF CONTRACTOR</font><font style="font-family:Arial;font-size:7pt;font-style:italic;">&#160;(No., street, county, State and ZIP Code)</font><font style="font-family:Arial;font-size:7pt;">&#160;&#160;&#160;</font></div><div style="padding-top:1px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.</font></div><div style="padding-top:1px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">EMERGENT PRODUCT DEVLOPMENT GAITHE</font></div><div style="padding-top:1px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">300 PROFESSIONAL DR # 100</font></div><div style="padding-top:1px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">GAITHERSBURG MD 208793419</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">X</font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">X</font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">9A. AMENDMENT OF SOLICITATION NO.</font></div><div style="padding-top:12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="padding-top:10px;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">9B.  DATED </font><font style="font-family:Arial;font-size:7pt;font-style:italic;">(See Item 11)</font></div><div style="padding-top:4px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="padding-top:6px;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">10A. MODIFICATION OF CONTRACT/ORDER NO.</font></div><div style="padding-top:12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">HHSO100201600030C</font></div><div style="padding-top:10px;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">10B. DATED </font><font style="font-family:Arial;font-size:7pt;font-style:italic;">(See Item 13)</font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div></td></tr><tr><td colspan="4" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="padding-top:1px;font-size:9pt;"><font style="font-family:Arial;font-size:7pt;">CODE     </font><font style="font-family:inherit;font-size:9pt;">1365869</font></div></td><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">FACILITY CODE</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">09/30/2016</font></div></td></tr><tr><td colspan="14" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS</font></div></td></tr><tr><td colspan="14" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:5px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#160;&#160;&#160;&#160;&#160;&#160;The  above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offers          is extended,        is not extended.</font></div><div style="padding-top:1px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended, by one of the following methods:</font></div><div style="padding-top:5px;font-size:9pt;"><font style="font-family:Arial;font-size:8pt;">(a) By completing Items 8 and 15, and returning </font><font style="font-family:inherit;font-size:9pt;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:8pt;">&#160;copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer</font></div><div style="padding-top:1px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">submitted; or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEGMENT </font></div><div style="padding-top:1px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT</font></div><div style="padding-top:1px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">IN  REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram or letter,</font></div><div style="padding-top:1px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.</font></div></td></tr><tr><td colspan="14" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">12. ACCOUNTING AND APPROPRIATION DATA </font><font style="font-family:Arial;font-size:7pt;font-style:italic;">(If required)</font></div><div style="padding-top:2px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">See Schedule</font></div></td></tr><tr><td colspan="14" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:1px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACTS/ORDERS,</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:5pt;"><font style="font-family:Arial;font-size:5pt;">CHECK ONE</font></div></td><td colspan="13" rowspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">A.   THIS CHANGE ORDER IS ISSUED PURSUANT TO: </font><font style="font-family:Arial;font-size:7pt;font-style:italic;">(Specify authority)</font><font style="font-family:Arial;font-size:7pt;">&#160;&#160;THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="13" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:4px;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">B.   THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES </font><font style="font-family:Arial;font-size:7pt;font-style:italic;">(such as changes in paying office, appropriation date, etc.)</font><font style="font-family:Arial;font-size:7pt;">&#160;SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b).     </font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="13" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">C.   THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:</font></div><div style="padding-top:2px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:8px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">X</font></div></td><td colspan="13" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">D.   OTHER </font><font style="font-family:Arial;font-size:7pt;font-style:italic;">(Specify type of modification and authority)</font></div><div style="padding-top:2px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">FAR 43.103(a) (3) Mutual Agreement of the Parties</font></div></td></tr><tr><td colspan="14" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-top:8px;font-size:8.5pt;"><font style="font-family:Arial;font-size:8.5pt;">E. IMPORTANT:  Contractor       is not,    x   is required to sign this document and return </font><font style="font-family:Arial;font-size:8.5pt;text-decoration:underline;">&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:8.5pt;text-decoration:underline;">1</font><font style="font-family:Arial;font-size:8.5pt;text-decoration:underline;">&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:8.5pt;">&#160;copies to the issuing office.</font></div></td></tr><tr><td colspan="14" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">14. DESCRIPTION OF AMENDMENT/MODIFICATION </font><font style="font-family:Arial;font-size:7pt;font-style:italic;">(Organized by UCF section headings, including solicitation/contract subject matter where feasible.)</font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Tax ID Number: [**]</font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">DUNS Number: [**]</font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">The purpose of this modification is to modify ARTICLES B.3. OPTION PRICES, B.5. ADVANCE UNDERSTANDINGS, F.3 DELIVERIES, G.1 CONTRACTING OFFICER, and G.4. INVOICE SUBMISSION.</font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Funds Obligated Prior to this Modification: $464,692,203</font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Funds Obligated with Mod #5: $0</font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total Funds Obligated to Date: $464,692,203</font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Expiration Date: September 29, 2021 (Unchanged)</font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Period of Performance: 09/30/2016 to 09/29/2021</font></div></td></tr><tr><td colspan="14" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect.</font></div></td></tr><tr><td colspan="8" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">15A.  NAME AND TITLE OF SIGNER </font><font style="font-family:Arial;font-size:7pt;font-style:italic;">(Type or print)</font></div><div style="padding-top:4px;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">Abigail Jenkins    SVP BU HEAD, Vaccines</font></div></td><td colspan="6" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">16A.  NAME OF CONTRACTING OFFICER</font></div><div style="padding-top:4px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">SABRINA J. MCINTYRE</font></div></td></tr><tr><td colspan="5" style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">15B. CONTRACTOR/OFFEROR</font></div><div style="padding-top:1px;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;"><br></font></div><div style="font-size:7pt;"><font style="font-family:Arial;font-size:7pt;text-decoration:underline;">/s/ Abigail Jenkins   </font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-style:italic;">(Signature of person authorized to sign)</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">15C.  DATE SIGNED</font></div><div style="font-size:7pt;"><font style="font-family:Arial;font-size:7pt;"><br></font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Apr 10, 2020</font></div></td><td colspan="5" style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">16B.  UNITED STATES OF AMERICA</font></div><div style="padding-top:1px;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;"><br></font></div><div style="font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">BY  </font><font style="font-family:Arial;font-size:7pt;text-decoration:underline;">/s/ Sabrina Mcintyre</font><font style="font-family:Arial;font-size:7pt;">&#160;&#160;&#160;</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:7pt;font-style:italic;">&#160;(Signature of Contracting Officer)</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">16C.  DATE SIGNED</font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4/10/20</font></div></td></tr></table></div></div><div style="line-height:100%;padding-top:1px;text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#32;&#32;&#32;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;STANDARD FORM 30 (REV. 11/2016)</font></div><div style="line-height:100%;text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#32;&#32;&#32;Previous Edition Unusable&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Prescribed by GSA</font></div><div style="line-height:100%;text-align:left;text-indent:592px;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">FAR (48 CFR) 53.243</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><a name="s39361BE9EB6D5FA9EB38C7A42DF0296E"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The purpose of this modification is to modify ARTICLES B.3 OPTION PRICES, B.5 ADVANCE UNDERSTANDINGS, F.3 DELIVERIES, G.1 CONTRACTING OFFICER, and G.4. INVOICE SUBMISSION.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE B.3.  OPTION PRICES are hereby modified as follows:</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.78632478632478%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:13%;"></td><td style="width:13%;"></td><td style="width:17%;"></td><td style="width:13%;"></td><td style="width:11%;"></td><td style="width:14%;"></td><td style="width:19%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">CLIN</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Period of Performance</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Supplies/Services</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Doses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Price per Dose</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Total Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Additional</font></div><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Doses****</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">CLIN 0004</font></div><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(Option -</font></div><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Funded)***</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[**] -</font></div><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">09/29/21</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Additional Surge</font></div><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Capacity (EUA)</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[**]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[**]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[**]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Dose number TBD</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**].</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">***CLIN 0004 is funded </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">****Additional Doses may be delivered to BARDA as consideration under the provision in Article B.5.I. In the event that EBS delivers doses [**] (see Article B.5.I), Emergent will provide a [**]% dose-replacement equivalent of additional doses to the Government. As set forth in Article B.5.l, BARDA may accept [**] if such doses are delivered along with the appropriate number of additional doses (&#8220;Additional Doses&#8221;). Additional Doses shall be calculated as [**]% of the number of delivered [**].</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE B.5.  ADVANCE UNDERSTANDINGS is hereby modified as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">I.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Stability</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">BARDA understands that the stability testing is ongoing to support long-term stability of AV7909. The contractor will continue to perform ICH compliant stability studies on AV7909. While EBS and BARDA believe that a [**] will be achieved, this cannot be confirmed until FDA licensure of the vaccine.</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">For the agreed upon price, AV7909 will be delivered to the SNS that is [**] from the date of manufacture stamped on the vial label.</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:120px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:72px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">BARDA does agree to a [**] to the [**] limitation to allow delivery of approximately [**] doses of AV7909 that were initially manufactured as PPQ material intended for qualification of a Redundant Fill Site at PAR.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:120px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:72px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">For CLIN 0004, BARDA agrees to allow delivery of and may accept doses dated [**] if such doses are delivered along with the appropriate number of additional doses (&#8220;Additional Doses&#8221;). Additional Doses shall be calculated as [**]% of the number of delivered [**]. EBS shall provide the Additional Doses as consideration for BARDA&#8217;s acceptance of [**] with a [**] for storage in the Strategic National Stockpile. The Additional Doses will be included with delivery of the [**] at no additional cost to BARDA or the US Government.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE F.3.  DELIVERIES is hereby modified as follows:</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Email Addresses: CO - </font><a style="font-family:inherit;font-size:12pt;" href="#"><font style="font-family:inherit;font-size:12pt;">[**]</font></a></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:108px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">COR - </font><a style="font-family:inherit;font-size:12pt;" href="#"><font style="font-family:inherit;font-size:12pt;">[**]</font></a></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE G.1.  CONTRACTING OFFICER is hereby modified as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The following Contracting Officer (CO) will represent the Government for the purpose of this contract:</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">HHS/OS/ASPR/BARDA</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">200 C St. SW</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">O&#8217;Neill House Office Building</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Washington, DC 20515</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE G.4.  INVOICE SUBMISSION is hereby modified as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">g.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Invoices shall be delivered electronically to the Contracting Officer (CO), the Contracting Officer&#8217;s Representative (COR), PSC, and e-Room electronically. Unless otherwise specified by the Contracting Officer, all deliverables, invoices, and reports furnished to the Government under the resultant contract shall be addressed as follows:</font></div></td></tr></table><div style="line-height:120%;text-align:right;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.35897435897436%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="3"></td></tr><tr><td style="width:33%;"></td><td style="width:37%;"></td><td style="width:30%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">[**]</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Contracting Officer</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">HHS/ASPR/BARDA</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">200 C Street, S.W.</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Washington, DC 20024</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Email: </font><a style="font-family:inherit;font-size:12pt;" name=""><font style="font-family:inherit;font-size:12pt;">[**]</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">[**]</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Contracting Officer Representative</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">HHS/ASPR/BARDA</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">200 C Street, S.W.</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Washington, DC 20024</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Email: </font><a style="font-family:inherit;font-size:12pt;" name=""><font style="font-family:inherit;font-size:12pt;">[**]</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Email invoices to:</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="font-size:12pt;"><a style="font-family:inherit;font-size:12pt;" name=""><font style="font-family:inherit;font-size:12pt;">PSC_Invoices@psc.hhs.gov</font></a></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">e-Room</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">All other terms and conditions of this contract remain unchanged.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">End of Modification #5</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>a311-kramercertificati.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s771B585051064269356BC7D129C1C92B"></a></div><div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">EXHIBIT 31.1</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">CERTIFICATION</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I, Robert G. Kramer, Sr., certify that:&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1)&#160;&#160;&#160;&#160;I have reviewed this Quarterly Report on Form 10-Q of Emergent BioSolutions Inc.; </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2)&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3)&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4)&#160;&#160;&#160;&#160;The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5)&#160;&#160;&#160;&#160;The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information, and </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Date:&#160;April 30, 2020&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">/s/ROBERT G. KRAMER, SR.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Robert G. Kramer, Sr.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Executive Officer</font></div><div><br></div><div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>a312-lindhalcertificat.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sEA1A596D2134D53EA5B4C7D3C1CF501F"></a></div><div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;font-weight:bold;">EXHIBIT 31.2</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">CERTIFICATION</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I, Richard S. Lindahl, certify that:&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1)&#160;&#160;&#160;&#160;I have reviewed this Quarterly Report on Form 10-Q of Emergent BioSolutions Inc.; </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2)&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3)&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4)&#160;&#160;&#160;&#160;The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5)&#160;&#160;&#160;&#160;The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information, and </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Date:&#160;April 30, 2020&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">/s/RICHARD S. LINDAHL</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Richard S. Lindahl</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Financial Officer</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:130%;padding-bottom:10px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>a321-kramercertificati.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sECC05AFA9C26E6AB44E7C7D45E621811"></a></div><div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;font-weight:bold;">EXHIBIT 32.1</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the Quarterly Report on Form&#160;10-Q&#160;of Emergent BioSolutions Inc. (the "Company") for the period ended&#160;March&#160;31, 2020&#160;as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned, Robert G. Kramer, Sr., Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:18px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Date:&#160;April&#160;30, 2020</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">/s/ROBERT G. KRAMER, SR.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Robert G. Kramer, Sr.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Executive Officer</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:130%;padding-bottom:10px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>a322-lindhalcertificat.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s991094E38E998F40E86EC7D4FAB25D73"></a></div><div></div><div><br></div><div style="line-height:144%;text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;font-weight:bold;">EXHIBIT 32.2</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the Quarterly Report on Form 10-Q of Emergent BioSolutions Inc. (the "Company") for the period ended&#160;March&#160;31, 2020&#160;as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned, Richard S. Lindahl, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that: </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></td></tr></table><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Date:&#160;April 30, 2020</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">/s/RICHARD S. LINDAHL</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Richard S. Lindahl</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Financial Officer</font></div><div style="line-height:130%;padding-bottom:10px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>ebs-20200331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://emergentbiosolutions.com/20200331" xmlns:ebs="http://emergentbiosolutions.com/20200331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/srt-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2019-01-31" schemaLocation="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2019-01-31" schemaLocation="https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ebs-20200331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ebs-20200331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ebs-20200331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ebs-20200331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="BasisOfPresentationAndPrinciplesOfConsolidation" roleURI="http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidation">
        <link:definition>2102100 - Disclosure - Basis of Presentation and Principles of Consolidation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisOfPresentationAndPrinciplesOfConsolidationDetails" roleURI="http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidationDetails">
        <link:definition>2402402 - Disclosure - Basis of Presentation and Principles of Consolidation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisOfPresentationAndPrinciplesOfConsolidationPolicies" roleURI="http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidationPolicies">
        <link:definition>2202201 - Disclosure - Basis of Presentation and Principles of Consolidation (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Business" roleURI="http://emergentbiosolutions.com/role/Business">
        <link:definition>2101100 - Disclosure - Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessDetails" roleURI="http://emergentbiosolutions.com/role/BusinessDetails">
        <link:definition>2401401 - Disclosure - Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingencies" roleURI="http://emergentbiosolutions.com/role/CommitmentsAndContingencies">
        <link:definition>2114100 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001000 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1001501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfCashFlows" roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows">
        <link:definition>1004000 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfChangesInStockholdersEquity" roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity">
        <link:definition>1005000 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical">
        <link:definition>1005501 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfComprehensiveIncome" roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome">
        <link:definition>1003000 - Statement - Condensed Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical" roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical">
        <link:definition>1003501 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfOperations" roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations">
        <link:definition>1002000 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingentConsideration" roleURI="http://emergentbiosolutions.com/role/ContingentConsideration">
        <link:definition>2107100 - Disclosure - Contingent consideration</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingentConsiderationContingentConsiderationFairValueLevel3OfSignificantUnobservableInputsDetails" roleURI="http://emergentbiosolutions.com/role/ContingentConsiderationContingentConsiderationFairValueLevel3OfSignificantUnobservableInputsDetails">
        <link:definition>2407403 - Disclosure - Contingent consideration Contingent consideration - Fair Value Level 3 of Significant Unobservable Inputs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingentConsiderationDetails" roleURI="http://emergentbiosolutions.com/role/ContingentConsiderationDetails">
        <link:definition>2407402 - Disclosure - Contingent consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingentConsiderationTables" roleURI="http://emergentbiosolutions.com/role/ContingentConsiderationTables">
        <link:definition>2307301 - Disclosure - Contingent consideration (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CoverPage" roleURI="http://emergentbiosolutions.com/role/CoverPage">
        <link:definition>0001000 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://emergentbiosolutions.com/role/Debt">
        <link:definition>2109100 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtNarrativeDetails" roleURI="http://emergentbiosolutions.com/role/DebtNarrativeDetails">
        <link:definition>2409403 - Disclosure - Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtScheduleDetails" roleURI="http://emergentbiosolutions.com/role/DebtScheduleDetails">
        <link:definition>2409402 - Disclosure - Debt - Schedule (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://emergentbiosolutions.com/role/DebtTables">
        <link:definition>2309301 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsAndHedgingActivities" roleURI="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivities">
        <link:definition>2108100 - Disclosure - Derivative instruments and hedging activities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsAndHedgingActivitiesCashFlowHedgingOnAociDetails" roleURI="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesCashFlowHedgingOnAociDetails">
        <link:definition>2408405 - Disclosure - Derivative instruments and hedging activities - Cash Flow Hedging on AOCI (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsAndHedgingActivitiesDerivativeDesignatedAsCashFlowHedgesDetails" roleURI="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesDerivativeDesignatedAsCashFlowHedgesDetails">
        <link:definition>2408403 - Disclosure - Derivative instruments and hedging activities - Derivative Designated as Cash Flow Hedges (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsAndHedgingActivitiesFairValueByBalanceSheetLocationDetails" roleURI="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesFairValueByBalanceSheetLocationDetails">
        <link:definition>2408404 - Disclosure - Derivative instruments and hedging activities - Fair Value by Balance Sheet Location (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails" roleURI="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails">
        <link:definition>2408402 - Disclosure - Derivative instruments and hedging activities - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsAndHedgingActivitiesTables" roleURI="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesTables">
        <link:definition>2308301 - Disclosure - Derivative instruments and hedging activities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://emergentbiosolutions.com/role/IncomeTaxes">
        <link:definition>2111100 - Disclosure - Income taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://emergentbiosolutions.com/role/IncomeTaxesDetails">
        <link:definition>2411401 - Disclosure - Income taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssets" roleURI="http://emergentbiosolutions.com/role/IntangibleAssets">
        <link:definition>2106100 - Disclosure - Intangible assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNarrativeDetails" roleURI="http://emergentbiosolutions.com/role/IntangibleAssetsNarrativeDetails">
        <link:definition>2406403 - Disclosure - Intangible assets - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails" roleURI="http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails">
        <link:definition>2406402 - Disclosure - Intangible assets - Schedule of Finite-lived Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsTables" roleURI="http://emergentbiosolutions.com/role/IntangibleAssetsTables">
        <link:definition>2306301 - Disclosure - Intangible assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://emergentbiosolutions.com/role/Inventories">
        <link:definition>2103100 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesDetails" roleURI="http://emergentbiosolutions.com/role/InventoriesDetails">
        <link:definition>2403402 - Disclosure - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://emergentbiosolutions.com/role/InventoriesTables">
        <link:definition>2303301 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://emergentbiosolutions.com/role/Leases">
        <link:definition>2105100 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesComponentsOfLeaseExpenseDetails" roleURI="http://emergentbiosolutions.com/role/LeasesComponentsOfLeaseExpenseDetails">
        <link:definition>2405403 - Disclosure - Leases - Components of Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://emergentbiosolutions.com/role/LeasesNarrativeDetails">
        <link:definition>2405402 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalBalanceSheetInformationDetails" roleURI="http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails">
        <link:definition>2405404 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://emergentbiosolutions.com/role/LeasesTables">
        <link:definition>2305301 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://emergentbiosolutions.com/role/NetLossPerShare">
        <link:definition>2112100 - Disclosure - Net loss per share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareDetails" roleURI="http://emergentbiosolutions.com/role/NetLossPerShareDetails">
        <link:definition>2412402 - Disclosure - Net loss per share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://emergentbiosolutions.com/role/NetLossPerShareTables">
        <link:definition>2312301 - Disclosure - Net loss per share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantAndEquipment" roleURI="http://emergentbiosolutions.com/role/PropertyPlantAndEquipment">
        <link:definition>2104100 - Disclosure - Property, plant and equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantAndEquipmentDetails" roleURI="http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentDetails">
        <link:definition>2404402 - Disclosure - Property, plant and equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantAndEquipmentTables" roleURI="http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentTables">
        <link:definition>2304301 - Disclosure - Property, plant and equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognition" roleURI="http://emergentbiosolutions.com/role/RevenueRecognition">
        <link:definition>2110100 - Disclosure - Revenue recognition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionAccountsReceivableDetails" roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionAccountsReceivableDetails">
        <link:definition>2410406 - Disclosure - Revenue recognition - Accounts Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionContractLiabilitiesDetails" roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionContractLiabilitiesDetails">
        <link:definition>2410405 - Disclosure - Revenue recognition - Contract Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionDisaggregationOfRevenueDetails" roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationOfRevenueDetails">
        <link:definition>2410404 - Disclosure - Revenue recognition - Disaggregation of Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionNarrativeDetails" roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionNarrativeDetails">
        <link:definition>2410402 - Disclosure - Revenue recognition - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionRemainingPerformanceObligationDetails" roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionRemainingPerformanceObligationDetails">
        <link:definition>2410403 - Disclosure - Revenue recognition - Remaining Performance Obligation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionTables" roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionTables">
        <link:definition>2310301 - Disclosure - Revenue recognition (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation" roleURI="http://emergentbiosolutions.com/role/ShareBasedCompensation">
        <link:definition>2113100 - Disclosure - Share-based compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationDetails" roleURI="http://emergentbiosolutions.com/role/ShareBasedCompensationDetails">
        <link:definition>2413401 - Disclosure - Share-based compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="ebs_AmendedCreditAgreementMember" name="AmendedCreditAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight" name="CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="ebs_ChangeInFairValueOfContingentConsideration" name="ChangeInFairValueOfContingentConsideration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ebs_ChangeinContractWithCustomerLiabilityRollForward" name="ChangeinContractWithCustomerLiabilityRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ebs_ContractManufacturingMember" name="ContractManufacturingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="ebs_ContractWithCustomerLiabilityAdditions" name="ContractWithCustomerLiabilityAdditions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ebs_ContractsAndGrantsMember" name="ContractsAndGrantsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ebs_ConvertibleSeniorNotesDue2021Member" name="ConvertibleSeniorNotesDue2021Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ebs_CreditAgreementMember" name="CreditAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="ebs_DebtInstrumentCovenantDebtServiceCoverageRatio" name="DebtInstrumentCovenantDebtServiceCoverageRatio" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" xbrli:periodType="duration" />
  <xsd:element id="ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod" name="DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="ebs_DebtInstrumentCovenantNetLeverageRatioOne" name="DebtInstrumentCovenantNetLeverageRatioOne" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" xbrli:periodType="duration" />
  <xsd:element id="ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod" name="DebtInstrumentCovenantNetLeverageRatioRollingPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="ebs_DebtInstrumentCovenantNetLeverageRatioThree" name="DebtInstrumentCovenantNetLeverageRatioThree" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" xbrli:periodType="duration" />
  <xsd:element id="ebs_DebtInstrumentCovenantNetLeverageRatioTwo" name="DebtInstrumentCovenantNetLeverageRatioTwo" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" xbrli:periodType="duration" />
  <xsd:element id="ebs_DerivativeNotionalAmount1" name="DerivativeNotionalAmount1" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="ebs_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue" name="FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="ebs_InProcessResearchAndDevelopment" name="InProcessResearchAndDevelopment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="ebs_LesseeOperatingLeaseTerminationPeriod" name="LesseeOperatingLeaseTerminationPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ebs_MeasurementInputProbabilityofPaymentMember" name="MeasurementInputProbabilityofPaymentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="ebs_NumberOfCategoriesOfPublicHealthThreats" name="NumberOfCategoriesOfPublicHealthThreats" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="ebs_NumberOfRevenueGeneratingProducts" name="NumberOfRevenueGeneratingProducts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="ebs_OperatingLeaseOtherLiabilityCurrent" name="OperatingLeaseOtherLiabilityCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="ebs_OtherLongTermDebtFacilityMember" name="OtherLongTermDebtFacilityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear" name="PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears" name="PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears" name="PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ebs_RaxibacumabMember" name="RaxibacumabMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="ebs_ScheduleOfLeasesSupplementalBalanceSheetsTableTextBlock" name="ScheduleOfLeasesSupplementalBalanceSheetsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="ebs_ScheduleofAccountsReceivableNetTableTextBlock" name="ScheduleofAccountsReceivableNetTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ebs_TermLoanFacilityMember" name="TermLoanFacilityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>ebs-20200331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidation" xlink:href="ebs-20200331.xsd#BasisOfPresentationAndPrinciplesOfConsolidation" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidationDetails" xlink:href="ebs-20200331.xsd#BasisOfPresentationAndPrinciplesOfConsolidationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidationPolicies" xlink:href="ebs-20200331.xsd#BasisOfPresentationAndPrinciplesOfConsolidationPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Business" xlink:href="ebs-20200331.xsd#Business" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/BusinessDetails" xlink:href="ebs-20200331.xsd#BusinessDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CommitmentsAndContingencies" xlink:href="ebs-20200331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets" xlink:href="ebs-20200331.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="ebs-20200331.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="ebs-20200331.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" xlink:href="ebs-20200331.xsd#CondensedConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" xlink:href="ebs-20200331.xsd#CondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" xlink:href="ebs-20200331.xsd#CondensedConsolidatedStatementsOfComprehensiveIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical" xlink:href="ebs-20200331.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="ebs-20200331.xsd#CondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/ContingentConsideration" xlink:href="ebs-20200331.xsd#ContingentConsideration" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/ContingentConsiderationContingentConsiderationFairValueLevel3OfSignificantUnobservableInputsDetails" xlink:href="ebs-20200331.xsd#ContingentConsiderationContingentConsiderationFairValueLevel3OfSignificantUnobservableInputsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/ContingentConsiderationDetails" xlink:href="ebs-20200331.xsd#ContingentConsiderationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/ContingentConsiderationTables" xlink:href="ebs-20200331.xsd#ContingentConsiderationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CoverPage" xlink:href="ebs-20200331.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Debt" xlink:href="ebs-20200331.xsd#Debt" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DebtNarrativeDetails" xlink:href="ebs-20200331.xsd#DebtNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DebtScheduleDetails" xlink:href="ebs-20200331.xsd#DebtScheduleDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DebtTables" xlink:href="ebs-20200331.xsd#DebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivities" xlink:href="ebs-20200331.xsd#DerivativeInstrumentsAndHedgingActivities" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesCashFlowHedgingOnAociDetails" xlink:href="ebs-20200331.xsd#DerivativeInstrumentsAndHedgingActivitiesCashFlowHedgingOnAociDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesDerivativeDesignatedAsCashFlowHedgesDetails" xlink:href="ebs-20200331.xsd#DerivativeInstrumentsAndHedgingActivitiesDerivativeDesignatedAsCashFlowHedgesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesFairValueByBalanceSheetLocationDetails" xlink:href="ebs-20200331.xsd#DerivativeInstrumentsAndHedgingActivitiesFairValueByBalanceSheetLocationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails" xlink:href="ebs-20200331.xsd#DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesTables" xlink:href="ebs-20200331.xsd#DerivativeInstrumentsAndHedgingActivitiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IncomeTaxes" xlink:href="ebs-20200331.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IncomeTaxesDetails" xlink:href="ebs-20200331.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IntangibleAssets" xlink:href="ebs-20200331.xsd#IntangibleAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IntangibleAssetsNarrativeDetails" xlink:href="ebs-20200331.xsd#IntangibleAssetsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails" xlink:href="ebs-20200331.xsd#IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IntangibleAssetsTables" xlink:href="ebs-20200331.xsd#IntangibleAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Inventories" xlink:href="ebs-20200331.xsd#Inventories" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/InventoriesDetails" xlink:href="ebs-20200331.xsd#InventoriesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/InventoriesTables" xlink:href="ebs-20200331.xsd#InventoriesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Leases" xlink:href="ebs-20200331.xsd#Leases" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LeasesComponentsOfLeaseExpenseDetails" xlink:href="ebs-20200331.xsd#LeasesComponentsOfLeaseExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LeasesNarrativeDetails" xlink:href="ebs-20200331.xsd#LeasesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:href="ebs-20200331.xsd#LeasesSupplementalBalanceSheetInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LeasesTables" xlink:href="ebs-20200331.xsd#LeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/NetLossPerShare" xlink:href="ebs-20200331.xsd#NetLossPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/NetLossPerShareDetails" xlink:href="ebs-20200331.xsd#NetLossPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/NetLossPerShareTables" xlink:href="ebs-20200331.xsd#NetLossPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/PropertyPlantAndEquipment" xlink:href="ebs-20200331.xsd#PropertyPlantAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentDetails" xlink:href="ebs-20200331.xsd#PropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentTables" xlink:href="ebs-20200331.xsd#PropertyPlantAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenueRecognition" xlink:href="ebs-20200331.xsd#RevenueRecognition" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionAccountsReceivableDetails" xlink:href="ebs-20200331.xsd#RevenueRecognitionAccountsReceivableDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionContractLiabilitiesDetails" xlink:href="ebs-20200331.xsd#RevenueRecognitionContractLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationOfRevenueDetails" xlink:href="ebs-20200331.xsd#RevenueRecognitionDisaggregationOfRevenueDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionNarrativeDetails" xlink:href="ebs-20200331.xsd#RevenueRecognitionNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionRemainingPerformanceObligationDetails" xlink:href="ebs-20200331.xsd#RevenueRecognitionRemainingPerformanceObligationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionTables" xlink:href="ebs-20200331.xsd#RevenueRecognitionTables" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/ShareBasedCompensation" xlink:href="ebs-20200331.xsd#ShareBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/ShareBasedCompensationDetails" xlink:href="ebs-20200331.xsd#ShareBasedCompensationDetails" xlink:type="simple" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidationPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/Business" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/BusinessDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1de780cc-9607-daa3-0bed-03c88ae94769" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1de780cc-9607-daa3-0bed-03c88ae94769" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_61f9319a-6aae-8e2f-f7d0-f41809896476" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_RestrictedCashCurrent_61f9319a-6aae-8e2f-f7d0-f41809896476" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_dd2cbe99-77d2-db20-3c91-750589881c79" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_dd2cbe99-77d2-db20-3c91-750589881c79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_cc720f44-4c90-5acc-2e7e-b88e80f2af28" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_InventoryNet_cc720f44-4c90-5acc-2e7e-b88e80f2af28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_us-gaap_IncomeTaxesReceivable_2dc645b8-e4db-c2c1-6eef-744beea03995" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_IncomeTaxesReceivable_2dc645b8-e4db-c2c1-6eef-744beea03995" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5fd9c643-899e-95d7-aab9-c3a9d6240218" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5fd9c643-899e-95d7-aab9-c3a9d6240218" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8889606b-88fa-2d5e-3fb9-238bccdf9597" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8889606b-88fa-2d5e-3fb9-238bccdf9597" xlink:type="arc" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_InProcessResearchAndDevelopment" xlink:label="loc_ebs_InProcessResearchAndDevelopment_fcd44d71-f562-9f38-659f-50ac74bd91f0" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_ebs_InProcessResearchAndDevelopment_fcd44d71-f562-9f38-659f-50ac74bd91f0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_37b440e2-656c-b624-0688-b7cf681bf981" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_Goodwill_37b440e2-656c-b624-0688-b7cf681bf981" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_60654fa3-82c2-3e38-ce88-436acda713ac" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_60654fa3-82c2-3e38-ce88-436acda713ac" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_bd8545de-cfc2-6f31-bff6-ed0d4012c357" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_bd8545de-cfc2-6f31-bff6-ed0d4012c357" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:to="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_928e20af-e738-4a2d-05b8-cf88fed11953" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_PreferredStockValue_928e20af-e738-4a2d-05b8-cf88fed11953" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_f05ab245-2bd1-7865-e7ed-1461a5a6155f" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_CommonStockValue_f05ab245-2bd1-7865-e7ed-1461a5a6155f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_e6069c8d-dfec-45ff-4b3f-643d125d5b29" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_TreasuryStockValue_e6069c8d-dfec-45ff-4b3f-643d125d5b29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_3d5a0ca6-0f59-67e6-adb5-6aecd22b693b" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_AdditionalPaidInCapital_3d5a0ca6-0f59-67e6-adb5-6aecd22b693b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_988c1346-b444-a867-fe80-f3aec1443d54" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_988c1346-b444-a867-fe80-f3aec1443d54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_62305d8f-d807-0fe8-d0ab-f2c2b3d03011" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_62305d8f-d807-0fe8-d0ab-f2c2b3d03011" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:to="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_eaedbb6a-5feb-d7b5-74ff-83d9e06de663" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_eaedbb6a-5feb-d7b5-74ff-83d9e06de663" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_aa2e73c1-d03e-7f76-3502-7a650f99607c" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_aa2e73c1-d03e-7f76-3502-7a650f99607c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_64993a75-9b0c-349a-1011-cc5a81c58412" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_64993a75-9b0c-349a-1011-cc5a81c58412" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2bf7259d-4c54-f092-3b62-ad288c59c828" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2bf7259d-4c54-f092-3b62-ad288c59c828" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8c850143-cd0c-0f85-9038-e19d8c4f7808" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_8c850143-cd0c-0f85-9038-e19d8c4f7808" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_9c889623-7b4f-c89a-bbb3-2bc9fb9ad9f5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_AccountsPayableCurrent_9c889623-7b4f-c89a-bbb3-2bc9fb9ad9f5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_c90cf113-b51b-4312-22d0-4adb9883d309" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_c90cf113-b51b-4312-22d0-4adb9883d309" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a2b836a7-cc87-0e4f-38a0-c91a29535622" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a2b836a7-cc87-0e4f-38a0-c91a29535622" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_a8f468a7-4768-419d-6f6c-e490a7380ed7" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_NotesPayableCurrent_a8f468a7-4768-419d-6f6c-e490a7380ed7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_ebb4c1f8-b5df-aab0-ee90-1e91fd21cf92" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_ebb4c1f8-b5df-aab0-ee90-1e91fd21cf92" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50231013-f048-89e7-0e20-ba139224c5f7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50231013-f048-89e7-0e20-ba139224c5f7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_2285f3f4-b3a8-b01c-280e-6c886bd81b27" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_2285f3f4-b3a8-b01c-280e-6c886bd81b27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_f73833cd-0af4-c4d5-a7c4-1151269f1da3" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_f73833cd-0af4-c4d5-a7c4-1151269f1da3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_07e50027-f2db-6d1b-93ed-b22d6bd39351" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_07e50027-f2db-6d1b-93ed-b22d6bd39351" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_9abe1476-4cfe-db17-21c0-084af9535335" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_9abe1476-4cfe-db17-21c0-084af9535335" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_05859378-438b-57d1-1cca-74dc23f15c9a" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_05859378-438b-57d1-1cca-74dc23f15c9a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfMediumTermNotes" xlink:label="loc_us-gaap_RepaymentsOfMediumTermNotes_b809302e-a185-fae0-28cd-f1c6d9f03474" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_RepaymentsOfMediumTermNotes_b809302e-a185-fae0-28cd-f1c6d9f03474" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50231013-f048-89e7-0e20-ba139224c5f7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0f8df60b-841f-6df5-83c3-e4049d366459" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0f8df60b-841f-6df5-83c3-e4049d366459" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50231013-f048-89e7-0e20-ba139224c5f7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_f0b9d825-b0b9-37fd-4d25-9294a8598890" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_ShareBasedCompensation_f0b9d825-b0b9-37fd-4d25-9294a8598890" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_ebef248a-da21-637d-9d28-3d42ff90e8e2" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_ebef248a-da21-637d-9d28-3d42ff90e8e2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_149d6655-b7f8-5049-ef74-296db479f8f9" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_149d6655-b7f8-5049-ef74-296db479f8f9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3421bed6-296e-da4e-f0e9-a2a8fa1f6d19" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3421bed6-296e-da4e-f0e9-a2a8fa1f6d19" xlink:type="arc" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_ChangeInFairValueOfContingentConsideration" xlink:label="loc_ebs_ChangeInFairValueOfContingentConsideration_ddaf8fdb-4b68-3fed-3e47-50ac74b52058" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_ebs_ChangeInFairValueOfContingentConsideration_ddaf8fdb-4b68-3fed-3e47-50ac74b52058" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_269710de-43ea-f1a2-1ab7-8a2fad8bcd72" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_269710de-43ea-f1a2-1ab7-8a2fad8bcd72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_09b7b41a-f5a1-c45e-d61b-846fff462802" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_09b7b41a-f5a1-c45e-d61b-846fff462802" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_f2b34f8d-2445-12ee-2c68-fa0c5409d5e0" xlink:type="locator" />
    <link:calculationArc order="9" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_f2b34f8d-2445-12ee-2c68-fa0c5409d5e0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_dfcbd6f7-83fa-00c2-bd9e-6c5c1de7d890" xlink:type="locator" />
    <link:calculationArc order="10" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_dfcbd6f7-83fa-00c2-bd9e-6c5c1de7d890" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_792166b2-b561-55ef-12fd-ca8b50f64a38" xlink:type="locator" />
    <link:calculationArc order="11" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_792166b2-b561-55ef-12fd-ca8b50f64a38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_c8705fc2-a98a-ac1d-2832-812bd5cae0da" xlink:type="locator" />
    <link:calculationArc order="12" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_c8705fc2-a98a-ac1d-2832-812bd5cae0da" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_300c5b66-f508-fab7-3859-345853a2ad7c" xlink:type="locator" />
    <link:calculationArc order="13" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_300c5b66-f508-fab7-3859-345853a2ad7c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_8fa19589-0da6-036d-a79e-4bd2fa365a6d" xlink:type="locator" />
    <link:calculationArc order="14" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_8fa19589-0da6-036d-a79e-4bd2fa365a6d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6bd7c3da-2a5b-cbc6-d33a-bb097a23c2f6" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50231013-f048-89e7-0e20-ba139224c5f7" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6bd7c3da-2a5b-cbc6-d33a-bb097a23c2f6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_21c019f0-62e8-3b20-07d1-495695054dce" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1de780cc-9607-daa3-0bed-03c88ae94769" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_21c019f0-62e8-3b20-07d1-495695054dce" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1de780cc-9607-daa3-0bed-03c88ae94769" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_61f9319a-6aae-8e2f-f7d0-f41809896476" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_21c019f0-62e8-3b20-07d1-495695054dce" xlink:to="loc_us-gaap_RestrictedCashCurrent_61f9319a-6aae-8e2f-f7d0-f41809896476" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:to="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5e0cb0dc-b25c-aaae-62f8-cb90f31a16a1" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5e0cb0dc-b25c-aaae-62f8-cb90f31a16a1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_68a2669c-01f8-c962-bf95-0b4231cd45da" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5e0cb0dc-b25c-aaae-62f8-cb90f31a16a1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_68a2669c-01f8-c962-bf95-0b4231cd45da" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_5d6a244f-545f-188e-391b-fc8aa0768131" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5e0cb0dc-b25c-aaae-62f8-cb90f31a16a1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_5d6a244f-545f-188e-391b-fc8aa0768131" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_63b9389e-c4aa-f3de-4a75-3d35dd33e202" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5e0cb0dc-b25c-aaae-62f8-cb90f31a16a1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_63b9389e-c4aa-f3de-4a75-3d35dd33e202" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d71649eb-5769-933d-7982-2a2ada9ea257" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d71649eb-5769-933d-7982-2a2ada9ea257" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d71649eb-5769-933d-7982-2a2ada9ea257" xlink:to="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b88c060f-09b3-b6c0-4cdb-a77cb8e75ec8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b88c060f-09b3-b6c0-4cdb-a77cb8e75ec8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_56b7d21b-74ce-ae0f-f005-529937985e54" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_56b7d21b-74ce-ae0f-f005-529937985e54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_3549c1c0-2f2a-e44b-026b-b4042153e489" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_56b7d21b-74ce-ae0f-f005-529937985e54" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_3549c1c0-2f2a-e44b-026b-b4042153e489" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_ef2ac9e8-006f-b467-3389-9a8ceec4bee5" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_56b7d21b-74ce-ae0f-f005-529937985e54" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_ef2ac9e8-006f-b467-3389-9a8ceec4bee5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_89fcc343-1933-1e77-588e-68d1c2f1a04f" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_56b7d21b-74ce-ae0f-f005-529937985e54" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_89fcc343-1933-1e77-588e-68d1c2f1a04f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_725ae160-1b15-a075-fa62-729d0bc8cda1" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_56b7d21b-74ce-ae0f-f005-529937985e54" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_725ae160-1b15-a075-fa62-729d0bc8cda1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_28fe77ae-e122-e428-d718-aff2ad445bc8" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d71649eb-5769-933d-7982-2a2ada9ea257" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_28fe77ae-e122-e428-d718-aff2ad445bc8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_16e9f6a6-5524-a7b1-7e7c-73ee97610ec6" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_28fe77ae-e122-e428-d718-aff2ad445bc8" xlink:to="loc_us-gaap_InterestExpense_16e9f6a6-5524-a7b1-7e7c-73ee97610ec6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_7a3a9730-2927-590e-4e76-6aeb4157256e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_28fe77ae-e122-e428-d718-aff2ad445bc8" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_7a3a9730-2927-590e-4e76-6aeb4157256e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/ContingentConsideration" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/ContingentConsiderationContingentConsiderationFairValueLevel3OfSignificantUnobservableInputsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/ContingentConsiderationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/ContingentConsiderationTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/CoverPage" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/Debt" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/DebtNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/DebtScheduleDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/DebtTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivities" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesCashFlowHedgingOnAociDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesDerivativeDesignatedAsCashFlowHedgesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesFairValueByBalanceSheetLocationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/IncomeTaxes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/IncomeTaxesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/IntangibleAssets" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/IntangibleAssetsNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:type="locator" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/IntangibleAssetsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/Inventories" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_cc720f44-4c90-5acc-2e7e-b88e80f2af28" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_c3595f04-2335-d8d9-6a42-7d0f781ae505" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_cc720f44-4c90-5acc-2e7e-b88e80f2af28" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_c3595f04-2335-d8d9-6a42-7d0f781ae505" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_f4920785-d6c0-a217-e01a-0e0ef529643a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_cc720f44-4c90-5acc-2e7e-b88e80f2af28" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_f4920785-d6c0-a217-e01a-0e0ef529643a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_2dee2782-8369-5635-44bf-51d0e8aa0f1e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_cc720f44-4c90-5acc-2e7e-b88e80f2af28" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_2dee2782-8369-5635-44bf-51d0e8aa0f1e" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/InventoriesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/Leases" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/LeasesComponentsOfLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_ac3b1889-9651-365f-e4fc-e6474385db69" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_e6bc46d1-fec7-6b3b-527e-4ad756896790" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_ac3b1889-9651-365f-e4fc-e6474385db69" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_e6bc46d1-fec7-6b3b-527e-4ad756896790" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_a4a8e3bb-2ee6-a2f3-d86b-f05bd98679a7" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_ac3b1889-9651-365f-e4fc-e6474385db69" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_a4a8e3bb-2ee6-a2f3-d86b-f05bd98679a7" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/LeasesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_b983c2d8-8318-0a7e-1a5c-6ab2933f7be5" xlink:type="locator" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_OperatingLeaseOtherLiabilityCurrent" xlink:label="loc_ebs_OperatingLeaseOtherLiabilityCurrent_3a76a2ff-5267-b2ec-f8c5-50ac74e71a6c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_b983c2d8-8318-0a7e-1a5c-6ab2933f7be5" xlink:to="loc_ebs_OperatingLeaseOtherLiabilityCurrent_3a76a2ff-5267-b2ec-f8c5-50ac74e71a6c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b91d2f01-85c2-f9fb-3250-26a4b1b39c5e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_b983c2d8-8318-0a7e-1a5c-6ab2933f7be5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b91d2f01-85c2-f9fb-3250-26a4b1b39c5e" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/LeasesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/NetLossPerShare" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/NetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8c9389ea-1fbb-7e45-ce1f-5a1d89572c0d" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fbdbb03d-8583-701f-d6e2-69f8229c6051" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8c9389ea-1fbb-7e45-ce1f-5a1d89572c0d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fbdbb03d-8583-701f-d6e2-69f8229c6051" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_90854703-859b-2c45-aef2-d270627b3141" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8c9389ea-1fbb-7e45-ce1f-5a1d89572c0d" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_90854703-859b-2c45-aef2-d270627b3141" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/NetLossPerShareTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/PropertyPlantAndEquipment" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7b7a3a8d-eb3d-0c85-68cc-b3d4d184ff23" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7b7a3a8d-eb3d-0c85-68cc-b3d4d184ff23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_94cd7971-9d17-1c6e-6642-d4d38fb682b6" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_94cd7971-9d17-1c6e-6642-d4d38fb682b6" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/RevenueRecognition" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/RevenueRecognitionAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_dd2cbe99-77d2-db20-3c91-750589881c79" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BilledContractReceivables" xlink:label="loc_us-gaap_BilledContractReceivables_b4c10f0f-de4a-d59c-6414-3b83211ee589" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_dd2cbe99-77d2-db20-3c91-750589881c79" xlink:to="loc_us-gaap_BilledContractReceivables_b4c10f0f-de4a-d59c-6414-3b83211ee589" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnbilledContractsReceivable" xlink:label="loc_us-gaap_UnbilledContractsReceivable_fa581462-617f-ce53-c4c3-3617f7ca0e74" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_dd2cbe99-77d2-db20-3c91-750589881c79" xlink:to="loc_us-gaap_UnbilledContractsReceivable_fa581462-617f-ce53-c4c3-3617f7ca0e74" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/RevenueRecognitionContractLiabilitiesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationOfRevenueDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/RevenueRecognitionNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/RevenueRecognitionRemainingPerformanceObligationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/RevenueRecognitionTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/ShareBasedCompensation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/ShareBasedCompensationDetails" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>ebs-20200331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidation" xlink:href="ebs-20200331.xsd#BasisOfPresentationAndPrinciplesOfConsolidation" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidationDetails" xlink:href="ebs-20200331.xsd#BasisOfPresentationAndPrinciplesOfConsolidationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidationPolicies" xlink:href="ebs-20200331.xsd#BasisOfPresentationAndPrinciplesOfConsolidationPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Business" xlink:href="ebs-20200331.xsd#Business" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/BusinessDetails" xlink:href="ebs-20200331.xsd#BusinessDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CommitmentsAndContingencies" xlink:href="ebs-20200331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets" xlink:href="ebs-20200331.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="ebs-20200331.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="ebs-20200331.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" xlink:href="ebs-20200331.xsd#CondensedConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" xlink:href="ebs-20200331.xsd#CondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" xlink:href="ebs-20200331.xsd#CondensedConsolidatedStatementsOfComprehensiveIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical" xlink:href="ebs-20200331.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="ebs-20200331.xsd#CondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/ContingentConsideration" xlink:href="ebs-20200331.xsd#ContingentConsideration" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/ContingentConsiderationContingentConsiderationFairValueLevel3OfSignificantUnobservableInputsDetails" xlink:href="ebs-20200331.xsd#ContingentConsiderationContingentConsiderationFairValueLevel3OfSignificantUnobservableInputsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/ContingentConsiderationDetails" xlink:href="ebs-20200331.xsd#ContingentConsiderationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/ContingentConsiderationTables" xlink:href="ebs-20200331.xsd#ContingentConsiderationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CoverPage" xlink:href="ebs-20200331.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Debt" xlink:href="ebs-20200331.xsd#Debt" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DebtNarrativeDetails" xlink:href="ebs-20200331.xsd#DebtNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DebtScheduleDetails" xlink:href="ebs-20200331.xsd#DebtScheduleDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DebtTables" xlink:href="ebs-20200331.xsd#DebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivities" xlink:href="ebs-20200331.xsd#DerivativeInstrumentsAndHedgingActivities" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesCashFlowHedgingOnAociDetails" xlink:href="ebs-20200331.xsd#DerivativeInstrumentsAndHedgingActivitiesCashFlowHedgingOnAociDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesDerivativeDesignatedAsCashFlowHedgesDetails" xlink:href="ebs-20200331.xsd#DerivativeInstrumentsAndHedgingActivitiesDerivativeDesignatedAsCashFlowHedgesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesFairValueByBalanceSheetLocationDetails" xlink:href="ebs-20200331.xsd#DerivativeInstrumentsAndHedgingActivitiesFairValueByBalanceSheetLocationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails" xlink:href="ebs-20200331.xsd#DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesTables" xlink:href="ebs-20200331.xsd#DerivativeInstrumentsAndHedgingActivitiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IncomeTaxes" xlink:href="ebs-20200331.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IncomeTaxesDetails" xlink:href="ebs-20200331.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IntangibleAssets" xlink:href="ebs-20200331.xsd#IntangibleAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IntangibleAssetsNarrativeDetails" xlink:href="ebs-20200331.xsd#IntangibleAssetsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails" xlink:href="ebs-20200331.xsd#IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IntangibleAssetsTables" xlink:href="ebs-20200331.xsd#IntangibleAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Inventories" xlink:href="ebs-20200331.xsd#Inventories" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/InventoriesDetails" xlink:href="ebs-20200331.xsd#InventoriesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/InventoriesTables" xlink:href="ebs-20200331.xsd#InventoriesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Leases" xlink:href="ebs-20200331.xsd#Leases" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LeasesComponentsOfLeaseExpenseDetails" xlink:href="ebs-20200331.xsd#LeasesComponentsOfLeaseExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LeasesNarrativeDetails" xlink:href="ebs-20200331.xsd#LeasesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:href="ebs-20200331.xsd#LeasesSupplementalBalanceSheetInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LeasesTables" xlink:href="ebs-20200331.xsd#LeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/NetLossPerShare" xlink:href="ebs-20200331.xsd#NetLossPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/NetLossPerShareDetails" xlink:href="ebs-20200331.xsd#NetLossPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/NetLossPerShareTables" xlink:href="ebs-20200331.xsd#NetLossPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/PropertyPlantAndEquipment" xlink:href="ebs-20200331.xsd#PropertyPlantAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentDetails" xlink:href="ebs-20200331.xsd#PropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentTables" xlink:href="ebs-20200331.xsd#PropertyPlantAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenueRecognition" xlink:href="ebs-20200331.xsd#RevenueRecognition" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionAccountsReceivableDetails" xlink:href="ebs-20200331.xsd#RevenueRecognitionAccountsReceivableDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionContractLiabilitiesDetails" xlink:href="ebs-20200331.xsd#RevenueRecognitionContractLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationOfRevenueDetails" xlink:href="ebs-20200331.xsd#RevenueRecognitionDisaggregationOfRevenueDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionNarrativeDetails" xlink:href="ebs-20200331.xsd#RevenueRecognitionNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionRemainingPerformanceObligationDetails" xlink:href="ebs-20200331.xsd#RevenueRecognitionRemainingPerformanceObligationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionTables" xlink:href="ebs-20200331.xsd#RevenueRecognitionTables" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/ShareBasedCompensation" xlink:href="ebs-20200331.xsd#ShareBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/ShareBasedCompensationDetails" xlink:href="ebs-20200331.xsd#ShareBasedCompensationDetails" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidationDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidationPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/Business" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/BusinessDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_73B9F38072A0130D748D5CDFFA837C4A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_673F8440EDCDF258BED65CDFFA8112AF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_73B9F38072A0130D748D5CDFFA837C4A" xlink:to="loc_us-gaap_StatementTable_673F8440EDCDF258BED65CDFFA8112AF" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4EFA1826D5921E5D1B575CDFFA827E78" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_673F8440EDCDF258BED65CDFFA8112AF" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4EFA1826D5921E5D1B575CDFFA827E78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_BD7A6B76148DAEA3D6735CDFFA82CDCA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4EFA1826D5921E5D1B575CDFFA827E78" xlink:to="loc_us-gaap_EquityComponentDomain_BD7A6B76148DAEA3D6735CDFFA82CDCA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_BD7A6B76148DAEA3D6735CDFFA82CDCA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4EFA1826D5921E5D1B575CDFFA827E78" xlink:to="loc_us-gaap_EquityComponentDomain_BD7A6B76148DAEA3D6735CDFFA82CDCA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_4FF3D5E14A095034CBDA5CDFFA821F7F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_BD7A6B76148DAEA3D6735CDFFA82CDCA" xlink:to="loc_us-gaap_CommonStockMember_4FF3D5E14A095034CBDA5CDFFA821F7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_0FA707C8BA0D112B7FD65CDFFA827569" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_BD7A6B76148DAEA3D6735CDFFA82CDCA" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_0FA707C8BA0D112B7FD65CDFFA827569" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_80DFA2D4099CB4879EC45CDFFA836C3D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_BD7A6B76148DAEA3D6735CDFFA82CDCA" xlink:to="loc_us-gaap_TreasuryStockMember_80DFA2D4099CB4879EC45CDFFA836C3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6215B3D331BFA747E1775CDFFA83B778" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_BD7A6B76148DAEA3D6735CDFFA82CDCA" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6215B3D331BFA747E1775CDFFA83B778" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_CBFDB09B70E01183054F5CDFFA83D79F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_BD7A6B76148DAEA3D6735CDFFA82CDCA" xlink:to="loc_us-gaap_RetainedEarningsMember_CBFDB09B70E01183054F5CDFFA83D79F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_20D58D5286079F7721615CDFFA838021" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_73B9F38072A0130D748D5CDFFA837C4A" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_20D58D5286079F7721615CDFFA838021" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_236D225D789B23FC11BE5CDFFA84494E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_20D58D5286079F7721615CDFFA838021" xlink:to="loc_us-gaap_CommonStockSharesIssued_236D225D789B23FC11BE5CDFFA84494E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_972889E90B0CD73B5D795CDFFA849226" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_20D58D5286079F7721615CDFFA838021" xlink:to="loc_us-gaap_StockholdersEquity_972889E90B0CD73B5D795CDFFA849226" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_CBD1CCBFB5D8B851B1B15CDFFA84DE33" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_20D58D5286079F7721615CDFFA838021" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_CBD1CCBFB5D8B851B1B15CDFFA84DE33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_632118AED180EF7EFBFF5CDFFA847C67" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_20D58D5286079F7721615CDFFA838021" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_632118AED180EF7EFBFF5CDFFA847C67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_CC69E37BC8E643CE4C045CDFFA841EA5" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_20D58D5286079F7721615CDFFA838021" xlink:to="loc_us-gaap_NetIncomeLoss_CC69E37BC8E643CE4C045CDFFA841EA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_F6FFDB03DB871B663D185CEBC339B4BD" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_20D58D5286079F7721615CDFFA838021" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_F6FFDB03DB871B663D185CEBC339B4BD" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_89A18430FE3BA17BA5BABC1D2397A4C1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_7A0B2945B5EC8FF5B112BC1D2396A082" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_89A18430FE3BA17BA5BABC1D2397A4C1" xlink:to="loc_us-gaap_StatementTable_7A0B2945B5EC8FF5B112BC1D2396A082" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_8E652C1003E8275D89B9BC1D2396D0E1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_7A0B2945B5EC8FF5B112BC1D2396A082" xlink:to="loc_srt_ProductOrServiceAxis_8E652C1003E8275D89B9BC1D2396D0E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_E5EE7A9B6C69C2A6F259BC1D23965CED_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_8E652C1003E8275D89B9BC1D2396D0E1" xlink:to="loc_srt_ProductsAndServicesDomain_E5EE7A9B6C69C2A6F259BC1D23965CED_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_E5EE7A9B6C69C2A6F259BC1D23965CED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_8E652C1003E8275D89B9BC1D2396D0E1" xlink:to="loc_srt_ProductsAndServicesDomain_E5EE7A9B6C69C2A6F259BC1D23965CED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_5B617E52A2EA721BFC61BC1D23964562" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_E5EE7A9B6C69C2A6F259BC1D23965CED" xlink:to="loc_us-gaap_ProductMember_5B617E52A2EA721BFC61BC1D23964562" xlink:type="arc" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_ContractManufacturingMember" xlink:label="loc_ebs_ContractManufacturingMember_5B1BFFDF3CA395FBC448BC1D23979A92" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_E5EE7A9B6C69C2A6F259BC1D23965CED" xlink:to="loc_ebs_ContractManufacturingMember_5B1BFFDF3CA395FBC448BC1D23979A92" xlink:type="arc" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_ContractsAndGrantsMember" xlink:label="loc_ebs_ContractsAndGrantsMember_B29B9756A6DA935CABB8BC1D239702BC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_E5EE7A9B6C69C2A6F259BC1D23965CED" xlink:to="loc_ebs_ContractsAndGrantsMember_B29B9756A6DA935CABB8BC1D239702BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_502A7FC7342B13592D2EBC1D23971CA8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_89A18430FE3BA17BA5BABC1D2397A4C1" xlink:to="loc_us-gaap_RevenuesAbstract_502A7FC7342B13592D2EBC1D23971CA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_DB4E042F8EE4213A8DB2BC1D23986AFF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_502A7FC7342B13592D2EBC1D23971CA8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_DB4E042F8EE4213A8DB2BC1D23986AFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_F7B98C87F9A0D299F7CABC1D23988FC4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_89A18430FE3BA17BA5BABC1D2397A4C1" xlink:to="loc_us-gaap_OperatingExpensesAbstract_F7B98C87F9A0D299F7CABC1D23988FC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_245BC73DD9A8BE4776C7BC207D6B099E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_F7B98C87F9A0D299F7CABC1D23988FC4" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_245BC73DD9A8BE4776C7BC207D6B099E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_49A71F52BCD416A017B1BC1D2399A791" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_F7B98C87F9A0D299F7CABC1D23988FC4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_49A71F52BCD416A017B1BC1D2399A791" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_EB157FEED18B6F767074BC1D2399BC7E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_F7B98C87F9A0D299F7CABC1D23988FC4" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_EB157FEED18B6F767074BC1D2399BC7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_048F8B491F7939D3BCF8BC1D23995183" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_F7B98C87F9A0D299F7CABC1D23988FC4" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_048F8B491F7939D3BCF8BC1D23995183" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_2BE14451A51CD1D3C85DBC20B1E74AA0" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_F7B98C87F9A0D299F7CABC1D23988FC4" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_2BE14451A51CD1D3C85DBC20B1E74AA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_155CA80794276238DFA5BC1D23990F77" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_89A18430FE3BA17BA5BABC1D2397A4C1" xlink:to="loc_us-gaap_OperatingIncomeLoss_155CA80794276238DFA5BC1D23990F77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_E570DC29749B03D39542BC1D239913A0" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_89A18430FE3BA17BA5BABC1D2397A4C1" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_E570DC29749B03D39542BC1D239913A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_301E91A24798DDC339BABC1D2399B2EA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_E570DC29749B03D39542BC1D239913A0" xlink:to="loc_us-gaap_InterestExpense_301E91A24798DDC339BABC1D2399B2EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_1741DC2A0F6642CC1C64BC1D239A4072" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_E570DC29749B03D39542BC1D239913A0" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_1741DC2A0F6642CC1C64BC1D239A4072" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_DE586ED275DE4F24CDB7BC1D239A1874" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_E570DC29749B03D39542BC1D239913A0" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_DE586ED275DE4F24CDB7BC1D239A1874" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5DB93784C619C179491EBC1D239A5282" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_89A18430FE3BA17BA5BABC1D2397A4C1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5DB93784C619C179491EBC1D239A5282" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4094F5CB2665F197C9C1BC1D239A3D2D" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_89A18430FE3BA17BA5BABC1D2397A4C1" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4094F5CB2665F197C9C1BC1D239A3D2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_DB91CC66225F94FA86A1BC1D239A8724" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_89A18430FE3BA17BA5BABC1D2397A4C1" xlink:to="loc_us-gaap_NetIncomeLoss_DB91CC66225F94FA86A1BC1D239A8724" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_E66A16814A6C50352127BC1D239B4197" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_89A18430FE3BA17BA5BABC1D2397A4C1" xlink:to="loc_us-gaap_EarningsPerShareAbstract_E66A16814A6C50352127BC1D239B4197" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_8E984D46AB3DE0FEADC2BC1D239BD33E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_E66A16814A6C50352127BC1D239B4197" xlink:to="loc_us-gaap_EarningsPerShareBasic_8E984D46AB3DE0FEADC2BC1D239BD33E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_D2BF8ED65BAF88705CFEBC1D239BF342" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_E66A16814A6C50352127BC1D239B4197" xlink:to="loc_us-gaap_EarningsPerShareDiluted_D2BF8ED65BAF88705CFEBC1D239BF342" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_2184440AD3B330E390E9BC1D239BD417" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_89A18430FE3BA17BA5BABC1D2397A4C1" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_2184440AD3B330E390E9BC1D239BD417" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0A0D91DBF78A8E066B3FBC1D239BF393" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_2184440AD3B330E390E9BC1D239BD417" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0A0D91DBF78A8E066B3FBC1D239BF393" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_E47D080D0B684FC6D913BC1D239C364B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_2184440AD3B330E390E9BC1D239BD417" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_E47D080D0B684FC6D913BC1D239C364B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/ContingentConsideration" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/ContingentConsiderationContingentConsiderationFairValueLevel3OfSignificantUnobservableInputsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_6B0D3A79C04942BDC4A3B80346843B38" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_236089CBDF20EF36E294B803467124E2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_6B0D3A79C04942BDC4A3B80346843B38" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_236089CBDF20EF36E294B803467124E2" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="loc_us-gaap_ValuationTechniqueAxis_EF83DF043E1ECF00670DB8065D013987" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_236089CBDF20EF36E294B803467124E2" xlink:to="loc_us-gaap_ValuationTechniqueAxis_EF83DF043E1ECF00670DB8065D013987" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="loc_us-gaap_ValuationTechniqueDomain_7B72E3A8790D428B4C23B80BB11CB440_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_EF83DF043E1ECF00670DB8065D013987" xlink:to="loc_us-gaap_ValuationTechniqueDomain_7B72E3A8790D428B4C23B80BB11CB440_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="loc_us-gaap_ValuationTechniqueDomain_7B72E3A8790D428B4C23B80BB11CB440" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_EF83DF043E1ECF00670DB8065D013987" xlink:to="loc_us-gaap_ValuationTechniqueDomain_7B72E3A8790D428B4C23B80BB11CB440" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_D72B73EB6651F51BCBCBB8067FE4EFFF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_7B72E3A8790D428B4C23B80BB11CB440" xlink:to="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_D72B73EB6651F51BCBCBB8067FE4EFFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_AB9C5A6A385EED76D82CB8059EAEFCCD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_236089CBDF20EF36E294B803467124E2" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_AB9C5A6A385EED76D82CB8059EAEFCCD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3DA9064A21A72084EAFCB8059EAF5C9C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_AB9C5A6A385EED76D82CB8059EAEFCCD" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3DA9064A21A72084EAFCB8059EAF5C9C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3DA9064A21A72084EAFCB8059EAF5C9C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_AB9C5A6A385EED76D82CB8059EAEFCCD" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3DA9064A21A72084EAFCB8059EAF5C9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_290F8BD4B8BCA9EC6216B805B8956BE5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3DA9064A21A72084EAFCB8059EAF5C9C" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_290F8BD4B8BCA9EC6216B805B8956BE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_62AD8D608833DCC3ED0EB804504BC8CC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_236089CBDF20EF36E294B803467124E2" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_62AD8D608833DCC3ED0EB804504BC8CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_FF0844313C3F347F269EB804504C4E41_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_62AD8D608833DCC3ED0EB804504BC8CC" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_FF0844313C3F347F269EB804504C4E41_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_FF0844313C3F347F269EB804504C4E41" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_62AD8D608833DCC3ED0EB804504BC8CC" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_FF0844313C3F347F269EB804504C4E41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_D3E548E7A03A3FF533F0B80468F1E72A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_FF0844313C3F347F269EB804504C4E41" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_D3E548E7A03A3FF533F0B80468F1E72A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_77FFDED8ACB36A47DECEB803F3926C19" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_236089CBDF20EF36E294B803467124E2" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_77FFDED8ACB36A47DECEB803F3926C19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1BAF448C6CBD73AE3E9BB803F393EA0F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_77FFDED8ACB36A47DECEB803F3926C19" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1BAF448C6CBD73AE3E9BB803F393EA0F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1BAF448C6CBD73AE3E9BB803F393EA0F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_77FFDED8ACB36A47DECEB803F3926C19" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1BAF448C6CBD73AE3E9BB803F393EA0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_DEECD93DCAC19130E576B804CA401238" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1BAF448C6CBD73AE3E9BB803F393EA0F" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_DEECD93DCAC19130E576B804CA401238" xlink:type="arc" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_MeasurementInputProbabilityofPaymentMember" xlink:label="loc_ebs_MeasurementInputProbabilityofPaymentMember_F57AB88BAAA3D866D3BDB80569AA22EC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1BAF448C6CBD73AE3E9BB803F393EA0F" xlink:to="loc_ebs_MeasurementInputProbabilityofPaymentMember_F57AB88BAAA3D866D3BDB80569AA22EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_9FAABD94B406FE04D17BB803675D89C1" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_236089CBDF20EF36E294B803467124E2" xlink:to="loc_srt_RangeAxis_9FAABD94B406FE04D17BB803675D89C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_3221BF2139081BCD7FDBB803676098C8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9FAABD94B406FE04D17BB803675D89C1" xlink:to="loc_srt_RangeMember_3221BF2139081BCD7FDBB803676098C8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_3221BF2139081BCD7FDBB803676098C8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9FAABD94B406FE04D17BB803675D89C1" xlink:to="loc_srt_RangeMember_3221BF2139081BCD7FDBB803676098C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_0BEFCF030B2FC54E678DB80B36E8E6ED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3221BF2139081BCD7FDBB803676098C8" xlink:to="loc_srt_MinimumMember_0BEFCF030B2FC54E678DB80B36E8E6ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_2D6890618CB02181720FB80B575CED76" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3221BF2139081BCD7FDBB803676098C8" xlink:to="loc_srt_MaximumMember_2D6890618CB02181720FB80B575CED76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_WeightedAverageMember" xlink:label="loc_srt_WeightedAverageMember_572F882FFB805363501FB8038AEB0E70" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3221BF2139081BCD7FDBB803676098C8" xlink:to="loc_srt_WeightedAverageMember_572F882FFB805363501FB8038AEB0E70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6F132EA61C39EBA3F93AB7FC4F53F330" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_6B0D3A79C04942BDC4A3B80346843B38" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6F132EA61C39EBA3F93AB7FC4F53F330" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_080D29F44AC057F86E70B802812E93C0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_6B0D3A79C04942BDC4A3B80346843B38" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_080D29F44AC057F86E70B802812E93C0" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/ContingentConsiderationDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/ContingentConsiderationTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/CoverPage" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/Debt" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0317E2577949153D5D669E56B0FE8C59" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_3A26E82C506A2109FC559E56B0FA4290" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0317E2577949153D5D669E56B0FE8C59" xlink:to="loc_us-gaap_DebtInstrumentTable_3A26E82C506A2109FC559E56B0FA4290" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_7FBEC7C5C2D469D2FFF39E56B0FA14DE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3A26E82C506A2109FC559E56B0FA4290" xlink:to="loc_us-gaap_CreditFacilityAxis_7FBEC7C5C2D469D2FFF39E56B0FA14DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_A7B8D5FD9C40832A044E9E56B0FB0A1F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_7FBEC7C5C2D469D2FFF39E56B0FA14DE" xlink:to="loc_us-gaap_CreditFacilityDomain_A7B8D5FD9C40832A044E9E56B0FB0A1F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_A7B8D5FD9C40832A044E9E56B0FB0A1F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_7FBEC7C5C2D469D2FFF39E56B0FA14DE" xlink:to="loc_us-gaap_CreditFacilityDomain_A7B8D5FD9C40832A044E9E56B0FB0A1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_AB3EB6BDA67FDDD7076D9E56B0FB1F2C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_A7B8D5FD9C40832A044E9E56B0FB0A1F" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_AB3EB6BDA67FDDD7076D9E56B0FB1F2C" xlink:type="arc" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_TermLoanFacilityMember" xlink:label="loc_ebs_TermLoanFacilityMember_0297DE37BD74977371B59E56B0FB349D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_A7B8D5FD9C40832A044E9E56B0FB0A1F" xlink:to="loc_ebs_TermLoanFacilityMember_0297DE37BD74977371B59E56B0FB349D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_0C95F38460B7DFEE5F4E9E56B0FB383A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3A26E82C506A2109FC559E56B0FA4290" xlink:to="loc_us-gaap_DebtInstrumentAxis_0C95F38460B7DFEE5F4E9E56B0FB383A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_EF23D947A2D2F9B280D09E56B0FB2089_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_0C95F38460B7DFEE5F4E9E56B0FB383A" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_EF23D947A2D2F9B280D09E56B0FB2089_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_EF23D947A2D2F9B280D09E56B0FB2089" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_0C95F38460B7DFEE5F4E9E56B0FB383A" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_EF23D947A2D2F9B280D09E56B0FB2089" xlink:type="arc" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_CreditAgreementMember" xlink:label="loc_ebs_CreditAgreementMember_FAD6C713A21A1D41EBD09E56B0FC1EEC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_EF23D947A2D2F9B280D09E56B0FB2089" xlink:to="loc_ebs_CreditAgreementMember_FAD6C713A21A1D41EBD09E56B0FC1EEC" xlink:type="arc" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_AmendedCreditAgreementMember" xlink:label="loc_ebs_AmendedCreditAgreementMember_55596D6B5C809D2B5FF49E56B0FC6C77" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_EF23D947A2D2F9B280D09E56B0FB2089" xlink:to="loc_ebs_AmendedCreditAgreementMember_55596D6B5C809D2B5FF49E56B0FC6C77" xlink:type="arc" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_ConvertibleSeniorNotesDue2021Member" xlink:label="loc_ebs_ConvertibleSeniorNotesDue2021Member_16649CB3A5571263452D9E56B0FC5084" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_EF23D947A2D2F9B280D09E56B0FB2089" xlink:to="loc_ebs_ConvertibleSeniorNotesDue2021Member_16649CB3A5571263452D9E56B0FC5084" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_DFC01E95B05AC369D90E9E56B0FC0B4F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3A26E82C506A2109FC559E56B0FA4290" xlink:to="loc_us-gaap_VariableRateAxis_DFC01E95B05AC369D90E9E56B0FC0B4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_37E00A0850EB99E4BA9C9E56B0FC99E3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_DFC01E95B05AC369D90E9E56B0FC0B4F" xlink:to="loc_us-gaap_VariableRateDomain_37E00A0850EB99E4BA9C9E56B0FC99E3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_37E00A0850EB99E4BA9C9E56B0FC99E3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_DFC01E95B05AC369D90E9E56B0FC0B4F" xlink:to="loc_us-gaap_VariableRateDomain_37E00A0850EB99E4BA9C9E56B0FC99E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EurodollarMember" xlink:label="loc_us-gaap_EurodollarMember_41F970E045976237CC1B9E56B0FD8593" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_37E00A0850EB99E4BA9C9E56B0FC99E3" xlink:to="loc_us-gaap_EurodollarMember_41F970E045976237CC1B9E56B0FD8593" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FederalFundsEffectiveSwapRateMember" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember_8B9FF9A5EA697E8539BF9E56B0FDFA98" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_37E00A0850EB99E4BA9C9E56B0FC99E3" xlink:to="loc_us-gaap_FederalFundsEffectiveSwapRateMember_8B9FF9A5EA697E8539BF9E56B0FDFA98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BaseRateMember" xlink:label="loc_us-gaap_BaseRateMember_9E0042F2F5ED31B0FFB99E56B0FDA3F2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_37E00A0850EB99E4BA9C9E56B0FC99E3" xlink:to="loc_us-gaap_BaseRateMember_9E0042F2F5ED31B0FFB99E56B0FDA3F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_CBBCA839AA495418E0489E56B0FD5BE5" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3A26E82C506A2109FC559E56B0FA4290" xlink:to="loc_srt_RangeAxis_CBBCA839AA495418E0489E56B0FD5BE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_864CB00C40F42248F95E9E56B0FD04C5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_CBBCA839AA495418E0489E56B0FD5BE5" xlink:to="loc_srt_RangeMember_864CB00C40F42248F95E9E56B0FD04C5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_864CB00C40F42248F95E9E56B0FD04C5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_CBBCA839AA495418E0489E56B0FD5BE5" xlink:to="loc_srt_RangeMember_864CB00C40F42248F95E9E56B0FD04C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_C45783B140293BBF17489E56B0FEF6BA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_864CB00C40F42248F95E9E56B0FD04C5" xlink:to="loc_srt_MinimumMember_C45783B140293BBF17489E56B0FEF6BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_35F250C933600C81BA5D9E56B0FEFBD7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_864CB00C40F42248F95E9E56B0FD04C5" xlink:to="loc_srt_MaximumMember_35F250C933600C81BA5D9E56B0FEFBD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_C86AB87CC06D3C94D0719E56B0FF317D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0317E2577949153D5D669E56B0FE8C59" xlink:to="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_C86AB87CC06D3C94D0719E56B0FF317D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_9E9DE11098CAB58A297C9E56B0FF001A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0317E2577949153D5D669E56B0FE8C59" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_9E9DE11098CAB58A297C9E56B0FF001A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_9EC514F8D5D89645C34D9E56B0FF0A18" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0317E2577949153D5D669E56B0FE8C59" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_9EC514F8D5D89645C34D9E56B0FF0A18" xlink:type="arc" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears" xlink:label="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears_2E8FC1A4D3C51799860B9E56B0FF5F02" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0317E2577949153D5D669E56B0FE8C59" xlink:to="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears_2E8FC1A4D3C51799860B9E56B0FF5F02" xlink:type="arc" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear" xlink:label="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear_E7D4440EF7C81C65A3979E56B0FFFF0B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0317E2577949153D5D669E56B0FE8C59" xlink:to="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear_E7D4440EF7C81C65A3979E56B0FFFF0B" xlink:type="arc" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears" xlink:label="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears_DB482A3298198FBE44FB9E56B0FF9944" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0317E2577949153D5D669E56B0FE8C59" xlink:to="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears_DB482A3298198FBE44FB9E56B0FF9944" xlink:type="arc" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight" xlink:label="loc_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight_D29200E065EF0EF624ED9E56B0FFD804" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0317E2577949153D5D669E56B0FE8C59" xlink:to="loc_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight_D29200E065EF0EF624ED9E56B0FFD804" xlink:type="arc" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_DebtInstrumentCovenantDebtServiceCoverageRatio" xlink:label="loc_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio_D013DCC7650F545CA85B9E95B6B6922A" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0317E2577949153D5D669E56B0FE8C59" xlink:to="loc_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio_D013DCC7650F545CA85B9E95B6B6922A" xlink:type="arc" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioOne" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioOne_BBBCB39E6A7F50D035719E9C4A1BF2B5" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0317E2577949153D5D669E56B0FE8C59" xlink:to="loc_ebs_DebtInstrumentCovenantNetLeverageRatioOne_BBBCB39E6A7F50D035719E9C4A1BF2B5" xlink:type="arc" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioTwo" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioTwo_02AF74F62D13E4DE90919E9E05389C5C" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0317E2577949153D5D669E56B0FE8C59" xlink:to="loc_ebs_DebtInstrumentCovenantNetLeverageRatioTwo_02AF74F62D13E4DE90919E9E05389C5C" xlink:type="arc" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioThree" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioThree_67DB66E6E22F2747C5729E9EC900CFA7" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0317E2577949153D5D669E56B0FE8C59" xlink:to="loc_ebs_DebtInstrumentCovenantNetLeverageRatioThree_67DB66E6E22F2747C5729E9EC900CFA7" xlink:type="arc" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod_7965B54AA9CEACC745A59E56B100500C" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0317E2577949153D5D669E56B0FE8C59" xlink:to="loc_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod_7965B54AA9CEACC745A59E56B100500C" xlink:type="arc" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod_8C9CCDA760E5DEB4FB969E56B10016BA" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0317E2577949153D5D669E56B0FE8C59" xlink:to="loc_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod_8C9CCDA760E5DEB4FB969E56B10016BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_877F783E432E4ED26BA89E56B1004CB8" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0317E2577949153D5D669E56B0FE8C59" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_877F783E432E4ED26BA89E56B1004CB8" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/DebtScheduleDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_A5C7304B37901F4F6250BEB54DBB81B6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_29FA5D054DF86FFF1CFCBEB54DB6B672" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A5C7304B37901F4F6250BEB54DBB81B6" xlink:to="loc_us-gaap_DebtInstrumentTable_29FA5D054DF86FFF1CFCBEB54DB6B672" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_19636C3D1EC13971D396BEB54DBAA865" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_29FA5D054DF86FFF1CFCBEB54DB6B672" xlink:to="loc_us-gaap_CreditFacilityAxis_19636C3D1EC13971D396BEB54DBAA865" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_C528A764FF9135A424FEBEB54DBADF11_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_19636C3D1EC13971D396BEB54DBAA865" xlink:to="loc_us-gaap_CreditFacilityDomain_C528A764FF9135A424FEBEB54DBADF11_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_C528A764FF9135A424FEBEB54DBADF11" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_19636C3D1EC13971D396BEB54DBAA865" xlink:to="loc_us-gaap_CreditFacilityDomain_C528A764FF9135A424FEBEB54DBADF11" xlink:type="arc" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_TermLoanFacilityMember" xlink:label="loc_ebs_TermLoanFacilityMember_F729A6999A6452497C1FBEB54DBACE55" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_C528A764FF9135A424FEBEB54DBADF11" xlink:to="loc_ebs_TermLoanFacilityMember_F729A6999A6452497C1FBEB54DBACE55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_3B0E01373362C95D71D0BEB54DBB6C69" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_C528A764FF9135A424FEBEB54DBADF11" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_3B0E01373362C95D71D0BEB54DBB6C69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_BB516432B1B051F8667EBEB54DBB2030" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_29FA5D054DF86FFF1CFCBEB54DB6B672" xlink:to="loc_us-gaap_DebtInstrumentAxis_BB516432B1B051F8667EBEB54DBB2030" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2FD7AB7BCA25DBC13C5BBEB54DBB3636_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_BB516432B1B051F8667EBEB54DBB2030" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2FD7AB7BCA25DBC13C5BBEB54DBB3636_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2FD7AB7BCA25DBC13C5BBEB54DBB3636" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_BB516432B1B051F8667EBEB54DBB2030" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2FD7AB7BCA25DBC13C5BBEB54DBB3636" xlink:type="arc" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_ConvertibleSeniorNotesDue2021Member" xlink:label="loc_ebs_ConvertibleSeniorNotesDue2021Member_7A87C06F1FF19FB8CF95BEB54DBB5608" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2FD7AB7BCA25DBC13C5BBEB54DBB3636" xlink:to="loc_ebs_ConvertibleSeniorNotesDue2021Member_7A87C06F1FF19FB8CF95BEB54DBB5608" xlink:type="arc" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_OtherLongTermDebtFacilityMember" xlink:label="loc_ebs_OtherLongTermDebtFacilityMember_60ABFC64BE05842B158ABEB54DBB2CBE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2FD7AB7BCA25DBC13C5BBEB54DBB3636" xlink:to="loc_ebs_OtherLongTermDebtFacilityMember_60ABFC64BE05842B158ABEB54DBB2CBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_B2A484E74662134609E5BEB54DBC4AB7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A5C7304B37901F4F6250BEB54DBB81B6" xlink:to="loc_us-gaap_LongTermDebt_B2A484E74662134609E5BEB54DBC4AB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_A83E41715FDF32FFCB8BBEB54DBC22EB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A5C7304B37901F4F6250BEB54DBB81B6" xlink:to="loc_us-gaap_LongTermDebtCurrent_A83E41715FDF32FFCB8BBEB54DBC22EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_2CBE3659CE19154CE361BEB54DBCF5FC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A5C7304B37901F4F6250BEB54DBB81B6" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_2CBE3659CE19154CE361BEB54DBCF5FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_8A978A68C6587CA0289ABEB54DBC793E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A5C7304B37901F4F6250BEB54DBB81B6" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_8A978A68C6587CA0289ABEB54DBC793E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_F547D2BFEF46E716DF4FBEB7450A6110" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A5C7304B37901F4F6250BEB54DBB81B6" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_F547D2BFEF46E716DF4FBEB7450A6110" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/DebtTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivities" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesCashFlowHedgingOnAociDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_71EA605577277DCF2F59C9409BF6F065" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_C0859B225DE28ED876B2C9409BF65E0F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_71EA605577277DCF2F59C9409BF6F065" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_C0859B225DE28ED876B2C9409BF65E0F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6DEBE9C6C948FA24C018C9409BF619DB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_C0859B225DE28ED876B2C9409BF65E0F" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6DEBE9C6C948FA24C018C9409BF619DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_DAEE2CBF623582D45B04C9409BF6D39E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6DEBE9C6C948FA24C018C9409BF619DB" xlink:to="loc_us-gaap_HedgingRelationshipDomain_DAEE2CBF623582D45B04C9409BF6D39E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_DAEE2CBF623582D45B04C9409BF6D39E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6DEBE9C6C948FA24C018C9409BF619DB" xlink:to="loc_us-gaap_HedgingRelationshipDomain_DAEE2CBF623582D45B04C9409BF6D39E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowHedgingMember" xlink:label="loc_us-gaap_CashFlowHedgingMember_37BB8332D80452461AF0C9409BF60A6B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_DAEE2CBF623582D45B04C9409BF6D39E" xlink:to="loc_us-gaap_CashFlowHedgingMember_37BB8332D80452461AF0C9409BF60A6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_49B7B052B7AEBBE1D451C9409BF66361" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_C0859B225DE28ED876B2C9409BF65E0F" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_49B7B052B7AEBBE1D451C9409BF66361" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_98AE09F23C48C07605A4C9409BF6DF1B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_49B7B052B7AEBBE1D451C9409BF66361" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_98AE09F23C48C07605A4C9409BF6DF1B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_98AE09F23C48C07605A4C9409BF6DF1B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_49B7B052B7AEBBE1D451C9409BF66361" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_98AE09F23C48C07605A4C9409BF6DF1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseMember" xlink:label="loc_us-gaap_InterestExpenseMember_FB53E012674154AF661AC9409BF6A29E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_98AE09F23C48C07605A4C9409BF6DF1B" xlink:to="loc_us-gaap_InterestExpenseMember_FB53E012674154AF661AC9409BF6A29E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_580EAF7E382C25BC8E5DC9409BF63AE7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_C0859B225DE28ED876B2C9409BF65E0F" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_580EAF7E382C25BC8E5DC9409BF63AE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_E349859E0C9D0A3147F7C9409BF6E9BF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_580EAF7E382C25BC8E5DC9409BF63AE7" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_E349859E0C9D0A3147F7C9409BF6E9BF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_E349859E0C9D0A3147F7C9409BF6E9BF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_580EAF7E382C25BC8E5DC9409BF63AE7" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_E349859E0C9D0A3147F7C9409BF6E9BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_B61FB951C6E23763CED5C9409BF621A9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_E349859E0C9D0A3147F7C9409BF6E9BF" xlink:to="loc_us-gaap_InterestRateSwapMember_B61FB951C6E23763CED5C9409BF621A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_F0CF3ED1F5C4A768D574C9409BF6F442" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_71EA605577277DCF2F59C9409BF6F065" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_F0CF3ED1F5C4A768D574C9409BF6F442" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_01C84B65D9F8A32A48D4C9409BF6A091" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_71EA605577277DCF2F59C9409BF6F065" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_01C84B65D9F8A32A48D4C9409BF6A091" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesDerivativeDesignatedAsCashFlowHedgesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_41D37F6918CDE628C0F29E56B12184C4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_34D0E958B9304B2BBBB29E56B12117B2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_41D37F6918CDE628C0F29E56B12184C4" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_34D0E958B9304B2BBBB29E56B12117B2" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_AF524064B1D7FDD07C339E56B121A8BA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_34D0E958B9304B2BBBB29E56B12117B2" xlink:to="loc_us-gaap_HedgingDesignationAxis_AF524064B1D7FDD07C339E56B121A8BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_67B8C8923381E72136F59E56B1210DC1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_AF524064B1D7FDD07C339E56B121A8BA" xlink:to="loc_us-gaap_HedgingDesignationDomain_67B8C8923381E72136F59E56B1210DC1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_67B8C8923381E72136F59E56B1210DC1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_AF524064B1D7FDD07C339E56B121A8BA" xlink:to="loc_us-gaap_HedgingDesignationDomain_67B8C8923381E72136F59E56B1210DC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_8DD69019D10F94A414A59E56B1216E87" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_67B8C8923381E72136F59E56B1210DC1" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_8DD69019D10F94A414A59E56B1216E87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_CD8CEFB66B3F875E76119E56B1214A92" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_34D0E958B9304B2BBBB29E56B12117B2" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_CD8CEFB66B3F875E76119E56B1214A92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_BA480F19C1E8363B46B49E56B121AFA5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_CD8CEFB66B3F875E76119E56B1214A92" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_BA480F19C1E8363B46B49E56B121AFA5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_BA480F19C1E8363B46B49E56B121AFA5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_CD8CEFB66B3F875E76119E56B1214A92" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_BA480F19C1E8363B46B49E56B121AFA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_FA8DE5981CF89300D4F99E56B121241C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_BA480F19C1E8363B46B49E56B121AFA5" xlink:to="loc_us-gaap_InterestRateSwapMember_FA8DE5981CF89300D4F99E56B121241C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfInterestRateDerivativesHeld" xlink:label="loc_us-gaap_NumberOfInterestRateDerivativesHeld_CC28A6A1360ACFDBE5399E56B1219E80" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_41D37F6918CDE628C0F29E56B12184C4" xlink:to="loc_us-gaap_NumberOfInterestRateDerivativesHeld_CC28A6A1360ACFDBE5399E56B1219E80" xlink:type="arc" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_DerivativeNotionalAmount1" xlink:label="loc_ebs_DerivativeNotionalAmount1_C29088311E848A64077B9E56B1213114" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_41D37F6918CDE628C0F29E56B12184C4" xlink:to="loc_ebs_DerivativeNotionalAmount1_C29088311E848A64077B9E56B1213114" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesFairValueByBalanceSheetLocationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_0A252FE4B0227C702A169E56B11EAA57" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_D4140DD0B30D6561EBD39E56B11BEFDA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0A252FE4B0227C702A169E56B11EAA57" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_D4140DD0B30D6561EBD39E56B11BEFDA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_19A5F7EF1083352034DE9E56B11B27D5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_D4140DD0B30D6561EBD39E56B11BEFDA" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_19A5F7EF1083352034DE9E56B11B27D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_895E7580751B4D1A363A9E56B11CF00C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_19A5F7EF1083352034DE9E56B11B27D5" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_895E7580751B4D1A363A9E56B11CF00C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_895E7580751B4D1A363A9E56B11CF00C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_19A5F7EF1083352034DE9E56B11B27D5" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_895E7580751B4D1A363A9E56B11CF00C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_E03FD7907E28659A506E9E56B11CACCF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_895E7580751B4D1A363A9E56B11CF00C" xlink:to="loc_us-gaap_InterestRateSwapMember_E03FD7907E28659A506E9E56B11CACCF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_B004F6775C459C446D029E56B11CA8CF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_D4140DD0B30D6561EBD39E56B11BEFDA" xlink:to="loc_us-gaap_HedgingDesignationAxis_B004F6775C459C446D029E56B11CA8CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_C3D83C684821E3E340249E56B11C4348_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_B004F6775C459C446D029E56B11CA8CF" xlink:to="loc_us-gaap_HedgingDesignationDomain_C3D83C684821E3E340249E56B11C4348_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_C3D83C684821E3E340249E56B11C4348" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_B004F6775C459C446D029E56B11CA8CF" xlink:to="loc_us-gaap_HedgingDesignationDomain_C3D83C684821E3E340249E56B11C4348" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_0712B391C6C0F06935929E56B11D745E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_C3D83C684821E3E340249E56B11C4348" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_0712B391C6C0F06935929E56B11D745E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_AC78D2FA47A532637F319E56B11D3529" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_D4140DD0B30D6561EBD39E56B11BEFDA" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_AC78D2FA47A532637F319E56B11D3529" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1BBD1E39EF5209523EA09E56B11DD7F3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_AC78D2FA47A532637F319E56B11D3529" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1BBD1E39EF5209523EA09E56B11DD7F3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1BBD1E39EF5209523EA09E56B11DD7F3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_AC78D2FA47A532637F319E56B11D3529" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1BBD1E39EF5209523EA09E56B11DD7F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_22FA726EC7059230EAD59E77FCF3D17F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1BBD1E39EF5209523EA09E56B11DD7F3" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_22FA726EC7059230EAD59E77FCF3D17F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsMember" xlink:label="loc_us-gaap_OtherAssetsMember_D04ED8424BD888F3DC1E9E56B11D2CD7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1BBD1E39EF5209523EA09E56B11DD7F3" xlink:to="loc_us-gaap_OtherAssetsMember_D04ED8424BD888F3DC1E9E56B11D2CD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_62F278C8A0770C561F939E56B11D40D3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1BBD1E39EF5209523EA09E56B11DD7F3" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_62F278C8A0770C561F939E56B11D40D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesMember" xlink:label="loc_us-gaap_OtherLiabilitiesMember_1FB79D7B80207255050E9E7855CEF4BD" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1BBD1E39EF5209523EA09E56B11DD7F3" xlink:to="loc_us-gaap_OtherLiabilitiesMember_1FB79D7B80207255050E9E7855CEF4BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_C37453496FE9A98E11929E56B11EF9BF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0A252FE4B0227C702A169E56B11EAA57" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_C37453496FE9A98E11929E56B11EF9BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_3FA2A94BADEAA799628C9E56B11EE081" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0A252FE4B0227C702A169E56B11EAA57" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_3FA2A94BADEAA799628C9E56B11EE081" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_D945B350C692BEC199C99E56B12B36E9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_04285B755F553EB5C90D9E56B12ADDD3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_D945B350C692BEC199C99E56B12B36E9" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_04285B755F553EB5C90D9E56B12ADDD3" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_90CC8EF3D99DB6D0BBFD9E56B12ADEF1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_04285B755F553EB5C90D9E56B12ADDD3" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_90CC8EF3D99DB6D0BBFD9E56B12ADEF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_06EA585DA310F4B9747C9E56B12BA887_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_90CC8EF3D99DB6D0BBFD9E56B12ADEF1" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_06EA585DA310F4B9747C9E56B12BA887_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_06EA585DA310F4B9747C9E56B12BA887" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_90CC8EF3D99DB6D0BBFD9E56B12ADEF1" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_06EA585DA310F4B9747C9E56B12BA887" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_67A15CECA06BAD02DFEC9E56B12B73D8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_06EA585DA310F4B9747C9E56B12BA887" xlink:to="loc_us-gaap_InterestRateSwapMember_67A15CECA06BAD02DFEC9E56B12B73D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:label="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_3335ADA5FEFE9E6CFD4C9E56B12BBA16" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_D945B350C692BEC199C99E56B12B36E9" xlink:to="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_3335ADA5FEFE9E6CFD4C9E56B12BBA16" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/IncomeTaxes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/IncomeTaxesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/IntangibleAssets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/IntangibleAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_E88615DB7479E8F7DDB69E56B13F887C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5DCD31518FC9A304614A9E56B13E7597" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_E88615DB7479E8F7DDB69E56B13F887C" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5DCD31518FC9A304614A9E56B13E7597" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_63764033C90FC537D9559E56B13FEB9F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5DCD31518FC9A304614A9E56B13E7597" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_63764033C90FC537D9559E56B13FEB9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3E19AAE024F55E05D1CF9E56B13F036E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_63764033C90FC537D9559E56B13FEB9F" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3E19AAE024F55E05D1CF9E56B13F036E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3E19AAE024F55E05D1CF9E56B13F036E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_63764033C90FC537D9559E56B13FEB9F" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3E19AAE024F55E05D1CF9E56B13F036E" xlink:type="arc" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_RaxibacumabMember" xlink:label="loc_ebs_RaxibacumabMember_5FCBE344EDBA633ADA099E56B13F4C59" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3E19AAE024F55E05D1CF9E56B13F036E" xlink:to="loc_ebs_RaxibacumabMember_5FCBE344EDBA633ADA099E56B13F4C59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_F0DEC2457BAAFD60719C9E56B13FBC95" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_E88615DB7479E8F7DDB69E56B13F887C" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_F0DEC2457BAAFD60719C9E56B13FBC95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_1C5FF26DFB5A96C0FC089E56B1403AD8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_E88615DB7479E8F7DDB69E56B13F887C" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_1C5FF26DFB5A96C0FC089E56B1403AD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_52F148F1A4D3C80274819E56B140A57E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_E88615DB7479E8F7DDB69E56B13F887C" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_52F148F1A4D3C80274819E56B140A57E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_159CD58DBA983B64FED49E6E5696BB6B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_E88615DB7479E8F7DDB69E56B13F887C" xlink:to="loc_us-gaap_Goodwill_159CD58DBA983B64FED49E6E5696BB6B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8163A70B45F54D03C2A1BC1D232C60E8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_63431193F268054CE9C3BC1D23294EA1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8163A70B45F54D03C2A1BC1D232C60E8" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_63431193F268054CE9C3BC1D23294EA1" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_355EC80F65AA9E3B794EBC1D2329AAF1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_63431193F268054CE9C3BC1D23294EA1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_355EC80F65AA9E3B794EBC1D2329AAF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_D86F113E6DA0B7D79432BC1D232A2DF6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_355EC80F65AA9E3B794EBC1D2329AAF1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_D86F113E6DA0B7D79432BC1D232A2DF6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_D86F113E6DA0B7D79432BC1D232A2DF6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_355EC80F65AA9E3B794EBC1D2329AAF1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_D86F113E6DA0B7D79432BC1D232A2DF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_836ED38AD4823110423CBC1D232AC212" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_D86F113E6DA0B7D79432BC1D232A2DF6" xlink:to="loc_us-gaap_ProductMember_836ED38AD4823110423CBC1D232AC212" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaap_CustomerRelationshipsMember_F23B9AE855B4AB6EF9BDBC1D232A3DA2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_D86F113E6DA0B7D79432BC1D232A2DF6" xlink:to="loc_us-gaap_CustomerRelationshipsMember_F23B9AE855B4AB6EF9BDBC1D232A3DA2" xlink:type="arc" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_ContractManufacturingMember" xlink:label="loc_ebs_ContractManufacturingMember_652CC6699B20D554F5B4BC1D232BF995" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_D86F113E6DA0B7D79432BC1D232A2DF6" xlink:to="loc_ebs_ContractManufacturingMember_652CC6699B20D554F5B4BC1D232BF995" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_6C3602837552DB07B61BBC1D232B0765" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_63431193F268054CE9C3BC1D23294EA1" xlink:to="loc_srt_RangeAxis_6C3602837552DB07B61BBC1D232B0765" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_D8CF112FE82E35743DDBBC1D232B21E9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_6C3602837552DB07B61BBC1D232B0765" xlink:to="loc_srt_RangeMember_D8CF112FE82E35743DDBBC1D232B21E9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_D8CF112FE82E35743DDBBC1D232B21E9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_6C3602837552DB07B61BBC1D232B0765" xlink:to="loc_srt_RangeMember_D8CF112FE82E35743DDBBC1D232B21E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_F17A9CE957FBF7C8CF5EBC1D232BD7F6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_D8CF112FE82E35743DDBBC1D232B21E9" xlink:to="loc_srt_MinimumMember_F17A9CE957FBF7C8CF5EBC1D232BD7F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_BB034B145D28EFDC6C37BC1D232B2D67" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_D8CF112FE82E35743DDBBC1D232B21E9" xlink:to="loc_srt_MaximumMember_BB034B145D28EFDC6C37BC1D232B2D67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_3EF8A217EF74F594299BBC1D232CD734" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8163A70B45F54D03C2A1BC1D232C60E8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_3EF8A217EF74F594299BBC1D232CD734" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_BFDA95206586563938D3BC1D232C85E6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8163A70B45F54D03C2A1BC1D232C60E8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_BFDA95206586563938D3BC1D232C85E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_8D1474AD6B0246229B1CBC1D232CD67E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_BFDA95206586563938D3BC1D232C85E6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_8D1474AD6B0246229B1CBC1D232CD67E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_4A5D5AA8F9C1A239E088BC1D232CBE32" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_BFDA95206586563938D3BC1D232C85E6" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_4A5D5AA8F9C1A239E088BC1D232CBE32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_C642FC3958717E0EB6ABBC1D232D3CB9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_BFDA95206586563938D3BC1D232C85E6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_C642FC3958717E0EB6ABBC1D232D3CB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_FA561057BD5C5A9296CBBC1D232D337E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_BFDA95206586563938D3BC1D232C85E6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_FA561057BD5C5A9296CBBC1D232D337E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/IntangibleAssetsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/Inventories" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/InventoriesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/InventoriesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/Leases" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/LeasesComponentsOfLeaseExpenseDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_ECAEA5C584C6309EBC4A50AC9D41093B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_9BA650CEBBF617CFCD5150AC9D4022E3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ECAEA5C584C6309EBC4A50AC9D41093B" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_9BA650CEBBF617CFCD5150AC9D4022E3" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_FBA7A9B26033494B18DF50AC9D405A5F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_9BA650CEBBF617CFCD5150AC9D4022E3" xlink:to="loc_srt_RangeAxis_FBA7A9B26033494B18DF50AC9D405A5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_4BDC190BBAA7EF64C26250AC9D41CF0E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_FBA7A9B26033494B18DF50AC9D405A5F" xlink:to="loc_srt_RangeMember_4BDC190BBAA7EF64C26250AC9D41CF0E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_4BDC190BBAA7EF64C26250AC9D41CF0E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_FBA7A9B26033494B18DF50AC9D405A5F" xlink:to="loc_srt_RangeMember_4BDC190BBAA7EF64C26250AC9D41CF0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_6AE600A778534BCBA2F450AC9D41E1C3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4BDC190BBAA7EF64C26250AC9D41CF0E" xlink:to="loc_srt_MinimumMember_6AE600A778534BCBA2F450AC9D41E1C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_5C0AEC4C340F6F37D56F50AC9D415F98" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4BDC190BBAA7EF64C26250AC9D41CF0E" xlink:to="loc_srt_MaximumMember_5C0AEC4C340F6F37D56F50AC9D415F98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_07BD2C0104170056189350AC9D412917" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ECAEA5C584C6309EBC4A50AC9D41093B" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_07BD2C0104170056189350AC9D412917" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_457123CA08CFECF5E4AF50AC9D420927" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ECAEA5C584C6309EBC4A50AC9D41093B" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_457123CA08CFECF5E4AF50AC9D420927" xlink:type="arc" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_LesseeOperatingLeaseTerminationPeriod" xlink:label="loc_ebs_LesseeOperatingLeaseTerminationPeriod_D7CC300D5B1C88D713B150AC9D4235D5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ECAEA5C584C6309EBC4A50AC9D41093B" xlink:to="loc_ebs_LesseeOperatingLeaseTerminationPeriod_D7CC300D5B1C88D713B150AC9D4235D5" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/LeasesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/NetLossPerShare" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/NetLossPerShareDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/NetLossPerShareTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/PropertyPlantAndEquipment" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_B9189E2A52C2FC5E5C7D9E56B17B20EA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3AEB026013FF109C795A9E56B1794A13" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_B9189E2A52C2FC5E5C7D9E56B17B20EA" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3AEB026013FF109C795A9E56B1794A13" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8021DE5C9D40C80A4E9D9E56B1791834" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3AEB026013FF109C795A9E56B1794A13" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8021DE5C9D40C80A4E9D9E56B1791834" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9E748081E94E97B525BE9E56B179C870_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8021DE5C9D40C80A4E9D9E56B1791834" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9E748081E94E97B525BE9E56B179C870_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9E748081E94E97B525BE9E56B179C870" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8021DE5C9D40C80A4E9D9E56B1791834" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9E748081E94E97B525BE9E56B179C870" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LandAndLandImprovementsMember" xlink:label="loc_us-gaap_LandAndLandImprovementsMember_250E88996435BAE636EE9E56B17AC151" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9E748081E94E97B525BE9E56B179C870" xlink:to="loc_us-gaap_LandAndLandImprovementsMember_250E88996435BAE636EE9E56B17AC151" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_F2108DD77B88D96FE16C9E56B17A76BA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9E748081E94E97B525BE9E56B179C870" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_F2108DD77B88D96FE16C9E56B17A76BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_12524A90DB9E5C26172D9E56B17A9E49" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9E748081E94E97B525BE9E56B179C870" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_12524A90DB9E5C26172D9E56B17A9E49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_DC9DF4B643EDFC3E10BA9E56B17AA057" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9E748081E94E97B525BE9E56B179C870" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_DC9DF4B643EDFC3E10BA9E56B17AA057" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_F99C10D86CB61E6A3C539E56B17B5E03" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9E748081E94E97B525BE9E56B179C870" xlink:to="loc_us-gaap_ConstructionInProgressMember_F99C10D86CB61E6A3C539E56B17B5E03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_E54D8E8C33552D4EFDA09E56B17BB017" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_B9189E2A52C2FC5E5C7D9E56B17B20EA" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_E54D8E8C33552D4EFDA09E56B17BB017" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_4665B9B6FF5A538849D49E56B17B8616" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_E54D8E8C33552D4EFDA09E56B17BB017" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_4665B9B6FF5A538849D49E56B17B8616" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_86B88581CE148E53CA779E56B17BF7B2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_E54D8E8C33552D4EFDA09E56B17BB017" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_86B88581CE148E53CA779E56B17BF7B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5EADEB99DEAD9423B8449E56B17C66FD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_E54D8E8C33552D4EFDA09E56B17BB017" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_5EADEB99DEAD9423B8449E56B17C66FD" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/RevenueRecognition" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/RevenueRecognitionAccountsReceivableDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/RevenueRecognitionContractLiabilitiesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationOfRevenueDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_3A3E57B47249756F1AF5B7DCF570F69F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_1E470C1CF93EB567F8BCB7DCF56E7497" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3A3E57B47249756F1AF5B7DCF570F69F" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_1E470C1CF93EB567F8BCB7DCF56E7497" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_2C76173360254469219FB7DCF56E0F1B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1E470C1CF93EB567F8BCB7DCF56E7497" xlink:to="loc_srt_ProductOrServiceAxis_2C76173360254469219FB7DCF56E0F1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_AC22D1F72325E4F5331EB7DCF56E4DE1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_2C76173360254469219FB7DCF56E0F1B" xlink:to="loc_srt_ProductsAndServicesDomain_AC22D1F72325E4F5331EB7DCF56E4DE1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_AC22D1F72325E4F5331EB7DCF56E4DE1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_2C76173360254469219FB7DCF56E0F1B" xlink:to="loc_srt_ProductsAndServicesDomain_AC22D1F72325E4F5331EB7DCF56E4DE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_7222CA10DE186D94E091B7DCF56F3C93" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_AC22D1F72325E4F5331EB7DCF56E4DE1" xlink:to="loc_us-gaap_ProductMember_7222CA10DE186D94E091B7DCF56F3C93" xlink:type="arc" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_ContractManufacturingMember" xlink:label="loc_ebs_ContractManufacturingMember_42459EACA9B70C832528B7DCF56F7CE1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_AC22D1F72325E4F5331EB7DCF56E4DE1" xlink:to="loc_ebs_ContractManufacturingMember_42459EACA9B70C832528B7DCF56F7CE1" xlink:type="arc" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_ContractsAndGrantsMember" xlink:label="loc_ebs_ContractsAndGrantsMember_B7AAA2E5D7274EF53C6AB7DCF56FC175" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_AC22D1F72325E4F5331EB7DCF56E4DE1" xlink:to="loc_ebs_ContractsAndGrantsMember_B7AAA2E5D7274EF53C6AB7DCF56FC175" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_69A61BDEFC0E9B08FB82B7DCF56FCF3D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1E470C1CF93EB567F8BCB7DCF56E7497" xlink:to="loc_srt_StatementGeographicalAxis_69A61BDEFC0E9B08FB82B7DCF56FCF3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_19D49D083F36352456C3B7DCF56FC11D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_69A61BDEFC0E9B08FB82B7DCF56FCF3D" xlink:to="loc_srt_SegmentGeographicalDomain_19D49D083F36352456C3B7DCF56FC11D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_19D49D083F36352456C3B7DCF56FC11D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_69A61BDEFC0E9B08FB82B7DCF56FCF3D" xlink:to="loc_srt_SegmentGeographicalDomain_19D49D083F36352456C3B7DCF56FC11D" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_72A81804137B69178192B7DCF570177A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_19D49D083F36352456C3B7DCF56FC11D" xlink:to="loc_country_US_72A81804137B69178192B7DCF570177A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaap_NonUsMember_DA8D4574E8A3C820268CB7DCF5700278" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_19D49D083F36352456C3B7DCF56FC11D" xlink:to="loc_us-gaap_NonUsMember_DA8D4574E8A3C820268CB7DCF5700278" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_E70F39A273843236A734B7DCF570AC53" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3A3E57B47249756F1AF5B7DCF570F69F" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_E70F39A273843236A734B7DCF570AC53" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/RevenueRecognitionNarrativeDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/RevenueRecognitionRemainingPerformanceObligationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_B9A925966FA44D0EDA4250AE202733C0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_F82042A7FECCF758134450AE2026A42E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_B9A925966FA44D0EDA4250AE202733C0" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_F82042A7FECCF758134450AE2026A42E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_34E650987B5D21F9E27250AE20278B09" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_F82042A7FECCF758134450AE2026A42E" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_34E650987B5D21F9E27250AE20278B09" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/RevenueRecognitionTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/ShareBasedCompensation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/ShareBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_90B7DAFD72A247A8BC0179DDB09462F8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_BE082120B24A4EF1C9AC79DDB08CA5DD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_90B7DAFD72A247A8BC0179DDB09462F8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_BE082120B24A4EF1C9AC79DDB08CA5DD" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_DB211463A3D71E91DE5979DDB08DFF3E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_BE082120B24A4EF1C9AC79DDB08CA5DD" xlink:to="loc_us-gaap_VestingAxis_DB211463A3D71E91DE5979DDB08DFF3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_780B75C4BF70B6A39E8F79DDB08D031F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_DB211463A3D71E91DE5979DDB08DFF3E" xlink:to="loc_us-gaap_VestingDomain_780B75C4BF70B6A39E8F79DDB08D031F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_780B75C4BF70B6A39E8F79DDB08D031F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_DB211463A3D71E91DE5979DDB08DFF3E" xlink:to="loc_us-gaap_VestingDomain_780B75C4BF70B6A39E8F79DDB08D031F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_CA7FC2FA48DA5BD380FF79DDB08D0C07" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_780B75C4BF70B6A39E8F79DDB08D031F" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_CA7FC2FA48DA5BD380FF79DDB08D0C07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_0028CDD8BF45952C4CA979DDB08E178A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_780B75C4BF70B6A39E8F79DDB08D031F" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_0028CDD8BF45952C4CA979DDB08E178A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_F8B9098CEF597BDBA3DE79DDB08EE9BC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_780B75C4BF70B6A39E8F79DDB08D031F" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_F8B9098CEF597BDBA3DE79DDB08EE9BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_936FF14D40FCF9B8581E79DDB08E985F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_BE082120B24A4EF1C9AC79DDB08CA5DD" xlink:to="loc_us-gaap_AwardTypeAxis_936FF14D40FCF9B8581E79DDB08E985F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F9F9B322D55F40570F4579DDB08E4BBD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_936FF14D40FCF9B8581E79DDB08E985F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F9F9B322D55F40570F4579DDB08E4BBD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F9F9B322D55F40570F4579DDB08E4BBD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_936FF14D40FCF9B8581E79DDB08E985F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F9F9B322D55F40570F4579DDB08E4BBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_D893004C0295BA83BDDD79DDB08E0284" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F9F9B322D55F40570F4579DDB08E4BBD" xlink:to="loc_us-gaap_EmployeeStockOptionMember_D893004C0295BA83BDDD79DDB08E0284" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_3C95134323D2916B99F779DDB094E174" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F9F9B322D55F40570F4579DDB08E4BBD" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_3C95134323D2916B99F779DDB094E174" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract_39EFB8036BC6EFBAFC4B79DDB0941533" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_90B7DAFD72A247A8BC0179DDB09462F8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract_39EFB8036BC6EFBAFC4B79DDB0941533" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_56DD46FEFD4DD055015679DDB0957323" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract_39EFB8036BC6EFBAFC4B79DDB0941533" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_56DD46FEFD4DD055015679DDB0957323" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_F3C54E30E012BD840AF579DDB095C6A7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract_39EFB8036BC6EFBAFC4B79DDB0941533" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_F3C54E30E012BD840AF579DDB095C6A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_22830B326A574E380C3979DDB0957D43" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract_39EFB8036BC6EFBAFC4B79DDB0941533" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_22830B326A574E380C3979DDB0957D43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5D9D0F86A91F3101639D79DDB095A6E7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract_39EFB8036BC6EFBAFC4B79DDB0941533" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5D9D0F86A91F3101639D79DDB095A6E7" xlink:type="arc" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>ebs-20200331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0A07BCA2ACF1EA0F145DB7DCF64D2CB3_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0A07BCA2ACF1EA0F145DB7DCF64D2CB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0A07BCA2ACF1EA0F145DB7DCF64D2CB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0A07BCA2ACF1EA0F145DB7DCF64D2CB3" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0A07BCA2ACF1EA0F145DB7DCF64D2CB3" xlink:type="arc" />
    <link:label id="lab_ebs_NumberOfCategoriesOfPublicHealthThreats_BE1E92600B51BE6BAFD5B7DCF64DD441_terseLabel_en-US" xlink:label="lab_ebs_NumberOfCategoriesOfPublicHealthThreats_BE1E92600B51BE6BAFD5B7DCF64DD441" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of categories of public health threats</link:label>
    <link:label id="lab_ebs_NumberOfCategoriesOfPublicHealthThreats_BE1E92600B51BE6BAFD5B7DCF64DD441_label_en-US" xlink:label="lab_ebs_NumberOfCategoriesOfPublicHealthThreats_BE1E92600B51BE6BAFD5B7DCF64DD441" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Categories Of Public Health Threats</link:label>
    <link:label id="lab_ebs_NumberOfCategoriesOfPublicHealthThreats_BE1E92600B51BE6BAFD5B7DCF64DD441_documentation_en-US" xlink:label="lab_ebs_NumberOfCategoriesOfPublicHealthThreats_BE1E92600B51BE6BAFD5B7DCF64DD441" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to the number of categories of public health threats.</link:label>
    <link:loc xlink:href="ebs-20200331.xsd#ebs_NumberOfCategoriesOfPublicHealthThreats" xlink:label="loc_ebs_NumberOfCategoriesOfPublicHealthThreats_BE1E92600B51BE6BAFD5B7DCF64DD441" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_NumberOfCategoriesOfPublicHealthThreats_BE1E92600B51BE6BAFD5B7DCF64DD441" xlink:to="lab_ebs_NumberOfCategoriesOfPublicHealthThreats_BE1E92600B51BE6BAFD5B7DCF64DD441" xlink:type="arc" />
    <link:label id="lab_ebs_NumberOfRevenueGeneratingProducts_12FD7E000DCE0CCF96A8B7E29D8A86E9_terseLabel_en-US" xlink:label="lab_ebs_NumberOfRevenueGeneratingProducts_12FD7E000DCE0CCF96A8B7E29D8A86E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of revenue generating products</link:label>
    <link:label id="lab_ebs_NumberOfRevenueGeneratingProducts_12FD7E000DCE0CCF96A8B7E29D8A86E9_label_en-US" xlink:label="lab_ebs_NumberOfRevenueGeneratingProducts_12FD7E000DCE0CCF96A8B7E29D8A86E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Revenue Generating Products</link:label>
    <link:label id="lab_ebs_NumberOfRevenueGeneratingProducts_12FD7E000DCE0CCF96A8B7E29D8A86E9_documentation_en-US" xlink:label="lab_ebs_NumberOfRevenueGeneratingProducts_12FD7E000DCE0CCF96A8B7E29D8A86E9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to the number of revenue generating products.</link:label>
    <link:loc xlink:href="ebs-20200331.xsd#ebs_NumberOfRevenueGeneratingProducts" xlink:label="loc_ebs_NumberOfRevenueGeneratingProducts_12FD7E000DCE0CCF96A8B7E29D8A86E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_NumberOfRevenueGeneratingProducts_12FD7E000DCE0CCF96A8B7E29D8A86E9" xlink:to="lab_ebs_NumberOfRevenueGeneratingProducts_12FD7E000DCE0CCF96A8B7E29D8A86E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_87AAE758FD22D26EA89FB7DCF64E6983_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_87AAE758FD22D26EA89FB7DCF64E6983" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_87AAE758FD22D26EA89FB7DCF64E6983_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_87AAE758FD22D26EA89FB7DCF64E6983" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_87AAE758FD22D26EA89FB7DCF64E6983" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments_87AAE758FD22D26EA89FB7DCF64E6983" xlink:to="lab_us-gaap_NumberOfOperatingSegments_87AAE758FD22D26EA89FB7DCF64E6983" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_D8392ED7FC7F9F921073B7FBB3D1B05F_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_D8392ED7FC7F9F921073B7FBB3D1B05F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_D8392ED7FC7F9F921073B7FBB3D1B05F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_D8392ED7FC7F9F921073B7FBB3D1B05F" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_D8392ED7FC7F9F921073B7FBB3D1B05F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_236089CBDF20EF36E294B803467124E2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_236089CBDF20EF36E294B803467124E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_236089CBDF20EF36E294B803467124E2_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_236089CBDF20EF36E294B803467124E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_236089CBDF20EF36E294B803467124E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_236089CBDF20EF36E294B803467124E2" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_236089CBDF20EF36E294B803467124E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_EF83DF043E1ECF00670DB8065D013987_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis_EF83DF043E1ECF00670DB8065D013987" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_EF83DF043E1ECF00670DB8065D013987_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis_EF83DF043E1ECF00670DB8065D013987" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="loc_us-gaap_ValuationTechniqueAxis_EF83DF043E1ECF00670DB8065D013987" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueAxis_EF83DF043E1ECF00670DB8065D013987" xlink:to="lab_us-gaap_ValuationTechniqueAxis_EF83DF043E1ECF00670DB8065D013987" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_7B72E3A8790D428B4C23B80BB11CB440_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain_7B72E3A8790D428B4C23B80BB11CB440" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_7B72E3A8790D428B4C23B80BB11CB440_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain_7B72E3A8790D428B4C23B80BB11CB440" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="loc_us-gaap_ValuationTechniqueDomain_7B72E3A8790D428B4C23B80BB11CB440" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDomain_7B72E3A8790D428B4C23B80BB11CB440" xlink:to="lab_us-gaap_ValuationTechniqueDomain_7B72E3A8790D428B4C23B80BB11CB440" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember_D72B73EB6651F51BCBCBB8067FE4EFFF_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember_D72B73EB6651F51BCBCBB8067FE4EFFF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discounted cash flow</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember_D72B73EB6651F51BCBCBB8067FE4EFFF_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember_D72B73EB6651F51BCBCBB8067FE4EFFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Technique, Discounted Cash Flow [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_D72B73EB6651F51BCBCBB8067FE4EFFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_D72B73EB6651F51BCBCBB8067FE4EFFF" xlink:to="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember_D72B73EB6651F51BCBCBB8067FE4EFFF" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_AB9C5A6A385EED76D82CB8059EAEFCCD_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_AB9C5A6A385EED76D82CB8059EAEFCCD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_AB9C5A6A385EED76D82CB8059EAEFCCD_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_AB9C5A6A385EED76D82CB8059EAEFCCD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_AB9C5A6A385EED76D82CB8059EAEFCCD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_AB9C5A6A385EED76D82CB8059EAEFCCD" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_AB9C5A6A385EED76D82CB8059EAEFCCD" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3DA9064A21A72084EAFCB8059EAF5C9C_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3DA9064A21A72084EAFCB8059EAF5C9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3DA9064A21A72084EAFCB8059EAF5C9C_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3DA9064A21A72084EAFCB8059EAF5C9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3DA9064A21A72084EAFCB8059EAF5C9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3DA9064A21A72084EAFCB8059EAF5C9C" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3DA9064A21A72084EAFCB8059EAF5C9C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_290F8BD4B8BCA9EC6216B805B8956BE5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_290F8BD4B8BCA9EC6216B805B8956BE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_290F8BD4B8BCA9EC6216B805B8956BE5_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_290F8BD4B8BCA9EC6216B805B8956BE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_290F8BD4B8BCA9EC6216B805B8956BE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_290F8BD4B8BCA9EC6216B805B8956BE5" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_290F8BD4B8BCA9EC6216B805B8956BE5" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_62AD8D608833DCC3ED0EB804504BC8CC_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_62AD8D608833DCC3ED0EB804504BC8CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_62AD8D608833DCC3ED0EB804504BC8CC_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_62AD8D608833DCC3ED0EB804504BC8CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_62AD8D608833DCC3ED0EB804504BC8CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_62AD8D608833DCC3ED0EB804504BC8CC" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis_62AD8D608833DCC3ED0EB804504BC8CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_FF0844313C3F347F269EB804504C4E41_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_FF0844313C3F347F269EB804504C4E41" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_FF0844313C3F347F269EB804504C4E41_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_FF0844313C3F347F269EB804504C4E41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_FF0844313C3F347F269EB804504C4E41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_FF0844313C3F347F269EB804504C4E41" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain_FF0844313C3F347F269EB804504C4E41" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_D3E548E7A03A3FF533F0B80468F1E72A_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_D3E548E7A03A3FF533F0B80468F1E72A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_D3E548E7A03A3FF533F0B80468F1E72A_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_D3E548E7A03A3FF533F0B80468F1E72A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_D3E548E7A03A3FF533F0B80468F1E72A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember_D3E548E7A03A3FF533F0B80468F1E72A" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember_D3E548E7A03A3FF533F0B80468F1E72A" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_77FFDED8ACB36A47DECEB803F3926C19_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis_77FFDED8ACB36A47DECEB803F3926C19" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_77FFDED8ACB36A47DECEB803F3926C19_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis_77FFDED8ACB36A47DECEB803F3926C19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_77FFDED8ACB36A47DECEB803F3926C19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_77FFDED8ACB36A47DECEB803F3926C19" xlink:to="lab_us-gaap_MeasurementInputTypeAxis_77FFDED8ACB36A47DECEB803F3926C19" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_1BAF448C6CBD73AE3E9BB803F393EA0F_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain_1BAF448C6CBD73AE3E9BB803F393EA0F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_1BAF448C6CBD73AE3E9BB803F393EA0F_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain_1BAF448C6CBD73AE3E9BB803F393EA0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1BAF448C6CBD73AE3E9BB803F393EA0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1BAF448C6CBD73AE3E9BB803F393EA0F" xlink:to="lab_us-gaap_MeasurementInputTypeDomain_1BAF448C6CBD73AE3E9BB803F393EA0F" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_DEECD93DCAC19130E576B804CA401238_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember_DEECD93DCAC19130E576B804CA401238" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_DEECD93DCAC19130E576B804CA401238_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember_DEECD93DCAC19130E576B804CA401238" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_DEECD93DCAC19130E576B804CA401238" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember_DEECD93DCAC19130E576B804CA401238" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember_DEECD93DCAC19130E576B804CA401238" xlink:type="arc" />
    <link:label id="lab_ebs_MeasurementInputProbabilityofPaymentMember_F57AB88BAAA3D866D3BDB80569AA22EC_terseLabel_en-US" xlink:label="lab_ebs_MeasurementInputProbabilityofPaymentMember_F57AB88BAAA3D866D3BDB80569AA22EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Probability of payment</link:label>
    <link:label id="lab_ebs_MeasurementInputProbabilityofPaymentMember_F57AB88BAAA3D866D3BDB80569AA22EC_label_en-US" xlink:label="lab_ebs_MeasurementInputProbabilityofPaymentMember_F57AB88BAAA3D866D3BDB80569AA22EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Probability of Payment [Member]</link:label>
    <link:label id="lab_ebs_MeasurementInputProbabilityofPaymentMember_F57AB88BAAA3D866D3BDB80569AA22EC_documentation_en-US" xlink:label="lab_ebs_MeasurementInputProbabilityofPaymentMember_F57AB88BAAA3D866D3BDB80569AA22EC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Measurement Input, Probability of Payment [Member]</link:label>
    <link:loc xlink:href="ebs-20200331.xsd#ebs_MeasurementInputProbabilityofPaymentMember" xlink:label="loc_ebs_MeasurementInputProbabilityofPaymentMember_F57AB88BAAA3D866D3BDB80569AA22EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_MeasurementInputProbabilityofPaymentMember_F57AB88BAAA3D866D3BDB80569AA22EC" xlink:to="lab_ebs_MeasurementInputProbabilityofPaymentMember_F57AB88BAAA3D866D3BDB80569AA22EC" xlink:type="arc" />
    <link:label id="lab_srt_RangeAxis_9FAABD94B406FE04D17BB803675D89C1_terseLabel_en-US" xlink:label="lab_srt_RangeAxis_9FAABD94B406FE04D17BB803675D89C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_9FAABD94B406FE04D17BB803675D89C1_label_en-US" xlink:label="lab_srt_RangeAxis_9FAABD94B406FE04D17BB803675D89C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_9FAABD94B406FE04D17BB803675D89C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_9FAABD94B406FE04D17BB803675D89C1" xlink:to="lab_srt_RangeAxis_9FAABD94B406FE04D17BB803675D89C1" xlink:type="arc" />
    <link:label id="lab_srt_RangeMember_3221BF2139081BCD7FDBB803676098C8_terseLabel_en-US" xlink:label="lab_srt_RangeMember_3221BF2139081BCD7FDBB803676098C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_3221BF2139081BCD7FDBB803676098C8_label_en-US" xlink:label="lab_srt_RangeMember_3221BF2139081BCD7FDBB803676098C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_3221BF2139081BCD7FDBB803676098C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember_3221BF2139081BCD7FDBB803676098C8" xlink:to="lab_srt_RangeMember_3221BF2139081BCD7FDBB803676098C8" xlink:type="arc" />
    <link:label id="lab_srt_MinimumMember_0BEFCF030B2FC54E678DB80B36E8E6ED_terseLabel_en-US" xlink:label="lab_srt_MinimumMember_0BEFCF030B2FC54E678DB80B36E8E6ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_0BEFCF030B2FC54E678DB80B36E8E6ED_label_en-US" xlink:label="lab_srt_MinimumMember_0BEFCF030B2FC54E678DB80B36E8E6ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_0BEFCF030B2FC54E678DB80B36E8E6ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_0BEFCF030B2FC54E678DB80B36E8E6ED" xlink:to="lab_srt_MinimumMember_0BEFCF030B2FC54E678DB80B36E8E6ED" xlink:type="arc" />
    <link:label id="lab_srt_MaximumMember_2D6890618CB02181720FB80B575CED76_terseLabel_en-US" xlink:label="lab_srt_MaximumMember_2D6890618CB02181720FB80B575CED76" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_2D6890618CB02181720FB80B575CED76_label_en-US" xlink:label="lab_srt_MaximumMember_2D6890618CB02181720FB80B575CED76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_2D6890618CB02181720FB80B575CED76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_2D6890618CB02181720FB80B575CED76" xlink:to="lab_srt_MaximumMember_2D6890618CB02181720FB80B575CED76" xlink:type="arc" />
    <link:label id="lab_srt_WeightedAverageMember_572F882FFB805363501FB8038AEB0E70_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember_572F882FFB805363501FB8038AEB0E70" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average</link:label>
    <link:label id="lab_srt_WeightedAverageMember_572F882FFB805363501FB8038AEB0E70_label_en-US" xlink:label="lab_srt_WeightedAverageMember_572F882FFB805363501FB8038AEB0E70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_WeightedAverageMember" xlink:label="loc_srt_WeightedAverageMember_572F882FFB805363501FB8038AEB0E70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember_572F882FFB805363501FB8038AEB0E70" xlink:to="lab_srt_WeightedAverageMember_572F882FFB805363501FB8038AEB0E70" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_6B0D3A79C04942BDC4A3B80346843B38_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_6B0D3A79C04942BDC4A3B80346843B38" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_6B0D3A79C04942BDC4A3B80346843B38_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_6B0D3A79C04942BDC4A3B80346843B38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_6B0D3A79C04942BDC4A3B80346843B38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_6B0D3A79C04942BDC4A3B80346843B38" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_6B0D3A79C04942BDC4A3B80346843B38" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6F132EA61C39EBA3F93AB7FC4F53F330_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6F132EA61C39EBA3F93AB7FC4F53F330" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value, measurement with unobservable inputs reconciliation, recurring basis, liability value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6F132EA61C39EBA3F93AB7FC4F53F330_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6F132EA61C39EBA3F93AB7FC4F53F330" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6F132EA61C39EBA3F93AB7FC4F53F330" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6F132EA61C39EBA3F93AB7FC4F53F330" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6F132EA61C39EBA3F93AB7FC4F53F330" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_080D29F44AC057F86E70B802812E93C0_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_080D29F44AC057F86E70B802812E93C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business combination, contingent consideration, liability, measurement input</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_080D29F44AC057F86E70B802812E93C0_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_080D29F44AC057F86E70B802812E93C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_080D29F44AC057F86E70B802812E93C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_080D29F44AC057F86E70B802812E93C0" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_080D29F44AC057F86E70B802812E93C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_A785C503AFF8C844322A9E56B11B35BD_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_A785C503AFF8C844322A9E56B11B35BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_A785C503AFF8C844322A9E56B11B35BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_A785C503AFF8C844322A9E56B11B35BD" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_A785C503AFF8C844322A9E56B11B35BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_D4140DD0B30D6561EBD39E56B11BEFDA_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_D4140DD0B30D6561EBD39E56B11BEFDA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_D4140DD0B30D6561EBD39E56B11BEFDA_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_D4140DD0B30D6561EBD39E56B11BEFDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_D4140DD0B30D6561EBD39E56B11BEFDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_D4140DD0B30D6561EBD39E56B11BEFDA" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_D4140DD0B30D6561EBD39E56B11BEFDA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_19A5F7EF1083352034DE9E56B11B27D5_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis_19A5F7EF1083352034DE9E56B11B27D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_19A5F7EF1083352034DE9E56B11B27D5_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis_19A5F7EF1083352034DE9E56B11B27D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_19A5F7EF1083352034DE9E56B11B27D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_19A5F7EF1083352034DE9E56B11B27D5" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis_19A5F7EF1083352034DE9E56B11B27D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_895E7580751B4D1A363A9E56B11CF00C_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain_895E7580751B4D1A363A9E56B11CF00C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_895E7580751B4D1A363A9E56B11CF00C_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain_895E7580751B4D1A363A9E56B11CF00C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_895E7580751B4D1A363A9E56B11CF00C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_895E7580751B4D1A363A9E56B11CF00C" xlink:to="lab_us-gaap_DerivativeContractTypeDomain_895E7580751B4D1A363A9E56B11CF00C" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestRateSwapMember_E03FD7907E28659A506E9E56B11CACCF_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember_E03FD7907E28659A506E9E56B11CACCF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate swaps</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_E03FD7907E28659A506E9E56B11CACCF_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember_E03FD7907E28659A506E9E56B11CACCF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_E03FD7907E28659A506E9E56B11CACCF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember_E03FD7907E28659A506E9E56B11CACCF" xlink:to="lab_us-gaap_InterestRateSwapMember_E03FD7907E28659A506E9E56B11CACCF" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgingDesignationAxis_B004F6775C459C446D029E56B11CA8CF_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis_B004F6775C459C446D029E56B11CA8CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_B004F6775C459C446D029E56B11CA8CF_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis_B004F6775C459C446D029E56B11CA8CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_B004F6775C459C446D029E56B11CA8CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis_B004F6775C459C446D029E56B11CA8CF" xlink:to="lab_us-gaap_HedgingDesignationAxis_B004F6775C459C446D029E56B11CA8CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgingDesignationDomain_C3D83C684821E3E340249E56B11C4348_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain_C3D83C684821E3E340249E56B11C4348" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_C3D83C684821E3E340249E56B11C4348_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain_C3D83C684821E3E340249E56B11C4348" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_C3D83C684821E3E340249E56B11C4348" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain_C3D83C684821E3E340249E56B11C4348" xlink:to="lab_us-gaap_HedgingDesignationDomain_C3D83C684821E3E340249E56B11C4348" xlink:type="arc" />
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_0712B391C6C0F06935929E56B11D745E_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember_0712B391C6C0F06935929E56B11D745E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_0712B391C6C0F06935929E56B11D745E_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember_0712B391C6C0F06935929E56B11D745E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_0712B391C6C0F06935929E56B11D745E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember_0712B391C6C0F06935929E56B11D745E" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember_0712B391C6C0F06935929E56B11D745E" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_AC78D2FA47A532637F319E56B11D3529_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_AC78D2FA47A532637F319E56B11D3529" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_AC78D2FA47A532637F319E56B11D3529_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_AC78D2FA47A532637F319E56B11D3529" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_AC78D2FA47A532637F319E56B11D3529" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_AC78D2FA47A532637F319E56B11D3529" xlink:to="lab_us-gaap_BalanceSheetLocationAxis_AC78D2FA47A532637F319E56B11D3529" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_1BBD1E39EF5209523EA09E56B11DD7F3_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_1BBD1E39EF5209523EA09E56B11DD7F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_1BBD1E39EF5209523EA09E56B11DD7F3_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_1BBD1E39EF5209523EA09E56B11DD7F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1BBD1E39EF5209523EA09E56B11DD7F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1BBD1E39EF5209523EA09E56B11DD7F3" xlink:to="lab_us-gaap_BalanceSheetLocationDomain_1BBD1E39EF5209523EA09E56B11DD7F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_22FA726EC7059230EAD59E77FCF3D17F_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember_22FA726EC7059230EAD59E77FCF3D17F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Current Assets</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_22FA726EC7059230EAD59E77FCF3D17F_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember_22FA726EC7059230EAD59E77FCF3D17F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_22FA726EC7059230EAD59E77FCF3D17F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsMember_22FA726EC7059230EAD59E77FCF3D17F" xlink:to="lab_us-gaap_OtherCurrentAssetsMember_22FA726EC7059230EAD59E77FCF3D17F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsMember_D04ED8424BD888F3DC1E9E56B11D2CD7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsMember_D04ED8424BD888F3DC1E9E56B11D2CD7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsMember_D04ED8424BD888F3DC1E9E56B11D2CD7_label_en-US" xlink:label="lab_us-gaap_OtherAssetsMember_D04ED8424BD888F3DC1E9E56B11D2CD7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsMember" xlink:label="loc_us-gaap_OtherAssetsMember_D04ED8424BD888F3DC1E9E56B11D2CD7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsMember_D04ED8424BD888F3DC1E9E56B11D2CD7" xlink:to="lab_us-gaap_OtherAssetsMember_D04ED8424BD888F3DC1E9E56B11D2CD7" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_62F278C8A0770C561F939E56B11D40D3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember_62F278C8A0770C561F939E56B11D40D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_62F278C8A0770C561F939E56B11D40D3_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember_62F278C8A0770C561F939E56B11D40D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_62F278C8A0770C561F939E56B11D40D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember_62F278C8A0770C561F939E56B11D40D3" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember_62F278C8A0770C561F939E56B11D40D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesMember_1FB79D7B80207255050E9E7855CEF4BD_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesMember_1FB79D7B80207255050E9E7855CEF4BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesMember_1FB79D7B80207255050E9E7855CEF4BD_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesMember_1FB79D7B80207255050E9E7855CEF4BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesMember" xlink:label="loc_us-gaap_OtherLiabilitiesMember_1FB79D7B80207255050E9E7855CEF4BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesMember_1FB79D7B80207255050E9E7855CEF4BD" xlink:to="lab_us-gaap_OtherLiabilitiesMember_1FB79D7B80207255050E9E7855CEF4BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_0A252FE4B0227C702A169E56B11EAA57_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems_0A252FE4B0227C702A169E56B11EAA57" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_0A252FE4B0227C702A169E56B11EAA57_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems_0A252FE4B0227C702A169E56B11EAA57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_0A252FE4B0227C702A169E56B11EAA57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0A252FE4B0227C702A169E56B11EAA57" xlink:to="lab_us-gaap_DerivativesFairValueLineItems_0A252FE4B0227C702A169E56B11EAA57" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_C37453496FE9A98E11929E56B11EF9BF_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_C37453496FE9A98E11929E56B11EF9BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Derivatives</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_C37453496FE9A98E11929E56B11EF9BF_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_C37453496FE9A98E11929E56B11EF9BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_C37453496FE9A98E11929E56B11EF9BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_C37453496FE9A98E11929E56B11EF9BF" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_C37453496FE9A98E11929E56B11EF9BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_3FA2A94BADEAA799628C9E56B11EE081_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_3FA2A94BADEAA799628C9E56B11EE081" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability Derivatives</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_3FA2A94BADEAA799628C9E56B11EE081_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_3FA2A94BADEAA799628C9E56B11EE081" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_3FA2A94BADEAA799628C9E56B11EE081" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_3FA2A94BADEAA799628C9E56B11EE081" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_3FA2A94BADEAA799628C9E56B11EE081" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_3D681E4A73035D352ACF50AC9D43B496_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract_3D681E4A73035D352ACF50AC9D43B496" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_3D681E4A73035D352ACF50AC9D43B496" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3D681E4A73035D352ACF50AC9D43B496" xlink:to="lab_us-gaap_DebtDisclosureAbstract_3D681E4A73035D352ACF50AC9D43B496" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_956CC4B516E9D350F6F650AC9D442556_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock_956CC4B516E9D350F6F650AC9D442556" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_956CC4B516E9D350F6F650AC9D442556_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock_956CC4B516E9D350F6F650AC9D442556" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_956CC4B516E9D350F6F650AC9D442556" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock_956CC4B516E9D350F6F650AC9D442556" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock_956CC4B516E9D350F6F650AC9D442556" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_CE986E0F923F629DC36C50AC9D221954_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract_CE986E0F923F629DC36C50AC9D221954" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_CE986E0F923F629DC36C50AC9D221954" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_CE986E0F923F629DC36C50AC9D221954" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract_CE986E0F923F629DC36C50AC9D221954" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_44298423508C74DA091250AC9D22B8B8_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_44298423508C74DA091250AC9D22B8B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_44298423508C74DA091250AC9D22B8B8_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_44298423508C74DA091250AC9D22B8B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_44298423508C74DA091250AC9D22B8B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_44298423508C74DA091250AC9D22B8B8" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_44298423508C74DA091250AC9D22B8B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_08ACBEE9FDCDEFAB9B3B50AC9D223521_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_08ACBEE9FDCDEFAB9B3B50AC9D223521" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rollforward of Contract Liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_08ACBEE9FDCDEFAB9B3B50AC9D223521_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_08ACBEE9FDCDEFAB9B3B50AC9D223521" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset and Liability [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_08ACBEE9FDCDEFAB9B3B50AC9D223521" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_08ACBEE9FDCDEFAB9B3B50AC9D223521" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_08ACBEE9FDCDEFAB9B3B50AC9D223521" xlink:type="arc" />
    <link:label id="lab_ebs_ScheduleofAccountsReceivableNetTableTextBlock_CC8902744F85737448F150AC9D22D967_terseLabel_en-US" xlink:label="lab_ebs_ScheduleofAccountsReceivableNetTableTextBlock_CC8902744F85737448F150AC9D22D967" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accounts Receivable, Net</link:label>
    <link:label id="lab_ebs_ScheduleofAccountsReceivableNetTableTextBlock_CC8902744F85737448F150AC9D22D967_label_en-US" xlink:label="lab_ebs_ScheduleofAccountsReceivableNetTableTextBlock_CC8902744F85737448F150AC9D22D967" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accounts Receivable, Net [Table Text Block]</link:label>
    <link:label id="lab_ebs_ScheduleofAccountsReceivableNetTableTextBlock_CC8902744F85737448F150AC9D22D967_documentation_en-US" xlink:label="lab_ebs_ScheduleofAccountsReceivableNetTableTextBlock_CC8902744F85737448F150AC9D22D967" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Accounts Receivable, Net [Table Text Block]</link:label>
    <link:loc xlink:href="ebs-20200331.xsd#ebs_ScheduleofAccountsReceivableNetTableTextBlock" xlink:label="loc_ebs_ScheduleofAccountsReceivableNetTableTextBlock_CC8902744F85737448F150AC9D22D967" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ScheduleofAccountsReceivableNetTableTextBlock_CC8902744F85737448F150AC9D22D967" xlink:to="lab_ebs_ScheduleofAccountsReceivableNetTableTextBlock_CC8902744F85737448F150AC9D22D967" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_15EAB90AF61A935AEEFABEB4C4E33628_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_15EAB90AF61A935AEEFABEB4C4E33628" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_15EAB90AF61A935AEEFABEB4C4E33628_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_15EAB90AF61A935AEEFABEB4C4E33628" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_15EAB90AF61A935AEEFABEB4C4E33628" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_15EAB90AF61A935AEEFABEB4C4E33628" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_15EAB90AF61A935AEEFABEB4C4E33628" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_A325C439637C8AAEF9BABEB5235F6157_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_A325C439637C8AAEF9BABEB5235F6157" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_A325C439637C8AAEF9BABEB5235F6157_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_A325C439637C8AAEF9BABEB5235F6157" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_A325C439637C8AAEF9BABEB5235F6157" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_A325C439637C8AAEF9BABEB5235F6157" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_A325C439637C8AAEF9BABEB5235F6157" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_46C6ABC2875E20B6E3C050AC9CAACFEE_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation_46C6ABC2875E20B6E3C050AC9CAACFEE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, remaining performance obligation, amount</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_46C6ABC2875E20B6E3C050AC9CAACFEE_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation_46C6ABC2875E20B6E3C050AC9CAACFEE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_46C6ABC2875E20B6E3C050AC9CAACFEE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation_46C6ABC2875E20B6E3C050AC9CAACFEE" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation_46C6ABC2875E20B6E3C050AC9CAACFEE" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredCostsCurrent_DF0D4A5643CDCCD1F1E050AC9CAA2D22_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCurrent_DF0D4A5643CDCCD1F1E050AC9CAA2D22" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred costs, current</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCurrent_DF0D4A5643CDCCD1F1E050AC9CAA2D22_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCurrent_DF0D4A5643CDCCD1F1E050AC9CAA2D22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Costs, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="loc_us-gaap_DeferredCostsCurrent_DF0D4A5643CDCCD1F1E050AC9CAA2D22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCurrent_DF0D4A5643CDCCD1F1E050AC9CAA2D22" xlink:to="lab_us-gaap_DeferredCostsCurrent_DF0D4A5643CDCCD1F1E050AC9CAA2D22" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_C1D01EBBEE47B9F346A750AC9CF482C6_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_C1D01EBBEE47B9F346A750AC9CF482C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_C1D01EBBEE47B9F346A750AC9CF482C6_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_C1D01EBBEE47B9F346A750AC9CF482C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_C1D01EBBEE47B9F346A750AC9CF482C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_C1D01EBBEE47B9F346A750AC9CF482C6" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_C1D01EBBEE47B9F346A750AC9CF482C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_1E470C1CF93EB567F8BCB7DCF56E7497_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable_1E470C1CF93EB567F8BCB7DCF56E7497" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_1E470C1CF93EB567F8BCB7DCF56E7497_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable_1E470C1CF93EB567F8BCB7DCF56E7497" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_1E470C1CF93EB567F8BCB7DCF56E7497" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1E470C1CF93EB567F8BCB7DCF56E7497" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable_1E470C1CF93EB567F8BCB7DCF56E7497" xlink:type="arc" />
    <link:label id="lab_srt_ProductOrServiceAxis_2C76173360254469219FB7DCF56E0F1B_verboseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis_2C76173360254469219FB7DCF56E0F1B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Products and Services [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_2C76173360254469219FB7DCF56E0F1B_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis_2C76173360254469219FB7DCF56E0F1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_2C76173360254469219FB7DCF56E0F1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis_2C76173360254469219FB7DCF56E0F1B" xlink:to="lab_srt_ProductOrServiceAxis_2C76173360254469219FB7DCF56E0F1B" xlink:type="arc" />
    <link:label id="lab_srt_ProductsAndServicesDomain_AC22D1F72325E4F5331EB7DCF56E4DE1_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_AC22D1F72325E4F5331EB7DCF56E4DE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_AC22D1F72325E4F5331EB7DCF56E4DE1_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_AC22D1F72325E4F5331EB7DCF56E4DE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_AC22D1F72325E4F5331EB7DCF56E4DE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain_AC22D1F72325E4F5331EB7DCF56E4DE1" xlink:to="lab_srt_ProductsAndServicesDomain_AC22D1F72325E4F5331EB7DCF56E4DE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductMember_7222CA10DE186D94E091B7DCF56F3C93_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember_7222CA10DE186D94E091B7DCF56F3C93" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product sales, net</link:label>
    <link:label id="lab_us-gaap_ProductMember_7222CA10DE186D94E091B7DCF56F3C93_label_en-US" xlink:label="lab_us-gaap_ProductMember_7222CA10DE186D94E091B7DCF56F3C93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_7222CA10DE186D94E091B7DCF56F3C93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember_7222CA10DE186D94E091B7DCF56F3C93" xlink:to="lab_us-gaap_ProductMember_7222CA10DE186D94E091B7DCF56F3C93" xlink:type="arc" />
    <link:label id="lab_ebs_ContractManufacturingMember_42459EACA9B70C832528B7DCF56F7CE1_verboseLabel_en-US" xlink:label="lab_ebs_ContractManufacturingMember_42459EACA9B70C832528B7DCF56F7CE1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contract development and manufacturing services</link:label>
    <link:label id="lab_ebs_ContractManufacturingMember_42459EACA9B70C832528B7DCF56F7CE1_label_en-US" xlink:label="lab_ebs_ContractManufacturingMember_42459EACA9B70C832528B7DCF56F7CE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Manufacturing [Member]</link:label>
    <link:label id="lab_ebs_ContractManufacturingMember_42459EACA9B70C832528B7DCF56F7CE1_documentation_en-US" xlink:label="lab_ebs_ContractManufacturingMember_42459EACA9B70C832528B7DCF56F7CE1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue earned during the period arising from manufacturing sale under the terms of a contract.</link:label>
    <link:loc xlink:href="ebs-20200331.xsd#ebs_ContractManufacturingMember" xlink:label="loc_ebs_ContractManufacturingMember_42459EACA9B70C832528B7DCF56F7CE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ContractManufacturingMember_42459EACA9B70C832528B7DCF56F7CE1" xlink:to="lab_ebs_ContractManufacturingMember_42459EACA9B70C832528B7DCF56F7CE1" xlink:type="arc" />
    <link:label id="lab_ebs_ContractsAndGrantsMember_B7AAA2E5D7274EF53C6AB7DCF56FC175_terseLabel_en-US" xlink:label="lab_ebs_ContractsAndGrantsMember_B7AAA2E5D7274EF53C6AB7DCF56FC175" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contracts and grants</link:label>
    <link:label id="lab_ebs_ContractsAndGrantsMember_B7AAA2E5D7274EF53C6AB7DCF56FC175_label_en-US" xlink:label="lab_ebs_ContractsAndGrantsMember_B7AAA2E5D7274EF53C6AB7DCF56FC175" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contracts and Grants [Member]</link:label>
    <link:label id="lab_ebs_ContractsAndGrantsMember_B7AAA2E5D7274EF53C6AB7DCF56FC175_documentation_en-US" xlink:label="lab_ebs_ContractsAndGrantsMember_B7AAA2E5D7274EF53C6AB7DCF56FC175" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of revenue earned from products sold or services provided under the terms of a contract, including, but not limited to, government contracts and grants.</link:label>
    <link:loc xlink:href="ebs-20200331.xsd#ebs_ContractsAndGrantsMember" xlink:label="loc_ebs_ContractsAndGrantsMember_B7AAA2E5D7274EF53C6AB7DCF56FC175" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ContractsAndGrantsMember_B7AAA2E5D7274EF53C6AB7DCF56FC175" xlink:to="lab_ebs_ContractsAndGrantsMember_B7AAA2E5D7274EF53C6AB7DCF56FC175" xlink:type="arc" />
    <link:label id="lab_srt_StatementGeographicalAxis_69A61BDEFC0E9B08FB82B7DCF56FCF3D_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis_69A61BDEFC0E9B08FB82B7DCF56FCF3D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_69A61BDEFC0E9B08FB82B7DCF56FCF3D_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis_69A61BDEFC0E9B08FB82B7DCF56FCF3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_69A61BDEFC0E9B08FB82B7DCF56FCF3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis_69A61BDEFC0E9B08FB82B7DCF56FCF3D" xlink:to="lab_srt_StatementGeographicalAxis_69A61BDEFC0E9B08FB82B7DCF56FCF3D" xlink:type="arc" />
    <link:label id="lab_srt_SegmentGeographicalDomain_19D49D083F36352456C3B7DCF56FC11D_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain_19D49D083F36352456C3B7DCF56FC11D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_19D49D083F36352456C3B7DCF56FC11D_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain_19D49D083F36352456C3B7DCF56FC11D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_19D49D083F36352456C3B7DCF56FC11D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain_19D49D083F36352456C3B7DCF56FC11D" xlink:to="lab_srt_SegmentGeographicalDomain_19D49D083F36352456C3B7DCF56FC11D" xlink:type="arc" />
    <link:label id="lab_country_US_72A81804137B69178192B7DCF570177A_terseLabel_en-US" xlink:label="lab_country_US_72A81804137B69178192B7DCF570177A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Government</link:label>
    <link:label id="lab_country_US_72A81804137B69178192B7DCF570177A_label_en-US" xlink:label="lab_country_US_72A81804137B69178192B7DCF570177A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_72A81804137B69178192B7DCF570177A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US_72A81804137B69178192B7DCF570177A" xlink:to="lab_country_US_72A81804137B69178192B7DCF570177A" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonUsMember_DA8D4574E8A3C820268CB7DCF5700278_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember_DA8D4574E8A3C820268CB7DCF5700278" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-U.S. Government</link:label>
    <link:label id="lab_us-gaap_NonUsMember_DA8D4574E8A3C820268CB7DCF5700278_label_en-US" xlink:label="lab_us-gaap_NonUsMember_DA8D4574E8A3C820268CB7DCF5700278" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaap_NonUsMember_DA8D4574E8A3C820268CB7DCF5700278" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember_DA8D4574E8A3C820268CB7DCF5700278" xlink:to="lab_us-gaap_NonUsMember_DA8D4574E8A3C820268CB7DCF5700278" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_3A3E57B47249756F1AF5B7DCF570F69F_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems_3A3E57B47249756F1AF5B7DCF570F69F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_3A3E57B47249756F1AF5B7DCF570F69F_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems_3A3E57B47249756F1AF5B7DCF570F69F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_3A3E57B47249756F1AF5B7DCF570F69F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3A3E57B47249756F1AF5B7DCF570F69F" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems_3A3E57B47249756F1AF5B7DCF570F69F" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_E70F39A273843236A734B7DCF570AC53_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_E70F39A273843236A734B7DCF570AC53" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_E70F39A273843236A734B7DCF570AC53_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_E70F39A273843236A734B7DCF570AC53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_E70F39A273843236A734B7DCF570AC53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_E70F39A273843236A734B7DCF570AC53" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_E70F39A273843236A734B7DCF570AC53" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_3CA68639F1D6469EF58AB7DCF54A9E3C_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_3CA68639F1D6469EF58AB7DCF54A9E3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_3CA68639F1D6469EF58AB7DCF54A9E3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3CA68639F1D6469EF58AB7DCF54A9E3C" xlink:to="lab_us-gaap_EarningsPerShareAbstract_3CA68639F1D6469EF58AB7DCF54A9E3C" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_10273C9711B22AD6AB03B7DCF54AEF01_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_10273C9711B22AD6AB03B7DCF54AEF01" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_10273C9711B22AD6AB03B7DCF54AEF01_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_10273C9711B22AD6AB03B7DCF54AEF01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_10273C9711B22AD6AB03B7DCF54AEF01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_10273C9711B22AD6AB03B7DCF54AEF01" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_10273C9711B22AD6AB03B7DCF54AEF01" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeasesAbstract_C593842F94DD661458BE50AC9E170AB3_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract_C593842F94DD661458BE50AC9E170AB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_C593842F94DD661458BE50AC9E170AB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract_C593842F94DD661458BE50AC9E170AB3" xlink:to="lab_us-gaap_LeasesAbstract_C593842F94DD661458BE50AC9E170AB3" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_636DACFC9CAB34AB57DE50AC9E17EB6D_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock_636DACFC9CAB34AB57DE50AC9E17EB6D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_636DACFC9CAB34AB57DE50AC9E17EB6D_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock_636DACFC9CAB34AB57DE50AC9E17EB6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_636DACFC9CAB34AB57DE50AC9E17EB6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock_636DACFC9CAB34AB57DE50AC9E17EB6D" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock_636DACFC9CAB34AB57DE50AC9E17EB6D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_94A6B7870AA641B6983E50AC9E1744B6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock_94A6B7870AA641B6983E50AC9E1744B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_94A6B7870AA641B6983E50AC9E1744B6_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock_94A6B7870AA641B6983E50AC9E1744B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_94A6B7870AA641B6983E50AC9E1744B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock_94A6B7870AA641B6983E50AC9E1744B6" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock_94A6B7870AA641B6983E50AC9E1744B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_499C16E0BEE5FB41307E9E56B130E197_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_499C16E0BEE5FB41307E9E56B130E197" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_499C16E0BEE5FB41307E9E56B130E197_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_499C16E0BEE5FB41307E9E56B130E197" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_499C16E0BEE5FB41307E9E56B130E197" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_499C16E0BEE5FB41307E9E56B130E197" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_499C16E0BEE5FB41307E9E56B130E197" xlink:type="arc" />
    <link:label id="lab_ebs_ChangeinContractWithCustomerLiabilityRollForward_D2A0CFF24CAA7906922450AC9DBE8B2F_terseLabel_en-US" xlink:label="lab_ebs_ChangeinContractWithCustomerLiabilityRollForward_D2A0CFF24CAA7906922450AC9DBE8B2F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Contract With Customer, Liability [Roll Forward]</link:label>
    <link:label id="lab_ebs_ChangeinContractWithCustomerLiabilityRollForward_D2A0CFF24CAA7906922450AC9DBE8B2F_label_en-US" xlink:label="lab_ebs_ChangeinContractWithCustomerLiabilityRollForward_D2A0CFF24CAA7906922450AC9DBE8B2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Contract With Customer, Liability [Roll Forward]</link:label>
    <link:label id="lab_ebs_ChangeinContractWithCustomerLiabilityRollForward_D2A0CFF24CAA7906922450AC9DBE8B2F_documentation_en-US" xlink:label="lab_ebs_ChangeinContractWithCustomerLiabilityRollForward_D2A0CFF24CAA7906922450AC9DBE8B2F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in Contract With Customer, Liability [Roll Forward]</link:label>
    <link:loc xlink:href="ebs-20200331.xsd#ebs_ChangeinContractWithCustomerLiabilityRollForward" xlink:label="loc_ebs_ChangeinContractWithCustomerLiabilityRollForward_D2A0CFF24CAA7906922450AC9DBE8B2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ChangeinContractWithCustomerLiabilityRollForward_D2A0CFF24CAA7906922450AC9DBE8B2F" xlink:to="lab_ebs_ChangeinContractWithCustomerLiabilityRollForward_D2A0CFF24CAA7906922450AC9DBE8B2F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_CE4AD2E1C7A3B77187C050AC9DBE952D_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability_CE4AD2E1C7A3B77187C050AC9DBE952D" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning of period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_CE4AD2E1C7A3B77187C050AC9DBE952D_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability_CE4AD2E1C7A3B77187C050AC9DBE952D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_CE4AD2E1C7A3B77187C050AC9DBE952D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability_CE4AD2E1C7A3B77187C050AC9DBE952D" xlink:to="lab_us-gaap_ContractWithCustomerLiability_CE4AD2E1C7A3B77187C050AC9DBE952D" xlink:type="arc" />
    <link:label id="lab_ebs_ContractWithCustomerLiabilityAdditions_3607EBC9EC893E1284D050AC9DBE11AA_terseLabel_en-US" xlink:label="lab_ebs_ContractWithCustomerLiabilityAdditions_3607EBC9EC893E1284D050AC9DBE11AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferral of revenue</link:label>
    <link:label id="lab_ebs_ContractWithCustomerLiabilityAdditions_3607EBC9EC893E1284D050AC9DBE11AA_label_en-US" xlink:label="lab_ebs_ContractWithCustomerLiabilityAdditions_3607EBC9EC893E1284D050AC9DBE11AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Additions</link:label>
    <link:label id="lab_ebs_ContractWithCustomerLiabilityAdditions_3607EBC9EC893E1284D050AC9DBE11AA_documentation_en-US" xlink:label="lab_ebs_ContractWithCustomerLiabilityAdditions_3607EBC9EC893E1284D050AC9DBE11AA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable recorded during the current reporting period.</link:label>
    <link:loc xlink:href="ebs-20200331.xsd#ebs_ContractWithCustomerLiabilityAdditions" xlink:label="loc_ebs_ContractWithCustomerLiabilityAdditions_3607EBC9EC893E1284D050AC9DBE11AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ContractWithCustomerLiabilityAdditions_3607EBC9EC893E1284D050AC9DBE11AA" xlink:to="lab_ebs_ContractWithCustomerLiabilityAdditions_3607EBC9EC893E1284D050AC9DBE11AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_8D1A1077E13DA3E439F150AC9DBE1250_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_8D1A1077E13DA3E439F150AC9DBE1250" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_8D1A1077E13DA3E439F150AC9DBE1250_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_8D1A1077E13DA3E439F150AC9DBE1250" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_8D1A1077E13DA3E439F150AC9DBE1250" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_8D1A1077E13DA3E439F150AC9DBE1250" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_8D1A1077E13DA3E439F150AC9DBE1250" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_DF821F0719D21300A99B50AC9DBFDF2F_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability_DF821F0719D21300A99B50AC9DBFDF2F" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">End of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_DF821F0719D21300A99B50AC9DBFDF2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability_DF821F0719D21300A99B50AC9DBFDF2F" xlink:to="lab_us-gaap_ContractWithCustomerLiability_DF821F0719D21300A99B50AC9DBFDF2F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_EB1B5330252568B1006950AC9D65B8C0_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract_EB1B5330252568B1006950AC9D65B8C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_EB1B5330252568B1006950AC9D65B8C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_EB1B5330252568B1006950AC9D65B8C0" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract_EB1B5330252568B1006950AC9D65B8C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8AA9CE683C5868A0343650AC9D664864_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8AA9CE683C5868A0343650AC9D664864" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8AA9CE683C5868A0343650AC9D664864_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8AA9CE683C5868A0343650AC9D664864" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8AA9CE683C5868A0343650AC9D664864" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8AA9CE683C5868A0343650AC9D664864" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8AA9CE683C5868A0343650AC9D664864" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseCostAbstract_C6A8EA91CBD0582923AB50B544CE6932_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract_C6A8EA91CBD0582923AB50B544CE6932" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease cost:</link:label>
    <link:label id="lab_us-gaap_LeaseCostAbstract_C6A8EA91CBD0582923AB50B544CE6932_label_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract_C6A8EA91CBD0582923AB50B544CE6932" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostAbstract" xlink:label="loc_us-gaap_LeaseCostAbstract_C6A8EA91CBD0582923AB50B544CE6932" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostAbstract_C6A8EA91CBD0582923AB50B544CE6932" xlink:to="lab_us-gaap_LeaseCostAbstract_C6A8EA91CBD0582923AB50B544CE6932" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_A768E5BEDB063DC0288750B544D3847B_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_A768E5BEDB063DC0288750B544D3847B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of right-of-use assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_A768E5BEDB063DC0288750B544D3847B_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_A768E5BEDB063DC0288750B544D3847B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_A768E5BEDB063DC0288750B544D3847B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_A768E5BEDB063DC0288750B544D3847B" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_A768E5BEDB063DC0288750B544D3847B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_AB495C806E9E3B91705C50B544D47AF1_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense_AB495C806E9E3B91705C50B544D47AF1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest on lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_AB495C806E9E3B91705C50B544D47AF1_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense_AB495C806E9E3B91705C50B544D47AF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_AB495C806E9E3B91705C50B544D47AF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense_AB495C806E9E3B91705C50B544D47AF1" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense_AB495C806E9E3B91705C50B544D47AF1" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseCost_F51DE270D3408A24481750B544D4FC8A_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost_F51DE270D3408A24481750B544D4FC8A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_F51DE270D3408A24481750B544D4FC8A_label_en-US" xlink:label="lab_us-gaap_LeaseCost_F51DE270D3408A24481750B544D4FC8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_F51DE270D3408A24481750B544D4FC8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost_F51DE270D3408A24481750B544D4FC8A" xlink:to="lab_us-gaap_LeaseCost_F51DE270D3408A24481750B544D4FC8A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_24F2712929D4BFECB3DD9E56B12ECD15_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_24F2712929D4BFECB3DD9E56B12ECD15" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_24F2712929D4BFECB3DD9E56B12ECD15_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_24F2712929D4BFECB3DD9E56B12ECD15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Derivative Instruments [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_24F2712929D4BFECB3DD9E56B12ECD15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_24F2712929D4BFECB3DD9E56B12ECD15" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_24F2712929D4BFECB3DD9E56B12ECD15" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_3A09684EC3CF2B1BDDB29E56B12E1485_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_3A09684EC3CF2B1BDDB29E56B12E1485" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_3A09684EC3CF2B1BDDB29E56B12E1485_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_3A09684EC3CF2B1BDDB29E56B12E1485" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_3A09684EC3CF2B1BDDB29E56B12E1485" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_3A09684EC3CF2B1BDDB29E56B12E1485" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_3A09684EC3CF2B1BDDB29E56B12E1485" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_1E6058582DD1172B48959E56B12ECAA7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_1E6058582DD1172B48959E56B12ECAA7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_1E6058582DD1172B48959E56B12ECAA7_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_1E6058582DD1172B48959E56B12ECAA7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_1E6058582DD1172B48959E56B12ECAA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_1E6058582DD1172B48959E56B12ECAA7" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_1E6058582DD1172B48959E56B12ECAA7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTable_29FA5D054DF86FFF1CFCBEB54DB6B672_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_29FA5D054DF86FFF1CFCBEB54DB6B672" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_29FA5D054DF86FFF1CFCBEB54DB6B672_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_29FA5D054DF86FFF1CFCBEB54DB6B672" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_29FA5D054DF86FFF1CFCBEB54DB6B672" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_29FA5D054DF86FFF1CFCBEB54DB6B672" xlink:to="lab_us-gaap_DebtInstrumentTable_29FA5D054DF86FFF1CFCBEB54DB6B672" xlink:type="arc" />
    <link:label id="lab_us-gaap_CreditFacilityAxis_19636C3D1EC13971D396BEB54DBAA865_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis_19636C3D1EC13971D396BEB54DBAA865" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_19636C3D1EC13971D396BEB54DBAA865_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis_19636C3D1EC13971D396BEB54DBAA865" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_19636C3D1EC13971D396BEB54DBAA865" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis_19636C3D1EC13971D396BEB54DBAA865" xlink:to="lab_us-gaap_CreditFacilityAxis_19636C3D1EC13971D396BEB54DBAA865" xlink:type="arc" />
    <link:label id="lab_us-gaap_CreditFacilityDomain_C528A764FF9135A424FEBEB54DBADF11_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain_C528A764FF9135A424FEBEB54DBADF11" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_C528A764FF9135A424FEBEB54DBADF11_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain_C528A764FF9135A424FEBEB54DBADF11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_C528A764FF9135A424FEBEB54DBADF11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain_C528A764FF9135A424FEBEB54DBADF11" xlink:to="lab_us-gaap_CreditFacilityDomain_C528A764FF9135A424FEBEB54DBADF11" xlink:type="arc" />
    <link:label id="lab_ebs_TermLoanFacilityMember_F729A6999A6452497C1FBEB54DBACE55_terseLabel_en-US" xlink:label="lab_ebs_TermLoanFacilityMember_F729A6999A6452497C1FBEB54DBACE55" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior secured credit agreement - Term loan due 2023</link:label>
    <link:label id="lab_ebs_TermLoanFacilityMember_F729A6999A6452497C1FBEB54DBACE55_label_en-US" xlink:label="lab_ebs_TermLoanFacilityMember_F729A6999A6452497C1FBEB54DBACE55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Loan Facility [Member]</link:label>
    <link:label id="lab_ebs_TermLoanFacilityMember_F729A6999A6452497C1FBEB54DBACE55_documentation_en-US" xlink:label="lab_ebs_TermLoanFacilityMember_F729A6999A6452497C1FBEB54DBACE55" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term loan dated December 2013.</link:label>
    <link:loc xlink:href="ebs-20200331.xsd#ebs_TermLoanFacilityMember" xlink:label="loc_ebs_TermLoanFacilityMember_F729A6999A6452497C1FBEB54DBACE55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_TermLoanFacilityMember_F729A6999A6452497C1FBEB54DBACE55" xlink:to="lab_ebs_TermLoanFacilityMember_F729A6999A6452497C1FBEB54DBACE55" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_3B0E01373362C95D71D0BEB54DBB6C69_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember_3B0E01373362C95D71D0BEB54DBB6C69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior secured credit agreement - Revolver loan due 2023</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_3B0E01373362C95D71D0BEB54DBB6C69_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember_3B0E01373362C95D71D0BEB54DBB6C69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_3B0E01373362C95D71D0BEB54DBB6C69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember_3B0E01373362C95D71D0BEB54DBB6C69" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember_3B0E01373362C95D71D0BEB54DBB6C69" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentAxis_BB516432B1B051F8667EBEB54DBB2030_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_BB516432B1B051F8667EBEB54DBB2030" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_BB516432B1B051F8667EBEB54DBB2030_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_BB516432B1B051F8667EBEB54DBB2030" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_BB516432B1B051F8667EBEB54DBB2030" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_BB516432B1B051F8667EBEB54DBB2030" xlink:to="lab_us-gaap_DebtInstrumentAxis_BB516432B1B051F8667EBEB54DBB2030" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_2FD7AB7BCA25DBC13C5BBEB54DBB3636_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_2FD7AB7BCA25DBC13C5BBEB54DBB3636" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_2FD7AB7BCA25DBC13C5BBEB54DBB3636_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_2FD7AB7BCA25DBC13C5BBEB54DBB3636" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2FD7AB7BCA25DBC13C5BBEB54DBB3636" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2FD7AB7BCA25DBC13C5BBEB54DBB3636" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_2FD7AB7BCA25DBC13C5BBEB54DBB3636" xlink:type="arc" />
    <link:label id="lab_ebs_ConvertibleSeniorNotesDue2021Member_7A87C06F1FF19FB8CF95BEB54DBB5608_terseLabel_en-US" xlink:label="lab_ebs_ConvertibleSeniorNotesDue2021Member_7A87C06F1FF19FB8CF95BEB54DBB5608" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2.875% Convertible Senior Notes due 2021</link:label>
    <link:label id="lab_ebs_ConvertibleSeniorNotesDue2021Member_7A87C06F1FF19FB8CF95BEB54DBB5608_label_en-US" xlink:label="lab_ebs_ConvertibleSeniorNotesDue2021Member_7A87C06F1FF19FB8CF95BEB54DBB5608" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Senior Notes Due 2021 [Member]</link:label>
    <link:label id="lab_ebs_ConvertibleSeniorNotesDue2021Member_7A87C06F1FF19FB8CF95BEB54DBB5608_documentation_en-US" xlink:label="lab_ebs_ConvertibleSeniorNotesDue2021Member_7A87C06F1FF19FB8CF95BEB54DBB5608" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Senior Notes Due 2021 [Member]</link:label>
    <link:loc xlink:href="ebs-20200331.xsd#ebs_ConvertibleSeniorNotesDue2021Member" xlink:label="loc_ebs_ConvertibleSeniorNotesDue2021Member_7A87C06F1FF19FB8CF95BEB54DBB5608" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ConvertibleSeniorNotesDue2021Member_7A87C06F1FF19FB8CF95BEB54DBB5608" xlink:to="lab_ebs_ConvertibleSeniorNotesDue2021Member_7A87C06F1FF19FB8CF95BEB54DBB5608" xlink:type="arc" />
    <link:label id="lab_ebs_OtherLongTermDebtFacilityMember_60ABFC64BE05842B158ABEB54DBB2CBE_terseLabel_en-US" xlink:label="lab_ebs_OtherLongTermDebtFacilityMember_60ABFC64BE05842B158ABEB54DBB2CBE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_ebs_OtherLongTermDebtFacilityMember_60ABFC64BE05842B158ABEB54DBB2CBE_label_en-US" xlink:label="lab_ebs_OtherLongTermDebtFacilityMember_60ABFC64BE05842B158ABEB54DBB2CBE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Long Term Debt Facility [Member]</link:label>
    <link:label id="lab_ebs_OtherLongTermDebtFacilityMember_60ABFC64BE05842B158ABEB54DBB2CBE_documentation_en-US" xlink:label="lab_ebs_OtherLongTermDebtFacilityMember_60ABFC64BE05842B158ABEB54DBB2CBE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Long Term Debt Facility [Member]</link:label>
    <link:loc xlink:href="ebs-20200331.xsd#ebs_OtherLongTermDebtFacilityMember" xlink:label="loc_ebs_OtherLongTermDebtFacilityMember_60ABFC64BE05842B158ABEB54DBB2CBE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_OtherLongTermDebtFacilityMember_60ABFC64BE05842B158ABEB54DBB2CBE" xlink:to="lab_ebs_OtherLongTermDebtFacilityMember_60ABFC64BE05842B158ABEB54DBB2CBE" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_A5C7304B37901F4F6250BEB54DBB81B6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_A5C7304B37901F4F6250BEB54DBB81B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_A5C7304B37901F4F6250BEB54DBB81B6_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_A5C7304B37901F4F6250BEB54DBB81B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_A5C7304B37901F4F6250BEB54DBB81B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A5C7304B37901F4F6250BEB54DBB81B6" xlink:to="lab_us-gaap_DebtInstrumentLineItems_A5C7304B37901F4F6250BEB54DBB81B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_B2A484E74662134609E5BEB54DBC4AB7_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_B2A484E74662134609E5BEB54DBC4AB7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_B2A484E74662134609E5BEB54DBC4AB7_label_en-US" xlink:label="lab_us-gaap_LongTermDebt_B2A484E74662134609E5BEB54DBC4AB7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_B2A484E74662134609E5BEB54DBC4AB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_B2A484E74662134609E5BEB54DBC4AB7" xlink:to="lab_us-gaap_LongTermDebt_B2A484E74662134609E5BEB54DBC4AB7" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtCurrent_A83E41715FDF32FFCB8BBEB54DBC22EB_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent_A83E41715FDF32FFCB8BBEB54DBC22EB" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Current portion of long-term debt, net of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_A83E41715FDF32FFCB8BBEB54DBC22EB_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent_A83E41715FDF32FFCB8BBEB54DBC22EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_A83E41715FDF32FFCB8BBEB54DBC22EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent_A83E41715FDF32FFCB8BBEB54DBC22EB" xlink:to="lab_us-gaap_LongTermDebtCurrent_A83E41715FDF32FFCB8BBEB54DBC22EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredFinanceCostsNoncurrentNet_2CBE3659CE19154CE361BEB54DBCF5FC_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNoncurrentNet_2CBE3659CE19154CE361BEB54DBCF5FC" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unamortized debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNoncurrentNet_2CBE3659CE19154CE361BEB54DBCF5FC_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNoncurrentNet_2CBE3659CE19154CE361BEB54DBCF5FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Noncurrent, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_2CBE3659CE19154CE361BEB54DBCF5FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_2CBE3659CE19154CE361BEB54DBCF5FC" xlink:to="lab_us-gaap_DeferredFinanceCostsNoncurrentNet_2CBE3659CE19154CE361BEB54DBCF5FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_8A978A68C6587CA0289ABEB54DBC793E_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_8A978A68C6587CA0289ABEB54DBC793E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current portion of debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_8A978A68C6587CA0289ABEB54DBC793E_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_8A978A68C6587CA0289ABEB54DBC793E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_8A978A68C6587CA0289ABEB54DBC793E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_8A978A68C6587CA0289ABEB54DBC793E" xlink:to="lab_us-gaap_LongTermDebtNoncurrent_8A978A68C6587CA0289ABEB54DBC793E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_F547D2BFEF46E716DF4FBEB7450A6110_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_F547D2BFEF46E716DF4FBEB7450A6110" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stated percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_F547D2BFEF46E716DF4FBEB7450A6110_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_F547D2BFEF46E716DF4FBEB7450A6110" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_F547D2BFEF46E716DF4FBEB7450A6110" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_F547D2BFEF46E716DF4FBEB7450A6110" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_F547D2BFEF46E716DF4FBEB7450A6110" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_085CE8382AD5BD9A9F7F9E56B14E1E6E_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_085CE8382AD5BD9A9F7F9E56B14E1E6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_085CE8382AD5BD9A9F7F9E56B14E1E6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_085CE8382AD5BD9A9F7F9E56B14E1E6E" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_085CE8382AD5BD9A9F7F9E56B14E1E6E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_3EBB950517A3889C544C9E56B14E7994_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_3EBB950517A3889C544C9E56B14E7994" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_3EBB950517A3889C544C9E56B14E7994_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_3EBB950517A3889C544C9E56B14E7994" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_3EBB950517A3889C544C9E56B14E7994" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_3EBB950517A3889C544C9E56B14E7994" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_3EBB950517A3889C544C9E56B14E7994" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_7E8577C616A87A66E489B7DCF6465736_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_7E8577C616A87A66E489B7DCF6465736" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7E8577C616A87A66E489B7DCF6465736" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7E8577C616A87A66E489B7DCF6465736" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_7E8577C616A87A66E489B7DCF6465736" xlink:type="arc" />
    <link:label id="lab_us-gaap_MoneyMarketFundsAtCarryingValue_C840A0918012F2F78BFFB7DCF647EA6A_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsAtCarryingValue_C840A0918012F2F78BFFB7DCF647EA6A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsAtCarryingValue_C840A0918012F2F78BFFB7DCF647EA6A_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsAtCarryingValue_C840A0918012F2F78BFFB7DCF647EA6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="loc_us-gaap_MoneyMarketFundsAtCarryingValue_C840A0918012F2F78BFFB7DCF647EA6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsAtCarryingValue_C840A0918012F2F78BFFB7DCF647EA6A" xlink:to="lab_us-gaap_MoneyMarketFundsAtCarryingValue_C840A0918012F2F78BFFB7DCF647EA6A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_A83E6B096A25D3A83B679E56B1844E5E_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_A83E6B096A25D3A83B679E56B1844E5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property Plant and Equipment Income Statement Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_A83E6B096A25D3A83B679E56B1844E5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_A83E6B096A25D3A83B679E56B1844E5E" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_A83E6B096A25D3A83B679E56B1844E5E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_791761EFBB06F973830F9E56B184A800_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_791761EFBB06F973830F9E56B184A800" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_791761EFBB06F973830F9E56B184A800_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_791761EFBB06F973830F9E56B184A800" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_791761EFBB06F973830F9E56B184A800" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_791761EFBB06F973830F9E56B184A800" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_791761EFBB06F973830F9E56B184A800" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5DCD31518FC9A304614A9E56B13E7597_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5DCD31518FC9A304614A9E56B13E7597" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5DCD31518FC9A304614A9E56B13E7597_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5DCD31518FC9A304614A9E56B13E7597" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5DCD31518FC9A304614A9E56B13E7597" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5DCD31518FC9A304614A9E56B13E7597" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5DCD31518FC9A304614A9E56B13E7597" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_63764033C90FC537D9559E56B13FEB9F_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_63764033C90FC537D9559E56B13FEB9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_63764033C90FC537D9559E56B13FEB9F_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_63764033C90FC537D9559E56B13FEB9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_63764033C90FC537D9559E56B13FEB9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_63764033C90FC537D9559E56B13FEB9F" xlink:to="lab_us-gaap_BusinessAcquisitionAxis_63764033C90FC537D9559E56B13FEB9F" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_3E19AAE024F55E05D1CF9E56B13F036E_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_3E19AAE024F55E05D1CF9E56B13F036E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_3E19AAE024F55E05D1CF9E56B13F036E_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_3E19AAE024F55E05D1CF9E56B13F036E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3E19AAE024F55E05D1CF9E56B13F036E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3E19AAE024F55E05D1CF9E56B13F036E" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain_3E19AAE024F55E05D1CF9E56B13F036E" xlink:type="arc" />
    <link:label id="lab_ebs_RaxibacumabMember_5FCBE344EDBA633ADA099E56B13F4C59_terseLabel_en-US" xlink:label="lab_ebs_RaxibacumabMember_5FCBE344EDBA633ADA099E56B13F4C59" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raxibacumab</link:label>
    <link:label id="lab_ebs_RaxibacumabMember_5FCBE344EDBA633ADA099E56B13F4C59_label_en-US" xlink:label="lab_ebs_RaxibacumabMember_5FCBE344EDBA633ADA099E56B13F4C59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Raxibacumab [Member]</link:label>
    <link:label id="lab_ebs_RaxibacumabMember_5FCBE344EDBA633ADA099E56B13F4C59_documentation_en-US" xlink:label="lab_ebs_RaxibacumabMember_5FCBE344EDBA633ADA099E56B13F4C59" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Raxibacumab [Member]</link:label>
    <link:loc xlink:href="ebs-20200331.xsd#ebs_RaxibacumabMember" xlink:label="loc_ebs_RaxibacumabMember_5FCBE344EDBA633ADA099E56B13F4C59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_RaxibacumabMember_5FCBE344EDBA633ADA099E56B13F4C59" xlink:to="lab_ebs_RaxibacumabMember_5FCBE344EDBA633ADA099E56B13F4C59" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_E88615DB7479E8F7DDB69E56B13F887C_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_E88615DB7479E8F7DDB69E56B13F887C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_E88615DB7479E8F7DDB69E56B13F887C_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_E88615DB7479E8F7DDB69E56B13F887C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_E88615DB7479E8F7DDB69E56B13F887C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_E88615DB7479E8F7DDB69E56B13F887C" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems_E88615DB7479E8F7DDB69E56B13F887C" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_F0DEC2457BAAFD60719C9E56B13FBC95_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_F0DEC2457BAAFD60719C9E56B13FBC95" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in amount of contingent consideration, liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_F0DEC2457BAAFD60719C9E56B13FBC95_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_F0DEC2457BAAFD60719C9E56B13FBC95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_F0DEC2457BAAFD60719C9E56B13FBC95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_F0DEC2457BAAFD60719C9E56B13FBC95" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_F0DEC2457BAAFD60719C9E56B13FBC95" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_1C5FF26DFB5A96C0FC089E56B1403AD8_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_1C5FF26DFB5A96C0FC089E56B1403AD8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_1C5FF26DFB5A96C0FC089E56B1403AD8_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_1C5FF26DFB5A96C0FC089E56B1403AD8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_1C5FF26DFB5A96C0FC089E56B1403AD8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets_1C5FF26DFB5A96C0FC089E56B1403AD8" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets_1C5FF26DFB5A96C0FC089E56B1403AD8" xlink:type="arc" />
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_52F148F1A4D3C80274819E56B140A57E_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_52F148F1A4D3C80274819E56B140A57E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average amortization period</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_52F148F1A4D3C80274819E56B140A57E_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_52F148F1A4D3C80274819E56B140A57E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_52F148F1A4D3C80274819E56B140A57E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_52F148F1A4D3C80274819E56B140A57E" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_52F148F1A4D3C80274819E56B140A57E" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_159CD58DBA983B64FED49E6E5696BB6B_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_159CD58DBA983B64FED49E6E5696BB6B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_159CD58DBA983B64FED49E6E5696BB6B_label_en-US" xlink:label="lab_us-gaap_Goodwill_159CD58DBA983B64FED49E6E5696BB6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_159CD58DBA983B64FED49E6E5696BB6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_159CD58DBA983B64FED49E6E5696BB6B" xlink:to="lab_us-gaap_Goodwill_159CD58DBA983B64FED49E6E5696BB6B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_136638A996BA9BC3BFE9B811883E00DD_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_136638A996BA9BC3BFE9B811883E00DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_136638A996BA9BC3BFE9B811883E00DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_136638A996BA9BC3BFE9B811883E00DD" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_136638A996BA9BC3BFE9B811883E00DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_095D33ED6AAEEEEF1CC8B811883E4C21_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_095D33ED6AAEEEEF1CC8B811883E4C21" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_095D33ED6AAEEEEF1CC8B811883E4C21_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_095D33ED6AAEEEEF1CC8B811883E4C21" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_095D33ED6AAEEEEF1CC8B811883E4C21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_095D33ED6AAEEEEF1CC8B811883E4C21" xlink:to="lab_us-gaap_AssetsAbstract_095D33ED6AAEEEEF1CC8B811883E4C21" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_9EE025FD83105B95AD41B811883EE5CD_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_9EE025FD83105B95AD41B811883EE5CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_9EE025FD83105B95AD41B811883EE5CD_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_9EE025FD83105B95AD41B811883EE5CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_9EE025FD83105B95AD41B811883EE5CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9EE025FD83105B95AD41B811883EE5CD" xlink:to="lab_us-gaap_AssetsCurrentAbstract_9EE025FD83105B95AD41B811883EE5CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_7E509F09DE49FF0ACE0EB811883F0B74_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_7E509F09DE49FF0ACE0EB811883F0B74" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_7E509F09DE49FF0ACE0EB811883F0B74_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_7E509F09DE49FF0ACE0EB811883F0B74" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7E509F09DE49FF0ACE0EB811883F0B74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7E509F09DE49FF0ACE0EB811883F0B74" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_7E509F09DE49FF0ACE0EB811883F0B74" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashCurrent_7D2239938A0E0100B58DB811883F4CFC_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent_7D2239938A0E0100B58DB811883F4CFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_7D2239938A0E0100B58DB811883F4CFC_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent_7D2239938A0E0100B58DB811883F4CFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_7D2239938A0E0100B58DB811883F4CFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent_7D2239938A0E0100B58DB811883F4CFC" xlink:to="lab_us-gaap_RestrictedCashCurrent_7D2239938A0E0100B58DB811883F4CFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_E9774E84F90E17DAC24AB811883FEC11_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_E9774E84F90E17DAC24AB811883FEC11" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_E9774E84F90E17DAC24AB811883FEC11_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_E9774E84F90E17DAC24AB811883FEC11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_E9774E84F90E17DAC24AB811883FEC11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_E9774E84F90E17DAC24AB811883FEC11" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_E9774E84F90E17DAC24AB811883FEC11" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_7C8DB698FA16F0872DD0B81188406886_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_7C8DB698FA16F0872DD0B81188406886" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_7C8DB698FA16F0872DD0B81188406886_label_en-US" xlink:label="lab_us-gaap_InventoryNet_7C8DB698FA16F0872DD0B81188406886" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_7C8DB698FA16F0872DD0B81188406886" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_7C8DB698FA16F0872DD0B81188406886" xlink:to="lab_us-gaap_InventoryNet_7C8DB698FA16F0872DD0B81188406886" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_2ADD48CA504D89B4017DB8118840DF9F_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable_2ADD48CA504D89B4017DB8118840DF9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax receivable, net</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_2ADD48CA504D89B4017DB8118840DF9F_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable_2ADD48CA504D89B4017DB8118840DF9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Receivable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_us-gaap_IncomeTaxesReceivable_2ADD48CA504D89B4017DB8118840DF9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesReceivable_2ADD48CA504D89B4017DB8118840DF9F" xlink:to="lab_us-gaap_IncomeTaxesReceivable_2ADD48CA504D89B4017DB8118840DF9F" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_517856A1608B0ACF6CBFB81188401CF4_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_517856A1608B0ACF6CBFB81188401CF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_517856A1608B0ACF6CBFB81188401CF4_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_517856A1608B0ACF6CBFB81188401CF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_517856A1608B0ACF6CBFB81188401CF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_517856A1608B0ACF6CBFB81188401CF4" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_517856A1608B0ACF6CBFB81188401CF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_8DE2EC5AAA6EA6B7F00AB8118840057C_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_8DE2EC5AAA6EA6B7F00AB8118840057C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_8DE2EC5AAA6EA6B7F00AB8118840057C_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_8DE2EC5AAA6EA6B7F00AB8118840057C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_8DE2EC5AAA6EA6B7F00AB8118840057C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_8DE2EC5AAA6EA6B7F00AB8118840057C" xlink:to="lab_us-gaap_AssetsCurrent_8DE2EC5AAA6EA6B7F00AB8118840057C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_3114215BDAE311EE03D5B8118840748C_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_3114215BDAE311EE03D5B8118840748C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_3114215BDAE311EE03D5B8118840748C_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_3114215BDAE311EE03D5B8118840748C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3114215BDAE311EE03D5B8118840748C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_3114215BDAE311EE03D5B8118840748C" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_3114215BDAE311EE03D5B8118840748C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_015B066309A41829AE4CB8118840229B_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_015B066309A41829AE4CB8118840229B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_015B066309A41829AE4CB8118840229B_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_015B066309A41829AE4CB8118840229B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_015B066309A41829AE4CB8118840229B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_015B066309A41829AE4CB8118840229B" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_015B066309A41829AE4CB8118840229B" xlink:type="arc" />
    <link:label id="lab_ebs_InProcessResearchAndDevelopment_32E8830337FBD3FB9EB5B81188418850_terseLabel_en-US" xlink:label="lab_ebs_InProcessResearchAndDevelopment_32E8830337FBD3FB9EB5B81188418850" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_ebs_InProcessResearchAndDevelopment_32E8830337FBD3FB9EB5B81188418850_label_en-US" xlink:label="lab_ebs_InProcessResearchAndDevelopment_32E8830337FBD3FB9EB5B81188418850" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research And Development</link:label>
    <link:label id="lab_ebs_InProcessResearchAndDevelopment_32E8830337FBD3FB9EB5B81188418850_documentation_en-US" xlink:label="lab_ebs_InProcessResearchAndDevelopment_32E8830337FBD3FB9EB5B81188418850" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying amount of purchased research and development assets acquired in a business combination that have an indefinite life until completion or abandonment of the associated research and development efforts.</link:label>
    <link:loc xlink:href="ebs-20200331.xsd#ebs_InProcessResearchAndDevelopment" xlink:label="loc_ebs_InProcessResearchAndDevelopment_32E8830337FBD3FB9EB5B81188418850" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_InProcessResearchAndDevelopment_32E8830337FBD3FB9EB5B81188418850" xlink:to="lab_ebs_InProcessResearchAndDevelopment_32E8830337FBD3FB9EB5B81188418850" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_72A3AAEB9810BCB07334B81188418987_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet_72A3AAEB9810BCB07334B81188418987" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_72A3AAEB9810BCB07334B81188418987_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet_72A3AAEB9810BCB07334B81188418987" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_72A3AAEB9810BCB07334B81188418987" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet_72A3AAEB9810BCB07334B81188418987" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet_72A3AAEB9810BCB07334B81188418987" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_F0C3968D4E3A9A0945DFB81188417787_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_F0C3968D4E3A9A0945DFB81188417787" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_F0C3968D4E3A9A0945DFB81188417787_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_F0C3968D4E3A9A0945DFB81188417787" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_F0C3968D4E3A9A0945DFB81188417787" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_F0C3968D4E3A9A0945DFB81188417787" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_F0C3968D4E3A9A0945DFB81188417787" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_9D9ED4C7ED9B38988E8BB8118841C5C1_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_9D9ED4C7ED9B38988E8BB8118841C5C1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_9D9ED4C7ED9B38988E8BB8118841C5C1_label_en-US" xlink:label="lab_us-gaap_Assets_9D9ED4C7ED9B38988E8BB8118841C5C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_9D9ED4C7ED9B38988E8BB8118841C5C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_9D9ED4C7ED9B38988E8BB8118841C5C1" xlink:to="lab_us-gaap_Assets_9D9ED4C7ED9B38988E8BB8118841C5C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9ED0BC06DBF41F316CCCB8118841DB71_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9ED0BC06DBF41F316CCCB8118841DB71" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9ED0BC06DBF41F316CCCB8118841DB71_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9ED0BC06DBF41F316CCCB8118841DB71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9ED0BC06DBF41F316CCCB8118841DB71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9ED0BC06DBF41F316CCCB8118841DB71" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9ED0BC06DBF41F316CCCB8118841DB71" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_D9980E942D6CFAB52091B81188425A79_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_D9980E942D6CFAB52091B81188425A79" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_D9980E942D6CFAB52091B81188425A79_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_D9980E942D6CFAB52091B81188425A79" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_D9980E942D6CFAB52091B81188425A79" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_D9980E942D6CFAB52091B81188425A79" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_D9980E942D6CFAB52091B81188425A79" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_FDEDA48ACFFC42AC4E33B8118842AC68_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_FDEDA48ACFFC42AC4E33B8118842AC68" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_FDEDA48ACFFC42AC4E33B8118842AC68_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_FDEDA48ACFFC42AC4E33B8118842AC68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_FDEDA48ACFFC42AC4E33B8118842AC68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_FDEDA48ACFFC42AC4E33B8118842AC68" xlink:to="lab_us-gaap_AccountsPayableCurrent_FDEDA48ACFFC42AC4E33B8118842AC68" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_FC0A46738A578808C890B81188427E76_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_FC0A46738A578808C890B81188427E76" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_FC0A46738A578808C890B81188427E76_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_FC0A46738A578808C890B81188427E76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_FC0A46738A578808C890B81188427E76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_FC0A46738A578808C890B81188427E76" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_FC0A46738A578808C890B81188427E76" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_24E5C1CB4700BEF57F85B81188427C68_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_24E5C1CB4700BEF57F85B81188427C68" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Debt, current portion</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_24E5C1CB4700BEF57F85B81188427C68_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_24E5C1CB4700BEF57F85B81188427C68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_24E5C1CB4700BEF57F85B81188427C68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_24E5C1CB4700BEF57F85B81188427C68" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_24E5C1CB4700BEF57F85B81188427C68" xlink:type="arc" />
    <link:label id="lab_us-gaap_NotesPayableCurrent_D39C5A9F08DE1D9397F6B811884309CD_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent_D39C5A9F08DE1D9397F6B811884309CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt, current portion</link:label>
    <link:label id="lab_us-gaap_NotesPayableCurrent_D39C5A9F08DE1D9397F6B811884309CD_label_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent_D39C5A9F08DE1D9397F6B811884309CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_D39C5A9F08DE1D9397F6B811884309CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrent_D39C5A9F08DE1D9397F6B811884309CD" xlink:to="lab_us-gaap_NotesPayableCurrent_D39C5A9F08DE1D9397F6B811884309CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_3BAA16601961E224C380B81188439514_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_3BAA16601961E224C380B81188439514" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_3BAA16601961E224C380B81188439514_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_3BAA16601961E224C380B81188439514" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_3BAA16601961E224C380B81188439514" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_3BAA16601961E224C380B81188439514" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_3BAA16601961E224C380B81188439514" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_6507EA7FD738BE789845B8118843610F_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_6507EA7FD738BE789845B8118843610F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_6507EA7FD738BE789845B8118843610F_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_6507EA7FD738BE789845B8118843610F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_6507EA7FD738BE789845B8118843610F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_6507EA7FD738BE789845B8118843610F" xlink:to="lab_us-gaap_LiabilitiesCurrent_6507EA7FD738BE789845B8118843610F" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_36BB22436221A583BC58B8118843093D_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_36BB22436221A583BC58B8118843093D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration, net of current portion</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_36BB22436221A583BC58B8118843093D_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_36BB22436221A583BC58B8118843093D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_36BB22436221A583BC58B8118843093D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_36BB22436221A583BC58B8118843093D" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_36BB22436221A583BC58B8118843093D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_AB5E9E3C7057078BBE9BB8118843E4FF_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_AB5E9E3C7057078BBE9BB8118843E4FF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Debt, net of current portion</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_AB5E9E3C7057078BBE9BB8118843E4FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_AB5E9E3C7057078BBE9BB8118843E4FF" xlink:to="lab_us-gaap_LongTermDebtNoncurrent_AB5E9E3C7057078BBE9BB8118843E4FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_6F991DC8B3C87160093CB81188436D70_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_6F991DC8B3C87160093CB81188436D70" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_6F991DC8B3C87160093CB81188436D70_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_6F991DC8B3C87160093CB81188436D70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_6F991DC8B3C87160093CB81188436D70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_6F991DC8B3C87160093CB81188436D70" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_6F991DC8B3C87160093CB81188436D70" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_53EF9C0A06F4DB493ED7B811884470EE_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_53EF9C0A06F4DB493ED7B811884470EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_53EF9C0A06F4DB493ED7B811884470EE_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_53EF9C0A06F4DB493ED7B811884470EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_53EF9C0A06F4DB493ED7B811884470EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_53EF9C0A06F4DB493ED7B811884470EE" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_53EF9C0A06F4DB493ED7B811884470EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_8BFECA39DA5E51CDC856B81188447061_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_8BFECA39DA5E51CDC856B81188447061" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_8BFECA39DA5E51CDC856B81188447061_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_8BFECA39DA5E51CDC856B81188447061" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8BFECA39DA5E51CDC856B81188447061" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_8BFECA39DA5E51CDC856B81188447061" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_8BFECA39DA5E51CDC856B81188447061" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_6EA3AAC019557C765E9DB81188440936_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_6EA3AAC019557C765E9DB81188440936" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_6EA3AAC019557C765E9DB81188440936_label_en-US" xlink:label="lab_us-gaap_Liabilities_6EA3AAC019557C765E9DB81188440936" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_6EA3AAC019557C765E9DB81188440936" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_6EA3AAC019557C765E9DB81188440936" xlink:to="lab_us-gaap_Liabilities_6EA3AAC019557C765E9DB81188440936" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_93E8E7B3CDAF5A0B9EE3B811884436F0_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_93E8E7B3CDAF5A0B9EE3B811884436F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_93E8E7B3CDAF5A0B9EE3B811884436F0_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_93E8E7B3CDAF5A0B9EE3B811884436F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_93E8E7B3CDAF5A0B9EE3B811884436F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_93E8E7B3CDAF5A0B9EE3B811884436F0" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_93E8E7B3CDAF5A0B9EE3B811884436F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValue_91F8899655A83A2CB56EB8118844012A_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_91F8899655A83A2CB56EB8118844012A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.001 par value; 15.0 shares authorized, no shares issued or outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_91F8899655A83A2CB56EB8118844012A_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue_91F8899655A83A2CB56EB8118844012A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_91F8899655A83A2CB56EB8118844012A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_91F8899655A83A2CB56EB8118844012A" xlink:to="lab_us-gaap_PreferredStockValue_91F8899655A83A2CB56EB8118844012A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_DD725F1F1BCE70783561B811884461A1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_DD725F1F1BCE70783561B811884461A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value; 200.0 shares authorized, 53.5 and 53.0 shares issued; 52.3 and 51.7 shares outstanding, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_DD725F1F1BCE70783561B811884461A1_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_DD725F1F1BCE70783561B811884461A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_DD725F1F1BCE70783561B811884461A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_DD725F1F1BCE70783561B811884461A1" xlink:to="lab_us-gaap_CommonStockValue_DD725F1F1BCE70783561B811884461A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockValue_571491ADCCF1876C2991B81188455769_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_571491ADCCF1876C2991B81188455769" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, at cost, 1.2 common shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_571491ADCCF1876C2991B81188455769_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_571491ADCCF1876C2991B81188455769" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_571491ADCCF1876C2991B81188455769" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue_571491ADCCF1876C2991B81188455769" xlink:to="lab_us-gaap_TreasuryStockValue_571491ADCCF1876C2991B81188455769" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_B65E4B4B4810E6F5EC5FB8118845053F_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_B65E4B4B4810E6F5EC5FB8118845053F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_B65E4B4B4810E6F5EC5FB8118845053F_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_B65E4B4B4810E6F5EC5FB8118845053F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_B65E4B4B4810E6F5EC5FB8118845053F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital_B65E4B4B4810E6F5EC5FB8118845053F" xlink:to="lab_us-gaap_AdditionalPaidInCapital_B65E4B4B4810E6F5EC5FB8118845053F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_C6B1C68F1E172ED15101B811884549A3_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_C6B1C68F1E172ED15101B811884549A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss, net</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_C6B1C68F1E172ED15101B811884549A3_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_C6B1C68F1E172ED15101B811884549A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_C6B1C68F1E172ED15101B811884549A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_C6B1C68F1E172ED15101B811884549A3" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_C6B1C68F1E172ED15101B811884549A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_AC389314260BBBCDB7CBB81188454297_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_AC389314260BBBCDB7CBB81188454297" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_AC389314260BBBCDB7CBB81188454297_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_AC389314260BBBCDB7CBB81188454297" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_AC389314260BBBCDB7CBB81188454297" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_AC389314260BBBCDB7CBB81188454297" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_AC389314260BBBCDB7CBB81188454297" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_1F8E072408F426C40256B81188452FE5_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_1F8E072408F426C40256B81188452FE5" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_1F8E072408F426C40256B81188452FE5_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_1F8E072408F426C40256B81188452FE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_1F8E072408F426C40256B81188452FE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_1F8E072408F426C40256B81188452FE5" xlink:to="lab_us-gaap_StockholdersEquity_1F8E072408F426C40256B81188452FE5" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_98A1EE830A95379B794BB8118846F8B6_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_98A1EE830A95379B794BB8118846F8B6" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_98A1EE830A95379B794BB8118846F8B6_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_98A1EE830A95379B794BB8118846F8B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_98A1EE830A95379B794BB8118846F8B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_98A1EE830A95379B794BB8118846F8B6" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_98A1EE830A95379B794BB8118846F8B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_3AF06F290AA051C4AD76B8118808E044_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_3AF06F290AA051C4AD76B8118808E044" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_3AF06F290AA051C4AD76B8118808E044" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3AF06F290AA051C4AD76B8118808E044" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_3AF06F290AA051C4AD76B8118808E044" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_E1131A35B668B3216E75B8118809B517_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_E1131A35B668B3216E75B8118809B517" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_E1131A35B668B3216E75B8118809B517_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_E1131A35B668B3216E75B8118809B517" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_E1131A35B668B3216E75B8118809B517" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_E1131A35B668B3216E75B8118809B517" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_E1131A35B668B3216E75B8118809B517" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_5E0F11667945E24E671EB8118809C24C_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_5E0F11667945E24E671EB8118809C24C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_5E0F11667945E24E671EB8118809C24C_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_5E0F11667945E24E671EB8118809C24C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_5E0F11667945E24E671EB8118809C24C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_5E0F11667945E24E671EB8118809C24C" xlink:to="lab_us-gaap_NetIncomeLoss_5E0F11667945E24E671EB8118809C24C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9C7BD1C67A05B6227466B8118809C677_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9C7BD1C67A05B6227466B8118809C677" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9C7BD1C67A05B6227466B8118809C677_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9C7BD1C67A05B6227466B8118809C677" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9C7BD1C67A05B6227466B8118809C677" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9C7BD1C67A05B6227466B8118809C677" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9C7BD1C67A05B6227466B8118809C677" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_FF6CDDB0456F7781E8D9B81188091FE7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_FF6CDDB0456F7781E8D9B81188091FE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_FF6CDDB0456F7781E8D9B81188091FE7_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_FF6CDDB0456F7781E8D9B81188091FE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_FF6CDDB0456F7781E8D9B81188091FE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_FF6CDDB0456F7781E8D9B81188091FE7" xlink:to="lab_us-gaap_ShareBasedCompensation_FF6CDDB0456F7781E8D9B81188091FE7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_9E70CF8E658EC36386D8B811880AFAA8_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_9E70CF8E658EC36386D8B811880AFAA8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_9E70CF8E658EC36386D8B811880AFAA8_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_9E70CF8E658EC36386D8B811880AFAA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_9E70CF8E658EC36386D8B811880AFAA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_9E70CF8E658EC36386D8B811880AFAA8" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_9E70CF8E658EC36386D8B811880AFAA8" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_1F47647EEF41F7C7685BB811880A75C5_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts_1F47647EEF41F7C7685BB811880A75C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of deferred financing costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_1F47647EEF41F7C7685BB811880A75C5_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts_1F47647EEF41F7C7685BB811880A75C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_1F47647EEF41F7C7685BB811880A75C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts_1F47647EEF41F7C7685BB811880A75C5" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts_1F47647EEF41F7C7685BB811880A75C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_F0B2E832ADE44CE67488B811880A4B90_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_F0B2E832ADE44CE67488B811880A4B90" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_F0B2E832ADE44CE67488B811880A4B90_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_F0B2E832ADE44CE67488B811880A4B90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_F0B2E832ADE44CE67488B811880A4B90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_F0B2E832ADE44CE67488B811880A4B90" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_F0B2E832ADE44CE67488B811880A4B90" xlink:type="arc" />
    <link:label id="lab_ebs_ChangeInFairValueOfContingentConsideration_21A546A0158047A9CE41B811880A724C_terseLabel_en-US" xlink:label="lab_ebs_ChangeInFairValueOfContingentConsideration_21A546A0158047A9CE41B811880A724C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of contingent consideration, net</link:label>
    <link:label id="lab_ebs_ChangeInFairValueOfContingentConsideration_21A546A0158047A9CE41B811880A724C_label_en-US" xlink:label="lab_ebs_ChangeInFairValueOfContingentConsideration_21A546A0158047A9CE41B811880A724C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Fair Value Of Contingent Consideration</link:label>
    <link:label id="lab_ebs_ChangeInFairValueOfContingentConsideration_21A546A0158047A9CE41B811880A724C_documentation_en-US" xlink:label="lab_ebs_ChangeInFairValueOfContingentConsideration_21A546A0158047A9CE41B811880A724C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair value measurement of contingent value rights and contingent purchase considerations granted under purchase agreements.</link:label>
    <link:loc xlink:href="ebs-20200331.xsd#ebs_ChangeInFairValueOfContingentConsideration" xlink:label="loc_ebs_ChangeInFairValueOfContingentConsideration_21A546A0158047A9CE41B811880A724C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ChangeInFairValueOfContingentConsideration_21A546A0158047A9CE41B811880A724C" xlink:to="lab_ebs_ChangeInFairValueOfContingentConsideration_21A546A0158047A9CE41B811880A724C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_35D0101F9CE7843CDEECB811880A9CA6_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_35D0101F9CE7843CDEECB811880A9CA6" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_35D0101F9CE7843CDEECB811880A9CA6_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_35D0101F9CE7843CDEECB811880A9CA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_35D0101F9CE7843CDEECB811880A9CA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense_35D0101F9CE7843CDEECB811880A9CA6" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense_35D0101F9CE7843CDEECB811880A9CA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4CC77432963443BA9B3FB811880A200C_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4CC77432963443BA9B3FB811880A200C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4CC77432963443BA9B3FB811880A200C_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4CC77432963443BA9B3FB811880A200C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4CC77432963443BA9B3FB811880A200C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4CC77432963443BA9B3FB811880A200C" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4CC77432963443BA9B3FB811880A200C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_8C31B3F0A3815D130AD4B811880B4B81_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_8C31B3F0A3815D130AD4B811880B4B81" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_8C31B3F0A3815D130AD4B811880B4B81_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_8C31B3F0A3815D130AD4B811880B4B81" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8C31B3F0A3815D130AD4B811880B4B81" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8C31B3F0A3815D130AD4B811880B4B81" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_8C31B3F0A3815D130AD4B811880B4B81" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_2E5C9B78CF4032794036B811880BB5C4_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_2E5C9B78CF4032794036B811880BB5C4" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_2E5C9B78CF4032794036B811880BB5C4_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_2E5C9B78CF4032794036B811880BB5C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_2E5C9B78CF4032794036B811880BB5C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories_2E5C9B78CF4032794036B811880BB5C4" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories_2E5C9B78CF4032794036B811880BB5C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_EC5C7757B82732BDC60BB811880B3EE4_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_EC5C7757B82732BDC60BB811880B3EE4" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_EC5C7757B82732BDC60BB811880B3EE4_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_EC5C7757B82732BDC60BB811880B3EE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_EC5C7757B82732BDC60BB811880B3EE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_EC5C7757B82732BDC60BB811880B3EE4" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_EC5C7757B82732BDC60BB811880B3EE4" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_1E5847B602B1A82F0817B811880BF5FC_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_1E5847B602B1A82F0817B811880BF5FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_1E5847B602B1A82F0817B811880BF5FC_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_1E5847B602B1A82F0817B811880BF5FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_1E5847B602B1A82F0817B811880BF5FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable_1E5847B602B1A82F0817B811880BF5FC" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable_1E5847B602B1A82F0817B811880BF5FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_E3EE31C4CC33BCC6B4FCB811880B1F85_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_E3EE31C4CC33BCC6B4FCB811880B1F85" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_E3EE31C4CC33BCC6B4FCB811880B1F85_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_E3EE31C4CC33BCC6B4FCB811880B1F85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_E3EE31C4CC33BCC6B4FCB811880B1F85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_E3EE31C4CC33BCC6B4FCB811880B1F85" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_E3EE31C4CC33BCC6B4FCB811880B1F85" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_16F2F2AF5DA671D6D1BEB811880C9860_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_16F2F2AF5DA671D6D1BEB811880C9860" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_16F2F2AF5DA671D6D1BEB811880C9860_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_16F2F2AF5DA671D6D1BEB811880C9860" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_16F2F2AF5DA671D6D1BEB811880C9860" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_16F2F2AF5DA671D6D1BEB811880C9860" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_16F2F2AF5DA671D6D1BEB811880C9860" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_5B3889AC20CA7DF62A25B811880CD918_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_5B3889AC20CA7DF62A25B811880CD918" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_5B3889AC20CA7DF62A25B811880CD918_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_5B3889AC20CA7DF62A25B811880CD918" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_5B3889AC20CA7DF62A25B811880CD918" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_5B3889AC20CA7DF62A25B811880CD918" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_5B3889AC20CA7DF62A25B811880CD918" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_74A3A47001A41393E100B811880CF3D6_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_74A3A47001A41393E100B811880CF3D6" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_74A3A47001A41393E100B811880CF3D6_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_74A3A47001A41393E100B811880CF3D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_74A3A47001A41393E100B811880CF3D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_74A3A47001A41393E100B811880CF3D6" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_74A3A47001A41393E100B811880CF3D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_E55BBBF8447A7873959DB811880C48DA_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_E55BBBF8447A7873959DB811880C48DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows used in investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_E55BBBF8447A7873959DB811880C48DA_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_E55BBBF8447A7873959DB811880C48DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_E55BBBF8447A7873959DB811880C48DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_E55BBBF8447A7873959DB811880C48DA" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_E55BBBF8447A7873959DB811880C48DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_969F51FADE634ADA8A55B811880CA1BE_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_969F51FADE634ADA8A55B811880CA1BE" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property, plant and equipment and other</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_969F51FADE634ADA8A55B811880CA1BE_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_969F51FADE634ADA8A55B811880CA1BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_969F51FADE634ADA8A55B811880CA1BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_969F51FADE634ADA8A55B811880CA1BE" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_969F51FADE634ADA8A55B811880CA1BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_7A3C985E8D2C58B77223B811880D8E52_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_7A3C985E8D2C58B77223B811880D8E52" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_7A3C985E8D2C58B77223B811880D8E52_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_7A3C985E8D2C58B77223B811880D8E52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7A3C985E8D2C58B77223B811880D8E52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7A3C985E8D2C58B77223B811880D8E52" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_7A3C985E8D2C58B77223B811880D8E52" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D1E8951034D6B23D4DAAB811880D16D8_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D1E8951034D6B23D4DAAB811880D16D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows used in financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D1E8951034D6B23D4DAAB811880D16D8_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D1E8951034D6B23D4DAAB811880D16D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D1E8951034D6B23D4DAAB811880D16D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D1E8951034D6B23D4DAAB811880D16D8" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D1E8951034D6B23D4DAAB811880D16D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_CE24924B5728B207150EB811880D19EF_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit_CE24924B5728B207150EB811880D19EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from revolving credit facility</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_CE24924B5728B207150EB811880D19EF_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit_CE24924B5728B207150EB811880D19EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Lines of Credit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_CE24924B5728B207150EB811880D19EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLinesOfCredit_CE24924B5728B207150EB811880D19EF" xlink:to="lab_us-gaap_ProceedsFromLinesOfCredit_CE24924B5728B207150EB811880D19EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_1DB04C98CBF6739CBF2AB811880E79CB_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit_1DB04C98CBF6739CBF2AB811880E79CB" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Principal payments on revolving credit facility</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_1DB04C98CBF6739CBF2AB811880E79CB_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit_1DB04C98CBF6739CBF2AB811880E79CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Lines of Credit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_1DB04C98CBF6739CBF2AB811880E79CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLinesOfCredit_1DB04C98CBF6739CBF2AB811880E79CB" xlink:to="lab_us-gaap_RepaymentsOfLinesOfCredit_1DB04C98CBF6739CBF2AB811880E79CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfMediumTermNotes_24B0B12A224EF465A61EB811880EC348_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfMediumTermNotes_24B0B12A224EF465A61EB811880EC348" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Principal payments on term loan facility</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfMediumTermNotes_24B0B12A224EF465A61EB811880EC348_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfMediumTermNotes_24B0B12A224EF465A61EB811880EC348" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Medium-term Notes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfMediumTermNotes" xlink:label="loc_us-gaap_RepaymentsOfMediumTermNotes_24B0B12A224EF465A61EB811880EC348" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfMediumTermNotes_24B0B12A224EF465A61EB811880EC348" xlink:to="lab_us-gaap_RepaymentsOfMediumTermNotes_24B0B12A224EF465A61EB811880EC348" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_93B11A6AAF28EB45EBC3B811880EA9BB_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_93B11A6AAF28EB45EBC3B811880EA9BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock upon exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_93B11A6AAF28EB45EBC3B811880EA9BB_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_93B11A6AAF28EB45EBC3B811880EA9BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_93B11A6AAF28EB45EBC3B811880EA9BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_93B11A6AAF28EB45EBC3B811880EA9BB" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_93B11A6AAF28EB45EBC3B811880EA9BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_FAEA47A6B700F2048637B811880EA21C_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_FAEA47A6B700F2048637B811880EA21C" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Taxes paid on behalf of employees for equity activity</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_FAEA47A6B700F2048637B811880EA21C_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_FAEA47A6B700F2048637B811880EA21C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_FAEA47A6B700F2048637B811880EA21C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_FAEA47A6B700F2048637B811880EA21C" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_FAEA47A6B700F2048637B811880EA21C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_6098D00F2EB3BDB06EC5B811880E5262_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_6098D00F2EB3BDB06EC5B811880E5262" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration payments</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_6098D00F2EB3BDB06EC5B811880E5262_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_6098D00F2EB3BDB06EC5B811880E5262" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_6098D00F2EB3BDB06EC5B811880E5262" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_6098D00F2EB3BDB06EC5B811880E5262" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_6098D00F2EB3BDB06EC5B811880E5262" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_072ED0E87F0F49EF4646B811880EBFAD_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_072ED0E87F0F49EF4646B811880EBFAD" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_072ED0E87F0F49EF4646B811880EBFAD_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_072ED0E87F0F49EF4646B811880EBFAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_072ED0E87F0F49EF4646B811880EBFAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_072ED0E87F0F49EF4646B811880EBFAD" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_072ED0E87F0F49EF4646B811880EBFAD" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_32C911DF8D97FFAA5DF9B811880F677D_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_32C911DF8D97FFAA5DF9B811880F677D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_32C911DF8D97FFAA5DF9B811880F677D_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_32C911DF8D97FFAA5DF9B811880F677D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_32C911DF8D97FFAA5DF9B811880F677D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_32C911DF8D97FFAA5DF9B811880F677D" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_32C911DF8D97FFAA5DF9B811880F677D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_241D5BC6D587E5BBB7B6B811880FFE2F_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_241D5BC6D587E5BBB7B6B811880FFE2F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_241D5BC6D587E5BBB7B6B811880FFE2F_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_241D5BC6D587E5BBB7B6B811880FFE2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_241D5BC6D587E5BBB7B6B811880FFE2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_241D5BC6D587E5BBB7B6B811880FFE2F" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_241D5BC6D587E5BBB7B6B811880FFE2F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_AAB68CB76E59EBAE0998B811880FBEAC_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_AAB68CB76E59EBAE0998B811880FBEAC" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_AAB68CB76E59EBAE0998B811880FBEAC_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_AAB68CB76E59EBAE0998B811880FBEAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_AAB68CB76E59EBAE0998B811880FBEAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_AAB68CB76E59EBAE0998B811880FBEAC" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_AAB68CB76E59EBAE0998B811880FBEAC" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_A3240B527306660EA19FB811880FE41D_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_A3240B527306660EA19FB811880FE41D" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_A3240B527306660EA19FB811880FE41D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_A3240B527306660EA19FB811880FE41D" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_A3240B527306660EA19FB811880FE41D" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_3C86CFD560A5260CFA78B811880FA9BF_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_3C86CFD560A5260CFA78B811880FA9BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_3C86CFD560A5260CFA78B811880FA9BF_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_3C86CFD560A5260CFA78B811880FA9BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_3C86CFD560A5260CFA78B811880FA9BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_3C86CFD560A5260CFA78B811880FA9BF" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_3C86CFD560A5260CFA78B811880FA9BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPaidNet_9B4CC952D5F0ECB1BD04B811881068EF_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet_9B4CC952D5F0ECB1BD04B811881068EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid during the period for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_9B4CC952D5F0ECB1BD04B811881068EF_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet_9B4CC952D5F0ECB1BD04B811881068EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_9B4CC952D5F0ECB1BD04B811881068EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet_9B4CC952D5F0ECB1BD04B811881068EF" xlink:to="lab_us-gaap_InterestPaidNet_9B4CC952D5F0ECB1BD04B811881068EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxesPaid_F1197754E6693E61BF38B81188101979_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid_F1197754E6693E61BF38B81188101979" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid during the period for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_F1197754E6693E61BF38B81188101979_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid_F1197754E6693E61BF38B81188101979" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_F1197754E6693E61BF38B81188101979" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid_F1197754E6693E61BF38B81188101979" xlink:to="lab_us-gaap_IncomeTaxesPaid_F1197754E6693E61BF38B81188101979" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_F8EBAF8AEF38DB6588CEB8118810E4B2_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_F8EBAF8AEF38DB6588CEB8118810E4B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental information on non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_F8EBAF8AEF38DB6588CEB8118810E4B2_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_F8EBAF8AEF38DB6588CEB8118810E4B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_F8EBAF8AEF38DB6588CEB8118810E4B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_F8EBAF8AEF38DB6588CEB8118810E4B2" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_F8EBAF8AEF38DB6588CEB8118810E4B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_0648ABD922D3A8314633B8118810780E_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_0648ABD922D3A8314633B8118810780E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchases of property, plant and equipment unpaid at period end</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_0648ABD922D3A8314633B8118810780E_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_0648ABD922D3A8314633B8118810780E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_0648ABD922D3A8314633B8118810780E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_0648ABD922D3A8314633B8118810780E" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_0648ABD922D3A8314633B8118810780E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_1E632CFF27C086C69A82B8118810BC1B_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_1E632CFF27C086C69A82B8118810BC1B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of cash and cash equivalent and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_1E632CFF27C086C69A82B8118810BC1B_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_1E632CFF27C086C69A82B8118810BC1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_1E632CFF27C086C69A82B8118810BC1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_1E632CFF27C086C69A82B8118810BC1B" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_1E632CFF27C086C69A82B8118810BC1B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_C6D33E93701C186C905DB8118811243E_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_C6D33E93701C186C905DB8118811243E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cash, cash equivalents and restricted cash</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_C6D33E93701C186C905DB8118811243E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_C6D33E93701C186C905DB8118811243E" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_C6D33E93701C186C905DB8118811243E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_04285B755F553EB5C90D9E56B12ADDD3_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_04285B755F553EB5C90D9E56B12ADDD3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_04285B755F553EB5C90D9E56B12ADDD3_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_04285B755F553EB5C90D9E56B12ADDD3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_04285B755F553EB5C90D9E56B12ADDD3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_04285B755F553EB5C90D9E56B12ADDD3" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_04285B755F553EB5C90D9E56B12ADDD3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_D945B350C692BEC199C99E56B12B36E9_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_D945B350C692BEC199C99E56B12B36E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_D945B350C692BEC199C99E56B12B36E9_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_D945B350C692BEC199C99E56B12B36E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_D945B350C692BEC199C99E56B12B36E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_D945B350C692BEC199C99E56B12B36E9" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_D945B350C692BEC199C99E56B12B36E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_3335ADA5FEFE9E6CFD4C9E56B12BBA16_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_3335ADA5FEFE9E6CFD4C9E56B12BBA16" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net deferred losses from accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_3335ADA5FEFE9E6CFD4C9E56B12BBA16_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_3335ADA5FEFE9E6CFD4C9E56B12BBA16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow Hedge Gain (Loss) to be Reclassified within Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:label="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_3335ADA5FEFE9E6CFD4C9E56B12BBA16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_3335ADA5FEFE9E6CFD4C9E56B12BBA16" xlink:to="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_3335ADA5FEFE9E6CFD4C9E56B12BBA16" xlink:type="arc" />
    <link:label id="lab_ebs_CreditAgreementMember_FAD6C713A21A1D41EBD09E56B0FC1EEC_terseLabel_en-US" xlink:label="lab_ebs_CreditAgreementMember_FAD6C713A21A1D41EBD09E56B0FC1EEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017 Credit Agreement</link:label>
    <link:label id="lab_ebs_CreditAgreementMember_FAD6C713A21A1D41EBD09E56B0FC1EEC_label_en-US" xlink:label="lab_ebs_CreditAgreementMember_FAD6C713A21A1D41EBD09E56B0FC1EEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Agreement [Member]</link:label>
    <link:label id="lab_ebs_CreditAgreementMember_FAD6C713A21A1D41EBD09E56B0FC1EEC_documentation_en-US" xlink:label="lab_ebs_CreditAgreementMember_FAD6C713A21A1D41EBD09E56B0FC1EEC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Credit agreement dated September 2017.</link:label>
    <link:loc xlink:href="ebs-20200331.xsd#ebs_CreditAgreementMember" xlink:label="loc_ebs_CreditAgreementMember_FAD6C713A21A1D41EBD09E56B0FC1EEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_CreditAgreementMember_FAD6C713A21A1D41EBD09E56B0FC1EEC" xlink:to="lab_ebs_CreditAgreementMember_FAD6C713A21A1D41EBD09E56B0FC1EEC" xlink:type="arc" />
    <link:label id="lab_ebs_AmendedCreditAgreementMember_55596D6B5C809D2B5FF49E56B0FC6C77_terseLabel_en-US" xlink:label="lab_ebs_AmendedCreditAgreementMember_55596D6B5C809D2B5FF49E56B0FC6C77" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amended Credit Agreement</link:label>
    <link:label id="lab_ebs_AmendedCreditAgreementMember_55596D6B5C809D2B5FF49E56B0FC6C77_label_en-US" xlink:label="lab_ebs_AmendedCreditAgreementMember_55596D6B5C809D2B5FF49E56B0FC6C77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amended Credit Agreement [Member]</link:label>
    <link:label id="lab_ebs_AmendedCreditAgreementMember_55596D6B5C809D2B5FF49E56B0FC6C77_documentation_en-US" xlink:label="lab_ebs_AmendedCreditAgreementMember_55596D6B5C809D2B5FF49E56B0FC6C77" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amended credit agreement dated October 15, 2018.</link:label>
    <link:loc xlink:href="ebs-20200331.xsd#ebs_AmendedCreditAgreementMember" xlink:label="loc_ebs_AmendedCreditAgreementMember_55596D6B5C809D2B5FF49E56B0FC6C77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_AmendedCreditAgreementMember_55596D6B5C809D2B5FF49E56B0FC6C77" xlink:to="lab_ebs_AmendedCreditAgreementMember_55596D6B5C809D2B5FF49E56B0FC6C77" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableRateAxis_DFC01E95B05AC369D90E9E56B0FC0B4F_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis_DFC01E95B05AC369D90E9E56B0FC0B4F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_DFC01E95B05AC369D90E9E56B0FC0B4F_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis_DFC01E95B05AC369D90E9E56B0FC0B4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_DFC01E95B05AC369D90E9E56B0FC0B4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis_DFC01E95B05AC369D90E9E56B0FC0B4F" xlink:to="lab_us-gaap_VariableRateAxis_DFC01E95B05AC369D90E9E56B0FC0B4F" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableRateDomain_37E00A0850EB99E4BA9C9E56B0FC99E3_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain_37E00A0850EB99E4BA9C9E56B0FC99E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_37E00A0850EB99E4BA9C9E56B0FC99E3_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain_37E00A0850EB99E4BA9C9E56B0FC99E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_37E00A0850EB99E4BA9C9E56B0FC99E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain_37E00A0850EB99E4BA9C9E56B0FC99E3" xlink:to="lab_us-gaap_VariableRateDomain_37E00A0850EB99E4BA9C9E56B0FC99E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_EurodollarMember_41F970E045976237CC1B9E56B0FD8593_terseLabel_en-US" xlink:label="lab_us-gaap_EurodollarMember_41F970E045976237CC1B9E56B0FD8593" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Eurocurrency</link:label>
    <link:label id="lab_us-gaap_EurodollarMember_41F970E045976237CC1B9E56B0FD8593_label_en-US" xlink:label="lab_us-gaap_EurodollarMember_41F970E045976237CC1B9E56B0FD8593" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eurodollar [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EurodollarMember" xlink:label="loc_us-gaap_EurodollarMember_41F970E045976237CC1B9E56B0FD8593" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EurodollarMember_41F970E045976237CC1B9E56B0FD8593" xlink:to="lab_us-gaap_EurodollarMember_41F970E045976237CC1B9E56B0FD8593" xlink:type="arc" />
    <link:label id="lab_us-gaap_FederalFundsEffectiveSwapRateMember_8B9FF9A5EA697E8539BF9E56B0FDFA98_terseLabel_en-US" xlink:label="lab_us-gaap_FederalFundsEffectiveSwapRateMember_8B9FF9A5EA697E8539BF9E56B0FDFA98" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal Funds Rate</link:label>
    <link:label id="lab_us-gaap_FederalFundsEffectiveSwapRateMember_8B9FF9A5EA697E8539BF9E56B0FDFA98_label_en-US" xlink:label="lab_us-gaap_FederalFundsEffectiveSwapRateMember_8B9FF9A5EA697E8539BF9E56B0FDFA98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fed Funds Effective Rate Overnight Index Swap Rate [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FederalFundsEffectiveSwapRateMember" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember_8B9FF9A5EA697E8539BF9E56B0FDFA98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalFundsEffectiveSwapRateMember_8B9FF9A5EA697E8539BF9E56B0FDFA98" xlink:to="lab_us-gaap_FederalFundsEffectiveSwapRateMember_8B9FF9A5EA697E8539BF9E56B0FDFA98" xlink:type="arc" />
    <link:label id="lab_us-gaap_BaseRateMember_9E0042F2F5ED31B0FFB99E56B0FDA3F2_terseLabel_en-US" xlink:label="lab_us-gaap_BaseRateMember_9E0042F2F5ED31B0FFB99E56B0FDA3F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Base Rate</link:label>
    <link:label id="lab_us-gaap_BaseRateMember_9E0042F2F5ED31B0FFB99E56B0FDA3F2_label_en-US" xlink:label="lab_us-gaap_BaseRateMember_9E0042F2F5ED31B0FFB99E56B0FDA3F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BaseRateMember" xlink:label="loc_us-gaap_BaseRateMember_9E0042F2F5ED31B0FFB99E56B0FDA3F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BaseRateMember_9E0042F2F5ED31B0FFB99E56B0FDA3F2" xlink:to="lab_us-gaap_BaseRateMember_9E0042F2F5ED31B0FFB99E56B0FDA3F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_C86AB87CC06D3C94D0719E56B0FF317D_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_C86AB87CC06D3C94D0719E56B0FF317D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_C86AB87CC06D3C94D0719E56B0FF317D_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_C86AB87CC06D3C94D0719E56B0FF317D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Current Borrowing Capacity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_C86AB87CC06D3C94D0719E56B0FF317D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_C86AB87CC06D3C94D0719E56B0FF317D" xlink:to="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_C86AB87CC06D3C94D0719E56B0FF317D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_9E9DE11098CAB58A297C9E56B0FF001A_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_9E9DE11098CAB58A297C9E56B0FF001A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_9E9DE11098CAB58A297C9E56B0FF001A_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_9E9DE11098CAB58A297C9E56B0FF001A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_9E9DE11098CAB58A297C9E56B0FF001A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_9E9DE11098CAB58A297C9E56B0FF001A" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_9E9DE11098CAB58A297C9E56B0FF001A" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_9EC514F8D5D89645C34D9E56B0FF0A18_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_9EC514F8D5D89645C34D9E56B0FF0A18" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitment fee percentage</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_9EC514F8D5D89645C34D9E56B0FF0A18_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_9EC514F8D5D89645C34D9E56B0FF0A18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Commitment Fee Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_9EC514F8D5D89645C34D9E56B0FF0A18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_9EC514F8D5D89645C34D9E56B0FF0A18" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_9EC514F8D5D89645C34D9E56B0FF0A18" xlink:type="arc" />
    <link:label id="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears_2E8FC1A4D3C51799860B9E56B0FF5F02_terseLabel_en-US" xlink:label="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears_2E8FC1A4D3C51799860B9E56B0FF5F02" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of original principal amount required to repay in the first two years</link:label>
    <link:label id="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears_2E8FC1A4D3C51799860B9E56B0FF5F02_label_en-US" xlink:label="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears_2E8FC1A4D3C51799860B9E56B0FF5F02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of Original Principal Amount Required to Repay in First Two Years</link:label>
    <link:label id="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears_2E8FC1A4D3C51799860B9E56B0FF5F02_documentation_en-US" xlink:label="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears_2E8FC1A4D3C51799860B9E56B0FF5F02" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The rate of interest that was being paid on the original debt issue that is to repay in the first two years.</link:label>
    <link:loc xlink:href="ebs-20200331.xsd#ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears" xlink:label="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears_2E8FC1A4D3C51799860B9E56B0FF5F02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears_2E8FC1A4D3C51799860B9E56B0FF5F02" xlink:to="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears_2E8FC1A4D3C51799860B9E56B0FF5F02" xlink:type="arc" />
    <link:label id="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear_E7D4440EF7C81C65A3979E56B0FFFF0B_terseLabel_en-US" xlink:label="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear_E7D4440EF7C81C65A3979E56B0FFFF0B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of original principal amount required to repay during the third year</link:label>
    <link:label id="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear_E7D4440EF7C81C65A3979E56B0FFFF0B_label_en-US" xlink:label="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear_E7D4440EF7C81C65A3979E56B0FFFF0B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of Original Principal Amount Required to Repay During the Third Year</link:label>
    <link:label id="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear_E7D4440EF7C81C65A3979E56B0FFFF0B_documentation_en-US" xlink:label="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear_E7D4440EF7C81C65A3979E56B0FFFF0B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The rate of interest that was being paid on the original debt issue that is to repay in the third year.</link:label>
    <link:loc xlink:href="ebs-20200331.xsd#ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear" xlink:label="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear_E7D4440EF7C81C65A3979E56B0FFFF0B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear_E7D4440EF7C81C65A3979E56B0FFFF0B" xlink:to="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear_E7D4440EF7C81C65A3979E56B0FFFF0B" xlink:type="arc" />
    <link:label id="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears_DB482A3298198FBE44FB9E56B0FF9944_terseLabel_en-US" xlink:label="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears_DB482A3298198FBE44FB9E56B0FF9944" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of original principal amount required to repay remaining year</link:label>
    <link:label id="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears_DB482A3298198FBE44FB9E56B0FF9944_label_en-US" xlink:label="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears_DB482A3298198FBE44FB9E56B0FF9944" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of Original Principal Amount Required to Repay Remaining Years</link:label>
    <link:label id="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears_DB482A3298198FBE44FB9E56B0FF9944_documentation_en-US" xlink:label="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears_DB482A3298198FBE44FB9E56B0FF9944" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The rate of interest that was being paid on the original debt issue that is to repay in remaining years.</link:label>
    <link:loc xlink:href="ebs-20200331.xsd#ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears" xlink:label="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears_DB482A3298198FBE44FB9E56B0FF9944" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears_DB482A3298198FBE44FB9E56B0FF9944" xlink:to="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears_DB482A3298198FBE44FB9E56B0FF9944" xlink:type="arc" />
    <link:label id="lab_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight_D29200E065EF0EF624ED9E56B0FFD804_terseLabel_en-US" xlink:label="lab_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight_D29200E065EF0EF624ED9E56B0FFD804" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash proceeds excess amount from dispositions of property or casualty events subject to certain reinvestment right</link:label>
    <link:label id="lab_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight_D29200E065EF0EF624ED9E56B0FFD804_label_en-US" xlink:label="lab_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight_D29200E065EF0EF624ED9E56B0FFD804" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Proceeds Excess Amount from Dispositions of Property or Casualty Events Subject to Certain Reinvestment Right</link:label>
    <link:label id="lab_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight_D29200E065EF0EF624ED9E56B0FFD804_documentation_en-US" xlink:label="lab_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight_D29200E065EF0EF624ED9E56B0FFD804" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The cash proceeds in excess during the term of the Senior Secured Credit Facility from certain dispositions of property or from casualty events involving their property, subject to certain reinvestment rights.</link:label>
    <link:loc xlink:href="ebs-20200331.xsd#ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight" xlink:label="loc_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight_D29200E065EF0EF624ED9E56B0FFD804" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight_D29200E065EF0EF624ED9E56B0FFD804" xlink:to="lab_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight_D29200E065EF0EF624ED9E56B0FFD804" xlink:type="arc" />
    <link:label id="lab_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio_D013DCC7650F545CA85B9E95B6B6922A_verboseLabel_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio_D013DCC7650F545CA85B9E95B6B6922A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Debt covenant, consolidated debt service coverage ratio, minimum</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio_D013DCC7650F545CA85B9E95B6B6922A_label_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio_D013DCC7650F545CA85B9E95B6B6922A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Debt Service Coverage Ratio</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio_D013DCC7650F545CA85B9E95B6B6922A_documentation_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio_D013DCC7650F545CA85B9E95B6B6922A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Debt Service Coverage Ratio</link:label>
    <link:loc xlink:href="ebs-20200331.xsd#ebs_DebtInstrumentCovenantDebtServiceCoverageRatio" xlink:label="loc_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio_D013DCC7650F545CA85B9E95B6B6922A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio_D013DCC7650F545CA85B9E95B6B6922A" xlink:to="lab_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio_D013DCC7650F545CA85B9E95B6B6922A" xlink:type="arc" />
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioOne_BBBCB39E6A7F50D035719E9C4A1BF2B5_terseLabel_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioOne_BBBCB39E6A7F50D035719E9C4A1BF2B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, covenant, net leverage ratio through June 30, 2019</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioOne_BBBCB39E6A7F50D035719E9C4A1BF2B5_label_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioOne_BBBCB39E6A7F50D035719E9C4A1BF2B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Net Leverage Ratio, One</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioOne_BBBCB39E6A7F50D035719E9C4A1BF2B5_documentation_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioOne_BBBCB39E6A7F50D035719E9C4A1BF2B5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Net Leverage Ratio, One</link:label>
    <link:loc xlink:href="ebs-20200331.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioOne" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioOne_BBBCB39E6A7F50D035719E9C4A1BF2B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DebtInstrumentCovenantNetLeverageRatioOne_BBBCB39E6A7F50D035719E9C4A1BF2B5" xlink:to="lab_ebs_DebtInstrumentCovenantNetLeverageRatioOne_BBBCB39E6A7F50D035719E9C4A1BF2B5" xlink:type="arc" />
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioTwo_02AF74F62D13E4DE90919E9E05389C5C_terseLabel_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioTwo_02AF74F62D13E4DE90919E9E05389C5C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, covenant, net leverage ratio to September 30, 2019</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioTwo_02AF74F62D13E4DE90919E9E05389C5C_label_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioTwo_02AF74F62D13E4DE90919E9E05389C5C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Net Leverage Ratio, Two</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioTwo_02AF74F62D13E4DE90919E9E05389C5C_documentation_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioTwo_02AF74F62D13E4DE90919E9E05389C5C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Net Leverage Ratio, Two</link:label>
    <link:loc xlink:href="ebs-20200331.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioTwo" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioTwo_02AF74F62D13E4DE90919E9E05389C5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DebtInstrumentCovenantNetLeverageRatioTwo_02AF74F62D13E4DE90919E9E05389C5C" xlink:to="lab_ebs_DebtInstrumentCovenantNetLeverageRatioTwo_02AF74F62D13E4DE90919E9E05389C5C" xlink:type="arc" />
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioThree_67DB66E6E22F2747C5729E9EC900CFA7_terseLabel_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioThree_67DB66E6E22F2747C5729E9EC900CFA7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, covenant, net leverage ratio from October 1, 2019 to September 29, 2020</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioThree_67DB66E6E22F2747C5729E9EC900CFA7_label_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioThree_67DB66E6E22F2747C5729E9EC900CFA7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Net Leverage Ratio, Three</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioThree_67DB66E6E22F2747C5729E9EC900CFA7_documentation_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioThree_67DB66E6E22F2747C5729E9EC900CFA7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Net Leverage Ratio, Three</link:label>
    <link:loc xlink:href="ebs-20200331.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioThree" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioThree_67DB66E6E22F2747C5729E9EC900CFA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DebtInstrumentCovenantNetLeverageRatioThree_67DB66E6E22F2747C5729E9EC900CFA7" xlink:to="lab_ebs_DebtInstrumentCovenantNetLeverageRatioThree_67DB66E6E22F2747C5729E9EC900CFA7" xlink:type="arc" />
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod_7965B54AA9CEACC745A59E56B100500C_terseLabel_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod_7965B54AA9CEACC745A59E56B100500C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, covenant, net leverage ratio rolling period</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod_7965B54AA9CEACC745A59E56B100500C_label_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod_7965B54AA9CEACC745A59E56B100500C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Net Leverage Ratio Rolling Period</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod_7965B54AA9CEACC745A59E56B100500C_documentation_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod_7965B54AA9CEACC745A59E56B100500C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Net Leverage Ratio Rolling Period</link:label>
    <link:loc xlink:href="ebs-20200331.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod_7965B54AA9CEACC745A59E56B100500C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod_7965B54AA9CEACC745A59E56B100500C" xlink:to="lab_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod_7965B54AA9CEACC745A59E56B100500C" xlink:type="arc" />
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod_8C9CCDA760E5DEB4FB969E56B10016BA_terseLabel_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod_8C9CCDA760E5DEB4FB969E56B10016BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, covenant, net leverage ratio adjustment period</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod_8C9CCDA760E5DEB4FB969E56B10016BA_label_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod_8C9CCDA760E5DEB4FB969E56B10016BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Net Leverage Ratio Adjustment Period</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod_8C9CCDA760E5DEB4FB969E56B10016BA_documentation_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod_8C9CCDA760E5DEB4FB969E56B10016BA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Net Leverage Ratio Adjustment Period</link:label>
    <link:loc xlink:href="ebs-20200331.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod_8C9CCDA760E5DEB4FB969E56B10016BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod_8C9CCDA760E5DEB4FB969E56B10016BA" xlink:to="lab_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod_8C9CCDA760E5DEB4FB969E56B10016BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_BilledContractReceivables_84E3CE5D2287B8087A86BC1D227D6285_terseLabel_en-US" xlink:label="lab_us-gaap_BilledContractReceivables_84E3CE5D2287B8087A86BC1D227D6285" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Billed, net</link:label>
    <link:label id="lab_us-gaap_BilledContractReceivables_84E3CE5D2287B8087A86BC1D227D6285_label_en-US" xlink:label="lab_us-gaap_BilledContractReceivables_84E3CE5D2287B8087A86BC1D227D6285" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Billed Contracts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BilledContractReceivables" xlink:label="loc_us-gaap_BilledContractReceivables_84E3CE5D2287B8087A86BC1D227D6285" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BilledContractReceivables_84E3CE5D2287B8087A86BC1D227D6285" xlink:to="lab_us-gaap_BilledContractReceivables_84E3CE5D2287B8087A86BC1D227D6285" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnbilledContractsReceivable_5E4A3CF3F0E20272982DBC1D227D6A67_terseLabel_en-US" xlink:label="lab_us-gaap_UnbilledContractsReceivable_5E4A3CF3F0E20272982DBC1D227D6A67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unbilled</link:label>
    <link:label id="lab_us-gaap_UnbilledContractsReceivable_5E4A3CF3F0E20272982DBC1D227D6A67_label_en-US" xlink:label="lab_us-gaap_UnbilledContractsReceivable_5E4A3CF3F0E20272982DBC1D227D6A67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unbilled Contracts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnbilledContractsReceivable" xlink:label="loc_us-gaap_UnbilledContractsReceivable_5E4A3CF3F0E20272982DBC1D227D6A67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnbilledContractsReceivable_5E4A3CF3F0E20272982DBC1D227D6A67" xlink:to="lab_us-gaap_UnbilledContractsReceivable_5E4A3CF3F0E20272982DBC1D227D6A67" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_16E1C3DD8EAF5ADD8FB7BC1D227D3D7F_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_16E1C3DD8EAF5ADD8FB7BC1D227D3D7F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_16E1C3DD8EAF5ADD8FB7BC1D227D3D7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_16E1C3DD8EAF5ADD8FB7BC1D227D3D7F" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_16E1C3DD8EAF5ADD8FB7BC1D227D3D7F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_7CE6FB950A3F23658D65BC2282AD4E17_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_7CE6FB950A3F23658D65BC2282AD4E17" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowance for doubtful accounts receivable</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_7CE6FB950A3F23658D65BC2282AD4E17_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_7CE6FB950A3F23658D65BC2282AD4E17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_7CE6FB950A3F23658D65BC2282AD4E17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_7CE6FB950A3F23658D65BC2282AD4E17" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_7CE6FB950A3F23658D65BC2282AD4E17" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_8FD7960B8723066C5833B7DCF5437C77_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_8FD7960B8723066C5833B7DCF5437C77" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and Diluted Net Income per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_8FD7960B8723066C5833B7DCF5437C77_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_8FD7960B8723066C5833B7DCF5437C77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_8FD7960B8723066C5833B7DCF5437C77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_8FD7960B8723066C5833B7DCF5437C77" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_8FD7960B8723066C5833B7DCF5437C77" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_935DF722D95D86EF866C9E56B13CA2A9_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_935DF722D95D86EF866C9E56B13CA2A9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contingent Consideration</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_935DF722D95D86EF866C9E56B13CA2A9_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_935DF722D95D86EF866C9E56B13CA2A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_935DF722D95D86EF866C9E56B13CA2A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock_935DF722D95D86EF866C9E56B13CA2A9" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock_935DF722D95D86EF866C9E56B13CA2A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_63431193F268054CE9C3BC1D23294EA1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_63431193F268054CE9C3BC1D23294EA1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_63431193F268054CE9C3BC1D23294EA1_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_63431193F268054CE9C3BC1D23294EA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_63431193F268054CE9C3BC1D23294EA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_63431193F268054CE9C3BC1D23294EA1" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_63431193F268054CE9C3BC1D23294EA1" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_355EC80F65AA9E3B794EBC1D2329AAF1_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_355EC80F65AA9E3B794EBC1D2329AAF1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_355EC80F65AA9E3B794EBC1D2329AAF1_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_355EC80F65AA9E3B794EBC1D2329AAF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_355EC80F65AA9E3B794EBC1D2329AAF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_355EC80F65AA9E3B794EBC1D2329AAF1" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_355EC80F65AA9E3B794EBC1D2329AAF1" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_D86F113E6DA0B7D79432BC1D232A2DF6_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_D86F113E6DA0B7D79432BC1D232A2DF6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_D86F113E6DA0B7D79432BC1D232A2DF6_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_D86F113E6DA0B7D79432BC1D232A2DF6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_D86F113E6DA0B7D79432BC1D232A2DF6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_D86F113E6DA0B7D79432BC1D232A2DF6" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_D86F113E6DA0B7D79432BC1D232A2DF6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductMember_836ED38AD4823110423CBC1D232AC212_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductMember_836ED38AD4823110423CBC1D232AC212" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Products</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_836ED38AD4823110423CBC1D232AC212" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember_836ED38AD4823110423CBC1D232AC212" xlink:to="lab_us-gaap_ProductMember_836ED38AD4823110423CBC1D232AC212" xlink:type="arc" />
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_F23B9AE855B4AB6EF9BDBC1D232A3DA2_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember_F23B9AE855B4AB6EF9BDBC1D232A3DA2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_F23B9AE855B4AB6EF9BDBC1D232A3DA2_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember_F23B9AE855B4AB6EF9BDBC1D232A3DA2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaap_CustomerRelationshipsMember_F23B9AE855B4AB6EF9BDBC1D232A3DA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember_F23B9AE855B4AB6EF9BDBC1D232A3DA2" xlink:to="lab_us-gaap_CustomerRelationshipsMember_F23B9AE855B4AB6EF9BDBC1D232A3DA2" xlink:type="arc" />
    <link:label id="lab_ebs_ContractManufacturingMember_652CC6699B20D554F5B4BC1D232BF995_terseLabel_en-US" xlink:label="lab_ebs_ContractManufacturingMember_652CC6699B20D554F5B4BC1D232BF995" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract development and manufacturing services</link:label>
    <link:loc xlink:href="ebs-20200331.xsd#ebs_ContractManufacturingMember" xlink:label="loc_ebs_ContractManufacturingMember_652CC6699B20D554F5B4BC1D232BF995" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ContractManufacturingMember_652CC6699B20D554F5B4BC1D232BF995" xlink:to="lab_ebs_ContractManufacturingMember_652CC6699B20D554F5B4BC1D232BF995" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_8163A70B45F54D03C2A1BC1D232C60E8_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_8163A70B45F54D03C2A1BC1D232C60E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_8163A70B45F54D03C2A1BC1D232C60E8_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_8163A70B45F54D03C2A1BC1D232C60E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8163A70B45F54D03C2A1BC1D232C60E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8163A70B45F54D03C2A1BC1D232C60E8" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_8163A70B45F54D03C2A1BC1D232C60E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_3EF8A217EF74F594299BBC1D232CD734_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_3EF8A217EF74F594299BBC1D232CD734" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization period of intangible asset</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_3EF8A217EF74F594299BBC1D232CD734_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_3EF8A217EF74F594299BBC1D232CD734" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_3EF8A217EF74F594299BBC1D232CD734" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_3EF8A217EF74F594299BBC1D232CD734" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_3EF8A217EF74F594299BBC1D232CD734" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_BFDA95206586563938D3BC1D232C85E6_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_BFDA95206586563938D3BC1D232C85E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_BFDA95206586563938D3BC1D232C85E6_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_BFDA95206586563938D3BC1D232C85E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_BFDA95206586563938D3BC1D232C85E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_BFDA95206586563938D3BC1D232C85E6" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_BFDA95206586563938D3BC1D232C85E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_8D1474AD6B0246229B1CBC1D232CD67E_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_8D1474AD6B0246229B1CBC1D232CD67E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, gross</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_8D1474AD6B0246229B1CBC1D232CD67E_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_8D1474AD6B0246229B1CBC1D232CD67E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_8D1474AD6B0246229B1CBC1D232CD67E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross_8D1474AD6B0246229B1CBC1D232CD67E" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross_8D1474AD6B0246229B1CBC1D232CD67E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_4A5D5AA8F9C1A239E088BC1D232CBE32_terseLabel_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_4A5D5AA8F9C1A239E088BC1D232CBE32" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-lived intangible assets acquired</link:label>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_4A5D5AA8F9C1A239E088BC1D232CBE32_label_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_4A5D5AA8F9C1A239E088BC1D232CBE32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-lived Intangible Assets Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_4A5D5AA8F9C1A239E088BC1D232CBE32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_4A5D5AA8F9C1A239E088BC1D232CBE32" xlink:to="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_4A5D5AA8F9C1A239E088BC1D232CBE32" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_C642FC3958717E0EB6ABBC1D232D3CB9_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_C642FC3958717E0EB6ABBC1D232D3CB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-lived intangible assets, accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_C642FC3958717E0EB6ABBC1D232D3CB9_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_C642FC3958717E0EB6ABBC1D232D3CB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_C642FC3958717E0EB6ABBC1D232D3CB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_C642FC3958717E0EB6ABBC1D232D3CB9" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_C642FC3958717E0EB6ABBC1D232D3CB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_FA561057BD5C5A9296CBBC1D232D337E_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_FA561057BD5C5A9296CBBC1D232D337E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_FA561057BD5C5A9296CBBC1D232D337E_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_FA561057BD5C5A9296CBBC1D232D337E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_FA561057BD5C5A9296CBBC1D232D337E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_FA561057BD5C5A9296CBBC1D232D337E" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet_FA561057BD5C5A9296CBBC1D232D337E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_BE082120B24A4EF1C9AC79DDB08CA5DD_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_BE082120B24A4EF1C9AC79DDB08CA5DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_BE082120B24A4EF1C9AC79DDB08CA5DD_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_BE082120B24A4EF1C9AC79DDB08CA5DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_BE082120B24A4EF1C9AC79DDB08CA5DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_BE082120B24A4EF1C9AC79DDB08CA5DD" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_BE082120B24A4EF1C9AC79DDB08CA5DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_VestingAxis_DB211463A3D71E91DE5979DDB08DFF3E_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis_DB211463A3D71E91DE5979DDB08DFF3E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_DB211463A3D71E91DE5979DDB08DFF3E_label_en-US" xlink:label="lab_us-gaap_VestingAxis_DB211463A3D71E91DE5979DDB08DFF3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_DB211463A3D71E91DE5979DDB08DFF3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis_DB211463A3D71E91DE5979DDB08DFF3E" xlink:to="lab_us-gaap_VestingAxis_DB211463A3D71E91DE5979DDB08DFF3E" xlink:type="arc" />
    <link:label id="lab_us-gaap_VestingDomain_780B75C4BF70B6A39E8F79DDB08D031F_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain_780B75C4BF70B6A39E8F79DDB08D031F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_780B75C4BF70B6A39E8F79DDB08D031F_label_en-US" xlink:label="lab_us-gaap_VestingDomain_780B75C4BF70B6A39E8F79DDB08D031F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_780B75C4BF70B6A39E8F79DDB08D031F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain_780B75C4BF70B6A39E8F79DDB08D031F" xlink:to="lab_us-gaap_VestingDomain_780B75C4BF70B6A39E8F79DDB08D031F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_CA7FC2FA48DA5BD380FF79DDB08D0C07_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_CA7FC2FA48DA5BD380FF79DDB08D0C07" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche One</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_CA7FC2FA48DA5BD380FF79DDB08D0C07_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_CA7FC2FA48DA5BD380FF79DDB08D0C07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_CA7FC2FA48DA5BD380FF79DDB08D0C07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_CA7FC2FA48DA5BD380FF79DDB08D0C07" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_CA7FC2FA48DA5BD380FF79DDB08D0C07" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_0028CDD8BF45952C4CA979DDB08E178A_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_0028CDD8BF45952C4CA979DDB08E178A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche Two</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_0028CDD8BF45952C4CA979DDB08E178A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_0028CDD8BF45952C4CA979DDB08E178A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_0028CDD8BF45952C4CA979DDB08E178A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_0028CDD8BF45952C4CA979DDB08E178A" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_0028CDD8BF45952C4CA979DDB08E178A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_F8B9098CEF597BDBA3DE79DDB08EE9BC_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_F8B9098CEF597BDBA3DE79DDB08EE9BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche Three</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_F8B9098CEF597BDBA3DE79DDB08EE9BC_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_F8B9098CEF597BDBA3DE79DDB08EE9BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Tranche Three [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_F8B9098CEF597BDBA3DE79DDB08EE9BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_F8B9098CEF597BDBA3DE79DDB08EE9BC" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_F8B9098CEF597BDBA3DE79DDB08EE9BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_936FF14D40FCF9B8581E79DDB08E985F_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_936FF14D40FCF9B8581E79DDB08E985F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_936FF14D40FCF9B8581E79DDB08E985F_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_936FF14D40FCF9B8581E79DDB08E985F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_936FF14D40FCF9B8581E79DDB08E985F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_936FF14D40FCF9B8581E79DDB08E985F" xlink:to="lab_us-gaap_AwardTypeAxis_936FF14D40FCF9B8581E79DDB08E985F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F9F9B322D55F40570F4579DDB08E4BBD_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F9F9B322D55F40570F4579DDB08E4BBD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F9F9B322D55F40570F4579DDB08E4BBD_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F9F9B322D55F40570F4579DDB08E4BBD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F9F9B322D55F40570F4579DDB08E4BBD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F9F9B322D55F40570F4579DDB08E4BBD" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F9F9B322D55F40570F4579DDB08E4BBD" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_D893004C0295BA83BDDD79DDB08E0284_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_D893004C0295BA83BDDD79DDB08E0284" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_D893004C0295BA83BDDD79DDB08E0284_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_D893004C0295BA83BDDD79DDB08E0284" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_D893004C0295BA83BDDD79DDB08E0284" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_D893004C0295BA83BDDD79DDB08E0284" xlink:to="lab_us-gaap_EmployeeStockOptionMember_D893004C0295BA83BDDD79DDB08E0284" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_3C95134323D2916B99F779DDB094E174_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_3C95134323D2916B99F779DDB094E174" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_3C95134323D2916B99F779DDB094E174_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_3C95134323D2916B99F779DDB094E174" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_3C95134323D2916B99F779DDB094E174" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_3C95134323D2916B99F779DDB094E174" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember_3C95134323D2916B99F779DDB094E174" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_90B7DAFD72A247A8BC0179DDB09462F8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_90B7DAFD72A247A8BC0179DDB09462F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_90B7DAFD72A247A8BC0179DDB09462F8_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_90B7DAFD72A247A8BC0179DDB09462F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_90B7DAFD72A247A8BC0179DDB09462F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_90B7DAFD72A247A8BC0179DDB09462F8" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_90B7DAFD72A247A8BC0179DDB09462F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract_39EFB8036BC6EFBAFC4B79DDB0941533_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract_39EFB8036BC6EFBAFC4B79DDB0941533" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issued or granted during period [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract_39EFB8036BC6EFBAFC4B79DDB0941533_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract_39EFB8036BC6EFBAFC4B79DDB0941533" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Granted or Issued, Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract_39EFB8036BC6EFBAFC4B79DDB0941533" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract_39EFB8036BC6EFBAFC4B79DDB0941533" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract_39EFB8036BC6EFBAFC4B79DDB0941533" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_56DD46FEFD4DD055015679DDB0957323_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_56DD46FEFD4DD055015679DDB0957323" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_56DD46FEFD4DD055015679DDB0957323_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_56DD46FEFD4DD055015679DDB0957323" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_56DD46FEFD4DD055015679DDB0957323" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_56DD46FEFD4DD055015679DDB0957323" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_56DD46FEFD4DD055015679DDB0957323" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_F3C54E30E012BD840AF579DDB095C6A7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_F3C54E30E012BD840AF579DDB095C6A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_F3C54E30E012BD840AF579DDB095C6A7_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_F3C54E30E012BD840AF579DDB095C6A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_F3C54E30E012BD840AF579DDB095C6A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_F3C54E30E012BD840AF579DDB095C6A7" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_F3C54E30E012BD840AF579DDB095C6A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_22830B326A574E380C3979DDB0957D43_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_22830B326A574E380C3979DDB0957D43" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award vesting rights, percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_22830B326A574E380C3979DDB0957D43_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_22830B326A574E380C3979DDB0957D43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_22830B326A574E380C3979DDB0957D43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_22830B326A574E380C3979DDB0957D43" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_22830B326A574E380C3979DDB0957D43" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5D9D0F86A91F3101639D79DDB095A6E7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5D9D0F86A91F3101639D79DDB095A6E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5D9D0F86A91F3101639D79DDB095A6E7_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5D9D0F86A91F3101639D79DDB095A6E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5D9D0F86A91F3101639D79DDB095A6E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5D9D0F86A91F3101639D79DDB095A6E7" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5D9D0F86A91F3101639D79DDB095A6E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_DFC5F6F34FC96B03AAD47A38D3CBB676_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_DFC5F6F34FC96B03AAD47A38D3CBB676" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_DFC5F6F34FC96B03AAD47A38D3CBB676" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_DFC5F6F34FC96B03AAD47A38D3CBB676" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_DFC5F6F34FC96B03AAD47A38D3CBB676" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_83E89AD8E4C68BBEF10B7A3946B7DB1A_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_83E89AD8E4C68BBEF10B7A3946B7DB1A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_83E89AD8E4C68BBEF10B7A3946B7DB1A_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_83E89AD8E4C68BBEF10B7A3946B7DB1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_83E89AD8E4C68BBEF10B7A3946B7DB1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_83E89AD8E4C68BBEF10B7A3946B7DB1A" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_83E89AD8E4C68BBEF10B7A3946B7DB1A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_8A2FF2C809C1AB2CAB7550AC9E192D42_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_8A2FF2C809C1AB2CAB7550AC9E192D42" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_8A2FF2C809C1AB2CAB7550AC9E192D42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8A2FF2C809C1AB2CAB7550AC9E192D42" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_8A2FF2C809C1AB2CAB7550AC9E192D42" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_FD7AFA70CF561AC8BF1350AC9E193AA3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_FD7AFA70CF561AC8BF1350AC9E193AA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_FD7AFA70CF561AC8BF1350AC9E193AA3_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_FD7AFA70CF561AC8BF1350AC9E193AA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_FD7AFA70CF561AC8BF1350AC9E193AA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_FD7AFA70CF561AC8BF1350AC9E193AA3" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_FD7AFA70CF561AC8BF1350AC9E193AA3" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_92E89B2394A7992A82F950AC9D02B45B_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_92E89B2394A7992A82F950AC9D02B45B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_92E89B2394A7992A82F950AC9D02B45B_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_92E89B2394A7992A82F950AC9D02B45B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_92E89B2394A7992A82F950AC9D02B45B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_92E89B2394A7992A82F950AC9D02B45B" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_92E89B2394A7992A82F950AC9D02B45B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_3646A1E8D07536DC294450AC9D0264E0_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_3646A1E8D07536DC294450AC9D0264E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_3646A1E8D07536DC294450AC9D0264E0_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_3646A1E8D07536DC294450AC9D0264E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_3646A1E8D07536DC294450AC9D0264E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_3646A1E8D07536DC294450AC9D0264E0" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_3646A1E8D07536DC294450AC9D0264E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_21EFD333955194DDE19550AC9D0293FD_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_21EFD333955194DDE19550AC9D0293FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_21EFD333955194DDE19550AC9D0293FD_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_21EFD333955194DDE19550AC9D0293FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_21EFD333955194DDE19550AC9D0293FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_21EFD333955194DDE19550AC9D0293FD" xlink:to="lab_us-gaap_PreferredStockSharesIssued_21EFD333955194DDE19550AC9D0293FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_C844CF6C481B4887A78850AC9D02E8CA_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_C844CF6C481B4887A78850AC9D02E8CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_C844CF6C481B4887A78850AC9D02E8CA_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_C844CF6C481B4887A78850AC9D02E8CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_C844CF6C481B4887A78850AC9D02E8CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_C844CF6C481B4887A78850AC9D02E8CA" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_C844CF6C481B4887A78850AC9D02E8CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_635020CF274EE9139E7250AC9D02E998_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_635020CF274EE9139E7250AC9D02E998" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_635020CF274EE9139E7250AC9D02E998_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_635020CF274EE9139E7250AC9D02E998" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_635020CF274EE9139E7250AC9D02E998" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_635020CF274EE9139E7250AC9D02E998" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_635020CF274EE9139E7250AC9D02E998" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_A9ED70EFF6FA76C80A4050AC9D02AB15_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_A9ED70EFF6FA76C80A4050AC9D02AB15" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_A9ED70EFF6FA76C80A4050AC9D02AB15_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_A9ED70EFF6FA76C80A4050AC9D02AB15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_A9ED70EFF6FA76C80A4050AC9D02AB15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_A9ED70EFF6FA76C80A4050AC9D02AB15" xlink:to="lab_us-gaap_CommonStockSharesIssued_A9ED70EFF6FA76C80A4050AC9D02AB15" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_02CC6E093967EA9A40B450AC9D02224F_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_02CC6E093967EA9A40B450AC9D02224F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_02CC6E093967EA9A40B450AC9D02224F_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_02CC6E093967EA9A40B450AC9D02224F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_02CC6E093967EA9A40B450AC9D02224F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_02CC6E093967EA9A40B450AC9D02224F" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_02CC6E093967EA9A40B450AC9D02224F" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockShares_E65610B9457379323DE550AC9D02B3CC_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares_E65610B9457379323DE550AC9D02B3CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_E65610B9457379323DE550AC9D02B3CC_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares_E65610B9457379323DE550AC9D02B3CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares_E65610B9457379323DE550AC9D02B3CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares_E65610B9457379323DE550AC9D02B3CC" xlink:to="lab_us-gaap_TreasuryStockShares_E65610B9457379323DE550AC9D02B3CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_A748004BE09C8B0B07C050AC9C8A6ECB_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_A748004BE09C8B0B07C050AC9C8A6ECB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_A748004BE09C8B0B07C050AC9C8A6ECB_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_A748004BE09C8B0B07C050AC9C8A6ECB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_A748004BE09C8B0B07C050AC9C8A6ECB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock_A748004BE09C8B0B07C050AC9C8A6ECB" xlink:to="lab_us-gaap_DebtDisclosureTextBlock_A748004BE09C8B0B07C050AC9C8A6ECB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6DEBE9C6C948FA24C018C9409BF619DB_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6DEBE9C6C948FA24C018C9409BF619DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6DEBE9C6C948FA24C018C9409BF619DB_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6DEBE9C6C948FA24C018C9409BF619DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6DEBE9C6C948FA24C018C9409BF619DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6DEBE9C6C948FA24C018C9409BF619DB" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6DEBE9C6C948FA24C018C9409BF619DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_DAEE2CBF623582D45B04C9409BF6D39E_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain_DAEE2CBF623582D45B04C9409BF6D39E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_DAEE2CBF623582D45B04C9409BF6D39E_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain_DAEE2CBF623582D45B04C9409BF6D39E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_DAEE2CBF623582D45B04C9409BF6D39E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain_DAEE2CBF623582D45B04C9409BF6D39E" xlink:to="lab_us-gaap_HedgingRelationshipDomain_DAEE2CBF623582D45B04C9409BF6D39E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashFlowHedgingMember_37BB8332D80452461AF0C9409BF60A6B_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember_37BB8332D80452461AF0C9409BF60A6B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Flow Hedging</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_37BB8332D80452461AF0C9409BF60A6B_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember_37BB8332D80452461AF0C9409BF60A6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowHedgingMember" xlink:label="loc_us-gaap_CashFlowHedgingMember_37BB8332D80452461AF0C9409BF60A6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember_37BB8332D80452461AF0C9409BF60A6B" xlink:to="lab_us-gaap_CashFlowHedgingMember_37BB8332D80452461AF0C9409BF60A6B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_49B7B052B7AEBBE1D451C9409BF66361_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_49B7B052B7AEBBE1D451C9409BF66361" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_49B7B052B7AEBBE1D451C9409BF66361_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_49B7B052B7AEBBE1D451C9409BF66361" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_49B7B052B7AEBBE1D451C9409BF66361" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_49B7B052B7AEBBE1D451C9409BF66361" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_49B7B052B7AEBBE1D451C9409BF66361" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_98AE09F23C48C07605A4C9409BF6DF1B_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_98AE09F23C48C07605A4C9409BF6DF1B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_98AE09F23C48C07605A4C9409BF6DF1B_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_98AE09F23C48C07605A4C9409BF6DF1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_98AE09F23C48C07605A4C9409BF6DF1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_98AE09F23C48C07605A4C9409BF6DF1B" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_98AE09F23C48C07605A4C9409BF6DF1B" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpenseMember_FB53E012674154AF661AC9409BF6A29E_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseMember_FB53E012674154AF661AC9409BF6A29E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseMember_FB53E012674154AF661AC9409BF6A29E_label_en-US" xlink:label="lab_us-gaap_InterestExpenseMember_FB53E012674154AF661AC9409BF6A29E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseMember" xlink:label="loc_us-gaap_InterestExpenseMember_FB53E012674154AF661AC9409BF6A29E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseMember_FB53E012674154AF661AC9409BF6A29E" xlink:to="lab_us-gaap_InterestExpenseMember_FB53E012674154AF661AC9409BF6A29E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_F0CF3ED1F5C4A768D574C9409BF6F442_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_F0CF3ED1F5C4A768D574C9409BF6F442" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative Amount of Gain/(Loss) Recognized in OCI on Derivative</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_F0CF3ED1F5C4A768D574C9409BF6F442_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_F0CF3ED1F5C4A768D574C9409BF6F442" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_F0CF3ED1F5C4A768D574C9409BF6F442" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_F0CF3ED1F5C4A768D574C9409BF6F442" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_F0CF3ED1F5C4A768D574C9409BF6F442" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_01C84B65D9F8A32A48D4C9409BF6A091_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_01C84B65D9F8A32A48D4C9409BF6A091" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of Gain/(Loss) Reclassified from Accumulated OCI into Income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_01C84B65D9F8A32A48D4C9409BF6A091_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_01C84B65D9F8A32A48D4C9409BF6A091" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_01C84B65D9F8A32A48D4C9409BF6A091" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_01C84B65D9F8A32A48D4C9409BF6A091" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_01C84B65D9F8A32A48D4C9409BF6A091" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_DF3F8ACF760233C79AFB50AC9D0F4C11_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_DF3F8ACF760233C79AFB50AC9D0F4C11" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective annual tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_DF3F8ACF760233C79AFB50AC9D0F4C11_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_DF3F8ACF760233C79AFB50AC9D0F4C11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_DF3F8ACF760233C79AFB50AC9D0F4C11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_DF3F8ACF760233C79AFB50AC9D0F4C11" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_DF3F8ACF760233C79AFB50AC9D0F4C11" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_A5EF4595F44F509550A750AC9D0F1CE9_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_A5EF4595F44F509550A750AC9D0F1CE9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discrete tax benefit</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_A5EF4595F44F509550A750AC9D0F1CE9_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_A5EF4595F44F509550A750AC9D0F1CE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_A5EF4595F44F509550A750AC9D0F1CE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_A5EF4595F44F509550A750AC9D0F1CE9" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_A5EF4595F44F509550A750AC9D0F1CE9" xlink:type="arc" />
    <link:label id="lab_dei_CoverAbstract_3D22CF21BFF7CED68A4250AC9DA74BBF_label_en-US" xlink:label="lab_dei_CoverAbstract_3D22CF21BFF7CED68A4250AC9DA74BBF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_3D22CF21BFF7CED68A4250AC9DA74BBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract_3D22CF21BFF7CED68A4250AC9DA74BBF" xlink:to="lab_dei_CoverAbstract_3D22CF21BFF7CED68A4250AC9DA74BBF" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_B225146CFC1F9DB2BE6E50AC9DA7BBE2_terseLabel_en-US" xlink:label="lab_dei_DocumentType_B225146CFC1F9DB2BE6E50AC9DA7BBE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_B225146CFC1F9DB2BE6E50AC9DA7BBE2_label_en-US" xlink:label="lab_dei_DocumentType_B225146CFC1F9DB2BE6E50AC9DA7BBE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_B225146CFC1F9DB2BE6E50AC9DA7BBE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_B225146CFC1F9DB2BE6E50AC9DA7BBE2" xlink:to="lab_dei_DocumentType_B225146CFC1F9DB2BE6E50AC9DA7BBE2" xlink:type="arc" />
    <link:label id="lab_dei_DocumentQuarterlyReport_A170CDC3BA0DCBECE75C50AC9DA79428_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport_A170CDC3BA0DCBECE75C50AC9DA79428" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_A170CDC3BA0DCBECE75C50AC9DA79428_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport_A170CDC3BA0DCBECE75C50AC9DA79428" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_A170CDC3BA0DCBECE75C50AC9DA79428" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport_A170CDC3BA0DCBECE75C50AC9DA79428" xlink:to="lab_dei_DocumentQuarterlyReport_A170CDC3BA0DCBECE75C50AC9DA79428" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_AEB470C26158D7F905B750AC9DA79164_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_AEB470C26158D7F905B750AC9DA79164" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_AEB470C26158D7F905B750AC9DA79164_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_AEB470C26158D7F905B750AC9DA79164" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_AEB470C26158D7F905B750AC9DA79164" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_AEB470C26158D7F905B750AC9DA79164" xlink:to="lab_dei_DocumentPeriodEndDate_AEB470C26158D7F905B750AC9DA79164" xlink:type="arc" />
    <link:label id="lab_dei_DocumentTransitionReport_2C8DD3EA25D3B740E99750AC9DA73B68_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport_2C8DD3EA25D3B740E99750AC9DA73B68" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_2C8DD3EA25D3B740E99750AC9DA73B68_label_en-US" xlink:label="lab_dei_DocumentTransitionReport_2C8DD3EA25D3B740E99750AC9DA73B68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_2C8DD3EA25D3B740E99750AC9DA73B68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport_2C8DD3EA25D3B740E99750AC9DA73B68" xlink:to="lab_dei_DocumentTransitionReport_2C8DD3EA25D3B740E99750AC9DA73B68" xlink:type="arc" />
    <link:label id="lab_dei_EntityFileNumber_7DD7D0EEC4EDAAF890C150AC9DA72D66_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber_7DD7D0EEC4EDAAF890C150AC9DA72D66" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_7DD7D0EEC4EDAAF890C150AC9DA72D66_label_en-US" xlink:label="lab_dei_EntityFileNumber_7DD7D0EEC4EDAAF890C150AC9DA72D66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_7DD7D0EEC4EDAAF890C150AC9DA72D66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber_7DD7D0EEC4EDAAF890C150AC9DA72D66" xlink:to="lab_dei_EntityFileNumber_7DD7D0EEC4EDAAF890C150AC9DA72D66" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_EA8D1F3563F5C0D4C4DC50AC9DA76F1C_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_EA8D1F3563F5C0D4C4DC50AC9DA76F1C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_EA8D1F3563F5C0D4C4DC50AC9DA76F1C_label_en-US" xlink:label="lab_dei_EntityRegistrantName_EA8D1F3563F5C0D4C4DC50AC9DA76F1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_EA8D1F3563F5C0D4C4DC50AC9DA76F1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_EA8D1F3563F5C0D4C4DC50AC9DA76F1C" xlink:to="lab_dei_EntityRegistrantName_EA8D1F3563F5C0D4C4DC50AC9DA76F1C" xlink:type="arc" />
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_47E79AA071E4676AB18850AC9DA72372_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_47E79AA071E4676AB18850AC9DA72372" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_47E79AA071E4676AB18850AC9DA72372_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_47E79AA071E4676AB18850AC9DA72372" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_47E79AA071E4676AB18850AC9DA72372" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode_47E79AA071E4676AB18850AC9DA72372" xlink:to="lab_dei_EntityIncorporationStateCountryCode_47E79AA071E4676AB18850AC9DA72372" xlink:type="arc" />
    <link:label id="lab_dei_EntityTaxIdentificationNumber_27D3EB38BF338127E67250AC9DA78755_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_27D3EB38BF338127E67250AC9DA78755" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_27D3EB38BF338127E67250AC9DA78755_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_27D3EB38BF338127E67250AC9DA78755" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_27D3EB38BF338127E67250AC9DA78755" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber_27D3EB38BF338127E67250AC9DA78755" xlink:to="lab_dei_EntityTaxIdentificationNumber_27D3EB38BF338127E67250AC9DA78755" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressAddressLine1_C7001EFA463CFE92577A50AC9DADAEAC_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_C7001EFA463CFE92577A50AC9DADAEAC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_C7001EFA463CFE92577A50AC9DADAEAC_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_C7001EFA463CFE92577A50AC9DADAEAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_C7001EFA463CFE92577A50AC9DADAEAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1_C7001EFA463CFE92577A50AC9DADAEAC" xlink:to="lab_dei_EntityAddressAddressLine1_C7001EFA463CFE92577A50AC9DADAEAC" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressCityOrTown_1407CECA9DD7960CB59C50AC9DADC35E_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_1407CECA9DD7960CB59C50AC9DADC35E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_1407CECA9DD7960CB59C50AC9DADC35E_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_1407CECA9DD7960CB59C50AC9DADC35E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_1407CECA9DD7960CB59C50AC9DADC35E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown_1407CECA9DD7960CB59C50AC9DADC35E" xlink:to="lab_dei_EntityAddressCityOrTown_1407CECA9DD7960CB59C50AC9DADC35E" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressStateOrProvince_6AB9405CE04D7E583FB050AC9DAE83BC_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_6AB9405CE04D7E583FB050AC9DAE83BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_6AB9405CE04D7E583FB050AC9DAE83BC_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_6AB9405CE04D7E583FB050AC9DAE83BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_6AB9405CE04D7E583FB050AC9DAE83BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince_6AB9405CE04D7E583FB050AC9DAE83BC" xlink:to="lab_dei_EntityAddressStateOrProvince_6AB9405CE04D7E583FB050AC9DAE83BC" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressPostalZipCode_AA05B107D5F87608C64E50AC9DAEA90C_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_AA05B107D5F87608C64E50AC9DAEA90C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_AA05B107D5F87608C64E50AC9DAEA90C_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_AA05B107D5F87608C64E50AC9DAEA90C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_AA05B107D5F87608C64E50AC9DAEA90C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode_AA05B107D5F87608C64E50AC9DAEA90C" xlink:to="lab_dei_EntityAddressPostalZipCode_AA05B107D5F87608C64E50AC9DAEA90C" xlink:type="arc" />
    <link:label id="lab_dei_CityAreaCode_A168A7BC961FC79D865450AC9DAED67B_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode_A168A7BC961FC79D865450AC9DAED67B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_A168A7BC961FC79D865450AC9DAED67B_label_en-US" xlink:label="lab_dei_CityAreaCode_A168A7BC961FC79D865450AC9DAED67B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_A168A7BC961FC79D865450AC9DAED67B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode_A168A7BC961FC79D865450AC9DAED67B" xlink:to="lab_dei_CityAreaCode_A168A7BC961FC79D865450AC9DAED67B" xlink:type="arc" />
    <link:label id="lab_dei_LocalPhoneNumber_20C35C2586C60FA99F5B50AC9DAE695A_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber_20C35C2586C60FA99F5B50AC9DAE695A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_20C35C2586C60FA99F5B50AC9DAE695A_label_en-US" xlink:label="lab_dei_LocalPhoneNumber_20C35C2586C60FA99F5B50AC9DAE695A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_20C35C2586C60FA99F5B50AC9DAE695A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber_20C35C2586C60FA99F5B50AC9DAE695A" xlink:to="lab_dei_LocalPhoneNumber_20C35C2586C60FA99F5B50AC9DAE695A" xlink:type="arc" />
    <link:label id="lab_dei_Security12bTitle_E2AF39F7515F053B3FFD50AC9DAE5826_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle_E2AF39F7515F053B3FFD50AC9DAE5826" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_E2AF39F7515F053B3FFD50AC9DAE5826_label_en-US" xlink:label="lab_dei_Security12bTitle_E2AF39F7515F053B3FFD50AC9DAE5826" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_E2AF39F7515F053B3FFD50AC9DAE5826" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle_E2AF39F7515F053B3FFD50AC9DAE5826" xlink:to="lab_dei_Security12bTitle_E2AF39F7515F053B3FFD50AC9DAE5826" xlink:type="arc" />
    <link:label id="lab_dei_TradingSymbol_1194FBC6510EC03035C850AC9DAEF0A4_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol_1194FBC6510EC03035C850AC9DAEF0A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_1194FBC6510EC03035C850AC9DAEF0A4_label_en-US" xlink:label="lab_dei_TradingSymbol_1194FBC6510EC03035C850AC9DAEF0A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_1194FBC6510EC03035C850AC9DAEF0A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_1194FBC6510EC03035C850AC9DAEF0A4" xlink:to="lab_dei_TradingSymbol_1194FBC6510EC03035C850AC9DAEF0A4" xlink:type="arc" />
    <link:label id="lab_dei_SecurityExchangeName_FC5D5AFD38469CC2CDAB50AC9DAF6A9F_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName_FC5D5AFD38469CC2CDAB50AC9DAF6A9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_FC5D5AFD38469CC2CDAB50AC9DAF6A9F_label_en-US" xlink:label="lab_dei_SecurityExchangeName_FC5D5AFD38469CC2CDAB50AC9DAF6A9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_FC5D5AFD38469CC2CDAB50AC9DAF6A9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName_FC5D5AFD38469CC2CDAB50AC9DAF6A9F" xlink:to="lab_dei_SecurityExchangeName_FC5D5AFD38469CC2CDAB50AC9DAF6A9F" xlink:type="arc" />
    <link:label id="lab_dei_EntityCurrentReportingStatus_0A12364BC23107D9EE8C50AC9DB0A00B_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_0A12364BC23107D9EE8C50AC9DB0A00B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_0A12364BC23107D9EE8C50AC9DB0A00B_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_0A12364BC23107D9EE8C50AC9DB0A00B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_0A12364BC23107D9EE8C50AC9DB0A00B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_0A12364BC23107D9EE8C50AC9DB0A00B" xlink:to="lab_dei_EntityCurrentReportingStatus_0A12364BC23107D9EE8C50AC9DB0A00B" xlink:type="arc" />
    <link:label id="lab_dei_EntityInteractiveDataCurrent_C1C5CD05E7FDF2007B8A50AC9DB0FB4A_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent_C1C5CD05E7FDF2007B8A50AC9DB0FB4A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_C1C5CD05E7FDF2007B8A50AC9DB0FB4A_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent_C1C5CD05E7FDF2007B8A50AC9DB0FB4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_C1C5CD05E7FDF2007B8A50AC9DB0FB4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent_C1C5CD05E7FDF2007B8A50AC9DB0FB4A" xlink:to="lab_dei_EntityInteractiveDataCurrent_C1C5CD05E7FDF2007B8A50AC9DB0FB4A" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_1A02D7C3DA05D7E6A02B50AC9DB0E297_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_1A02D7C3DA05D7E6A02B50AC9DB0E297" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_1A02D7C3DA05D7E6A02B50AC9DB0E297_label_en-US" xlink:label="lab_dei_EntityFilerCategory_1A02D7C3DA05D7E6A02B50AC9DB0E297" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_1A02D7C3DA05D7E6A02B50AC9DB0E297" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_1A02D7C3DA05D7E6A02B50AC9DB0E297" xlink:to="lab_dei_EntityFilerCategory_1A02D7C3DA05D7E6A02B50AC9DB0E297" xlink:type="arc" />
    <link:label id="lab_dei_EntitySmallBusiness_051A1203C12B1DA494C550AC9DB0771F_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness_051A1203C12B1DA494C550AC9DB0771F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_051A1203C12B1DA494C550AC9DB0771F_label_en-US" xlink:label="lab_dei_EntitySmallBusiness_051A1203C12B1DA494C550AC9DB0771F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_051A1203C12B1DA494C550AC9DB0771F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness_051A1203C12B1DA494C550AC9DB0771F" xlink:to="lab_dei_EntitySmallBusiness_051A1203C12B1DA494C550AC9DB0771F" xlink:type="arc" />
    <link:label id="lab_dei_EntityEmergingGrowthCompany_ADA731FADCB298DD0C1250AC9DB151C7_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_ADA731FADCB298DD0C1250AC9DB151C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_ADA731FADCB298DD0C1250AC9DB151C7_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_ADA731FADCB298DD0C1250AC9DB151C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_ADA731FADCB298DD0C1250AC9DB151C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_ADA731FADCB298DD0C1250AC9DB151C7" xlink:to="lab_dei_EntityEmergingGrowthCompany_ADA731FADCB298DD0C1250AC9DB151C7" xlink:type="arc" />
    <link:label id="lab_dei_EntityShellCompany_E62523FC07F92F93098550AC9DB1A26D_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany_E62523FC07F92F93098550AC9DB1A26D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_E62523FC07F92F93098550AC9DB1A26D_label_en-US" xlink:label="lab_dei_EntityShellCompany_E62523FC07F92F93098550AC9DB1A26D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_E62523FC07F92F93098550AC9DB1A26D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany_E62523FC07F92F93098550AC9DB1A26D" xlink:to="lab_dei_EntityShellCompany_E62523FC07F92F93098550AC9DB1A26D" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_834ACBDB07ADC46A3EBB50AC9DB197F2_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_834ACBDB07ADC46A3EBB50AC9DB197F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_834ACBDB07ADC46A3EBB50AC9DB197F2_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_834ACBDB07ADC46A3EBB50AC9DB197F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_834ACBDB07ADC46A3EBB50AC9DB197F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_834ACBDB07ADC46A3EBB50AC9DB197F2" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_834ACBDB07ADC46A3EBB50AC9DB197F2" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_6DFE74FF93DA14B057EB50AC9DB1B101_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_6DFE74FF93DA14B057EB50AC9DB1B101" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_6DFE74FF93DA14B057EB50AC9DB1B101_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_6DFE74FF93DA14B057EB50AC9DB1B101" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_6DFE74FF93DA14B057EB50AC9DB1B101" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_6DFE74FF93DA14B057EB50AC9DB1B101" xlink:to="lab_dei_EntityCentralIndexKey_6DFE74FF93DA14B057EB50AC9DB1B101" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_082B27168740232ED2F750AC9DB1CA11_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_082B27168740232ED2F750AC9DB1CA11" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_082B27168740232ED2F750AC9DB1CA11_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_082B27168740232ED2F750AC9DB1CA11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_082B27168740232ED2F750AC9DB1CA11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_082B27168740232ED2F750AC9DB1CA11" xlink:to="lab_dei_CurrentFiscalYearEndDate_082B27168740232ED2F750AC9DB1CA11" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_400C1CD76CB6148AEC5F50AC9DB2E114_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_400C1CD76CB6148AEC5F50AC9DB2E114" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_400C1CD76CB6148AEC5F50AC9DB2E114_label_en-US" xlink:label="lab_dei_AmendmentFlag_400C1CD76CB6148AEC5F50AC9DB2E114" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_400C1CD76CB6148AEC5F50AC9DB2E114" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_400C1CD76CB6148AEC5F50AC9DB2E114" xlink:to="lab_dei_AmendmentFlag_400C1CD76CB6148AEC5F50AC9DB2E114" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_6649AF2B248E0A152F1850AC9DB2FFD6_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_6649AF2B248E0A152F1850AC9DB2FFD6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_6649AF2B248E0A152F1850AC9DB2FFD6_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_6649AF2B248E0A152F1850AC9DB2FFD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_6649AF2B248E0A152F1850AC9DB2FFD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_6649AF2B248E0A152F1850AC9DB2FFD6" xlink:to="lab_dei_DocumentFiscalYearFocus_6649AF2B248E0A152F1850AC9DB2FFD6" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_76A7EC9FFB50C61B46E050AC9DB2E434_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_76A7EC9FFB50C61B46E050AC9DB2E434" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_76A7EC9FFB50C61B46E050AC9DB2E434_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_76A7EC9FFB50C61B46E050AC9DB2E434" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_76A7EC9FFB50C61B46E050AC9DB2E434" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_76A7EC9FFB50C61B46E050AC9DB2E434" xlink:to="lab_dei_DocumentFiscalPeriodFocus_76A7EC9FFB50C61B46E050AC9DB2E434" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_536DA0B1C3FB3BAA1B089E56B18B5A04_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_536DA0B1C3FB3BAA1B089E56B18B5A04" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_536DA0B1C3FB3BAA1B089E56B18B5A04_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_536DA0B1C3FB3BAA1B089E56B18B5A04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_536DA0B1C3FB3BAA1B089E56B18B5A04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_536DA0B1C3FB3BAA1B089E56B18B5A04" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_536DA0B1C3FB3BAA1B089E56B18B5A04" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_796A7888752E5472192650AC9D155891_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract_796A7888752E5472192650AC9D155891" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_796A7888752E5472192650AC9D155891" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_796A7888752E5472192650AC9D155891" xlink:to="lab_us-gaap_InventoryDisclosureAbstract_796A7888752E5472192650AC9D155891" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_F47845CA29EDF23D37B050AC9D16ABF9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_F47845CA29EDF23D37B050AC9D16ABF9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_F47845CA29EDF23D37B050AC9D16ABF9_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_F47845CA29EDF23D37B050AC9D16ABF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_F47845CA29EDF23D37B050AC9D16ABF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_F47845CA29EDF23D37B050AC9D16ABF9" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_F47845CA29EDF23D37B050AC9D16ABF9" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_673F8440EDCDF258BED65CDFFA8112AF_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_673F8440EDCDF258BED65CDFFA8112AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_673F8440EDCDF258BED65CDFFA8112AF_label_en-US" xlink:label="lab_us-gaap_StatementTable_673F8440EDCDF258BED65CDFFA8112AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_673F8440EDCDF258BED65CDFFA8112AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_673F8440EDCDF258BED65CDFFA8112AF" xlink:to="lab_us-gaap_StatementTable_673F8440EDCDF258BED65CDFFA8112AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_4EFA1826D5921E5D1B575CDFFA827E78_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_4EFA1826D5921E5D1B575CDFFA827E78" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_4EFA1826D5921E5D1B575CDFFA827E78_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_4EFA1826D5921E5D1B575CDFFA827E78" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4EFA1826D5921E5D1B575CDFFA827E78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4EFA1826D5921E5D1B575CDFFA827E78" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_4EFA1826D5921E5D1B575CDFFA827E78" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_BD7A6B76148DAEA3D6735CDFFA82CDCA_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_BD7A6B76148DAEA3D6735CDFFA82CDCA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_BD7A6B76148DAEA3D6735CDFFA82CDCA_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_BD7A6B76148DAEA3D6735CDFFA82CDCA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_BD7A6B76148DAEA3D6735CDFFA82CDCA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_BD7A6B76148DAEA3D6735CDFFA82CDCA" xlink:to="lab_us-gaap_EquityComponentDomain_BD7A6B76148DAEA3D6735CDFFA82CDCA" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_4FF3D5E14A095034CBDA5CDFFA821F7F_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_4FF3D5E14A095034CBDA5CDFFA821F7F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$0.001 Par Value Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_4FF3D5E14A095034CBDA5CDFFA821F7F_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_4FF3D5E14A095034CBDA5CDFFA821F7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_4FF3D5E14A095034CBDA5CDFFA821F7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_4FF3D5E14A095034CBDA5CDFFA821F7F" xlink:to="lab_us-gaap_CommonStockMember_4FF3D5E14A095034CBDA5CDFFA821F7F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_0FA707C8BA0D112B7FD65CDFFA827569_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_0FA707C8BA0D112B7FD65CDFFA827569" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_0FA707C8BA0D112B7FD65CDFFA827569_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_0FA707C8BA0D112B7FD65CDFFA827569" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_0FA707C8BA0D112B7FD65CDFFA827569" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_0FA707C8BA0D112B7FD65CDFFA827569" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_0FA707C8BA0D112B7FD65CDFFA827569" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockMember_80DFA2D4099CB4879EC45CDFFA836C3D_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember_80DFA2D4099CB4879EC45CDFFA836C3D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_80DFA2D4099CB4879EC45CDFFA836C3D_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember_80DFA2D4099CB4879EC45CDFFA836C3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_80DFA2D4099CB4879EC45CDFFA836C3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember_80DFA2D4099CB4879EC45CDFFA836C3D" xlink:to="lab_us-gaap_TreasuryStockMember_80DFA2D4099CB4879EC45CDFFA836C3D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6215B3D331BFA747E1775CDFFA83B778_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6215B3D331BFA747E1775CDFFA83B778" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6215B3D331BFA747E1775CDFFA83B778_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6215B3D331BFA747E1775CDFFA83B778" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6215B3D331BFA747E1775CDFFA83B778" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6215B3D331BFA747E1775CDFFA83B778" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6215B3D331BFA747E1775CDFFA83B778" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_CBFDB09B70E01183054F5CDFFA83D79F_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_CBFDB09B70E01183054F5CDFFA83D79F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_CBFDB09B70E01183054F5CDFFA83D79F_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_CBFDB09B70E01183054F5CDFFA83D79F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_CBFDB09B70E01183054F5CDFFA83D79F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_CBFDB09B70E01183054F5CDFFA83D79F" xlink:to="lab_us-gaap_RetainedEarningsMember_CBFDB09B70E01183054F5CDFFA83D79F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_73B9F38072A0130D748D5CDFFA837C4A_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_73B9F38072A0130D748D5CDFFA837C4A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_73B9F38072A0130D748D5CDFFA837C4A_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_73B9F38072A0130D748D5CDFFA837C4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_73B9F38072A0130D748D5CDFFA837C4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_73B9F38072A0130D748D5CDFFA837C4A" xlink:to="lab_us-gaap_StatementLineItems_73B9F38072A0130D748D5CDFFA837C4A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_20D58D5286079F7721615CDFFA838021_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_20D58D5286079F7721615CDFFA838021" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_20D58D5286079F7721615CDFFA838021_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_20D58D5286079F7721615CDFFA838021" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_20D58D5286079F7721615CDFFA838021" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_20D58D5286079F7721615CDFFA838021" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_20D58D5286079F7721615CDFFA838021" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_236D225D789B23FC11BE5CDFFA84494E_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_236D225D789B23FC11BE5CDFFA84494E" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_236D225D789B23FC11BE5CDFFA84494E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_236D225D789B23FC11BE5CDFFA84494E" xlink:to="lab_us-gaap_CommonStockSharesIssued_236D225D789B23FC11BE5CDFFA84494E" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_972889E90B0CD73B5D795CDFFA849226_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_972889E90B0CD73B5D795CDFFA849226" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_972889E90B0CD73B5D795CDFFA849226" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_972889E90B0CD73B5D795CDFFA849226" xlink:to="lab_us-gaap_StockholdersEquity_972889E90B0CD73B5D795CDFFA849226" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_CBD1CCBFB5D8B851B1B15CDFFA84DE33_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_CBD1CCBFB5D8B851B1B15CDFFA84DE33" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee equity plans activity (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_CBD1CCBFB5D8B851B1B15CDFFA84DE33_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_CBD1CCBFB5D8B851B1B15CDFFA84DE33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_CBD1CCBFB5D8B851B1B15CDFFA84DE33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_CBD1CCBFB5D8B851B1B15CDFFA84DE33" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_CBD1CCBFB5D8B851B1B15CDFFA84DE33" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_632118AED180EF7EFBFF5CDFFA847C67_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_632118AED180EF7EFBFF5CDFFA847C67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee equity plans activity</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_632118AED180EF7EFBFF5CDFFA847C67_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_632118AED180EF7EFBFF5CDFFA847C67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_632118AED180EF7EFBFF5CDFFA847C67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_632118AED180EF7EFBFF5CDFFA847C67" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_632118AED180EF7EFBFF5CDFFA847C67" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_F6FFDB03DB871B663D185CEBC339B4BD_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_F6FFDB03DB871B663D185CEBC339B4BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_F6FFDB03DB871B663D185CEBC339B4BD_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_F6FFDB03DB871B663D185CEBC339B4BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_F6FFDB03DB871B663D185CEBC339B4BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_F6FFDB03DB871B663D185CEBC339B4BD" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_F6FFDB03DB871B663D185CEBC339B4BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_0E174A1DD7B740ABC6A05CDFFA8573FA_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_0E174A1DD7B740ABC6A05CDFFA8573FA" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_0E174A1DD7B740ABC6A05CDFFA8573FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_0E174A1DD7B740ABC6A05CDFFA8573FA" xlink:to="lab_us-gaap_CommonStockSharesIssued_0E174A1DD7B740ABC6A05CDFFA8573FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_F85345A70493B4EA6BD25CDFFA85182F_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_F85345A70493B4EA6BD25CDFFA85182F" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_F85345A70493B4EA6BD25CDFFA85182F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_F85345A70493B4EA6BD25CDFFA85182F" xlink:to="lab_us-gaap_StockholdersEquity_F85345A70493B4EA6BD25CDFFA85182F" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_9EA19EF2A9B4A8309F0150AE2026F098_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_9EA19EF2A9B4A8309F0150AE2026F098" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, remaining performance obligation, expected timing of satisfaction, period</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_9EA19EF2A9B4A8309F0150AE2026F098_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_9EA19EF2A9B4A8309F0150AE2026F098" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_9EA19EF2A9B4A8309F0150AE2026F098" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_9EA19EF2A9B4A8309F0150AE2026F098" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_9EA19EF2A9B4A8309F0150AE2026F098" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_F82042A7FECCF758134450AE2026A42E_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_F82042A7FECCF758134450AE2026A42E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_F82042A7FECCF758134450AE2026A42E_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_F82042A7FECCF758134450AE2026A42E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_F82042A7FECCF758134450AE2026A42E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_F82042A7FECCF758134450AE2026A42E" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_F82042A7FECCF758134450AE2026A42E" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_34E650987B5D21F9E27250AE20278B09_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_34E650987B5D21F9E27250AE20278B09" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_34E650987B5D21F9E27250AE20278B09_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_34E650987B5D21F9E27250AE20278B09" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_34E650987B5D21F9E27250AE20278B09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_34E650987B5D21F9E27250AE20278B09" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_34E650987B5D21F9E27250AE20278B09" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_B9A925966FA44D0EDA4250AE202733C0_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_B9A925966FA44D0EDA4250AE202733C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_B9A925966FA44D0EDA4250AE202733C0_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_B9A925966FA44D0EDA4250AE202733C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_B9A925966FA44D0EDA4250AE202733C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_B9A925966FA44D0EDA4250AE202733C0" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_B9A925966FA44D0EDA4250AE202733C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_9BA650CEBBF617CFCD5150AC9D4022E3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable_9BA650CEBBF617CFCD5150AC9D4022E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_9BA650CEBBF617CFCD5150AC9D4022E3_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable_9BA650CEBBF617CFCD5150AC9D4022E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_9BA650CEBBF617CFCD5150AC9D4022E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_9BA650CEBBF617CFCD5150AC9D4022E3" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable_9BA650CEBBF617CFCD5150AC9D4022E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_ECAEA5C584C6309EBC4A50AC9D41093B_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems_ECAEA5C584C6309EBC4A50AC9D41093B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_ECAEA5C584C6309EBC4A50AC9D41093B_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems_ECAEA5C584C6309EBC4A50AC9D41093B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_ECAEA5C584C6309EBC4A50AC9D41093B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ECAEA5C584C6309EBC4A50AC9D41093B" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems_ECAEA5C584C6309EBC4A50AC9D41093B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_07BD2C0104170056189350AC9D412917_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract_07BD2C0104170056189350AC9D412917" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, term of contract</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_07BD2C0104170056189350AC9D412917_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract_07BD2C0104170056189350AC9D412917" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_07BD2C0104170056189350AC9D412917" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract_07BD2C0104170056189350AC9D412917" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract_07BD2C0104170056189350AC9D412917" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_457123CA08CFECF5E4AF50AC9D420927_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_457123CA08CFECF5E4AF50AC9D420927" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_457123CA08CFECF5E4AF50AC9D420927_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_457123CA08CFECF5E4AF50AC9D420927" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_457123CA08CFECF5E4AF50AC9D420927" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_457123CA08CFECF5E4AF50AC9D420927" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_457123CA08CFECF5E4AF50AC9D420927" xlink:type="arc" />
    <link:label id="lab_ebs_LesseeOperatingLeaseTerminationPeriod_D7CC300D5B1C88D713B150AC9D4235D5_terseLabel_en-US" xlink:label="lab_ebs_LesseeOperatingLeaseTerminationPeriod_D7CC300D5B1C88D713B150AC9D4235D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, termination period</link:label>
    <link:label id="lab_ebs_LesseeOperatingLeaseTerminationPeriod_D7CC300D5B1C88D713B150AC9D4235D5_label_en-US" xlink:label="lab_ebs_LesseeOperatingLeaseTerminationPeriod_D7CC300D5B1C88D713B150AC9D4235D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Termination Period</link:label>
    <link:label id="lab_ebs_LesseeOperatingLeaseTerminationPeriod_D7CC300D5B1C88D713B150AC9D4235D5_documentation_en-US" xlink:label="lab_ebs_LesseeOperatingLeaseTerminationPeriod_D7CC300D5B1C88D713B150AC9D4235D5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Termination Period</link:label>
    <link:loc xlink:href="ebs-20200331.xsd#ebs_LesseeOperatingLeaseTerminationPeriod" xlink:label="loc_ebs_LesseeOperatingLeaseTerminationPeriod_D7CC300D5B1C88D713B150AC9D4235D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_LesseeOperatingLeaseTerminationPeriod_D7CC300D5B1C88D713B150AC9D4235D5" xlink:to="lab_ebs_LesseeOperatingLeaseTerminationPeriod_D7CC300D5B1C88D713B150AC9D4235D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_76BA78D8AF24A6D2589250AC9CC3FD44_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_76BA78D8AF24A6D2589250AC9CC3FD44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_76BA78D8AF24A6D2589250AC9CC3FD44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_76BA78D8AF24A6D2589250AC9CC3FD44" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_76BA78D8AF24A6D2589250AC9CC3FD44" xlink:type="arc" />
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_B5BF75AA5AF685E4474B50AC9CC30C10_terseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock_B5BF75AA5AF685E4474B50AC9CC30C10" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_B5BF75AA5AF685E4474B50AC9CC30C10_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock_B5BF75AA5AF685E4474B50AC9CC30C10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_B5BF75AA5AF685E4474B50AC9CC30C10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock_B5BF75AA5AF685E4474B50AC9CC30C10" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock_B5BF75AA5AF685E4474B50AC9CC30C10" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8D776BEB6BC6990D634E9E3BC2D7CE1F_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8D776BEB6BC6990D634E9E3BC2D7CE1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8D776BEB6BC6990D634E9E3BC2D7CE1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8D776BEB6BC6990D634E9E3BC2D7CE1F" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8D776BEB6BC6990D634E9E3BC2D7CE1F" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_945BCB50BAA5672B1A2B9E3BC2D88757_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_945BCB50BAA5672B1A2B9E3BC2D88757" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_945BCB50BAA5672B1A2B9E3BC2D88757" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_945BCB50BAA5672B1A2B9E3BC2D88757" xlink:to="lab_us-gaap_NetIncomeLoss_945BCB50BAA5672B1A2B9E3BC2D88757" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_6677910F96EA707FC3889E3BC2D8CDE4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_6677910F96EA707FC3889E3BC2D8CDE4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive (loss) income, net of tax:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_6677910F96EA707FC3889E3BC2D8CDE4_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_6677910F96EA707FC3889E3BC2D8CDE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_6677910F96EA707FC3889E3BC2D8CDE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_6677910F96EA707FC3889E3BC2D8CDE4" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_6677910F96EA707FC3889E3BC2D8CDE4" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_07E947C1EB5F7CB29B189E3BC2D8BAE6_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_07E947C1EB5F7CB29B189E3BC2D8BAE6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_07E947C1EB5F7CB29B189E3BC2D8BAE6_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_07E947C1EB5F7CB29B189E3BC2D8BAE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_07E947C1EB5F7CB29B189E3BC2D8BAE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_07E947C1EB5F7CB29B189E3BC2D8BAE6" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_07E947C1EB5F7CB29B189E3BC2D8BAE6" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_FE2E1C64EF78A759B6A79E3BC2D9BD73_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_FE2E1C64EF78A759B6A79E3BC2D9BD73" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized losses on hedging activities, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_FE2E1C64EF78A759B6A79E3BC2D9BD73_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_FE2E1C64EF78A759B6A79E3BC2D9BD73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_FE2E1C64EF78A759B6A79E3BC2D9BD73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_FE2E1C64EF78A759B6A79E3BC2D9BD73" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_FE2E1C64EF78A759B6A79E3BC2D9BD73" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_57AB74D4C10EE85DD28B9E3BC2D984BF_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_57AB74D4C10EE85DD28B9E3BC2D984BF" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unrealized losses on pension benefit obligation, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_57AB74D4C10EE85DD28B9E3BC2D984BF_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_57AB74D4C10EE85DD28B9E3BC2D984BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_57AB74D4C10EE85DD28B9E3BC2D984BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_57AB74D4C10EE85DD28B9E3BC2D984BF" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_57AB74D4C10EE85DD28B9E3BC2D984BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_008680E3B6BCBBDCC9809E3BC2D95221_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_008680E3B6BCBBDCC9809E3BC2D95221" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other comprehensive (loss) income, net of tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_008680E3B6BCBBDCC9809E3BC2D95221" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_008680E3B6BCBBDCC9809E3BC2D95221" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_008680E3B6BCBBDCC9809E3BC2D95221" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_0EDD659AB5916C57D5DF9E3BC2D922E8_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_0EDD659AB5916C57D5DF9E3BC2D922E8" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_0EDD659AB5916C57D5DF9E3BC2D922E8_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_0EDD659AB5916C57D5DF9E3BC2D922E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_0EDD659AB5916C57D5DF9E3BC2D922E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_0EDD659AB5916C57D5DF9E3BC2D922E8" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_0EDD659AB5916C57D5DF9E3BC2D922E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_9C129C91522C42F8BBCE9E56B1B6B8BF_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_9C129C91522C42F8BBCE9E56B1B6B8BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of presentation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_9C129C91522C42F8BBCE9E56B1B6B8BF_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_9C129C91522C42F8BBCE9E56B1B6B8BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_9C129C91522C42F8BBCE9E56B1B6B8BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_9C129C91522C42F8BBCE9E56B1B6B8BF" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_9C129C91522C42F8BBCE9E56B1B6B8BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_6E1770C74BB9359027AB9E56B1B76BC0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_6E1770C74BB9359027AB9E56B1B76BC0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_6E1770C74BB9359027AB9E56B1B76BC0_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_6E1770C74BB9359027AB9E56B1B76BC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_6E1770C74BB9359027AB9E56B1B76BC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_6E1770C74BB9359027AB9E56B1B76BC0" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_6E1770C74BB9359027AB9E56B1B76BC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_32429552E4BEE763C4679E56B1B75702_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_32429552E4BEE763C4679E56B1B75702" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recently issued accounting standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_32429552E4BEE763C4679E56B1B75702_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_32429552E4BEE763C4679E56B1B75702" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_32429552E4BEE763C4679E56B1B75702" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_32429552E4BEE763C4679E56B1B75702" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_32429552E4BEE763C4679E56B1B75702" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3AEB026013FF109C795A9E56B1794A13_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3AEB026013FF109C795A9E56B1794A13" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3AEB026013FF109C795A9E56B1794A13_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3AEB026013FF109C795A9E56B1794A13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3AEB026013FF109C795A9E56B1794A13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3AEB026013FF109C795A9E56B1794A13" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3AEB026013FF109C795A9E56B1794A13" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8021DE5C9D40C80A4E9D9E56B1791834_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8021DE5C9D40C80A4E9D9E56B1791834" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8021DE5C9D40C80A4E9D9E56B1791834_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8021DE5C9D40C80A4E9D9E56B1791834" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8021DE5C9D40C80A4E9D9E56B1791834" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8021DE5C9D40C80A4E9D9E56B1791834" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8021DE5C9D40C80A4E9D9E56B1791834" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_9E748081E94E97B525BE9E56B179C870_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_9E748081E94E97B525BE9E56B179C870" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_9E748081E94E97B525BE9E56B179C870_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_9E748081E94E97B525BE9E56B179C870" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9E748081E94E97B525BE9E56B179C870" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9E748081E94E97B525BE9E56B179C870" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_9E748081E94E97B525BE9E56B179C870" xlink:type="arc" />
    <link:label id="lab_us-gaap_LandAndLandImprovementsMember_250E88996435BAE636EE9E56B17AC151_terseLabel_en-US" xlink:label="lab_us-gaap_LandAndLandImprovementsMember_250E88996435BAE636EE9E56B17AC151" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Land and improvements</link:label>
    <link:label id="lab_us-gaap_LandAndLandImprovementsMember_250E88996435BAE636EE9E56B17AC151_label_en-US" xlink:label="lab_us-gaap_LandAndLandImprovementsMember_250E88996435BAE636EE9E56B17AC151" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Land and Land Improvements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LandAndLandImprovementsMember" xlink:label="loc_us-gaap_LandAndLandImprovementsMember_250E88996435BAE636EE9E56B17AC151" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandAndLandImprovementsMember_250E88996435BAE636EE9E56B17AC151" xlink:to="lab_us-gaap_LandAndLandImprovementsMember_250E88996435BAE636EE9E56B17AC151" xlink:type="arc" />
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_F2108DD77B88D96FE16C9E56B17A76BA_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember_F2108DD77B88D96FE16C9E56B17A76BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Buildings, building improvements and leasehold improvements</link:label>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_F2108DD77B88D96FE16C9E56B17A76BA_label_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember_F2108DD77B88D96FE16C9E56B17A76BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Building and Building Improvements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_F2108DD77B88D96FE16C9E56B17A76BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingAndBuildingImprovementsMember_F2108DD77B88D96FE16C9E56B17A76BA" xlink:to="lab_us-gaap_BuildingAndBuildingImprovementsMember_F2108DD77B88D96FE16C9E56B17A76BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_12524A90DB9E5C26172D9E56B17A9E49_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_12524A90DB9E5C26172D9E56B17A9E49" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and equipment</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_12524A90DB9E5C26172D9E56B17A9E49_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_12524A90DB9E5C26172D9E56B17A9E49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_12524A90DB9E5C26172D9E56B17A9E49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember_12524A90DB9E5C26172D9E56B17A9E49" xlink:to="lab_us-gaap_FurnitureAndFixturesMember_12524A90DB9E5C26172D9E56B17A9E49" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_DC9DF4B643EDFC3E10BA9E56B17AA057_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_DC9DF4B643EDFC3E10BA9E56B17AA057" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Software</link:label>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_DC9DF4B643EDFC3E10BA9E56B17AA057_label_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_DC9DF4B643EDFC3E10BA9E56B17AA057" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Software, Intangible Asset [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_DC9DF4B643EDFC3E10BA9E56B17AA057" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_DC9DF4B643EDFC3E10BA9E56B17AA057" xlink:to="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_DC9DF4B643EDFC3E10BA9E56B17AA057" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConstructionInProgressMember_F99C10D86CB61E6A3C539E56B17B5E03_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember_F99C10D86CB61E6A3C539E56B17B5E03" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction-in-progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_F99C10D86CB61E6A3C539E56B17B5E03_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember_F99C10D86CB61E6A3C539E56B17B5E03" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_F99C10D86CB61E6A3C539E56B17B5E03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember_F99C10D86CB61E6A3C539E56B17B5E03" xlink:to="lab_us-gaap_ConstructionInProgressMember_F99C10D86CB61E6A3C539E56B17B5E03" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_B9189E2A52C2FC5E5C7D9E56B17B20EA_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_B9189E2A52C2FC5E5C7D9E56B17B20EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_B9189E2A52C2FC5E5C7D9E56B17B20EA_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_B9189E2A52C2FC5E5C7D9E56B17B20EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_B9189E2A52C2FC5E5C7D9E56B17B20EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_B9189E2A52C2FC5E5C7D9E56B17B20EA" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_B9189E2A52C2FC5E5C7D9E56B17B20EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract_E54D8E8C33552D4EFDA09E56B17BB017_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract_E54D8E8C33552D4EFDA09E56B17BB017" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract_E54D8E8C33552D4EFDA09E56B17BB017_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract_E54D8E8C33552D4EFDA09E56B17BB017" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_E54D8E8C33552D4EFDA09E56B17BB017" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_E54D8E8C33552D4EFDA09E56B17BB017" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract_E54D8E8C33552D4EFDA09E56B17BB017" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_4665B9B6FF5A538849D49E56B17B8616_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_4665B9B6FF5A538849D49E56B17B8616" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_4665B9B6FF5A538849D49E56B17B8616_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_4665B9B6FF5A538849D49E56B17B8616" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_4665B9B6FF5A538849D49E56B17B8616" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_4665B9B6FF5A538849D49E56B17B8616" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross_4665B9B6FF5A538849D49E56B17B8616" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_86B88581CE148E53CA779E56B17BF7B2_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_86B88581CE148E53CA779E56B17BF7B2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_86B88581CE148E53CA779E56B17BF7B2_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_86B88581CE148E53CA779E56B17BF7B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_86B88581CE148E53CA779E56B17BF7B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_86B88581CE148E53CA779E56B17BF7B2" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_86B88581CE148E53CA779E56B17BF7B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_5EADEB99DEAD9423B8449E56B17C66FD_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_5EADEB99DEAD9423B8449E56B17C66FD" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total property, plant and equipment, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5EADEB99DEAD9423B8449E56B17C66FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_5EADEB99DEAD9423B8449E56B17C66FD" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_5EADEB99DEAD9423B8449E56B17C66FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_362CFF49B1E1EA45CD0450AC9CF298F4_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock_362CFF49B1E1EA45CD0450AC9CF298F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_362CFF49B1E1EA45CD0450AC9CF298F4_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock_362CFF49B1E1EA45CD0450AC9CF298F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_362CFF49B1E1EA45CD0450AC9CF298F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock_362CFF49B1E1EA45CD0450AC9CF298F4" xlink:to="lab_us-gaap_LeaseCostTableTextBlock_362CFF49B1E1EA45CD0450AC9CF298F4" xlink:type="arc" />
    <link:label id="lab_ebs_ScheduleOfLeasesSupplementalBalanceSheetsTableTextBlock_898E0F09AA84B4409BF650AC9CF2EDBA_terseLabel_en-US" xlink:label="lab_ebs_ScheduleOfLeasesSupplementalBalanceSheetsTableTextBlock_898E0F09AA84B4409BF650AC9CF2EDBA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Leases Supplemental Balance Sheets</link:label>
    <link:label id="lab_ebs_ScheduleOfLeasesSupplementalBalanceSheetsTableTextBlock_898E0F09AA84B4409BF650AC9CF2EDBA_label_en-US" xlink:label="lab_ebs_ScheduleOfLeasesSupplementalBalanceSheetsTableTextBlock_898E0F09AA84B4409BF650AC9CF2EDBA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Leases Supplemental Balance Sheets [Table Text Block]</link:label>
    <link:label id="lab_ebs_ScheduleOfLeasesSupplementalBalanceSheetsTableTextBlock_898E0F09AA84B4409BF650AC9CF2EDBA_documentation_en-US" xlink:label="lab_ebs_ScheduleOfLeasesSupplementalBalanceSheetsTableTextBlock_898E0F09AA84B4409BF650AC9CF2EDBA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Leases Supplemental Balance Sheets [Table Text Block]</link:label>
    <link:loc xlink:href="ebs-20200331.xsd#ebs_ScheduleOfLeasesSupplementalBalanceSheetsTableTextBlock" xlink:label="loc_ebs_ScheduleOfLeasesSupplementalBalanceSheetsTableTextBlock_898E0F09AA84B4409BF650AC9CF2EDBA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ScheduleOfLeasesSupplementalBalanceSheetsTableTextBlock_898E0F09AA84B4409BF650AC9CF2EDBA" xlink:to="lab_ebs_ScheduleOfLeasesSupplementalBalanceSheetsTableTextBlock_898E0F09AA84B4409BF650AC9CF2EDBA" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_9E21F54C4AE9591E65CDBC1D23951023_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_9E21F54C4AE9591E65CDBC1D23951023" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_9E21F54C4AE9591E65CDBC1D23951023" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_9E21F54C4AE9591E65CDBC1D23951023" xlink:to="lab_us-gaap_IncomeStatementAbstract_9E21F54C4AE9591E65CDBC1D23951023" xlink:type="arc" />
    <link:label id="lab_srt_ProductOrServiceAxis_8E652C1003E8275D89B9BC1D2396D0E1_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis_8E652C1003E8275D89B9BC1D2396D0E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_8E652C1003E8275D89B9BC1D2396D0E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis_8E652C1003E8275D89B9BC1D2396D0E1" xlink:to="lab_srt_ProductOrServiceAxis_8E652C1003E8275D89B9BC1D2396D0E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenuesAbstract_502A7FC7342B13592D2EBC1D23971CA8_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_502A7FC7342B13592D2EBC1D23971CA8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_502A7FC7342B13592D2EBC1D23971CA8_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_502A7FC7342B13592D2EBC1D23971CA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_502A7FC7342B13592D2EBC1D23971CA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract_502A7FC7342B13592D2EBC1D23971CA8" xlink:to="lab_us-gaap_RevenuesAbstract_502A7FC7342B13592D2EBC1D23971CA8" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_F7B98C87F9A0D299F7CABC1D23988FC4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_F7B98C87F9A0D299F7CABC1D23988FC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_F7B98C87F9A0D299F7CABC1D23988FC4_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_F7B98C87F9A0D299F7CABC1D23988FC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_F7B98C87F9A0D299F7CABC1D23988FC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_F7B98C87F9A0D299F7CABC1D23988FC4" xlink:to="lab_us-gaap_OperatingExpensesAbstract_F7B98C87F9A0D299F7CABC1D23988FC4" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_245BC73DD9A8BE4776C7BC207D6B099E_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_245BC73DD9A8BE4776C7BC207D6B099E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of product sales and contract development and manufacturing services</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_245BC73DD9A8BE4776C7BC207D6B099E_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_245BC73DD9A8BE4776C7BC207D6B099E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_245BC73DD9A8BE4776C7BC207D6B099E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold_245BC73DD9A8BE4776C7BC207D6B099E" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold_245BC73DD9A8BE4776C7BC207D6B099E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_49A71F52BCD416A017B1BC1D2399A791_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_49A71F52BCD416A017B1BC1D2399A791" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_49A71F52BCD416A017B1BC1D2399A791_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_49A71F52BCD416A017B1BC1D2399A791" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_49A71F52BCD416A017B1BC1D2399A791" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_49A71F52BCD416A017B1BC1D2399A791" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_49A71F52BCD416A017B1BC1D2399A791" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_EB157FEED18B6F767074BC1D2399BC7E_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_EB157FEED18B6F767074BC1D2399BC7E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_EB157FEED18B6F767074BC1D2399BC7E_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_EB157FEED18B6F767074BC1D2399BC7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_EB157FEED18B6F767074BC1D2399BC7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense_EB157FEED18B6F767074BC1D2399BC7E" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense_EB157FEED18B6F767074BC1D2399BC7E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_048F8B491F7939D3BCF8BC1D23995183_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_048F8B491F7939D3BCF8BC1D23995183" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_048F8B491F7939D3BCF8BC1D23995183" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets_048F8B491F7939D3BCF8BC1D23995183" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets_048F8B491F7939D3BCF8BC1D23995183" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingCostsAndExpenses_2BE14451A51CD1D3C85DBC20B1E74AA0_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpenses_2BE14451A51CD1D3C85DBC20B1E74AA0" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingCostsAndExpenses_2BE14451A51CD1D3C85DBC20B1E74AA0_label_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpenses_2BE14451A51CD1D3C85DBC20B1E74AA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Costs and Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_2BE14451A51CD1D3C85DBC20B1E74AA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_2BE14451A51CD1D3C85DBC20B1E74AA0" xlink:to="lab_us-gaap_OperatingCostsAndExpenses_2BE14451A51CD1D3C85DBC20B1E74AA0" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_155CA80794276238DFA5BC1D23990F77_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_155CA80794276238DFA5BC1D23990F77" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_155CA80794276238DFA5BC1D23990F77_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_155CA80794276238DFA5BC1D23990F77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_155CA80794276238DFA5BC1D23990F77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_155CA80794276238DFA5BC1D23990F77" xlink:to="lab_us-gaap_OperatingIncomeLoss_155CA80794276238DFA5BC1D23990F77" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_E570DC29749B03D39542BC1D239913A0_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_E570DC29749B03D39542BC1D239913A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other (expense) income:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_E570DC29749B03D39542BC1D239913A0_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_E570DC29749B03D39542BC1D239913A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_E570DC29749B03D39542BC1D239913A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_E570DC29749B03D39542BC1D239913A0" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract_E570DC29749B03D39542BC1D239913A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpense_301E91A24798DDC339BABC1D2399B2EA_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_301E91A24798DDC339BABC1D2399B2EA" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_301E91A24798DDC339BABC1D2399B2EA_label_en-US" xlink:label="lab_us-gaap_InterestExpense_301E91A24798DDC339BABC1D2399B2EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_301E91A24798DDC339BABC1D2399B2EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_301E91A24798DDC339BABC1D2399B2EA" xlink:to="lab_us-gaap_InterestExpense_301E91A24798DDC339BABC1D2399B2EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_1741DC2A0F6642CC1C64BC1D239A4072_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_1741DC2A0F6642CC1C64BC1D239A4072" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_1741DC2A0F6642CC1C64BC1D239A4072_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_1741DC2A0F6642CC1C64BC1D239A4072" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_1741DC2A0F6642CC1C64BC1D239A4072" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_1741DC2A0F6642CC1C64BC1D239A4072" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_1741DC2A0F6642CC1C64BC1D239A4072" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_DE586ED275DE4F24CDB7BC1D239A1874_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_DE586ED275DE4F24CDB7BC1D239A1874" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other expense, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_DE586ED275DE4F24CDB7BC1D239A1874_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_DE586ED275DE4F24CDB7BC1D239A1874" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_DE586ED275DE4F24CDB7BC1D239A1874" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_DE586ED275DE4F24CDB7BC1D239A1874" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_DE586ED275DE4F24CDB7BC1D239A1874" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5DB93784C619C179491EBC1D239A5282_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5DB93784C619C179491EBC1D239A5282" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5DB93784C619C179491EBC1D239A5282_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5DB93784C619C179491EBC1D239A5282" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5DB93784C619C179491EBC1D239A5282" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5DB93784C619C179491EBC1D239A5282" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5DB93784C619C179491EBC1D239A5282" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_4094F5CB2665F197C9C1BC1D239A3D2D_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_4094F5CB2665F197C9C1BC1D239A3D2D" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_4094F5CB2665F197C9C1BC1D239A3D2D_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_4094F5CB2665F197C9C1BC1D239A3D2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4094F5CB2665F197C9C1BC1D239A3D2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_4094F5CB2665F197C9C1BC1D239A3D2D" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_4094F5CB2665F197C9C1BC1D239A3D2D" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_DB91CC66225F94FA86A1BC1D239A8724_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_DB91CC66225F94FA86A1BC1D239A8724" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_DB91CC66225F94FA86A1BC1D239A8724" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_DB91CC66225F94FA86A1BC1D239A8724" xlink:to="lab_us-gaap_NetIncomeLoss_DB91CC66225F94FA86A1BC1D239A8724" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_E66A16814A6C50352127BC1D239B4197_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_E66A16814A6C50352127BC1D239B4197" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per common share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_E66A16814A6C50352127BC1D239B4197" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_E66A16814A6C50352127BC1D239B4197" xlink:to="lab_us-gaap_EarningsPerShareAbstract_E66A16814A6C50352127BC1D239B4197" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasic_8E984D46AB3DE0FEADC2BC1D239BD33E_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_8E984D46AB3DE0FEADC2BC1D239BD33E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_8E984D46AB3DE0FEADC2BC1D239BD33E_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_8E984D46AB3DE0FEADC2BC1D239BD33E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_8E984D46AB3DE0FEADC2BC1D239BD33E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_8E984D46AB3DE0FEADC2BC1D239BD33E" xlink:to="lab_us-gaap_EarningsPerShareBasic_8E984D46AB3DE0FEADC2BC1D239BD33E" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_D2BF8ED65BAF88705CFEBC1D239BF342_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_D2BF8ED65BAF88705CFEBC1D239BF342" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_D2BF8ED65BAF88705CFEBC1D239BF342_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_D2BF8ED65BAF88705CFEBC1D239BF342" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_D2BF8ED65BAF88705CFEBC1D239BF342" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_D2BF8ED65BAF88705CFEBC1D239BF342" xlink:to="lab_us-gaap_EarningsPerShareDiluted_D2BF8ED65BAF88705CFEBC1D239BF342" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_2184440AD3B330E390E9BC1D239BD417_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_2184440AD3B330E390E9BC1D239BD417" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares used in computing loss per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_2184440AD3B330E390E9BC1D239BD417_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_2184440AD3B330E390E9BC1D239BD417" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_2184440AD3B330E390E9BC1D239BD417" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_2184440AD3B330E390E9BC1D239BD417" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_2184440AD3B330E390E9BC1D239BD417" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0A0D91DBF78A8E066B3FBC1D239BF393_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0A0D91DBF78A8E066B3FBC1D239BF393" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0A0D91DBF78A8E066B3FBC1D239BF393_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0A0D91DBF78A8E066B3FBC1D239BF393" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0A0D91DBF78A8E066B3FBC1D239BF393" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0A0D91DBF78A8E066B3FBC1D239BF393" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0A0D91DBF78A8E066B3FBC1D239BF393" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_E47D080D0B684FC6D913BC1D239C364B_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_E47D080D0B684FC6D913BC1D239C364B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_E47D080D0B684FC6D913BC1D239C364B_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_E47D080D0B684FC6D913BC1D239C364B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_E47D080D0B684FC6D913BC1D239C364B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_E47D080D0B684FC6D913BC1D239C364B" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_E47D080D0B684FC6D913BC1D239C364B" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_C92C3E86F73AB1B02F6050AC9CC721E9_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_C92C3E86F73AB1B02F6050AC9CC721E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raw materials and supplies</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_C92C3E86F73AB1B02F6050AC9CC721E9_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_C92C3E86F73AB1B02F6050AC9CC721E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials and Supplies, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_C92C3E86F73AB1B02F6050AC9CC721E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_C92C3E86F73AB1B02F6050AC9CC721E9" xlink:to="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_C92C3E86F73AB1B02F6050AC9CC721E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_0D497FA5780BFA07EDCD50AC9CC83EA7_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves_0D497FA5780BFA07EDCD50AC9CC83EA7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_0D497FA5780BFA07EDCD50AC9CC83EA7_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves_0D497FA5780BFA07EDCD50AC9CC83EA7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_0D497FA5780BFA07EDCD50AC9CC83EA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves_0D497FA5780BFA07EDCD50AC9CC83EA7" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves_0D497FA5780BFA07EDCD50AC9CC83EA7" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_BF458FB61F38B2FEC6CF50AC9CC87616_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_BF458FB61F38B2FEC6CF50AC9CC87616" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_BF458FB61F38B2FEC6CF50AC9CC87616_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_BF458FB61F38B2FEC6CF50AC9CC87616" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_BF458FB61F38B2FEC6CF50AC9CC87616" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_BF458FB61F38B2FEC6CF50AC9CC87616" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_BF458FB61F38B2FEC6CF50AC9CC87616" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_6A943C5444648999872E50AC9CC88293_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_6A943C5444648999872E50AC9CC88293" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_6A943C5444648999872E50AC9CC88293" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_6A943C5444648999872E50AC9CC88293" xlink:to="lab_us-gaap_InventoryNet_6A943C5444648999872E50AC9CC88293" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_E988C6EA8997E44BF5E99E56B1337E28_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_E988C6EA8997E44BF5E99E56B1337E28" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unobservable Input Reconciliation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_E988C6EA8997E44BF5E99E56B1337E28_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_E988C6EA8997E44BF5E99E56B1337E28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_E988C6EA8997E44BF5E99E56B1337E28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_E988C6EA8997E44BF5E99E56B1337E28" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_E988C6EA8997E44BF5E99E56B1337E28" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_A6DC5333CF7ABFE4766F9E56B1349CFC_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_A6DC5333CF7ABFE4766F9E56B1349CFC" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, beginning of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_A6DC5333CF7ABFE4766F9E56B1349CFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_A6DC5333CF7ABFE4766F9E56B1349CFC" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_A6DC5333CF7ABFE4766F9E56B1349CFC" xlink:type="arc" />
    <link:label id="lab_ebs_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue_99880F0216B4A7E973D09E56B134147C_terseLabel_en-US" xlink:label="lab_ebs_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue_99880F0216B4A7E973D09E56B134147C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value</link:label>
    <link:label id="lab_ebs_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue_99880F0216B4A7E973D09E56B134147C_label_en-US" xlink:label="lab_ebs_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue_99880F0216B4A7E973D09E56B134147C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Change In Fair Value</link:label>
    <link:label id="lab_ebs_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue_99880F0216B4A7E973D09E56B134147C_documentation_en-US" xlink:label="lab_ebs_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue_99880F0216B4A7E973D09E56B134147C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Change In Fair Value</link:label>
    <link:loc xlink:href="ebs-20200331.xsd#ebs_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue" xlink:label="loc_ebs_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue_99880F0216B4A7E973D09E56B134147C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue_99880F0216B4A7E973D09E56B134147C" xlink:to="lab_ebs_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue_99880F0216B4A7E973D09E56B134147C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_3360D2AA10C78E2A948A9E56B1343AA3_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_3360D2AA10C78E2A948A9E56B1343AA3" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_3360D2AA10C78E2A948A9E56B1343AA3_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_3360D2AA10C78E2A948A9E56B1343AA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_3360D2AA10C78E2A948A9E56B1343AA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_3360D2AA10C78E2A948A9E56B1343AA3" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_3360D2AA10C78E2A948A9E56B1343AA3" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_418BC624135549B1BD4D9E56B13487B7_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_418BC624135549B1BD4D9E56B13487B7" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_418BC624135549B1BD4D9E56B13487B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_418BC624135549B1BD4D9E56B13487B7" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_418BC624135549B1BD4D9E56B13487B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_F24435442C0670E0501650AC9D1DA806_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_F24435442C0670E0501650AC9D1DA806" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_F24435442C0670E0501650AC9D1DA806_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_F24435442C0670E0501650AC9D1DA806" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_F24435442C0670E0501650AC9D1DA806" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_F24435442C0670E0501650AC9D1DA806" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_F24435442C0670E0501650AC9D1DA806" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_6956BE7A04770778A6AA9E56701B6A09_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_6956BE7A04770778A6AA9E56701B6A09" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized losses on hedging activities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_6956BE7A04770778A6AA9E56701B6A09_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_6956BE7A04770778A6AA9E56701B6A09" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_6956BE7A04770778A6AA9E56701B6A09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_6956BE7A04770778A6AA9E56701B6A09" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_6956BE7A04770778A6AA9E56701B6A09" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax_51D67465395727AECD079E5DEE4180E9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax_51D67465395727AECD079E5DEE4180E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized losses related to foreign currency translations</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax_51D67465395727AECD079E5DEE4180E9_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax_51D67465395727AECD079E5DEE4180E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Translation Gain (Loss) Arising During Period, Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax_51D67465395727AECD079E5DEE4180E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax_51D67465395727AECD079E5DEE4180E9" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax_51D67465395727AECD079E5DEE4180E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_7CD82F037E303236280D50AC9DA34EFD_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_7CD82F037E303236280D50AC9DA34EFD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_7CD82F037E303236280D50AC9DA34EFD_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_7CD82F037E303236280D50AC9DA34EFD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_7CD82F037E303236280D50AC9DA34EFD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock_7CD82F037E303236280D50AC9DA34EFD" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock_7CD82F037E303236280D50AC9DA34EFD" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_0A9D1ECE439C603C38A150AC9C88B6C9_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_0A9D1ECE439C603C38A150AC9C88B6C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_0A9D1ECE439C603C38A150AC9C88B6C9_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_0A9D1ECE439C603C38A150AC9C88B6C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_0A9D1ECE439C603C38A150AC9C88B6C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_0A9D1ECE439C603C38A150AC9C88B6C9" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_0A9D1ECE439C603C38A150AC9C88B6C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfInterestRateDerivativesHeld_CC28A6A1360ACFDBE5399E56B1219E80_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfInterestRateDerivativesHeld_CC28A6A1360ACFDBE5399E56B1219E80" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Instruments</link:label>
    <link:label id="lab_us-gaap_NumberOfInterestRateDerivativesHeld_CC28A6A1360ACFDBE5399E56B1219E80_label_en-US" xlink:label="lab_us-gaap_NumberOfInterestRateDerivativesHeld_CC28A6A1360ACFDBE5399E56B1219E80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Interest Rate Derivatives Held</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfInterestRateDerivativesHeld" xlink:label="loc_us-gaap_NumberOfInterestRateDerivativesHeld_CC28A6A1360ACFDBE5399E56B1219E80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfInterestRateDerivativesHeld_CC28A6A1360ACFDBE5399E56B1219E80" xlink:to="lab_us-gaap_NumberOfInterestRateDerivativesHeld_CC28A6A1360ACFDBE5399E56B1219E80" xlink:type="arc" />
    <link:label id="lab_ebs_DerivativeNotionalAmount1_C29088311E848A64077B9E56B1213114_terseLabel_en-US" xlink:label="lab_ebs_DerivativeNotionalAmount1_C29088311E848A64077B9E56B1213114" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notional</link:label>
    <link:label id="lab_ebs_DerivativeNotionalAmount1_C29088311E848A64077B9E56B1213114_label_en-US" xlink:label="lab_ebs_DerivativeNotionalAmount1_C29088311E848A64077B9E56B1213114" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Notional Amount1</link:label>
    <link:label id="lab_ebs_DerivativeNotionalAmount1_C29088311E848A64077B9E56B1213114_documentation_en-US" xlink:label="lab_ebs_DerivativeNotionalAmount1_C29088311E848A64077B9E56B1213114" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derivative, Notional Amount1</link:label>
    <link:loc xlink:href="ebs-20200331.xsd#ebs_DerivativeNotionalAmount1" xlink:label="loc_ebs_DerivativeNotionalAmount1_C29088311E848A64077B9E56B1213114" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DerivativeNotionalAmount1_C29088311E848A64077B9E56B1213114" xlink:to="lab_ebs_DerivativeNotionalAmount1_C29088311E848A64077B9E56B1213114" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_E78C6EE76C3671FBC2519E3BC231BFD7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_E78C6EE76C3671FBC2519E3BC231BFD7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_E78C6EE76C3671FBC2519E3BC231BFD7_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_E78C6EE76C3671FBC2519E3BC231BFD7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_E78C6EE76C3671FBC2519E3BC231BFD7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_E78C6EE76C3671FBC2519E3BC231BFD7" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_E78C6EE76C3671FBC2519E3BC231BFD7" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_6091D9CE4181783850539E3BC231DD56_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_6091D9CE4181783850539E3BC231DD56" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_6091D9CE4181783850539E3BC231DD56_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_6091D9CE4181783850539E3BC231DD56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_6091D9CE4181783850539E3BC231DD56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_6091D9CE4181783850539E3BC231DD56" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_6091D9CE4181783850539E3BC231DD56" xlink:type="arc" />
    <link:label id="lab_ebs_OperatingLeaseOtherLiabilityCurrent_00F32F783EEB24C3BC139E3BC2324236_terseLabel_en-US" xlink:label="lab_ebs_OperatingLeaseOtherLiabilityCurrent_00F32F783EEB24C3BC139E3BC2324236" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities, current portion</link:label>
    <link:label id="lab_ebs_OperatingLeaseOtherLiabilityCurrent_00F32F783EEB24C3BC139E3BC2324236_label_en-US" xlink:label="lab_ebs_OperatingLeaseOtherLiabilityCurrent_00F32F783EEB24C3BC139E3BC2324236" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Other Liability, Current</link:label>
    <link:label id="lab_ebs_OperatingLeaseOtherLiabilityCurrent_00F32F783EEB24C3BC139E3BC2324236_documentation_en-US" xlink:label="lab_ebs_OperatingLeaseOtherLiabilityCurrent_00F32F783EEB24C3BC139E3BC2324236" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease, Other Liability, Current</link:label>
    <link:loc xlink:href="ebs-20200331.xsd#ebs_OperatingLeaseOtherLiabilityCurrent" xlink:label="loc_ebs_OperatingLeaseOtherLiabilityCurrent_00F32F783EEB24C3BC139E3BC2324236" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_OperatingLeaseOtherLiabilityCurrent_00F32F783EEB24C3BC139E3BC2324236" xlink:to="lab_ebs_OperatingLeaseOtherLiabilityCurrent_00F32F783EEB24C3BC139E3BC2324236" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_5F66FB218FFC21BE86249E3BC23263BC_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_5F66FB218FFC21BE86249E3BC23263BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_5F66FB218FFC21BE86249E3BC23263BC_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_5F66FB218FFC21BE86249E3BC23263BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_5F66FB218FFC21BE86249E3BC23263BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_5F66FB218FFC21BE86249E3BC23263BC" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_5F66FB218FFC21BE86249E3BC23263BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiability_1855AFDD7F2D359F10749E3BC232FDCF_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_1855AFDD7F2D359F10749E3BC232FDCF" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_1855AFDD7F2D359F10749E3BC232FDCF_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_1855AFDD7F2D359F10749E3BC232FDCF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_1855AFDD7F2D359F10749E3BC232FDCF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_1855AFDD7F2D359F10749E3BC232FDCF" xlink:to="lab_us-gaap_OperatingLeaseLiability_1855AFDD7F2D359F10749E3BC232FDCF" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseCostAbstract_9A717034F738F6FD0A619E3BC232316B_verboseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract_9A717034F738F6FD0A619E3BC232316B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating leases:</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostAbstract" xlink:label="loc_us-gaap_LeaseCostAbstract_9A717034F738F6FD0A619E3BC232316B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostAbstract_9A717034F738F6FD0A619E3BC232316B" xlink:to="lab_us-gaap_LeaseCostAbstract_9A717034F738F6FD0A619E3BC232316B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_B0DA386EFEEB74C46DFD9E3BC232D85A_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_B0DA386EFEEB74C46DFD9E3BC232D85A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining lease term (years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_B0DA386EFEEB74C46DFD9E3BC232D85A_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_B0DA386EFEEB74C46DFD9E3BC232D85A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_B0DA386EFEEB74C46DFD9E3BC232D85A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_B0DA386EFEEB74C46DFD9E3BC232D85A" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_B0DA386EFEEB74C46DFD9E3BC232D85A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DirectFinancingLeaseLeaseIncomeAbstract_45CBF69BB2108BBE82779E3BC23391EB_terseLabel_en-US" xlink:label="lab_us-gaap_DirectFinancingLeaseLeaseIncomeAbstract_45CBF69BB2108BBE82779E3BC23391EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating leases:</link:label>
    <link:label id="lab_us-gaap_DirectFinancingLeaseLeaseIncomeAbstract_45CBF69BB2108BBE82779E3BC23391EB_label_en-US" xlink:label="lab_us-gaap_DirectFinancingLeaseLeaseIncomeAbstract_45CBF69BB2108BBE82779E3BC23391EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Direct Financing Lease, Lease Income [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DirectFinancingLeaseLeaseIncomeAbstract" xlink:label="loc_us-gaap_DirectFinancingLeaseLeaseIncomeAbstract_45CBF69BB2108BBE82779E3BC23391EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DirectFinancingLeaseLeaseIncomeAbstract_45CBF69BB2108BBE82779E3BC23391EB" xlink:to="lab_us-gaap_DirectFinancingLeaseLeaseIncomeAbstract_45CBF69BB2108BBE82779E3BC23391EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_096F12765CD70338D6AB9E3BC2333018_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_096F12765CD70338D6AB9E3BC2333018" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_096F12765CD70338D6AB9E3BC2333018_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_096F12765CD70338D6AB9E3BC2333018" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_096F12765CD70338D6AB9E3BC2333018" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_096F12765CD70338D6AB9E3BC2333018" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_096F12765CD70338D6AB9E3BC2333018" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_EBF2D851D06B76339E229E56B1501A4E_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_EBF2D851D06B76339E229E56B1501A4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_EBF2D851D06B76339E229E56B1501A4E_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_EBF2D851D06B76339E229E56B1501A4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_EBF2D851D06B76339E229E56B1501A4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_EBF2D851D06B76339E229E56B1501A4E" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_EBF2D851D06B76339E229E56B1501A4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_E79A1D8FF731779EB656B7DCF5399AC5_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_E79A1D8FF731779EB656B7DCF5399AC5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_E79A1D8FF731779EB656B7DCF5399AC5_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_E79A1D8FF731779EB656B7DCF5399AC5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_E79A1D8FF731779EB656B7DCF5399AC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_E79A1D8FF731779EB656B7DCF5399AC5" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_E79A1D8FF731779EB656B7DCF5399AC5" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_9FB912C47D2EC06E8EA1B7DCF5396336_netLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_9FB912C47D2EC06E8EA1B7DCF5396336" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_9FB912C47D2EC06E8EA1B7DCF5396336" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_9FB912C47D2EC06E8EA1B7DCF5396336" xlink:to="lab_us-gaap_NetIncomeLoss_9FB912C47D2EC06E8EA1B7DCF5396336" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_2AB2C79AC6279FB0DC39B7DCF53F693D_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_2AB2C79AC6279FB0DC39B7DCF53F693D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_2AB2C79AC6279FB0DC39B7DCF53F693D_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_2AB2C79AC6279FB0DC39B7DCF53F693D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_2AB2C79AC6279FB0DC39B7DCF53F693D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_2AB2C79AC6279FB0DC39B7DCF53F693D" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_2AB2C79AC6279FB0DC39B7DCF53F693D" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4B465BBFE20A7E51614BB7DCF53F5192_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4B465BBFE20A7E51614BB7DCF53F5192" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average number of shares-basic (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4B465BBFE20A7E51614BB7DCF53F5192" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4B465BBFE20A7E51614BB7DCF53F5192" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4B465BBFE20A7E51614BB7DCF53F5192" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_418635E13421044C3377B7DCF53FA507_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_418635E13421044C3377B7DCF53FA507" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dilutive securities-equity awards (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_418635E13421044C3377B7DCF53FA507_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_418635E13421044C3377B7DCF53FA507" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_418635E13421044C3377B7DCF53FA507" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_418635E13421044C3377B7DCF53FA507" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_418635E13421044C3377B7DCF53FA507" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8E5B5CC6C85445EC1A26B7DCF53FFBA9_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8E5B5CC6C85445EC1A26B7DCF53FFBA9" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Weighted-average number of shares-diluted (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8E5B5CC6C85445EC1A26B7DCF53FFBA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8E5B5CC6C85445EC1A26B7DCF53FFBA9" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8E5B5CC6C85445EC1A26B7DCF53FFBA9" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasic_B2BDFA7C0E07E159A11EB7DCF5400069_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_B2BDFA7C0E07E159A11EB7DCF5400069" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share - basic (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_B2BDFA7C0E07E159A11EB7DCF5400069" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_B2BDFA7C0E07E159A11EB7DCF5400069" xlink:to="lab_us-gaap_EarningsPerShareBasic_B2BDFA7C0E07E159A11EB7DCF5400069" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_9A3FC9AD9A1BF0D1C360B7DCF54023BB_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_9A3FC9AD9A1BF0D1C360B7DCF54023BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share - diluted (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_9A3FC9AD9A1BF0D1C360B7DCF54023BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_9A3FC9AD9A1BF0D1C360B7DCF54023BB" xlink:to="lab_us-gaap_EarningsPerShareDiluted_9A3FC9AD9A1BF0D1C360B7DCF54023BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_A19B0A10EC799E60CDC2B7DCF5404A51_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_A19B0A10EC799E60CDC2B7DCF5404A51" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_A19B0A10EC799E60CDC2B7DCF5404A51_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_A19B0A10EC799E60CDC2B7DCF5404A51" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_A19B0A10EC799E60CDC2B7DCF5404A51" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_A19B0A10EC799E60CDC2B7DCF5404A51" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_A19B0A10EC799E60CDC2B7DCF5404A51" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>ebs-20200331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidation" xlink:href="ebs-20200331.xsd#BasisOfPresentationAndPrinciplesOfConsolidation" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidationDetails" xlink:href="ebs-20200331.xsd#BasisOfPresentationAndPrinciplesOfConsolidationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidationPolicies" xlink:href="ebs-20200331.xsd#BasisOfPresentationAndPrinciplesOfConsolidationPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Business" xlink:href="ebs-20200331.xsd#Business" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/BusinessDetails" xlink:href="ebs-20200331.xsd#BusinessDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CommitmentsAndContingencies" xlink:href="ebs-20200331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets" xlink:href="ebs-20200331.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="ebs-20200331.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="ebs-20200331.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" xlink:href="ebs-20200331.xsd#CondensedConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" xlink:href="ebs-20200331.xsd#CondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" xlink:href="ebs-20200331.xsd#CondensedConsolidatedStatementsOfComprehensiveIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical" xlink:href="ebs-20200331.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="ebs-20200331.xsd#CondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/ContingentConsideration" xlink:href="ebs-20200331.xsd#ContingentConsideration" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/ContingentConsiderationContingentConsiderationFairValueLevel3OfSignificantUnobservableInputsDetails" xlink:href="ebs-20200331.xsd#ContingentConsiderationContingentConsiderationFairValueLevel3OfSignificantUnobservableInputsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/ContingentConsiderationDetails" xlink:href="ebs-20200331.xsd#ContingentConsiderationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/ContingentConsiderationTables" xlink:href="ebs-20200331.xsd#ContingentConsiderationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CoverPage" xlink:href="ebs-20200331.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Debt" xlink:href="ebs-20200331.xsd#Debt" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DebtNarrativeDetails" xlink:href="ebs-20200331.xsd#DebtNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DebtScheduleDetails" xlink:href="ebs-20200331.xsd#DebtScheduleDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DebtTables" xlink:href="ebs-20200331.xsd#DebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivities" xlink:href="ebs-20200331.xsd#DerivativeInstrumentsAndHedgingActivities" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesCashFlowHedgingOnAociDetails" xlink:href="ebs-20200331.xsd#DerivativeInstrumentsAndHedgingActivitiesCashFlowHedgingOnAociDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesDerivativeDesignatedAsCashFlowHedgesDetails" xlink:href="ebs-20200331.xsd#DerivativeInstrumentsAndHedgingActivitiesDerivativeDesignatedAsCashFlowHedgesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesFairValueByBalanceSheetLocationDetails" xlink:href="ebs-20200331.xsd#DerivativeInstrumentsAndHedgingActivitiesFairValueByBalanceSheetLocationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails" xlink:href="ebs-20200331.xsd#DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesTables" xlink:href="ebs-20200331.xsd#DerivativeInstrumentsAndHedgingActivitiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IncomeTaxes" xlink:href="ebs-20200331.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IncomeTaxesDetails" xlink:href="ebs-20200331.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IntangibleAssets" xlink:href="ebs-20200331.xsd#IntangibleAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IntangibleAssetsNarrativeDetails" xlink:href="ebs-20200331.xsd#IntangibleAssetsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails" xlink:href="ebs-20200331.xsd#IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IntangibleAssetsTables" xlink:href="ebs-20200331.xsd#IntangibleAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Inventories" xlink:href="ebs-20200331.xsd#Inventories" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/InventoriesDetails" xlink:href="ebs-20200331.xsd#InventoriesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/InventoriesTables" xlink:href="ebs-20200331.xsd#InventoriesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Leases" xlink:href="ebs-20200331.xsd#Leases" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LeasesComponentsOfLeaseExpenseDetails" xlink:href="ebs-20200331.xsd#LeasesComponentsOfLeaseExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LeasesNarrativeDetails" xlink:href="ebs-20200331.xsd#LeasesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:href="ebs-20200331.xsd#LeasesSupplementalBalanceSheetInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LeasesTables" xlink:href="ebs-20200331.xsd#LeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/NetLossPerShare" xlink:href="ebs-20200331.xsd#NetLossPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/NetLossPerShareDetails" xlink:href="ebs-20200331.xsd#NetLossPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/NetLossPerShareTables" xlink:href="ebs-20200331.xsd#NetLossPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/PropertyPlantAndEquipment" xlink:href="ebs-20200331.xsd#PropertyPlantAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentDetails" xlink:href="ebs-20200331.xsd#PropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentTables" xlink:href="ebs-20200331.xsd#PropertyPlantAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenueRecognition" xlink:href="ebs-20200331.xsd#RevenueRecognition" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionAccountsReceivableDetails" xlink:href="ebs-20200331.xsd#RevenueRecognitionAccountsReceivableDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionContractLiabilitiesDetails" xlink:href="ebs-20200331.xsd#RevenueRecognitionContractLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationOfRevenueDetails" xlink:href="ebs-20200331.xsd#RevenueRecognitionDisaggregationOfRevenueDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionNarrativeDetails" xlink:href="ebs-20200331.xsd#RevenueRecognitionNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionRemainingPerformanceObligationDetails" xlink:href="ebs-20200331.xsd#RevenueRecognitionRemainingPerformanceObligationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionTables" xlink:href="ebs-20200331.xsd#RevenueRecognitionTables" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/ShareBasedCompensation" xlink:href="ebs-20200331.xsd#ShareBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/ShareBasedCompensationDetails" xlink:href="ebs-20200331.xsd#ShareBasedCompensationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_A1CEB79042559091D46A50AC9D1D9D88" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_F24435442C0670E0501650AC9D1DA806" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_A1CEB79042559091D46A50AC9D1D9D88" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_F24435442C0670E0501650AC9D1DA806" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7E8577C616A87A66E489B7DCF6465736" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="loc_us-gaap_MoneyMarketFundsAtCarryingValue_C840A0918012F2F78BFFB7DCF647EA6A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7E8577C616A87A66E489B7DCF6465736" xlink:to="loc_us-gaap_MoneyMarketFundsAtCarryingValue_C840A0918012F2F78BFFB7DCF647EA6A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidationPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_60FFF62D8A3B538849EE9E56B1B6C6A7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_9C129C91522C42F8BBCE9E56B1B6B8BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_60FFF62D8A3B538849EE9E56B1B6C6A7" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_9C129C91522C42F8BBCE9E56B1B6B8BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_6E1770C74BB9359027AB9E56B1B76BC0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_60FFF62D8A3B538849EE9E56B1B6C6A7" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_6E1770C74BB9359027AB9E56B1B76BC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_32429552E4BEE763C4679E56B1B75702" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_60FFF62D8A3B538849EE9E56B1B6C6A7" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_32429552E4BEE763C4679E56B1B75702" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Business" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2FFFD93D38BD9D1AC02350AC9CF442D5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_C1D01EBBEE47B9F346A750AC9CF482C6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2FFFD93D38BD9D1AC02350AC9CF442D5" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_C1D01EBBEE47B9F346A750AC9CF482C6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/BusinessDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0A07BCA2ACF1EA0F145DB7DCF64D2CB3" xlink:type="locator" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_NumberOfCategoriesOfPublicHealthThreats" xlink:label="loc_ebs_NumberOfCategoriesOfPublicHealthThreats_BE1E92600B51BE6BAFD5B7DCF64DD441" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0A07BCA2ACF1EA0F145DB7DCF64D2CB3" xlink:to="loc_ebs_NumberOfCategoriesOfPublicHealthThreats_BE1E92600B51BE6BAFD5B7DCF64DD441" xlink:type="arc" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_NumberOfRevenueGeneratingProducts" xlink:label="loc_ebs_NumberOfRevenueGeneratingProducts_12FD7E000DCE0CCF96A8B7E29D8A86E9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0A07BCA2ACF1EA0F145DB7DCF64D2CB3" xlink:to="loc_ebs_NumberOfRevenueGeneratingProducts_12FD7E000DCE0CCF96A8B7E29D8A86E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_87AAE758FD22D26EA89FB7DCF64E6983" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0A07BCA2ACF1EA0F145DB7DCF64D2CB3" xlink:to="loc_us-gaap_NumberOfOperatingSegments_87AAE758FD22D26EA89FB7DCF64E6983" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/CommitmentsAndContingencies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_76BA78D8AF24A6D2589250AC9CC3FD44" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_B5BF75AA5AF685E4474B50AC9CC30C10" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_76BA78D8AF24A6D2589250AC9CC3FD44" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_B5BF75AA5AF685E4474B50AC9CC30C10" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_136638A996BA9BC3BFE9B811883E00DD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_095D33ED6AAEEEEF1CC8B811883E4C21" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_136638A996BA9BC3BFE9B811883E00DD" xlink:to="loc_us-gaap_AssetsAbstract_095D33ED6AAEEEEF1CC8B811883E4C21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_9EE025FD83105B95AD41B811883EE5CD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_095D33ED6AAEEEEF1CC8B811883E4C21" xlink:to="loc_us-gaap_AssetsCurrentAbstract_9EE025FD83105B95AD41B811883EE5CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7E509F09DE49FF0ACE0EB811883F0B74" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9EE025FD83105B95AD41B811883EE5CD" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7E509F09DE49FF0ACE0EB811883F0B74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_7D2239938A0E0100B58DB811883F4CFC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9EE025FD83105B95AD41B811883EE5CD" xlink:to="loc_us-gaap_RestrictedCashCurrent_7D2239938A0E0100B58DB811883F4CFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_E9774E84F90E17DAC24AB811883FEC11" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9EE025FD83105B95AD41B811883EE5CD" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_E9774E84F90E17DAC24AB811883FEC11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_7C8DB698FA16F0872DD0B81188406886" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9EE025FD83105B95AD41B811883EE5CD" xlink:to="loc_us-gaap_InventoryNet_7C8DB698FA16F0872DD0B81188406886" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_us-gaap_IncomeTaxesReceivable_2ADD48CA504D89B4017DB8118840DF9F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9EE025FD83105B95AD41B811883EE5CD" xlink:to="loc_us-gaap_IncomeTaxesReceivable_2ADD48CA504D89B4017DB8118840DF9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_517856A1608B0ACF6CBFB81188401CF4" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9EE025FD83105B95AD41B811883EE5CD" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_517856A1608B0ACF6CBFB81188401CF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_8DE2EC5AAA6EA6B7F00AB8118840057C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9EE025FD83105B95AD41B811883EE5CD" xlink:to="loc_us-gaap_AssetsCurrent_8DE2EC5AAA6EA6B7F00AB8118840057C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3114215BDAE311EE03D5B8118840748C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_095D33ED6AAEEEEF1CC8B811883E4C21" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3114215BDAE311EE03D5B8118840748C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_015B066309A41829AE4CB8118840229B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_095D33ED6AAEEEEF1CC8B811883E4C21" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_015B066309A41829AE4CB8118840229B" xlink:type="arc" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_InProcessResearchAndDevelopment" xlink:label="loc_ebs_InProcessResearchAndDevelopment_32E8830337FBD3FB9EB5B81188418850" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_095D33ED6AAEEEEF1CC8B811883E4C21" xlink:to="loc_ebs_InProcessResearchAndDevelopment_32E8830337FBD3FB9EB5B81188418850" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_732D0FAA007FECA6586FB8118841287D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_095D33ED6AAEEEEF1CC8B811883E4C21" xlink:to="loc_us-gaap_Goodwill_732D0FAA007FECA6586FB8118841287D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_72A3AAEB9810BCB07334B81188418987" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_095D33ED6AAEEEEF1CC8B811883E4C21" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_72A3AAEB9810BCB07334B81188418987" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_F0C3968D4E3A9A0945DFB81188417787" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_095D33ED6AAEEEEF1CC8B811883E4C21" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_F0C3968D4E3A9A0945DFB81188417787" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_9D9ED4C7ED9B38988E8BB8118841C5C1" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_095D33ED6AAEEEEF1CC8B811883E4C21" xlink:to="loc_us-gaap_Assets_9D9ED4C7ED9B38988E8BB8118841C5C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9ED0BC06DBF41F316CCCB8118841DB71" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_136638A996BA9BC3BFE9B811883E00DD" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9ED0BC06DBF41F316CCCB8118841DB71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_D9980E942D6CFAB52091B81188425A79" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9ED0BC06DBF41F316CCCB8118841DB71" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_D9980E942D6CFAB52091B81188425A79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_FDEDA48ACFFC42AC4E33B8118842AC68" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_D9980E942D6CFAB52091B81188425A79" xlink:to="loc_us-gaap_AccountsPayableCurrent_FDEDA48ACFFC42AC4E33B8118842AC68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_FC0A46738A578808C890B81188427E76" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_D9980E942D6CFAB52091B81188425A79" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_FC0A46738A578808C890B81188427E76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_24E5C1CB4700BEF57F85B81188427C68" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_D9980E942D6CFAB52091B81188425A79" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_24E5C1CB4700BEF57F85B81188427C68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_D39C5A9F08DE1D9397F6B811884309CD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_D9980E942D6CFAB52091B81188425A79" xlink:to="loc_us-gaap_NotesPayableCurrent_D39C5A9F08DE1D9397F6B811884309CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_3BAA16601961E224C380B81188439514" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_D9980E942D6CFAB52091B81188425A79" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_3BAA16601961E224C380B81188439514" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_6507EA7FD738BE789845B8118843610F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_D9980E942D6CFAB52091B81188425A79" xlink:to="loc_us-gaap_LiabilitiesCurrent_6507EA7FD738BE789845B8118843610F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_36BB22436221A583BC58B8118843093D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9ED0BC06DBF41F316CCCB8118841DB71" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_36BB22436221A583BC58B8118843093D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_AB5E9E3C7057078BBE9BB8118843E4FF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9ED0BC06DBF41F316CCCB8118841DB71" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_AB5E9E3C7057078BBE9BB8118843E4FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_6F991DC8B3C87160093CB81188436D70" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9ED0BC06DBF41F316CCCB8118841DB71" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_6F991DC8B3C87160093CB81188436D70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_53EF9C0A06F4DB493ED7B811884470EE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9ED0BC06DBF41F316CCCB8118841DB71" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_53EF9C0A06F4DB493ED7B811884470EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8BFECA39DA5E51CDC856B81188447061" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9ED0BC06DBF41F316CCCB8118841DB71" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_8BFECA39DA5E51CDC856B81188447061" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_6EA3AAC019557C765E9DB81188440936" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9ED0BC06DBF41F316CCCB8118841DB71" xlink:to="loc_us-gaap_Liabilities_6EA3AAC019557C765E9DB81188440936" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_93E8E7B3CDAF5A0B9EE3B811884436F0" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9ED0BC06DBF41F316CCCB8118841DB71" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_93E8E7B3CDAF5A0B9EE3B811884436F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_91F8899655A83A2CB56EB8118844012A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_93E8E7B3CDAF5A0B9EE3B811884436F0" xlink:to="loc_us-gaap_PreferredStockValue_91F8899655A83A2CB56EB8118844012A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_DD725F1F1BCE70783561B811884461A1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_93E8E7B3CDAF5A0B9EE3B811884436F0" xlink:to="loc_us-gaap_CommonStockValue_DD725F1F1BCE70783561B811884461A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_571491ADCCF1876C2991B81188455769" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_93E8E7B3CDAF5A0B9EE3B811884436F0" xlink:to="loc_us-gaap_TreasuryStockValue_571491ADCCF1876C2991B81188455769" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_B65E4B4B4810E6F5EC5FB8118845053F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_93E8E7B3CDAF5A0B9EE3B811884436F0" xlink:to="loc_us-gaap_AdditionalPaidInCapital_B65E4B4B4810E6F5EC5FB8118845053F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_C6B1C68F1E172ED15101B811884549A3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_93E8E7B3CDAF5A0B9EE3B811884436F0" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_C6B1C68F1E172ED15101B811884549A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_AC389314260BBBCDB7CBB81188454297" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_93E8E7B3CDAF5A0B9EE3B811884436F0" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_AC389314260BBBCDB7CBB81188454297" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_1F8E072408F426C40256B81188452FE5" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_93E8E7B3CDAF5A0B9EE3B811884436F0" xlink:to="loc_us-gaap_StockholdersEquity_1F8E072408F426C40256B81188452FE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_98A1EE830A95379B794BB8118846F8B6" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9ED0BC06DBF41F316CCCB8118841DB71" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_98A1EE830A95379B794BB8118846F8B6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_D652D1FA685E3CFE764150AC9D021B33" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3A021E0260D7E2BF98F350AC9D026026" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_D652D1FA685E3CFE764150AC9D021B33" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3A021E0260D7E2BF98F350AC9D026026" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_183AB0D1342D4BA78E2050AC9D02B914" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3A021E0260D7E2BF98F350AC9D026026" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_183AB0D1342D4BA78E2050AC9D02B914" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_92E89B2394A7992A82F950AC9D02B45B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_183AB0D1342D4BA78E2050AC9D02B914" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_92E89B2394A7992A82F950AC9D02B45B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_3646A1E8D07536DC294450AC9D0264E0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_183AB0D1342D4BA78E2050AC9D02B914" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_3646A1E8D07536DC294450AC9D0264E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_21EFD333955194DDE19550AC9D0293FD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_183AB0D1342D4BA78E2050AC9D02B914" xlink:to="loc_us-gaap_PreferredStockSharesIssued_21EFD333955194DDE19550AC9D0293FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_C844CF6C481B4887A78850AC9D02E8CA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_183AB0D1342D4BA78E2050AC9D02B914" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_C844CF6C481B4887A78850AC9D02E8CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_2BACFFA338E5B6786A2950AC9D026E01" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_183AB0D1342D4BA78E2050AC9D02B914" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_2BACFFA338E5B6786A2950AC9D026E01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_635020CF274EE9139E7250AC9D02E998" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_183AB0D1342D4BA78E2050AC9D02B914" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_635020CF274EE9139E7250AC9D02E998" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_A9ED70EFF6FA76C80A4050AC9D02AB15" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_183AB0D1342D4BA78E2050AC9D02B914" xlink:to="loc_us-gaap_CommonStockSharesIssued_A9ED70EFF6FA76C80A4050AC9D02AB15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_02CC6E093967EA9A40B450AC9D02224F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_183AB0D1342D4BA78E2050AC9D02B914" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_02CC6E093967EA9A40B450AC9D02224F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares_E65610B9457379323DE550AC9D02B3CC" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_183AB0D1342D4BA78E2050AC9D02B914" xlink:to="loc_us-gaap_TreasuryStockShares_E65610B9457379323DE550AC9D02B3CC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_3AF06F290AA051C4AD76B8118808E044" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_E1131A35B668B3216E75B8118809B517" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3AF06F290AA051C4AD76B8118808E044" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_E1131A35B668B3216E75B8118809B517" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_5E0F11667945E24E671EB8118809C24C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_E1131A35B668B3216E75B8118809B517" xlink:to="loc_us-gaap_NetIncomeLoss_5E0F11667945E24E671EB8118809C24C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9C7BD1C67A05B6227466B8118809C677" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_E1131A35B668B3216E75B8118809B517" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9C7BD1C67A05B6227466B8118809C677" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_FF6CDDB0456F7781E8D9B81188091FE7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9C7BD1C67A05B6227466B8118809C677" xlink:to="loc_us-gaap_ShareBasedCompensation_FF6CDDB0456F7781E8D9B81188091FE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_9E70CF8E658EC36386D8B811880AFAA8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9C7BD1C67A05B6227466B8118809C677" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_9E70CF8E658EC36386D8B811880AFAA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_1F47647EEF41F7C7685BB811880A75C5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9C7BD1C67A05B6227466B8118809C677" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_1F47647EEF41F7C7685BB811880A75C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_F0B2E832ADE44CE67488B811880A4B90" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9C7BD1C67A05B6227466B8118809C677" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_F0B2E832ADE44CE67488B811880A4B90" xlink:type="arc" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_ChangeInFairValueOfContingentConsideration" xlink:label="loc_ebs_ChangeInFairValueOfContingentConsideration_21A546A0158047A9CE41B811880A724C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9C7BD1C67A05B6227466B8118809C677" xlink:to="loc_ebs_ChangeInFairValueOfContingentConsideration_21A546A0158047A9CE41B811880A724C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_35D0101F9CE7843CDEECB811880A9CA6" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9C7BD1C67A05B6227466B8118809C677" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_35D0101F9CE7843CDEECB811880A9CA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4CC77432963443BA9B3FB811880A200C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9C7BD1C67A05B6227466B8118809C677" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4CC77432963443BA9B3FB811880A200C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8C31B3F0A3815D130AD4B811880B4B81" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4CC77432963443BA9B3FB811880A200C" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8C31B3F0A3815D130AD4B811880B4B81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_2E5C9B78CF4032794036B811880BB5C4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4CC77432963443BA9B3FB811880A200C" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_2E5C9B78CF4032794036B811880BB5C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_EC5C7757B82732BDC60BB811880B3EE4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4CC77432963443BA9B3FB811880A200C" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_EC5C7757B82732BDC60BB811880B3EE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_1E5847B602B1A82F0817B811880BF5FC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4CC77432963443BA9B3FB811880A200C" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_1E5847B602B1A82F0817B811880BF5FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_E3EE31C4CC33BCC6B4FCB811880B1F85" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4CC77432963443BA9B3FB811880A200C" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_E3EE31C4CC33BCC6B4FCB811880B1F85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_16F2F2AF5DA671D6D1BEB811880C9860" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4CC77432963443BA9B3FB811880A200C" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_16F2F2AF5DA671D6D1BEB811880C9860" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_5B3889AC20CA7DF62A25B811880CD918" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4CC77432963443BA9B3FB811880A200C" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_5B3889AC20CA7DF62A25B811880CD918" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_74A3A47001A41393E100B811880CF3D6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_E1131A35B668B3216E75B8118809B517" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_74A3A47001A41393E100B811880CF3D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_E55BBBF8447A7873959DB811880C48DA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3AF06F290AA051C4AD76B8118808E044" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_E55BBBF8447A7873959DB811880C48DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_969F51FADE634ADA8A55B811880CA1BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_E55BBBF8447A7873959DB811880C48DA" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_969F51FADE634ADA8A55B811880CA1BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7A3C985E8D2C58B77223B811880D8E52" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_E55BBBF8447A7873959DB811880C48DA" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7A3C985E8D2C58B77223B811880D8E52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D1E8951034D6B23D4DAAB811880D16D8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3AF06F290AA051C4AD76B8118808E044" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D1E8951034D6B23D4DAAB811880D16D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_CE24924B5728B207150EB811880D19EF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D1E8951034D6B23D4DAAB811880D16D8" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_CE24924B5728B207150EB811880D19EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_1DB04C98CBF6739CBF2AB811880E79CB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D1E8951034D6B23D4DAAB811880D16D8" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_1DB04C98CBF6739CBF2AB811880E79CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfMediumTermNotes" xlink:label="loc_us-gaap_RepaymentsOfMediumTermNotes_24B0B12A224EF465A61EB811880EC348" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D1E8951034D6B23D4DAAB811880D16D8" xlink:to="loc_us-gaap_RepaymentsOfMediumTermNotes_24B0B12A224EF465A61EB811880EC348" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_93B11A6AAF28EB45EBC3B811880EA9BB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D1E8951034D6B23D4DAAB811880D16D8" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_93B11A6AAF28EB45EBC3B811880EA9BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_FAEA47A6B700F2048637B811880EA21C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D1E8951034D6B23D4DAAB811880D16D8" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_FAEA47A6B700F2048637B811880EA21C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_6098D00F2EB3BDB06EC5B811880E5262" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D1E8951034D6B23D4DAAB811880D16D8" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_6098D00F2EB3BDB06EC5B811880E5262" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_072ED0E87F0F49EF4646B811880EBFAD" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D1E8951034D6B23D4DAAB811880D16D8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_072ED0E87F0F49EF4646B811880EBFAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_32C911DF8D97FFAA5DF9B811880F677D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3AF06F290AA051C4AD76B8118808E044" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_32C911DF8D97FFAA5DF9B811880F677D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_241D5BC6D587E5BBB7B6B811880FFE2F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3AF06F290AA051C4AD76B8118808E044" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_241D5BC6D587E5BBB7B6B811880FFE2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_AAB68CB76E59EBAE0998B811880FBEAC" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3AF06F290AA051C4AD76B8118808E044" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_AAB68CB76E59EBAE0998B811880FBEAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_A3240B527306660EA19FB811880FE41D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3AF06F290AA051C4AD76B8118808E044" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_A3240B527306660EA19FB811880FE41D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_3C86CFD560A5260CFA78B811880FA9BF" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3AF06F290AA051C4AD76B8118808E044" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_3C86CFD560A5260CFA78B811880FA9BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_9B4CC952D5F0ECB1BD04B811881068EF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_3C86CFD560A5260CFA78B811880FA9BF" xlink:to="loc_us-gaap_InterestPaidNet_9B4CC952D5F0ECB1BD04B811881068EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_F1197754E6693E61BF38B81188101979" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_3C86CFD560A5260CFA78B811880FA9BF" xlink:to="loc_us-gaap_IncomeTaxesPaid_F1197754E6693E61BF38B81188101979" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_F8EBAF8AEF38DB6588CEB8118810E4B2" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3AF06F290AA051C4AD76B8118808E044" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_F8EBAF8AEF38DB6588CEB8118810E4B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_0648ABD922D3A8314633B8118810780E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_F8EBAF8AEF38DB6588CEB8118810E4B2" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_0648ABD922D3A8314633B8118810780E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_1E632CFF27C086C69A82B8118810BC1B" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3AF06F290AA051C4AD76B8118808E044" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_1E632CFF27C086C69A82B8118810BC1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9787559967F0A4DEF028B8118811AA93" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_1E632CFF27C086C69A82B8118810BC1B" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9787559967F0A4DEF028B8118811AA93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_4E7F3799594F52B92C81B811881184BF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_1E632CFF27C086C69A82B8118810BC1B" xlink:to="loc_us-gaap_RestrictedCashCurrent_4E7F3799594F52B92C81B811881184BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_C6D33E93701C186C905DB8118811243E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_1E632CFF27C086C69A82B8118810BC1B" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_C6D33E93701C186C905DB8118811243E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_C69A3237DC75BA187E075CDFFA81FA58" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_673F8440EDCDF258BED65CDFFA8112AF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_C69A3237DC75BA187E075CDFFA81FA58" xlink:to="loc_us-gaap_StatementTable_673F8440EDCDF258BED65CDFFA8112AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4EFA1826D5921E5D1B575CDFFA827E78" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_673F8440EDCDF258BED65CDFFA8112AF" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4EFA1826D5921E5D1B575CDFFA827E78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_BD7A6B76148DAEA3D6735CDFFA82CDCA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4EFA1826D5921E5D1B575CDFFA827E78" xlink:to="loc_us-gaap_EquityComponentDomain_BD7A6B76148DAEA3D6735CDFFA82CDCA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_4FF3D5E14A095034CBDA5CDFFA821F7F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_BD7A6B76148DAEA3D6735CDFFA82CDCA" xlink:to="loc_us-gaap_CommonStockMember_4FF3D5E14A095034CBDA5CDFFA821F7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_0FA707C8BA0D112B7FD65CDFFA827569" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_BD7A6B76148DAEA3D6735CDFFA82CDCA" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_0FA707C8BA0D112B7FD65CDFFA827569" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_80DFA2D4099CB4879EC45CDFFA836C3D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_BD7A6B76148DAEA3D6735CDFFA82CDCA" xlink:to="loc_us-gaap_TreasuryStockMember_80DFA2D4099CB4879EC45CDFFA836C3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6215B3D331BFA747E1775CDFFA83B778" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_BD7A6B76148DAEA3D6735CDFFA82CDCA" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6215B3D331BFA747E1775CDFFA83B778" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_CBFDB09B70E01183054F5CDFFA83D79F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_BD7A6B76148DAEA3D6735CDFFA82CDCA" xlink:to="loc_us-gaap_RetainedEarningsMember_CBFDB09B70E01183054F5CDFFA83D79F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_73B9F38072A0130D748D5CDFFA837C4A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_673F8440EDCDF258BED65CDFFA8112AF" xlink:to="loc_us-gaap_StatementLineItems_73B9F38072A0130D748D5CDFFA837C4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_20D58D5286079F7721615CDFFA838021" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_73B9F38072A0130D748D5CDFFA837C4A" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_20D58D5286079F7721615CDFFA838021" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_236D225D789B23FC11BE5CDFFA84494E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_20D58D5286079F7721615CDFFA838021" xlink:to="loc_us-gaap_CommonStockSharesIssued_236D225D789B23FC11BE5CDFFA84494E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_972889E90B0CD73B5D795CDFFA849226" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_20D58D5286079F7721615CDFFA838021" xlink:to="loc_us-gaap_StockholdersEquity_972889E90B0CD73B5D795CDFFA849226" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_CBD1CCBFB5D8B851B1B15CDFFA84DE33" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_20D58D5286079F7721615CDFFA838021" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_CBD1CCBFB5D8B851B1B15CDFFA84DE33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_632118AED180EF7EFBFF5CDFFA847C67" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_20D58D5286079F7721615CDFFA838021" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_632118AED180EF7EFBFF5CDFFA847C67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_CC69E37BC8E643CE4C045CDFFA841EA5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_20D58D5286079F7721615CDFFA838021" xlink:to="loc_us-gaap_NetIncomeLoss_CC69E37BC8E643CE4C045CDFFA841EA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_F6FFDB03DB871B663D185CEBC339B4BD" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_20D58D5286079F7721615CDFFA838021" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_F6FFDB03DB871B663D185CEBC339B4BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_0E174A1DD7B740ABC6A05CDFFA8573FA" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_20D58D5286079F7721615CDFFA838021" xlink:to="loc_us-gaap_CommonStockSharesIssued_0E174A1DD7B740ABC6A05CDFFA8573FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_F85345A70493B4EA6BD25CDFFA85182F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_20D58D5286079F7721615CDFFA838021" xlink:to="loc_us-gaap_StockholdersEquity_F85345A70493B4EA6BD25CDFFA85182F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_DFC5F6F34FC96B03AAD47A38D3CBB676" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_83E89AD8E4C68BBEF10B7A3946B7DB1A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_DFC5F6F34FC96B03AAD47A38D3CBB676" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_83E89AD8E4C68BBEF10B7A3946B7DB1A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8D776BEB6BC6990D634E9E3BC2D7CE1F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_945BCB50BAA5672B1A2B9E3BC2D88757" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8D776BEB6BC6990D634E9E3BC2D7CE1F" xlink:to="loc_us-gaap_NetIncomeLoss_945BCB50BAA5672B1A2B9E3BC2D88757" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_6677910F96EA707FC3889E3BC2D8CDE4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8D776BEB6BC6990D634E9E3BC2D7CE1F" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_6677910F96EA707FC3889E3BC2D8CDE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_07E947C1EB5F7CB29B189E3BC2D8BAE6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_6677910F96EA707FC3889E3BC2D8CDE4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_07E947C1EB5F7CB29B189E3BC2D8BAE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_FE2E1C64EF78A759B6A79E3BC2D9BD73" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_6677910F96EA707FC3889E3BC2D8CDE4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_FE2E1C64EF78A759B6A79E3BC2D9BD73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_57AB74D4C10EE85DD28B9E3BC2D984BF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_6677910F96EA707FC3889E3BC2D8CDE4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_57AB74D4C10EE85DD28B9E3BC2D984BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_008680E3B6BCBBDCC9809E3BC2D95221" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_6677910F96EA707FC3889E3BC2D8CDE4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_008680E3B6BCBBDCC9809E3BC2D95221" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_0EDD659AB5916C57D5DF9E3BC2D922E8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8D776BEB6BC6990D634E9E3BC2D7CE1F" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_0EDD659AB5916C57D5DF9E3BC2D922E8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_D827BE78349B9FBA51B49E55C80F4F0C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_6956BE7A04770778A6AA9E56701B6A09" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_D827BE78349B9FBA51B49E55C80F4F0C" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_6956BE7A04770778A6AA9E56701B6A09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax_51D67465395727AECD079E5DEE4180E9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_D827BE78349B9FBA51B49E55C80F4F0C" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax_51D67465395727AECD079E5DEE4180E9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_9E21F54C4AE9591E65CDBC1D23951023" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_7A0B2945B5EC8FF5B112BC1D2396A082" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9E21F54C4AE9591E65CDBC1D23951023" xlink:to="loc_us-gaap_StatementTable_7A0B2945B5EC8FF5B112BC1D2396A082" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_8E652C1003E8275D89B9BC1D2396D0E1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7A0B2945B5EC8FF5B112BC1D2396A082" xlink:to="loc_srt_ProductOrServiceAxis_8E652C1003E8275D89B9BC1D2396D0E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_E5EE7A9B6C69C2A6F259BC1D23965CED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_8E652C1003E8275D89B9BC1D2396D0E1" xlink:to="loc_srt_ProductsAndServicesDomain_E5EE7A9B6C69C2A6F259BC1D23965CED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_5B617E52A2EA721BFC61BC1D23964562" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_E5EE7A9B6C69C2A6F259BC1D23965CED" xlink:to="loc_us-gaap_ProductMember_5B617E52A2EA721BFC61BC1D23964562" xlink:type="arc" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_ContractManufacturingMember" xlink:label="loc_ebs_ContractManufacturingMember_5B1BFFDF3CA395FBC448BC1D23979A92" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_E5EE7A9B6C69C2A6F259BC1D23965CED" xlink:to="loc_ebs_ContractManufacturingMember_5B1BFFDF3CA395FBC448BC1D23979A92" xlink:type="arc" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_ContractsAndGrantsMember" xlink:label="loc_ebs_ContractsAndGrantsMember_B29B9756A6DA935CABB8BC1D239702BC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_E5EE7A9B6C69C2A6F259BC1D23965CED" xlink:to="loc_ebs_ContractsAndGrantsMember_B29B9756A6DA935CABB8BC1D239702BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_89A18430FE3BA17BA5BABC1D2397A4C1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7A0B2945B5EC8FF5B112BC1D2396A082" xlink:to="loc_us-gaap_StatementLineItems_89A18430FE3BA17BA5BABC1D2397A4C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_502A7FC7342B13592D2EBC1D23971CA8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_89A18430FE3BA17BA5BABC1D2397A4C1" xlink:to="loc_us-gaap_RevenuesAbstract_502A7FC7342B13592D2EBC1D23971CA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_DB4E042F8EE4213A8DB2BC1D23986AFF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_502A7FC7342B13592D2EBC1D23971CA8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_DB4E042F8EE4213A8DB2BC1D23986AFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_F7B98C87F9A0D299F7CABC1D23988FC4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_89A18430FE3BA17BA5BABC1D2397A4C1" xlink:to="loc_us-gaap_OperatingExpensesAbstract_F7B98C87F9A0D299F7CABC1D23988FC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_245BC73DD9A8BE4776C7BC207D6B099E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_F7B98C87F9A0D299F7CABC1D23988FC4" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_245BC73DD9A8BE4776C7BC207D6B099E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_49A71F52BCD416A017B1BC1D2399A791" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_F7B98C87F9A0D299F7CABC1D23988FC4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_49A71F52BCD416A017B1BC1D2399A791" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_EB157FEED18B6F767074BC1D2399BC7E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_F7B98C87F9A0D299F7CABC1D23988FC4" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_EB157FEED18B6F767074BC1D2399BC7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_048F8B491F7939D3BCF8BC1D23995183" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_F7B98C87F9A0D299F7CABC1D23988FC4" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_048F8B491F7939D3BCF8BC1D23995183" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_2BE14451A51CD1D3C85DBC20B1E74AA0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_F7B98C87F9A0D299F7CABC1D23988FC4" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_2BE14451A51CD1D3C85DBC20B1E74AA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_155CA80794276238DFA5BC1D23990F77" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_89A18430FE3BA17BA5BABC1D2397A4C1" xlink:to="loc_us-gaap_OperatingIncomeLoss_155CA80794276238DFA5BC1D23990F77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_E570DC29749B03D39542BC1D239913A0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_89A18430FE3BA17BA5BABC1D2397A4C1" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_E570DC29749B03D39542BC1D239913A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_301E91A24798DDC339BABC1D2399B2EA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_E570DC29749B03D39542BC1D239913A0" xlink:to="loc_us-gaap_InterestExpense_301E91A24798DDC339BABC1D2399B2EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_1741DC2A0F6642CC1C64BC1D239A4072" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_E570DC29749B03D39542BC1D239913A0" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_1741DC2A0F6642CC1C64BC1D239A4072" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_DE586ED275DE4F24CDB7BC1D239A1874" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_E570DC29749B03D39542BC1D239913A0" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_DE586ED275DE4F24CDB7BC1D239A1874" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5DB93784C619C179491EBC1D239A5282" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_89A18430FE3BA17BA5BABC1D2397A4C1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5DB93784C619C179491EBC1D239A5282" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4094F5CB2665F197C9C1BC1D239A3D2D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_89A18430FE3BA17BA5BABC1D2397A4C1" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4094F5CB2665F197C9C1BC1D239A3D2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_DB91CC66225F94FA86A1BC1D239A8724" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_89A18430FE3BA17BA5BABC1D2397A4C1" xlink:to="loc_us-gaap_NetIncomeLoss_DB91CC66225F94FA86A1BC1D239A8724" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_E66A16814A6C50352127BC1D239B4197" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_89A18430FE3BA17BA5BABC1D2397A4C1" xlink:to="loc_us-gaap_EarningsPerShareAbstract_E66A16814A6C50352127BC1D239B4197" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_8E984D46AB3DE0FEADC2BC1D239BD33E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_E66A16814A6C50352127BC1D239B4197" xlink:to="loc_us-gaap_EarningsPerShareBasic_8E984D46AB3DE0FEADC2BC1D239BD33E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_D2BF8ED65BAF88705CFEBC1D239BF342" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_E66A16814A6C50352127BC1D239B4197" xlink:to="loc_us-gaap_EarningsPerShareDiluted_D2BF8ED65BAF88705CFEBC1D239BF342" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_2184440AD3B330E390E9BC1D239BD417" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_89A18430FE3BA17BA5BABC1D2397A4C1" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_2184440AD3B330E390E9BC1D239BD417" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0A0D91DBF78A8E066B3FBC1D239BF393" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_2184440AD3B330E390E9BC1D239BD417" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0A0D91DBF78A8E066B3FBC1D239BF393" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_E47D080D0B684FC6D913BC1D239C364B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_2184440AD3B330E390E9BC1D239BD417" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_E47D080D0B684FC6D913BC1D239C364B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/ContingentConsideration" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_82CFD1FC17C7375EE7599E56B13B1C9F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_935DF722D95D86EF866C9E56B13CA2A9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_82CFD1FC17C7375EE7599E56B13B1C9F" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_935DF722D95D86EF866C9E56B13CA2A9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/ContingentConsiderationContingentConsiderationFairValueLevel3OfSignificantUnobservableInputsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_D8392ED7FC7F9F921073B7FBB3D1B05F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_236089CBDF20EF36E294B803467124E2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_D8392ED7FC7F9F921073B7FBB3D1B05F" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_236089CBDF20EF36E294B803467124E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="loc_us-gaap_ValuationTechniqueAxis_EF83DF043E1ECF00670DB8065D013987" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_236089CBDF20EF36E294B803467124E2" xlink:to="loc_us-gaap_ValuationTechniqueAxis_EF83DF043E1ECF00670DB8065D013987" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="loc_us-gaap_ValuationTechniqueDomain_7B72E3A8790D428B4C23B80BB11CB440" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_EF83DF043E1ECF00670DB8065D013987" xlink:to="loc_us-gaap_ValuationTechniqueDomain_7B72E3A8790D428B4C23B80BB11CB440" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_D72B73EB6651F51BCBCBB8067FE4EFFF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_7B72E3A8790D428B4C23B80BB11CB440" xlink:to="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_D72B73EB6651F51BCBCBB8067FE4EFFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_AB9C5A6A385EED76D82CB8059EAEFCCD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_236089CBDF20EF36E294B803467124E2" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_AB9C5A6A385EED76D82CB8059EAEFCCD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3DA9064A21A72084EAFCB8059EAF5C9C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_AB9C5A6A385EED76D82CB8059EAEFCCD" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3DA9064A21A72084EAFCB8059EAF5C9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_290F8BD4B8BCA9EC6216B805B8956BE5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3DA9064A21A72084EAFCB8059EAF5C9C" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_290F8BD4B8BCA9EC6216B805B8956BE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_62AD8D608833DCC3ED0EB804504BC8CC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_236089CBDF20EF36E294B803467124E2" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_62AD8D608833DCC3ED0EB804504BC8CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_FF0844313C3F347F269EB804504C4E41" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_62AD8D608833DCC3ED0EB804504BC8CC" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_FF0844313C3F347F269EB804504C4E41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_D3E548E7A03A3FF533F0B80468F1E72A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_FF0844313C3F347F269EB804504C4E41" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_D3E548E7A03A3FF533F0B80468F1E72A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_77FFDED8ACB36A47DECEB803F3926C19" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_236089CBDF20EF36E294B803467124E2" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_77FFDED8ACB36A47DECEB803F3926C19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1BAF448C6CBD73AE3E9BB803F393EA0F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_77FFDED8ACB36A47DECEB803F3926C19" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1BAF448C6CBD73AE3E9BB803F393EA0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_DEECD93DCAC19130E576B804CA401238" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1BAF448C6CBD73AE3E9BB803F393EA0F" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_DEECD93DCAC19130E576B804CA401238" xlink:type="arc" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_MeasurementInputProbabilityofPaymentMember" xlink:label="loc_ebs_MeasurementInputProbabilityofPaymentMember_F57AB88BAAA3D866D3BDB80569AA22EC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1BAF448C6CBD73AE3E9BB803F393EA0F" xlink:to="loc_ebs_MeasurementInputProbabilityofPaymentMember_F57AB88BAAA3D866D3BDB80569AA22EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_9FAABD94B406FE04D17BB803675D89C1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_236089CBDF20EF36E294B803467124E2" xlink:to="loc_srt_RangeAxis_9FAABD94B406FE04D17BB803675D89C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_3221BF2139081BCD7FDBB803676098C8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9FAABD94B406FE04D17BB803675D89C1" xlink:to="loc_srt_RangeMember_3221BF2139081BCD7FDBB803676098C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_0BEFCF030B2FC54E678DB80B36E8E6ED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3221BF2139081BCD7FDBB803676098C8" xlink:to="loc_srt_MinimumMember_0BEFCF030B2FC54E678DB80B36E8E6ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_2D6890618CB02181720FB80B575CED76" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3221BF2139081BCD7FDBB803676098C8" xlink:to="loc_srt_MaximumMember_2D6890618CB02181720FB80B575CED76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_WeightedAverageMember" xlink:label="loc_srt_WeightedAverageMember_572F882FFB805363501FB8038AEB0E70" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3221BF2139081BCD7FDBB803676098C8" xlink:to="loc_srt_WeightedAverageMember_572F882FFB805363501FB8038AEB0E70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_6B0D3A79C04942BDC4A3B80346843B38" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_236089CBDF20EF36E294B803467124E2" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_6B0D3A79C04942BDC4A3B80346843B38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6F132EA61C39EBA3F93AB7FC4F53F330" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_6B0D3A79C04942BDC4A3B80346843B38" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6F132EA61C39EBA3F93AB7FC4F53F330" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_080D29F44AC057F86E70B802812E93C0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_6B0D3A79C04942BDC4A3B80346843B38" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_080D29F44AC057F86E70B802812E93C0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/ContingentConsiderationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_74707AB357EA170749A39E56B133BD12" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_E988C6EA8997E44BF5E99E56B1337E28" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_74707AB357EA170749A39E56B133BD12" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_E988C6EA8997E44BF5E99E56B1337E28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_A6DC5333CF7ABFE4766F9E56B1349CFC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_E988C6EA8997E44BF5E99E56B1337E28" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_A6DC5333CF7ABFE4766F9E56B1349CFC" xlink:type="arc" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue" xlink:label="loc_ebs_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue_99880F0216B4A7E973D09E56B134147C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_E988C6EA8997E44BF5E99E56B1337E28" xlink:to="loc_ebs_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue_99880F0216B4A7E973D09E56B134147C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_3360D2AA10C78E2A948A9E56B1343AA3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_E988C6EA8997E44BF5E99E56B1337E28" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_3360D2AA10C78E2A948A9E56B1343AA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_418BC624135549B1BD4D9E56B13487B7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_E988C6EA8997E44BF5E99E56B1337E28" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_418BC624135549B1BD4D9E56B13487B7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/ContingentConsiderationTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8A5CD3FD2DCFA0BB6165BEB4C4E3ED29" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_15EAB90AF61A935AEEFABEB4C4E33628" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8A5CD3FD2DCFA0BB6165BEB4C4E3ED29" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_15EAB90AF61A935AEEFABEB4C4E33628" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_A325C439637C8AAEF9BABEB5235F6157" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8A5CD3FD2DCFA0BB6165BEB4C4E3ED29" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_A325C439637C8AAEF9BABEB5235F6157" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_3D22CF21BFF7CED68A4250AC9DA74BBF" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_B225146CFC1F9DB2BE6E50AC9DA7BBE2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3D22CF21BFF7CED68A4250AC9DA74BBF" xlink:to="loc_dei_DocumentType_B225146CFC1F9DB2BE6E50AC9DA7BBE2" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_A170CDC3BA0DCBECE75C50AC9DA79428" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3D22CF21BFF7CED68A4250AC9DA74BBF" xlink:to="loc_dei_DocumentQuarterlyReport_A170CDC3BA0DCBECE75C50AC9DA79428" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_AEB470C26158D7F905B750AC9DA79164" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3D22CF21BFF7CED68A4250AC9DA74BBF" xlink:to="loc_dei_DocumentPeriodEndDate_AEB470C26158D7F905B750AC9DA79164" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_2C8DD3EA25D3B740E99750AC9DA73B68" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3D22CF21BFF7CED68A4250AC9DA74BBF" xlink:to="loc_dei_DocumentTransitionReport_2C8DD3EA25D3B740E99750AC9DA73B68" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_7DD7D0EEC4EDAAF890C150AC9DA72D66" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3D22CF21BFF7CED68A4250AC9DA74BBF" xlink:to="loc_dei_EntityFileNumber_7DD7D0EEC4EDAAF890C150AC9DA72D66" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_EA8D1F3563F5C0D4C4DC50AC9DA76F1C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3D22CF21BFF7CED68A4250AC9DA74BBF" xlink:to="loc_dei_EntityRegistrantName_EA8D1F3563F5C0D4C4DC50AC9DA76F1C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_47E79AA071E4676AB18850AC9DA72372" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3D22CF21BFF7CED68A4250AC9DA74BBF" xlink:to="loc_dei_EntityIncorporationStateCountryCode_47E79AA071E4676AB18850AC9DA72372" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_27D3EB38BF338127E67250AC9DA78755" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3D22CF21BFF7CED68A4250AC9DA74BBF" xlink:to="loc_dei_EntityTaxIdentificationNumber_27D3EB38BF338127E67250AC9DA78755" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_C7001EFA463CFE92577A50AC9DADAEAC" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3D22CF21BFF7CED68A4250AC9DA74BBF" xlink:to="loc_dei_EntityAddressAddressLine1_C7001EFA463CFE92577A50AC9DADAEAC" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_1407CECA9DD7960CB59C50AC9DADC35E" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3D22CF21BFF7CED68A4250AC9DA74BBF" xlink:to="loc_dei_EntityAddressCityOrTown_1407CECA9DD7960CB59C50AC9DADC35E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_6AB9405CE04D7E583FB050AC9DAE83BC" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3D22CF21BFF7CED68A4250AC9DA74BBF" xlink:to="loc_dei_EntityAddressStateOrProvince_6AB9405CE04D7E583FB050AC9DAE83BC" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_AA05B107D5F87608C64E50AC9DAEA90C" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3D22CF21BFF7CED68A4250AC9DA74BBF" xlink:to="loc_dei_EntityAddressPostalZipCode_AA05B107D5F87608C64E50AC9DAEA90C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_A168A7BC961FC79D865450AC9DAED67B" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3D22CF21BFF7CED68A4250AC9DA74BBF" xlink:to="loc_dei_CityAreaCode_A168A7BC961FC79D865450AC9DAED67B" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_20C35C2586C60FA99F5B50AC9DAE695A" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3D22CF21BFF7CED68A4250AC9DA74BBF" xlink:to="loc_dei_LocalPhoneNumber_20C35C2586C60FA99F5B50AC9DAE695A" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_E2AF39F7515F053B3FFD50AC9DAE5826" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3D22CF21BFF7CED68A4250AC9DA74BBF" xlink:to="loc_dei_Security12bTitle_E2AF39F7515F053B3FFD50AC9DAE5826" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_1194FBC6510EC03035C850AC9DAEF0A4" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3D22CF21BFF7CED68A4250AC9DA74BBF" xlink:to="loc_dei_TradingSymbol_1194FBC6510EC03035C850AC9DAEF0A4" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_FC5D5AFD38469CC2CDAB50AC9DAF6A9F" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3D22CF21BFF7CED68A4250AC9DA74BBF" xlink:to="loc_dei_SecurityExchangeName_FC5D5AFD38469CC2CDAB50AC9DAF6A9F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_0A12364BC23107D9EE8C50AC9DB0A00B" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3D22CF21BFF7CED68A4250AC9DA74BBF" xlink:to="loc_dei_EntityCurrentReportingStatus_0A12364BC23107D9EE8C50AC9DB0A00B" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_C1C5CD05E7FDF2007B8A50AC9DB0FB4A" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3D22CF21BFF7CED68A4250AC9DA74BBF" xlink:to="loc_dei_EntityInteractiveDataCurrent_C1C5CD05E7FDF2007B8A50AC9DB0FB4A" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_1A02D7C3DA05D7E6A02B50AC9DB0E297" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3D22CF21BFF7CED68A4250AC9DA74BBF" xlink:to="loc_dei_EntityFilerCategory_1A02D7C3DA05D7E6A02B50AC9DB0E297" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_051A1203C12B1DA494C550AC9DB0771F" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3D22CF21BFF7CED68A4250AC9DA74BBF" xlink:to="loc_dei_EntitySmallBusiness_051A1203C12B1DA494C550AC9DB0771F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_ADA731FADCB298DD0C1250AC9DB151C7" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3D22CF21BFF7CED68A4250AC9DA74BBF" xlink:to="loc_dei_EntityEmergingGrowthCompany_ADA731FADCB298DD0C1250AC9DB151C7" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_E62523FC07F92F93098550AC9DB1A26D" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3D22CF21BFF7CED68A4250AC9DA74BBF" xlink:to="loc_dei_EntityShellCompany_E62523FC07F92F93098550AC9DB1A26D" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_834ACBDB07ADC46A3EBB50AC9DB197F2" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3D22CF21BFF7CED68A4250AC9DA74BBF" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_834ACBDB07ADC46A3EBB50AC9DB197F2" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_6DFE74FF93DA14B057EB50AC9DB1B101" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3D22CF21BFF7CED68A4250AC9DA74BBF" xlink:to="loc_dei_EntityCentralIndexKey_6DFE74FF93DA14B057EB50AC9DB1B101" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_082B27168740232ED2F750AC9DB1CA11" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3D22CF21BFF7CED68A4250AC9DA74BBF" xlink:to="loc_dei_CurrentFiscalYearEndDate_082B27168740232ED2F750AC9DB1CA11" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_400C1CD76CB6148AEC5F50AC9DB2E114" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3D22CF21BFF7CED68A4250AC9DA74BBF" xlink:to="loc_dei_AmendmentFlag_400C1CD76CB6148AEC5F50AC9DB2E114" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_6649AF2B248E0A152F1850AC9DB2FFD6" xlink:type="locator" />
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3D22CF21BFF7CED68A4250AC9DA74BBF" xlink:to="loc_dei_DocumentFiscalYearFocus_6649AF2B248E0A152F1850AC9DB2FFD6" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_76A7EC9FFB50C61B46E050AC9DB2E434" xlink:type="locator" />
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3D22CF21BFF7CED68A4250AC9DA74BBF" xlink:to="loc_dei_DocumentFiscalPeriodFocus_76A7EC9FFB50C61B46E050AC9DB2E434" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Debt" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_47068FFCF70DD1CD0DDA50AC9C8A5300" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_A748004BE09C8B0B07C050AC9C8A6ECB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_47068FFCF70DD1CD0DDA50AC9C8A5300" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_A748004BE09C8B0B07C050AC9C8A6ECB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_C0E2105C9D0D62BE096F9E56B0FADDEF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_3A26E82C506A2109FC559E56B0FA4290" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_C0E2105C9D0D62BE096F9E56B0FADDEF" xlink:to="loc_us-gaap_DebtInstrumentTable_3A26E82C506A2109FC559E56B0FA4290" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_7FBEC7C5C2D469D2FFF39E56B0FA14DE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3A26E82C506A2109FC559E56B0FA4290" xlink:to="loc_us-gaap_CreditFacilityAxis_7FBEC7C5C2D469D2FFF39E56B0FA14DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_A7B8D5FD9C40832A044E9E56B0FB0A1F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_7FBEC7C5C2D469D2FFF39E56B0FA14DE" xlink:to="loc_us-gaap_CreditFacilityDomain_A7B8D5FD9C40832A044E9E56B0FB0A1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_AB3EB6BDA67FDDD7076D9E56B0FB1F2C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_A7B8D5FD9C40832A044E9E56B0FB0A1F" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_AB3EB6BDA67FDDD7076D9E56B0FB1F2C" xlink:type="arc" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_TermLoanFacilityMember" xlink:label="loc_ebs_TermLoanFacilityMember_0297DE37BD74977371B59E56B0FB349D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_A7B8D5FD9C40832A044E9E56B0FB0A1F" xlink:to="loc_ebs_TermLoanFacilityMember_0297DE37BD74977371B59E56B0FB349D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_0C95F38460B7DFEE5F4E9E56B0FB383A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3A26E82C506A2109FC559E56B0FA4290" xlink:to="loc_us-gaap_DebtInstrumentAxis_0C95F38460B7DFEE5F4E9E56B0FB383A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_EF23D947A2D2F9B280D09E56B0FB2089" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_0C95F38460B7DFEE5F4E9E56B0FB383A" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_EF23D947A2D2F9B280D09E56B0FB2089" xlink:type="arc" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_CreditAgreementMember" xlink:label="loc_ebs_CreditAgreementMember_FAD6C713A21A1D41EBD09E56B0FC1EEC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_EF23D947A2D2F9B280D09E56B0FB2089" xlink:to="loc_ebs_CreditAgreementMember_FAD6C713A21A1D41EBD09E56B0FC1EEC" xlink:type="arc" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_AmendedCreditAgreementMember" xlink:label="loc_ebs_AmendedCreditAgreementMember_55596D6B5C809D2B5FF49E56B0FC6C77" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_EF23D947A2D2F9B280D09E56B0FB2089" xlink:to="loc_ebs_AmendedCreditAgreementMember_55596D6B5C809D2B5FF49E56B0FC6C77" xlink:type="arc" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_ConvertibleSeniorNotesDue2021Member" xlink:label="loc_ebs_ConvertibleSeniorNotesDue2021Member_16649CB3A5571263452D9E56B0FC5084" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_EF23D947A2D2F9B280D09E56B0FB2089" xlink:to="loc_ebs_ConvertibleSeniorNotesDue2021Member_16649CB3A5571263452D9E56B0FC5084" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_DFC01E95B05AC369D90E9E56B0FC0B4F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3A26E82C506A2109FC559E56B0FA4290" xlink:to="loc_us-gaap_VariableRateAxis_DFC01E95B05AC369D90E9E56B0FC0B4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_37E00A0850EB99E4BA9C9E56B0FC99E3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_DFC01E95B05AC369D90E9E56B0FC0B4F" xlink:to="loc_us-gaap_VariableRateDomain_37E00A0850EB99E4BA9C9E56B0FC99E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EurodollarMember" xlink:label="loc_us-gaap_EurodollarMember_41F970E045976237CC1B9E56B0FD8593" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_37E00A0850EB99E4BA9C9E56B0FC99E3" xlink:to="loc_us-gaap_EurodollarMember_41F970E045976237CC1B9E56B0FD8593" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FederalFundsEffectiveSwapRateMember" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember_8B9FF9A5EA697E8539BF9E56B0FDFA98" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_37E00A0850EB99E4BA9C9E56B0FC99E3" xlink:to="loc_us-gaap_FederalFundsEffectiveSwapRateMember_8B9FF9A5EA697E8539BF9E56B0FDFA98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BaseRateMember" xlink:label="loc_us-gaap_BaseRateMember_9E0042F2F5ED31B0FFB99E56B0FDA3F2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_37E00A0850EB99E4BA9C9E56B0FC99E3" xlink:to="loc_us-gaap_BaseRateMember_9E0042F2F5ED31B0FFB99E56B0FDA3F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_CBBCA839AA495418E0489E56B0FD5BE5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3A26E82C506A2109FC559E56B0FA4290" xlink:to="loc_srt_RangeAxis_CBBCA839AA495418E0489E56B0FD5BE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_864CB00C40F42248F95E9E56B0FD04C5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_CBBCA839AA495418E0489E56B0FD5BE5" xlink:to="loc_srt_RangeMember_864CB00C40F42248F95E9E56B0FD04C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_C45783B140293BBF17489E56B0FEF6BA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_864CB00C40F42248F95E9E56B0FD04C5" xlink:to="loc_srt_MinimumMember_C45783B140293BBF17489E56B0FEF6BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_35F250C933600C81BA5D9E56B0FEFBD7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_864CB00C40F42248F95E9E56B0FD04C5" xlink:to="loc_srt_MaximumMember_35F250C933600C81BA5D9E56B0FEFBD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0317E2577949153D5D669E56B0FE8C59" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3A26E82C506A2109FC559E56B0FA4290" xlink:to="loc_us-gaap_DebtInstrumentLineItems_0317E2577949153D5D669E56B0FE8C59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_C86AB87CC06D3C94D0719E56B0FF317D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0317E2577949153D5D669E56B0FE8C59" xlink:to="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_C86AB87CC06D3C94D0719E56B0FF317D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_9E9DE11098CAB58A297C9E56B0FF001A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0317E2577949153D5D669E56B0FE8C59" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_9E9DE11098CAB58A297C9E56B0FF001A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_9EC514F8D5D89645C34D9E56B0FF0A18" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0317E2577949153D5D669E56B0FE8C59" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_9EC514F8D5D89645C34D9E56B0FF0A18" xlink:type="arc" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears" xlink:label="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears_2E8FC1A4D3C51799860B9E56B0FF5F02" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0317E2577949153D5D669E56B0FE8C59" xlink:to="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears_2E8FC1A4D3C51799860B9E56B0FF5F02" xlink:type="arc" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear" xlink:label="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear_E7D4440EF7C81C65A3979E56B0FFFF0B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0317E2577949153D5D669E56B0FE8C59" xlink:to="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear_E7D4440EF7C81C65A3979E56B0FFFF0B" xlink:type="arc" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears" xlink:label="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears_DB482A3298198FBE44FB9E56B0FF9944" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0317E2577949153D5D669E56B0FE8C59" xlink:to="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears_DB482A3298198FBE44FB9E56B0FF9944" xlink:type="arc" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight" xlink:label="loc_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight_D29200E065EF0EF624ED9E56B0FFD804" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0317E2577949153D5D669E56B0FE8C59" xlink:to="loc_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight_D29200E065EF0EF624ED9E56B0FFD804" xlink:type="arc" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_DebtInstrumentCovenantDebtServiceCoverageRatio" xlink:label="loc_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio_D013DCC7650F545CA85B9E95B6B6922A" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0317E2577949153D5D669E56B0FE8C59" xlink:to="loc_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio_D013DCC7650F545CA85B9E95B6B6922A" xlink:type="arc" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioOne" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioOne_BBBCB39E6A7F50D035719E9C4A1BF2B5" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0317E2577949153D5D669E56B0FE8C59" xlink:to="loc_ebs_DebtInstrumentCovenantNetLeverageRatioOne_BBBCB39E6A7F50D035719E9C4A1BF2B5" xlink:type="arc" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioTwo" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioTwo_02AF74F62D13E4DE90919E9E05389C5C" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0317E2577949153D5D669E56B0FE8C59" xlink:to="loc_ebs_DebtInstrumentCovenantNetLeverageRatioTwo_02AF74F62D13E4DE90919E9E05389C5C" xlink:type="arc" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioThree" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioThree_67DB66E6E22F2747C5729E9EC900CFA7" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0317E2577949153D5D669E56B0FE8C59" xlink:to="loc_ebs_DebtInstrumentCovenantNetLeverageRatioThree_67DB66E6E22F2747C5729E9EC900CFA7" xlink:type="arc" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod_7965B54AA9CEACC745A59E56B100500C" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0317E2577949153D5D669E56B0FE8C59" xlink:to="loc_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod_7965B54AA9CEACC745A59E56B100500C" xlink:type="arc" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod_8C9CCDA760E5DEB4FB969E56B10016BA" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0317E2577949153D5D669E56B0FE8C59" xlink:to="loc_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod_8C9CCDA760E5DEB4FB969E56B10016BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_877F783E432E4ED26BA89E56B1004CB8" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0317E2577949153D5D669E56B0FE8C59" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_877F783E432E4ED26BA89E56B1004CB8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/DebtScheduleDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_CC8D7FE272350ADBC63FBEB54DB69A08" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_29FA5D054DF86FFF1CFCBEB54DB6B672" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_CC8D7FE272350ADBC63FBEB54DB69A08" xlink:to="loc_us-gaap_DebtInstrumentTable_29FA5D054DF86FFF1CFCBEB54DB6B672" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_19636C3D1EC13971D396BEB54DBAA865" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_29FA5D054DF86FFF1CFCBEB54DB6B672" xlink:to="loc_us-gaap_CreditFacilityAxis_19636C3D1EC13971D396BEB54DBAA865" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_C528A764FF9135A424FEBEB54DBADF11" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_19636C3D1EC13971D396BEB54DBAA865" xlink:to="loc_us-gaap_CreditFacilityDomain_C528A764FF9135A424FEBEB54DBADF11" xlink:type="arc" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_TermLoanFacilityMember" xlink:label="loc_ebs_TermLoanFacilityMember_F729A6999A6452497C1FBEB54DBACE55" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_C528A764FF9135A424FEBEB54DBADF11" xlink:to="loc_ebs_TermLoanFacilityMember_F729A6999A6452497C1FBEB54DBACE55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_3B0E01373362C95D71D0BEB54DBB6C69" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_C528A764FF9135A424FEBEB54DBADF11" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_3B0E01373362C95D71D0BEB54DBB6C69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_BB516432B1B051F8667EBEB54DBB2030" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_29FA5D054DF86FFF1CFCBEB54DB6B672" xlink:to="loc_us-gaap_DebtInstrumentAxis_BB516432B1B051F8667EBEB54DBB2030" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2FD7AB7BCA25DBC13C5BBEB54DBB3636" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_BB516432B1B051F8667EBEB54DBB2030" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2FD7AB7BCA25DBC13C5BBEB54DBB3636" xlink:type="arc" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_ConvertibleSeniorNotesDue2021Member" xlink:label="loc_ebs_ConvertibleSeniorNotesDue2021Member_7A87C06F1FF19FB8CF95BEB54DBB5608" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2FD7AB7BCA25DBC13C5BBEB54DBB3636" xlink:to="loc_ebs_ConvertibleSeniorNotesDue2021Member_7A87C06F1FF19FB8CF95BEB54DBB5608" xlink:type="arc" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_OtherLongTermDebtFacilityMember" xlink:label="loc_ebs_OtherLongTermDebtFacilityMember_60ABFC64BE05842B158ABEB54DBB2CBE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2FD7AB7BCA25DBC13C5BBEB54DBB3636" xlink:to="loc_ebs_OtherLongTermDebtFacilityMember_60ABFC64BE05842B158ABEB54DBB2CBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_A5C7304B37901F4F6250BEB54DBB81B6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_29FA5D054DF86FFF1CFCBEB54DB6B672" xlink:to="loc_us-gaap_DebtInstrumentLineItems_A5C7304B37901F4F6250BEB54DBB81B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_B2A484E74662134609E5BEB54DBC4AB7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A5C7304B37901F4F6250BEB54DBB81B6" xlink:to="loc_us-gaap_LongTermDebt_B2A484E74662134609E5BEB54DBC4AB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_A83E41715FDF32FFCB8BBEB54DBC22EB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A5C7304B37901F4F6250BEB54DBB81B6" xlink:to="loc_us-gaap_LongTermDebtCurrent_A83E41715FDF32FFCB8BBEB54DBC22EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_2CBE3659CE19154CE361BEB54DBCF5FC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A5C7304B37901F4F6250BEB54DBB81B6" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_2CBE3659CE19154CE361BEB54DBCF5FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_8A978A68C6587CA0289ABEB54DBC793E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A5C7304B37901F4F6250BEB54DBB81B6" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_8A978A68C6587CA0289ABEB54DBC793E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_F547D2BFEF46E716DF4FBEB7450A6110" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A5C7304B37901F4F6250BEB54DBB81B6" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_F547D2BFEF46E716DF4FBEB7450A6110" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_3D681E4A73035D352ACF50AC9D43B496" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_956CC4B516E9D350F6F650AC9D442556" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3D681E4A73035D352ACF50AC9D43B496" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_956CC4B516E9D350F6F650AC9D442556" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivities" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_597F905F7E2C6A15AC899E56B13031ED" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_499C16E0BEE5FB41307E9E56B130E197" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_597F905F7E2C6A15AC899E56B13031ED" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_499C16E0BEE5FB41307E9E56B130E197" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesCashFlowHedgingOnAociDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_EB9E5024394F5FE0CFDDC9409BF680A7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_C0859B225DE28ED876B2C9409BF65E0F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_EB9E5024394F5FE0CFDDC9409BF680A7" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_C0859B225DE28ED876B2C9409BF65E0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6DEBE9C6C948FA24C018C9409BF619DB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_C0859B225DE28ED876B2C9409BF65E0F" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6DEBE9C6C948FA24C018C9409BF619DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_DAEE2CBF623582D45B04C9409BF6D39E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6DEBE9C6C948FA24C018C9409BF619DB" xlink:to="loc_us-gaap_HedgingRelationshipDomain_DAEE2CBF623582D45B04C9409BF6D39E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowHedgingMember" xlink:label="loc_us-gaap_CashFlowHedgingMember_37BB8332D80452461AF0C9409BF60A6B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_DAEE2CBF623582D45B04C9409BF6D39E" xlink:to="loc_us-gaap_CashFlowHedgingMember_37BB8332D80452461AF0C9409BF60A6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_49B7B052B7AEBBE1D451C9409BF66361" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_C0859B225DE28ED876B2C9409BF65E0F" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_49B7B052B7AEBBE1D451C9409BF66361" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_98AE09F23C48C07605A4C9409BF6DF1B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_49B7B052B7AEBBE1D451C9409BF66361" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_98AE09F23C48C07605A4C9409BF6DF1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseMember" xlink:label="loc_us-gaap_InterestExpenseMember_FB53E012674154AF661AC9409BF6A29E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_98AE09F23C48C07605A4C9409BF6DF1B" xlink:to="loc_us-gaap_InterestExpenseMember_FB53E012674154AF661AC9409BF6A29E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_580EAF7E382C25BC8E5DC9409BF63AE7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_C0859B225DE28ED876B2C9409BF65E0F" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_580EAF7E382C25BC8E5DC9409BF63AE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_E349859E0C9D0A3147F7C9409BF6E9BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_580EAF7E382C25BC8E5DC9409BF63AE7" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_E349859E0C9D0A3147F7C9409BF6E9BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_B61FB951C6E23763CED5C9409BF621A9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_E349859E0C9D0A3147F7C9409BF6E9BF" xlink:to="loc_us-gaap_InterestRateSwapMember_B61FB951C6E23763CED5C9409BF621A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_71EA605577277DCF2F59C9409BF6F065" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_C0859B225DE28ED876B2C9409BF65E0F" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_71EA605577277DCF2F59C9409BF6F065" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_F0CF3ED1F5C4A768D574C9409BF6F442" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_71EA605577277DCF2F59C9409BF6F065" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_F0CF3ED1F5C4A768D574C9409BF6F442" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_01C84B65D9F8A32A48D4C9409BF6A091" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_71EA605577277DCF2F59C9409BF6F065" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_01C84B65D9F8A32A48D4C9409BF6A091" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesDerivativeDesignatedAsCashFlowHedgesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_68A3999B9FEB033FA74B9E56B1215989" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_34D0E958B9304B2BBBB29E56B12117B2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_68A3999B9FEB033FA74B9E56B1215989" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_34D0E958B9304B2BBBB29E56B12117B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_AF524064B1D7FDD07C339E56B121A8BA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_34D0E958B9304B2BBBB29E56B12117B2" xlink:to="loc_us-gaap_HedgingDesignationAxis_AF524064B1D7FDD07C339E56B121A8BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_67B8C8923381E72136F59E56B1210DC1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_AF524064B1D7FDD07C339E56B121A8BA" xlink:to="loc_us-gaap_HedgingDesignationDomain_67B8C8923381E72136F59E56B1210DC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_8DD69019D10F94A414A59E56B1216E87" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_67B8C8923381E72136F59E56B1210DC1" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_8DD69019D10F94A414A59E56B1216E87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_CD8CEFB66B3F875E76119E56B1214A92" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_34D0E958B9304B2BBBB29E56B12117B2" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_CD8CEFB66B3F875E76119E56B1214A92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_BA480F19C1E8363B46B49E56B121AFA5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_CD8CEFB66B3F875E76119E56B1214A92" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_BA480F19C1E8363B46B49E56B121AFA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_FA8DE5981CF89300D4F99E56B121241C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_BA480F19C1E8363B46B49E56B121AFA5" xlink:to="loc_us-gaap_InterestRateSwapMember_FA8DE5981CF89300D4F99E56B121241C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_41D37F6918CDE628C0F29E56B12184C4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_34D0E958B9304B2BBBB29E56B12117B2" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_41D37F6918CDE628C0F29E56B12184C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfInterestRateDerivativesHeld" xlink:label="loc_us-gaap_NumberOfInterestRateDerivativesHeld_CC28A6A1360ACFDBE5399E56B1219E80" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_41D37F6918CDE628C0F29E56B12184C4" xlink:to="loc_us-gaap_NumberOfInterestRateDerivativesHeld_CC28A6A1360ACFDBE5399E56B1219E80" xlink:type="arc" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_DerivativeNotionalAmount1" xlink:label="loc_ebs_DerivativeNotionalAmount1_C29088311E848A64077B9E56B1213114" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_41D37F6918CDE628C0F29E56B12184C4" xlink:to="loc_ebs_DerivativeNotionalAmount1_C29088311E848A64077B9E56B1213114" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesFairValueByBalanceSheetLocationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_A785C503AFF8C844322A9E56B11B35BD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_D4140DD0B30D6561EBD39E56B11BEFDA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_A785C503AFF8C844322A9E56B11B35BD" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_D4140DD0B30D6561EBD39E56B11BEFDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_19A5F7EF1083352034DE9E56B11B27D5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_D4140DD0B30D6561EBD39E56B11BEFDA" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_19A5F7EF1083352034DE9E56B11B27D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_895E7580751B4D1A363A9E56B11CF00C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_19A5F7EF1083352034DE9E56B11B27D5" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_895E7580751B4D1A363A9E56B11CF00C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_E03FD7907E28659A506E9E56B11CACCF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_895E7580751B4D1A363A9E56B11CF00C" xlink:to="loc_us-gaap_InterestRateSwapMember_E03FD7907E28659A506E9E56B11CACCF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_B004F6775C459C446D029E56B11CA8CF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_D4140DD0B30D6561EBD39E56B11BEFDA" xlink:to="loc_us-gaap_HedgingDesignationAxis_B004F6775C459C446D029E56B11CA8CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_C3D83C684821E3E340249E56B11C4348" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_B004F6775C459C446D029E56B11CA8CF" xlink:to="loc_us-gaap_HedgingDesignationDomain_C3D83C684821E3E340249E56B11C4348" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_0712B391C6C0F06935929E56B11D745E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_C3D83C684821E3E340249E56B11C4348" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_0712B391C6C0F06935929E56B11D745E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_AC78D2FA47A532637F319E56B11D3529" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_D4140DD0B30D6561EBD39E56B11BEFDA" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_AC78D2FA47A532637F319E56B11D3529" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1BBD1E39EF5209523EA09E56B11DD7F3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_AC78D2FA47A532637F319E56B11D3529" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1BBD1E39EF5209523EA09E56B11DD7F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_22FA726EC7059230EAD59E77FCF3D17F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1BBD1E39EF5209523EA09E56B11DD7F3" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_22FA726EC7059230EAD59E77FCF3D17F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsMember" xlink:label="loc_us-gaap_OtherAssetsMember_D04ED8424BD888F3DC1E9E56B11D2CD7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1BBD1E39EF5209523EA09E56B11DD7F3" xlink:to="loc_us-gaap_OtherAssetsMember_D04ED8424BD888F3DC1E9E56B11D2CD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_62F278C8A0770C561F939E56B11D40D3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1BBD1E39EF5209523EA09E56B11DD7F3" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_62F278C8A0770C561F939E56B11D40D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesMember" xlink:label="loc_us-gaap_OtherLiabilitiesMember_1FB79D7B80207255050E9E7855CEF4BD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1BBD1E39EF5209523EA09E56B11DD7F3" xlink:to="loc_us-gaap_OtherLiabilitiesMember_1FB79D7B80207255050E9E7855CEF4BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_0A252FE4B0227C702A169E56B11EAA57" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_D4140DD0B30D6561EBD39E56B11BEFDA" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_0A252FE4B0227C702A169E56B11EAA57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_C37453496FE9A98E11929E56B11EF9BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0A252FE4B0227C702A169E56B11EAA57" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_C37453496FE9A98E11929E56B11EF9BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_3FA2A94BADEAA799628C9E56B11EE081" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0A252FE4B0227C702A169E56B11EAA57" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_3FA2A94BADEAA799628C9E56B11EE081" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_D37177860C1C17AB2E319E56B12A4D4D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_04285B755F553EB5C90D9E56B12ADDD3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_D37177860C1C17AB2E319E56B12A4D4D" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_04285B755F553EB5C90D9E56B12ADDD3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_90CC8EF3D99DB6D0BBFD9E56B12ADEF1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_04285B755F553EB5C90D9E56B12ADDD3" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_90CC8EF3D99DB6D0BBFD9E56B12ADEF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_06EA585DA310F4B9747C9E56B12BA887" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_90CC8EF3D99DB6D0BBFD9E56B12ADEF1" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_06EA585DA310F4B9747C9E56B12BA887" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_67A15CECA06BAD02DFEC9E56B12B73D8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_06EA585DA310F4B9747C9E56B12BA887" xlink:to="loc_us-gaap_InterestRateSwapMember_67A15CECA06BAD02DFEC9E56B12B73D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_D945B350C692BEC199C99E56B12B36E9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_04285B755F553EB5C90D9E56B12ADDD3" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_D945B350C692BEC199C99E56B12B36E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:label="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_3335ADA5FEFE9E6CFD4C9E56B12BBA16" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_D945B350C692BEC199C99E56B12B36E9" xlink:to="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_3335ADA5FEFE9E6CFD4C9E56B12BBA16" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_658D0B5DB9055B7375129E56B12E0A1C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_24F2712929D4BFECB3DD9E56B12ECD15" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_658D0B5DB9055B7375129E56B12E0A1C" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_24F2712929D4BFECB3DD9E56B12ECD15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_3A09684EC3CF2B1BDDB29E56B12E1485" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_658D0B5DB9055B7375129E56B12E0A1C" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_3A09684EC3CF2B1BDDB29E56B12E1485" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_1E6058582DD1172B48959E56B12ECAA7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_658D0B5DB9055B7375129E56B12E0A1C" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_1E6058582DD1172B48959E56B12ECAA7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_8A2FF2C809C1AB2CAB7550AC9E192D42" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_FD7AFA70CF561AC8BF1350AC9E193AA3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8A2FF2C809C1AB2CAB7550AC9E192D42" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_FD7AFA70CF561AC8BF1350AC9E193AA3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_03637C5FE639A58BBD2850AC9D0F8D9F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_DF3F8ACF760233C79AFB50AC9D0F4C11" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_03637C5FE639A58BBD2850AC9D0F8D9F" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_DF3F8ACF760233C79AFB50AC9D0F4C11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_A5EF4595F44F509550A750AC9D0F1CE9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_03637C5FE639A58BBD2850AC9D0F8D9F" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_A5EF4595F44F509550A750AC9D0F1CE9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/IntangibleAssets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5182E6DD9E06A6E9532D9E56B150667D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_EBF2D851D06B76339E229E56B1501A4E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5182E6DD9E06A6E9532D9E56B150667D" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_EBF2D851D06B76339E229E56B1501A4E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/IntangibleAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_B1972D65EC7C40DD36B69E56B13E47EB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5DCD31518FC9A304614A9E56B13E7597" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_B1972D65EC7C40DD36B69E56B13E47EB" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5DCD31518FC9A304614A9E56B13E7597" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_63764033C90FC537D9559E56B13FEB9F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5DCD31518FC9A304614A9E56B13E7597" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_63764033C90FC537D9559E56B13FEB9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3E19AAE024F55E05D1CF9E56B13F036E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_63764033C90FC537D9559E56B13FEB9F" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3E19AAE024F55E05D1CF9E56B13F036E" xlink:type="arc" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_RaxibacumabMember" xlink:label="loc_ebs_RaxibacumabMember_5FCBE344EDBA633ADA099E56B13F4C59" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3E19AAE024F55E05D1CF9E56B13F036E" xlink:to="loc_ebs_RaxibacumabMember_5FCBE344EDBA633ADA099E56B13F4C59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_E88615DB7479E8F7DDB69E56B13F887C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5DCD31518FC9A304614A9E56B13E7597" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_E88615DB7479E8F7DDB69E56B13F887C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_F0DEC2457BAAFD60719C9E56B13FBC95" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_E88615DB7479E8F7DDB69E56B13F887C" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_F0DEC2457BAAFD60719C9E56B13FBC95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_1C5FF26DFB5A96C0FC089E56B1403AD8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_E88615DB7479E8F7DDB69E56B13F887C" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_1C5FF26DFB5A96C0FC089E56B1403AD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_52F148F1A4D3C80274819E56B140A57E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_E88615DB7479E8F7DDB69E56B13F887C" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_52F148F1A4D3C80274819E56B140A57E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_159CD58DBA983B64FED49E6E5696BB6B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_E88615DB7479E8F7DDB69E56B13F887C" xlink:to="loc_us-gaap_Goodwill_159CD58DBA983B64FED49E6E5696BB6B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_FF563A7892864AEB383DBC1D23292D4F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_63431193F268054CE9C3BC1D23294EA1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_FF563A7892864AEB383DBC1D23292D4F" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_63431193F268054CE9C3BC1D23294EA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_355EC80F65AA9E3B794EBC1D2329AAF1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_63431193F268054CE9C3BC1D23294EA1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_355EC80F65AA9E3B794EBC1D2329AAF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_D86F113E6DA0B7D79432BC1D232A2DF6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_355EC80F65AA9E3B794EBC1D2329AAF1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_D86F113E6DA0B7D79432BC1D232A2DF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_836ED38AD4823110423CBC1D232AC212" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_D86F113E6DA0B7D79432BC1D232A2DF6" xlink:to="loc_us-gaap_ProductMember_836ED38AD4823110423CBC1D232AC212" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaap_CustomerRelationshipsMember_F23B9AE855B4AB6EF9BDBC1D232A3DA2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_D86F113E6DA0B7D79432BC1D232A2DF6" xlink:to="loc_us-gaap_CustomerRelationshipsMember_F23B9AE855B4AB6EF9BDBC1D232A3DA2" xlink:type="arc" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_ContractManufacturingMember" xlink:label="loc_ebs_ContractManufacturingMember_652CC6699B20D554F5B4BC1D232BF995" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_D86F113E6DA0B7D79432BC1D232A2DF6" xlink:to="loc_ebs_ContractManufacturingMember_652CC6699B20D554F5B4BC1D232BF995" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_6C3602837552DB07B61BBC1D232B0765" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_63431193F268054CE9C3BC1D23294EA1" xlink:to="loc_srt_RangeAxis_6C3602837552DB07B61BBC1D232B0765" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_D8CF112FE82E35743DDBBC1D232B21E9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6C3602837552DB07B61BBC1D232B0765" xlink:to="loc_srt_RangeMember_D8CF112FE82E35743DDBBC1D232B21E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_F17A9CE957FBF7C8CF5EBC1D232BD7F6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_D8CF112FE82E35743DDBBC1D232B21E9" xlink:to="loc_srt_MinimumMember_F17A9CE957FBF7C8CF5EBC1D232BD7F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_BB034B145D28EFDC6C37BC1D232B2D67" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_D8CF112FE82E35743DDBBC1D232B21E9" xlink:to="loc_srt_MaximumMember_BB034B145D28EFDC6C37BC1D232B2D67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8163A70B45F54D03C2A1BC1D232C60E8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_63431193F268054CE9C3BC1D23294EA1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8163A70B45F54D03C2A1BC1D232C60E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_3EF8A217EF74F594299BBC1D232CD734" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8163A70B45F54D03C2A1BC1D232C60E8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_3EF8A217EF74F594299BBC1D232CD734" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_BFDA95206586563938D3BC1D232C85E6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8163A70B45F54D03C2A1BC1D232C60E8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_BFDA95206586563938D3BC1D232C85E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_8D1474AD6B0246229B1CBC1D232CD67E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_BFDA95206586563938D3BC1D232C85E6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_8D1474AD6B0246229B1CBC1D232CD67E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_4A5D5AA8F9C1A239E088BC1D232CBE32" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_BFDA95206586563938D3BC1D232C85E6" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_4A5D5AA8F9C1A239E088BC1D232CBE32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_C642FC3958717E0EB6ABBC1D232D3CB9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_BFDA95206586563938D3BC1D232C85E6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_C642FC3958717E0EB6ABBC1D232D3CB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_FA561057BD5C5A9296CBBC1D232D337E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_BFDA95206586563938D3BC1D232C85E6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_FA561057BD5C5A9296CBBC1D232D337E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/IntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_085CE8382AD5BD9A9F7F9E56B14E1E6E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_3EBB950517A3889C544C9E56B14E7994" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_085CE8382AD5BD9A9F7F9E56B14E1E6E" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_3EBB950517A3889C544C9E56B14E7994" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_FE1C9E6891612B66E57F50AC9DA38082" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_7CD82F037E303236280D50AC9DA34EFD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_FE1C9E6891612B66E57F50AC9DA38082" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_7CD82F037E303236280D50AC9DA34EFD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_321CE5D1AE869626905A50AC9CC724F3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_C92C3E86F73AB1B02F6050AC9CC721E9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_321CE5D1AE869626905A50AC9CC724F3" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_C92C3E86F73AB1B02F6050AC9CC721E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_0D497FA5780BFA07EDCD50AC9CC83EA7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_321CE5D1AE869626905A50AC9CC724F3" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_0D497FA5780BFA07EDCD50AC9CC83EA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_BF458FB61F38B2FEC6CF50AC9CC87616" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_321CE5D1AE869626905A50AC9CC724F3" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_BF458FB61F38B2FEC6CF50AC9CC87616" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_6A943C5444648999872E50AC9CC88293" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_321CE5D1AE869626905A50AC9CC724F3" xlink:to="loc_us-gaap_InventoryNet_6A943C5444648999872E50AC9CC88293" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_796A7888752E5472192650AC9D155891" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_F47845CA29EDF23D37B050AC9D16ABF9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_796A7888752E5472192650AC9D155891" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_F47845CA29EDF23D37B050AC9D16ABF9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Leases" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_C593842F94DD661458BE50AC9E170AB3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_636DACFC9CAB34AB57DE50AC9E17EB6D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_C593842F94DD661458BE50AC9E170AB3" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_636DACFC9CAB34AB57DE50AC9E17EB6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_94A6B7870AA641B6983E50AC9E1744B6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_C593842F94DD661458BE50AC9E170AB3" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_94A6B7870AA641B6983E50AC9E1744B6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/LeasesComponentsOfLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_C96A485206B1FF78BE8450AE209D1951" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostAbstract" xlink:label="loc_us-gaap_LeaseCostAbstract_C6A8EA91CBD0582923AB50B544CE6932" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_C96A485206B1FF78BE8450AE209D1951" xlink:to="loc_us-gaap_LeaseCostAbstract_C6A8EA91CBD0582923AB50B544CE6932" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_E95333C14BC8411BD2BD50AE209D036E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_C6A8EA91CBD0582923AB50B544CE6932" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_E95333C14BC8411BD2BD50AE209D036E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_2BF7228F52C7BE22C86550AE209D2266" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_C6A8EA91CBD0582923AB50B544CE6932" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_2BF7228F52C7BE22C86550AE209D2266" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_3117CE24D4CC6FFE38F550AE209EE594" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_C6A8EA91CBD0582923AB50B544CE6932" xlink:to="loc_us-gaap_LeaseCost_3117CE24D4CC6FFE38F550AE209EE594" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_9AD7BDB979AB552F448A50AC9D4017A3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_9BA650CEBBF617CFCD5150AC9D4022E3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9AD7BDB979AB552F448A50AC9D4017A3" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_9BA650CEBBF617CFCD5150AC9D4022E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_FBA7A9B26033494B18DF50AC9D405A5F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_9BA650CEBBF617CFCD5150AC9D4022E3" xlink:to="loc_srt_RangeAxis_FBA7A9B26033494B18DF50AC9D405A5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_4BDC190BBAA7EF64C26250AC9D41CF0E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_FBA7A9B26033494B18DF50AC9D405A5F" xlink:to="loc_srt_RangeMember_4BDC190BBAA7EF64C26250AC9D41CF0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_6AE600A778534BCBA2F450AC9D41E1C3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4BDC190BBAA7EF64C26250AC9D41CF0E" xlink:to="loc_srt_MinimumMember_6AE600A778534BCBA2F450AC9D41E1C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_5C0AEC4C340F6F37D56F50AC9D415F98" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4BDC190BBAA7EF64C26250AC9D41CF0E" xlink:to="loc_srt_MaximumMember_5C0AEC4C340F6F37D56F50AC9D415F98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_ECAEA5C584C6309EBC4A50AC9D41093B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_9BA650CEBBF617CFCD5150AC9D4022E3" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_ECAEA5C584C6309EBC4A50AC9D41093B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_07BD2C0104170056189350AC9D412917" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ECAEA5C584C6309EBC4A50AC9D41093B" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_07BD2C0104170056189350AC9D412917" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_457123CA08CFECF5E4AF50AC9D420927" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ECAEA5C584C6309EBC4A50AC9D41093B" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_457123CA08CFECF5E4AF50AC9D420927" xlink:type="arc" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_LesseeOperatingLeaseTerminationPeriod" xlink:label="loc_ebs_LesseeOperatingLeaseTerminationPeriod_D7CC300D5B1C88D713B150AC9D4235D5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ECAEA5C584C6309EBC4A50AC9D41093B" xlink:to="loc_ebs_LesseeOperatingLeaseTerminationPeriod_D7CC300D5B1C88D713B150AC9D4235D5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_4A7DBD9D0179CDB41B129E3BC231D68F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_E78C6EE76C3671FBC2519E3BC231BFD7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4A7DBD9D0179CDB41B129E3BC231D68F" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_E78C6EE76C3671FBC2519E3BC231BFD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_6091D9CE4181783850539E3BC231DD56" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_E78C6EE76C3671FBC2519E3BC231BFD7" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_6091D9CE4181783850539E3BC231DD56" xlink:type="arc" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_OperatingLeaseOtherLiabilityCurrent" xlink:label="loc_ebs_OperatingLeaseOtherLiabilityCurrent_00F32F783EEB24C3BC139E3BC2324236" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_E78C6EE76C3671FBC2519E3BC231BFD7" xlink:to="loc_ebs_OperatingLeaseOtherLiabilityCurrent_00F32F783EEB24C3BC139E3BC2324236" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_5F66FB218FFC21BE86249E3BC23263BC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_E78C6EE76C3671FBC2519E3BC231BFD7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_5F66FB218FFC21BE86249E3BC23263BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_1855AFDD7F2D359F10749E3BC232FDCF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_E78C6EE76C3671FBC2519E3BC231BFD7" xlink:to="loc_us-gaap_OperatingLeaseLiability_1855AFDD7F2D359F10749E3BC232FDCF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostAbstract" xlink:label="loc_us-gaap_LeaseCostAbstract_9A717034F738F6FD0A619E3BC232316B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4A7DBD9D0179CDB41B129E3BC231D68F" xlink:to="loc_us-gaap_LeaseCostAbstract_9A717034F738F6FD0A619E3BC232316B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_B0DA386EFEEB74C46DFD9E3BC232D85A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_9A717034F738F6FD0A619E3BC232316B" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_B0DA386EFEEB74C46DFD9E3BC232D85A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DirectFinancingLeaseLeaseIncomeAbstract" xlink:label="loc_us-gaap_DirectFinancingLeaseLeaseIncomeAbstract_45CBF69BB2108BBE82779E3BC23391EB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4A7DBD9D0179CDB41B129E3BC231D68F" xlink:to="loc_us-gaap_DirectFinancingLeaseLeaseIncomeAbstract_45CBF69BB2108BBE82779E3BC23391EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_096F12765CD70338D6AB9E3BC2333018" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DirectFinancingLeaseLeaseIncomeAbstract_45CBF69BB2108BBE82779E3BC23391EB" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_096F12765CD70338D6AB9E3BC2333018" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_9AB10BCAAE083BA055DC50AC9CF2538B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_362CFF49B1E1EA45CD0450AC9CF298F4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9AB10BCAAE083BA055DC50AC9CF2538B" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_362CFF49B1E1EA45CD0450AC9CF298F4" xlink:type="arc" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_ScheduleOfLeasesSupplementalBalanceSheetsTableTextBlock" xlink:label="loc_ebs_ScheduleOfLeasesSupplementalBalanceSheetsTableTextBlock_898E0F09AA84B4409BF650AC9CF2EDBA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9AB10BCAAE083BA055DC50AC9CF2538B" xlink:to="loc_ebs_ScheduleOfLeasesSupplementalBalanceSheetsTableTextBlock_898E0F09AA84B4409BF650AC9CF2EDBA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_3CA68639F1D6469EF58AB7DCF54A9E3C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_10273C9711B22AD6AB03B7DCF54AEF01" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3CA68639F1D6469EF58AB7DCF54A9E3C" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_10273C9711B22AD6AB03B7DCF54AEF01" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/NetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_45B092A591BF972B7E66B7DCF5396033" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_E79A1D8FF731779EB656B7DCF5399AC5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_45B092A591BF972B7E66B7DCF5396033" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_E79A1D8FF731779EB656B7DCF5399AC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_9FB912C47D2EC06E8EA1B7DCF5396336" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_E79A1D8FF731779EB656B7DCF5399AC5" xlink:to="loc_us-gaap_NetIncomeLoss_9FB912C47D2EC06E8EA1B7DCF5396336" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_2AB2C79AC6279FB0DC39B7DCF53F693D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_45B092A591BF972B7E66B7DCF5396033" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_2AB2C79AC6279FB0DC39B7DCF53F693D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4B465BBFE20A7E51614BB7DCF53F5192" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_2AB2C79AC6279FB0DC39B7DCF53F693D" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4B465BBFE20A7E51614BB7DCF53F5192" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_418635E13421044C3377B7DCF53FA507" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_2AB2C79AC6279FB0DC39B7DCF53F693D" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_418635E13421044C3377B7DCF53FA507" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8E5B5CC6C85445EC1A26B7DCF53FFBA9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_2AB2C79AC6279FB0DC39B7DCF53F693D" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8E5B5CC6C85445EC1A26B7DCF53FFBA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_B2BDFA7C0E07E159A11EB7DCF5400069" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_45B092A591BF972B7E66B7DCF5396033" xlink:to="loc_us-gaap_EarningsPerShareBasic_B2BDFA7C0E07E159A11EB7DCF5400069" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_9A3FC9AD9A1BF0D1C360B7DCF54023BB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_45B092A591BF972B7E66B7DCF5396033" xlink:to="loc_us-gaap_EarningsPerShareDiluted_9A3FC9AD9A1BF0D1C360B7DCF54023BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_A19B0A10EC799E60CDC2B7DCF5404A51" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_45B092A591BF972B7E66B7DCF5396033" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_A19B0A10EC799E60CDC2B7DCF5404A51" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_E67E8EC38C953AD36847B7DCF54333E2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_8FD7960B8723066C5833B7DCF5437C77" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_E67E8EC38C953AD36847B7DCF54333E2" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_8FD7960B8723066C5833B7DCF5437C77" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/PropertyPlantAndEquipment" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_296E1766571BCF51E02E9E56B18BB247" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_536DA0B1C3FB3BAA1B089E56B18B5A04" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_296E1766571BCF51E02E9E56B18BB247" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_536DA0B1C3FB3BAA1B089E56B18B5A04" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_AEB07307E631FBC6FE1F9E56B17905C0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3AEB026013FF109C795A9E56B1794A13" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_AEB07307E631FBC6FE1F9E56B17905C0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3AEB026013FF109C795A9E56B1794A13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8021DE5C9D40C80A4E9D9E56B1791834" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3AEB026013FF109C795A9E56B1794A13" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8021DE5C9D40C80A4E9D9E56B1791834" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9E748081E94E97B525BE9E56B179C870" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8021DE5C9D40C80A4E9D9E56B1791834" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9E748081E94E97B525BE9E56B179C870" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LandAndLandImprovementsMember" xlink:label="loc_us-gaap_LandAndLandImprovementsMember_250E88996435BAE636EE9E56B17AC151" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9E748081E94E97B525BE9E56B179C870" xlink:to="loc_us-gaap_LandAndLandImprovementsMember_250E88996435BAE636EE9E56B17AC151" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_F2108DD77B88D96FE16C9E56B17A76BA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9E748081E94E97B525BE9E56B179C870" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_F2108DD77B88D96FE16C9E56B17A76BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_12524A90DB9E5C26172D9E56B17A9E49" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9E748081E94E97B525BE9E56B179C870" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_12524A90DB9E5C26172D9E56B17A9E49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_DC9DF4B643EDFC3E10BA9E56B17AA057" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9E748081E94E97B525BE9E56B179C870" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_DC9DF4B643EDFC3E10BA9E56B17AA057" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_F99C10D86CB61E6A3C539E56B17B5E03" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9E748081E94E97B525BE9E56B179C870" xlink:to="loc_us-gaap_ConstructionInProgressMember_F99C10D86CB61E6A3C539E56B17B5E03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_B9189E2A52C2FC5E5C7D9E56B17B20EA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3AEB026013FF109C795A9E56B1794A13" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_B9189E2A52C2FC5E5C7D9E56B17B20EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_E54D8E8C33552D4EFDA09E56B17BB017" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_B9189E2A52C2FC5E5C7D9E56B17B20EA" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_E54D8E8C33552D4EFDA09E56B17BB017" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_4665B9B6FF5A538849D49E56B17B8616" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_E54D8E8C33552D4EFDA09E56B17BB017" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_4665B9B6FF5A538849D49E56B17B8616" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_86B88581CE148E53CA779E56B17BF7B2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_E54D8E8C33552D4EFDA09E56B17BB017" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_86B88581CE148E53CA779E56B17BF7B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5EADEB99DEAD9423B8449E56B17C66FD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_E54D8E8C33552D4EFDA09E56B17BB017" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_5EADEB99DEAD9423B8449E56B17C66FD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_A83E6B096A25D3A83B679E56B1844E5E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_791761EFBB06F973830F9E56B184A800" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_A83E6B096A25D3A83B679E56B1844E5E" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_791761EFBB06F973830F9E56B184A800" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/RevenueRecognition" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_E1C6EC04E6469BE6CE3A50AC9C88D83C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_0A9D1ECE439C603C38A150AC9C88B6C9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_E1C6EC04E6469BE6CE3A50AC9C88D83C" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_0A9D1ECE439C603C38A150AC9C88B6C9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/RevenueRecognitionAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_04EE57A67C6C9F28255ABC1D227C22A4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BilledContractReceivables" xlink:label="loc_us-gaap_BilledContractReceivables_84E3CE5D2287B8087A86BC1D227D6285" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_04EE57A67C6C9F28255ABC1D227C22A4" xlink:to="loc_us-gaap_BilledContractReceivables_84E3CE5D2287B8087A86BC1D227D6285" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnbilledContractsReceivable" xlink:label="loc_us-gaap_UnbilledContractsReceivable_5E4A3CF3F0E20272982DBC1D227D6A67" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_04EE57A67C6C9F28255ABC1D227C22A4" xlink:to="loc_us-gaap_UnbilledContractsReceivable_5E4A3CF3F0E20272982DBC1D227D6A67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_16E1C3DD8EAF5ADD8FB7BC1D227D3D7F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_04EE57A67C6C9F28255ABC1D227C22A4" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_16E1C3DD8EAF5ADD8FB7BC1D227D3D7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_7CE6FB950A3F23658D65BC2282AD4E17" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_04EE57A67C6C9F28255ABC1D227C22A4" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_7CE6FB950A3F23658D65BC2282AD4E17" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/RevenueRecognitionContractLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6FF92AECB12221234B1650AC9DBD7C0E" xlink:type="locator" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_ChangeinContractWithCustomerLiabilityRollForward" xlink:label="loc_ebs_ChangeinContractWithCustomerLiabilityRollForward_D2A0CFF24CAA7906922450AC9DBE8B2F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6FF92AECB12221234B1650AC9DBD7C0E" xlink:to="loc_ebs_ChangeinContractWithCustomerLiabilityRollForward_D2A0CFF24CAA7906922450AC9DBE8B2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_CE4AD2E1C7A3B77187C050AC9DBE952D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_ChangeinContractWithCustomerLiabilityRollForward_D2A0CFF24CAA7906922450AC9DBE8B2F" xlink:to="loc_us-gaap_ContractWithCustomerLiability_CE4AD2E1C7A3B77187C050AC9DBE952D" xlink:type="arc" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_ContractWithCustomerLiabilityAdditions" xlink:label="loc_ebs_ContractWithCustomerLiabilityAdditions_3607EBC9EC893E1284D050AC9DBE11AA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_ChangeinContractWithCustomerLiabilityRollForward_D2A0CFF24CAA7906922450AC9DBE8B2F" xlink:to="loc_ebs_ContractWithCustomerLiabilityAdditions_3607EBC9EC893E1284D050AC9DBE11AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_8D1A1077E13DA3E439F150AC9DBE1250" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_ChangeinContractWithCustomerLiabilityRollForward_D2A0CFF24CAA7906922450AC9DBE8B2F" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_8D1A1077E13DA3E439F150AC9DBE1250" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_DF821F0719D21300A99B50AC9DBFDF2F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_ChangeinContractWithCustomerLiabilityRollForward_D2A0CFF24CAA7906922450AC9DBE8B2F" xlink:to="loc_us-gaap_ContractWithCustomerLiability_DF821F0719D21300A99B50AC9DBFDF2F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationOfRevenueDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_FB126378C7627FD4B670B7DCF56E0775" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_1E470C1CF93EB567F8BCB7DCF56E7497" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_FB126378C7627FD4B670B7DCF56E0775" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_1E470C1CF93EB567F8BCB7DCF56E7497" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_2C76173360254469219FB7DCF56E0F1B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1E470C1CF93EB567F8BCB7DCF56E7497" xlink:to="loc_srt_ProductOrServiceAxis_2C76173360254469219FB7DCF56E0F1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_AC22D1F72325E4F5331EB7DCF56E4DE1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_2C76173360254469219FB7DCF56E0F1B" xlink:to="loc_srt_ProductsAndServicesDomain_AC22D1F72325E4F5331EB7DCF56E4DE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_7222CA10DE186D94E091B7DCF56F3C93" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_AC22D1F72325E4F5331EB7DCF56E4DE1" xlink:to="loc_us-gaap_ProductMember_7222CA10DE186D94E091B7DCF56F3C93" xlink:type="arc" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_ContractManufacturingMember" xlink:label="loc_ebs_ContractManufacturingMember_42459EACA9B70C832528B7DCF56F7CE1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_AC22D1F72325E4F5331EB7DCF56E4DE1" xlink:to="loc_ebs_ContractManufacturingMember_42459EACA9B70C832528B7DCF56F7CE1" xlink:type="arc" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_ContractsAndGrantsMember" xlink:label="loc_ebs_ContractsAndGrantsMember_B7AAA2E5D7274EF53C6AB7DCF56FC175" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_AC22D1F72325E4F5331EB7DCF56E4DE1" xlink:to="loc_ebs_ContractsAndGrantsMember_B7AAA2E5D7274EF53C6AB7DCF56FC175" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_69A61BDEFC0E9B08FB82B7DCF56FCF3D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1E470C1CF93EB567F8BCB7DCF56E7497" xlink:to="loc_srt_StatementGeographicalAxis_69A61BDEFC0E9B08FB82B7DCF56FCF3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_19D49D083F36352456C3B7DCF56FC11D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_69A61BDEFC0E9B08FB82B7DCF56FCF3D" xlink:to="loc_srt_SegmentGeographicalDomain_19D49D083F36352456C3B7DCF56FC11D" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_72A81804137B69178192B7DCF570177A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_19D49D083F36352456C3B7DCF56FC11D" xlink:to="loc_country_US_72A81804137B69178192B7DCF570177A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaap_NonUsMember_DA8D4574E8A3C820268CB7DCF5700278" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_19D49D083F36352456C3B7DCF56FC11D" xlink:to="loc_us-gaap_NonUsMember_DA8D4574E8A3C820268CB7DCF5700278" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_3A3E57B47249756F1AF5B7DCF570F69F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1E470C1CF93EB567F8BCB7DCF56E7497" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_3A3E57B47249756F1AF5B7DCF570F69F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_E70F39A273843236A734B7DCF570AC53" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3A3E57B47249756F1AF5B7DCF570F69F" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_E70F39A273843236A734B7DCF570AC53" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/RevenueRecognitionNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_BC89AF77B57696CF9AAF50AC9CAA0FFE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_F0BE5D46394F58827C7E50AC9CAAEB30" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_BC89AF77B57696CF9AAF50AC9CAA0FFE" xlink:to="loc_us-gaap_NumberOfOperatingSegments_F0BE5D46394F58827C7E50AC9CAAEB30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_46C6ABC2875E20B6E3C050AC9CAACFEE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_BC89AF77B57696CF9AAF50AC9CAA0FFE" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_46C6ABC2875E20B6E3C050AC9CAACFEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="loc_us-gaap_DeferredCostsCurrent_DF0D4A5643CDCCD1F1E050AC9CAA2D22" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_BC89AF77B57696CF9AAF50AC9CAA0FFE" xlink:to="loc_us-gaap_DeferredCostsCurrent_DF0D4A5643CDCCD1F1E050AC9CAA2D22" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/RevenueRecognitionRemainingPerformanceObligationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6829B544A1F60456EE0150AE20264845" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_9EA19EF2A9B4A8309F0150AE2026F098" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6829B544A1F60456EE0150AE20264845" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_9EA19EF2A9B4A8309F0150AE2026F098" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_F82042A7FECCF758134450AE2026A42E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6829B544A1F60456EE0150AE20264845" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_F82042A7FECCF758134450AE2026A42E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_34E650987B5D21F9E27250AE20278B09" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_F82042A7FECCF758134450AE2026A42E" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_34E650987B5D21F9E27250AE20278B09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_B9A925966FA44D0EDA4250AE202733C0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_F82042A7FECCF758134450AE2026A42E" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_B9A925966FA44D0EDA4250AE202733C0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/RevenueRecognitionTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_CE986E0F923F629DC36C50AC9D221954" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_44298423508C74DA091250AC9D22B8B8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_CE986E0F923F629DC36C50AC9D221954" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_44298423508C74DA091250AC9D22B8B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_08ACBEE9FDCDEFAB9B3B50AC9D223521" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_CE986E0F923F629DC36C50AC9D221954" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_08ACBEE9FDCDEFAB9B3B50AC9D223521" xlink:type="arc" />
    <link:loc xlink:href="ebs-20200331.xsd#ebs_ScheduleofAccountsReceivableNetTableTextBlock" xlink:label="loc_ebs_ScheduleofAccountsReceivableNetTableTextBlock_CC8902744F85737448F150AC9D22D967" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_CE986E0F923F629DC36C50AC9D221954" xlink:to="loc_ebs_ScheduleofAccountsReceivableNetTableTextBlock_CC8902744F85737448F150AC9D22D967" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/ShareBasedCompensation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_EB1B5330252568B1006950AC9D65B8C0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8AA9CE683C5868A0343650AC9D664864" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_EB1B5330252568B1006950AC9D65B8C0" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8AA9CE683C5868A0343650AC9D664864" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/ShareBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_391073A663ED7464845B79DDB08C4D98" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_BE082120B24A4EF1C9AC79DDB08CA5DD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_391073A663ED7464845B79DDB08C4D98" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_BE082120B24A4EF1C9AC79DDB08CA5DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_DB211463A3D71E91DE5979DDB08DFF3E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_BE082120B24A4EF1C9AC79DDB08CA5DD" xlink:to="loc_us-gaap_VestingAxis_DB211463A3D71E91DE5979DDB08DFF3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_780B75C4BF70B6A39E8F79DDB08D031F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_DB211463A3D71E91DE5979DDB08DFF3E" xlink:to="loc_us-gaap_VestingDomain_780B75C4BF70B6A39E8F79DDB08D031F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_CA7FC2FA48DA5BD380FF79DDB08D0C07" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_780B75C4BF70B6A39E8F79DDB08D031F" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_CA7FC2FA48DA5BD380FF79DDB08D0C07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_0028CDD8BF45952C4CA979DDB08E178A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_780B75C4BF70B6A39E8F79DDB08D031F" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_0028CDD8BF45952C4CA979DDB08E178A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_F8B9098CEF597BDBA3DE79DDB08EE9BC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_780B75C4BF70B6A39E8F79DDB08D031F" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_F8B9098CEF597BDBA3DE79DDB08EE9BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_936FF14D40FCF9B8581E79DDB08E985F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_BE082120B24A4EF1C9AC79DDB08CA5DD" xlink:to="loc_us-gaap_AwardTypeAxis_936FF14D40FCF9B8581E79DDB08E985F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F9F9B322D55F40570F4579DDB08E4BBD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_936FF14D40FCF9B8581E79DDB08E985F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F9F9B322D55F40570F4579DDB08E4BBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_D893004C0295BA83BDDD79DDB08E0284" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F9F9B322D55F40570F4579DDB08E4BBD" xlink:to="loc_us-gaap_EmployeeStockOptionMember_D893004C0295BA83BDDD79DDB08E0284" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_3C95134323D2916B99F779DDB094E174" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F9F9B322D55F40570F4579DDB08E4BBD" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_3C95134323D2916B99F779DDB094E174" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_90B7DAFD72A247A8BC0179DDB09462F8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_BE082120B24A4EF1C9AC79DDB08CA5DD" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_90B7DAFD72A247A8BC0179DDB09462F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract_39EFB8036BC6EFBAFC4B79DDB0941533" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_90B7DAFD72A247A8BC0179DDB09462F8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract_39EFB8036BC6EFBAFC4B79DDB0941533" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_56DD46FEFD4DD055015679DDB0957323" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract_39EFB8036BC6EFBAFC4B79DDB0941533" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_56DD46FEFD4DD055015679DDB0957323" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_F3C54E30E012BD840AF579DDB095C6A7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract_39EFB8036BC6EFBAFC4B79DDB0941533" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_F3C54E30E012BD840AF579DDB095C6A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_22830B326A574E380C3979DDB0957D43" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract_39EFB8036BC6EFBAFC4B79DDB0941533" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_22830B326A574E380C3979DDB0957D43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5D9D0F86A91F3101639D79DDB095A6E7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract_39EFB8036BC6EFBAFC4B79DDB0941533" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5D9D0F86A91F3101639D79DDB095A6E7" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>chart-7be1608b6ea75fd5aa6.jpg
<TEXT>
begin 644 chart-7be1608b6ea75fd5aa6.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $* 2H# 2(  A$! Q$!_\0
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M.3/^"2/_ $CH_9!_\,CX/_\ D*C_ (<F?\$D?^D='[(/_AD?!_\ \A5^HU%
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M %]_^")G_*)'_@G1_P!F@_!'_P!0^RK]1J_+G_@B9_RB1_X)T?\ 9H/P1_\
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M0U"U\(Z#X[UK1-1L_#NDW.J1^%-)BT:QUH&\OCJ.N1:9=Z#X"GO8=,UF2)[
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M+77]2G_!M'_R%?VQ/^P?\"?_ $I^*]?AOTDO^3*\:_X>'_\ UJLC/WKZ,?\
MR>_@G_%G_P#ZR^=']6E%%%?Y,G^NP4444 ,D^Z/]^/\ ]&+7^&+_ ,%!/^3]
M/VW/^SN_VD__ %<OC2O]SJ3[H_WX_P#T8M?X8O\ P4$_Y/T_;<_[.[_:3_\
M5R^-* /]??\ X(F?\HD?^"='_9H/P1_]0^RK]1J_+G_@B9_RB1_X)T?]F@_!
M'_U#[*OU&H **** .'^)O_).?'O_ &)?BO\ ]1_4:_R[8_\ 50?]>]O_ .B(
MZ_U$OB;_ ,DY\>_]B7XK_P#4?U&O\NV/_50?]>]O_P"B(Z_O;Z%G^Y>(?_85
MPQ_Z9ST_S_\ IN?[UX>?]>>)?_2\C'4445_<1_!Y6O+RVL+<W5V[I")K2W'E
M0374\MS?WEOI]C:VUK;))<75W>7UU;6EK;0QM)-<3Q1KC<6'/6WC#3KC1CK3
M:9XFM%-U96,>DWFAS+K=Q?:G?'3M,M;.WAFFL+UKVYPOVFWU)K&Q E;5KK3D
MMYWCU=<L8M3TJYL)]'@U^WNI+)+G2+B^_LP7=NFH6DTS6^H93['J-FD9O]*G
M^T6)CU*TM&74],?;J%MY9X3;Q;X,\&:I=VOA[QWXAAA@TV/PUX-US7;#6/%*
MW]QJ&JV^M.^HW%_>75CX:6.;2;Z6WU/6=:U=$L]7N=,M&%[86,_P.?YYG> X
MGP6 H1K0R7$<.YSBZ^*PN1YCFU7"8_")5*>(KJA2A2JTH05*EA<)@L1B,=7Q
M>(^JXC+VL;E^*I?HG#N0Y%F/"V.Q^(E0GGF'XDR7"8?"XO/\MRBEB\OQDO9U
M,-0^L59U*56<Y5:N*Q>.PV'P-#"8?ZUA\P3P6886KW@\8Z;%'J:ZA9ZMIVI:
M1-H-O=Z'+;6UWJD\_BJ>2T\,II#:;>7NG:PNN7L-S8V4MI?^7%>66H0ZBU@E
MC<3)HZ3KL&JSZE8/:7NEZOHYL#J>D:B+1KFW@U6&:?3+Z"YTZ[O].U#3K]+:
M\CM[VQO)HUN[&^LKA8+JTEBKS.RT35-:T^;69M&\3KXPM?&W@;QAJ3^)],T[
MPM%XA3PK<3_9O#GABUCUK6K;2]"TC2;K4X-%BU.\\X:S=_VCK.HS7^KW^I6W
M31KJMIJWBGQS'X;URYDO- \'^&M+\,F33+?7KZVT76?$%[>ZF\#ZC+INF 3>
M+9V2TFU$W$UAHMQ=R+'/=V=O)S9=GG$;Q> ECL/BXX.4J]6M#^RJM:H\IY.(
MZ\,5BZ^!P]2C#.L+'!9'A,7@L#*>'GC,1B882ABJ>9Y76PW5F60<,K"8^. Q
M&$>-C&A2H5/[6I4:<<X]IPSAZF%P>'QV(IUJF1XN6.SW&83&Y@H8B&#H8:>+
MKX6IE>:4<3T$_BC18/$>F>%#<23:UJD>IR1PVT#S6]B-*TM=9EBU6[7$%A=7
M>G,+G3K)V>\NX UT(([/;<OT->4^+-4U>'QYX,N+/P/X\UK3?"ESXU%_JNCZ
M-I=QIUROB'PI%I6GS:8]SX@LKB\3[6%AO&>UMWMEB)*R)&N?5R,$@'([&OJ<
MFQ^,Q>,XBPV,LXY?G7U?+IPP.*P=.KEL\JRO$0DIXB=6&,G2Q];,<)6Q5":H
MU*N&FH4J*BJ<?DL[R[!8/!<-XG!<REF.2/$9C">/PN-J4LSAFV:8><90P\*4
ML%"KE]'+L71PE>FZU*EB8.=:M*3J-**.^.YZ#N:>T4J)YCQND8ZR.C)&/K(P
M"#J.K=Q7O6;O97MJ_)=WV^9\]U2V;T2>E_0_1_\ X)#_ /*1W]E?_L=O$7_J
MM/'5?Z$B?<7_ '5_D*_S??\ @FI^T%\!O@M^WU^S=XP^+WQL^$?PP\*>'_&.
MNW&N^(_'WQ)\&^$]&T:";X?^,+"&74]0UO6K*WL4FOKZSLHC<O$)+J[MK="9
M9XD;^Q)O^"YG_!,J_P!0;0OAW\?]=^//B$1:@UMHO[-/P%_:*_:,N;[^REG^
MW?9+WX.?"?Q?HCQV[V[1RW,FK16<326YFN8XKB*1O\VOIA8G#XCQ#R#ZO7HU
MW1X/PU*LJ-6%1TJJSK.Y.G54)2=.HHRC)PG:2C).UFC_ $V^AKA<3AO#C/7B
M,/6H*MQ?C*M%UJ4Z?M:3R;(XJI3YXQYX.4914HWC>,E>Z9^N5?BA_P %^?\
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MYVKJE0A""=DEI'9);)'^AOT.\?CLQ\/^(L3F&,Q>/Q#XRQD7B,9B*V*KN/\
M8V1RM*K7G.HUS2D[.3U;>[8AC0G)56(XRP#''3&3D_K7XI_\%^0!_P $^-;
M&!_PM_X1\#_L.7M?M?7XH?\ !?G_ )1\:Y_V5_X1_P#I\O:_&_!O_DZOA_\
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M)?\ U.HG[MXR_P#)J?$'_LE,X_\ 42H?PS4445_L:?XM!1110 4444 %%%%
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M?]>>)?\ TO(QU%%%?W$?P>%%%% !1110 4444 %%%% 'Z1?\$A_^4CO[*_\
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M_ASY_P $I?\ I&Y^PU_XBW\&_P#YD:;_ ,.>O^"4O_2-[]A[_P 1@^#_ /\
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M (<]?\$I?^D;W[#W_B,'P?\ _F4H_P"'/7_!*7_I&]^P]_XC!\'_ /YE*/\
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M_G%_5WY6/^)(<!_T<;%_^(O1\O\ J?\ K_6W^=Q_PE?A3_H:_"O_ (4V@_\
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M_P!#7X5_\*;0?_EC7^B/_P .>O\ @E+_ -(WOV'O_$8/@_\ _,I1_P .>O\
M@E+_ -(WOV'O_$8/@_\ _,I1_P 3IXW_ *-YA?\ Q)JO_P XOZN_*Q_Q)#@/
M^CC8O_Q%Z/E_U/\ U_K;_.X_X2OPI_T-?A7_ ,*;0?\ Y8T?\)7X4_Z&OPK_
M .%-H/\ \L:_T1_^'/7_  2E_P"D;W[#W_B,'P?_ /F4H_X<]?\ !*7_ *1O
M?L/?^(P?!_\ ^92C_B=/&_\ 1O,+_P")-5_^<7]7?E8_XDAP'_1QL7_XB]'R
M_P"I_P"O];?YW'_"5^%/^AK\*_\ A3:#_P#+&OZ;O^#<;XO?"?PCJ?[73>*?
MB?\ #GPZM]8? \61UOQYX2TL7AMKGXH_:!:F^UB 3&#SX3+Y9/EB6/?@N@;]
MV?\ ASU_P2E_Z1O?L/?^(P?!_P#^92E'_!'O_@E*/^<;O[#A_P![]E[X.M^6
M[PF<?AU[]*^(\1OI08KQ!X,SGA"IP;0RJ&;K *6/AGM3&2H?4<TP.9JV&>4X
M95/:O!*B_P!_3Y%4<_>Y5"7W7AK]%C!^'/&N2\94N-<1FU3)WCW'+YY#3P4<
M1]>RS&9:T\3'-\4Z7LUC'65J$^=TU#W5/FC]9I^TE^SW*Z11_'3X.222ND4<
M:?%+P$[R22.(XXT1?$)9WD=E1$4%F9@J@D@5[77YU6O_  2&_P""5]C<V][9
M?\$Y/V(+2\M)X;JUNK;]F#X/0W%O<V\J303PRQ^$U>*6&:-)8I$8,DB*RD,
M:_16OY4/ZR"BBB@!DGW1_OQ_^C%K_#%_X*"?\GZ?MN?]G=_M)_\ JY?&E?[G
M4GW1_OQ_^C%K_#%_X*"?\GZ?MN?]G=_M)_\ JY?&E '^OO\ \$3/^42/_!.C
M_LT'X(_^H?95^HU?ES_P1,_Y1(_\$Z/^S0?@C_ZA]E7ZC4 %%%% !1110 44
M44 ?&/[6W[96B?LP:A\&OA]H7PQ\>_'O]H']HWQ1XG\*? OX$?#6[\&:-XD\
M92^!?"MQXU^(/BG5_%GQ'\2^$/ G@KP!\/\ PU#;WWBSQ3K^NJUO<:MH>DZ1
MI>LZQJ]G8O\ /<W_  5Q_9WT#]F3XE_M _$+PC\7O 7C#X/?$_XF_ 'XB?LS
MW/@Z+QI\?-+_ &AOA1X&U3XF>)/A'HNB?#34?&/A7Q7/>_#K2V^).B?$#0_%
M,_PQD^&5U#X_UOQ=H/A^TU>?3;O[=W[-?QR\2_M!_L8?MM?LW>&/!OQ0^*'[
M'T_[0'A75_@AXY\=7'POL?BE\*_VE/ F@^%?%B^%_B,WAWQAI/A;X@^#?$7@
MSP;XC\/KXA\.GP]XAT@>(] U'6-$GNM/U"+\R/@CX:_:X\>?L<_\% ?B-\._
MV5KOQI^T[_P41_:2_:%TSXZ? _QSXS\0_LWV?[(=OJ7[/.D? WP/X8@\2_&[
MX7:!;_M 7/@OPWH_A>Z\6?$#X9Z+:^ _'OB+Q+KC^!O$FIZ!X?BGE /Z&OV?
M/C'I'[0GP ^!OQ_T'2[[1-"^.7P@^&/Q?T71=3GM+K4M'TGXG>#=#\9:;I>H
MW-@[V%Q?:?::Y!:WD]D[VDT\,DELS0LA/P/+_P %0W\7>$OA)>_L_P#['O[3
M'[07Q$^+=K\>?$MI\,_"B_"GP>_@_P"'O[/'Q@U3X,^+?&7C3XC_ !'^(/AC
MX8:?/XJ\3Z?;#X:>"=.\3ZKXV\5QZK;-=Z+H5M9ZO>Z?Z3_P2]T3]I?X>_L?
M_!CX$_M.? 71O@AXJ_9R^$WP:^ ^B7&A?&7PQ\8;#XG:3\+_ (4^$_"-Y\0H
M9O#6AZ,O@^/5=8T>\2#PMJ<FJ7]M L=PVH2I(HKP;_@IOI/_  4A\40^"/@G
M^P_\*M/A^!?B_1/$#_M!_$WX>?'3X<?!/]H*&SU2[U"U?X<_!74_B'X4\3>%
M?AG?^(;>=]0\1_&5/#'C'Q5I=EJEY;^!]/\ #'BZWMO%T0!JV'_!7SX8?%7P
M-^SGK_[(_P "?CC^UGX\_:.^#'BS]HG2?@[X"_X5EX"\<_#[X-_#KQ;9_#SX
M@:]\2KSXN>/_  9X/T7Q'HWQ.N9OA;HG@O2_$>MZOXP\>Z9K-EH4CZ!HVI^)
M+7]"/V;_ -H/X:?M6? KX6?M%?![5+S5OAO\7O!VE>-/"UQJ5C)I6L6UGJ*.
MEUI&O:5*\LFD^(M U.WO]!\1:2\TS:9KFF:A8F:;[.)7_%WX?_LA?M2?LP>,
MOV8_VH?V2/V-/@[X4O\ P[^PS<_L*>//V'_$_P"T_'I-A\)]$\&_&R]^*?P7
M^(OASX_V/PY\9Z3\1TCO=5\83?%^"ZT+3O%VNQ^+[37K/4?$_B?1[VPOOTY_
MX)T_LIZE^Q)^Q;\!?V9==\3:?XQ\4?#GPSJUSXW\2Z/;W=IH6K?$+Q[XP\2?
M$OXAW/ARWU#&H0^&%\;>,M>M_#4=^D5\N@P:=]L@M[DRP1@'VM1110 4444
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6+R>:[OKZ[FFN;NYFEGGEDED=R ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>chart-45f5bcfaac85917cb05.jpg
<TEXT>
begin 644 chart-45f5bcfaac85917cb05.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #I 2P# 2(  A$! Q$!_\0
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M.3/^"2/_ $CH_9!_\,CX/_\ D*C_ (<F?\$D?^D='[(/_AD?!_\ \A5^HU%
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M?EQ_P1+_ .42'_!.C_LT+X)_^HC9U^H] !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %?Y7G_!XY_REO\/_ /9H7P7_ /4N^+%?ZH=?Y7G_  >.?\I;_#__ &:%
M\%__ %+OBQ0!_?Y_P1+_ .42'_!.C_LT+X)_^HC9U^H]?EQ_P1+_ .42'_!.
MC_LT+X)_^HC9U^H] !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'ZJ@Y ((((!R.AR.H]CUI:0   #H  ,G)P!CDGD_6EH **** "BBB@ HHHH
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MH^:]E;^CW_B)&_:(_P"C=O@I_P"%'\0/_C]'_$2-^T1_T;M\%/\ PH_B!_\
M'Z_G$HK^M/\ B7WP<_Z(;+O_  LS?R_ZF/DC^0O^)B_&?_HN,?\ ^$>5_P#S
M#Y+[C^CO_B)&_:(_Z-V^"G_A1_$#_P"/T?\ $2-^T1_T;M\%/_"C^('_ ,?K
M^<2BC_B7WP<_Z(;+O_"S-_+_ *F/D@_XF+\9_P#HN,?_ .$>5_\ S#Y+[C^C
MO_B)&_:(_P"C=O@I_P"%'\0/_C]'_$2-^T1_T;M\%/\ PH_B!_\ 'Z_G$HH_
MXE]\'/\ HALN_P#"S-_+_J8^2#_B8OQG_P"BXQ__ (1Y7_\ ,/DON/Z._P#B
M)&_:(_Z-V^"G_A1_$#_X_1_Q$C?M$?\ 1NWP4_\ "C^('_Q^OYQ**/\ B7WP
M<_Z(;+O_  LS?R_ZF/D@_P")B_&?_HN,?_X1Y7_\P^2^X_H[_P"(D;]HC_HW
M;X*?^%'\0/\ X_1_Q$C?M$?]&[?!3_PH_B!_\?K^<2BC_B7WP<_Z(;+O_"S-
M_+_J8^2#_B8OQG_Z+C'_ /A'E?\ \P^2^X_J<_9Z_P""_P!\>/C'\>_@I\)-
M7^ _PATC2?B?\5_ 'P_U/5=-U_QQ-J.F6'B_Q1IN@W>H6$-W,;66\M(;YY[>
M.Y!@>5$64;"U?U6 Y_,C\CBO\V#]A?\ Y/4_9(_[.5^"/_JQ?#U?Z3PZ?BW\
MS7\7?2BX&X3X&S[A;"<*9-A\FP^.RC&8C%TJ%7%556K4L9&E3G)XJO7DG&G[
MJ4'%6U:;U/[;^BMQ[Q;Q[P]Q5C.+<YK9QB<!G.#PV$JUJ6&I.C0J8'VLZ<5A
MJ-&+4I^\W)2?1-+06O*/CE\9?!O[/?PE\>?&CX@G55\%_#GP_<^)/$3:'IQU
M;5AIMK+!#+]@TY9K<WEQON(]L(FCW#<=PVUZO7Y\_P#!5C_E'=^UM_V2'6/_
M $X:77\]<*Y=A\XXGX<RC%^T^J9IGV3Y=BO924*OU?'9AA\-7]G-QFH5/9U9
M<DG&2C*S<6E9_P!%\4YEB,GX9XBS?"*F\5E>1YMF.&56+G2>(P6 Q&)H^T@G
M%RA[2G'GBI)RC=75[GR6?^#@']@ $@W7QKR"0<?"BYQP<?\ 0=I/^(@+]@#_
M )^OC7_X:BY_^7M?PZR?ZR3_ 'V_]"-,K_1I?1(\*6D_:<4[+_F;X7R_ZEGE
M^+[G^;'_ !.%XK?] _"__AJQ/_SP\OS[L_N-_P"(@+]@#_GZ^-?_ (:BY_\
ME[1_Q$!?L ?\_7QK_P##47/_ ,O:_ARHI_\ $I'A3_S\XI_\.^%\O^I9Y?B^
MXO\ B<+Q7_Y\<+?^&K$__/#R_/NS^XW_ (B OV /^?KXU_\ AJ+G_P"7M'_$
M0%^P!_S]?&O_ ,-1<_\ R]K^'*BC_B4CPI_Y^<4_^'?"^7_4L\OQ?</^)PO%
M?_GQPM_X:L3_ //#R_/NS^XW_B("_8 _Y^OC7_X:BY_^7M'_ !$!?L ?\_7Q
MK_\ #47/_P O:_ARHH_XE(\*?^?G%/\ X=\+Y?\ 4L\OQ?</^)PO%?\ Y\<+
M?^&K$_\ SP\OS[L_N-_XB OV /\ GZ^-?_AJ+G_Y>T?\1 7[ '_/U\:__#47
M/_R]K^'*BC_B4CPI_P"?G%/_ (=\+Y?]2SR_%]P_XG"\5_\ GQPM_P"&K$__
M #P\OS[L_N-_XB OV /^?KXU_P#AJ+G_ .7M>]_LS_\ !7/]D?\ :P^,'A_X
M(?">?XFR>-_$NG^(=3TU?$O@";0=(-MX9TBXUO4_M&IOJMT(9/L5M*;=/(83
M3!8MR%@:_P _>OUZ_P""&'_*2+X._P#8H_&3_P!5MK-?)\>?1A\->'.">+<_
MR^IQ&\?DO#F<9I@UB,TP]2@\5@<OKXFA[:G'+J<IT_:4H\\(S@Y1<DI*]S[#
MP_\ I2^)7$_''"7#N8T>'8X#.^(LHRO&/#Y;B*==8;&X^AAZSHU)8Z<85/9U
M)<DG"2C+5Q>J?]YU%%%?YY'^BP4444 %?Y7G_!XY_P I;_#_ /V:%\%__4N^
M+%?ZH=?Y7G_!XY_REO\ #_\ V:%\%_\ U+OBQ0!_?Y_P1+_Y1(?\$Z/^S0O@
MG_ZB-G7ZCU^7'_!$O_E$A_P3H_[-"^"?_J(V=?J/0 4444 <EX]_Y$CQA_V*
MWB+_ -,M]7^7$G^KB_ZXP_\ HI*_U'?'O_(D>,/^Q6\1?^F6^K_+B3_5Q?\
M7&'_ -%)7]Z?0K_W3Q%_[".%O_3?$!_ 'TW?]Y\.?^O7%/\ Z5P^.HHHK^Y#
M^#@HHHH **** "BBB@ HHHH ^J?V%_\ D]3]DC_LY7X(_P#JQ?#U?Z3PZ?BW
M\S7^;#^PO_R>I^R1_P!G*_!'_P!6+X>K_2>'3\6_F:_SV^F=_P E-P7_ -B+
M,/\ U81/]&/H3_\ )*\;?]E!@/\ U7"U^?/_  58_P"4=W[6W_9(=8_].&EU
M^@U?GS_P58_Y1W?M;?\ 9(=8_P#3AI=?R[P!_P EWP5_V5O#G_JXP1_5?'W_
M "0O&G_9*<0_^JC%G^>!)_K)/]]O_0C3*?)_K)/]]O\ T(TRO]JH[+T7Y'^'
M@4444P"BBB@ HHHH **** "OUZ_X(8?\I(O@[_V*/QD_]5MK-?D+7Z]?\$,/
M^4D7P=_[%'XR?^JVUFOSWQ:_Y-=XB?\ 9%\2_P#JHQ9^D^#G_)UO#K_LL^'/
M_5MA#^\ZBBBO\:3_ &G"BBB@ K_*\_X/'/\ E+?X?_[-"^"__J7?%BO]4.O\
MKS_@\<_Y2W^'_P#LT+X+_P#J7?%B@#^_S_@B7_RB0_X)T?\ 9H7P3_\ 41LZ
M_4>ORX_X(E_\HD/^"='_ &:%\$__ %$;.OU'H **** .2\>_\B1XP_[%;Q%_
MZ9;ZO\N)/]7%_P!<8?\ T4E?ZCOCW_D2/&'_ &*WB+_TRWU?Y<2?ZN+_ *XP
M_P#HI*_O3Z%?^Z>(O_81PM_Z;X@/X ^F[_O/AS_UZXI_]*X?'4445_<A_!P4
M444 %%%% !1110 4444 ?5/["_\ R>I^R1_V<K\$?_5B^'J_TGAT_%OYFO\
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MT*_]T\1?^PCA;_TWQ ?P!]-W_>?#G_KUQ3_Z5P^.HHHK^Y#^#@HHHH ****
M"BBB@ HHHH ^J?V%_P#D]3]DC_LY7X(_^K%\/5_I/#I^+?S-?YL/["__ ">I
M^R1_V<K\$?\ U8OAZO\ 2>'3\6_F:_SV^F=_R4W!?_8BS#_U81/]&/H3_P#)
M*\;?]E!@/_5<+7Y\_P#!5C_E'=^UM_V2'6/_ $X:77Z#5^?/_!5C_E'=^UM_
MV2'6/_3AI=?R[P!_R7?!7_96\.?^KC!']5\??\D+QI_V2G$/_JHQ9_G@2?ZR
M3_?;_P!"-,I\G^LD_P!]O_0C3*_VJCLO1?D?X>!1113 **** "BBB@ HHHH
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M^7> /^2[X*_[*WAS_P!7&"/ZKX^_Y(7C3_LE.(?_ %48L_SP)/\ 62?[[?\
MH1IE/D_UDG^^W_H1IE?[51V7HOR/\/ HHHI@%%%% !1110 4444 %?KU_P $
M,/\ E)%\'?\ L4?C)_ZK;6:_(6OUZ_X(8?\ *2+X._\ 8H_&3_U6VLU^>^+7
M_)KO$3_LB^)?_51BS])\'/\ DZWAU_V6?#G_ *ML(?WG4445_C2?[3A1110
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M_DUWB)_V1?$O_JHQ9^D^#G_)UO#K_LL^'/\ U;80_O.HHHK_ !I/]IPHHHH
M*_RO/^#QS_E+?X?_ .S0O@O_ .I=\6*_U0Z_RO/^#QS_ )2W^'_^S0O@O_ZE
MWQ8H _O\_P"")?\ RB0_X)T?]FA?!/\ ]1&SK]1Z_+C_ ((E_P#*)#_@G1_V
M:%\$_P#U$;.OU'H *^,OVN/^"@_['_["A\!#]JSXRZ?\)3\3CXE'@;[=X3^(
M7BC^WCX0&BMXB$7_  @GA#Q5]B_LT>(M'+_VI]A^T?;5^Q_:?)N?)^S:",^O
MYD?RH _$3Q?_ ,%__P#@D5J7A7Q+I]E^V)H4]Y?>'];L[2!?A1^T"&FN;G2K
MR"WB4O\ "1$!EFD2,%F !8$FOX#T^/OPF$<8/B/5P1%$I'_"O/B?P5C4$<>"
M\<$=J_UJL#W_ #/^-&![_F?\:_8/"SQHXC\):>=TL@RS(\PCGL\OJ8IYS1S"
MJZ3RV.,C16'^HYC@%%36-J^U]JJK?+3Y'"TN;\=\5?!/ACQ>GDE3B',L^R]Y
M#',(X59+B,NH*JLQ>"=;ZQ]?RS,')P^HTO9>R=)+GJ<ZG>/+_DK_ /"_?A+_
M -#)J_\ X;OXG_\ S%4?\+]^$O\ T,FK_P#AN_B?_P#,57^M1@>_YG_&C ]_
MS/\ C7ZS_P 3D>(G_1-\$?\ A'G_ /\ 1#_5WY6_(?\ B2WPT_Z*/CO_ ,+^
M'_\ Z&_7^EK_ )*__"_?A+_T,FK_ /AN_B?_ /,51_POWX2_]#)J_P#X;OXG
M_P#S%5_K48'O^9_QHP/?\S_C1_Q.1XB?]$WP1_X1Y_\ _1#_ %=^5C_B2WPT
M_P"BCX[_ /"_A_\ ^AOU_I:_Y*__  OWX2_]#)J__AN_B?\ _,51_P +]^$O
M_0R:O_X;OXG_ /S%5_K48'O^9_QHP/?\S_C1_P 3D>(G_1-\$?\ A'G_ /\
M1#_5WY6/^)+?#3_HH^.__"_A_P#^AOU_I:_Y*_\ POWX2_\ 0R:O_P"&[^)_
M_P Q5'_"_?A+_P!#)J__ (;OXG__ #%5_K48'O\ F?\ &C ]_P S_C1_Q.1X
MB?\ 1-\$?^$>?_\ T0_U=^5C_B2WPT_Z*/CO_P +^'__ *&_7^EK_DK_ /"_
M?A+_ -#)J_\ X;OXG_\ S%4?\+]^$O\ T,FK_P#AN_B?_P#,57^M1@>_YG_&
MC ]_S/\ C1_Q.1XB?]$WP1_X1Y__ /1#_5WY6/\ B2WPT_Z*/CO_ ,+^'_\
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M7\/_ /T-^O\ 2U_R5_\ A?OPE_Z&35__  W?Q/\ _F*H_P"%^_"7_H9-7_\
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M:,#W_,_XT?\ $Y'B)_T3?!'_ (1Y_P#_ $0_U=^5C_B2WPT_Z*/CO_POX?\
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MA32;^ZU33?#MWXTT.VUB;1[+4;V*&[OK:P-QY$=W<0PRSA/,>*,ML7YKUO\
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M;6].^"'P>\$_L>_&&U^ ?Q7\6-\3OAU\.?%WB?XE:'XV^+VHZ1X4^#6H>&O
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M_P""</[:/QD_X)-V?[&'POD^'WP.U3]IK3OV@/$/[;.K_MB>#;N3XYW/QO\
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M^]C_ ,+A^%'_ $4SX??^%MX6_P#EM1_PN'X4?]%,^'W_ (6WA;_Y;5_@G44
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H&]T?4;+5+03+XK^*DK0FYL9[B 2K'-$[1^9O"21OC:Z,W\L%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>chart-93d7bf203aab502f964.jpg
<TEXT>
begin 644 chart-93d7bf203aab502f964.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #I 2H# 2(  A$! Q$!_\0
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M.3/^"2/_ $CH_9!_\,CX/_\ D*C_ (<F?\$D?^D='[(/_AD?!_\ \A5^HU%
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M)]T?[\?_ *,6O\,7_@H)_P GZ?MN?]G=_M)_^KE\:4 ?Z^__  1,_P"42/\
MP3H_[-!^"/\ ZA]E7ZC5^7/_  1,_P"42/\ P3H_[-!^"/\ ZA]E7ZC4 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 R3[H_P!^/_T8M?X8O_!03_D_3]MS_L[O
M]I/_ -7+XTK_ '.I/NC_ 'X__1BU_AB_\%!/^3]/VW/^SN_VD_\ U<OC2@#_
M %]_^")G_*)'_@G1_P!F@_!'_P!0^RK]1J_+G_@B9_RB1_X)T?\ 9H/P1_\
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M9H\3CQ1\?(_A/X 7XQ_#WP+>?$[XC76M7^N:II_Q-UZ/4[3X<>"=)MM' /U
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M ?<#)[FEWI_>7_OH?XU_G1_\/-_^"@/_ $=U\;O_  J(/_E;1_P\W_X* _\
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MX%^)WB[^S_V7+_PQX2A^$VL?$/X2>(-(UR.7Q+<_\(OX$OT\%77A3T'X=_\
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M" ^"-3L[O64\3>,(?B#%K,>E>&&MOTU_X;"_9(_Z.E_9S_\ #W?#/_YIZ/\
MAL+]DC_HZ7]G/_P]WPS_ /FGH_U=X@_Z$6<_^&S&_P#RCS7WA_K'P]_T/LE_
M\.F!_P#E_FOO/HRBOG/_ (;"_9(_Z.E_9S_\/=\,_P#YIZ/^&POV2/\ HZ7]
MG/\ \/=\,_\ YIZ/]7>(/^A%G/\ X;,;_P#*/-?>'^L?#W_0^R7_ ,.F!_\
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M)'_@G1_V:#\$?_4/LJ_4:ORY_P"")G_*)'_@G1_V:#\$?_4/LJ_4:@ HHHH
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M_P#,3:G_ #SB_P"_4?\ \31M3_GG%_WZC_\ B:6BB[[O^O\ AE]P<\_YI?\
M@3_S$VI_SSB_[]1__$T;4_YYQ?\ ?J/_ .)I:*+ON_Z_X9?<'//^:7_@3_S$
MVI_SSB_[]1__ !-&U/\ GG%_WZC_ /B:6BB[[O\ K_AE]P<\_P":7_@3_P Q
M-J?\\XO^_4?_ ,31M3_GG%_WZC_^)I:*+ON_Z_X9?<'//^:7_@3_ ,Q-J?\
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M9)]/M-;\/:K-I.M:<',=U<Z+?L8))(T#31W?]F:MIXN+8W7VNV2W%Z\D_9^
M]%^'/PJTK3_AIX)GTWP];65P4AT5-3EEOKG5M16*Y9M2O9I&-UX@U*%H)DMK
MNX74[JT6V%E9_88K=(_Q&AEGBA0\1<WXDEXC\+TO#[-Z-/#<.Y?CZ53-,+*O
M5CAEA\)ALOH8[(Z*QD9T<4WCL+G=:KC$TY8:LJDZ>$_=*^:>%=?PVR?AF/AM
MQ56\1,HKU,3Q'F&7U:>58J-"E*N\3B\3F-? 9[6E@IQKX2*P&*R.C2P;4N7%
M473A4Q?&S_M.? >U7?=?$6SMHRVP27/AWQM!&7()"B2;PNB%B%8A0=Q"L0,
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M(;/4=-\2^ /!^O6%_:K\-O'#I!>6>K:+>6]S%%(B30I-&XAFCBFBV2Q1NO\
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M$_\ I3\5Z_EKK^I3_@VC_P"0K^V)_P!@_P"!/_I3\5Z_#?I)?\F5XU_P\/\
M_K59&?O7T8_^3W\$_P"+/_\ UE\Z/ZM****_R9/]=@HHHH 9)]T?[\?_ *,6
MO\,7_@H)_P GZ?MN?]G=_M)_^KE\:5_N=2?='^_'_P"C%K_#%_X*"?\ )^G[
M;G_9W?[2?_JY?&E '^OO_P $3/\ E$C_ ,$Z/^S0?@C_ .H?95^HU?ES_P $
M3/\ E$C_ ,$Z/^S0?@C_ .H?95^HU !7QA^UO_P4)_8^_85?P''^U7\9M/\
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M#?K_ $M?\E?_ (7[\)?^ADU?_P -W\3_ /YBJ/\ A?OPE_Z&35__  W?Q/\
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M^9_QH_XG(\1/^B;X(_\ "//_ /Z(?ZN_*Q_Q);X:?]%'QW_X7\/_ /T-^O\
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M:^E\06$]S;:]J%M*9[G]U/AO'\0X_A]X,B^+,W@R?XGIX8T9/'T_PZMM?LO
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M;PM_\MJ/^%P_"C_HIGP^_P#"V\+?_+:O\$ZB@#_>O?XP?"@@8^)GP^^_&?\
MD=_"PZ.I/75_0?CT'-?X@W[?D\%U^W=^VM<VL\%U:W/[6W[1\]M=6L\-U:W,
C$WQC\920SVUS;O)!<031LLD,\$DD,L;+)&[HRL?DFB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>chart-937e1a19d8725011b0d.jpg
<TEXT>
begin 644 chart-937e1a19d8725011b0d.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %  40# 2(  A$! Q$!_\0
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M5J.F2S:U!I']D1+>R^0^ /\ @IO^QG\3/C-8_ [PA\3M;O/$FO\ CCQC\+_
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M+;326]Q$)[:26$R6]Q%)!/&'+PS1O'(JNI6KM?SZ_P#!)*_\ ?#C]JW]K/\
M9X^'/@#]BUM)A^#/[.'QJU#XJ?\ !./5/'&F?LOQMXGUCXJ>"] ^&'CCX5ZM
M\0/'OP_\&_M!Z9I7AB?Q1J'COP1<Z7KGQE^&VI>%/$/CS1M,ET7PU;C^@J@
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MU2&^TB]OK"Y_SZ-[_P!YO^^C_C1O?^\W_?1_QH_XDTX._P"BMXE_\$Y7Y?\
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MK3Z3X8M]*L)M3O3&AN[^6W>[N"J^=,^T8[__ (>1_L$?]'??L]_^'/\ #?\
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MD6TIK1$;5=7LH6N-2M;R31[$:<AO;R;T\G))XYYPH"J/954!54= J@*H "@
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M_P#]FA?!?_U+OBQ11_P>.?\ *6_P_P#]FA?!?_U+OBQ10!_?Y_P1+_Y1(?\
M!.C_ +-"^"?_ *B-G7ZCU^7'_!$O_E$A_P $Z/\ LT+X)_\ J(V=?J/0 444
M4 (>GXK_ #%?YL/[='_)ZG[6_P#V<K\;O_5B^(:_TGCT_%?YBO\ -A_;H_Y/
M4_:W_P"SE?C=_P"K%\0U_9WT,?\ DI^-/^Q#@/\ U8,_B?Z;'_)+<%?]C[,/
M_5? ^5J***_T*/\ .<**** "BBB@ HHHH **** "GQ_ZR/\ WU_]"%,I\?\
MK(_]]?\ T(4#CNO5?F?Z#'_!'G_E&S^RM_V)WB7_ -6/XUK]+:_-+_@CS_RC
M9_96_P"Q.\2_^K'\:U^EM?XM^)'_ "<3CW_LM.*?_5YCC_;OPW_Y-WP%_P!D
M7PM_ZH\"%?R6?\'*W_(]_LE?]BA\9/\ T_\ PZK^M.OY+/\ @Y6_Y'O]DK_L
M4/C)_P"G_P"'5?I7T8?^3T\*_P#8/Q#_ .LYFI^8?2C_ .3)\6_]?<@_]:/*
M3^8JBBBO]6C_ "2"BBB@ HHHH **** "BBB@ HHHH _I)_X-M?\ DNW[2O\
MV2+P3_ZG&H5_7_7\@'_!MK_R7;]I7_LD7@G_ -3C4*_K_K_*WZ4?_)Y.(/\
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M ,]8?^_T7_Q=%GV?]?\ #K[PY)_RR_\  7_D.HIN^/\ YZP_]_HO_BZ-\?\
MSUA_[_1?_%T6?9_U_P .OO#DG_++_P !?^0ZBF[X_P#GK#_W^B_^+HWQ_P#/
M6'_O]%_\719]G_7_  Z^\.2?\LO_  %_Y#J*;OC_ .>L/_?Z+_XNC?'_ ,]8
M?^_T7_Q=%GV?]?\ #K[PY)_RR_\  7_D.I\?^LC_ -]?_0A46^/_ )ZP_P#?
MZ+_XNGQR1B1#YL/WU_Y;1>H_VZ5GV_K^FOO&H3NO=ENOLOOZ'^@U_P $>?\
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MPXJE10J5'%U>)\GI0]RE&<W><XK2+M>[LDVOY1J*^@/^%)VG_0Q77_@MA_\
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MA_KQPS_T,)_^$6._^9O/\^S/W)_X-M?^2[?M*_\ 9(O!/_J<:A7]?]?RD_\
M!O9X"@\(?&K]H>ZBU2:_-Y\+/!UN4EM8[<1B/QG>RAPR32EB2V,$#'7/:OZM
MJ_R/^EC@<5EOC;Q'A,93]E7IX#AZ4X*=.I95,BP%2+YJ<IP=XR3TE=;-)W1_
ML1]$C,,)F?@;PSC,%5=;#U,=Q!&$W3J4VW3SG&0FN2K"$U:46M8J^ZN@HHHK
M^;C^E0HHHH _RO/^#QS_ )2W^'_^S0O@O_ZEWQ8HH_X/'/\ E+?X?_[-"^"_
M_J7?%BB@#^_S_@B7_P HD/\ @G1_V:%\$_\ U$;.OU'K\N/^")?_ "B0_P""
M='_9H7P3_P#41LZ_4>@ HHHH *_+?X@? OX(:OX[\9ZKJWP8^$>JZIJ7BK7[
M_4=2U+X9^"+_ %#4+Z[U2YFNKV^OKO0IKJ\N[J9WFN;JYEEGGF=Y99'=F8_J
M17P5XP_Y&SQ-_P!A_5__ $ON*_2_#3$8C#X_,GAZ]:@Y8.DI.C4G3<DJR:3<
M)1;2>MGI<_+_ !/P^'Q&!RM8BA1KJ.+K.*K4H55%NBDW%3C))M:75F?/O_#/
M7P _Z(3\%O\ PU'@#_YG:/\ AGKX ?\ 1"?@M_X:CP!_\SM>OT5^Q?VEF/\
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M38_Y2%XK_P"Q9PK_ .LUE9_O!]!W_E'/A#_L9<4?^M!CPHHHK^3C^N HHHH
M_P KS_@\<_Y2W^'_ /LT+X+_ /J7?%BBC_@\<_Y2W^'_ /LT+X+_ /J7?%BB
M@#^_S_@B7_RB0_X)T?\ 9H7P3_\ 41LZ_4>ORX_X(E_\HD/^"='_ &:%\$__
M %$;.OU'H **** "O@KQA_R-GB;_ +#^K_\ I?<5]ZU\%>,/^1L\3?\ 8?U?
M_P!+[BOT7PY_W[,?^P2G_P"GD?FOB3_N66?]A5;_ -,HYRBBBOUL_(0HHHH
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M>%__ )*H_P")HO!K_HH<P_\ $=SW_P"8/ZL_*Y_Q*AXU?]"#+/\ Q(\C\O\
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MOG+P]DFVTFKIN-DTG9M:ZJZ:TZZ='?ZA_M;2?^@IIO\ X'VG_P >H_M;2?\
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M.C_LT+X)_P#J(V=?J/7Y<?\ !$O_ )1(?\$Z/^S0O@G_ .HC9U^H] !1110
M5^-_Q._Y*3\0/^QT\3?^GB[K]D*_'#XG*W_"R?B!\C_\CIXF_@;_ *#%W@CC
MD'L:^_X _P!\S#_L&I?^G3\\\0_]SR[_ +":W_II'#44NUO[C_\ ?#?X4;6_
MN/\ ]\-_A7ZE9]G_ %_PZ^\_*A**7:W]Q_\ OAO\*-K?W'_[X;_"BS[/^O\
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M?ULT3*$9V4HQDEJN9)V^\\R_M;5?^@KJG_@SO_\ Y)H_M;5?^@KJG_@SO_\
MY)K/HJO;5?\ G[4_\#E_F1[&C_SZI_\ @$?\O+\^[-#^UM5_Z"NJ?^#._P#_
M ))H_M;5?^@KJG_@SO\ _P"2:SZ*/;5?^?M3_P #E_F'L:/_ #ZI_P#@$?\
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MRT(2:?-J+ZSK,][J#01Z/^Q/_#GG_@HI_P!&^+_X='X2?_-K1_PYY_X**?\
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M^?\ !$O_ )1(?\$Z/^S0O@G_ .HC9U^H]?EQ_P $2_\ E$A_P3H_[-"^"?\
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M\>7G[/FN>/M>M_#O@KX=?LN>&/V:?"_C+_A9OC/1_"']O>+OBIXCMOC%HGQ
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M%_X>SPC_ /)E 'ZCT5^7'_#[3_@DA_TD7_9"_P##V>$?_DRC_A]I_P $D/\
MI(O^R%_X>SPC_P#)E 'ZCT5^7'_#[3_@DA_TD7_9"_\ #V>$?_DRC_A]I_P2
M0_Z2+_LA?^'L\(__ "90!^H]%?EQ_P /M/\ @DA_TD7_ &0O_#V>$?\ Y,H_
MX?:?\$D/^DB_[(7_ (>SPC_\F4 ?J/17Y<?\/M/^"2'_ $D7_9"_\/9X1_\
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<-4T]GMAJ=E;:CIUS<VH9GAAOK5GPTFU2@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>chart-ade9397b4ccf58cca64.jpg
<TEXT>
begin 644 chart-ade9397b4ccf58cca64.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #I 2H# 2(  A$! Q$!_\0
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M.3/^"2/_ $CH_9!_\,CX/_\ D*C_ (<F?\$D?^D='[(/_AD?!_\ \A5^HU%
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M)]T?[\?_ *,6O\,7_@H)_P GZ?MN?]G=_M)_^KE\:4 ?Z^__  1,_P"42/\
MP3H_[-!^"/\ ZA]E7ZC5^7/_  1,_P"42/\ P3H_[-!^"/\ ZA]E7ZC4 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 R3[H_P!^/_T8M?X8O_!03_D_3]MS_L[O
M]I/_ -7+XTK_ '.I/NC_ 'X__1BU_AB_\%!/^3]/VW/^SN_VD_\ U<OC2@#_
M %]_^")G_*)'_@G1_P!F@_!'_P!0^RK]1J_+G_@B9_RB1_X)T?\ 9H/P1_\
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MTK_<ZD^Z/]^/_P!&+7^&+_P4$_Y/T_;<_P"SN_VD_P#U<OC2@#_7W_X(F?\
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M(/AA\:(/#VG^$M-^'-UIO[,/[-_BWPO;_#SX=0W.MZ)X7^'7AKQUXFO-2LO
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MR[8_]5!_U[V__HB.O]1+XF_\DY\>_P#8E^*__4?U&O\ +MC_ -5!_P!>]O\
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MEU"]:-7O+Z2XNG >9A7IM%% !7XH?\%^?^4?&N?]E?\ A'_Z?+VOVOK\4/\
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MAW2M&@ABL_AS;>(O$6L>#M TIM-T6R\5WNF>*+FSNM6\,^'Y;'Z-    &
M!Z < 4M% !1110 4444 ,D^Z/]^/_P!&+7^&+_P4$_Y/T_;<_P"SN_VD_P#U
M<OC2O]SJ3[H_WX__ $8M?X8O_!03_D_3]MS_ +.[_:3_ /5R^-* /]??_@B9
M_P HD?\ @G1_V:#\$?\ U#[*OU&K\N?^")G_ "B1_P""='_9H/P1_P#4/LJ_
M4:@ HHHH X?XF_\ ).?'O_8E^*__ %']1K_+MC_U4'_7O;_^B(Z_U$OB;_R3
MGQ[_ -B7XK_]1_4:_P NV/\ U4'_ %[V_P#Z(CK^]OH6?[EXA_\ 85PQ_P"F
M<]/\_P#Z;G^]>'G_ %YXE_\ 2\C'4445_<1_!X4444 ?VT?\&[W_ "8IXO\
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M'_U#[*OU&K\N?^")G_*)'_@G1_V:#\$?_4/LJ_4:@ HHHH X?XF_\DY\>_\
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M_B?Z:'_(FX$_[&6>?^HV7']S?0E_Y'''G_8MR;_U*QA[E1117^?Y_H4%%%%
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MX*5_]$*T#_P\OPE_^:RC_B*_A?\ ]'$X(_\ $HR7_P";?/\ /LP_XA!XJ_\
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M06GPY^('Q O?"=M;:5<B6PD /Z(Z*** "BBB@ HHHH **** "OQ0_P""_/\
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MPJ^)WPH^-E[X0\$_&>#PGXRT+X#_  J_9D^(?@'XA_#[XGIJ6B^/1<Z#\!O
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M !1110 4444 %&!G..>F>^/2BB@ HHHH   .@Q]**** "BBB@ HHHH ****
M"BBB@ HHHH 9)]T?[\?_ *,6O\,7_@H)_P GZ?MN?]G=_M)_^KE\:5_N=2?=
M'^_'_P"C%K_#%_X*"?\ )^G[;G_9W?[2?_JY?&E '^OO_P $3/\ E$C_ ,$Z
M/^S0?@C_ .H?95^HU?ES_P $3/\ E$C_ ,$Z/^S0?@C_ .H?95^HU !1110
M4444 %%%% 'Y\_MH?MA>/?@A\1_V:?V9_@%\.O!_Q,_:=_:VU;XIK\-=/^)W
MC76?A]\)O!?@;X'^#;3QG\5?B5\1?$OA?PIXX\5RZ?H<.M>%/#V@>%O#7AFX
MU;Q1XC\464 U#1]-L=2U&'YHC_X*L^-M&_9F_:7\;>(_V4/&?B;]J+]DGXN_
M%/X!?&#X&?"'Q-:^+?A[9>-?AQ\(+CXYZ;\59_C/XGTSP7#X-_9N\:?"^31?
M%-GX_P#''A;2?%&FZEJZ_#JR\&^)?B =)TC6_I#]M/\ 8_\ B)\:?B9^S/\
MM0?L]?$#P1\/?VG?V2-0^+,7P[?XK>#]=\;?"+Q[X"^.W@ZQ\&_%+X<?$/2/
M"'B/PCXRTZ#41H7A/Q3X8\7>&=<;4?#7B3PM;B?1];TG5M3L7_-_X-?LC_\
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M /J.BBB@ HHHH **** "BBB@!"0 2>  23[#K7XW?'C_ (*+?M'6'Q9_:_\
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M_P .K;7[+P'+XO6QA&O2>#[7Q/>7WB2V\-/J(G.D0:Y>W6JQV)B2^N);@.Y
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MK]1J "BBB@ HHHH **** "D  S@ 9.3@8R?4^I]Z6B@ HHHH **** "BBB@
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K;75K/#=6MS!-\8_&4D,]M<V[R07$$T;+)#/!))#+&RR1NZ,K'Y)HH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>chart-aeca25847b2a5d44978.jpg
<TEXT>
begin 644 chart-aeca25847b2a5d44978.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #D 2H# 2(  A$! Q$!_\0
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MH_9"_P##)^$?_D.OU'HH _+C_AR7_P $D/\ I'1^R%_X9/PC_P#(='_#DO\
MX)(?](Z/V0O_  R?A'_Y#K]1Z* /RX_X<E_\$D/^D='[(7_AD_"/_P AT?\
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M %<OC2O]SJ3[H_WX_P#T8M?X8O\ P4$_Y/T_;<_[.[_:3_\ 5R^-* /]??\
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M;4[9[/4=(U:RM=2TN_M),"2VO-.OHKBRNH'P-\,\$D;8PRD5^7GQ"_X(I_\
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MV:#\$?\ U#[*OU&H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M  1,_P"42/\ P3H_[-!^"/\ ZA]E7ZC5^7/_  1,_P"42/\ P3H_[-!^"/\
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M  1,_P"42/\ P3H_[-!^"/\ ZA]E7ZC5^7/_  1,_P"42/\ P3H_[-!^"/\
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M]$S_ &EO_"/^''_STJ/^(%>+O_1!9]_X)H?_ "_S_/LP_P"(\^#W_1P,@_\
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MJZ=+'2E[.C1IU*M6=E&G3A*I-QA%N/\ HL?\/6/^"=W_ $=M\(?_  <:A_\
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M (>L?\$[O^CMOA#_ .#C4/\ Y5T?\/6/^"=W_1VWPA_\'&H?_*NO\\#S)/\
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MXA_]A7#'_IK/3_/_ .FY_O7AY_UYXE_]+R,=1117]Q77=?U_PZ^\_@^S[/\
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M&%PF$P6%5187 X3"X.E0H4RBBBO?NNZ_K_AU]Y\[9]G_ %_PZ^\_2+_@D/\
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MZK_@I)_XDEX'_P#G*5_3517I?ZY\8_\ 16\4?^)!F_\ \V>7Y]V>=_J;P?\
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M_P""LWPH/B@::/$A\"?M;>%/#_\ ;HT;[?\ V0-4^R?!8"[_ +,_M34OL7F
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M'_27:..O'0[CNZ@XW9W$$@9!.#@9IP  P!@#@ = /2@ HHHH **** "BBB@
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MC_LT'X(_^H?95^HU?ES_ ,$3/^42/_!.C_LT'X(_^H?95^HU !1110 4444
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M -D+_P ,OXN_^>Q110 ?\1CG_!6__H7_ -D+_P ,OXN_^>Q1_P 1CG_!6_\
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M_P 1CG_!6_\ Z%_]D+_PR_B[_P">Q110 ?\ $8Y_P5O_ .A?_9"_\,OXN_\
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):>8H9&** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>chart-f886e6c0564f5edb9d1.jpg
<TEXT>
begin 644 chart-f886e6c0564f5edb9d1.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #I 2H# 2(  A$! Q$!_\0
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M.3/^"2/_ $CH_9!_\,CX/_\ D*C_ (<F?\$D?^D='[(/_AD?!_\ \A5^HU%
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M)]T?[\?_ *,6O\,7_@H)_P GZ?MN?]G=_M)_^KE\:4 ?Z^__  1,_P"42/\
MP3H_[-!^"/\ ZA]E7ZC5^7/_  1,_P"42/\ P3H_[-!^"/\ ZA]E7ZC4 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 R3[H_P!^/_T8M?X8O_!03_D_3]MS_L[O
M]I/_ -7+XTK_ '.I/NC_ 'X__1BU_AB_\%!/^3]/VW/^SN_VD_\ U<OC2@#_
M %]_^")G_*)'_@G1_P!F@_!'_P!0^RK]1J_+G_@B9_RB1_X)T?\ 9H/P1_\
M4/LJ_4:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** &2?='^_'_ .C%K_#%_P""
M@G_)^G[;G_9W?[2?_JY?&E?[G4GW1_OQ_P#HQ:_PQ?\ @H)_R?I^VY_V=W^T
MG_ZN7QI0!_K[_P#!$S_E$C_P3H_[-!^"/_J'V5?J-7Y<_P#!$S_E$C_P3H_[
M-!^"/_J'V5?J-0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #)/NC_?C_\ 1BU_
MAB_\%!/^3]/VW/\ L[O]I/\ ]7+XTK_<ZD^Z/]^/_P!&+7^&+_P4$_Y/T_;<
M_P"SN_VD_P#U<OC2@#_7W_X(F?\ *)'_ ()T?]F@_!'_ -0^RK]1J_+G_@B9
M_P HD?\ @G1_V:#\$?\ U#[*OU&H **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "D8X4D<D G'/8>P)_($^U+0>1UQ[^G^?\ ]= '
M\Y&D_P#!6GXWZY_P50G_ &2M6\5_LL_!KPOH7Q-^)?PE7]F;X\/\1_A;\=?B
M9X9T#XA?";POX+^.GPV^,'B;2X/AWXZ\0?%#PMXC\8?$OX*_"'P#HFNZ1XH\
M'^']9\(^*?%^F>/;[2]3\+X;_P#!:;XGZ!\4K3Q;XS\1?L>Z9\';S_@HC?\
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M_P %2?$'[&'C/X"Z;\(/@O8?LF?%_P".G@CQ!XJUVRUSXN?$K5/AM^TE\/\
MX(6GC@Z=X8UF_P#"W@/X5^*K'7M9UOP-H&JR:O\ $'Q!I,VD^)/%$7@*5AX1
MDY'_ (*I?\%!?B#^Q'XF_9=\-:/XK^!/P ^'/QZ\0_$K0?&G[7?[3W@SXE?$
M/X)_"KQ)X.\/:/K?@;X::AX6^&'BKP%?IXP^+R7?B6]T'Q%XK\>>%_"6AZ-X
M \2/+_:^IW-I:V^9<?\ !/#]MV?]O+3_ -N,?M__  C34]*^&_B'X V/P\'[
M"H^QK^SSXE^-'AWXQ:EX+N/$J_M1K//X^-QX8TS0X?B<-'CM8T-WJ1\"O+<_
M98^Z^,G_  3U^/WQ.^)?PS^/^E?MFZ9IG[0/PKB_:<\!^'O$?CO]EOX?_$[X
M377P"_:&^(NC>,-*^&^I_!NX\9^%8[3QQ\,O#/A+P;\/K'XU>%/&?AKQ3XYT
M/3=<7QQIFJ:;XIU#18@#Z2_X)[_M%_$#]K']D/X0?'_XF>%O"?A;Q/\ $.Q\
M37T;> ;_ %:^\ ^,O#.E>-/$?A_P3\5? B>(L>*=)\%_%[P?I.B?$WPOX<\7
M*OBWPSHWBFTT'Q(9-6T^YED^SZ^.OV%/V._"W[#/[/NE_ KPOXHU'QG_ ,5M
M\3OB9XF\1W>@>&_!>FZAXX^,'CW7/B/XT/A+X>>"[/3_  9\-O!%OX@\07EK
MX0^'_A2SBT7POH4-I812WUT+O4;O[%H **** "BBB@ HHHH 9)]T?[\?_HQ:
M_P ,7_@H)_R?I^VY_P!G=_M)_P#JY?&E?[G4GW1_OQ_^C%K_  Q?^"@G_)^G
M[;G_ &=W^TG_ .KE\:4 ?Z^__!$S_E$C_P $Z/\ LT'X(_\ J'V5?J-7Y<_\
M$3/^42/_  3H_P"S0?@C_P"H?95^HU !1110 4444 %%%% ",<#/'4<G. "0
M">/0?AZD#D?SA?\ !.[_ (*S_'G]KK]LSQC\'_'?B_\ 94\#/=>$H9M0_8U\
M51?$WX3?M9_LZ^)],E^,;ZGHSVWQ#TVT;]I+Q!X>_P"$1\%6_P 8QX1T+PEX
M/T?2/&&B>,_AOK^H:+HNM6_BK^CJ6,2QR1%I$$B,A>)VCD4.I4F.1"'C< G:
MZ$,C892& (_%'X<_\$GOB1:?M@>"?CY\>?VM_%7[0'P^^ ^J_#CQ?\ ]/\5^
M O!&F_'"[\7_  ]\'_M ?#WP[_PO3XS:'IEAJ/C_ $OPCX2^.^N+!=:'IWA;
M4OB=K"Z1J7Q,%Y)X3C'B< H>&OVK_P#@HG\.OVN(/@S\?_%?["?Q"^&/PP^
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MZ;X>?##Q7KOA;PO!#X9^'%MK$EU#XC\?Q^+_ !-9V^J( >;_ +=G_!2GXW?
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MX+GA\MS?,,#0G6RW.I5I4<)BZM"E*K*'$-*$JCA33FX4Z<7*[C"*E9?WQ?\
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M^9GD?E_U3GD_O8?\3F>*/_0FX'_\->>>7_52?U\V?WQ?\/OO^":O_1?=1_\
M#1?&/_YA:/\ A]]_P35_Z+[J/_AHOC'_ /,+7\#N3ZG\S1D^I_,T?\2>^&/_
M $..-^G_ #,\C\O^J<\G][#_ (G,\4?^A-P/_P"&O//+_JI/Z^;/]-[X ?M!
M_"?]I[X:Z7\7?@KXEE\6> =9U#6M+T_6IM$UWP])/>^'M2GTC5HCIGB/3M+U
M2(6U_;S0B2:S2.<+YL#R1,KGVFOQS_X(1?\ *.CX:_\ 8^?&+_U8FLU^QE?P
M!QWD>#X8XTXJX=R^>(JX'),_S7*\)4Q<Z=3%3P^"QE;#T98BI2I4*4ZTH4XN
MI*G1I0E.[C3@FHK_ $-X#SW&<3\%\*\19A3P]+'9WD&59IBZ>$A4IX:&(QN"
MHXBM&A"M5KU84E.I)4XU*U6:C92J2=VRBBBODSZP9)]T?[\?_HQ:_P ,7_@H
M)_R?I^VY_P!G=_M)_P#JY?&E?[G4GW1_OQ_^C%K_  Q?^"@G_)^G[;G_ &=W
M^TG_ .KE\:4 ?Z^__!$S_E$C_P $Z/\ LT'X(_\ J'V5?J-7Y<_\$3/^42/_
M  3H_P"S0?@C_P"H?95^HU !1110 ?Y_.OR>O/\ @MO_ ,$W;&[NK&Y^.VJ1
MW-E=7-G<QCX2?%YQ'<6D\EO/'O3P2R/LFB==Z,R-C<K%2"?U@/3\5_F*_P M
MGQ83_P )3XFY/_(R>(>__4:OZ_I+Z/'A!PSXKU.+8<1XO.L(LBAD<L'_ &/B
M<%AG4>92S95_K'US+LP4U%8"C[+V:I<O-4Y^=2BH_P S_2-\8^*/"2CPC4X:
MP>28N6?5,[CC%G.%QV)4(Y:LH=#ZNL%F67N#D\?6]K[1U5)1I\O):7/_ '??
M\/P?^":W_1>-5_\ #1?&#_YB*/\ A^#_ ,$UO^B\:K_X:+XP?_,17\$.3ZG\
MS1D^I_,U_3/_ !)[X8_]#?C;_P .>2>7_5.^7X^M_P"7?^)S/%+_ *$_ _3_
M )E6>?W?^JD\G]_FS^][_A^#_P $UO\ HO&J_P#AHOC!_P#,11_P_!_X)K?]
M%XU7_P -%\8/_F(K^"')]3^9HR?4_F:/^)/?#'_H;\;?^'/)/+_JG?+\?6Y_
MQ.9XI?\ 0GX'Z?\ ,JSS^[_U4GD_O\V?WO?\/P?^":W_ $7C5?\ PT7Q@_\
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MF@N:$HR5XM-E%%%=1RA1110!_=Y_P0B_Y1T?#7_L?/C%_P"K$UFOV,K\<_\
M@A%_RCH^&O\ V/GQB_\ 5B:S7[&5_C9XO?\ )T_$/_LL>(?_ %9XD_VJ\(/^
M36^'W_9'\/?^JO"A1117YT?HPR3[H_WX_P#T8M?X8O\ P4$_Y/T_;<_[.[_:
M3_\ 5R^-*_W.I/NC_?C_ /1BU_AB_P#!03_D_3]MS_L[O]I/_P!7+XTH _U]
M_P#@B9_RB1_X)T?]F@_!'_U#[*OU&K\N?^")G_*)'_@G1_V:#\$?_4/LJ_4:
M@ HHHH 0]/Q7^8K_ "V/%G_(T^)O^QD\0_\ IZOZ_P!2<]/Q7^8K_+8\6?\
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MQ%#"931>+I>F45@^'-7.MV$]\\MH)#?W2C3X)(GO-%M&*MIVF:XD<\S6^O\
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M+_T,FK_^&[^)_P#\Q5?ZU&![_F?\:,#W_,_XU^O_ /$Y'B)_T3?!'_A'G_\
M]$/]7?E;\<_XDM\-/^BCX[_\+^'_ /Z&_7^EK_DK_P#"_?A+_P!#)J__ (;O
MXG__ #%4Y_V@?A3(09/$^M.1G!?X??%%R << MX+) X' X]J_P!:; ]_S/\
MC1@>_P"9_P :/^)R?$7_ *)S@G_PCS_7_P V'^KORL?\26^&FC_UCXZNNOU[
MA[RO;_C&^O\ EVU_R6!\?_A.,8\3:R-IRN/A[\4!M/'*X\%_*>!R,'@<\"C_
M (7_ /"?YO\ BIM8^;EO^+>_%#YCG.6_XHOGGGGOS7^M/@>_YG_&C ]_S/\
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MRC>*[+P;?:;XGN-+^R_:@R:-?6UZ9S 1+Y0D5OQ7_9;_ ."?O_!07X:?#_\
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MX(_^H?95^HU !1110 4444 %%%% !28&<X&<8SCG'IGKBEHH **** "BBB@
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>emergentlogo01.jpg
<TEXT>
begin 644 emergentlogo01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %- P\# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 444UG5%+,P  Y).* %H. .37&:W\1-,TXM%9_Z=../W9P@/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ML7LS0HHHJCSPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MS5V"&*WA6*&-8XT "JHP !Z5)WHC!1#'9C5Q<M=(]$+1115'GA1110 4444
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MZCBO<+&\AO[*&[@;,4J!U/L1FM(S4CQ,PRZ>#DKZI[,LC/>EI*Q->\36'AZ
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MIJ,5JD95LPQ-:')4G= W2OGG5_\ D-7_ /U\2?\ H1KZ&/3\*^>=7_Y#5_\
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M_P#017M=>*?$+_D<KO\ W8__ $$5%78]/(/]Z?H_T.7KK/AQ_P C=%_UR?\
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M?Z0_^SU%/XD>OG/^Y3^7YGI=%%%=!\,%%%% "'I^%?/.K_\ (:O_ /KXD_\
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M4_\ KW?^5:/8\+#_ ,:/JCP2BBBN8_2%L>W?#_\ Y$K3_K)_Z,:NFKF?A_\
M\B5I_P!9/_1C5TU=*V1^=8S_ 'BIZO\ ,****9SA7,_$#_D2M0^L?_HQ:Z:N
M9^('_(E:A]8__1BTGLSHP?\ O%/U7YGB-%%%<Q^BO8]Z\)_\BIIG_7NG\JV:
MQ_"G_(JZ9G_GW3^5;%=*V/S?$?Q9>K.'^)]FTWA^"Y49^SS M[ \?SQ7DE?1
M.H64.H6$]G.NZ.9"K"O#->T&[\/Z@UO<*3&3^ZE ^5U_H?4=OI@UE4CK<^ER
M'%P]FZ$G9]#-@F>WN(IXS\\;AU/H0<C]17T#I.I6^K:9!>V[ I(H.,_=/<'W
M!KYZK5T;Q%J6A2%K*?",<O$_*-]1V/T(^M3"7*SMS7+GBX)P^)?B>_TE>80_
M%:X5,3:3'(WJLY7]-I_G5#4?B9J]TI2TBAM%/\0&]A]"?\*U]I$^=CDN,<K.
M-O.YZK-?VEO*D,UU#')(<(C. 6^@[U9XQ7A&F:+K'BF^WIYDFYOWES,257\3
MU/L.:]R@C,%O'&SEBBA2QZGWIQES=#''8.&%:BI\TNOD344451P!4;QI*A1U
M5E88(89S4E% )V.6U#P#H-^2RVS6SG^*W;;^G3]*P9_A3"3^XU61!_TTA#?J
M"*]&Z45+C%]#LI9CBJ2M&;_KU/,/^%4W'_06C_[\G_&K$'PIC!S<:JS#N(X0
MO\R:](HI<D39YQC&K<_Y',:;X$T'365UMC<2K_'.=_Z?=S^%=*JJBX4  #M2
MTM79+8X:E:I5=YR;"BBB@S$ZBN.U3X=:7J6H2W?GW$#S-N=8R-I8G)/(SD]^
M:[*DXH:3W-:.(J4)<U-V9P/_  JO3O\ G^N__'?\*Z3P_P"&[+PY;216AD=I
M#EY)""6/8< # ],5MTGUI**3ND:U<;B*T>2I-M"T444SE"BBB@!#R*XW4OAS
MI>HW\UV)KB!Y6+,D97;G\1GWZ]Z[.DZ4FD]S6C7JT'S4Y69P/_"J]-_Y_KO_
M ,=_PKI?#_ARS\.6SPVAD8R'<[R$;F/3L.GI6U10HI;(TJXW$5H\E2;:"BBB
MF<P4444 (>17&:C\.-+U"^ENQ/<0M*Q9E0KMR3DGD9_6NTI.E)I/<UHXBK0?
M-3=F<#_PJS3?^?Z[_P#'?\*Z;0/#MGX=M&@M"[;VW.\A!9C^  _2MFDH44G=
M(TK8W$5H\M2;:%HHHIG,%! /4444 <_J7@W0]4RTMBD<IZR0G8<^^.OXUSEQ
M\*K1S_HVI31^GF('Q^6*]" Q2TG&+Z'72Q^)I*T)L\P/PHG#<:M'CMF _P#Q
M521?"@Y!FU;([A(/Z[OZ5Z714^SB=#SC&-6Y_P $<A8?#K0K)@\J2W3CG]\W
M'Y  '\<UU,%O#;0K%!$D<:C 5%P!4O:CFJ22V.&MB*M9WJ2;%HHHIF0E<SK_
M (*T[Q!=K=3230SA=I:(CYA[@@]*Z>DH:35F:4JU2C+FINS.!_X57IW_ #_7
M?_CO^%;'A_P9I_A^Z>ZADFEG*[0TA'R@]<  =<#K7344E&*=TC>IC\34CR3F
MVA:***9R!1110 E-=U1"SD!0.233J\Q^(WB64W!T6U<H@&;@@\MD<+].Y]<@
M>M*3Y5<Z<'A98JJJ<?Z18\3_ !"M"DMCIUO'=ALJ\LPS'] /XOY?6O,W;?(S
M;57))PHP!GL!Z4E:N@:#=>(-0%M;_*J\R2L"51??U)[#O^9KG;<F?:T,-0P%
M)M;+=OJ9B(\L@2-6=F. J@DD^P%:G_",ZYC/]E7?08_=FO8]#\,Z=H,(6U@#
M2D?-,XR[?C_0<5LX'I6BI::L\:OQ"^:U*.GF>!_\(QKO_0)N_P#OT:/^$8UW
M_H$W?_?HU[[@48%'LT8_ZPU_Y4> /X;UQ!DZ3>XSVA8G\A5&>UN+9@+B"6(G
MIYB%3^HKZ-P/2HY(8ID*21HZ'J&4$4.EYEPXAJ)^_!-'SA17K7B/X>V5]$\^
MEHMK<@9V+PCGZ=OPKRB6*2"9XI49)$8JRD8((."#^-9RBXO4][!8^EBXMPT:
MZ%K2M4N=&U&*]M7*NAY&>'7NI^O_ -?K7O.E:C%JNEP7T'^KF3< >H/<'W!_
ME7SS7JWPMNVET>[M6.1#,&7/8,.GY@_G5TWK8\S/L+&5)5UNM&=]1116Q\D5
M;RPM+Z'RKNWCGC_NR(&KEKWX:Z)=$O;^?:D\XC?(S_P+/Z8KLOPI:32>YM1Q
M-:C_  Y-'FDOPH.<PZM@=@\']=W]*C'PHGSSJT>,_P#/ Y_]"KT_BDXJ?9Q.
MU9QC$K<_X(\^M?A59(0;K49Y<=HT"9_/-=1I?AC2-'(:SLD60?\ +5OF;\SS
M6S2U2BELCFK8[$5E:<VPHHHIG*%07-O'=VTMO,H>*5"CJ>X(P:FZTM )V=T<
M$WPLTLL2M[=J#V^4X_2D'PLTS/-]=D=P"HS^E=]14\D>QW?VGB[6YV4].T^#
M2[&&RMEVQ1+M49R?J?J:M]Z.:6J.%MMW84444 )BJ>I:?!JEA+972[H91AA_
M7\ZNTF* 3:=T<$?A9IF>+Z[ [ E3C]*5/A9I:NI:]NV4')7*\_I7>T5/)'L=
MW]IXNUN=D-O!':V\<$2A8HD"(HZ  8'Z5-1FBJ.%MMW8G>JMY8VNH0-!=01S
M1MU5U!%6NM% )M.Z9PM]\,-+G8M:7,]MG^'[ZC\^?UK+;X43@_+JR%?> _\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@".21(8R\CJB#JS' HCD2:,/&ZNAZ,IR*P?'/\
MR)NH_P"ZO_H0H\#?\B=IW^ZW_H1I7]ZQO[#_ &?VU^MOPN=%1113, HHHH 0
MC-'>BLS7-631-'GU%XVD6+;E5(R<D#^M'0<8N<E&.[-/O1CFJ.D:BNK:7!?(
MA19EW!2>15[K1TT"47&3B]T0&[M_M'D&XB$W3RRPW?E4X/%<M-X-6;Q>->-X
MP8.K^3L]%"XSGVS754DWU+JQII+D=]-?4****9F%%%% !1110 4444 %%%%
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M?B>*Y3X7V;0Z)<73# GFPONJ\?SR/PH?Q(*'NX.JWU:2-KQS_P B;J/^ZO\
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M'L""3].,?C6OX4LFT_PSI]LZ[76+<PQT+?,?U-/[?R'+3 )/K*Z^XYSXJ?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6791755920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Lease, Cost</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;padding-top:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">The components of lease expense were as follows:&#160;</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:12px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:61%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Three months ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2020</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease cost:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization of right-of-use assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest on lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total operating lease cost</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_ScheduleOfLeasesSupplementalBalanceSheetsTableTextBlock', window );">Schedule of Leases Supplemental Balance Sheets</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">Supplemental balance sheet information related to leases was as follows:</span></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:39%;"/><td style="width:21%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;font-style:italic;">(In millions, except lease term and discount rate)</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Balance Sheet location</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">March&#160;31, 2020</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease right-of-use assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>25.6</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>24.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease liabilities, current portion</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>22.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>22.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>26.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>25.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating leases:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average remaining lease term (years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>7.7</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>8.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average discount rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_ScheduleOfLeasesSupplementalBalanceSheetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Leases Supplemental Balance Sheets [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_ScheduleOfLeasesSupplementalBalanceSheetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6791734224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and contingencies <div style="line-height:120%;padding-bottom:12px;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">ANDA Litigation - Perrigo 4mg</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">On September 14, 2018,  Adapt Pharma Inc.,  Adapt Pharma Operations Limited and Adapt Pharma Ltd. (collectively, "Adapt Pharma"), and Opiant Pharmaceuticals, Inc. ("Opiant"), received notice from Perrigo UK FINCO Limited Partnership ("Perrigo"), that Perrigo had filed an Abbreviated New Drug Application ("ANDA"), with the United States Food and Drug Administration seeking regulatory approval to market a generic version of NARCAN&#174;(naloxone hydrochloride) Nasal Spray 4mg/spray before the expiration of U.S. Patent Nos. 9,211,253, (the "&#8216;253 Patent"), 9,468,747 (the "&#8216;747 Patent"), 9,561,177, (the "&#8216;177 Patent"), 9,629,965, (the "&#8216;965 Patent") and 9,775,838 (the "&#8216;838 Patent"). On or about October 25, 2018, Perrigo sent a subsequent notice letter relating to U.S. Patent No. 10,085,937 (the "937 Patent"). Perrigo&#8217;s notice letters assert that its generic product will not infringe any valid and enforceable claim of these patents.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">On October 25, 2018, Emergent BioSolutions&#8217; Adapt Pharma subsidiaries and Opiant, (collectively, the "Plaintiffs"), filed a complaint for patent infringement of the &#8216;253, &#8216;747, &#8216;177, &#8216;965, and the &#8216;838 Patents against Perrigo in the United States District Court for the District of New Jersey arising from Perrigo&#8217;s ANDA filing with the FDA. Plaintiffs filed a second complaint against Perrigo on December 7, 2018, for the infringement of the &#8216;937 Patent. On February 12, 2020, Adapt Pharma and Perrigo entered into a settlement agreement to resolve the ongoing litigation.  Under the terms of the settlement, Perrigo has received a non-exclusive license under Adapt Pharma's patents to make, have made and market its generic naloxone hydrochloride nasal spray under its own ANDA. Perrigo&#8217;s license will be effective as of January 5, 2033 or earlier under certain circumstances including circumstances related to the outcome of the current litigation against Teva (as defined below) or litigation against future ANDA filers.  The Perrigo settlement agreement is subject to review by the U.S. Department of Justice and the Federal Trade Commission, and entry of an order dismissing the litigation by the U.S. District Court for the District of New Jersey.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">ANDA Litigation - Teva 2mg</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">On or about February 27, 2018, Adapt Pharma Inc. and Adapt Pharma Operations Limited and Opiant received notice from Teva Pharmaceuticals Industries Ltd. and Teva Pharmaceuticals USA, Inc. (collectively "Teva"), that Teva had filed an ANDA with the FDA seeking regulatory approval to market a generic version of NARCAN&#174; (naloxone hydrochloride) Nasal Spray 2 mg/spray before the expiration of U.S. Patent No. 9,480,644, (the "&#8216;644 Patent"), and U.S. Patent No. 9,707,226, (the "'226 Patent"). Teva's notice letter asserts that the commercial manufacture, use or sale of its generic drug product described in its ANDA will not infringe the '644 Patent or the '226 Patent, or that the '644 Patent and '226 Patent are invalid or unenforceable. Adapt Pharma Inc. and Adapt Pharma Operations Limited and Opiant filed a complaint for patent infringement against Teva in the United States District Court for the District of New Jersey.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">ANDA Litigation - Teva 4mg</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">On or about September 13, 2016, Adapt Pharma Inc. and Adapt Pharma Operations Limited and Opiant received notice from Teva that Teva had filed an ANDA with the FDA seeking regulatory approval to market a generic version of NARCAN&#174; (naloxone hydrochloride) Nasal Spray 4 mg/spray before the expiration of U.S. Patent No. 9,211,253 (the "'253 Patent"). Adapt Pharma Inc. and Adapt Pharma Operations Limited and Opiant received additional notices from Teva relating to the '747, the '177, the '965, the '838, and the &#8216;937 Patents. Teva's notice letters assert that the commercial manufacture, use or sale of its generic drug product described in its ANDA will not infringe the '253, the '747, the '177, the '965, the '838, or the &#8216;937 Patent, or that the '253, the '747, the '177, the '965, the '838, and the &#8216;937 Patents are invalid or unenforceable. Adapt Pharma Inc. and Adapt Pharma Operations Limited and Opiant filed a complaint for patent infringement against Teva in the United States District Court for the District of New Jersey with respect to the '253 Patent. Adapt Pharma Inc. and Adapt Pharma Operations Limited and Opiant also filed complaints for patent infringement against Teva in the United States District Court for the District of New Jersey with respect to the '747, the '177, the '965, and the '838 Patents. All five proceedings have been consolidated. As of the date of this filing, Adapt Pharma Inc., Adapt Pharma Operations Limited, and Opiant, have not filed a complaint related to the &#8216;937 Patent. Closing arguments took place on February 26, 2020. </span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">In the complaints described in the paragraphs above, the Plaintiffs seek, among other relief, orders that the effective date of FDA approvals of the Teva ANDA products and the Perrigo ANDA product be a date not earlier than the expiration of the patents listed for each product, equitable relief enjoining Teva and Perrigo from making, using, offering to sell, selling, or importing the products that are the subject of Teva and Perrigo&#8217;s respective ANDAs, until after the expiration of the patents listed for each product, and monetary relief or other relief as deemed just and proper by the court.</span></div>Nalox-1 Pharmaceuticals, a non-practicing entity, filed petitions with the United States Patent and Trademark Office Patent Trial and Appeal Board (the "PTAB") requesting inter parties review ("IPR") of five of the six patents listed in the Orange Book related to NARCAN&#174; Nasal Spray 4mg/spray. In a series of decisions, the PTAB agreed to institute a review of the '253 Patent, the '747 Patent and the '965 Patent but denied review of the '177 Patent and the '838 Patent. Nalox-1 did not request review of the '937 Patent.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6806679040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="nump">$ 14.8<span></span>
</td>
<td class="nump">$ 14.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted average amortization period</a></td>
<td class="text">13 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 266.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 266.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ebs_RaxibacumabMember', window );">Raxibacumab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in amount of contingent consideration, liability</a></td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ebs_RaxibacumabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ebs_RaxibacumabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6805078912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative instruments and hedging activities - Derivative Designated as Cash Flow Hedges (Details) - Designated as Hedging Instrument - Interest rate swaps<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($) </div>
<div>instrument</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfInterestRateDerivativesHeld', window );">Number of Instruments | instrument</a></td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_DerivativeNotionalAmount1', window );">Notional | $</a></td>
<td class="nump">$ 350,000,000.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DerivativeNotionalAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivative, Notional Amount1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DerivativeNotionalAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfInterestRateDerivativesHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of interest rate derivative instruments held by the entity at the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579245-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5580258-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfInterestRateDerivativesHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>26
<FILENAME>0001367644-20-000047-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001367644-20-000047-xbrl.zip
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M(B=-)9]U93F>B (B 8]8YR'W9%4Z*9!@XJ[]# )HC9ID\V+N=3= _H-QRPF
MHD=N3**?DIE EL;YNR,[+L4%49$A(5Y <<I"15'T%6R.3,(B6'<I0K01HTN2
MK"BC%X=>9QB2#,NUC0P: +H#SBSR 16^->8 @U>$Q9ULC*P+W255(Q=\)+PM
M-Q#F=JR1 Q'\?L30N!O:L?I6!#W*J4AA(TVKQ=UA_%U.37@5 +^TW@]YPJ(8
MKL?U0"(2. AEXEPS+?$%.O"J$J6%)97TI/(!VL],V0<SE*DDX0B?LO"5 +60
MY3@1O,I,##=!%DS8<:7;%=T&U&U8HFQSU6QZ7\M.%\LVI+Z?Z#!*$G2H/5EJ
M,:W)D?!BJ9E(%+" 4"L"E<'UB^L_85OQ#@60E6/+*(EZL9B(CT1T$]%KNFMX
M@5DA!B3@;7D@'[ O!C,X4FD\)DX.9?5'[J+5RE$Q"^H$0[$7BT_9TI38S0@*
MIJ\&,KQ(],?2?3RT!0?#J)^%>(*!47C#388Y8HMY%BC:QKWQ):')11WYHBP:
M)PP@GX( YP 6\@\8YVC'5>PH"(CQB$FC*43;%\ NA9D=CG;+H0D*HD.:K0$+
MPI&*&T/V5P0N7.$8*'@(H>PRDJ>W6#/!2?MK(!J1#G#);X3C2+J,D<H<[Q&E
MG<0\3D)@]87Q!"."%L:I$>4(6$NB]]@P1!),#6H&A&7WJ?&C-H@VK8UTC70\
M@<]P,* -:3#)"Y% CB$\A7_\<-3+O@DNR=TC79=FJN6L+"".[-RE@J0DPJ/]
M-0+E*TBS1;E4\>QFY%@**S ?PX:)!6=QG>[ 03JTQ[.A\C*HNU)@>U$0>R*&
M/3#\1^;(X1EAX,8W9+Z<N!-%M3&9)\J=,P$1AL?I>?QC"N.CT'@J]6]^(%QV
M<5SY+14V'W]6+HZ>[;BDU,:VB;R%=#9@G1J#604*]PA6FSWY=8N@;+I<N, _
MOZS9-FAP4Z)Y>A_W?S;!;1ENGY3U25F?E+55",T0]9^DMEU ?M+>IU3[E&J?
ME/5)61^0LC[UY1[JRP]8)V,?"7//P/@?0+6K;/[\F4M??UR[MA4O2E,K7;QZ
MJEK<QN+A6XQ6*9B.(9:7YM>*2J^!R;I/H[)/FPOZ;W&2FB-*AZ6KTY$OY;7"
M]UO>62GNCBXWQP%+CDR:4<QTSC#%W[_$%UW7&E[]>IGK!P/[ZM]02P,$%
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M,[W!D *%V$\4AO(')/18_S)<-]QQCM@],AQU'=N$)I8=F Y0L24 K<)%2HP
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MHMUBG 5,Y5H'3.6:\D6Y;[98[.564MMWBJ97.]HM41OR'MEOT;QFI[6_N91
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M5+S79+?OV$(:-68$$;VER& 60O,'Z1LTU3OW[7VM2VU@JB/FUT4F*8,QF[-
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MMAMNDKJ_X1F$4A=DHNV0WZG['6D%?O0O+5+MD#M%JN7(%\,T00]>9):M?+;
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MO$[^6J\,@3D*)8VEF3^04H$<:\H7@8@B<U.D6U\OEKG;9;5\^F1[HX HW"U
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MP1G3U?%QHAJA6ZPM=K&!0*2Y4_V2$W!RT=H1*H;)LH[95.T>/S**]XI!B2G
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M4R8^^/J#K_^\?)UM <IV7N18BP9U.=V9E<%H*YXT$S^]+VH":^5_8YOI'\/
M%/K]0'CTGI8Z;3, !S>.LLJ:W->!")NZ1%X6M&?G% &CC=F22T[93#ALHQ,S
MIP=F;I:TLL,%*2XKXTV>X4L^O72B10B:?LW.8_7*JR$7'-J>0C'L]]_B+UW/
M&G_^Z2;?#P?.Y_\'4$L#!!0    (  ^2GE 2@$<F[@8  &PC   :    83,Q
M,2UK<F%M97)C97)T:69I8V%T:2YH=&WM6EUSXC84?=[]%6HZ;;,S!D,^=KN$
M,A,(VS)M=UN6SK:/PKX&362+E6P(_?4]5S8)"62:M*7# P\A2+Z2KG2/SCV2
M:7]Q]:$W^N.7OICFJ1:__-;]:= 31[4P_'3:"\.KT97X8?3S3^*LWFB*D969
M4[DRF=1AV']_)(ZF>3YKA>%BL:@O3NO&3L+1,.2NSD)MC*-ZG,='G9=MKNJ\
M?-&>DHSQ_T7[BUI-7)FH2"G+161)YA2+PJEL(C[%Y*Y%4]1JMY8],UM:-9GF
MXJ1QTA"?C+U6<[FRR%6NJ=._F:JQRMMA6<1@835:>VSB9:<=J[EP^5+3=T>)
MR?):(E.EEZV12LF)][000Y/*[,(_<^I/:C4;L_R"O4?+3EN*3*9HZ]Z\:7;/
MOSUOG#<;K\].7K\]/7_=[;VY:IZ\[35[;T^Z1YUV*/'G6_F/M:]CNU9<N:-5
M1K4I\01;S9/&5Q<YW>0UJ=4D:_EI;SK5YIIMTWF'(%VC0_&]R:<J$EUCK@.'
MP-4<694\[,D7%^708Z-C=-W__8=!=S 2I\UZLQVRP3-=CA!3LKOS^:C3ZP]'
M@W>#WN5H\.']/_)14[+#53WJ# + :4PV%]_7Q8\6R+&!^&CK@8A0J9*ER*<R
M;WW]9?-UXV(O9U!"=0\=.VZ^*I=M\W,@IG).PM)<T0*$@@Z=^+60%GC42S&D
MF4%$3";>&9N*9J/VJS")Z",X$^:AKC(?C2Z8X9P89%']0OSS%?!EE<7HN'7V
M[>QFETORV'KL9_Q.'HU?5SI$#?%)E^(Z,PM-\82",HRV#%YLP-:90=) OQ+#
MRFPIBBRW!<$[I!&?41!5*5*4K)):)#)"E14F5;G(36FW89!11,Y)NV235%X3
MQEWKTZ$NAC,84OM4A#'8(%(6:0QF&9K#DYBL6& AIL(5_''7?D&6JDYX JER
M&@F*4]Y"Y5-,T,TH\@YROS.X9F),<XYFL1@OUY?A ,Q= //T^< DD:@,H6<4
MW84Z "IACL=V[;G*$M".9'K!]T@7,?J$?VMQ#0!%Q50U QH8R QPK>^06H'$
M/1@:FR'VRBQ@BT+# / TP) LV8S]B:2;BD2;A5MAU])$N1SKE O)E:7?\#)8
M@Z!;.;/A[0&%NT#AV:,H'-T+V3>N0EBE*)A(3)(H%'T8!T):\H ! -18$P=6
M$% ZULI-V9S-4I H$RF78^4B;5R!=DROUN@2.3-K(HI1[<0Q@!(3D%>BH7\3
M364V(7$)YAH6&A;-4UEKGA_3*]^T>1Z7I;*H6!IF)6*Y?\'TM@;D$ECLRY,'
M2NX-E& @GN=#>,."M4'K -D=0%8^"MDK<O  (?3)\._Q%7">CF3AGMZ$$^:8
M@)5JI#(%F\*B S#87#G/B["BS/?#RON.4==9V9*6'GQ5#KX#4% Q-C]48%?X
MXHQ6L3^WNF+L5*RD53P!52H%GR<R[JEPG+W]7G4^U7L6Q>D8#N&PZAO-H%%5
M5&C)Y(]I>2?N5 !:E)IB70KAVYC8$/R,]A0?^'@7X!X_$=Q/IK8-C#^=%)\,
M=6R/N8H9P=*93#+[2P?TLTIE6$L;KR &T"LY5EKE2]8%VX;E#>?1Z(%6[I5[
MIFLJUR>9FVI"L\+. '3G=4P4&1M[![S>Q9$+\D0#[WA",]Y(; (M7V(:&T[-
MP/,'5.\"U=&CJ.[/I2X\KW'(*4F@-]4<P7);="-$R!,8NBQN%Y$>OF@(=G6E
M5!V;(G]\[*?D$'EK3:S#D[\_4(GQ2N'['4GE&L"?"]_Y 8'_/0+CQWFU#/$F
M5/BL7\E _^0!$I_!HRP!3!05EJ&PEF_O]9<:EZ.&[S/1BXO0Q>?R,DD<;Q@G
MP#%8[8%=Y2:.7N0O)?B^(BMN?7E5>C*5[E:0,!]ZW%/L$X6??47B2Z'5->GJ
MAN*!?? O%N2 \EVA_/P_.\WYJ\UXM36".\9B EV'ZAUY,>2>(4LV5"^<DM"\
MN;'N5@/X"G26IBK/B;:FA+&!ON GL8)/OODQH P&=LSP^,^:>[7GZ'.AX++?
M9446^0N+5X>#VO][4+O44''P00%R?&#FHW>D"!BI\O?M@6E!\IH3<JGJ?$KV
M>M3?L*YNG)Z%O.IL4UY7;*$Z&:.AHUNFVX+22K_"&("#S Q*/> @!ER1ICB:
M_4E^&E4FV7HK%QQ8\'\_0UTBI2<6I!( !>09$#CR]^,5X((R1ZIL;O2<.%%F
M<E)=\]N*-"F=:;,D/%U,3<F4\AZ< ;]_J1GJ>[FR>_N6[@K1JUYO7N(LI\5I
M(_!O[_<8IGNZF'Z@F&G-LU3+G_K9'8P1NG#XH=L?COQ[YN'ES_UA(#X.]Q.L
M6]^([Z6GO:FB1/1O*"KX_"D^E$ILP]<'/^BHOKZH:D+_PY.7;?^+F,Y?4$L#
M!!0    (  ^2GE#[+^;7%P<  .0D   :    83,Q,BUL:6YD:&%L8V5R=&EF
M:6-A="YH=&WM6F%S(C<2_;S[*Q2G[N*M&CQ@[.0.<U1AP+=4;783A]1>/HJ1
MAE%9,R*2!DQ^?5YK!AL;G+6SZRU7'1^,F9E6ZTG]]+JEH?O-\,-@\MM/(Y;Y
M7+.??CU_-QZP@T8<?VP/XG@X&;*WDQ_?L9.C9HM-+"^<\LH47,?QZ/T!.\B\
MGW?B>+E<'BW;1\;.XLEE3*Y.8FV,DT?"BX/>ZR[=ZKU^U<TD%_C_JOM-H\&&
M)BES67B66,F]%*QTJIBQCT*Z*]9BC<:-Y<#,5U;-,L^.F\=-]M'8*[7@:PNO
MO):]T76FILIWX^H2G<5U;]VI$:M>5Z@%<WZEY7\.4E/X1LISI5>=B<JE8^_E
MDEV:G!=GX9E3?\A.JSGW9X0>+7M=S@J>HZT;]5O]TW]_/SQNM4^&I^U1__3\
M9/##L#UH#2Y.FZV+@UXWYO@+K<+'QM>IW;A<P]&JD(U,T@ [K>/F/\Z\O/8-
MKM6LZ(1A;X/JTIU=P[E D*[@D/W7^$PE[$<I5)E'#J%K.&E5>M]7N%Q6G4^-
M%G ^^M_;\?EXPMJMH^-N3 9/!)T@JM)^!NIS8Z[^ O-!;S"ZG(POQH/^9/SA
M_=_"J&7Z.?/Z283CB%VJ).-6L%^.V#M5")[IB"72>I6NF,^X[_SSV];WS;,7
M";]BZ@L$=MAZ4TW;]N>897PAF94+)9?0$SAT[.>26Y!1K]BEG!OKF2G8A;$Y
M:S4;/S.3LE$N[8QDZ%R97XPN2> <&Q?)T1G[^S,0KA%T..Z<_&M^_9Q3\M!\
MO,SX'3\8OW/N$#7$)U^QJ\(LM10S&55AM%7PA(%8%P8Y WXYNN7%BI6%MZ4$
M.F21D% 05<YR7%G%-4MY@EN6F5QYYDUEMV50R$0ZQ^V*3')^)='OAD^'>P)@
MT*4.F0A]D$&B++(8S HT!Q(A+5MB(C+F2OJX;;^45M9.: "Y<AKYB3+>4OD,
M W1SF02 Y'<.:$9@F LT$VRZVIR&/3&?@YCMIQ-3LE05"#VQZ#;4$5@)<SRV
M&\]5D4)V.,D+OB>Z%/ )?!MQC4!%15(U!QN(R$1PK6^96I/$W>L:BT&$PBPB
MBU+# /0TX!"OU(SP)-QE+-5FZ=;<M7*FG,<\><;I9H4;**,-"KHUF"VT>Q8^
M!PM/'F3AY$[(OG,UP^J*@H3$I*G"90CCF'$K V%  #75D@++)%@ZU<IE9$YF
M.424A)2NA7*)-JY$.Y)7:W3%G+DUB12X[=@AB"(DF%>Q872-"J>82=:'<EV6
M&A:M-F^T3@_EF]"T=2JJJ^I245U85(PE_XSD;8/(%;$(RZ,[2N]TE*(C&N=]
M>L.":H/.GK+/0%G^(&6'T@$!0AB2X:?Y%5&>3GCI'M^$$N94@BMU3U4*-J6%
M RC80KF@B["21?!#E?>MHFZJLI6:!_+5.?B60%&MV/1005V!Q1FM1-BVNG+J
ME%#<*AJ JBJ%D"<*\E0ZRMYAK;J0ZH.*8G,,0-BKAD9SU*@J*34G\<>P HC;
M*@ MJIIBLQ3"MZDD0^@SVDNQU^/G(/?TD>1^M+1M<?SQHOAHJF-Y+)0@!G-G
M"D[JSQW83U4JT1J[TC7%0'K%ITHKOZ*Z8%>WM. "&P/1JK5RQW2CR@U)YKH>
MT+RT<Q#=A3HF28P5 4"H=['E0GFBP7<\D7-:2&2"6K[B-!:<FD/G]ZQ^#E8G
M#[)ZM."Z#+I&(9=IBGI3+1 LMZ-N1!'R"(6N+G<7D8&^: AU=56I.C6E?[CO
MQ^00?F,MJ0Y//[VA8M-UA1]6I*SF 'C.@O,] [\\ \7#NEJ%>)LJM->OR\#P
MY!X3GZ"C5 *8)"DM46$CW][QEQOG<8<.,^'%)7#Q>W68Q ZWC%/P&*IVSZZ&
MB:V7#(<2=%Y1E#=8WE1(,NYN"A+2P\![*4*B"*.O17S%M+J2NCZAN&<??<:$
M[%G^7"P__6*[N7"T*=9+([I5+!+03:K>BA=1[@EER5;5"U <-:\WUMW4 .$&
MG.6Y\E[*G2EA:NC4&T^$ J;0_!!4A@([4GC\IYI[O>;D[Z4"Y+#*RB()!Q9O
M]ANUK[M1ZVM4<<"@0#G:,-/6.U$2'*GS]\V&:2GY%27DJJH+*3G4H^&$=7WB
M]"3FU7N;ZKABA]1Q@89.WBC=#I;6]2N,03B4F5%5#S@4 Z[,<VS-_I!A&'4F
MV7DJ%^U5\*OOH?I(Z:F%J$1@@0P*"!Z%\_&:<%&5(U6Q,'HA*5$6?%8?\]M:
M-&4^UV8E\729F4HI^1TZ@WZ?63,<O<B9?;%OZ8:(7OUZLX^]G&;M9A1>WG\]
MFJH"U%"[6KS,20L="9*OH$:=L+LG..@C=O'E>/"V?SD,+Y/'[X?]M^]>X!@.
M>MOOO%\DS$&F9,HN;M;YAZK6^K_@Y1< T : .1=TB-28&N]-3CZN_PI4Z\F@
M6@^#NO=#FOKKJ_I.''[P\[H;?HG4^Q-02P,$%     @ #Y*>4./J$D=M!
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MZ/NAEC1<]YV.B&<)8GVL%$U-OP1"P[T#0;#X+97]PR2.,HADEK%(MRQ8<)6
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MSE/S,]-'G2TS\#4^7KBJL"(Y*F+TR8A [ZNM#I5QDRKO2NOCEBRK0"SUJ-&
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M,@J\[OA^?&Z&R2^3N^!E56F"FJ#/I<JC9R=SMG3\>LPR!Z %$2-#^>:D/]X
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M?>C0JU.BA,#2RA3HG"\L8X.DMO'7"P%F*AL4 AM<)TSD1);."X$U!U%+;85
MNSGN%!8VLL((@6]Z.&83F6V'Y=G83*%#Q-K4" $XAI#7>5ABI!4V,T8D-82
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M)+OM]VREDV:#ZK)<(LT]M^7CV<"WQ"U#O57R<"A89TLNR1"HS+QKA=6(^X3
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M3;OM#1U5@MVPG["EH[$T1LZ@ 4H)XI 66@FA-KC7N&9P!^3#7V<X[<VDKIE
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M^^3EM7M^SMMT,.7W%YKD:S:K;$Q^S5F=!>P!5CDOVUZ*K;]28&^;;ILBAEK
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M7!$P5\VE3'TI@4,AM&!G*F+$!4D] >*"0UT?4;SMV+5T3CM!#($H$\M*J0#
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MZE&QOD/'J8IKP14SEU#%KS_NP0*[V^HPVY"4NO8_<%0ED^&-;A5B7$;MM/Y
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M?1QI?__Z<<]NS>>#T1^M'SVZJ&YY[IQ;>^C6-OXK].!48_@<9<IQB\H'F9"
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M;-QF"S8H,59J5%M<DC'&\[5]Z.!AIQ2,VYCL^]9T7^S4E:OQZ[,_-5Y!YR?
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M&N]ZU$Y5,]E3IS)!?$U=O__:^JK9A-W"]ND[4\-[O?8>#7(817;6:$ $T%M
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MUQ@];5,9S%Z(*R-G67[J%%YV8KNES*W5:7L S:P-+P! 3$%XNFNN@8\8](8
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M$7 ?Z\#]@MZTH.VW(&57KZCOC_)+<X3<\K3S]+J#>18Y.]QL93ZR[1NF<T0
M@TF!5.A?C&+0RPLX$0"0EP-(0=]G*G2A9<X@JR[3(UWP*U3+(J^9Z.J\/7$X
MT"NJ[+9:9( /M=%'[YE_<W40**>7WNO$N%4B+O,D-4'LFE2@94?1;V<,7N:L
MW[G)3XMS7'S-IEL'UQMN"A /P6,)P7@9XNGX@81W'$K4/&KM9&E?^B E4DD_
M*L^SL-SI3 G')61W_@"XEM!F6M*NMWY;DC,4XO-BPHYY5=\Q]'F/FDQ<W4R
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M)Q5UBU>UA<C!W-^<YV!?O4:]FO,;5'Z4'^6GPHS^!VM>JL) &? .I*,+&+-
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M:!KZ3Y^Q]K$6F#S:Z!MN^O&ZO]S"W*S[A#,Q\:=6J-3 >C4"WW%FGRM+>6]
M7@1'\0DGA;60/1F+7!]=8+8E(?;$\!EHHY?TK4Q;_HTRQSE.A+V<7$3U:A*:
M$#9")7S'0H@)<@4*CSTRK>183R]WGL)0A4F6<MB$WI!H'>'IFHJ*JJM ^ED=
M[Z)U&)ATCW>8)VHE@D>]%AP:51A^+HBZS,P XA]<P\ M_U+K&"B>F,0I7LLW
M,M?H>3^S=-+$.S\I]B*6!/JR+CX<;+%O+!W22\7I49G[JIX\R7[Q-O"D_\JA
MEPM?YQ'2[@I"8V/C'@8\.RTCE$B*G*(B:QVY62+BBLG><W33+G8LL-@]U[/
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MB#79JREL?[ CROL24=7_GU!+ P04    "  /DIY0YZU9+N8X  #*20  '0
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M3J"H@! Z>9]$P+.7POLB8.$"W,'X-/&/NES&][*0M6B$ZZ$1'AL&]M\5R(F
M+NLW#)>2V=%_XTX1D)>L]\_7RCO<B!3!UF&,%'RE&;'D[OQ]N&T-3+#OLK+A
M4-='EASM%.#9=)DQ2Z?R[.H'5663.15-#V[>'[<,N>WZF3BAO+C=>V"P><Y)
M?W,F<8=@C; 6]!,! S[LT48PF;9&!)S!Q=?I0[H-,C9-.T'%BB6RO?_=>FBV
ML\&S>J%"!"36!(HG:G<:"4S84I-XF6 UY'?.=) 4#A.9P%R?$9EPL,LHK"OG
MZ&]HS<W'2PLV<1-X6X5WZ]0C%]EMS3/)0W)<_)60D(JVU<A[5A^!._#MP]O&
M@36/S&;BLGRU:YZU5]!48)T1PI46-<\$([L"7!*+265/8C$P[7#7--GBH0C8
MFH.-!<_A!SQYNNA&90BTX3W85/Q9[!I'4A',K&=LJ-M&:7D+848"TJW\H!9$
M,H*+X40T4OM#W5)</U*4"'Q';[(-[)(?R>)4)5FM#&3/2(S7K8:O<$V."&GT
MTQWA.#G66(Z>^$(HQ$<D<7PI@0OLPK49H?XN H(8L6IM#=38:SZ?R#[<9_"D
M8T<8-6']I5C3'*/\$;FRRNSHN^,4G?U^;!G7Y0^&^.9=+7%EX?$;L6["7'P0
ML7^&]QB*$0%4?  QA2(%5[#3M+RRF3G3,U<73,Y'L!FRS! 2>1F3;.K8=[9B
M1CK8GE#SM"NOHV9OP7A5YWAVC^5U64>_*-)YW3E'#E:&;"<L")L9$ 'N53"-
M[T\.%-XF2PP3^U@CC%ATK;0D$"*\/6["NP'1IZ,A9=[M'HJN+>39@!7;9BU.
M^:!I)'P(!N 2UO=4^EIS"QL,[1NJOQ8R1WMK;-AM8I%/%QNK"[J\(SH8C_'I
MB!9LSKLL9#"&\VCJX:QDK&S=.L&OT.C45LAQ/W<T'O0C);/$#"E&Y$-051(Y
M=+B6V"@")!BGJ0I413*9RL9?5A[!,EDKALC.<%IX*7$RYP&-:^Y+/5(.GQ^^
MHS-H#PA_Z4&CYB$#<J:M(_LR8(DRI$\$B(714R\1J6T-[^W9W3/IAK]R;6F-
M>SEK:PQ$P-KPYMR/R S16CM'0^:L=)U?4$;+Z?OO)@KGU\I&B5M=@V/W8G]?
MA3U/S&0I4U,H>\!Z#^L5@A5<Y00K%-*DI_DXR@>UMND[)42-#2XBX*H"1WQZ
M-P=,2H)2AIWCRB8R T?V]YRKDX ]"?!-KN<AJ)>7VM$'#S82,8)0LP0>[8I@
M-WABN1'ESA^E,7=_ G<&<^*(I)<(6*UVA2<#M<6&D:0$%IUU>H)@&"U4:;DZ
ML!\;5!+80?0&7,)T@4 <.I<]@M$,TMS"924;7:U22ZLM3#35(YM _/H!9\9(
MF\;0L2';>^,] Q>II9.6OXJ/+R@M>7'?(I)'.)@KB#PLD8_I!YL@2@=+(\3:
M*%AKV+Z)E$R3MI:%26S2%3" _]G$ :[GXCE5+?TS-2<@E@WL53B!;(8\[@QC
MUX^A6S;"<1,!LH)URW8IA?9%D]@^ZQ#N)"+YED.-1:2%-\U4P5/\]W@.MJ4M
M002H66M'TE]AU?!!A/Z2X35I$,C$KD+3[B4;J2@-$@$JY!.<4D\V+JT<JQ9Y
MB],25P@3'\'XQEZYR,&&*IZF3GE59?+WZ T IO^-P1MTIR>;0'F*/"S.$4^W
MD@F$!AL1'/0Y(=$,ORH0L8+:&B<-5U=LG^OW[H=1I'\5Z=F4M6@9[<7RF;1<
M>;#@LWUD;$?4R%Y3FBH%Y2DN;6N17EH%=OH('P]CV,TO"B,->!>A%I2TK(?-
M1](6$TTG&3*"F(\4O6"&4LVF* X)&%M?*141.'Q'N1DO+CB>%PDV95^JF*8W
M;C!PY]K]'HR)QX4Y'?$"A)O_!I)_7&(9,>V( %PV#A88@\-W:;,46N6H\ YK
M&@6IDNSF&\BHZ[_;X;H84B<"?J8BB"A1^IFX6*WH\LMJ\TM@%#AS#S%KA1'>
MC!.$2ZV0DDH*P9TE;^4XOMU=='1;3Z]'M>$\;ZZQ4?:IC6G@MK-[Q;K4U4\R
MVG;BX:T,@:+4FZNT@9F1\X:KMK4@\HEKO/+LM$><)@Y:+$P2GT6Z#%=&<;JW
MS582;OE[G;J@?S/&:M^[NA>7VHS3=[A]QCYD3Y;L_75BZ]SLRP_J5<=Z!,0F
M^H8+V+4/3X7-/2HQ>Y<;+4V&9@R72U$>&%"C5O10>+I6.4IX0?WV;9;TB]("
M$= >_5<+3$F$&9QP'M_,^$!%-$EHRHBAY*L:_BP"XO9C!:7Y/VND]X(<I\A!
M)+EL/?\9";><O8QH!HPPN);'4+ZVGZ$H K[A1,"M6K" OFRTWJ;[NA E9&HE
M@8$G3BC4^Y," Z6SS:NH2N7;!YL7+Z5]68X3=MI+YIDU+0B[WT]_F9*N\HQ0
M^.P\2S#-,%]"P8GY'@6HN_CY".(&!E2$$N ;Y>#/VAISN%5"I6.&BZ>'B NX
M!8$5$]%U_!T_ELVA"5!",Q=!GT=+J>U=/R#MU6@N4;<L4CMC>Y2*U<4F5:H*
MJT5]*2%"'!]]<89IE7JEW@P)8T!S(*R'$6KT-L\(]%':^S4$^Y,FKDY-"#JL
MIU1,?U6VT%$(8K:+@*2.8<+R%KA0!!B#@L^30D.PG70A8'?S@1;6"++T06QQ
MI>Z+@B':$)$_!J:!=[ "*Q8BN5($V(=S7XH R43\DH_]3]L.TC> [>X-K(LA
M7T6 *\HFF>_PG+#G"D@29:L(>$<4 >:71( C<?[8/X^^H9/_5@3$8+CTN7Q4
M%]Q",_@7<.Q[G3G(=D%U@<&9?Z,QR6R$M*S_W.?[^QK&!'$2CDH0.&>O -MQ
M3?BE%-3%,\3Q8"3E]^N0ZL'Y56":)2,) ^L0IL?Y_@)/X4M\ #Z!A5*I0'PR
M8@+9)]7XE'G!"0W+/(;,MVN/O =A\6:U5%FB3\K:G*.<NB?EU;;R1CI5:<]F
M.8S*;@MWW>+#H(- MPDO;4*4#*U98W_KFP7%/['EJ]M<4/C3[B3>]OPCRBGU
M#T.7N]44>,D/UMVG;3L6M043G3-.661[)GO9IZAJ[K9NG14PC9C#H=XOG!R\
MJ-W"1Y.N#;]R+Q1C2GI*L:?9J5?=OQ2\5PT,WCFA5^;8G&L-Z3)#Y 1.7(7F
M.GD($S]27?$DLU'3E*M)98?([Q[L->[WJBLI\SUZU+#[4W)K\+G>%3X)KD^T
M'F]F["QP*+U4/O:QP+4BZ.GA H?K6UQ+#[8.;"]TEG2]?7_>)3FD5A[O6.)Q
M0S*TU+?4TC30]D.!][,TRS"V4I1SN$[7"<6*"YD'#?M[VHD6:,B?H+1BY\,8
MSVB(YDP\*.A$%8%,'%\;;.] /H!P=)TJ&L\$7_KRRT;L_.8/(-2?AL:B9O",
M%6V!FL 8B\E E64G&CMO!;U#,:K$#"QT%-=O,Q(P'<"W",I="[M#-)Z?\%[8
M\YHM7)U!'QC+MXWTRO;H$K@_&EN?A2HU9(M 'GY:Z3V/E['6$YAW38?OFIH*
M)\A4IHV$F#0N7E3.Q4%NU<<K%A8_@5 ?\:F]4 ,W-8J&TDLV3028SH-_;P)2
MQA47KGU&$^ST Y?L<_A,H1][9AE[B@&'O4+UJ0@P6Z3%>Z!P;-N6[+L2(DZ%
MC!B:,[%/&=/B(XQ^QV814'FHDO4TH$4C@*/.>-I$K\<-=#9=S#6">NLQ"2S9
M&OMA8M*0$=(FS,8)C-EZ%(5@K"PB'WGE0*]6=F,5'DJ!Y8562N%LPEXX E6*
M+<)\1@ ]#@N$S4B0T5"-)5$ZU1:9TWZ\RIYPW!7:AGG\!MB&O?CJ #X(GVK(
M-7>"0_F;R!Z9[(2FSP%,<%6=\OB1IN'=C(1<7=CQ@>/('=RA*XT7U5JN;/$A
MK6WBJ_[,9_:"G<I3J-:P=^2C?F9_AP-$P/L]V(D96?!CR@_/GS9'!6P4O0;?
M8ZTI N[Q'-$]/801 ;@Y8M02FV^&9BH>/,- 6?$3<285UBV[QR4R!SR9>\!A
MSVD<FY%*4Z^3"?;=#)&:\%=!6<28O.]64ZXT!$Z5H I<<6Q(KSV,%F>] IJA
M4C9&XIB652ETA49D?4>-P?#N-.5#%5G?O[/LOX&_,N MK!9<'XLW"+=S,SV%
M)8(HKN>P9@5_!^4]5HRB!MLTYBB_^BSER7@&Z]/DRZ=-?N%&)-2I"*3@B/S(
M@ ::^#Q1=GPG<2TFUFSW[EI_*Z>1M92-38]:"B)/E#*<0/9CQBGJLB6QOTT$
M8"*8>"00E<[Q#<(,_-@X&( 7[&%)BX"EPGSA<0YF62X #Y]%(V"6:K:8L-S"
M9,U;MX+0.+H+7Y'@&>O4O+K0GWX8V2#%0XM/?H'P-AI8BV03%+ARJ0L1B?@Q
M6[2%_6R#"'ACU3N$1<4.^)&_!77  Q3_LI?H-<L[DI?:?OKY6H576%5K68%G
MB(OU>H$;3.)NG3=[%A)"%ANA2D<VE8=W.;WN''0CKIO(2>KL$?3[2IE<W*1L
MU_%E;TV]T3MC5:/S5_.M[ RVOGO<M75VKK?Q5V.W,\P<EZM1$VX%*O8Y%U+]
MH@S>N"2_#-P#+0TYI91*6RN;OS7>E7Q[Z$,\%GNUU+MPV[&OK0YWO)R//7:^
M\#6E_$AF^\Y+MHHNOH'C<2@_D<[\3ET<0:M\"I&-(O7J52(@<UY8A9_Z_@./
MA<?J3.F+EO^PSUW,PB*:%#K@&VUP^ Z6=P:_"ES /*5W!0E>_+P=T,M+!MB(
MC@AHM>#."),HJ%CH EWHL]-4H1MV809E$GE:] 5Y&"TWVJ,M#-X6F"X"7(1V
MC+>5^(7#8&\M TE,9]36Q=&^^VX2 7V>TN#X[7D1@$=NT69\-<'>7-1!';/&
M72ZVX'EL/=M6\;#8WUSBX\H">2SBNIN/3MPWS<$)/7(MZ?/:A.>,[_19)20:
MA Z 2P=FIM!9_:H2&0O>D1.,C]>L.2*@FO':<ZE^_C6Z"PE,&L_N!+@0E8L=
M!S\R$*<V61'0'X ";+?1?DN& DH\& ZE*'[ O2OU'Z.4B %1X]U/B(!-+X?>
MK6VK,R%6*L'WT"U=0A.9'$SC>2(HN(S/\AAR$ EQIJ/\G>?^A;%\9[]PL-G)
M2I^[AC7O$(!=3CJ,J%XL%,RE($)4)C6V5^!';Q,7)_"(3E8RNMXR/F,248UI
M@5^TX;]E(ZB_WCD5BP K=/$,5$5Q34,(2Z/*PF4J6KD+\E+J9I;1A"#^%MJV
MA/*]W_%S"D%@VR[&3!<H<-IP!(E""1$%I0.<P#-Y,R\1!CO[D_H<$@@.$P2-
M [2Y#SC^ E8$*-AUB8#<\R +)9)PCK?>2S0XZ+#_HKB5",@APNA6&._\-U9L
M]$_+K?_Y8LV$!U$<*W=(*:'T%;@HWL$/VSGD%>/'\>N-[]P-4-W5=NAV./UK
M):.8 .^D(OL8E;K"*S]&&2<T71*8C&NS!'M]S7JG(!& 5%BH"<KQ4<L[' C-
MB(2S4]E9$6 W^&-]EO@2![T\1FNF,%Q2+^^RZC\X6B1^#___\?!1C"EP$@$9
MH2,LOKS 4P04(?G$KX/8Y2+\Y! +9<WVQ(DM7'/D8!L5G'+D$I'\Y30P^RPX
M<1?=\6A0**<!1L=(X3_5V(B QV4J(J#38AP!A>;XH1K4%W0KM$H4?/$KRDM&
M./@K#?]*$&,Z<+ V7G _@H=._ 35T<NE5N'$L0.T\^!GXA<# 0\-Z3]0;+W&
MZB<B+20Y<**<VPW>VQR#!DDX^ =][LHX6K%T,0GXJ=0&U*@Y*WP'6II P:U<
M-$N?MJ$8^O!88CA%#ZRG@%^Q:J/"&ZBL!Y?)M?2!9<%A%"P$*,I:F[7]R$MT
M5^:7HHF),%KG=#V9(H"O/TL4.N=1ID=P@AR:+#AU_0-^0?Z>P,3%5@EIIG$^
M_NMC6,\%E.FN01G1:T]>([H=X"N:<"M,)[X]#KK2H!"L( X\2^"+"U#_=="2
M%V!2AR-RB*Z&UE$T]18>OFX;JDL%9Z-A78$7&C]/E]J%WC^F.D2;?/Q??<J[
M#LLA"3)I:.'OR^8PA/8+Z*J-^M!!]XH 7]1-RYLM4<#$)3%FG<G1(N D$46&
M!6Q7L."EGPAP%Q=&HX$_ECC)'QSS0KYRL,*XWUJ0FVV$.31S7B +[%%A%(<H
MQ&EIV"IZ+LH)-!7='2?Y&CMZ'#\[\'H)SY+R#AK1==.'E#*B/%0VRVS2/+6H
M8&D30I*-^GXZ+'[MEQO=,KO(>^]^"GP6;!SL[1>X\P/W\X1AN+I'3Z@=UW9+
MQ3CM3<:;68N 6.6G+],W-.5$1Z9JGH)*9MW?;5<T<,00-:[D)\:K1;9^+$F^
MYURS/6RI]H&16X"+6[K:K=3KW'7ZU]6]KW<>FL[/^K8K>7OCQU=^P>R)D_=B
M"Q/SX^@>5[D5%C&Y\DHGG-V^)A>W:1ZRS"RQ/C-;_QDK1>D5 16T%$0<OO4+
MA/_=M%1EHK=:75.[NZ*6TNSDO'8:1R)-G0V;WMET+N2N28!3+H<W^^6#DG_L
MT)#*_72O6_FP+C\(5FZNDRCOLM8FZ,99G2"!UC>+!P,UE;BY]#SBVOS*+!G?
MYM&#[15%VS:]<$S+5@O_RO_D32!MNWO+8CHM&M=(CV7\.,:-/FZYV,@K//K\
MXRD:H;Q'L.?A^_N3WK^%:G1_2*$T2VBGK7328/%.EQ:FI/B%\UZ>JE*F:PMI
ME^>)"7C)\E(\NS VH).\)\3_-U<-)3,+_[H7W15*R5]ON=;FV)G[;NRZ=T;'
M,?AE7-?WTO5]7E[">(,P*E=--2!9T<KV/9SAJP75XC#/+IE"GW9GCXR[O=_^
ME.ZQRS^AX<33996I].1FN[#S3B./7WP.>M[8F:7VM-@RDO#9X%NN4B\TJ,O^
M$PYI<J_9_\:@JY&K>2*[N_#&R?Q]UTMJG'$*?_:^"J@HB+T=S-[\6.51>MJV
M#:Y?FUS"V$>4F]OXSF3QBN.+1+FST_F&CP^&LED;]JI>D)#4OM4P%I?HL6GO
MIWU/5@+7=E!0R  TE9ZC!;."O3;/W^/S^9W%08?-]^H?"[QFM0U\H9^_;L*@
MKR6QO/^(&S@]Z*75+IUP]&*=SAY3VV])IZHC2(9^:=/?-V6<"MSL>"OZULX_
MC@^VK;JTSNN*O=%QPAON&_/B!<^TV<+<AV^B5+0V,QSO(14G7Q3$<]*EFXZX
MA,00XTP<*H,*'(Q<[^!E]8W<O>,N&5YX\+"]Q.EM[G4.8WNCD7S#K+U2P^V0
MJ\4?KM<]:7KA;GVFVBVXJ%G)RBI_B^Z^6K76.=-QCWP7(X?'F=Q$_!GZY8BM
MWVRYF>SVXTU@-,=G=\#K9C \[-=;ZJG&J5JA3VZ)*V^$%Z&=XS<-$6.!\;4;
M$7^00]@PY5C<)YDF@4.4O\JJ*HO!RP<6-@6?L?3J7[>7\Z'O@B5VX;B]WV!%
M0%5"C=6[=T,:T)R)_+OW=\]\O9G4>MKOI->?N8[&VAD'M3."[QT>T9LEFK&3
M&7.SGW;?.CP-F3?M2CG^F?_&PS$BQJ*6L:HNV-_J"&%)_3E5CQ[BOM3!/F0V
M17\4=6XFSX,Q $(.Q('=O"BH2J"(Y9WJ%1"XH\.,!-,]YLW>@H'X9QQ,<NZJ
M=M-;*E_@\!&?,SDSKMUF?,<-)_9T0=[UHVU86KC5^G92SIEV1NT!D$3O._G+
M>OR@">_P'P_+V-AI#<C_]8CJ;O+9R#;*#0$*V/4&%$7!-FZA0-&$Y]]A=0)J
M83.2YTL)376;GG6%L>3AE?7+"W'"AX*=7.9]Y:Q+E2E1I%!%U\U.DDX;$D^G
M;\WKW^92+0+"<D8%"J,\*>[QVG)- V$2>(JHN#=8ZYAW/0?;7S)<^42FHO')
M(]<VDM)BK,Z!TQE;C@X=Z/;*=]_G4+12P%OV>=1A%?/'MH$'1(^JY?QXWHZW
M12?/N/*P@Q:]N(IX7;FD[,K1T0N_%;'?<#*J0U"^BI9F\>MOF9\6OBK.2;J!
M/9\\*^/]B#*)#Y]@^Y9P^&?%\4SVR?$+T69*^F3!FY"7IMGY@Y0NUC/;J9V+
M.\%RW*O!E]%%>;D]T:04QKK"^&\2[:=B@Z-.<@WNMQ]*IRI>>Z:=^.;UT>VZ
MLR:(5 'W"#L[#1RF^6XFKB7OA[#):JP1\8:]NU">DRHP+E4Y&FR>$7(],*>T
MW:[/9OK7#:>)&Y3^I,2CQ&)5*UIES[6%&%YG0(2VOK1IG5A'KQ#J5"&DU1H=
MZ'?F_N6[D*SF$;MW<6O6=-A2],'Z8,9P#@@1<%?PCWNJ.#-768]'IVY"@TTV
MG.R&:0ORP6'P,E9:@"LKC4.>1"E-9TQ4FR><G?'H^8[[_&DPZ>J1YHMOTE=,
M"T@-NHG4),$:Z'&^I^SS?-VP0([^AS@)M^5IHZ/=I<[IFPMV67@Y_';/V\7[
MX84^(;VI.X&B<I[3Y%QA9<(F]WL6)Q1(+MPC3%18%#BD.?1%NN40I75]K_NT
M?]A-:WTSU/?ZS1-6WX%W^QZVQ 1JF2A<?EALLOYDI*28]A] :XG9B GR@09\
M/ZTL+U"'([>( 6>L+(+/Y >LW>]A-R3[2FQN*?J#V.F3:U3Q4R.0_#?5C9EL
M;.S5"V4MQD>/^3B(;11D#OK:6#E=6^3<P*H>'SPH+CQW-'?',53JI33,50AO
MD=UO'?GVU&/4,79B]OB0H*Q0O]^A%<_ELI]O>>YCQ2DRW%,H.!FUQUZC;%P$
M-(<XYK[A?>.1VRC[YWG=\0&J!TZ?O^V_^5ISS(Z'=C'5G77O48YHW8M=Y!"1
MS37K!WD!L$R :G(O^P$U9(/%'RWKBCE%'U\"4DH$6;'G<8>==_RB>4.#-=4*
M&<UOS'P5*)[EE=!GY3Y2NJMRV.3;+9SB/G\IZO4#1W6.EIFK9:>,V#I/)L#N
MW4\7\;U6G.VU/]1;E[C!EHNT9]WC_M$/'I/737AQE=<_]*2@1"(SX\7 @/EJ
MCGS:8'O!GO754]&+_67@Z, ((D"Y9*/G.TTC(9VR$M9J7M04ZZTY0L[Y0(L1
MWGPTU#>6[1U_Y=Z$?H/%HP4G5_%/S[Q>DTOMISRR6PO?/65>:#55:%$^0N+O
M$FA6).N%"':7,:6UY)JPC6#2N)K,U]=N1-4BE^=/ELZGO4\]U3O:0D5%Y-#N
M+HI64+:O-!<7[P?I/"MI*]H;30^Z5#)9K71'^/;3,:_/_:W!4>%EQP(YGLD]
MW'"=;#<)Q<4Y[V..O[4NM261#X[L=+SQU1TVB'TJW;N!N*/ ?GMAW/MGTLMN
MV[_?RB#(^!BP QS2O$OZNUNB+WUD-N &.O*GM;RQ!; ?4U,RX.:#$)LT>"3Q
MPFTEZ:>E9^L>&.B]A2EF7/W[?KKJ[NJ]R?G>M6J$@2.OHB45&IV)U27$_@]Q
MA-Y=!<D<O3+#K\G1T8EYN4.1I[Q.Y$J,>/V:JWKXJ:-TNZ6C8M&[#+N)L7>/
M)#(>"XSO><,^3%\-J/9ZYS$OF+2W?5[*,25#IJFI,JW0)_ CP6(5U3)R.LMK
M1<;#*?>#[JN^>TZK1'G<0:?L3%/?7]1YX]+VXND3#N7WE#UNZQ<HN6Z_==WO
MR(W0^P7^T=A$CI:=2C+$=+]!MC)P3Y/L?##N7*KRP>'&P8YSSK<+5ZLZJ'=\
M"6G^WNNOZ.+]9]Q/B;*@HO??8-;Q0FW&ES=<.AP)B@#O1ZG"R3%4)NDR8L$F
MF@B8Q-W!=A<HNA"_M"(O5_]?=/[PS?I%C%]A?\N>^?;^;]]W39EYS5=U;YMW
M\IJFK[GU:"C.*2>F]G9_:I"G0M^@_9[&G:X3ZT&2 D8NE?79ESCQ^+C-PW$>
M2X6LP0F):.FI='V04N+%8$ZF:1JZ,FW$#U?<L,82"Z].GRN;)H4[R0Z55B6>
M6UCSHJ/BE@'N'G/'[1(EJ]1B_=_VKCHE^]O>C>G#?T3JW/EV0+)R\=/=U2'O
M;P"_KK9X#:@#VX'A7SV;SRM+=''4G22?O<M:%Z]6TNA:8(])<0](/.H GW&4
M<\T-ML%8!H6?,/>(QTC=LI=16XJ19F&N-'.*VZ9A4NK6W[ZMKU7Q)ZD2E9Q.
M3'J4)M;S]4[DFF"2<Y@=)==[Z9(9<5OK71K]C+WV/]EQ[\^3.U+M3%;'%1/>
MAQ$5O;VJDDCAQWV'^,S11DU,^SQ>U>RJ7!OGN&/C3@]+[\"JB$N&5W?FS.<X
MTZWOY'E%Q@YU[-:2F?<^-5?<;O3=(*NWQF<XAN3S @[VXV"EQGZK'W':R6\F
M["PN'%^.$P%)4U:V#^ ,PCHXPB'CS/<*G/Q$CC ^)W<3UZ1A6WFB]XASY^EN
M*QN]*W:+F]^=S_*+&]C1R#Z?EJ\;M_)R+3 L?81@E4M0SZT)&Z5KU.YVI3<L
MQ9&KLSR/F#>X-;PI,QOY2M1OY!C_^6F]?TKSR2?])YN[/Q0DWHMM;)%+:'#/
MO',V_)".6E#ESDHMN84<,YODV4_6_CX["S/]MI[L5I=\M2\^)(XY#!W]]$SB
M]X9A$_O?\S/L41T4GX552"U4DMPE&5ES2$-:1MT:.[%0$^W[+-KI?.Z&Z0&[
M&\5C%ZO?#U60-ISQQ880&R-RMSYY5IO>7CY>8:C%K,XM% $2I\L7/=M5"F[5
MJQU:- A>_WA1L[# UZEHW/MT?JA8Q0M&YS3.R)! XR>5;3QX*E6JB%TM]2+%
MSNA>\A>[U[JV?Q[(@[7]5J4&J&C[67PP[K2P6&A]O^D'L<S,(&AG=F5^RIEX
M#9\XY16_6SFAQ3GRT-DMRMG5)FYC%SR(+G%JW>?-1J6M5ZZI*[7'.)N.5U=P
M(Q/>2CXG&V$RK3F%-/_GTII:8BHG(9-41GE,N88#TA%[=*G[GKU4PE6N:KR9
M\'3=YOL3;FY%OT*3.07;[ Q44 6^8/^:=I_X[Q_13:-$$LW,KUJ,IPQA^M!F
M5!H'CCP4 ?OV\U.0"1&PB3@JWJF%.&/7@?VJ:'AT?XL$"]#;(F#)W,I&!/CG
MFHL MQ>R$__&L43%PO_RT1UQR<QZHPCHWWH;G-AB Y_.2S80IN&;[I;9-%5F
M@Z?Y9+G(23>4/N:^:=D/'1?69>L'G=S]\G7X"UWSY3U-G]^1-![<(9',OA?X
MG^UH'&?SQ^E&Q\(7TF+N]K&&-/9_FK0,%V3U\,R5<S0KBL;FAOJ\G4+/DP(B
MSXX>^)8^Y/.VLNJ.7\KA"F5/J>"8%:]M(U\@DG5^65T-)\;W/9IPP&MN9=?>
MN?XBV&Y'P\AVN/A(\=27QWW5F'73T[=XY8%VOC/K_*"E<X&.RDDEEF[C38.9
M4@NT,Y_NO;=SC<>))S4TE.(#54\^#N_9C*\_Z%KJX0+-* L./4U@%S]!!5P"
MFT]0<H)B%YL&$I(>F95@,9\^^_K OD+3<;)Q2)&&-6^/8V,=KO-<UM#:L+%S
M\[7FSMU^66]:#C_O+,W^/#]8M/!9_L.<0Q?[N1/!(64JYT,6S_OVOF^<MC?\
M\%M%+SOI6RJK6?I-FX]YUS8:RKQSW9BEM0]<"P>!ZPZRM?+Z;-B+'XUJC#52
M9>W2@O,^C\\%9@ST?][1&D[:6)Y[/'N?QPMEZ7,#GM6&!I8C3#6SKH>+LI]:
MSUJ9Q;#-.VR%GRR5FM.*V@+VO'[1/OTE_L/Q_;?TV%<\UN;$E3ZJNLCK;,P.
M#1C=D9J=O$/@;*) ;6&'DDJ_1-GY/FYO.?U<_^A9#XF3@1P-]4-?J67Y>CV\
M"A-L@+ @K;'[3E#Z53TV-(]DF[?M.F+<, R]H*Q4OAYS9,\'DZTG_2^_>=)]
M?M>QX 8WYL.^H/.O3GSBC$6K1464>YV3PCB8WIL>)<HE%H]^.QZ$D2?"H%,M
MUR,'9Z5*3U&I.?Y(*H6N%)EBWVMZYAM7/"[<Y'P)\X%9Y>5%UD#]+5M#% PP
M"0L&H/2@3<%GUM&Q,[F;_@Q^,NXY-U')\W8:*@D@G?,]?I*PVZ-7I[/<!Z\P
MN7/6UXZ'J%5F=3+WS3I^WK=[1NU3T/I%M;AVZ%'53'\_3#KTM"NOQ^HS\7"W
M80C.5&B)EOT>TD+*G<W,P]$'22%A6759;N7*%XYZF75WVN_,OUCYAVU4S/D5
M479Z-0;WZH77O@Q^:C3U"8YV]$]?'I>?E7+D=4]G>TEMM&3N+:VIGM@S>:#M
M45MHC/&-LC)YXN9L">Y.K(+CABO-'^^.C^B[I1.)&HFYJW\]X;DZJ9ZMZRAS
MI8%OL8TY&?G(#0IE=C:R'S_7WU5C;:Z0W-SK^_[<=C;9>7V9N&HL_;A;O6OA
MMH9X8D+\[LFY_%2FG_$?I4G-)X_OGQ4!#T_\=IU[G:OTV_-''CLKE>5BF2>V
MFV)M;14])Q*^_$[L*A1LL/^!((,*2+T(6 '.%W)J0<-PH0-87P[.*@F?X*>P
MD*X(<* 8]+(9!W%+.VJ"$4VL".@IT<)?6C9&:<?,,(T;@++KMZ/V"X'HP$L[
MP+)Z6\7#*[7Y^4(8A9B3O?!)%,+VXK\(\2%M_-V, 8((\,2E&0@_W/\'7?16
M"F-$P' 2;38)"^O:"W,P]5BAS53)@AK#"/Q9\^4?I]Z[P']T6"C<7_</&-,,
MZ5X /SL1Y"DQL<L!>_!M(N#!*+\W@;8PF@3.UZ2&H]SODST4^:\.:L66;5%A
MBF+F]73D#8J<NR-1HN=>F%XBE%#XCN.7H/0SE_7O/K#Y+68'_@L;&A5>^Y,H
M] U(6";.XU">&-J(YWF-@ N.U];1FS PKDV0/X)JMJ<,B"H""-D5?"(Q&0L1
M:4OVS2A3] ?96(2&"^9BUXB +Q,P2F']?5&-4]Q%^%SCCPYWA(,19MQL0?+<
M\/%!>GF,ODZ!]X^M^Y\NI  _/(!?DD3Z:#S,CR<?!7BER:5@^L011"9?!/Q!
MGTX2 ;_^>-*R?(3KRY!9/@BVWA@A0G]Y1.&ERN]MIR($$&6Y*7@T8/[FV<3%
M_^)G$Y[-V J&0%&79RV,([XZCW2#JN4BX"J=:VQU !'WF9$@VW#QO(E(VW);
MKEPBK-"@N74]L;^P\=+V\\6W%,[SNODJSV4_+>$#/MK%@#OP-P"*)CR*2"V@
M,Z;V6"ESIG68O*:/.G5= F..C/4'.8C&N[+&IV1Z,Z]G *WDZQ-GYPZEP+V0
M(;:%=77(;2-,]5Q](NXHV% #Y_[6*F^ 69*OCEUKS6'TE*QDS>%'[,09W\!F
MQJ_0L^9T;2@K*]QQX]L=5@T6TX=6'SKRX<PWI>-;_;E-S<E,H;WQ*[WB1_Z$
MX&DECZ43K]F!H10+#CV6;,R9/I15*/O-B^<[J^=W+\[+2,OH[L-']6R-@,1E
MQ.M/BUTQSCD%4[49QSI'C]1$@:U$1'FF@;BL:@8*S$'4]4O)^7_70E\H>K4H
M:(/;?Y]9HG'I/2#G@M5^-'M(L7B(BKI\+&'YY6S5%R)W2YT:V&[? L)$I@@0
MRBS_>%EGUA,MJGPH&XEW(HH &1:JO9"313]I*Q$&;=\C DP0TU^CD0#!C[=T
M7G,5D*0ZU)\-5B( G1 [,?.F17"0%$^;=^&R$&7H1ZL-A='1*[@A M@4 2IA
M[F6B$S(CN.BZ_GR(_TD;"O>I&/"="$A3T10!-T6 &OYG]J!<0-Z'72A4)$>@
MBQ6@S1]9?WG):@MJ'D,"'#O5+0*@SP(4P+[I4_^^B=&3_S<^I<*WJ7+XL5O#
M5($6"C'+FY RP2.P,0L.% &V6 UT\2 &Q4?S'V]3_0=\DH_H:C42EG5@+93M
MS:&[F0B6, RP/W7(G/F/XS1D@/C,O!X[&,&+@0NYCARGWBLU8L,LQ>!J:I+5
MP2*!.?S"+#<[\/PP03G0H\-I_9UAJ<D69;6L?+_3N4[EM_Q?I-V?9<L[T/HO
MH6E7#T('9.]B!W5_&19#Y2>:!5/XJ6N>4Q_^8OM?=YNBP8E(6F(EO^@1MVK[
MS<)CI=+E-^-?38O]%9]<?SQWCZ"<TJQ_0RNM>>2AY8<'.^[[I!WM_)(J_^!^
MP5;*)#LB[H7RU24=\TVOC?OK\!+I[_5/=P>-FCUV?R+;Z-[ WIY1Z'Q4?=V*
MC/PI*.Q^OOZ1G-L//MLKJ[1P:<AF:=3>7U U_F4,^V.[S^"1,/<E]#^K40X=
MVXPNWYP12.SK](#](4=>UF/N3/HY:VW!KMZ-$.\F5#524/NIVC>IY!CAX?%'
MU=D-@QMLTSLD/+Q6?LK?$:OE^<=#\X66?_+!7]Q-W,I4WYO"=M[4^CQ3S%XF
ML?G4S73E'<S#S7:/'E<$G]!OKK",3&POV5=>[.#B$'0CZ,CYZE3.@O7+)!B4
M:"+ON0T-69?IQ$M9O7UB<4Z_<IW;O>0"&R6GCF(KJQ)7NIV9GZJYN&O:T:T^
M.?+>V"^HD)!:9..$TCD,9 ,#!6E!D\O?-WDN=_U31OTE8'KG1P7.]HFT>2?(
M'I$;1<-"%BW!% \$K3))AE GDFR]&TTX!*W]8Z3>96\1D,$0X%A7&?,[@D0
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MFM]JGQM[T_(E1V^EJ/]_ %!+ P04    "  /DIY0+E1/J/TP  !P0@  '0
M &-H87)T+6%D93DS.3=B-&-C9C4X8V-A-C0N:G!G[;H)5!/;MC9:"(HT&I$>
M)%%!41&SE4X14RHB(ELBN@4%(?: B.A&-$A,J8CTQIXM*A$04%$CTBDB)22
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MR2QK%9"I>1Y&/GO68G">#44V"PL@V"A&\!+\1@NP58H&> +E ^CO$.ENLX2
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M#FT@4+,=W9KE(?.7NI_#9^+-#'WV;/0FKG5#IBEGH#5BB[VX%END=PRZL#0
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MUGSQI1=9-I3+P7=(JM;_ 5!+ P04    "  /DIY0LE+SSD,T   01   '0
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MVKL=(26O/SK6K-]DR-G,^V':7RS[QPR+^D]9]J^&_7]V#0(RXF+HYHG+ 7A
MF","H@Z#]9N8[#M$9?2)_J2@:3:!^80V_6*$'N^Q3TBK6P?GME ,>/@&@FP
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M)I8!X;@M*9=YE_ER4'L#1C)0:RW<=IDGS<$T$E90^NAE!<V$^&]N!=<$!T3
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M0[G\?B$*[W[,5!9$"(ZK5IX6\@@CZ37!(ZCZ[I]K9<?%6.Q%P8+60)"$OSO
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M:KK_!F%.G2SY-._Q'?1X*'RHDYL 2\>2:_4A6C/%# [BI1,5D+=JX=-%'-8
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M?N[G>/;Q'OMYWV-SK(ZL=<YYGO__^O\^_LL,R1=)/[!B_U[[O8"4% !(H=^
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M*">,F=PA%? BQT)Y# WD0P^8$A&:; H5U"'2D&^9((FI,2B^@RQ#6GK4:B<
M<AC"KNRT(,1!I+E^,?6+!O_ 31[^8M7J-1P%LAFO<1JW0LN#J5THD$=DK_.P
MZ6#%DLIZ;!JC/*0RO5IAB*-A(RVH;^(J4$?Y4&0-J&P9Z\?5?EL(#W#5:B5
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M#ZA=)3EMYIV1T]80EZ#0O <J,H*3;9>+0 %QU% @SZ4R,1?ZMHD?,(*:V!=
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MF/@LR)GG9.V2YFA)Y4ZW.5JT';$ZU^;A&'3[33#R6[;&P"B_ ,ZII>BT5/B
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M>H4&:!MT\;GXCDVD4(_$YA(;V)D2H!PSYEQ<5,.6$YUJL5U[DK::LI/4];O
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M*[@X'[T?I*'712R,]-!" FV4"KGT3=9/U6MKO'A3_I):,VM[7,V];3AE9Y5
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MF>-R)]-WBDW$14^0K"\],D^OVY.39I57S64:GS0FJ[2^IG5V]PCWH!R=UWG
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M.1^AYMF;_LEVV+F==?-Y]3II=!=I/G=GBUL&OQ=]30-6FG@/1I$*@K4<B,,
MA'NM+1I1*?,T0/&H$6W+R*P49C[@<K5H?%IN<Q=V+Q!KR]>*1L.IL:"L1=#(
M(L0J$$@33A.C39*B>CPFV!/#Q%@R*H6!^XZ%/W#58Z_80E8G^7B'QD!5!0;!
M,0+<&PJ5)%(;K:FO!JP2_(DA8F11E0+&]?G71>)V"Q!N%JN]KQB)0H#PAH"T
M:=%C:8L%IS5J$IF-3#]^X,43&_B!HBDWT-]B,+Y#=.N(KRE?L^"5D$X#BN#
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M='W+N\5^-:?S7RY1__L?_P]02P,$%     @ #Y*>4-IN[S[1,P  #'L" !0
M  !E8G,M,C R,# S,S%?9&5F+GAM;.U]:7/;2)+V]_T5?GL_>USW,;&]&W7V
M.L)M.2SW]+Z?$!0)2=BA" U ^MA?OP62H"Z2 '$1\NSTA"61587,)Q-565F9
M6?_V']_OYF^^QEF>I(M??X%_ ;^\B1?3=)8L;G[]Y8_+M^K2O'__RW_\^[_\
MV_][^_:_].</;VPZ7=W%B^4;D\6393Q[\RU9WK[Y<Q;G?W]SG:5W;_Y,L[\G
M7R=OWVXZO5G_,D\6?_]K\<_5)(_??,^3O^;3V_AN\B&=3I;K9]\NE_=_???N
MV[=O?_E^E<W_DF8W[Q  ^-VNU\$6Q5]ORV9OBX_>0O06P[]\SV>_O D<+O+U
MLVL\I&Q>?#M;[CH\;DS?;;[<-7TQ]#>\;@NEE._6W^Z:YLF^AF%0^.Z_?O]P
MN8;D;;+(EY/%-/[EW__ES9L-<EDZCS_'UV^*GW]\?K\;)+Z+LYL@C*LDS=/Y
MJD R_\LTO7M7-'RG)WF27UQ_RN(\M%GCK!:S3UFRF";W\SA\94+[=)[,UM\%
M*M</N\WBZU]_B:_R &4!S@;(?VTXVO+'??SK+WER%]K\\N;=P#S9>#E)YGFW
MK#T;]+P<?@J_39.X8Q:?C]HUCZL\6<1Y)='/FO5$14TEV=^Z8YI,>G>7+(L)
M-@_R"3)9AJDX3,G5$J[1LW-:%[-XD<>S!]6)9WHR+R:OR]LX7E:37'> P2G_
M-,E"[]MXF4PG\]9L[!UM")XNPZL>KW4BO."3_-;/TV^-I')TH,$YN9T$U<[?
M+RZ7Z?3OM^E\%BP8]X]5LOS1FK?JH4?$;6LM;?.<P7%([^ZS^#:T2;[&[X.5
M>A>W9OGPD"/@KEOIUAQ_:+XO[N-L;7*TGI9>CM0]+YLU=5F0D,RVCZNF^UBO
M86@\\+&?)-G?)O-5_"'^&L_QQ?5E<K-(KH,^+)9_+-*K/,Z^3J[F05_N5\N:
M=M* % R#72NVST+QEP*QA@0_[=LYO5_C[-/DIGKB?M:N8SIL?+6L(.%QDQZ>
M_G&2%7A_C>MIU[$N/5!7>")FJ_D)Q!WHT0-MM93[9</.*<F2KVMIO%_DRVQ5
M[KO^,Y[=A+=*3<-7R;)ZUW;R..?BHS3ZMU]<+%0Z3>KJ1X?/.!?_#PUMG(<U
MJK ^U!.*XYH+9)^//!<ZNV5<_WB\\2W=NQT#<]K3SH7)R5-\RW'/Q6?-";G1
M:!WSM-GW?)E\KZ1W3\O^:*FG((<[=$[9<K*X28(<5)Y7>_$.->^9JA-?K[K=
M>Z:ZM),NKGVR2);QAT#!['FC9APU&;IG;FM-#<<[=4[AU_!=FE5;9GM:]D=+
M78D?ZM ?935%>*!]QW1]B"=Y)3%/&_5"0>%,2Q<;M]/Z$_?]OO!-U1/C26/T
M0O^)<^?Q3KU0>+FZ#\,55L)D_MC&>[^X3K.[$XS*IL/UPE6MEVE?TXZI^5@8
MRWG^*<XN;R=9E3?F0.M^::HGW>.=^J6PEC"/]NF8OD]9>A]GRQ^?@GXO@VU=
MG-W<%SI?06-EOZ'HK"?SNMV'HKJ6'M3LW3'-G^.P+J]"QVEZ$TS"ZL.*PQUZ
MITQ-I^DJK(;AHSA9^_SKJ4.#D7KGI?"M9Y/I\D,RN4KF6V=.,V:JA^J=&YOD
MDYN;++Y9KY,7U]L633FJ-USO7)UH ]4?H'?*/\=WD[##6]R$565MO@1KYN)J
MGMR<8!:U'+5W'FM-JE7=.J9RO8+KR?H(^JZPU>L<_Q[O- B%]32B5M^#]$ZR
M:4GR]M?'5._B9Y/%\MTLN7NW;?-N,G\6V' @0K<,NBVB>^F:W$<]NR8J_%Z$
M2:2+M[/X>K*:+QN2>'"<'@E.BY>X/;U/ANF<W/7H;^_BNZLX:TKKOC&Z)O0V
MC)=-5U?QVQTT#<D],M)!HH/2))M9[4/X<]NZH*O?\.\-/?'W9;R8Q;-S4K1W
M[AD#8?NCH_NA;&\(=*^/&@[VVB'+/3W]M.CC,Q%Q)$IO.(IJA/^>B9BZ\;H[
M\@KB2O+FZ73??+Z>RZ\G^=5Z0E_E;V\FD_LPL4/Y+IXO\_*3M\4G;P'<IAK]
MZ_;C:$=?X#E^'W[=(36?7,7S7W\)CXT.-XXXUM)C 3A2 &)@.1&6&NN]$I@;
MHIXR-B].O=-L"_M G*WM[#I<K1M&C&,O" '.!C80%=I9MN4(0J1\'8X>5$EE
MTS=I%@3]ZR^P[+E=LD^R.(MTM>Z$D7:(0" V?+"V(?XZG:=!_W_]99FMXH</
MPUP9--IM?-K!?(AO-@Z[(95@\YH]G&.H[TDM3=_7+R+.*R@0LU0BZ*B%FO(M
M0(@[+@94D2/&VA&5.5'.A]2E W#6VC. (CPCU3[9-.Q1@+WM(VVY8IHS&%XL
MY12V <*2-V.-BO9NGGI5@(,;MR/B;R>WM#^D?BYM.(\6/.%EW$IP'N$7EGRZ
ML<%^?[(EWR/X%VTCXCVVU$&B@*0 $Z.M*GF"G@]I'NSU*[R4>$O9I-TB,I24
MU6RV1G@R_S1)9N\79G*?+"?S2HD?[1<!KSC@1F@%;%@C-?>[)1-QRF1CZ:/7
M(?TNT1E*$[YD\21?93_JO?%[6D<"6*^0)4!*HXG@TAE2VM7,8-M8ZOAU2+T]
M)H.]]=/IZFXU+W;>%\O;.-N325@] ]0=(V((4HTMQE 'S2?<05ZNEECS%OL
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M_B1\(YN[VGJ;![I7A2X1&BQ$(YZ',6]^BQ<!C7F@7,WN@A *)(K:2]5J46^
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MI-NRBUP2!4?CI.U2H ?SY#O%:M19\@<YU3^*@O 5V?$U>D<"(&B## K_C!%
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M"R2#W6Q? /5H]\O+MG\=U>H78>WF=2@\N-8^=OJ#4-K-(Q+L)GD=9A;MIN%
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M%7>M"Y,[#STTXXK$'G5)?J[I5%WM%A^K<KU?[3Y4G_/J:['*F_M#?!Q'7@Q
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MIAMB'O)FWJV7<]YV>#,DCF^WAPNI/MRUV5JQW'PLZV:3(ET6U5^7F_W)Q#Q
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M^.>R7'\K-ANT73/K[-7E>S::6RGJXS5?A\MZW"3$) &)C[(PS2""-*9M89^
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M$I,<B1_0:N:*UP,'Q?Z6%_</NWR-6-=?WN>_UOG=?O.NN,L7H4^](*$>"C*
M$]>/@\3K(:$PEEJ]L@K$<N;> W.6+3)G>=IMG_*J*->2LF>U601%<2XM(BF9
M'>S^ .WF_ ':&^?0:AUZIX7O</QC']%39WI(=,=HP)E(\BBNOCH(.!J_LA5,
M%EX(<18F68H@WY\?4)(%D$3, (S2-$IEI%GXH99EML<A)Z7BE(C)HA4VY"3N
M*A%6RZL,*(XT-_-0#WG8%^J=2/HMO&>\/XW3'.A?;E?%<O.Q[!;[^U,Y'H@B
MD"#(#"&88I!2 M/$\Y($$-?-,M$]R29L6=R'?#CYUI;(: $Z/<+)SL")T#:T
MV=@DZ_/H5&9=>KFIV#Q?PB.F)K ?BQ?!, . 9!%"A/T?]3!.>B,!]CVI,9#<
MHRV'6_3Y,_GR67+<(DF.X$C$'B^28XNN]LY4I3R>\3"4^:L1-@_A4 7_,CO7
MX4!.#+H*O =;D!#7#VF6 ,\-4QBB+/!Z6R3$F;PFR%JPO539E1Q>-N#^644C
MI#F3D0J;=*DHQO'2BVFEXP4O5Q5$E<<Y"8FR#V?U1(\145G!R_H!;=?\'WXP
M]>MRPY>V7A;NB$GH0NK"C 204A=AXI+.-G736*I:H1F+MF6'H6L.;*_X%_D1
MIYP &6)73)#&)U9.H Z<-E^<0)R\+I 0<P,29I;Y>4B:89]*F^^JG.1]RIFB
M%JM=WICO[Q:*,]\'$+)1G$M<SW53/K?2V0HPE=HYJV;!LJ0=036B)B=DBIR)
M"9=]NN2$ZH0I#NB04HTK2F=9&1 A/1;G(3J:/I0FWRNE\J/UIWR5,SF[W>3O
M\\.]903&<4"2@$*7>'&&L!^@WB3!GB>Y!4?'E/T-.!TZISK :VXRE%V5UJ%3
M=-5Y)!YE5Y4[ C^=$+B\8XKOH,VF_-9<&W975@ZN\G6Q<]Z5=3V11 TQ.+A:
M;(#X>0B6&5?.EWTUP8^H?+W=?F4/+ZL?_!ZR&"?\!$!"D1=1-XG]+'-;$X$;
M)4DD)U=2C[8N3SV:H;NK## DID#6J)%3G .,">X>/*5@0#*4F)J'1*A!+PV\
M*;(2P,LQ?EE^ST^$9^&C+ L2C$(WR!*8!B[3G-Y61N6*UJA9L#PLZNJ<[I;?
M]3(61?I$A<(V<[**T9#6 'J6ITR2AIQE9U!,=-B<BZIH^?!*7O09$:^^FC\M
MBS7Y_I1OZQQMUQ]V#WGU;,Y[$7IQ$D9,WMPD=1&F$4YI;]G#5&J^V80]RQK4
M073R%F/=S)*6'*:S>K;^)5N'U0#38@(U-LER<M7SV\%KZ&T .B\6S<8NP7J5
MM $5,TGY/#3-J$>OJK":9DMIX7Z19,0G.$0(101%:4Q=%_4VW) 7:"AWRXW"
M@OW5)TMIV &$<!_[PO]$2ZXDB5)8I3?*D=;J_(1+\J)+\<)DS4,\%+$/+;U+
M,J!=?IZ/[8#G!;X7IADB[$M"7)"%O<F8)6-RF8^&(>LIST"Y>87AEQZIHDG.
M2'S*9C<#=>8GF-(9HFDPGS' [CRTR(PKHG7DY?D1GQ)Z?L:(62+?5YO]NMC>
M'PXBN,RL&T7 A2CP$A\B$N#>M.]#J?,_1@Q:GS ZG.];=D%=8;+(!+&B<T<C
M<RH[E?3JN"1#Z/SQ@-'I0?YI[%FEZ[P-3C(9I'T>LF;6I5=34,;Y$BDP^G;+
M='65U_6GO,[9'_!=25G^-=^4C;8N@$^2!+@ Q#3- $TA27MA9?\-7=%RH[IV
MK(O:FZ<6GU-U )L\8GV$*%YU4YO386$;FTY9/7,Z:$Z/S6'@G&P2)L6KF8[)
MJ%IMT\,.T6/1LB?VT8=EG:\OOK5=C':6_5E]7O3,N>U+8:V.%7^<W<-RYSPL
MO_+Y0?:Q=7[7G+9V-L5=[O!K6#?\XT^;O"V14CG+6V:LW/9G!'</3490KHKE
M;@A1?G=75KOZ)ZVZK%>:ZTQ@,MG(T]=L->9):;X+R"7967Z75Q4_T-^MP1SB
MWR+V$4"(I##QW!2G;@Q <# ($ZD+F33,6(X]/;)F#58YI=:A42R1'HE!N7!S
M(.^X)'N:1X^;,E]F:"!1-D#K/-)C$XZ4QE\Y.3$Z615YS[SNYD&IBP&,DBP@
M $'DPB#,^H41+X[E=$C-@F4):A<#518M% D34QS[7,F)S?,UTR.D<57F+"L#
M J/'XCRT1=.'TN1[I;+\N8 9)%F 8Y+!%#!]2DB2]@_'(?;DUSVO/G*4!4_U
MA<[KE,BL<!IE0V5I<XH5S:M+F<*LS*.7RX(^NW@IZ;-H/^[+V!9YS89%GW?E
MZN\/Y8814O.%B-V/DW/*&4M(W"A+:>!1X$48]W-T7I;&4F5*C!FUG#^\>XO2
MM^_>?GE+/COH?>9\_O(!_]]_^? N(Y\^_Y-#_I]?WW[Y=SF-,$>WF(I,PK2<
MSIQ /*QQ[GY,5N= E+$!D3).^CQDS+Q;I>6755D*7Q9IR"!,7 (#/XLP16GH
MN[ KTA#X(8J%;B<S8,:RW/4E1C9'A)*5670HE!8TF^PI2]CTA5HN,R0F6:JT
MSDZDE!VY+$MZW,@>.OZX_,$W[/?;UFA&,A0D"%.* Q]A-J #O3&$(]F*_VI&
M9#J1WD'CIQ:8V@%C6>H$QV3V.9,<H_5D=8@F/C#\G)>A89P>D?.0&ETG+AP/
MUN)$0F*J?;Y^+6T+BET41#%(4!@GB9O@!/:G$/V8Q)%<27Y5*Y8SG0[8X62.
MM,BHDB>L,R/P)BTU#67G<IW1U>8\.\."H\GH;#1'UX_7LF.$&5'E(8]/F_)'
MGG_*-WP_Q1F[?D!"[.$TB%TW)32,:1(>[$KG.?KVK*<\67Z[NSF<L7GB-W_(
MWG)D@%4Q:1J73CF)ZK&]J5IP,]"JJW0-:)8YJN>A70;]*6V]E'):]K[<Y2_S
MM0Q '")(W20C7@8!C&G460(NE"O=J_)\Z[MZM+5*B34Q=;)-F)P>-6@F'IJ=
M861 <G3XFX?(:'E0FGN;%/;GG)$MD"+D11%KVL@COA]@D/0I&("A)U4P0=7&
M*'MT>D$YF7I6V+"CPJ"8L(Q!GIRXM+Q-G^%<8.;:QAT-+N<A--I>G-N\H\V*
M^EK7(@K=F*"89FS$EY(X@4G0IT@@\EPJLY5'X?&C;.O1EAD5WE07MHQ2IK^@
M-?4JEM3JE3!W\Q 3'0>NKE9)<B$J(>*W:Q^NRC[9E0BB-&5J!B+?]U"8@!2'
MR3&/ E+#)+M(;"^Z'Y ZJU.HS5D)?OY(:ZQEN9'$I&T^[2.G@CUNYP0XD\-C
M@^'G#79 /]TF:BVJ!Q1VG":<AQB/Y&LY12>1S!++[?V7O'KDDSXGQE :$D@
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MS$O[LAH8)I'4#F^CAD?2N]/CP;J:IT.SJO:-Q+ 1#>RQ.AW8.8GA91ZE1-%
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M1]A<8Z7U)MED,VERK<V_K15SZ?:=2PP8U6>3*^B*C(^S'P='&0 $@MCUL,=
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MW<0F.:_DHY,":^;BTZ=RP_[^_F->%>5Z$<,H3,, (8@)PC@.0A2VUWRY;LB
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MMOL[$;?_\978//!!2BF$.$UIEG#F)Z2/+0^-U*&5G8BN5[-TRNHK[Z;[\0G
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MI.'EX&(A%V6R#((ZRNW%PB)W#FK3\]_+ZF\?Y 7:ZZ)^%AG0*(,<Q3 %F",
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MA!-=R0\,3/$A]M#.:8D;1?O(=SP]G)9]K<-98CMS/YG-/Q;S=73W\<FA3O4
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M)]PA[IB2W38-(MJ=7?,B;V&V<#_&DV7Y[M9?B^+Z>SZ9'#1SCE</($H-&,-
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M[HUK^55 >@JZ'=Z 6.<'RN9E1P_?<'A:,G@()>>4.,8D=@QJCT4E3_R-'%B
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M:'63VASBO7>B]N.L9=V7;5=K.'CVU A6(*X=%YA(+;U6%&HB':5& $\\J/7
M0I\W0%WL?DJ:,TGCR.$*$![G[6A(,Z4BCHP#&.UID'+GN(=G,\EL:F4_<[H>
M+FVA[?):K/T46T%G^3R?WCX--CR/TN=^5:#0,DX8Q9)RQ)4S%L3M(;7.D3*B
M<6"WZ;MB=D?JZ-=Z>O6P>=AQ/H"54SH$/26&*">C;>/**X?:0(MP^=P@JN7L
M:OF\]<2L8''6U*@\_*+.".^I+E,\K"6*4Z=(R9W^AM:PVGH]G ?L-##/7(CF
ML\436L1_O:1$_*A\Q?IZ.5Y<S3YGLV_Y.-N3\FM?T2 B!,C B+ KLWQ8$6?
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M4.FKG%=)2';,#1^AJ.:\O^>+.[.<+^*6?.9^;![/5O-Y%O]WQ.-Y1FO!:N(
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M$A^[ONFR]C+)L]Y#EU';)&D6[3.GGOEL\63:B?]Z.>7$C\*GTJ^_QRI_]OO
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MO&%P&FJ*,4 4428T!(#)K088U:+7"N5[._Z2_KG.)%/['4$H)8UC ALJF%
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M7%$UHG]W_Y#^ET3_K__X?U!+ P04    "  /DIY0<\]=1&\? @#CG18 %
M &5B<RTR,#(P,#,S,7@Q,'$N:'1M[+UI=]LXLC#\^3Z_@H_G+LDYM@. "\BD
M)\\!MQ[?F]AIV^FY\WZ90TNPS6F*U)"4E_GU;X&+1$FD),N2+,I,SR22 ()
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M?@4**G_-CJ2+MRXX,)WKYR33/N-KW9/1#:@BWQ-IW(="<]>7S';.V?>#HC7
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MH4U51S@FLK[3RXC;9F]M-P]?WZ/S!WMQ^&0' .F0?^#K?B\W[URE4>^/^R@
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M3-["TVFFE_B]'1'SUL/_;Q%@>D7\J%TAHO^?O2]O;AO)\OPJ",_TM!TAJ?-
M7J[=CD@D@!KOEH^V5#T[?W5 )&2ABR0X &E;_>DW$P<!DJ)(42#%(ZNZ53Q
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MB'ZQVL$I:P>FQXZA[*H#F9/>ZK$4M&6UA$VTA#4(@6DKIS<,?4B@KV"( AH
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M/K*[/E[+-+,77#@ ]\GQ>4_F<UR/HNOL@<B1@VLL>U1JG$!- &Z $0R@HBH
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MW4>C;[%)4[R+DLSY'@VFL;&-#='I(9HT5?TR3_I%[$55\-Y*_^T,9-'R=M'
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M8O:8"NM%@VC4BTT]V+KX:[DF=078 W79G PBK-SYPZI,0%Q,8@@$;XJG> $
MGJN8D)PHZ1+*454\A6-$R5(*<1&M782AE ="'_)\&B^6M*Z2@_]1_>H?LQ2V
M,F+%A-&EHZ+ZV\\DGUW5NO?'@H9;R<5Y\;!V?O&'3^&F[8-PI_G%QU>VP-9O
MMD573KWH2@EM$#:]G)7B04!]!'U/\L G(,#*$YZ2G >$AW 1VMJQ=25.[1S5
MMB\JU665?PMH%M LH!THH.&F7G< *0]HB%A()9>8NT'HU05W S=8TM5V!&BR
M7R=>F;RK#Z,JZZHS<&.06G@[3W@[89OL[3I&)W#&Z+YI6,8#3#RA0J'97(BJ
MLK8*) #+E;5W:)35Z7/=FV6PV\J8ZTBGH?^7T,Y^1>.[U^:A8P(/JQN=FFZT
M%C-9@YD<(>8S 0"G@0I]S#P-J05F"L_3?_>D'#T-ET^J1+E>9_W9DYB)Q16U
MH&E!TX*F!<UM05.T0-.E(1;$4QZ@)$""!8C5H!E*Z._+HFP2[8L\^[DT^P^C
M7CJ,NX=2<24LDEHDM4AJD70[UQR"J"GP[B(?NA@#'@0B4,#G076,*KF'Z%(E
MYAT!:5UAHBXPT9E/SD6PT^Y9UB=G<<WBVH'B&FX4Q- E@!&7!UQ!Z0'@8U^6
MN.:YQ/7YMKC61=GX"\#YB7<$/9?XM6 X'J0/<5QT,YX\...!OM@Q&_K]\0(W
M-GCM9 ]*UJ%3ZYQ$A!@+T^\+8 @55Y30RN?G>033Q]&I/!OQIYE>A2]Z6&F_
M/#,I_GI1'O>-<J5MS\@\?@&^_+*9SG_?^ <2VP9.' '/62U[G1RQ0T&#__@W
MKBVL3L'14K&EXH.4:;QI%1="'P4"0"W,B.])%'@^*:,6&76)E!O*M**V]FY%
MVJ[C@*"-<CQ=5#@_)+#R[#0HU\JSM?(,PR;!2$A?(>#YH0* ATQP-_!J&RW
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M_:^WH@CL#EP-KQ%^B(Y:]S\&+K8BY$1%R('0U\%)B<,2!&OD (=-@!P-/<8
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M>-B7A$M(ZWA4G]"0;9U\#/G?W$.I(X:NW Y#I XVL-2RXC-8<=<PNTUPY@E
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M+S$!&TJ4OT>#:;Q;@;+K$ 9H QB.G*=/B(^M,#DFPCMK82)@$UR#@>!:B@
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M1&Z)W!*Y)7)+Y =*Y):P+6&?)&%;]+9$;HG\-(E\HTA5*IK*(QR:*D;4$YY
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M#.3)0O,UN$M.\T ?XY0%G9!4*,\&*O4:N*:[A$]R#@,/?H@*(#=DG)PRI )
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M<6<UV<UJ?Y:JRPL\6N^N:^FY-:Q:XYFZ2N]*U]M-/RRS?;YG!0OI5ZG_JV>
MZ*&E6D%H.XYB6H:LR[I6.K \S?(:#BPUU+S0"E5=-7535KW E<.R0:]K$F\_
M#JPSSS_A'HL'BNX7,6RHF)VC,SUNJ(JUK$O-FG'S".<._/9,$YQ.A ^%=Y1^
M\6[42/683C39,5&J=?W\OT_$6M^-:I6G9CL'SY8>H_?[LA.MHWGF%4K8K8N
MN0A8]T2I88"M<:VT<.-PJTH-U\#N/-VW)P3<1@X\K<4R!JR-FT:WD)N!W&NF
M"[7 VQ;MS@=:IPHUM"CS2GIK!>(K!&(;]RPG*-RQFHNO65>,<V[C?Z]J/GON
M[/O=8-A'HLT6O5H&UF+8&85"/Q+S:>GJ4'2UL+/SNK%W!P;0H=LF53E"&+F5
M[MH<H97Q^1M62>").AX^@*=-V6A3-M:D;!!9KO/&9,\@FN^$IBVK@6)HCBZ+
M:C[7=1W#6]Y?J(J%-R/I# G7I' (D<$D1BDPIA(P&%X+M.98/9/ <>Y)(,MK
MFOY-\ZP7%0-4*RR%*+^\ZP20=]_:[80<^&0R>AO6>L8<=%.>J=13=2VBJWH8
MRDZ@*XX>^*HG&R7/))I,]L,SB?TWK>69!^:99\L:/Z8.VY@=N6C83:O)MIKL
M-%?6:JZL$"L(/=N7;4>V-5_1B5)Q9=LCK]5DJ\R2?6JS4[-1WPE[GFO4;[4Z
M[7OT:KY/G;U!D:WB_BX5=Z,>>:#I:F#*EN)J!M$=)50=V[8#TR2AIGO$>JWB
MOD)$;*^\OT<1\2XU^!TR:-ZS*M^ZH5OE?4/.;).*,[N6[GB^+.LR"8BC&;[F
M&LB934MW/3TT3N:&;GTIK:Y^K@SX)"QW7X?Y]O33+1500AK]RCS5\V13#]W
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M<?&E&LS7N+<ZKFIR%GM >0][0/FT+WR#TU<N>Q6.,F1 Q;E3J7A/A:9BR5/
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MW'M\W!CU\""NL[3+>< U/9P4)_)>=?)6BK=2_*Q)>U-B;GBK%,M6%=WS5=#
M21#(KA^22HJ;EKD'8MZ73">72BO3/Z!,!_2ZZ,Y;Z\O]U:^(-JBC'U(OFV#.
MV2[AJ*620;R-5;0?++!QBAJY=5#<I8AN.Z"=85C 5D@C\\XT2!!JH6(1,W1U
M+0AETPZ(1@PMM/TY1MLTEVH&>[@ @;%?DVE[!#D*R;3AA;-@FV?('0_$#]\J
MV]N0T6EULQY@9ZYM*JHGNW(H!\#K5%'W8[N*I5K;,KH]J9&F;5UJ1V5T9\G/
M#M&SL=G5:OOV0VSGJ]HOO;*3V0H$)\MVLWO_J&EVJ(VF&R!=[-A2:O/.>:PW
M"/MRNC_;FLK(?8%C[6'NG5L=XC#/JAG852K==,<9]D8!IFAUV(A[;.8;I2\2
MZ]+")AZ/,RF"XUU=__H<CP?2<)*,XQ%PK(2F" RX&;8]GK!>NM)G?/PG7JLE
M.>6=G[Y<2MB5#*.EK"$97C7W^#CM)I,>E3['7V Q>5GX55[8%WEIXAU589@D
MWE;FK7WZ@F\H#_5XD.:2[S_7B#[=KKMHR*9F8,*?XIH6=E]6?,\.3-]40L_5
MR'PF+Z#C37^Z#DZ$1MPLS[-GK)*+L,\9 &%*(*(\M/ZF 2*HNY?%KJT/8/=4
M9[\NC?#J.MQ0%AOR?!YAV<1S1B(?[]0Y4402+'J2(W;V<$88(&!)=41E+:S@
M)S86_1PSY!Y7'7C$[:,<L#\>18EH.'K.*-SHUJ"$FFDX@6V$Q/545_9"G:.P
M2E13T^:K3PZ.PLL[.IP,;S7]'/&6<U'6"@IA5;'/SB>&J./LD6)F,$=0O'8I
MP^4RY9/0$>Z$])B^**9%*01*X3.,7H#)_VN"DV( ^7,&=2" FC;ZU;TX1YY=
M$Q7P!\!AY8*DSS3J E6ETJ>KQH-QFR <HH*E[N!_\?4Q_Q[_P(;P\ 7(0LSE
M22BH\-$CE7)LK@IP2!+I@<*R05K"O[!%( VDW(P?OO00%7%Q*>VM8?3Q]8F/
MH!!5?*8 T@93:PTJ,5J *^8)I<2("%%33#R*QJBYH 3 #M)1"IQ  AQ#K,ZD
MSQ&R?CK),VZU=E_$I<FD8!($6XK"1RF.'> #[4\E M9( +.>5N82QY)]A_A6
MJ(>N3!37$OG+3JB[UIS]/LU\7229NQ'0=>\F_7N4QVAAXE@',LW]_8K[$_V"
M_?QGD8__>0NPHHR!XU_?XC0>3H:;<7MGR.:9+V3ZU;W-%4TI2 $<8@^[NN9S
M8@*.G'VP6%)<**NC5I?*? CZ3Z<3$H"UYXJ"=46<95H^CLMS'5?5%6*J82A*
M8#W="KVYU*)#HF#TXZVCH'*Y0,T^(0I6C+0#^QD)FS-+FW;L3P6>%'.5 91Z
MBZ0WZ ^?'Y#]@I"FG.U^?H85#J2X8(\:P&N1@POC%/3Q(;^.:S=]"J("V'@?
M9$;18-MG2AU6[6!U-&(IFJ+95J!81//U,!0.5E<V+'(XZC@H]H?\/$(\CJ#?
MQR;Q3VP6$%ZY7X*0+Q?H[Z<C"&Y'+M(C8 ^H\U;*"%!.G/5.8TEF*6C*\,7@
M%!SCG FS[GCF^;(N6R"Q'#-T/%-WB%..*5"4T%'?)F$>3#,Z(Q)\@QJ[7?ML
M+-L(06,/'-<AJD,TQR>BPZ9C.R%9.$OE[6OLL&YZ"-G0ZNL;(F#=54I1+$56
M%%5U3=7T%$>U79$1[*F:X;Q3??TP"$C.2UO?14>?]@[&E7<.?9' :O^@TK\F
M40ZZ3?(BC:(7[K2K73BS,2>N#G6[^02>@"K3)!U%<:]6C\3ZLLFX&$=\R;47
M_B%*,&&UP^R%7GEM]) ]T?H)J'45E])5*J$;#$$_'5Z;V0,L&N?R#.,Q7Q^E
MQ5N0'4262:.:%@2':;NF+0>JX\NJY9?6A.HY9+X_Q2*'?P6#D-+O-,=A$8 %
MIY0?^Y,'I)4'&R)5G55NJ(9-'-T-56(3/;1]3_=+$]4+E6,CU;YDPOZ02CTG
M'K\?CPR;P A<= 2F>^ETB<0%O0A6#L";(.NM.>9&#OLY*0(DD%-DO<N9?1UR
M7>+IAZ76L@?S':(DX2NJQ$.4,IC TT85\M6N_[,EPCH;0?4T335 -_,<*U!M
MTU!461"AKAAFU=X7L/[GFKYN^C=Y#!(L2KZ7X'08-&^%X+O/;A'Z5VD8Y\7X
M_CG[/QKEQ<8VZEXCO,<@UD5]'4Y(JP*G,W%(KT'ZWB1',F&A5'%5'\]0&C]G
MT@N>XO*;.V>+\:0VA%W+)X$.>HSNJ)ZLZ[9?IIZZFN9Y^FX8[S/P 3.Z'\1Y
M#['^_2+].T-Y_':,I\;0?,7U:%:<+:+7GD;3# A8VCCS.Y!]S3/T,D#FNCHQ
MC=T0_99B2@3 [9US=O-=<O8FAN?L)%'%$A^P5)SESX&WQ G[<B[[;9E8B,82
M#[N-,;Z&5\$Y 3*5UOF<!;[B]65&#G9\9T.[HQ?TO$QK@(.(Q_=8X0.SPFMM
M<.$SQP-0$O&J83P98MP0--PH*17+K1)%&'2H]'F2)K0H .YY$J,>"U?"T8%^
M_ 4UR./CD$A1Y%4^99[B\9=QV::/GVVVU/TBSQIPSJST;!6 W2E0?9:_"-(:
MEE.GEQM3C.Z?\%%-=QGF^,&==Y.'(N[%48YY?Y@S%6.5CX00>0!:29&$T@SX
M&Z8G/L<%R[4"$Q'MS!7N0)$!D-,NC9^HU(V* >;N=2GML8Q"^J.+3S[?O%LB
MJ[4?#BPTW]-=6_<4+[!T-R25[NK:MN,W1;H'6_TN=AJP77(Y'N;9T(^+458P
MWV5QTX>K );CEYL<[ID@UPOPE HXDM_!3K_///@61,0MC=,G6C"K_!:W<M92
M?^O$77*6">=-);4AG^?]W^A2[O(#DWJ-<\8[1N*DD2SXA>+ .5TB192"#AX>
MY]4-':G@R("RM'QZWL '+FF+O3'U-@OV4'R]SYIRQ*!K=3,X]&A-/$646B8O
M)>MGES5B,B ,T'(H.RY$0"K,/3_M"B3*!4L,D?(," GPBS5>@GT\Q:SOTG3:
MUNFX\3IFK-7,6 &&&YBNYVNNZ: 'VR>Z'=@Z_*6&\$N3&4^S,D\ 'C^]XR#P
M! 1N$0 S=:T^+^#_OWM_XV#(J:I\5IM:\CH?VMJ.X<<-HF"8M4R\&O+XP/J4
MPS/&W3KV8MNA071"?$U6/",,+,6U &4]#5!7\^U@/>Y>T_%7VL#9FY2^"FT7
MAEO>(MJJE^;:_F''1UL6!Y_FU/V8,5Z>'UAP^3]M"Z(I2&RX+<\FCP/ICH[&
M#%+\:\5FIJ)\UOXOK0YMR!C4"#Q+]]1048@FRR%@MAW(NNXXBK8%CM\_OXXU
MOR,</T/6S+(N<AKU ;T[PK^$U64/5(IZJ'[Q_(MSQ52]#DD 0IJF8EF>; 2R
M8;N!K-B(J9ZMNK(Y;=9MB*D#0(./B:O:HMRH4^,JY\<1_)SD)4LN,[7A=7!.
M*>5H4A<6P[<\KBR\'%$7]&]NS%U*U_0Q&C./1J7$"P_+K ;?0<\PANI972=L
M*WTL.E(2PU-%=A-WT)0&I7#+P+H7>&"0]2<Q3>$)W+9DGMJH*.@8/F+I6K5-
M")^P5@.\T4!I-0YI_HB^YKRA2N'&QP#[@A\7?P][&F9<Y7$7]U\ZF2XEIW(T
M-1S/1=.T*< @H6(-,[E9#-S#41(S/S,'=Y)(4;\?(TXA3/'MZ1R WY7#$@D$
MN4.<3B).(>QC?F&YOU=MDBC3N^RRLY_:I_RJ;2ZA-J6+_RQJ5T+,F3VRGX.\
M?/@(N./% TB,/RZ8T/@Y2IZCEP*6\.=!/K77YC+NXR$M@-Z>I=ML&*4SW7A>
M>?0"*-N?]>9-733;7-C4)?@6W/X:7-]+[M7-W<W7W^ZO;J[OI*MK[W)O)<Q'
MW.4<YQ6[O+ZY#^ZD^QO)N[GV@^N[P,??8+]7OG,/?X17U\ZU=^5\E>[NX8-O
M )"[=[3]SY,TFH 8H#V6<26\E\B0?W1!JY>*092+\!GP8O$7<P\77[8&0\T!
MMN-KFS&NFCDUF-4,-V/*UCVLY(XF7*Y>>*YIN6#?$C4T?4_6+5L30XU#5;%D
MXT+9B;#?2DNGS713HRXD!)-* 7,I='3+LTU;]FS'*$,.LF4XJ]/VKT32-*;
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M!5E%VPFTFWGB!!(W 9LBY27PJG\,:"J-0,+A!VF72MD#+)9!IY"BG$II-I8
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M78?HNNS"+XJG@@ 2)H8<NOJR"2RW)35^KXGQIJ+%@\D?7=_ L#@>M"5X;H(
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M@D:47UALN_7NOK[=$6KSEE8G/UJ&X\BV#'J[IJJFYRBR+^IF7=>VS+FJDO*
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M]C^ AQ2X3AZSB&*3@598R^0A;!@OJ+A<Z#N74@V3"B %!76BUX#+[&J!U?C
MMIF$,<LS*Y>W G(U93'"#NE#/D$K@"C<5]>9/EN$7_E*%C9A<5N<@"P, ?:*
MZ!$T?O8;? .:?)8\<<:8I8\9[C>IU(!+"2!<FISPO&%1+K!^7J<A18I:.D5
MQ.D%Q9A^@58H2 \<>RU,V.:RP9X0E,OY_Q^T X^"6X91CX=5A$QHLHO%W!\^
M1N;/63Y_$]Z4/:?L0.>94[DJQG4>RO0R7&_$MOH_4<H S@A-55D&690G,3R8
M/[X+S S.6NK&>7<RQ.RV+J:BI9C*@+"<_IRQU=I< AZ-<Q)*F'8G>8['4L._
M0J1[^A1)GV%-/=H')H:Q["1[_H+K67!U?S*>@+ K<1C0'0X2S<2:_2_ AKA
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MMY* TR*8FR-A8)10JPS<G?<&>E8F-EAMKSCM_I;B0HD!/S6<'  "0-<^6I^
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M-EUCX'K 1-M?0#[UQ@-8- #MIZG+^TD6C7D_*7&19LU<<^@\Y17QBXVRE*_
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MJ;O]MB-H'6[-M"VO)'?'_@@"11)C$.#BD,S^ZU\>584"".J@))[UYNV,18(
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M/0Y5X:WWH>=ZW[%"+/)WR_ND[!I5,N/FWW(/FQ]1:2-]4CXST;/OA_']K\/
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MV/U+,*7%,$BS.$%C/9PX_2!R(P\.;BQRBV'#P$S!Z4ZD5U)2*$@(TY,G9$.
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MU\\>NF/G23\SIT;/W,&S6WO+,^X%/2'I)]-] 9?2,?(,S+7'-WZ?_A_&*(R
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M]C)O\2*^3[QV6#N=#O/,1[P[J@X)4"_L6TE0AW8B_C!/(GDG_-,T$8G9E29
M$GS2""9X6 ;1H[MRPY!_>Q;YMX;(/WLTV*/A38\&^!]T5(AJ7R, 6%MZ\+[Q
M"/5]H7!#C-[ ]QA.@:%2]-\-"^)]P_G  +:&KX5UK@VY\'A7#$US @%Y]L7
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ME80GW0^1GY:K5/ \;D@6T8ELK,Y-Y.0?-H=FQ7>Q=6!1@#Y<4K)U9,'4Q#@
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M>!]PX@-NLD9O4S 442,WXK>0W6+E;_4 Z#&HFR2^UHU,9Y%8UA(B_7"=(0B
MPW3"?1UZ"*(AVQ)TXR MGPU%^J32$FT\QHHX#*?(X$J&[%?(?X1V"DF4.8\X
M#.I<QK&,HF<5UT/KIZ7<FU!%%,E0-8X0;2<8Y%OPM1]X3'79=]( MHN;Z#NH
M@[QJT3:=&[XR))9!-8S2@W% V%VI\E,VPJ;ESGBG1/ *L%5,N=:I%]ATY2(;
ME+'52X>]9JQ15!YE<@]3$L?(W +'?4X !EP66 P\LNA8,@"X15]E@P\PG/!N
MT7;&/5;$&6PO\MO:L+M!]U4Y,IJ.;%DEHY\<_%0F:Q']_+4V#&(!-Q9PL^J
MFU/EHJ>R6QHE!_0YA<1/3*VO\!."#[;+ZX^J37FAJY4O1>=]18566\NE7CP6
M#/C$?:P1 ^6?6<2FW0\+'>2UZ6R2_\G6::/P8$N'&CG\<%@Q=V3<F)+[Z;T
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MF%8"0NCL/ ZA,"IH1X]1!(.FSM%[QQ#B1+B\Q+?M,%7T$[1I+WIZ9N[51M^
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MKKC8'V-3$@, ^ QNSAY,']WDHJFOF:&<I=L/R_&Y'1[V@=;-'NY1'.;XN+/
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MMPOXJ<F/_+(R,0:*H'W+OIYBEQ-BD;Y*5RLW:FP*TBV!%ZU-B0528\=7O-Q
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M.K4R,G2^,Q$*LX0,@$N'-3W#R?B1#0L;3&KGUOTP:.; F=X!&[ZG65/1Q)[
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M4M1P;I?0AE>[":XQ7)I>(>*/<S[->BWY&?20H]V.J$P1=-'=P^^\_\69"!<
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MF\DTLSN!WFW'ZT R.XASQW#]TAVBBGP;L].WEWUW1#7XQ%@^9FDJN75BC4M
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M<=;Z'W_]=O$F1:1SOFW2G7/U"/@9R;+R0Q_952E'-AX3E7;G&&L1$]B5Z98
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M=]7FWO6(<Z/N&6LJN0=0L@?B)JQ$L$FK]"*JOG/^1+#Y,:C%WWT7B]A2+C&
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MGDYN=]L5W>ZNND;)"#9H.7%><)ZV(.G&J!-/B'OAK.DOXM4W9)5E/O*RM-.
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MB3V#DK81P!6ERKR#F^3Y)&L"_?15P;2ZYRR_AOFJAT/CMQE0!B1<.[G.?+L
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MGC+RBVP?.?N(/I;V]\FEJ[RZ2]!NFF$E?J]%(U+D76"(MMR?]WZ/L:%6>,_
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MID<HE=*S_+] E92[*(,S745AET C[%BBU2>C*;];-*W$&-S>)Z4F=9&S&V^
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M<U&_+(^DHP7>U422.\M=V,H$\B;-/64]1]ENGFI:AXPU6A'2.% IF;%$&KP
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M$JE\R&.TW8:? M]E0/$4-]SO5Q_H;ATEPPH[&P%?8<?8GF3IEE53J6JG"&X
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MZ\.$N3AO7@YVUD'Q*NOKGX0P?IRP8D\KK>0T37C=OM(>&<RL?V->\8ED:JK
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M*0O,'%E+ TOKR2#]Y$&T\M=P9OL2E[4-X*2B7HH9ZVQ@]8$CCWKA .[Z3I/
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M(?9G$"I:6EKZ\_2L%RZPBEWCN";V/WV1&P"&<U1:U"!JJNO *08J:@8J<C,
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M?^#&0G]C/;CH<6)6#^)B<H/;G]#?X0A;*)8J+S]23*2_--%<I'Q9C3WTC I
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MB6 1]!'HGBS5>!7BTWB:Y>&7\8]=AB$E@/?D:^,3'U!C!0$>6:U 'W^&7<)
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M*HN\'"LO4=2W5D!/0T)8,:5NS!^6O!;]DW3>A=%IIG^KO?V++KM?-E70YAD
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M\/7;]EGG:B=QN;TO5MWZ'VO*X=9?VVJU^ ;]']_,U:/P_MB,C6(5WXZX7,@
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M6V%M+< <<;3&SVK1:+WP*).ZC,+W>)&07I @]]S<ST$ (*?;/S1V,YP].M?
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M5PB((K,R)]*"#$HE-86#AKVMY+AA^45?RO?+]BG7:H4VUX* EWSLNU>$'GC
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M>$QL[TXEPI[[;5\?2 Q=8H))56FCZ=P&0U\>Z3&:1<&30A^P_MIZ!_WQ=6&
MG:/+EM=[J$0""P"]*3V)7\,#S/:! ZF!/<=,R25G< C*I'4\!/BAX,J0:PA*
M,!@$&ZHJF8NL9X\9*X7&K#Z]?D'9 T_E@1QK.DW1W*5D;6"/H;\B7[ %L6DM
M/&_L++?;+!A=6U%=6_MV,>D2HXRTW\%.\O^=:(0$4&S5M,5AUSZ;%$5;_((F
M.!PZ3$'DL>@62M4]\/L\6*[+]R;.<U3$0>X)1.WR:LO843 @0!L8^</HQ,\_
MW*Y,'DD<='LY0]G,)-7%6II68@6X*_M%D::K1?0S.M55<6(D0:OG/-16_(M
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MF*ANT(' %@A3B8L6VI.]?-T8>%'QMQ=,R1</N.51@-NZMDWJJ41_A0(.;5S
MTA6=X#3P@ '2JS8L%VF+T^;T8&P9__Z4-;DE(?%GPOOK?%CV89#?E2BRE0/:
M8]8!.AX'9<%TIG[_2B91D!$!??/LS(D622DJLW#>$SL=+9?\]H=*;07K?203
MW."9\  G/.. !^BYX0&?96@>3LE9:E4XCX;I3LLSFV<\5(2-W<O5=TO8/VGZ
MHA)5[**^J7/BP&TZFL-F?M*MZU:!P@-66%SP &NC<XHUI;"BWW=C/7<[LPAW
M)7&78-F#+87C3<V%] 7B/$YCXZ;*@;AV[CO#?Y3D'=Q]B_E](:S4GZRBSBAV
M^& "KY\]^&[NJ%<LTW=FI(;R:+X+'U3YZ"1602NV2YC6/99E9AI?]=E$O[0
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M\?[/2AD0/_4_ %!+ 0(4 Q0    (  ^2GE!.Z!G-?A<  )>C   8
M      "  0    !A,3 Q+6)A<F1A878W.3 Y;6]D-"YH=&U02P$"% ,4
M"  /DIY0&8M/T ,6  #*K   &               @ &T%P  83$P,BUB87)D
M86%V-SDP.6UO9#4N:'1M4$L! A0#%     @ #Y*>4!* 1R;N!@  ;",  !H
M             ( ![2T  &$S,3$M:W)A;65R8V5R=&EF:6-A=&DN:'1M4$L!
M A0#%     @ #Y*>4/LOYM<7!P  Y"0  !H              ( !$S4  &$S
M,3(M;&EN9&AA;&-E<G1I9FEC870N:'1M4$L! A0#%     @ #Y*>4./J$D=M
M!   2!,  !H              ( !8CP  &$S,C$M:W)A;65R8V5R=&EF:6-A
M=&DN:'1M4$L! A0#%     @ #Y*>4!$0. UC!   <A$  !H
M ( !!T$  &$S,C(M;&EN9&AA;&-E<G1I9FEC870N:'1M4$L! A0#%     @
M#Y*>4(!_Q<*&)P  PC@  !T              ( !HD4  &-H87)T+30U9C5B
M8V9A86,X-3DQ-V-B,#4N:G!G4$L! A0#%     @ #Y*>4#-;1+]P.   \E
M !T              ( !8VT  &-H87)T+3=B93$V,#AB-F5A-S5F9#5A838N
M:G!G4$L! A0#%     @ #Y*>4*B?9L=/6   -&\  !T              ( !
M#J8  &-H87)T+3DS-V4Q83$Y9#@W,C4P,3%B,&0N:G!G4$L! A0#%     @
M#Y*>4.>M62[F.   RDD  !T              ( !F/X  &-H87)T+3DS9#=B
M9C(P,V%A8C4P,F8Y-C0N:G!G4$L! A0#%     @ #Y*>4"Y43ZC],   <$(
M !T              ( !N3<! &-H87)T+6%D93DS.3=B-&-C9C4X8V-A-C0N
M:G!G4$L! A0#%     @ #Y*>4+)2\\Y#-   $$0  !T              ( !
M\6@! &-H87)T+6%E8V$R-3@T-V(R835D-#0Y-S@N:G!G4$L! A0#%     @
M#Y*>4(%!3* [.@   TH  !T              ( !;YT! &-H87)T+68X.#9E
M-F,P-38T9C5E9&(Y9#$N:G!G4$L! A0#%     @ #Y*>4(=N[EU6#0  $9(
M !               ( !Y=<! &5B<RTR,#(P,#,S,2YX<V102P$"% ,4
M"  /DIY08W];T)$;  !:( $ %               @ %IY0$ 96)S+3(P,C P
M,S,Q7V-A;"YX;6Q02P$"% ,4    "  /DIY0VF[O/M$S   ,>P( %
M        @ $L 0( 96)S+3(P,C P,S,Q7V1E9BYX;6Q02P$"% ,4    "  /
MDIY0]E1@$SZ@  !4(0@ %               @ $O-0( 96)S+3(P,C P,S,Q
M7VQA8BYX;6Q02P$"% ,4    "  /DIY0*!* =")B  !NS00 %
M    @ &?U0( 96)S+3(P,C P,S,Q7W!R92YX;6Q02P$"% ,4    "  /DIY0
M<\]=1&\? @#CG18 %               @ 'S-P, 96)S+3(P,C P,S,Q>#$P
M<2YH=&U02P$"% ,4    "  /DIY0';7[\IQ;  "+9P  $@
M@ &45P4 96UE<F=E;G1L;V=O,#$N:G!G4$L%!@     4 !0 @04  &"S!0
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6793968416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net loss per share (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (12.5)<span></span>
</td>
<td class="num">$ (26.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of shares-basic (in shares)</a></td>
<td class="nump">52.0<span></span>
</td>
<td class="nump">51.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive securities-equity awards (in shares)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of shares-diluted (in shares)</a></td>
<td class="nump">52.0<span></span>
</td>
<td class="nump">51.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share - basic (in dollars per share)</a></td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.51)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share - diluted (in dollars per share)</a></td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.51)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">3.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1500-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6805543392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue recognition - Disaggregation of Revenue (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 192.5<span></span>
</td>
<td class="nump">$ 190.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S. Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">85.9<span></span>
</td>
<td class="nump">93.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-U.S. Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">106.6<span></span>
</td>
<td class="nump">96.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">148.2<span></span>
</td>
<td class="nump">153.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales, net | U.S. Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">63.9<span></span>
</td>
<td class="nump">73.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales, net | Non-U.S. Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">84.3<span></span>
</td>
<td class="nump">79.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractManufacturingMember', window );">Contract development and manufacturing services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">21.7<span></span>
</td>
<td class="nump">15.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractManufacturingMember', window );">Contract development and manufacturing services | U.S. Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractManufacturingMember', window );">Contract development and manufacturing services | Non-U.S. Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">21.7<span></span>
</td>
<td class="nump">15.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember', window );">Contracts and grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">22.6<span></span>
</td>
<td class="nump">21.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember', window );">Contracts and grants | U.S. Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">22.0<span></span>
</td>
<td class="nump">20.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember', window );">Contracts and grants | Non-U.S. Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_ContractManufacturingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_ContractManufacturingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6795235440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue recognition (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue</a></td>
<td class="text">The Company's revenues disaggregated by the major sources were as follows:<div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:23%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Three Months Ended March 31, 2020</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Three Months Ended March 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">U.S.<br/>Government</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Non-U.S.<br/>Government</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;Total</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">U.S.<br/>Government</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Non-U.S.<br/>Government</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product sales, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>63.9</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>84.3</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>148.2</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>73.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>79.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>153.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contract development and manufacturing services</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>21.7</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>21.7</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>15.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>15.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contracts and grants</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>22.0</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>22.6</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>20.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>21.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>85.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>106.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>192.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>93.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>96.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>190.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Rollforward of Contract Liabilities</a></td>
<td class="text">The following table presents the rollforward of the contract liability balances: <div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:82%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><span>88.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferral of revenue</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>6.4</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue recognized</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(5.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">March&#160;31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;font-weight:bold;"><span>89.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_ScheduleofAccountsReceivableNetTableTextBlock', window );">Schedule of Accounts Receivable, Net</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">Accounts receivable, including unbilled accounts receivable contract assets, consist of the following:</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> </span></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">March&#160;31, 2020</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Billed, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>119.4</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>227.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unbilled</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>43.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>43.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>162.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>270.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_ScheduleofAccountsReceivableNetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Accounts Receivable, Net [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_ScheduleofAccountsReceivableNetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contract balances and changes in contract balances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6785823152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves', window );">Raw materials and supplies</a></td>
<td class="nump">$ 77.7<span></span>
</td>
<td class="nump">$ 70.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">114.2<span></span>
</td>
<td class="nump">89.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">56.2<span></span>
</td>
<td class="nump">62.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="nump">$ 248.1<span></span>
</td>
<td class="nump">$ 222.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6805350928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 181.5<span></span>
</td>
<td class="nump">$ 167.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">162.5<span></span>
</td>
<td class="nump">270.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">248.1<span></span>
</td>
<td class="nump">222.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Income tax receivable, net</a></td>
<td class="nump">10.2<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">24.1<span></span>
</td>
<td class="nump">20.4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">626.6<span></span>
</td>
<td class="nump">686.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">549.2<span></span>
</td>
<td class="nump">542.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">708.1<span></span>
</td>
<td class="nump">712.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_InProcessResearchAndDevelopment', window );">In-process research and development</a></td>
<td class="nump">29.0<span></span>
</td>
<td class="nump">29.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">266.4<span></span>
</td>
<td class="nump">266.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="nump">17.6<span></span>
</td>
<td class="nump">13.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">81.8<span></span>
</td>
<td class="nump">76.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">2,278.7<span></span>
</td>
<td class="nump">2,327.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">84.2<span></span>
</td>
<td class="nump">94.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">41.5<span></span>
</td>
<td class="nump">39.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Debt, current portion</a></td>
<td class="nump">47.5<span></span>
</td>
<td class="nump">62.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Debt, current portion</a></td>
<td class="nump">26.3<span></span>
</td>
<td class="nump">12.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">7.6<span></span>
</td>
<td class="nump">6.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">207.1<span></span>
</td>
<td class="nump">216.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration, net of current portion</a></td>
<td class="nump">26.1<span></span>
</td>
<td class="nump">26.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Debt, net of current portion</a></td>
<td class="nump">762.9<span></span>
</td>
<td class="nump">798.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">63.9<span></span>
</td>
<td class="nump">63.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contract liabilities, net of current portion</a></td>
<td class="nump">85.0<span></span>
</td>
<td class="nump">85.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">58.9<span></span>
</td>
<td class="nump">48.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,203.9<span></span>
</td>
<td class="nump">1,238.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 15.0 shares authorized, no shares issued or outstanding</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 200.0 shares authorized, 53.5 and 53.0 shares issued; 52.3 and 51.7 shares outstanding, respectively</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost, 1.2 common shares</a></td>
<td class="num">(39.6)<span></span>
</td>
<td class="num">(39.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">726.2<span></span>
</td>
<td class="nump">716.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss, net</a></td>
<td class="num">(21.2)<span></span>
</td>
<td class="num">(9.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">409.3<span></span>
</td>
<td class="nump">421.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">1,074.8<span></span>
</td>
<td class="nump">1,088.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 2,278.7<span></span>
</td>
<td class="nump">$ 2,327.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_InProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of purchased research and development assets acquired in a business combination that have an indefinite life until completion or abandonment of the associated research and development efforts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_InProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31931-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.5(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6791711328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax', window );">Unrealized losses on hedging activities</a></td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax', window );">Unrealized losses related to foreign currency translations</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6593221296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets</a></td>
<td class="text">Intangible assets<div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">The Company's intangible as</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">sets consist of products acquired via business combinations or asset acquisitions. The following tables summarize the Company's intangible assets for the periods ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> and December 31, 2019:</span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"/></tr><tr><td style="width:30%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="12" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">March 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">(in millions)&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Estimated Life</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Cost</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Additions</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Accumulated Amortization</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Net</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Products</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9-22 years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;">$</span></div></td><td style="vertical-align:bottom;background-color:#ededed;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"><span>788.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ededed;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;">$</span></div></td><td style="vertical-align:bottom;background-color:#ededed;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"><span>10.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ededed;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;">$</span></div></td><td style="vertical-align:bottom;background-color:#ededed;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"><span>96.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;">$</span></div></td><td style="vertical-align:bottom;background-color:#ededed;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"><span>702.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Customer relationships</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>8 years</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"><span>28.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"><span>23.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"><span>4.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contract development and manufacturing</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>8 years</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;Total intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ededed;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ededed;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"><span>822.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ededed;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ededed;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ededed;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"><span>10.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ededed;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ededed;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ededed;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"><span>124.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ededed;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ededed;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ededed;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"><span>708.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ededed;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:43%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">(in millions)&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Estimated Life</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Cost</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Accumulated Amortization</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Net</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Products</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9-22 years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>788.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>82.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>705.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Customer relationships</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>8 years</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>28.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>23.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contract development and manufacturing</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>8 years</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;Total intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>822.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>109.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>712.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">During the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">three months ended March 31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">, the Company achieved a sales milestone that resulted in a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"><span>$10.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> obligation related to the Company's asset acquisition of raxibacumab in October 2017. The achievement of the milestone resulted in an increase to intangible assets with a corresponding increase in accounts payable. As of March 31, 2020 there are no remaining contractual obligations for sales milestones related to the raxibacumab acquisition. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">During the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">three months ended March 31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">, the Company recorded amortization expense for intangible assets of $</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"><span>14.8</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> million and $</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"><span>14.5</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> million, respectively. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">, the weighted average amortization period remaining for intangible assets was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"><span>13.3</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> years. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">In-process research and development (IPR&amp;D) assets are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. There were no changes to the Company's IPR&amp;D assets during the three months ended March 31, 2020. </span></div><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Goodwill was $</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"><span>266.4 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> and $</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"><span>266.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> for the periods ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">December&#160;31, 2019</span>, respectively. The change in the balance during the period was due to foreign currency translation adjustments.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6791751264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Principles of Consolidation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Principles of Consolidation</a></td>
<td class="text">Basis of Presentation and Principles of Consolidation<div style="line-height:120%;padding-bottom:8px;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Basis of presentation </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">The accompanying unaudited condensed consolidated financial statements include the accounts of Emergent and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements included herein have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X issued by the SEC. Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">, as filed with the SEC.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">All adjustments contained in the accompanying unaudited condensed consolidated financial statements are of a normal recurring nature and are necessary to present fairly the financial position of the Company as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">. Interim results are not necessarily indicative of results that may be expected for any other interim period or for an entire year.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-style:normal;text-decoration:none;">Significant accounting policies</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">During the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">three months ended March 31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">, there have been no significant changes to the Company's summary of significant accounting policies contained in the Company's Annual Report on Form 10-K for the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">, as filed with the SEC.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-style:normal;text-decoration:none;">Fair value measurements</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Separate disclosure is required for assets and liabilities measured at fair value on a recurring basis from those measured at fair value on a non-recurring basis. The Company has cash held in money market accounts (level 1), contingent purchase consideration (level 3) and interest rate swaps arrangements (level 2) that are measured at fair value on a recurring basis (Note 7 and Note 8). As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">, the Company held cash in money market accounts of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"><span>$90.7 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"><span>$52.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">, respectively. The Company also records the assets and liabilities of acquisitions at fair value. On a non-recurring basis, the Company measures its IPR&amp;D assets (level 3) using fair value measurements. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">, the Company had </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">no</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> other significant assets or liabilities that were measured at fair value. </span></div><div style="line-height:120%;padding-bottom:8px;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Recently issued accounting standards</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#0094ff;font-style:italic;text-decoration:underline;">Recently Adopted</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;">ASU 2016-13,&#160;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&#160;("ASU 2016-13")</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">In June 2016, the FASB issued ASU 2016-13. ASU 2016-13 provides guidance on measurement of credit losses on financial instruments that changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, held-to-maturity debt securities and loans, and that requires entities to use a new, forward-looking &#8220;expected loss&#8221; model that is expected to generally result in the earlier recognition of allowances for losses. The guidance&#160;became effective for annual periods beginning after December 15, 2019, including interim periods within those years. The Company adopted the standard as of January 1, 2020 and has evaluated the effects of this standard and determined that the adoption did not have a material impact on the Company's consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;">ASU 2018-13,&#160;Fair Value Measurement - Disclosure Framework (Topic 820)&#160;("ASU 2018-13")</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">In August 2018, the FASB issued ASU 2018-13. ASU 2018-13 improves the disclosure requirements on fair value measurements. The updated guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Early adoption is permitted for any removed or modified disclosures. The Company adopted the standard as of January 1, 2020 which has resulted in expanded disclosures around the Company's recurring level 3 fair value measurements. The disclosures are included in note 7 of the condensed consolidated financial statements. </span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;">ASU 2018-15,&#160;Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract ("ASU 2018-15")</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">In August 2018, the FASB issued ASU 2018-15. ASU 2018-15 clarifies the accounting for implementation costs in cloud computing arrangements. ASU 2018-15 is effective for all entities for fiscal years beginning after December 15, 2019. The Company adopted the standard as of January 1, 2020 and has evaluated the effects of this standard and determined that the adoption did not have a material impact on the Company's consolidated financial statements. </span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;">ASU 2017-4,&#160;Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment ("ASU 2017-4")</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">In January 2017, the FASB issued ASU 2017-4. ASU 2017-4 simplifies the subsequent measurement of goodwill and eliminates Step 2 from the goodwill impairment test. ASU 2017-4 is effective for annual and interim goodwill tests beginning after December 15, 2019. The Company's measurement period is September 30. The Company adopted the standard as of January 1, 2020 and has evaluated the effects of this standard and determined that the adoption will not have a material impact on the Company's consolidation financial statements. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#0094ff;font-style:italic;text-decoration:underline;">Not Yet Adopted</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;">ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">In March 2020, the FASB issued Topic 848. Topic 848 provides relief for impacted areas as it relates to impending reference rate reform. ASC 848 contains optional expedients and exceptions for applying US GAAP to debt arrangements, contracts, hedging relationships, and other areas or transactions that are impacted by reference rate reform. This guidance is effective for upon issuance for all entities and elections of certain optional expedients are required to apply the provisions of the guidance. The Company continues to assess all potential impacts of the standard and will disclose the nature and reason for any elections that the Company makes. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;">ASU 2018-14,&#160;Compensation -&#160;Retirement Benefits - Defined Benefit Plans - General (Topic 715-20):&#160;Disclosure Framework - Changes to the Disclosure Requirements for Defined Benefit Plans&#160;("ASU 2018-14")</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">In August 2018, the FASB issued ASU 2018-14. ASU 2018-14 modifies the disclosure requirements for defined benefit pension plans and other post-retirement plans. ASU 2018-14 is effective for all entities for fiscal years ending after December 15, 2020, and earlier adoption is permitted. The Company is currently evaluating the impact of adopting ASU 2018-14 on its consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;">ASU 2019-12, Simplifications to Accounting for Income Taxes ("ASU 2019-12")</span></div><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">In December 2019, the FASB issued ASU 2019-12. ASU 2019-12 removes certain exceptions for recognizing deferred taxes for investments, performing intra-period allocation and calculating income taxes in interim periods. The ASU also adds guidance to reduce complexity in certain areas, including deferred taxes for goodwill and allocating taxes for members of a consolidated group. ASU 2019-12 is effective for all entities for fiscal years beginning after December 15, 2020, and earlier adoption is permitted. The Company is currently evaluating the impact of adopting ASU 2019-12 on its consolidated financial statements.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6797092272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue recognition<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue recognition</a></td>
<td class="text">Revenue recognition<div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">The Company operates as </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"><span>one</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> operating segment. Therefore, results of its operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. The Company's revenues disaggregated by the major sources were as follows:</span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:23%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Three Months Ended March 31, 2020</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Three Months Ended March 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">U.S.<br/>Government</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Non-U.S.<br/>Government</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;Total</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">U.S.<br/>Government</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Non-U.S.<br/>Government</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product sales, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>63.9</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>84.3</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>148.2</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>73.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>79.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>153.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contract development and manufacturing services</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>21.7</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>21.7</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>15.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>15.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contracts and grants</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>22.0</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>22.6</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>20.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>21.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>85.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>106.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>192.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>93.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>96.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>190.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:0px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Contract liabilities </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">When performance obligations are not transferred to a customer at the end of a reporting period, cash received associated with amounts allocated to those performance obligations is reflected as contract liabilities on the consolidated balance sheets and is deferred until control of these performance obligations is transferred to the customer. The following table presents the rollforward of the contract liability balances: </span></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:82%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><span>88.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferral of revenue</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>6.4</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue recognized</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(5.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">March&#160;31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;font-weight:bold;"><span>89.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:0px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Transaction price allocated to remaining performance obligations</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;"> </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">, the Company expects future revenues of approximately $</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><span>555.9</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> million associated with performance obligations that have not been satisfied. The Company expects to recognize a majority of these revenues within the next </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><span>24</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> months, with the remainder recognized thereafter. However, the amount and timing of revenue recognition for unsatisfied performance obligations can materially change due to timing of funding appropriations from the USG and the overall success of the Company's development activities associated with its PHT product candidates that are then receiving development funding support from the USG under development contracts. In addition, the amount of future revenues associated with unsatisfied performance obligations excludes the value associated with unexercised option periods in the Company's contracts. </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:0px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Contract assets</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;"> </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">The Company considers unbilled accounts receivables and deferred costs associated with revenue generating contracts, which are not included in inventory or property, plant and equipment, as contract assets. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">, the Company had contract assets associated with deferred costs of $</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><span>36.3</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> million and $</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><span>34.0</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> million, respectively, which is reflected as a component of prepaid expenses and other current assets on the Company's consolidated balance sheets. </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:0px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Accounts receivable</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;"> </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">Accounts receivable, including unbilled accounts receivable contract assets, consist of the following:</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> </span></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">March&#160;31, 2020</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Billed, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>119.4</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>227.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unbilled</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>43.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>43.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>162.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>270.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">, allowances for doubtful accounts were </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><span>$0.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> and de minimis, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6805040016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective annual tax rate</a></td>
<td class="nump">26.00%<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Discrete tax benefit</a></td>
<td class="nump">$ 3.2<span></span>
</td>
<td class="nump">$ 1.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6806268352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenue recognition - Remaining Performance Obligation (Details)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2020-04-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-04-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">24 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2020-04-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2020-04-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>39
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ebs-20200331x10q.htm": {
   "axisCustom": 0,
   "axisStandard": 22,
   "contextCount": 139,
   "dts": {
    "calculationLink": {
     "local": [
      "ebs-20200331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ebs-20200331_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "ebs-20200331x10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ebs-20200331_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ebs-20200331_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "ebs-20200331.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd",
      "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd"
     ]
    }
   },
   "elementCount": 396,
   "entityCount": 1,
   "hidden": {
    "http://emergentbiosolutions.com/20200331": 2,
    "http://fasb.org/us-gaap/2019-01-31": 41,
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 48
   },
   "keyCustom": 21,
   "keyStandard": 278,
   "memberCustom": 9,
   "memberStandard": 39,
   "nsprefix": "ebs",
   "nsuri": "http://emergentbiosolutions.com/20200331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001000 - Document - Cover Page",
     "role": "http://emergentbiosolutions.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101100 - Disclosure - Business",
     "role": "http://emergentbiosolutions.com/role/Business",
     "shortName": "Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102100 - Disclosure - Basis of Presentation and Principles of Consolidation",
     "role": "http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidation",
     "shortName": "Basis of Presentation and Principles of Consolidation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103100 - Disclosure - Inventories",
     "role": "http://emergentbiosolutions.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104100 - Disclosure - Property, plant and equipment",
     "role": "http://emergentbiosolutions.com/role/PropertyPlantAndEquipment",
     "shortName": "Property, plant and equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2105100 - Disclosure - Leases",
     "role": "http://emergentbiosolutions.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106100 - Disclosure - Intangible assets",
     "role": "http://emergentbiosolutions.com/role/IntangibleAssets",
     "shortName": "Intangible assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107100 - Disclosure - Contingent consideration",
     "role": "http://emergentbiosolutions.com/role/ContingentConsideration",
     "shortName": "Contingent consideration",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108100 - Disclosure - Derivative instruments and hedging activities",
     "role": "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivities",
     "shortName": "Derivative instruments and hedging activities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109100 - Disclosure - Debt",
     "role": "http://emergentbiosolutions.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110100 - Disclosure - Revenue recognition",
     "role": "http://emergentbiosolutions.com/role/RevenueRecognition",
     "shortName": "Revenue recognition",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001000 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:IncomeTaxesReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111100 - Disclosure - Income taxes",
     "role": "http://emergentbiosolutions.com/role/IncomeTaxes",
     "shortName": "Income taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112100 - Disclosure - Net loss per share",
     "role": "http://emergentbiosolutions.com/role/NetLossPerShare",
     "shortName": "Net loss per share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113100 - Disclosure - Share-based compensation",
     "role": "http://emergentbiosolutions.com/role/ShareBasedCompensation",
     "shortName": "Share-based compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114100 - Disclosure - Commitments and Contingencies",
     "role": "http://emergentbiosolutions.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Basis of Presentation and Principles of Consolidation (Policies)",
     "role": "http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidationPolicies",
     "shortName": "Basis of Presentation and Principles of Consolidation (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2303301 - Disclosure - Inventories (Tables)",
     "role": "http://emergentbiosolutions.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2304301 - Disclosure - Property, plant and equipment (Tables)",
     "role": "http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentTables",
     "shortName": "Property, plant and equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Leases (Tables)",
     "role": "http://emergentbiosolutions.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2306301 - Disclosure - Intangible assets (Tables)",
     "role": "http://emergentbiosolutions.com/role/IntangibleAssetsTables",
     "shortName": "Intangible assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307301 - Disclosure - Contingent consideration (Tables)",
     "role": "http://emergentbiosolutions.com/role/ContingentConsiderationTables",
     "shortName": "Contingent consideration (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2308301 - Disclosure - Derivative instruments and hedging activities (Tables)",
     "role": "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesTables",
     "shortName": "Derivative instruments and hedging activities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2309301 - Disclosure - Debt (Tables)",
     "role": "http://emergentbiosolutions.com/role/DebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2310301 - Disclosure - Revenue recognition (Tables)",
     "role": "http://emergentbiosolutions.com/role/RevenueRecognitionTables",
     "shortName": "Revenue recognition (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312301 - Disclosure - Net loss per share (Tables)",
     "role": "http://emergentbiosolutions.com/role/NetLossPerShareTables",
     "shortName": "Net loss per share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ebs:NumberOfCategoriesOfPublicHealthThreats",
      "reportCount": 1,
      "unique": true,
      "unitRef": "category",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401401 - Disclosure - Business (Details)",
     "role": "http://emergentbiosolutions.com/role/BusinessDetails",
     "shortName": "Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ebs:NumberOfCategoriesOfPublicHealthThreats",
      "reportCount": 1,
      "unique": true,
      "unitRef": "category",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:MoneyMarketFundsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402402 - Disclosure - Basis of Presentation and Principles of Consolidation (Details)",
     "role": "http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidationDetails",
     "shortName": "Basis of Presentation and Principles of Consolidation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:MoneyMarketFundsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403402 - Disclosure - Inventories (Details)",
     "role": "http://emergentbiosolutions.com/role/InventoriesDetails",
     "shortName": "Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404402 - Disclosure - Property, plant and equipment (Details)",
     "role": "http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentDetails",
     "shortName": "Property, plant and equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRenewalTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Leases - Narrative (Details)",
     "role": "http://emergentbiosolutions.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRenewalTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405403 - Disclosure - Leases - Components of Lease Expense (Details)",
     "role": "http://emergentbiosolutions.com/role/LeasesComponentsOfLeaseExpenseDetails",
     "shortName": "Leases - Components of Lease Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002000 - Statement - Condensed Consolidated Statements of Operations",
     "role": "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ebs:ScheduleOfLeasesSupplementalBalanceSheetsTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405404 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)",
     "role": "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails",
     "shortName": "Leases - Supplemental Balance Sheet Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ebs:ScheduleOfLeasesSupplementalBalanceSheetsTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Intangible assets - Schedule of Finite-lived Intangible Assets (Details)",
     "role": "http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails",
     "shortName": "Intangible assets - Schedule of Finite-lived Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406403 - Disclosure - Intangible assets - Narrative (Details)",
     "role": "http://emergentbiosolutions.com/role/IntangibleAssetsNarrativeDetails",
     "shortName": "Intangible assets - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407402 - Disclosure - Contingent consideration (Details)",
     "role": "http://emergentbiosolutions.com/role/ContingentConsiderationDetails",
     "shortName": "Contingent consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-5",
      "lang": null,
      "name": "ebs:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Contingent consideration Contingent consideration - Fair Value Level 3 of Significant Unobservable Inputs (Details)",
     "role": "http://emergentbiosolutions.com/role/ContingentConsiderationContingentConsiderationFairValueLevel3OfSignificantUnobservableInputsDetails",
     "shortName": "Contingent consideration Contingent consideration - Fair Value Level 3 of Significant Unobservable Inputs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueDiscountedCashFlowMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408402 - Disclosure - Derivative instruments and hedging activities - Narrative (Details)",
     "role": "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails",
     "shortName": "Derivative instruments and hedging activities - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfInterestRateDerivativesHeld",
      "reportCount": 1,
      "unique": true,
      "unitRef": "instrument",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Derivative instruments and hedging activities - Derivative Designated as Cash Flow Hedges (Details)",
     "role": "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesDerivativeDesignatedAsCashFlowHedgesDetails",
     "shortName": "Derivative instruments and hedging activities - Derivative Designated as Cash Flow Hedges (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfInterestRateDerivativesHeld",
      "reportCount": 1,
      "unique": true,
      "unitRef": "instrument",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeFairValueOfDerivativeAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Derivative instruments and hedging activities - Fair Value by Balance Sheet Location (Details)",
     "role": "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesFairValueByBalanceSheetLocationDetails",
     "shortName": "Derivative instruments and hedging activities - Fair Value by Balance Sheet Location (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeFairValueOfDerivativeAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408405 - Disclosure - Derivative instruments and hedging activities - Cash Flow Hedging on AOCI (Details)",
     "role": "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesCashFlowHedgingOnAociDetails",
     "shortName": "Derivative instruments and hedging activities - Cash Flow Hedging on AOCI (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409402 - Disclosure - Debt - Schedule (Details)",
     "role": "http://emergentbiosolutions.com/role/DebtScheduleDetails",
     "shortName": "Debt - Schedule (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003000 - Statement - Condensed Consolidated Statements of Comprehensive Income",
     "role": "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "D2018Q4Oct15-Oct15_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:LineOfCreditFacilityCommitmentFeePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409403 - Disclosure - Debt - Narrative (Details)",
     "role": "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
     "shortName": "Debt - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "D2018Q4Oct15-Oct15_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:LineOfCreditFacilityCommitmentFeePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410402 - Disclosure - Revenue recognition - Narrative (Details)",
     "role": "http://emergentbiosolutions.com/role/RevenueRecognitionNarrativeDetails",
     "shortName": "Revenue recognition - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FI2020Q1_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2020-04-01",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410403 - Disclosure - Revenue recognition - Remaining Performance Obligation (Details)",
     "role": "http://emergentbiosolutions.com/role/RevenueRecognitionRemainingPerformanceObligationDetails",
     "shortName": "Revenue recognition - Remaining Performance Obligation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FI2020Q1_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2020-04-01",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Revenue recognition - Disaggregation of Revenue (Details)",
     "role": "http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationOfRevenueDetails",
     "shortName": "Revenue recognition - Disaggregation of Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1QTD_srt_StatementGeographicalAxis_country_US",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410405 - Disclosure - Revenue recognition - Contract Liabilities (Details)",
     "role": "http://emergentbiosolutions.com/role/RevenueRecognitionContractLiabilitiesDetails",
     "shortName": "Revenue recognition - Contract Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ebs:ScheduleofAccountsReceivableNetTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:BilledContractReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410406 - Disclosure - Revenue recognition - Accounts Receivable (Details)",
     "role": "http://emergentbiosolutions.com/role/RevenueRecognitionAccountsReceivableDetails",
     "shortName": "Revenue recognition - Accounts Receivable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ebs:ScheduleofAccountsReceivableNetTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:BilledContractReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411401 - Disclosure - Income taxes (Details)",
     "role": "http://emergentbiosolutions.com/role/IncomeTaxesDetails",
     "shortName": "Income taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412402 - Disclosure - Net loss per share (Details)",
     "role": "http://emergentbiosolutions.com/role/NetLossPerShareDetails",
     "shortName": "Net loss per share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413401 - Disclosure - Share-based compensation (Details)",
     "role": "http://emergentbiosolutions.com/role/ShareBasedCompensationDetails",
     "shortName": "Share-based compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003501 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical)",
     "role": "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004000 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005000 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity",
     "role": "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20200331x10q.htm",
      "contextRef": "FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005501 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)",
     "role": "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical",
     "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    }
   },
   "segmentCount": 50,
   "tag": {
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S. Government"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2017-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationOfRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "ebs_AmendedCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amended credit agreement dated October 15, 2018.",
        "label": "Amended Credit Agreement [Member]",
        "terseLabel": "Amended Credit Agreement"
       }
      }
     },
     "localname": "AmendedCreditAgreementMember",
     "nsuri": "http://emergentbiosolutions.com/20200331",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash proceeds in excess during the term of the Senior Secured Credit Facility from certain dispositions of property or from casualty events involving their property, subject to certain reinvestment rights.",
        "label": "Cash Proceeds Excess Amount from Dispositions of Property or Casualty Events Subject to Certain Reinvestment Right",
        "terseLabel": "Cash proceeds excess amount from dispositions of property or casualty events subject to certain reinvestment right"
       }
      }
     },
     "localname": "CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight",
     "nsuri": "http://emergentbiosolutions.com/20200331",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ebs_ChangeInFairValueOfContingentConsideration": {
     "auth_ref": [],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value measurement of contingent value rights and contingent purchase considerations granted under purchase agreements.",
        "label": "Change In Fair Value Of Contingent Consideration",
        "terseLabel": "Change in fair value of contingent consideration, net"
       }
      }
     },
     "localname": "ChangeInFairValueOfContingentConsideration",
     "nsuri": "http://emergentbiosolutions.com/20200331",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ebs_ChangeinContractWithCustomerLiabilityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Change in Contract With Customer, Liability [Roll Forward]",
        "label": "Change in Contract With Customer, Liability [Roll Forward]",
        "terseLabel": "Change in Contract With Customer, Liability [Roll Forward]"
       }
      }
     },
     "localname": "ChangeinContractWithCustomerLiabilityRollForward",
     "nsuri": "http://emergentbiosolutions.com/20200331",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionContractLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ebs_ContractManufacturingMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue earned during the period arising from manufacturing sale under the terms of a contract.",
        "label": "Contract Manufacturing [Member]",
        "terseLabel": "Contract development and manufacturing services",
        "verboseLabel": "Contract development and manufacturing services"
       }
      }
     },
     "localname": "ContractManufacturingMember",
     "nsuri": "http://emergentbiosolutions.com/20200331",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails",
      "http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationOfRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_ContractWithCustomerLiabilityAdditions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable recorded during the current reporting period.",
        "label": "Contract with Customer, Liability, Additions",
        "terseLabel": "Deferral of revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityAdditions",
     "nsuri": "http://emergentbiosolutions.com/20200331",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ebs_ContractsAndGrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue earned from products sold or services provided under the terms of a contract, including, but not limited to, government contracts and grants.",
        "label": "Contracts and Grants [Member]",
        "terseLabel": "Contracts and grants"
       }
      }
     },
     "localname": "ContractsAndGrantsMember",
     "nsuri": "http://emergentbiosolutions.com/20200331",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationOfRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_ConvertibleSeniorNotesDue2021Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Convertible Senior Notes Due 2021 [Member]",
        "label": "Convertible Senior Notes Due 2021 [Member]",
        "terseLabel": "2.875% Convertible Senior Notes due 2021"
       }
      }
     },
     "localname": "ConvertibleSeniorNotesDue2021Member",
     "nsuri": "http://emergentbiosolutions.com/20200331",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_CreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Credit agreement dated September 2017.",
        "label": "Credit Agreement [Member]",
        "terseLabel": "2017 Credit Agreement"
       }
      }
     },
     "localname": "CreditAgreementMember",
     "nsuri": "http://emergentbiosolutions.com/20200331",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_DebtInstrumentCovenantDebtServiceCoverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Debt Service Coverage Ratio",
        "label": "Debt Instrument, Covenant, Debt Service Coverage Ratio",
        "verboseLabel": "Debt covenant, consolidated debt service coverage ratio, minimum"
       }
      }
     },
     "localname": "DebtInstrumentCovenantDebtServiceCoverageRatio",
     "nsuri": "http://emergentbiosolutions.com/20200331",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Net Leverage Ratio Adjustment Period",
        "label": "Debt Instrument, Covenant, Net Leverage Ratio Adjustment Period",
        "terseLabel": "Debt instrument, covenant, net leverage ratio adjustment period"
       }
      }
     },
     "localname": "DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod",
     "nsuri": "http://emergentbiosolutions.com/20200331",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ebs_DebtInstrumentCovenantNetLeverageRatioOne": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Net Leverage Ratio, One",
        "label": "Debt Instrument, Covenant, Net Leverage Ratio, One",
        "terseLabel": "Debt instrument, covenant, net leverage ratio through June 30, 2019"
       }
      }
     },
     "localname": "DebtInstrumentCovenantNetLeverageRatioOne",
     "nsuri": "http://emergentbiosolutions.com/20200331",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Net Leverage Ratio Rolling Period",
        "label": "Debt Instrument, Covenant, Net Leverage Ratio Rolling Period",
        "terseLabel": "Debt instrument, covenant, net leverage ratio rolling period"
       }
      }
     },
     "localname": "DebtInstrumentCovenantNetLeverageRatioRollingPeriod",
     "nsuri": "http://emergentbiosolutions.com/20200331",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ebs_DebtInstrumentCovenantNetLeverageRatioThree": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Net Leverage Ratio, Three",
        "label": "Debt Instrument, Covenant, Net Leverage Ratio, Three",
        "terseLabel": "Debt instrument, covenant, net leverage ratio from October 1, 2019 to September 29, 2020"
       }
      }
     },
     "localname": "DebtInstrumentCovenantNetLeverageRatioThree",
     "nsuri": "http://emergentbiosolutions.com/20200331",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ebs_DebtInstrumentCovenantNetLeverageRatioTwo": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Net Leverage Ratio, Two",
        "label": "Debt Instrument, Covenant, Net Leverage Ratio, Two",
        "terseLabel": "Debt instrument, covenant, net leverage ratio to September 30, 2019"
       }
      }
     },
     "localname": "DebtInstrumentCovenantNetLeverageRatioTwo",
     "nsuri": "http://emergentbiosolutions.com/20200331",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ebs_DerivativeNotionalAmount1": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derivative, Notional Amount1",
        "label": "Derivative, Notional Amount1",
        "terseLabel": "Notional"
       }
      }
     },
     "localname": "DerivativeNotionalAmount1",
     "nsuri": "http://emergentbiosolutions.com/20200331",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesDerivativeDesignatedAsCashFlowHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ebs_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Change In Fair Value",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Change In Fair Value",
        "terseLabel": "Change in fair value"
       }
      }
     },
     "localname": "FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue",
     "nsuri": "http://emergentbiosolutions.com/20200331",
     "presentation": [
      "http://emergentbiosolutions.com/role/ContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ebs_InProcessResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount of purchased research and development assets acquired in a business combination that have an indefinite life until completion or abandonment of the associated research and development efforts.",
        "label": "In Process Research And Development",
        "terseLabel": "In-process research and development"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopment",
     "nsuri": "http://emergentbiosolutions.com/20200331",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ebs_LesseeOperatingLeaseTerminationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Termination Period",
        "label": "Lessee, Operating Lease, Termination Period",
        "terseLabel": "Operating lease, termination period"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTerminationPeriod",
     "nsuri": "http://emergentbiosolutions.com/20200331",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ebs_MeasurementInputProbabilityofPaymentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement Input, Probability of Payment [Member]",
        "label": "Measurement Input, Probability of Payment [Member]",
        "terseLabel": "Probability of payment"
       }
      }
     },
     "localname": "MeasurementInputProbabilityofPaymentMember",
     "nsuri": "http://emergentbiosolutions.com/20200331",
     "presentation": [
      "http://emergentbiosolutions.com/role/ContingentConsiderationContingentConsiderationFairValueLevel3OfSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_NumberOfCategoriesOfPublicHealthThreats": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Refers to the number of categories of public health threats.",
        "label": "Number Of Categories Of Public Health Threats",
        "terseLabel": "Number of categories of public health threats"
       }
      }
     },
     "localname": "NumberOfCategoriesOfPublicHealthThreats",
     "nsuri": "http://emergentbiosolutions.com/20200331",
     "presentation": [
      "http://emergentbiosolutions.com/role/BusinessDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ebs_NumberOfRevenueGeneratingProducts": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Refers to the number of revenue generating products.",
        "label": "Number Of Revenue Generating Products",
        "terseLabel": "Number of revenue generating products"
       }
      }
     },
     "localname": "NumberOfRevenueGeneratingProducts",
     "nsuri": "http://emergentbiosolutions.com/20200331",
     "presentation": [
      "http://emergentbiosolutions.com/role/BusinessDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ebs_OperatingLeaseOtherLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating Lease, Other Liability, Current",
        "label": "Operating Lease, Other Liability, Current",
        "terseLabel": "Operating lease liabilities, current portion"
       }
      }
     },
     "localname": "OperatingLeaseOtherLiabilityCurrent",
     "nsuri": "http://emergentbiosolutions.com/20200331",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ebs_OtherLongTermDebtFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Long Term Debt Facility [Member]",
        "label": "Other Long Term Debt Facility [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherLongTermDebtFacilityMember",
     "nsuri": "http://emergentbiosolutions.com/20200331",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The rate of interest that was being paid on the original debt issue that is to repay in the third year.",
        "label": "Percentage of Original Principal Amount Required to Repay During the Third Year",
        "terseLabel": "Percentage of original principal amount required to repay during the third year"
       }
      }
     },
     "localname": "PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear",
     "nsuri": "http://emergentbiosolutions.com/20200331",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The rate of interest that was being paid on the original debt issue that is to repay in the first two years.",
        "label": "Percentage of Original Principal Amount Required to Repay in First Two Years",
        "terseLabel": "Percentage of original principal amount required to repay in the first two years"
       }
      }
     },
     "localname": "PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears",
     "nsuri": "http://emergentbiosolutions.com/20200331",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The rate of interest that was being paid on the original debt issue that is to repay in remaining years.",
        "label": "Percentage of Original Principal Amount Required to Repay Remaining Years",
        "terseLabel": "Percentage of original principal amount required to repay remaining year"
       }
      }
     },
     "localname": "PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears",
     "nsuri": "http://emergentbiosolutions.com/20200331",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ebs_RaxibacumabMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Raxibacumab [Member]",
        "label": "Raxibacumab [Member]",
        "terseLabel": "Raxibacumab"
       }
      }
     },
     "localname": "RaxibacumabMember",
     "nsuri": "http://emergentbiosolutions.com/20200331",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_ScheduleOfLeasesSupplementalBalanceSheetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule Of Leases Supplemental Balance Sheets [Table Text Block]",
        "label": "Schedule Of Leases Supplemental Balance Sheets [Table Text Block]",
        "terseLabel": "Schedule of Leases Supplemental Balance Sheets"
       }
      }
     },
     "localname": "ScheduleOfLeasesSupplementalBalanceSheetsTableTextBlock",
     "nsuri": "http://emergentbiosolutions.com/20200331",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ebs_ScheduleofAccountsReceivableNetTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of Accounts Receivable, Net [Table Text Block]",
        "label": "Schedule of Accounts Receivable, Net [Table Text Block]",
        "terseLabel": "Schedule of Accounts Receivable, Net"
       }
      }
     },
     "localname": "ScheduleofAccountsReceivableNetTableTextBlock",
     "nsuri": "http://emergentbiosolutions.com/20200331",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ebs_TermLoanFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term loan dated December 2013.",
        "label": "Term Loan Facility [Member]",
        "terseLabel": "Senior secured credit agreement - Term loan due 2023"
       }
      }
     },
     "localname": "TermLoanFacilityMember",
     "nsuri": "http://emergentbiosolutions.com/20200331",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ContingentConsiderationContingentConsiderationFairValueLevel3OfSignificantUnobservableInputsDetails",
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails",
      "http://emergentbiosolutions.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ContingentConsiderationContingentConsiderationFairValueLevel3OfSignificantUnobservableInputsDetails",
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails",
      "http://emergentbiosolutions.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r124",
      "r174",
      "r177",
      "r296",
      "r297"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]",
        "verboseLabel": "Products and Services [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationOfRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationOfRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ContingentConsiderationContingentConsiderationFairValueLevel3OfSignificantUnobservableInputsDetails",
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails",
      "http://emergentbiosolutions.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ContingentConsiderationContingentConsiderationFairValueLevel3OfSignificantUnobservableInputsDetails",
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails",
      "http://emergentbiosolutions.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationOfRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r125",
      "r174",
      "r178",
      "r298",
      "r299",
      "r300"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationOfRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_WeightedAverageMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Weighted Average [Member]",
        "terseLabel": "Weighted Average"
       }
      }
     },
     "localname": "WeightedAverageMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ContingentConsiderationContingentConsiderationFairValueLevel3OfSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r3",
      "r18",
      "r126",
      "r127",
      "r175"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://emergentbiosolutions.com/role/RevenueRecognitionAccountsReceivableDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "totalLabel": "Total, net",
        "verboseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/RevenueRecognitionAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r35",
      "r152"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r60",
      "r62",
      "r63"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss, net"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r59",
      "r63",
      "r65",
      "r215"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Weighted average amortization period"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r128",
      "r130",
      "r131",
      "r132"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "terseLabel": "Allowance for doubtful accounts receivable"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r75",
      "r92",
      "r260"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of deferred financing costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r92",
      "r140",
      "r148"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets",
        "verboseLabel": "Amortization"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://emergentbiosolutions.com/role/IntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r123",
      "r278",
      "r288"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r53"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r185",
      "r193"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesFairValueByBalanceSheetLocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r226",
      "r230"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesFairValueByBalanceSheetLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BaseRateMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum rate investor will accept.",
        "label": "Base Rate [Member]",
        "terseLabel": "Base Rate"
       }
      }
     },
     "localname": "BaseRateMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BilledContractReceivables": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/RevenueRecognitionAccountsReceivableDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amounts due for billed services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the Company and, at a minimum, one other party. An example would be amounts billed to customers under contracts or programs but not paid as of the balance sheet date.",
        "label": "Billed Contracts Receivable",
        "terseLabel": "Billed, net"
       }
      }
     },
     "localname": "BilledContractReceivables",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BuildingAndBuildingImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Building and Building Improvements [Member]",
        "terseLabel": "Buildings, building improvements and leasehold improvements"
       }
      }
     },
     "localname": "BuildingAndBuildingImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r204",
      "r205"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r91",
      "r210"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Change in amount of contingent consideration, liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "terseLabel": "Business combination, contingent consideration, liability, measurement input"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ContingentConsiderationContingentConsiderationFairValueLevel3OfSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r208",
      "r209"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Contingent consideration, net of current portion"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r96",
      "r97",
      "r98"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchases of property, plant and equipment unpaid at period end"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r33",
      "r94"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r87",
      "r94",
      "r99"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "totalLabel": "Total cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Reconciliation of cash and cash equivalent and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r87",
      "r254"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths": {
     "auth_ref": [
      "r242"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated net amount of existing gains or losses on cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.",
        "label": "Cash Flow Hedge Gain (Loss) to be Reclassified within Twelve Months",
        "terseLabel": "Net deferred losses from accumulated other comprehensive loss"
       }
      }
     },
     "localname": "CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash Flow Hedging"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesCashFlowHedgingOnAociDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental information on non-cash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "$0.001 Par Value Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r17",
      "r159"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 200.0 shares authorized, 53.5 and 53.0 shares issued; 52.3 and 51.7 shares outstanding, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r68",
      "r70",
      "r71"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerSoftwareIntangibleAssetMember": {
     "auth_ref": [
      "r141",
      "r146",
      "r207"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.",
        "label": "Computer Software, Intangible Asset [Member]",
        "terseLabel": "Software"
       }
      }
     },
     "localname": "ComputerSoftwareIntangibleAssetMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r100",
      "r213",
      "r216",
      "r217"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Basis of presentation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction-in-progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r170"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of contract balances and changes in contract balances.",
        "label": "Contract with Customer, Asset and Liability [Table Text Block]",
        "terseLabel": "Rollforward of Contract Liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r168",
      "r169",
      "r175"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "periodEndLabel": "End of period",
        "periodStartLabel": "Beginning of period"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r168",
      "r169",
      "r175"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Contract liabilities, net of current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r176"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "negatedTerseLabel": "Revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of product sales and contract development and manufacturing services"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]",
        "terseLabel": "Customer relationships"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r279",
      "r280",
      "r287"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Debt instrument, basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Stated percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r44",
      "r102",
      "r160",
      "r161",
      "r162",
      "r163",
      "r258",
      "r259",
      "r261",
      "r286"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCostsCurrent": {
     "auth_ref": [
      "r52"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.",
        "label": "Deferred Costs, Current",
        "terseLabel": "Deferred costs, current"
       }
      }
     },
     "localname": "DeferredCostsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNoncurrentNet": {
     "auth_ref": [
      "r36",
      "r260"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Noncurrent, Net",
        "negatedTerseLabel": "Unamortized debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNoncurrentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r199"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r92",
      "r101",
      "r200",
      "r201"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r196",
      "r199"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r92",
      "r121"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesCashFlowHedgingOnAociDetails",
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesDerivativeDesignatedAsCashFlowHedgesDetails",
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesFairValueByBalanceSheetLocationDetails",
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "auth_ref": [
      "r54",
      "r55",
      "r228",
      "r275"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.",
        "label": "Derivative Asset, Fair Value, Gross Asset",
        "terseLabel": "Asset Derivatives"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesFairValueByBalanceSheetLocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r54",
      "r55",
      "r228",
      "r275"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Fair Value, Gross Liability",
        "terseLabel": "Liability Derivatives"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesFairValueByBalanceSheetLocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r227",
      "r229",
      "r233",
      "r236"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesCashFlowHedgingOnAociDetails",
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesDerivativeDesignatedAsCashFlowHedgesDetails",
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesFairValueByBalanceSheetLocationDetails",
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative Instruments and Hedging Activities Disclosures [Line Items]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Line Items]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesCashFlowHedgingOnAociDetails",
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesDerivativeDesignatedAsCashFlowHedgesDetails",
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about derivatives and hedging activities.",
        "label": "Derivative Instruments and Hedging Activities Disclosures [Table]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesCashFlowHedgingOnAociDetails",
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesDerivativeDesignatedAsCashFlowHedgesDetails",
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r224",
      "r227",
      "r233"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesCashFlowHedgingOnAociDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivatives, Fair Value [Line Items]",
        "terseLabel": "Derivatives, Fair Value [Line Items]"
       }
      }
     },
     "localname": "DerivativesFairValueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesFairValueByBalanceSheetLocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesDerivativeDesignatedAsCashFlowHedgesDetails",
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesFairValueByBalanceSheetLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DirectFinancingLeaseLeaseIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Direct Financing Lease, Lease Income [Abstract]",
        "terseLabel": "Operating leases:"
       }
      }
     },
     "localname": "DirectFinancingLeaseLeaseIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationOfRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationOfRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Net loss per common share"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r74",
      "r108",
      "r111",
      "r113",
      "r114",
      "r115",
      "r118",
      "r284",
      "r295"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share - basic (in dollars per share)",
        "verboseLabel": "Basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://emergentbiosolutions.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]",
        "terseLabel": "Shares used in computing loss per share"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r74",
      "r108",
      "r111",
      "r113",
      "r114",
      "r115",
      "r118",
      "r284",
      "r295"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share - diluted (in dollars per share)",
        "verboseLabel": "Diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://emergentbiosolutions.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net loss per share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r254"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r105",
      "r197",
      "r198"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective annual tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "verboseLabel": "Debt, current portion"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "auth_ref": [
      "r192"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, Tax Benefit",
        "terseLabel": "Discrete tax benefit"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EurodollarMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest rate based on U.S. dollar denominated deposits at foreign banks or foreign branches of U.S. banks.",
        "label": "Eurodollar [Member]",
        "terseLabel": "Eurocurrency"
       }
      }
     },
     "localname": "EurodollarMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ContingentConsiderationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r180",
      "r181",
      "r182",
      "r245",
      "r273"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ContingentConsiderationContingentConsiderationFairValueLevel3OfSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r244",
      "r245",
      "r247",
      "r248",
      "r253"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ContingentConsiderationContingentConsiderationFairValueLevel3OfSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "Contingent Consideration"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ContingentConsideration"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r180",
      "r181",
      "r182",
      "r245",
      "r274"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ContingentConsiderationContingentConsiderationFairValueLevel3OfSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Unobservable Input Reconciliation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ContingentConsiderationContingentConsiderationFairValueLevel3OfSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r249",
      "r252"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ContingentConsiderationContingentConsiderationFairValueLevel3OfSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r249",
      "r252"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ContingentConsiderationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ContingentConsiderationContingentConsiderationFairValueLevel3OfSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair value measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r250"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedLabel": "Settlements"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r249"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Balance, end of period",
        "periodStartLabel": "Balance, beginning of period",
        "terseLabel": "Fair value, measurement with unobservable inputs reconciliation, recurring basis, liability value"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ContingentConsiderationContingentConsiderationFairValueLevel3OfSignificantUnobservableInputsDetails",
      "http://emergentbiosolutions.com/role/ContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ContingentConsiderationContingentConsiderationFairValueLevel3OfSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r251",
      "r253"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ContingentConsiderationContingentConsiderationFairValueLevel3OfSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": {
     "auth_ref": [
      "r226",
      "r231",
      "r240"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]"
       }
      }
     },
     "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesFairValueByBalanceSheetLocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FederalFundsEffectiveSwapRateMember": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap having its variable-rate leg referenced to Federal Funds effective rate with no additional spread over Federal Funds effective rate on that variable-rate leg.",
        "label": "Fed Funds Effective Rate Overnight Index Swap Rate [Member]",
        "terseLabel": "Federal Funds Rate"
       }
      }
     },
     "localname": "FederalFundsEffectiveSwapRateMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r264",
      "r267",
      "r271"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/LeasesComponentsOfLeaseExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Interest on lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r264",
      "r267",
      "r271"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/LeasesComponentsOfLeaseExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Amortization of right-of-use assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Amortization period of intangible asset"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r147"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Finite-lived intangible assets, accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r141",
      "r144",
      "r147",
      "r149",
      "r277"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r147",
      "r277"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Intangible assets, gross"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r141",
      "r146"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r147"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net [Abstract]",
        "terseLabel": "Cost"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "auth_ref": [
      "r142"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.",
        "label": "Finite-lived Intangible Assets Acquired",
        "terseLabel": "Finite-lived intangible assets acquired"
       }
      }
     },
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and equipment"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r137",
      "r138"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/IntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r224",
      "r237"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesDerivativeDesignatedAsCashFlowHedgesDetails",
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesFairValueByBalanceSheetLocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesDerivativeDesignatedAsCashFlowHedgesDetails",
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesFairValueByBalanceSheetLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesCashFlowHedgingOnAociDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesCashFlowHedgingOnAociDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesCashFlowHedgingOnAociDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r101",
      "r122",
      "r202"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Income tax benefit"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r89",
      "r95"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Cash paid during the period for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesReceivable": {
     "auth_ref": [
      "r48",
      "r282",
      "r293"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.",
        "label": "Income Taxes Receivable, Current",
        "terseLabel": "Income tax receivable, net"
       }
      }
     },
     "localname": "IncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r112",
      "r117"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/NetLossPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Dilutive securities-equity awards (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r139",
      "r145"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r72",
      "r120",
      "r257",
      "r260",
      "r285"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseMember": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing interest expense.",
        "label": "Interest Expense [Member]",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesCashFlowHedgingOnAociDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r86",
      "r88",
      "r95"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid during the period for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Interest rate swaps"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesCashFlowHedgingOnAociDetails",
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesDerivativeDesignatedAsCashFlowHedgesDetails",
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesFairValueByBalanceSheetLocationDetails",
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r24",
      "r135"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/InventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r2",
      "r51",
      "r134"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://emergentbiosolutions.com/role/InventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "totalLabel": "Total inventories",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves": {
     "auth_ref": [
      "r26",
      "r27",
      "r135"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/InventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments.",
        "label": "Inventory, Raw Materials and Supplies, Net of Reserves",
        "terseLabel": "Raw materials and supplies"
       }
      }
     },
     "localname": "InventoryRawMaterialsAndSuppliesNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r25",
      "r135"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/InventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LandAndLandImprovementsMember": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Real estate held and assets that are an addition or improvement to real estate held.",
        "label": "Land and Land Improvements [Member]",
        "terseLabel": "Land and improvements"
       }
      }
     },
     "localname": "LandAndLandImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r270",
      "r271"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/LeasesComponentsOfLeaseExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total operating lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Operating lease cost:",
        "verboseLabel": "Operating leases:"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesComponentsOfLeaseExpenseDetails",
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Lease, Cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.",
        "label": "Legal Matters and Contingencies [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "LegalMattersAndContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.",
        "label": "Lessee, Finance Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeFinanceLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Operating lease, renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Operating lease, term of contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r23",
      "r281",
      "r291"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.",
        "label": "Line of Credit Facility, Commitment Fee Percentage",
        "terseLabel": "Commitment fee percentage"
       }
      }
     },
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": {
     "auth_ref": [
      "r38"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Current Borrowing Capacity",
        "terseLabel": "Current borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityCurrentBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r15",
      "r157",
      "r280",
      "r289"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r39"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "negatedTerseLabel": "Current portion of long-term debt, net of debt issuance costs"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Non-current portion of debt",
        "verboseLabel": "Debt, net of current portion"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/DebtScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ContingentConsiderationContingentConsiderationFairValueLevel3OfSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ContingentConsiderationContingentConsiderationFairValueLevel3OfSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ContingentConsiderationContingentConsiderationFairValueLevel3OfSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsAtCarryingValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.",
        "label": "Money Market Funds, at Carrying Value",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows used in financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows used in investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r87",
      "r90",
      "r93"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows provided by operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r66",
      "r69",
      "r73",
      "r93",
      "r117",
      "r283",
      "r294"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "netLabel": "Net loss",
        "terseLabel": "Net income",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://emergentbiosolutions.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently issued accounting standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Non-U.S. Government"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationOfRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other expense, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other (expense) income:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Notes Payable, Current",
        "terseLabel": "Debt, current portion"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfInterestRateDerivativesHeld": {
     "auth_ref": [
      "r220",
      "r222"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of interest rate derivative instruments held by the entity at the reporting date.",
        "label": "Number of Interest Rate Derivatives Held",
        "terseLabel": "Number of Instruments"
       }
      }
     },
     "localname": "NumberOfInterestRateDerivativesHeld",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesDerivativeDesignatedAsCashFlowHedgesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/BusinessDetails",
      "http://emergentbiosolutions.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingCostsAndExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.",
        "label": "Operating Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingCostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r263"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r263"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r262"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r269",
      "r271"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r268",
      "r271"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term (years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r218"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/Business"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsMember": {
     "auth_ref": [
      "r226",
      "r240"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other assets.",
        "label": "Other Assets [Member]",
        "terseLabel": "Other Assets"
       }
      }
     },
     "localname": "OtherAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesFairValueByBalanceSheetLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r58",
      "r60",
      "r211",
      "r214"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent",
        "negatedTerseLabel": "Unrealized losses on pension benefit obligation, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax": {
     "auth_ref": [
      "r56",
      "r61",
      "r256"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax expense (benefit), before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Gain (Loss) Arising During Period, Tax",
        "terseLabel": "Unrealized losses related to foreign currency translations"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "auth_ref": [
      "r57",
      "r60"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "terseLabel": "Unrealized losses on hedging activities, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax": {
     "auth_ref": [
      "r61"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax",
        "terseLabel": "Unrealized losses on hedging activities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax": {
     "auth_ref": [
      "r61"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax",
        "terseLabel": "Cumulative Amount of Gain/(Loss) Recognized in OCI on Derivative"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesCashFlowHedgingOnAociDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": {
     "auth_ref": [
      "r60",
      "r64",
      "r232"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax",
        "terseLabel": "Amount of Gain/(Loss) Reclassified from Accumulated OCI into Income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesCashFlowHedgingOnAociDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r56",
      "r255"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "verboseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive (loss) income, net of tax:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r67",
      "r70",
      "r211",
      "r212",
      "r214"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive income",
        "totalLabel": "Total other comprehensive (loss) income, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "auth_ref": [
      "r226",
      "r240"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current assets.",
        "label": "Other Current Assets [Member]",
        "terseLabel": "Other Current Assets"
       }
      }
     },
     "localname": "OtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesFairValueByBalanceSheetLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current liabilities.",
        "label": "Other Current Liabilities [Member]",
        "terseLabel": "Other Current Liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesFairValueByBalanceSheetLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r41"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesMember": {
     "auth_ref": [
      "r226",
      "r240"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other liabilities.",
        "label": "Other Liabilities [Member]",
        "terseLabel": "Other Liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesFairValueByBalanceSheetLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "negatedLabel": "Contingent consideration payments"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedLabel": "Taxes paid on behalf of employees for equity activity"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment and other"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value; 15.0 shares authorized, no shares issued or outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r31",
      "r32"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "auth_ref": [
      "r82",
      "r103"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Proceeds from Lines of Credit",
        "terseLabel": "Proceeds from revolving credit facility"
       }
      }
     },
     "localname": "ProceedsFromLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r81",
      "r194"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from issuance of common stock upon exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product sales, net",
        "verboseLabel": "Products"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails",
      "http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationOfRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r35",
      "r153"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "verboseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyPlantAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r34",
      "r151"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property, plant and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Property Plant and Equipment Income Statement Disclosures [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r11",
      "r12",
      "r153",
      "r292"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant and equipment, net",
        "totalLabel": "Total property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Property, Plant and Equipment, Net [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r11",
      "r153"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "verboseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r11",
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property, Plant and Equipment, Type [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "auth_ref": [
      "r84",
      "r103"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Repayments of Lines of Credit",
        "negatedTerseLabel": "Principal payments on revolving credit facility"
       }
      }
     },
     "localname": "RepaymentsOfLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfMediumTermNotes": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to pay off borrowing used to receive debt funding on a regular basis with maturities ranging from 5-10 years.",
        "label": "Repayments of Medium-term Notes",
        "negatedTerseLabel": "Principal payments on term loan facility"
       }
      }
     },
     "localname": "RepaymentsOfMediumTermNotes",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r195",
      "r301"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r1",
      "r10",
      "r99"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r20",
      "r164",
      "r290"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r173",
      "r174"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationOfRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognition"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r171"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Revenue, remaining performance obligation, amount"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionRemainingPerformanceObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "terseLabel": "Revenue, remaining performance obligation, expected timing of satisfaction, period"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionRemainingPerformanceObligationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in CCYY-MM-DD format.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionRemainingPerformanceObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionRemainingPerformanceObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Senior secured credit agreement - Revolver loan due 2023"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r204",
      "r205"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Schedule of Debt"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "auth_ref": [
      "r227",
      "r233",
      "r237"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "terseLabel": "Derivative Instruments, Gain (Loss)"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "terseLabel": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": {
     "auth_ref": [
      "r106",
      "r219",
      "r221",
      "r222",
      "r224",
      "r225",
      "r231",
      "r233",
      "r238",
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Schedule of Derivative Instruments [Table Text Block]",
        "terseLabel": "Schedule of Derivative Instruments"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Basic and Diluted Net Income per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r141",
      "r146"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r141",
      "r146"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r9",
      "r28",
      "r29",
      "r30"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r35",
      "r153"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r185",
      "r193"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r77",
      "r133"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Restricted stock units granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Stock options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r183",
      "r187"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Tranche One"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche Three [Member]",
        "terseLabel": "Tranche Three"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Tranche Two"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Award vesting rights, percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation and Principles of Consolidation"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r47",
      "r159"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Shares Granted or Issued, Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Stock issued or granted during period [Abstract]"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharebasedCompensationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r16",
      "r17",
      "r159",
      "r164"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Employee equity plans activity (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r16",
      "r17",
      "r164",
      "r184",
      "r190"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Employee equity plans activity"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r17",
      "r21",
      "r22",
      "r129"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ShareBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r46",
      "r165"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r46",
      "r165"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "terseLabel": "Treasury stock (in shares)"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r46",
      "r165",
      "r166"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury stock, at cost, 1.2 common shares"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnbilledContractsReceivable": {
     "auth_ref": [
      "r49",
      "r276"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/RevenueRecognitionAccountsReceivableDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet.",
        "label": "Unbilled Contracts Receivable",
        "terseLabel": "Unbilled"
       }
      }
     },
     "localname": "UnbilledContractsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationTechniqueAxis": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by valuation approach and technique.",
        "label": "Valuation Approach and Technique [Axis]",
        "terseLabel": "Valuation Approach and Technique [Axis]"
       }
      }
     },
     "localname": "ValuationTechniqueAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ContingentConsiderationContingentConsiderationFairValueLevel3OfSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationTechniqueDiscountedCashFlowMember": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Valuation technique calculating present value of future cash flows.",
        "label": "Valuation Technique, Discounted Cash Flow [Member]",
        "terseLabel": "Discounted cash flow"
       }
      }
     },
     "localname": "ValuationTechniqueDiscountedCashFlowMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ContingentConsiderationContingentConsiderationFairValueLevel3OfSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationTechniqueDomain": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Valuation approach and technique.",
        "label": "Valuation Approach and Technique [Domain]",
        "terseLabel": "Valuation Approach and Technique [Domain]"
       }
      }
     },
     "localname": "ValuationTechniqueDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ContingentConsiderationContingentConsiderationFairValueLevel3OfSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r110",
      "r115"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/NetLossPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Weighted-average number of shares-diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://emergentbiosolutions.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r109",
      "r115"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/NetLossPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average number of shares-basic (in shares)",
        "verboseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://emergentbiosolutions.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(n)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1500-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5074-111524"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955202&loc=SL82895884-210446"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130551-203045"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130556-203045"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130556-203045"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31931-109318"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5333-128473"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5504-128473"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-02)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355033-122828"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-03)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355100-122828"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579240-113959"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5580258-113959"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41638-113959"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624181-113959"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41641-113959"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41678-113959"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=116861445&loc=SL5629052-113961"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=118875152&loc=SL5864739-113975"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=112277219&loc=d3e80748-113994"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "http://asc.fasb.org/topic&trid=2229140"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b,c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=SL51823488-111719"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=118261985&loc=d3e55302-109406"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.5(c))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r302": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r303": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r304": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r305": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r306": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r307": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(c)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6812-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e640-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e689-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6904-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6797099168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">15,000,000.0<span></span>
</td>
<td class="nump">15,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000,000.0<span></span>
</td>
<td class="nump">200,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">53,500,000.0<span></span>
</td>
<td class="nump">53,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">52,300,000.0<span></span>
</td>
<td class="nump">51,700,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock (in shares)</a></td>
<td class="nump">1,200,000.0<span></span>
</td>
<td class="nump">1,200,000.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6797089920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="num">$ (12.5)<span></span>
</td>
<td class="num">$ (26.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">6.6<span></span>
</td>
<td class="nump">6.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">28.2<span></span>
</td>
<td class="nump">26.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(4.2)<span></span>
</td>
<td class="num">(11.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_ChangeInFairValueOfContingentConsideration', window );">Change in fair value of contingent consideration, net</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">108.2<span></span>
</td>
<td class="nump">141.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(25.6)<span></span>
</td>
<td class="num">(5.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(15.3)<span></span>
</td>
<td class="num">(16.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(15.6)<span></span>
</td>
<td class="nump">4.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation</a></td>
<td class="num">(14.9)<span></span>
</td>
<td class="num">(21.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">2.1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities:</a></td>
<td class="nump">57.8<span></span>
</td>
<td class="nump">104.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows used in investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment and other</a></td>
<td class="num">(24.2)<span></span>
</td>
<td class="num">(21.4)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities:</a></td>
<td class="num">(24.2)<span></span>
</td>
<td class="num">(21.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows used in financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from revolving credit facility</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">30.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Principal payments on revolving credit facility</a></td>
<td class="num">(20.0)<span></span>
</td>
<td class="num">(80.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfMediumTermNotes', window );">Principal payments on term loan facility</a></td>
<td class="num">(2.8)<span></span>
</td>
<td class="num">(2.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of common stock upon exercise of stock options</a></td>
<td class="nump">9.1<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid on behalf of employees for equity activity</a></td>
<td class="num">(5.6)<span></span>
</td>
<td class="num">(6.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Contingent consideration payments</a></td>
<td class="num">(0.7)<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities:</a></td>
<td class="num">(20.0)<span></span>
</td>
<td class="num">(58.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash, cash equivalents and restricted cash</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents and restricted cash</a></td>
<td class="nump">13.7<span></span>
</td>
<td class="nump">25.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">168.0<span></span>
</td>
<td class="nump">112.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">181.7<span></span>
</td>
<td class="nump">137.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid during the period for interest</a></td>
<td class="nump">7.4<span></span>
</td>
<td class="nump">8.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid during the period for income taxes</a></td>
<td class="nump">3.6<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental information on non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property, plant and equipment unpaid at period end</a></td>
<td class="nump">7.3<span></span>
</td>
<td class="nump">7.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of cash and cash equivalent and restricted cash</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 181.7<span></span>
</td>
<td class="nump">$ 137.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_ChangeInFairValueOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value measurement of contingent value rights and contingent purchase considerations granted under purchase agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_ChangeInFairValueOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfMediumTermNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to pay off borrowing used to receive debt funding on a regular basis with maturities ranging from 5-10 years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfMediumTermNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6791611840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net loss per share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and Diluted Net Income per Share</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:24px;text-indent:0px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">The following table presents the calculation of basic and diluted net loss per share:</span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td rowspan="2" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Three Months Ended March 31,</span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2020</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Numerator:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(12.5</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(26.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Denominator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average number of shares&#8212;basic</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>52.0</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>51.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dilutive securities&#8212;equity awards</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average number of shares&#8212;diluted</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>52.0</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>51.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net loss per share - basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(0.24</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.51</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net loss per share - diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(0.24</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.51</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6806330208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, plant and equipment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 771.0<span></span>
</td>
<td class="nump">$ 752.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(221.8)<span></span>
</td>
<td class="num">(210.4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property, plant and equipment, net</a></td>
<td class="nump">549.2<span></span>
</td>
<td class="nump">542.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndLandImprovementsMember', window );">Land and improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">46.6<span></span>
</td>
<td class="nump">46.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Buildings, building improvements and leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">242.3<span></span>
</td>
<td class="nump">234.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">340.0<span></span>
</td>
<td class="nump">334.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">55.6<span></span>
</td>
<td class="nump">55.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction-in-progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 86.5<span></span>
</td>
<td class="nump">$ 81.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndLandImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndLandImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6791745936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">Debt<div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">The components of debt are as follows:</span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">March&#160;31, 2020</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Senior secured credit agreement - Term loan due 2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>433.1</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>435.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Senior secured credit agreement - Revolver loan due 2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>353.0</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>373.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.875% Convertible Senior Notes due 2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>10.6</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>10.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total debt</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>799.7</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>822.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of long-term debt, net of debt issuance costs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(26.3</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(12.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unamortized debt issuance costs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(10.5</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(11.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current portion of debt</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>762.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>798.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:24px;font-size:11pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:11pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Senior secured credit agreement</span></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">In October 2018, the Company entered into a senior secured credit agreement with multiple lending institutions (the "Credit Agreement"). The terms of the credit agreement include (i) a revolving credit facility (the "Revolving Credit Facility") of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><span>$600 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> with a maturity date of October 13, 2023, and (ii) a term loan with a principal amount of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><span>$450 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> (the "Term Loan Facility," and together with the Revolving Credit Facility, the "Senior Secured Credit Facilities"). The Company may request incremental term loan facilities or increases in the Revolving Credit Facility (each an "Incremental Loan") as long as requirements relating to net leverage ratio will be maintained on a pro forma basis.  </span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">Borrowings under the Revolving Credit Facility and the Term Loan Facility will bear interest at a rate per annum equal to (a) a eurocurrency rate plus a margin ranging from </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><span>1.25%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><span>2.00%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> per annum, depending on the Company's consolidated net leverage ratio or (b) a base rate (which is the highest of the prime rate, the federal funds rate plus </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><span>0.50%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">, and a eurocurrency rate for an interest period of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">one month</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> plus </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><span>1%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> plus a margin ranging from </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><span>0.25%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><span>1.00%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">, depending on the Company's consolidated net leverage ratio. The Company is required to make quarterly payments under the Credit Agreement for accrued and unpaid interest on the outstanding principal balance, based on the above interest rates. In addition, the Company is required to pay commitment fees ranging from </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><span>0.15%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><span>0.30%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> per annum, depending on the Company's consolidated net leverage ratio, in respect of the average daily unused commitments under the Revolving Credit Facility. The Company is to repay the outstanding principal amount of the Term Loan Facility in quarterly installments based on an annual percentage equal to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><span>2.5%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> of the original principal amount of the Term Loan Facility during each of the first two years of the Term Loan Facility, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><span>5%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> of the original principal amount of the Term Loan Facility during the third year of the Term Loan Facility and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><span>7.5%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> of the original principal amount of the Term Loan Facility during each year of the remainder of the term of the Term Loan Facility until the maturity date of the Term Loan Facility, at which time the entire unpaid principal balance of the Term Loan Facility will be due and payable. The Company has the right to prepay the Term Loan Facility without premium or penalty. The Revolving Credit Facility and the Term Loan Facility mature (unless earlier terminated) on </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">October&#160;13, 2023</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">The Credit Agreement also requires mandatory prepayments of the Term Loan Facility in the event the Company or its Subsidiaries (a) incur indebtedness not otherwise permitted under the Credit Agreement or (b) receive cash proceeds in excess of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><span>$100 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> during the term of the Credit Agreement from certain dispositions of property or from casualty events involving their property, subject to certain reinvestment rights.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">The financial covenants under the Credit Agreement currently require the quarterly presentation of a minimum consolidated 12-month rolling debt service coverage ratio of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><span>2.50</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> to 1.00, and a maximum consolidated net leverage ratio of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><span>3.75</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> to 1.00 for the quarterly filing periods from October&#160;1, 2019 through September&#160;29, 2020 and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><span>3.50</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> to 1.0, thereafter, which may be adjusted to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><span>4.00</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> to 1.00 for a four quarter period in connection with a material permitted acquisition. Negative covenants in the Credit Agreement, among other things, limit the ability of the Company to incur indebtedness and liens, dispose of assets, make investments, enter into certain merger or consolidation transactions and make restricted payments. As of the date of these financial statements, the Company is in compliance with all affirmative and negative covenants.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;"><span>2.875%</span></span><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;"> Convertible senior notes due 2021</span></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">On </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">January&#160;29, 2014</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">, the Company issued </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><span>2.875%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> convertible senior notes due </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">2021</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> (the "Notes"). The Notes bear interest at a rate of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><span>2.875%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> per year, payable semi-annually in arrears on </span><span style="color:#000000;font-family:Franklin Gothic Book,sans-serif;font-weight:normal;">January 15</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> and </span><span style="color:#000000;font-family:Franklin Gothic Book,sans-serif;font-weight:normal;">July 15</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> of each year. The Notes mature on </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">January&#160;15, 2021</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6791747472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="line-height:120%;padding-bottom:10px;padding-top:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">The Company has operating leases for corporate offices, research and development facilities and manufacturing facilities. We determine if an arrangement is a lease at inception. Operating leases are included in right-of-use (ROU) assets and liabilities. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">ROU assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of the Company's leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company uses an implicit rate when readily determinable. At the beginning of a lease, the operating lease ROU asset also includes any concentrated lease payments expected to be paid and excludes lease incentives. The Company's lease ROU asset may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise those options. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company has lease agreements with lease and non-lease components, which are accounted for separately. The Company's leases have remaining lease terms of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><span>1</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> year to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><span>15</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> years, some of which include options to extend the leases for up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><span>5</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> years, and some of which include options to terminate the leases within </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><span>1</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> year.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">The components of lease expense were as follows:&#160;</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:12px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:61%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Three months ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2020</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease cost:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization of right-of-use assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest on lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total operating lease cost</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">Supplemental balance sheet information related to leases was as follows:</span></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:39%;"/><td style="width:21%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;font-style:italic;">(In millions, except lease term and discount rate)</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Balance Sheet location</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">March&#160;31, 2020</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease right-of-use assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>25.6</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>24.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease liabilities, current portion</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>22.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>22.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>26.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>25.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating leases:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average remaining lease term (years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>7.7</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>8.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average discount rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="line-height:120%;padding-bottom:10px;padding-top:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">The Company has operating leases for corporate offices, research and development facilities and manufacturing facilities. We determine if an arrangement is a lease at inception. Operating leases are included in right-of-use (ROU) assets and liabilities. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">ROU assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of the Company's leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company uses an implicit rate when readily determinable. At the beginning of a lease, the operating lease ROU asset also includes any concentrated lease payments expected to be paid and excludes lease incentives. The Company's lease ROU asset may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise those options. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company has lease agreements with lease and non-lease components, which are accounted for separately. The Company's leases have remaining lease terms of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><span>1</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> year to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><span>15</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> years, some of which include options to extend the leases for up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><span>5</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> years, and some of which include options to terminate the leases within </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><span>1</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> year.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">The components of lease expense were as follows:&#160;</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:12px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:61%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Three months ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2020</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease cost:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization of right-of-use assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest on lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total operating lease cost</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">Supplemental balance sheet information related to leases was as follows:</span></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:39%;"/><td style="width:21%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;font-style:italic;">(In millions, except lease term and discount rate)</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Balance Sheet location</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">March&#160;31, 2020</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease right-of-use assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>25.6</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>24.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease liabilities, current portion</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>22.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>22.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>26.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>25.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating leases:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average remaining lease term (years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>7.7</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>8.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average discount rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6795326576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Business</a></td>
<td class="text">Business<div style="line-height:120%;padding-bottom:12px;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Organization and business</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">Emergent BioSolutions Inc. (the "Company" or "Emergent") is a global life sciences company focused on providing civilian and military populations a portfolio of innovative preparedness and response products and solutions that address accidental, deliberate and naturally occurring public health threats ("PHTs," each a &#8220;PHT&#8221;).</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">The Company is focused on the following </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"><span>six</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> distinct PHT categories: Chemical, Biological, Radiological, Nuclear and Explosives ("CBRNE"); emerging infectious diseases ("EID"); travel health; </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">emerging health crises; acute/emergency care, and contract development and manufacturing ("CDMO")</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">. The Company has a product portfolio of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"><span>ten</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> products and product candidates (vaccines, therapeutics, and drug-device combination products) that contribute a substantial portion of our revenue. The Company also has two product candidates that are procured under special circumstances by certain government agencies, although they are not approved by the FDA or any health agency. The U.S. government (the "USG') is the Company's largest customer and provides the Company with substantial funding for the development of a number of it</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">s product candidates.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">The Company's product portfolio includes:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;font-style:italic;text-decoration:underline;">Vaccines</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:5px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">&#9642;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">ACAM2000</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> (Smallpox (Vaccinia) Vaccine, Live), the only single-dose smallpox vaccine licensed by the FDA for active immunization against smallpox disease for persons determined to be at high risk for smallpox infection;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:5px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">&#9642;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">BioThrax</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> (Anthrax Vaccine Adsorbed), the only vaccine licensed by the U.S. Food and Drug Administration ("FDA"), for the general use prophylaxis and post-exposure prophylaxis of anthrax disease;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:5px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">&#9642;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">Vaxchora&#174; (Cholera Vaccine, Live, Oral), the only FDA-licensed vaccine for the prevention of cholera; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">&#9642;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">Vivotif&#174; (Typhoid Vaccine Live Oral Ty21a), the only oral vaccine licensed by the FDA for the prevention of typhoid fever.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;font-style:italic;text-decoration:underline;">Devices</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:5px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">&#9642;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">NARCAN&#174; (naloxone HCl) Nasal Spray, the first needle-free formulation of naloxone approved by the FDA and Health Canada, for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:5px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">&#9642;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">RSDL</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> (Reactive Skin Decontamination Lotion Kit), the only medical device cleared by the FDA to remove or neutralize the following chemical warfare agents from the skin: tabun, sarin, soman, cyclohexyl sarin, VR, VX, mustard gas and T-2 toxin; </span></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;font-style:italic;text-decoration:underline;">Therapeutics</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:5px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">&#9642;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">raxibacumab (Anthrax Monoclonal), the first fully human monoclonal antibody therapeutic licensed by the FDA for the treatment and prophylaxis of inhalational anthrax;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:5px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">&#9642;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">Anthrasil</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> (Anthrax Immune Globulin Intravenous (Human)), the only polyclonal antibody therapeutic licensed by the FDA and Health Canada for the treatment of inhalational anthrax;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:5px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">&#9642;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">BAT&#174; (Botulism Antitoxin Heptavalent (A,B,C,D,E,F,G)-(Equine)), the only heptavalent antibody therapeutic licensed by the FDA and Health Canada for the treatment of botulism; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">&#9642;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">VIGIV (Vaccinia Immune Globulin Intravenous (Human)), the only polyclonal antibody therapeutic licensed by the FDA and Health Canada to address certain complications from smallpox vaccination.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;font-style:italic;text-decoration:underline;">Product Candidates</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">&#9642;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">AV7909</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;  </sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">(Anthrax Vaccine Absorbed with Adjuvant), is a product candidate being developed as a next generation anthrax vaccine for post-exposure prophylaxis of disease resulting from suspected or confirmed Bacillus anthracis exposure. The USG has started procuring AV7909 for the Strategic National Stockpile (SNS) prior to its approval by the FDA and has been reducing its purchases of BioThrax as a result; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">&#9642;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">Trobigard&#174; is a combination drug-device auto-injector product candidate that contains atropine sulfate and obidoxime chloride. It has not been approved by the FDA or any similar health regulatory body, but it is procured </span></div></td></tr></table><div style="line-height:120%;padding-left:48px;padding-bottom:12px;text-align:justify;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">by certain authorized government buyers under special circumstances for potential use as a nerve agent countermeasure. </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">The Company also generates revenue from contract development and manufacturing services on a clinical and commercial (small and large) scale by providing such services to the pharmaceutical and biotechnology industry.&#160; These services include process development and bulk drug substance and drug product manufacturing of biologics, fill/finish formulation and analytical development services for injectable and other sterile products, inclusive of process design, technical transfer, manufacturing validations, aseptic filling, lyophilization, final packaging and stability studies, as well as manufacturing of vial and pre-filled syringe formats across bacterial, viral and mammalian therapy technology platforms. </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">The Company operates as </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"><span>one</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">operating segment.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6798565584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract', window );"><strong>Property Plant and Equipment Income Statement Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, plant and equipment</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Property, plant and equipment consisted of the following:</span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">March&#160;31, 2020</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Land and improvements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>46.6</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>46.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Buildings, building improvements and leasehold improvements</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>242.3</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>234.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Furniture and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>340.0</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>334.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Software</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>55.6</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>55.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Construction-in-progress</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>86.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>81.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment, gross</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>771.0</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>752.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accumulated depreciation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(221.8</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(210.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total property, plant and equipment, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>549.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>542.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6791487664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Share-based compensation</a></td>
<td class="text">Share-based compensation<span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">During the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">three months ended March 31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">, the Company granted stock options to purchase </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"><span>0.4 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> shares of common stock and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"><span>0.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> restricted and performance stock units under the Emergent BioSolutions Inc. Stock Incentive Plan. The stock option and restricted stock unit grants vest over </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">three</span> equal annual installments beginning on the day prior to the anniversary of the grant date. The performance stock units settle in stock at the end of the three-year performance period based on the Company's results compared to the performance criteria.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>ebs-20200331x10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2017-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:ebs="http://emergentbiosolutions.com/20200331"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2019-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ebs-20200331.xsd" xlink:type="simple"/>
    <context id="FD2020Q1YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="I2020Q2Apr24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <instant>2020-04-24</instant>
        </period>
    </context>
    <context id="FI2020Q1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandAndLandImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandAndLandImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerSoftwareIntangibleAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerSoftwareIntangibleAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_srt_RangeAxis_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_srt_RangeAxis_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_BusinessAcquisitionAxis_ebs_RaxibacumabMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:RaxibacumabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ebs_ContractManufacturingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:ContractManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ebs_ContractManufacturingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:ContractManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ebs_ContractManufacturingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:ContractManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ebs_ContractManufacturingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:ContractManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_srt_RangeAxis_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_srt_RangeAxis_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2020Q1_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueDiscountedCashFlowMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueDiscountedCashFlowMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MeasurementInputTypeAxis_ebs_MeasurementInputProbabilityofPaymentMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueDiscountedCashFlowMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ebs:MeasurementInputProbabilityofPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MeasurementInputTypeAxis_ebs_MeasurementInputProbabilityofPaymentMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueDiscountedCashFlowMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ebs:MeasurementInputProbabilityofPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueDiscountedCashFlowMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MeasurementInputTypeAxis_ebs_MeasurementInputProbabilityofPaymentMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueDiscountedCashFlowMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ebs:MeasurementInputProbabilityofPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueDiscountedCashFlowMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_InterestExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_InterestExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="D2018Q4Oct15-Oct15_us-gaap_CreditFacilityAxis_ebs_TermLoanFacilityMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ebs:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-15</startDate>
            <endDate>2018-10-15</endDate>
        </period>
    </context>
    <context id="D2018Q4Oct15-Oct15_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-15</startDate>
            <endDate>2018-10-15</endDate>
        </period>
    </context>
    <context id="D2018Q4Oct15-Oct15_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_EurodollarMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-15</startDate>
            <endDate>2018-10-15</endDate>
        </period>
    </context>
    <context id="D2018Q4Oct15-Oct15_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_BaseRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-15</startDate>
            <endDate>2018-10-15</endDate>
        </period>
    </context>
    <context id="I2018Q4Oct31_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_DebtInstrumentAxis_ebs_CreditAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="I2018Q4Oct31_us-gaap_CreditFacilityAxis_ebs_TermLoanFacilityMember_us-gaap_DebtInstrumentAxis_ebs_CreditAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ebs:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="I2014Q1Jan29_us-gaap_DebtInstrumentAxis_ebs_ConvertibleSeniorNotesDue2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:ConvertibleSeniorNotesDue2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-01-29</instant>
        </period>
    </context>
    <context id="FD2020Q1YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_DebtInstrumentAxis_ebs_CreditAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_DebtInstrumentAxis_ebs_CreditAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="D2018Q4Oct15-Oct15_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_EurodollarMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-15</startDate>
            <endDate>2018-10-15</endDate>
        </period>
    </context>
    <context id="D2018Q4Oct15-Oct15_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_BaseRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-15</startDate>
            <endDate>2018-10-15</endDate>
        </period>
    </context>
    <context id="D2018Q4Oct15-Oct15_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_EurodollarMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-15</startDate>
            <endDate>2018-10-15</endDate>
        </period>
    </context>
    <context id="D2018Q4Oct15-Oct15_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_FederalFundsEffectiveSwapRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-15</startDate>
            <endDate>2018-10-15</endDate>
        </period>
    </context>
    <context id="D2018Q4Oct15-Oct15_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-15</startDate>
            <endDate>2018-10-15</endDate>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_DebtInstrumentAxis_ebs_ConvertibleSeniorNotesDue2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:ConvertibleSeniorNotesDue2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DebtInstrumentAxis_ebs_OtherLongTermDebtFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:OtherLongTermDebtFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_CreditFacilityAxis_ebs_TermLoanFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ebs:TermLoanFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_CreditFacilityAxis_ebs_TermLoanFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ebs:TermLoanFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DebtInstrumentAxis_ebs_ConvertibleSeniorNotesDue2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:ConvertibleSeniorNotesDue2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_DebtInstrumentAxis_ebs_OtherLongTermDebtFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:OtherLongTermDebtFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="D2019Q2Jun01-Jun30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2020-04-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2020-04-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractManufacturingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractManufacturingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractManufacturingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractManufacturingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <unit id="category">
        <measure>ebs:category</measure>
    </unit>
    <unit id="instrument">
        <measure>ebs:instrument</measure>
    </unit>
    <unit id="segment">
        <measure>ebs:segment</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="product">
        <measure>ebs:product</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="FD2020Q1YTD"
      id="Fact-0E48C724DA10C59FE81950AC63A01A52-wk-Fact-0E48C724DA10C59FE81950AC63A01A52">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="FD2020Q1YTD"
      id="Fact-4396D86F1A3FDBC19A9250AC639F06D1-wk-Fact-4396D86F1A3FDBC19A9250AC639F06D1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus
      contextRef="FD2020Q1YTD"
      id="Fact-37BE7E72F9D1211F809B50AC639BECEB-wk-Fact-37BE7E72F9D1211F809B50AC639BECEB">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus
      contextRef="FD2020Q1YTD"
      id="Fact-63014366F6CAC9253AF550AC63A32998-wk-Fact-63014366F6CAC9253AF550AC63A32998">2020</dei:DocumentFiscalYearFocus>
    <dei:EntityCentralIndexKey
      contextRef="FD2020Q1YTD"
      id="Fact-DFB26AB808743B9170D950AC639BC443-wk-Fact-DFB26AB808743B9170D950AC639BC443">0001367644</dei:EntityCentralIndexKey>
    <ebs:DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod
      contextRef="D2019Q2Jun01-Jun30"
      id="Fact-792A9376BDBEDC53AE2D9EA600438185-wk-Fact-792A9376BDBEDC53AE2D9EA600438185">P12M</ebs:DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod>
    <ebs:DebtInstrumentCovenantNetLeverageRatioRollingPeriod
      contextRef="D2019Q2Jun01-Jun30"
      id="Fact-74840B652875D67B158E9EA59E38C0FF-wk-Fact-74840B652875D67B158E9EA59E38C0FF">P12M</ebs:DebtInstrumentCovenantNetLeverageRatioRollingPeriod>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="FI2019Q4"
      decimals="-5"
      id="Fact-82AE42CE832629C215EE9EB3C093C1EE-wk-Fact-82AE42CE832629C215EE9EB3C093C1EE"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="FI2020Q1_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MeasurementInputTypeAxis_ebs_MeasurementInputProbabilityofPaymentMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueDiscountedCashFlowMember"
      decimals="3"
      id="Fact-4AC65DC8B32E9F044ABAB80AFA1983C3-wk-Fact-4AC65DC8B32E9F044ABAB80AFA1983C3"
      unitRef="number">0.400</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="FI2020Q1_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueDiscountedCashFlowMember"
      decimals="3"
      id="Fact-F9E0045F8ADC836B1187B80AEF872CAC-wk-Fact-F9E0045F8ADC836B1187B80AEF872CAC"
      unitRef="number">0.086</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="FI2020Q1_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MeasurementInputTypeAxis_ebs_MeasurementInputProbabilityofPaymentMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueDiscountedCashFlowMember"
      decimals="3"
      id="Fact-EC21897CE200076E02EDB80AF4DF7B99-wk-Fact-EC21897CE200076E02EDB80AF4DF7B99"
      unitRef="number">0.100</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="FI2020Q1_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueDiscountedCashFlowMember"
      decimals="3"
      id="Fact-3A474463AF0A5360DB6FB80AE7975568-wk-Fact-3A474463AF0A5360DB6FB80AE7975568"
      unitRef="number">0.025</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="FI2019Q1"
      decimals="INF"
      id="Fact-E20634217EA5EC624B867A3947029C47-wk-Fact-E20634217EA5EC624B867A3947029C47"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-C15AF22F31B6D3BF653950AC63BB4FC0-wk-Fact-C15AF22F31B6D3BF653950AC63BB4FC0"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="FI2020Q1"
      decimals="INF"
      id="Fact-B24104F24953598727B350AC63E51183-wk-Fact-B24104F24953598727B350AC63E51183"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-0B47661E1FC500879DBB50AC63C4AD59-wk-Fact-0B47661E1FC500879DBB50AC63C4AD59"
      unitRef="shares">200000000.0</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="FI2020Q1"
      decimals="INF"
      id="Fact-2452C7B85C317F8FC40D50AC63C5FEFB-wk-Fact-2452C7B85C317F8FC40D50AC63C5FEFB"
      unitRef="shares">200000000.0</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-CDEF45159D132E885F0450AC63E5B191-wk-Fact-CDEF45159D132E885F0450AC63E5B191"
      unitRef="shares">53000000.0</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2020Q1"
      decimals="INF"
      id="Fact-F77B42B38EF53C877AD350AC63C4FA21-wk-Fact-F77B42B38EF53C877AD350AC63C4FA21"
      unitRef="shares">53500000.0</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-C0616B95FA5D9DB05DB650AC63A5719F-wk-Fact-C0616B95FA5D9DB05DB650AC63A5719F"
      unitRef="shares">51700000.0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2020Q1"
      decimals="INF"
      id="Fact-2FF701A5C07CD02712E150AC63C50455-wk-Fact-2FF701A5C07CD02712E150AC63C50455"
      unitRef="shares">52300000.0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2020Q1_us-gaap_DebtInstrumentAxis_ebs_ConvertibleSeniorNotesDue2021Member"
      decimals="INF"
      id="Fact-1907CAB695D6B50981DABEB6F29AC3C9-wk-Fact-1907CAB695D6B50981DABEB6F29AC3C9"
      unitRef="number">0.02875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember"
      id="Fact-1F31B62DEACA9ADAC6EC50AC63C0B1EE-wk-Fact-1F31B62DEACA9ADAC6EC50AC63C0B1EE">P22Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember"
      id="Fact-9118AECFCECBCE5D09D450AC63BBDBA6-wk-Fact-9118AECFCECBCE5D09D450AC63BBDBA6">P9Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="FD2020Q1YTD_srt_RangeAxis_srt_MaximumMember"
      id="Fact-EEA09AA570F17F620DD950AC63C1A001-wk-Fact-EEA09AA570F17F620DD950AC63C1A001">P22Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="FD2020Q1YTD_srt_RangeAxis_srt_MinimumMember"
      id="Fact-0F5CD76F0FFA7669CAF950AC63C2BA6E-wk-Fact-0F5CD76F0FFA7669CAF950AC63C2BA6E">P9Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="Fact-28F10BE3DBDE7DD4EAFA9E5DEE964BB1-wk-Fact-28F10BE3DBDE7DD4EAFA9E5DEE964BB1"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="Fact-AF6392AD8B7C3AD1740A9E5DEE76C01F-wk-Fact-AF6392AD8B7C3AD1740A9E5DEE76C01F"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="Fact-3C07EDBFB2D5AB6707819E5670607F3B-wk-Fact-3C07EDBFB2D5AB6707819E5670607F3B"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="Fact-36580CA52809B6FD14519E56708A55E7-wk-Fact-36580CA52809B6FD14519E56708A55E7"
      unitRef="usd">2800000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-20991F85DEBD2590A10650AC63DCC0A7-wk-Fact-20991F85DEBD2590A10650AC63DCC0A7"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="FI2020Q1"
      decimals="INF"
      id="Fact-77D0BDC6D97591104E4050AC63E41A4B-wk-Fact-77D0BDC6D97591104E4050AC63E41A4B"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-33550EF448D84030613750AC63DA3B99-wk-Fact-33550EF448D84030613750AC63DA3B99"
      unitRef="shares">15000000.0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="FI2020Q1"
      decimals="INF"
      id="Fact-118A608FFA82F495C94350AC63C52749-wk-Fact-118A608FFA82F495C94350AC63C52749"
      unitRef="shares">15000000.0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-0E13776D0F7E27792D6150AC63E382AD-wk-Fact-0E13776D0F7E27792D6150AC63E382AD"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="FI2020Q1"
      decimals="INF"
      id="Fact-2894DAC3673B5A9A48E350AC63C38BBF-wk-Fact-2894DAC3673B5A9A48E350AC63C38BBF"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-C9170C6983974D800D9D50AC63C461C9-wk-Fact-C9170C6983974D800D9D50AC63C461C9"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="FI2020Q1"
      decimals="INF"
      id="Fact-E1800D4F844FEA794D6850AC63C3EA20-wk-Fact-E1800D4F844FEA794D6850AC63C3EA20"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      id="Fact-73263950C1D92479FFBC50AC63A0B4FB-wk-Fact-73263950C1D92479FFBC50AC63A0B4FB">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      id="Fact-35C4F50EB8FE20CCFE9850AC63A95FC9-wk-Fact-35C4F50EB8FE20CCFE9850AC63A95FC9">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember"
      decimals="4"
      id="Fact-32682A7A94DB39055A1150AC63A82951-wk-Fact-32682A7A94DB39055A1150AC63A82951"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember"
      decimals="4"
      id="Fact-24001A6C353632BC400250AC639F2C8E-wk-Fact-24001A6C353632BC400250AC639F2C8E"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember"
      decimals="4"
      id="Fact-96495D4C6A2EA38905D650AC63A97826-wk-Fact-96495D4C6A2EA38905D650AC63A97826"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember"
      decimals="4"
      id="Fact-9D796BDE9BDFD0C3E1E650AC639A9634-wk-Fact-9D796BDE9BDFD0C3E1E650AC639A9634"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember"
      decimals="4"
      id="Fact-66B837E236D2CE25D4DA50AC639F5AF2-wk-Fact-66B837E236D2CE25D4DA50AC639F5AF2"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember"
      decimals="4"
      id="Fact-771F2C6D94BC83AFEF9F50AC63992869-wk-Fact-771F2C6D94BC83AFEF9F50AC63992869"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:TreasuryStockShares
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-D73F2FB29977991040EC50AC63C68599-wk-Fact-D73F2FB29977991040EC50AC63C68599"
      unitRef="shares">1200000.0</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="FI2020Q1"
      decimals="INF"
      id="Fact-D2F73C42A3180429E09050AC63D780E1-wk-Fact-D2F73C42A3180429E09050AC63D780E1"
      unitRef="shares">1200000.0</us-gaap:TreasuryStockShares>
    <dei:DocumentType
      contextRef="FD2020Q1YTD"
      id="d17795988e571-wk-Fact-6DEAE98BF4E4CC5B31BA50AC639B4FB7">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="FD2020Q1YTD"
      id="d17795988e606-wk-Fact-BD771E682C415565483D50AC63DBB692">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="FD2020Q1YTD"
      id="d17795988e648-wk-Fact-16AE0F0436DAC9FA373050AC63DA7BAF">2020-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="FD2020Q1YTD"
      id="d17795988e686-wk-Fact-C9BBC1529E1A700AB13C50AC63DC9A1C">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="FD2020Q1YTD"
      id="d17795988e733-wk-Fact-6530F33A47CA90654E8950AC63A56A04">001-33137</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="FD2020Q1YTD"
      id="d17795988e743-wk-Fact-2C31B79B1C72985B4E3350AC63C30708">EMERGENT BIOSOLUTIONS INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="FD2020Q1YTD"
      id="d17795988e765-wk-Fact-983C045558B233D9139A50AC63DD24AD">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="FD2020Q1YTD"
      id="d17795988e775-wk-Fact-14E0D6B5959DBE5529F150AC63C6583E">14-1902018</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="FD2020Q1YTD"
      id="d17795988e818-wk-Fact-414452901DD31FEF35CA50AC63C419A9">400 Professional Drive Suite 400</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="FD2020Q1YTD"
      id="d17795988e834-wk-Fact-E6DD8063A830283A1B5750AC63C561C8">Gaithersburg,  </dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="FD2020Q1YTD"
      id="d17795988e839-wk-Fact-4E8A16F433DB7295520550AC63E34572">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="FD2020Q1YTD"
      id="d17795988e844-wk-Fact-F338C7B98F99E81C248F50AC63E5996A">20879</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="FD2020Q1YTD"
      id="d17795988e865-wk-Fact-FA62D83AA4734DB7F0ED50AC63A7BB86">240</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="FD2020Q1YTD"
      id="d17795988e870-wk-Fact-D6BA8FA29828958E4C0050AC639BD7A1">631-3200</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="FD2020Q1YTD"
      id="d17795988e924-wk-Fact-6A5D973F6182836FB76E50AC63BBBB05">Common Stock, Par Value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="FD2020Q1YTD"
      id="d17795988e929-wk-Fact-2E5E75E50F5188B99E5050AC63BB66DE">EBS</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="FD2020Q1YTD"
      id="d17795988e934-wk-Fact-767C979097CD02FB009E50AC63BA91AE">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="FD2020Q1YTD"
      id="d17795988e943-wk-Fact-1D83F2C7E0A581507F4150AC63A28A97">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="FD2020Q1YTD"
      id="d17795988e961-wk-Fact-B7AD05D5E90AF678F6D850AC63A43E62">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="FD2020Q1YTD"
      id="d17795988e991-wk-Fact-AA24FAEAD7693C489D8150AC63C92EC8">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="FD2020Q1YTD"
      id="d17795988e1027-wk-Fact-69D6192B18F0B2A7E52550AC63CECAB2">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="FD2020Q1YTD"
      id="d17795988e1049-wk-Fact-BBFF384C1B0AA61E44E250AC63CC5A7E">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="FD2020Q1YTD"
      id="d17795988e1061-wk-Fact-AF90944F6872DFE82A8050AC63A01975">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="I2020Q2Apr24"
      decimals="INF"
      id="d17795988e1073-wk-Fact-BE9BF63A9DC7E53BA14950AC63A0C27D"
      unitRef="shares">52427756</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17799691e723-wk-Fact-73115F8A6D878C47A0EB50AC63D25B5C"
      unitRef="usd">181500000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17799691e741-wk-Fact-E7531639DF62C4543F8750AC63E073A0"
      unitRef="usd">167800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17799691e756-wk-Fact-9C3A03D295A31EBA495650AC63AEC122"
      unitRef="usd">200000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17799691e774-wk-Fact-A58135F386AA24C78D2950AC63D6C50B"
      unitRef="usd">200000</us-gaap:RestrictedCashCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17799691e794-wk-Fact-33FB468D40ED33E2CA7E50AC63CE721D"
      unitRef="usd">162500000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17799691e812-wk-Fact-BF3721EEB20B5C10A7E650AC63C709EB"
      unitRef="usd">270700000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17799691e832-wk-Fact-F091EAB5DDEA37D108C650AC63DA852F"
      unitRef="usd">248100000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17799691e850-wk-Fact-ED5377811E6E36E4601D50AC63CE5708"
      unitRef="usd">222500000</us-gaap:InventoryNet>
    <us-gaap:IncomeTaxesReceivable
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17799691e870-wk-Fact-54837CD9CFA375A403F350AC63DCFB89"
      unitRef="usd">10200000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17799691e888-wk-Fact-4FB79AF7A858A2341DA950AC63D4374E"
      unitRef="usd">4600000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17799691e908-wk-Fact-4721DEFE865038E6CADF79E1416AFA2A"
      unitRef="usd">24100000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17799691e926-wk-Fact-0759214C7B45FD29009B50AC63AE075A"
      unitRef="usd">20400000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17799691e946-wk-Fact-FE7B86C0506DA35877F150AC63A5334C"
      unitRef="usd">626600000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17799691e965-wk-Fact-A81A28E49D8C32EC9A2550AC63BBA07D"
      unitRef="usd">686200000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17799691e1027-wk-Fact-99ED5AE3E83E32B0A84150AC63E1866C"
      unitRef="usd">549200000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17799691e1045-wk-Fact-1C28759FD7611ABEF76950AC6399C4F9"
      unitRef="usd">542300000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17799691e1065-wk-Fact-B49A570526091681767C50AC63B1DD0D"
      unitRef="usd">708100000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17799691e1083-wk-Fact-72A979EF03E562242D1450AC63AB4C9C"
      unitRef="usd">712900000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <ebs:InProcessResearchAndDevelopment
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17799691e1103-wk-Fact-4D5C23166D2307F0819050AC63ACCEE2"
      unitRef="usd">29000000.0</ebs:InProcessResearchAndDevelopment>
    <ebs:InProcessResearchAndDevelopment
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17799691e1121-wk-Fact-DB0D64C1BA6FEF98588750AC63AC530A"
      unitRef="usd">29000000.0</ebs:InProcessResearchAndDevelopment>
    <us-gaap:Goodwill
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17799691e1141-wk-Fact-F9685A10CF0BB5F123BD9E6E56E0368A"
      unitRef="usd">266400000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17799691e1159-wk-Fact-4537F01ABBB58F8704CB9E6E57053B1F"
      unitRef="usd">266600000</us-gaap:Goodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17799691e1179-wk-Fact-3FD72E9203D87B35604950AC63A38852"
      unitRef="usd">17600000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17799691e1197-wk-Fact-66C2214084B3C924149F50AC63DD3211"
      unitRef="usd">13400000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17799691e1217-wk-Fact-68E09D3467BF5A071DDC50AC63A841FE"
      unitRef="usd">81800000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17799691e1235-wk-Fact-70D0BD6868EF8CFCB83750AC63E2E56D"
      unitRef="usd">76900000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17799691e1260-wk-Fact-8289105D534674239F6D50AC63E0297E"
      unitRef="usd">2278700000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17799691e1279-wk-Fact-B9A72825751718913BFC50AC63A12F40"
      unitRef="usd">2327300000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17799691e1422-wk-Fact-5192F8833539EFE2FB2150AC63B30B21"
      unitRef="usd">84200000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17799691e1440-wk-Fact-80EABBBC6372D24F543050AC63A7397A"
      unitRef="usd">94800000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17799691e1456-wk-Fact-C32DE5D5524B841DAD5850AC63E3C74F"
      unitRef="usd">41500000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17799691e1474-wk-Fact-64582B022E3416FE1E3150AC63D4C29F"
      unitRef="usd">39500000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17799691e1494-wk-Fact-131921BFC22FDD16BE0650AC63B32091"
      unitRef="usd">47500000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17799691e1512-wk-Fact-F58E7639F289FFBAA84050AC63A6D5C3"
      unitRef="usd">62400000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17799691e1532-wk-Fact-EDFB84F5BCBDDB3725A550AC63DD854B"
      unitRef="usd">26300000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17799691e1550-wk-Fact-8E23349626858D270DF850AC63A9DADA"
      unitRef="usd">12900000</us-gaap:NotesPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17799691e1570-wk-Fact-891ECA6D8F117B66CDC150AC63A369E8"
      unitRef="usd">7600000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17799691e1588-wk-Fact-662DC37D9D46F2A55FA950AC63AEB68B"
      unitRef="usd">6700000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17799691e1608-wk-Fact-D2060A248A724782B40150AC63D7BDB7"
      unitRef="usd">207100000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17799691e1627-wk-Fact-F83E9C8D0A81971D54C450AC63ACF606"
      unitRef="usd">216300000</us-gaap:LiabilitiesCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17799691e1688-wk-Fact-3525AFAA6E6B6428C6C779E141549F48"
      unitRef="usd">26100000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17799691e1706-wk-Fact-9675E09614563F7AB24050AC63D6EE1D"
      unitRef="usd">26000000.0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17799691e1726-wk-Fact-71761EF4F2817FB54EF079E14164F9D7"
      unitRef="usd">762900000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17799691e1744-wk-Fact-64FB9723C0B0F0E7FB3A50AC639B2838"
      unitRef="usd">798400000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17799691e1764-wk-Fact-AF42ABBED13CCD4BEA3A79E1415FD331"
      unitRef="usd">63900000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17799691e1782-wk-Fact-AF95766366587A01D21E50AC639B65EA"
      unitRef="usd">63900000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17799691e1802-wk-Fact-E83B41BBD8F6FA973F4A79E14170DCE4"
      unitRef="usd">85000000.0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17799691e1820-wk-Fact-97288A5C7A024691416E50AC63BB628B"
      unitRef="usd">85600000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17799691e1840-wk-Fact-16A4886E2C7D095CD6E379E141762975"
      unitRef="usd">58900000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17799691e1858-wk-Fact-24CF32C26102222BC0DC50AC63C4DC4F"
      unitRef="usd">48600000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17799691e1884-wk-Fact-A3E6250EB4CC9585AC7C50AC63DD6486"
      unitRef="usd">1203900000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17799691e1903-wk-Fact-FAFC0EBAE0F639F0D4DC50AC63E475E8"
      unitRef="usd">1238800000</us-gaap:Liabilities>
    <us-gaap:PreferredStockValue
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17799691e1995-wk-Fact-6E0CE4CF2FF543719D2550AC63BB49B1"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17799691e2013-wk-Fact-06458A77AC6860E6C17750AC63D9EDE3"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17799691e2033-wk-Fact-0DD964487A8EED7993AB50AC63BB9605"
      unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17799691e2051-wk-Fact-2991BD9296A4754091F950AC63C80B24"
      unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17799691e2071-wk-Fact-B1AA53C2F1975AECAF0C50AC63DC1B9E"
      unitRef="usd">39600000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17799691e2090-wk-Fact-339985F5A48334107D9A50AC63BBF1A5"
      unitRef="usd">39600000</us-gaap:TreasuryStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17799691e2111-wk-Fact-B09F55E52E0C2B00D7E150AC63D9E7EE"
      unitRef="usd">726200000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17799691e2129-wk-Fact-FD222C34C01EB0E1DF9550AC639FFF95"
      unitRef="usd">716100000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17799691e2149-wk-Fact-75D07BE3D88B6FE7C68450AC63DC6586"
      unitRef="usd">-21200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17799691e2168-wk-Fact-D974F7E588DC56BC76D650AC63A42F69"
      unitRef="usd">-9900000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17799691e2189-wk-Fact-8D2C5E2E86A0799FBE1F50AC63B36413"
      unitRef="usd">409300000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17799691e2207-wk-Fact-E4D7E53D3B0CEBC5BD9350AC63BBCB15"
      unitRef="usd">421800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17799691e2227-wk-Fact-D7815A59ED29A9FB7CCF50AC63D5C63B"
      unitRef="usd">1074800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17799691e2245-wk-Fact-F4507548E8C1AB00D3DA50AC63B454D8"
      unitRef="usd">1088500000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17799691e2270-wk-Fact-A70AE53866C3EB44BA6150AC63C7EEA9"
      unitRef="usd">2278700000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17799691e2288-wk-Fact-192D80C3CBA4B307C85250AC63D2B93D"
      unitRef="usd">2327300000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d17799136e723-wk-Fact-15F576BF23B68ED3410550AC63B6D635"
      unitRef="usd">148200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d17799136e741-wk-Fact-100EA167C32CD4E7BF7F50AC63C22D94"
      unitRef="usd">153000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember"
      decimals="-5"
      id="d17799136e756-wk-Fact-C945A823FC8AB77DBA5A50AC63C78AD8"
      unitRef="usd">21700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember"
      decimals="-5"
      id="d17799136e774-wk-Fact-86B8A67AE3A5069C980750AC63B51F29"
      unitRef="usd">15900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember"
      decimals="-5"
      id="d17799136e794-wk-Fact-3612644390F14B60C4B550AC63CA1285"
      unitRef="usd">22600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember"
      decimals="-5"
      id="d17799136e812-wk-Fact-8EAC98B280127C3147AA50AC63C5A1FF"
      unitRef="usd">21700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17799136e832-wk-Fact-EE62D36AAC76E41DE0BE50AC63C826F6"
      unitRef="usd">192500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17799136e851-wk-Fact-4783103E7C9579FDD76750AC63CB769E"
      unitRef="usd">190600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17799136e952-wk-Fact-BA336E685E86F57C6D0D50AC63B4634B"
      unitRef="usd">76900000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17799136e970-wk-Fact-0BC613ED4D26B153FA5650AC63BA8BFC"
      unitRef="usd">91800000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17799136e990-wk-Fact-2B8E60DC76A9801A1FE950AC63B1087D"
      unitRef="usd">42700000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17799136e1008-wk-Fact-7BEDB621BDB5A994783B50AC63BA77D6"
      unitRef="usd">46100000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17799136e1029-wk-Fact-4600FDC44E9E0418798B50AC63BB32E0"
      unitRef="usd">69700000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17799136e1047-wk-Fact-78C0CF404ADD5B797E5650AC63C1B641"
      unitRef="usd">65400000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17799136e1067-wk-Fact-20A4A30F776CD2C76C8050AC63AE3F61"
      unitRef="usd">14800000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17799136e1085-wk-Fact-BCD7D8B56A51DBB9F81E50AC63C5640D"
      unitRef="usd">14500000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17799136e1105-wk-Fact-90E0AEBB8A82E78B6F5A50AC63C007FD"
      unitRef="usd">204100000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17799136e1124-wk-Fact-BBD73BF964A9A45FC8CF50AC63C21AA2"
      unitRef="usd">217800000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17799136e1184-wk-Fact-104EC02A9D5162DADE0950AC63C8F1B3"
      unitRef="usd">-11600000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17799136e1203-wk-Fact-2DCE31345877D0C7E09E50AC63CA3397"
      unitRef="usd">-27200000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17799136e1305-wk-Fact-C924066F66385D680AF19E4630872773"
      unitRef="usd">8600000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17799136e1324-wk-Fact-75106F69A5C39D9D72E750AC63BB0DE2"
      unitRef="usd">9600000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17799136e1345-wk-Fact-4E3D23064239778474469E4630A5BC2F"
      unitRef="usd">-1100000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17799136e1364-wk-Fact-A68B5F700B16A2E9A41850AC63AD7A24"
      unitRef="usd">-1000000.0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17799136e1385-wk-Fact-D76206CE7E7977D824CD9E4630A15853"
      unitRef="usd">-9700000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17799136e1405-wk-Fact-600160C34CC7B2DF82189E46309AF484"
      unitRef="usd">-10600000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17799136e1467-wk-Fact-550E5D1D072394C5C60050AC63AF1195"
      unitRef="usd">-21300000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17799136e1486-wk-Fact-7EC256BDE4B0C851EC3350AC63C6FFB9"
      unitRef="usd">-37800000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17799136e1507-wk-Fact-3112495982BCF3C558E450AC63AAAA8E"
      unitRef="usd">-8800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17799136e1525-wk-Fact-DD6E636C0FAA0013733950AC63AAA28D"
      unitRef="usd">-11800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17799136e1550-wk-Fact-2BE66961830A83F48E5050AC63AB2A6D"
      unitRef="usd">-12500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17799136e1570-wk-Fact-68AB7F5A194EFA0424DB50AC63CA9408"
      unitRef="usd">-26000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2020Q1YTD"
      decimals="2"
      id="d17799136e1673-wk-Fact-92317C4056EAA9BE7F9C50AC63C0B75A"
      unitRef="usdPerShare">-0.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2019Q1QTD"
      decimals="2"
      id="d17799136e1693-wk-Fact-398962EC77284B56EAE350AC63CB3AD7"
      unitRef="usdPerShare">-0.51</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2020Q1YTD"
      decimals="2"
      id="d17799136e1714-wk-Fact-F4635BF4F58F1DABA08450AC63C76B0E"
      unitRef="usdPerShare">-0.24</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2019Q1QTD"
      decimals="2"
      id="d17799136e1734-wk-Fact-3F3AD90A570B8318774450AC63B12D21"
      unitRef="usdPerShare">-0.51</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17799136e1791-wk-Fact-86AA0904084337CA20DD50AC63BB987B"
      unitRef="shares">52000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17799136e1809-wk-Fact-E5106EB7EC5DD52FFE1750AC63AAA0C9"
      unitRef="shares">51200000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17799136e1829-wk-Fact-FE0D54A71F3B22F2C1A650AC63BB0266"
      unitRef="shares">52000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17799136e1847-wk-Fact-025C9BBD3873347BD04350AC63AAE1F5"
      unitRef="shares">51200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17800287e681-wk-Fact-2BE66961830A83F48E5050AC63AB2A6D"
      unitRef="usd">-12500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17800287e701-wk-Fact-68AB7F5A194EFA0424DB50AC63CA9408"
      unitRef="usd">-26000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17800287e756-wk-Fact-A53862397182309EA63A50AC63E001ED"
      unitRef="usd">-100000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17800287e776-wk-Fact-96B2693D63C32DF527C850AC63C28C3C"
      unitRef="usd">1200000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17800287e796-wk-Fact-BFD2CECA667105B62EBC50AC63C41C07"
      unitRef="usd">-11200000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17800287e816-wk-Fact-15377C4CBC8E47785A2150AC63C79933"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17800287e836-wk-Fact-86FFD151DC1F2E6E0C2C50AC63C33BCA"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17800287e855-wk-Fact-F5F2648BC2AD1B5A0A9B50AC63BB0174"
      unitRef="usd">200000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17800287e876-wk-Fact-2AF3E574CF6A3F51147E50AC63C7A17E"
      unitRef="usd">-11300000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17800287e896-wk-Fact-EF2F7C8B369F4438E69250AC63D50C89"
      unitRef="usd">1000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17800287e921-wk-Fact-E321E1C6CE0BC0C66B0350AC63DD188F"
      unitRef="usd">-23800000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17800287e941-wk-Fact-8EC54BB1C591FEA38E0E50AC63E5F501"
      unitRef="usd">-25000000.0</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17802373e721-wk-Fact-2BE66961830A83F48E5050AC63AB2A6D"
      unitRef="usd">-12500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17802373e741-wk-Fact-68AB7F5A194EFA0424DB50AC63CA9408"
      unitRef="usd">-26000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17802373e798-wk-Fact-739507C483111AB19B8B50AC639F00E6"
      unitRef="usd">6600000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17802373e817-wk-Fact-72D70E05B77F63E1B16550AC63DC057D"
      unitRef="usd">6800000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17802373e837-wk-Fact-1DE51309ACCFE8B283B250AC63E3A642"
      unitRef="usd">28200000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17802373e856-wk-Fact-F57F9DA62263F8628FC750AC63E235DA"
      unitRef="usd">26600000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17802373e876-wk-Fact-60091772919504C1FC7250AC63A1DE52"
      unitRef="usd">700000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17802373e895-wk-Fact-6362222B217449806E6850AC63DAEF07"
      unitRef="usd">700000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17802373e915-wk-Fact-3F6E0290413999EC3F1850AC63DD34AE"
      unitRef="usd">-4200000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17802373e935-wk-Fact-32531DA821298C43466C50AC63DD51B3"
      unitRef="usd">-11400000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <ebs:ChangeInFairValueOfContingentConsideration
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17802373e956-wk-Fact-6EBBCA15A2A26C796ACD50AC63E0DD30"
      unitRef="usd">600000</ebs:ChangeInFairValueOfContingentConsideration>
    <ebs:ChangeInFairValueOfContingentConsideration
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17802373e975-wk-Fact-179F8013B589BE02F28C50AC63A6022B"
      unitRef="usd">1700000</ebs:ChangeInFairValueOfContingentConsideration>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17802373e995-wk-Fact-980561FB9B0682BC55F850AC639BFCB7"
      unitRef="usd">0</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17802373e1014-wk-Fact-76F4B60F1C885A21A34A50AC63DB0B22"
      unitRef="usd">100000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17802373e1077-wk-Fact-9459167624DEEA3EF92F50AC63E60698"
      unitRef="usd">-108200000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17802373e1096-wk-Fact-D0F9804277606C7DB99C50AC63A37980"
      unitRef="usd">-141600000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17802373e1116-wk-Fact-11A15607E213184500C750AC63DB4BBF"
      unitRef="usd">25600000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17802373e1136-wk-Fact-0A4207CA36C06EE1370750AC63DDC92C"
      unitRef="usd">5200000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17802373e1157-wk-Fact-9CF3C0B60DCFCBD3A03E50AC639B2D9C"
      unitRef="usd">15300000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17802373e1177-wk-Fact-F92A9D5670BB1F6AD5A250AC63E4AABE"
      unitRef="usd">16600000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17802373e1198-wk-Fact-4A4823A9A2368E86DA7C50AC63A75481"
      unitRef="usd">-15600000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17802373e1218-wk-Fact-668FD98B48F825D37C1050AC63A5CF39"
      unitRef="usd">4200000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17802373e1238-wk-Fact-F8D4040486E74D0F56D850AC63E10862"
      unitRef="usd">1100000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17802373e1257-wk-Fact-C1CFA3CA308F03407DB850AC63DDE506"
      unitRef="usd">1700000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17802373e1277-wk-Fact-985655A1E0A46438DFF450AC63E005F7"
      unitRef="usd">-14900000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17802373e1297-wk-Fact-56288A6590BC4AAD092C50AC63A50B76"
      unitRef="usd">-21300000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17802373e1318-wk-Fact-4074E36C6BD07D24A66D50AC639B577A"
      unitRef="usd">500000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17802373e1337-wk-Fact-5A15EA545F7122AA207B50AC63DA2EBE"
      unitRef="usd">2100000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17802373e1357-wk-Fact-12CB37B34743CE077A9650AC63A50D41"
      unitRef="usd">57800000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17802373e1376-wk-Fact-908BC741591EB58CAC9C50AC639BE65F"
      unitRef="usd">104800000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17802373e1437-wk-Fact-C4AFBE1D5DFF313E0CD750AC63A01EB8"
      unitRef="usd">24200000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17802373e1457-wk-Fact-732CB60DEDF9689506C150AC639F2F30"
      unitRef="usd">21400000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17802373e1479-wk-Fact-EBD36A64FC50C88B684750AC63A38736"
      unitRef="usd">-24200000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17802373e1499-wk-Fact-E8A65B1CE6618CD6331350AC63DA4D9A"
      unitRef="usd">-21400000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17802373e1561-wk-Fact-036411553056CA6996B350AC63DDEC95"
      unitRef="usd">0</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17802373e1580-wk-Fact-71CF40DA3FB2333B635A50AC63E302FE"
      unitRef="usd">30000000.0</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17802373e1600-wk-Fact-84D8CAE601269854BDBC50AC63DBE614"
      unitRef="usd">20000000.0</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17802373e1620-wk-Fact-2367615F6A83A7B4F98450AC63E25A92"
      unitRef="usd">80000000.0</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfMediumTermNotes
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17802373e1641-wk-Fact-54AE99CC8E559401E7A550AC63DDA262"
      unitRef="usd">2800000</us-gaap:RepaymentsOfMediumTermNotes>
    <us-gaap:RepaymentsOfMediumTermNotes
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17802373e1661-wk-Fact-B31B4A9B1A704D1DBBA550AC639B9EA3"
      unitRef="usd">2800000</us-gaap:RepaymentsOfMediumTermNotes>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17802373e1682-wk-Fact-34DA41A6E4F450796D1550AC63E0A588"
      unitRef="usd">9100000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17802373e1701-wk-Fact-7F56B3B8D7B35376C44850AC63E0029D"
      unitRef="usd">900000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17802373e1721-wk-Fact-AC2FA75F6595AFA8434250AC63A2187F"
      unitRef="usd">5600000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17802373e1741-wk-Fact-44DD65CE9AD52BB3136450AC63DD6DDA"
      unitRef="usd">6000000.0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17802373e1762-wk-Fact-BA3A647EC1AE184FBD8F50AC63A1AD11"
      unitRef="usd">700000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17802373e1782-wk-Fact-A4EB44574B1685CD5E4D50AC63DDDD9F"
      unitRef="usd">500000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17802373e1803-wk-Fact-F3B22C6688A93B448A1F50AC63E2BACD"
      unitRef="usd">-20000000.0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17802373e1823-wk-Fact-7A9AC0C6101EB8EF9C9E50AC639AA02D"
      unitRef="usd">-58400000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17802373e1844-wk-Fact-ECB7C97F0886EE5A70A350AC63DC0249"
      unitRef="usd">100000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17802373e1863-wk-Fact-A872686DD763EFA2AA8250AC63DACEAB"
      unitRef="usd">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17802373e1883-wk-Fact-AE7424ECD1DE706F27AD50AC63E4FF53"
      unitRef="usd">13700000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17802373e1902-wk-Fact-137055F36063B1BBA4BE50AC639BB8DC"
      unitRef="usd">25000000.0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17802373e1923-wk-Fact-1482B415680B1E1FEDA650AC63A4C847"
      unitRef="usd">168000000.0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2018Q4"
      decimals="-5"
      id="d17802373e1942-wk-Fact-A16160C5AF27529784EF50AC639F139D"
      unitRef="usd">112400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17802373e1967-wk-Fact-2F58183E8D39BA6B17BC79D8CF0E2E3F"
      unitRef="usd">181700000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2019Q1"
      decimals="-5"
      id="d17802373e1986-wk-Fact-84DDE874EEA34BD29B9F50AC63A4C53B"
      unitRef="usd">137400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17802373e2047-wk-Fact-245A8E2E59D47D8CB64979D69CA6EE92"
      unitRef="usd">7400000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17802373e2066-wk-Fact-5780A12AEABD58AC2D5379D69C94248F"
      unitRef="usd">8900000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17802373e2086-wk-Fact-899CD2D46D2D60EAD1DA79D6D6FD0EB6"
      unitRef="usd">3600000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17802373e2105-wk-Fact-F434AB870E0433BA6EF279D6D71DEB1D"
      unitRef="usd">5000000.0</us-gaap:IncomeTaxesPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17802373e2166-wk-Fact-4B5741A19C409247ACD979D742C8A374"
      unitRef="usd">7300000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17802373e2185-wk-Fact-98754DB7C539952D509079D742D0F656"
      unitRef="usd">7100000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17802373e2246-wk-Fact-73115F8A6D878C47A0EB50AC63D25B5C"
      unitRef="usd">181500000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17802373e2265-wk-Fact-E7531639DF62C4543F8750AC63E073A0"
      unitRef="usd">167800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17802373e2285-wk-Fact-9C3A03D295A31EBA495650AC63AEC122"
      unitRef="usd">200000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17802373e2299-wk-Fact-A58135F386AA24C78D2950AC63D6C50B"
      unitRef="usd">200000</us-gaap:RestrictedCashCurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17802373e2324-wk-Fact-2F58183E8D39BA6B17BC79D8CF0E2E3F"
      unitRef="usd">181700000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17802373e2343-wk-Fact-1482B415680B1E1FEDA650AC63A4C847"
      unitRef="usd">168000000.0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d17805435e1098-wk-Fact-ABE00B4C79A85CA4568250AC63D83265"
      unitRef="shares">53000000.0</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d17805435e1117-wk-Fact-CC8EE6D21DBA8ED50E3CB9BCA88E58F1"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d17805435e1136-wk-Fact-E168E6F27F6A8A384EFB50AC63E0E4E5"
      unitRef="usd">716100000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="INF"
      id="d17805435e1151-wk-Fact-D92478E35B9CF94EF99750AC63CEA000"
      unitRef="shares">1200000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d17805435e1171-wk-Fact-8227D790086ECFD37B1150AC639BBC63"
      unitRef="usd">-39600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d17805435e1191-wk-Fact-846F395BCB065E297E2750AC639BFA1D"
      unitRef="usd">-9900000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d17805435e1212-wk-Fact-242D143308EE9EC0D8E250AC63A8B267"
      unitRef="usd">421800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17805435e1231-wk-Fact-F4507548E8C1AB00D3DA50AC63B454D8"
      unitRef="usd">1088500000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d17805435e1251-wk-Fact-9F33978D20311C8C656150AC63BB5368"
      unitRef="shares">500000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d17805435e1284-wk-Fact-F1D2E901C655DBA2EBD5B9BCA87645AA"
      unitRef="usd">10100000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d17805435e1318-wk-Fact-9ADC20BDFC008F7984EB50AC63BBE3E0"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17805435e1376-wk-Fact-CBD9A0543FD6D6FC32DEB9BCA8834E58"
      unitRef="usd">10100000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d17805435e1507-wk-Fact-FA2798FC4BC99383B7DE50AC63AC5038"
      unitRef="usd">-12500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17805435e1527-wk-Fact-2BE66961830A83F48E5050AC63AB2A6D"
      unitRef="usd">-12500000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d17805435e1639-wk-Fact-80DDB522CA293FEF2FC2B9BCA893D055"
      unitRef="usd">-11300000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17805435e1679-wk-Fact-2AF3E574CF6A3F51147E50AC63C7A17E"
      unitRef="usd">-11300000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d17805435e1705-wk-Fact-273068F1982C62A6992D50AC63CDCC26"
      unitRef="shares">53500000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d17805435e1724-wk-Fact-10BE38BE28444D67433350AC63CBBBA2"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d17805435e1743-wk-Fact-D6CFBD9DCC5476F28C80B9BCA898DBCD"
      unitRef="usd">726200000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="INF"
      id="d17805435e1758-wk-Fact-74862663C92A269A7B9E50AC63CB06EA"
      unitRef="shares">1200000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d17805435e1778-wk-Fact-04596E6BA9E26B10608E50AC639B3101"
      unitRef="usd">-39600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d17805435e1798-wk-Fact-E1F20C5A2968660CACE7B9BCA8A8AB58"
      unitRef="usd">-21200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d17805435e1819-wk-Fact-6FB7700C7B0F47E7FC2A50AC63CB7872"
      unitRef="usd">409300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17805435e1838-wk-Fact-D7815A59ED29A9FB7CCF50AC63D5C63B"
      unitRef="usd">1074800000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d17805435e2174-wk-Fact-5D2567B870B3DA58A16A50AC63CD56F7"
      unitRef="shares">52400000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d17805435e2193-wk-Fact-4C034EF0D3338A29366350AC63AA4678"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d17805435e2212-wk-Fact-E02D12257B0932DBBCCE50AC63D95918"
      unitRef="usd">688600000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="INF"
      id="d17805435e2227-wk-Fact-95DC7D1CC9CC6FE5E13E50AC63E2B78D"
      unitRef="shares">1200000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d17805435e2247-wk-Fact-1A1ABC6942C3B10BE9C350AC63BB7E36"
      unitRef="usd">-39600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d17805435e2267-wk-Fact-40639A081310045BBA2850AC63A37C99"
      unitRef="usd">-5500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d17805435e2288-wk-Fact-4E9C2D54D4F142CDEC4C50AC63E4DF55"
      unitRef="usd">367300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4"
      decimals="-5"
      id="d17805435e2307-wk-Fact-E97D7327996A8B104B2A50AC63D0AD3F"
      unitRef="usd">1010900000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d17805435e2328-wk-Fact-DED4E400BF9308F35F8650AC63E10BBB"
      unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d17805435e2359-wk-Fact-A7BEF91734CC07C8AA8B50AC639BA350"
      unitRef="usd">1600000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d17805435e2391-wk-Fact-9309807C000204E3979D50AC63A06930"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17805435e2446-wk-Fact-5DA03859615691BD457F50AC63D2BC44"
      unitRef="usd">1600000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d17805435e2571-wk-Fact-480139014EC63EE487AB50AC63C9CB39"
      unitRef="usd">-26000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17805435e2590-wk-Fact-68AB7F5A194EFA0424DB50AC63CA9408"
      unitRef="usd">-26000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d17805435e2697-wk-Fact-81CDEC6B9B9234EFDE0B50AC63AEA6DD"
      unitRef="usd">1000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17805435e2734-wk-Fact-EF2F7C8B369F4438E69250AC63D50C89"
      unitRef="usd">1000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d17805435e2759-wk-Fact-214DBE4CBE85DBC2E60A50AC63B1A751"
      unitRef="shares">52600000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d17805435e2777-wk-Fact-F936351DECCF51FC1CC750AC63CF5F4E"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d17805435e2795-wk-Fact-8C4C79E98FB5423C622850AC63A2FF79"
      unitRef="usd">690200000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="INF"
      id="d17805435e2809-wk-Fact-CBACD24C8F887A547D0350AC63CD6A0F"
      unitRef="shares">1200000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d17805435e2828-wk-Fact-F615E3A3E6D641BAE4A450AC63ABFEEB"
      unitRef="usd">-39600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d17805435e2847-wk-Fact-6F53647C31426785422050AC63A27CFB"
      unitRef="usd">-4500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d17805435e2867-wk-Fact-98F004FB159337762E5B50AC63DD6FA9"
      unitRef="usd">341300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q1"
      decimals="-5"
      id="d17805435e2885-wk-Fact-BB6829A3D98510B088A450AC63D6C3F0"
      unitRef="usd">987500000</us-gaap:StockholdersEquity>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-83848454B326B83E353750AC63F1EC2C-0-wk-Fact-246B6739011B3AABBCCE50AC63D4F9BF">Business&lt;div style="line-height:120%;padding-bottom:12px;padding-left:24px;text-indent:-24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;"&gt;Organization and business&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;Emergent BioSolutions Inc. (the "Company" or "Emergent") is a global life sciences company focused on providing civilian and military populations a portfolio of innovative preparedness and response products and solutions that address accidental, deliberate and naturally occurring public health threats ("PHTs," each a &#x201c;PHT&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;The Company is focused on the following &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;&lt;span&gt;six&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt; distinct PHT categories: Chemical, Biological, Radiological, Nuclear and Explosives ("CBRNE"); emerging infectious diseases ("EID"); travel health; &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;emerging health crises; acute/emergency care, and contract development and manufacturing ("CDMO")&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;. The Company has a product portfolio of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;&lt;span&gt;ten&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt; products and product candidates (vaccines, therapeutics, and drug-device combination products) that contribute a substantial portion of our revenue. The Company also has two product candidates that are procured under special circumstances by certain government agencies, although they are not approved by the FDA or any health agency. The U.S. government (the "USG') is the Company's largest customer and provides the Company with substantial funding for the development of a number of it&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;s product candidates.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:24px;text-indent:-24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;"&gt;The Company's product portfolio includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:justify;padding-left:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;font-style:italic;text-decoration:underline;"&gt;Vaccines&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:5px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;&#x25aa;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;ACAM2000&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt; (Smallpox (Vaccinia) Vaccine, Live), the only single-dose smallpox vaccine licensed by the FDA for active immunization against smallpox disease for persons determined to be at high risk for smallpox infection;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:5px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;&#x25aa;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;BioThrax&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt; (Anthrax Vaccine Adsorbed), the only vaccine licensed by the U.S. Food and Drug Administration ("FDA"), for the general use prophylaxis and post-exposure prophylaxis of anthrax disease;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:5px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;&#x25aa;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;Vaxchora&#xae; (Cholera Vaccine, Live, Oral), the only FDA-licensed vaccine for the prevention of cholera; and&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;&#x25aa;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;Vivotif&#xae; (Typhoid Vaccine Live Oral Ty21a), the only oral vaccine licensed by the FDA for the prevention of typhoid fever.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:justify;padding-left:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;font-style:italic;text-decoration:underline;"&gt;Devices&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:5px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;&#x25aa;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;NARCAN&#xae; (naloxone HCl) Nasal Spray, the first needle-free formulation of naloxone approved by the FDA and Health Canada, for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression; and&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:5px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;&#x25aa;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;RSDL&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt; (Reactive Skin Decontamination Lotion Kit), the only medical device cleared by the FDA to remove or neutralize the following chemical warfare agents from the skin: tabun, sarin, soman, cyclohexyl sarin, VR, VX, mustard gas and T-2 toxin; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:justify;padding-left:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;font-style:italic;text-decoration:underline;"&gt;Therapeutics&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:5px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;&#x25aa;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;raxibacumab (Anthrax Monoclonal), the first fully human monoclonal antibody therapeutic licensed by the FDA for the treatment and prophylaxis of inhalational anthrax;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:5px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;&#x25aa;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;Anthrasil&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt; (Anthrax Immune Globulin Intravenous (Human)), the only polyclonal antibody therapeutic licensed by the FDA and Health Canada for the treatment of inhalational anthrax;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:5px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;&#x25aa;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;BAT&#xae; (Botulism Antitoxin Heptavalent (A,B,C,D,E,F,G)-(Equine)), the only heptavalent antibody therapeutic licensed by the FDA and Health Canada for the treatment of botulism; and&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;&#x25aa;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;VIGIV (Vaccinia Immune Globulin Intravenous (Human)), the only polyclonal antibody therapeutic licensed by the FDA and Health Canada to address certain complications from smallpox vaccination.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:justify;padding-left:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;font-style:italic;text-decoration:underline;"&gt;Product Candidates&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;&#x25aa;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;AV7909&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&#xae;  &lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;(Anthrax Vaccine Absorbed with Adjuvant), is a product candidate being developed as a next generation anthrax vaccine for post-exposure prophylaxis of disease resulting from suspected or confirmed Bacillus anthracis exposure. The USG has started procuring AV7909 for the Strategic National Stockpile (SNS) prior to its approval by the FDA and has been reducing its purchases of BioThrax as a result; and&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;&#x25aa;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;Trobigard&#xae; is a combination drug-device auto-injector product candidate that contains atropine sulfate and obidoxime chloride. It has not been approved by the FDA or any similar health regulatory body, but it is procured &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-left:48px;padding-bottom:12px;text-align:justify;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;by certain authorized government buyers under special circumstances for potential use as a nerve agent countermeasure. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;The Company also generates revenue from contract development and manufacturing services on a clinical and commercial (small and large) scale by providing such services to the pharmaceutical and biotechnology industry.&#160; These services include process development and bulk drug substance and drug product manufacturing of biologics, fill/finish formulation and analytical development services for injectable and other sterile products, inclusive of process design, technical transfer, manufacturing validations, aseptic filling, lyophilization, final packaging and stability studies, as well as manufacturing of vial and pre-filled syringe formats across bacterial, viral and mammalian therapy technology platforms. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;The Company operates as &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt; &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;operating segment.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <ebs:NumberOfCategoriesOfPublicHealthThreats
      contextRef="FD2020Q1YTD"
      decimals="INF"
      id="d17805584e579-wk-Fact-A0A2BDF6C42B23FF549850AC63D1E890"
      unitRef="category">6</ebs:NumberOfCategoriesOfPublicHealthThreats>
    <ebs:NumberOfRevenueGeneratingProducts
      contextRef="FD2020Q1YTD"
      decimals="INF"
      id="d17805584e587-wk-Fact-09821EF7F9824557603FB7E29D9BB39D"
      unitRef="product">10</ebs:NumberOfRevenueGeneratingProducts>
    <us-gaap:NumberOfOperatingSegments
      contextRef="FD2020Q1YTD"
      decimals="INF"
      id="d17805584e727-wk-Fact-D886683251CE85E78A9A50AC63D47DF7"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-511022022D53AA8F23A050AC63F111EC-0-wk-Fact-CA65C04E0271363D324F50AC63CD4C54">Basis of Presentation and Principles of Consolidation&lt;div style="line-height:120%;padding-bottom:8px;padding-left:24px;text-indent:-24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;"&gt;Basis of presentation &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;The accompanying unaudited condensed consolidated financial statements include the accounts of Emergent and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements included herein have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X issued by the SEC. Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;, as filed with the SEC.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;All adjustments contained in the accompanying unaudited condensed consolidated financial statements are of a normal recurring nature and are necessary to present fairly the financial position of the Company as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;. Interim results are not necessarily indicative of results that may be expected for any other interim period or for an entire year.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;text-indent:-24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-style:normal;text-decoration:none;"&gt;Significant accounting policies&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;During the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;three months ended March 31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;, there have been no significant changes to the Company's summary of significant accounting policies contained in the Company's Annual Report on Form 10-K for the year ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;, as filed with the SEC.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;text-indent:-24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-style:normal;text-decoration:none;"&gt;Fair value measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;Separate disclosure is required for assets and liabilities measured at fair value on a recurring basis from those measured at fair value on a non-recurring basis. The Company has cash held in money market accounts (level 1), contingent purchase consideration (level 3) and interest rate swaps arrangements (level 2) that are measured at fair value on a recurring basis (Note 7 and Note 8). As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;, the Company held cash in money market accounts of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;&lt;span&gt;$90.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;&lt;span&gt;$52.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;, respectively. The Company also records the assets and liabilities of acquisitions at fair value. On a non-recurring basis, the Company measures its IPR&amp;amp;D assets (level 3) using fair value measurements. As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;, the Company had &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;no&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt; other significant assets or liabilities that were measured at fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-left:24px;text-indent:-24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;"&gt;Recently issued accounting standards&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;font-size:10pt;"&gt;&lt;span style="font-family:;font-size:10pt;color:#0094ff;font-style:italic;text-decoration:underline;"&gt;Recently Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;"&gt;ASU 2016-13,&#160;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&#160;("ASU 2016-13")&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;In June 2016, the FASB issued ASU 2016-13. ASU 2016-13 provides guidance on measurement of credit losses on financial instruments that changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, held-to-maturity debt securities and loans, and that requires entities to use a new, forward-looking &#x201c;expected loss&#x201d; model that is expected to generally result in the earlier recognition of allowances for losses. The guidance&#160;became effective for annual periods beginning after December 15, 2019, including interim periods within those years. The Company adopted the standard as of January 1, 2020 and has evaluated the effects of this standard and determined that the adoption did not have a material impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;"&gt;ASU 2018-13,&#160;Fair Value Measurement - Disclosure Framework (Topic 820)&#160;("ASU 2018-13")&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;In August 2018, the FASB issued ASU 2018-13. ASU 2018-13 improves the disclosure requirements on fair value measurements. The updated guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Early adoption is permitted for any removed or modified disclosures. The Company adopted the standard as of January 1, 2020 which has resulted in expanded disclosures around the Company's recurring level 3 fair value measurements. The disclosures are included in note 7 of the condensed consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;"&gt;ASU 2018-15,&#160;Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer&#x2019;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract ("ASU 2018-15")&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;In August 2018, the FASB issued ASU 2018-15. ASU 2018-15 clarifies the accounting for implementation costs in cloud computing arrangements. ASU 2018-15 is effective for all entities for fiscal years beginning after December 15, 2019. The Company adopted the standard as of January 1, 2020 and has evaluated the effects of this standard and determined that the adoption did not have a material impact on the Company's consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;"&gt;ASU 2017-4,&#160;Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment ("ASU 2017-4")&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;In January 2017, the FASB issued ASU 2017-4. ASU 2017-4 simplifies the subsequent measurement of goodwill and eliminates Step 2 from the goodwill impairment test. ASU 2017-4 is effective for annual and interim goodwill tests beginning after December 15, 2019. The Company's measurement period is September 30. The Company adopted the standard as of January 1, 2020 and has evaluated the effects of this standard and determined that the adoption will not have a material impact on the Company's consolidation financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;font-size:10pt;"&gt;&lt;span style="font-family:;font-size:10pt;color:#0094ff;font-style:italic;text-decoration:underline;"&gt;Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;"&gt;ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;In March 2020, the FASB issued Topic 848. Topic 848 provides relief for impacted areas as it relates to impending reference rate reform. ASC 848 contains optional expedients and exceptions for applying US GAAP to debt arrangements, contracts, hedging relationships, and other areas or transactions that are impacted by reference rate reform. This guidance is effective for upon issuance for all entities and elections of certain optional expedients are required to apply the provisions of the guidance. The Company continues to assess all potential impacts of the standard and will disclose the nature and reason for any elections that the Company makes. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;"&gt;ASU 2018-14,&#160;Compensation -&#160;Retirement Benefits - Defined Benefit Plans - General (Topic 715-20):&#160;Disclosure Framework - Changes to the Disclosure Requirements for Defined Benefit Plans&#160;("ASU 2018-14")&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;In August 2018, the FASB issued ASU 2018-14. ASU 2018-14 modifies the disclosure requirements for defined benefit pension plans and other post-retirement plans. ASU 2018-14 is effective for all entities for fiscal years ending after December 15, 2020, and earlier adoption is permitted. The Company is currently evaluating the impact of adopting ASU 2018-14 on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;"&gt;ASU 2019-12, Simplifications to Accounting for Income Taxes ("ASU 2019-12")&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;In December 2019, the FASB issued ASU 2019-12. ASU 2019-12 removes certain exceptions for recognizing deferred taxes for investments, performing intra-period allocation and calculating income taxes in interim periods. The ASU also adds guidance to reduce complexity in certain areas, including deferred taxes for goodwill and allocating taxes for members of a consolidated group. ASU 2019-12 is effective for all entities for fiscal years beginning after December 15, 2020, and earlier adoption is permitted. The Company is currently evaluating the impact of adopting ASU 2019-12 on its consolidated financial statements.&lt;/span&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-397B6AAF0A92F463659450AC63F1B2B9-0-wk-Fact-14E6AF8434DB2E74C66050AC63D07EA0">&lt;div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;The accompanying unaudited condensed consolidated financial statements include the accounts of Emergent and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements included herein have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X issued by the SEC. Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;, as filed with the SEC.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;All adjustments contained in the accompanying unaudited condensed consolidated financial statements are of a normal recurring nature and are necessary to present fairly the financial position of the Company as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;. Interim results are not necessarily indicative of results that may be expected for any other interim period or for an entire year.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-11330CC0B52BE73E273550AC63F1AEB2-0-wk-Fact-F7F57C61B75A989915CA50AC63D8FA1B">Separate disclosure is required for assets and liabilities measured at fair value on a recurring basis from those measured at fair value on a non-recurring basis. The Company has cash held in money market accounts (level 1), contingent purchase consideration (level 3) and interest rate swaps arrangements (level 2) that are measured at fair value on a recurring basis (Note 7 and Note 8).</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17805776e629-wk-Fact-ACF0E9E8BC6FAA9A25355CEE99E0CA2B"
      unitRef="usd">90700000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17805776e633-wk-Fact-C75BE7655975F3CD729DB7E3EF8F4D15"
      unitRef="usd">52200000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-94C351BABA3BFD27A0F250AC63F11BF5-0-wk-Fact-CDC5C92C1FB553F0A1E750AC639B3E08">&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;font-size:10pt;"&gt;&lt;span style="font-family:;font-size:10pt;color:#0094ff;font-style:italic;text-decoration:underline;"&gt;Recently Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;"&gt;ASU 2016-13,&#160;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&#160;("ASU 2016-13")&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;In June 2016, the FASB issued ASU 2016-13. ASU 2016-13 provides guidance on measurement of credit losses on financial instruments that changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, held-to-maturity debt securities and loans, and that requires entities to use a new, forward-looking &#x201c;expected loss&#x201d; model that is expected to generally result in the earlier recognition of allowances for losses. The guidance&#160;became effective for annual periods beginning after December 15, 2019, including interim periods within those years. The Company adopted the standard as of January 1, 2020 and has evaluated the effects of this standard and determined that the adoption did not have a material impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;"&gt;ASU 2018-13,&#160;Fair Value Measurement - Disclosure Framework (Topic 820)&#160;("ASU 2018-13")&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;In August 2018, the FASB issued ASU 2018-13. ASU 2018-13 improves the disclosure requirements on fair value measurements. The updated guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Early adoption is permitted for any removed or modified disclosures. The Company adopted the standard as of January 1, 2020 which has resulted in expanded disclosures around the Company's recurring level 3 fair value measurements. The disclosures are included in note 7 of the condensed consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;"&gt;ASU 2018-15,&#160;Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer&#x2019;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract ("ASU 2018-15")&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;In August 2018, the FASB issued ASU 2018-15. ASU 2018-15 clarifies the accounting for implementation costs in cloud computing arrangements. ASU 2018-15 is effective for all entities for fiscal years beginning after December 15, 2019. The Company adopted the standard as of January 1, 2020 and has evaluated the effects of this standard and determined that the adoption did not have a material impact on the Company's consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;"&gt;ASU 2017-4,&#160;Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment ("ASU 2017-4")&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;In January 2017, the FASB issued ASU 2017-4. ASU 2017-4 simplifies the subsequent measurement of goodwill and eliminates Step 2 from the goodwill impairment test. ASU 2017-4 is effective for annual and interim goodwill tests beginning after December 15, 2019. The Company's measurement period is September 30. The Company adopted the standard as of January 1, 2020 and has evaluated the effects of this standard and determined that the adoption will not have a material impact on the Company's consolidation financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;font-size:10pt;"&gt;&lt;span style="font-family:;font-size:10pt;color:#0094ff;font-style:italic;text-decoration:underline;"&gt;Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;"&gt;ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;In March 2020, the FASB issued Topic 848. Topic 848 provides relief for impacted areas as it relates to impending reference rate reform. ASC 848 contains optional expedients and exceptions for applying US GAAP to debt arrangements, contracts, hedging relationships, and other areas or transactions that are impacted by reference rate reform. This guidance is effective for upon issuance for all entities and elections of certain optional expedients are required to apply the provisions of the guidance. The Company continues to assess all potential impacts of the standard and will disclose the nature and reason for any elections that the Company makes. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;"&gt;ASU 2018-14,&#160;Compensation -&#160;Retirement Benefits - Defined Benefit Plans - General (Topic 715-20):&#160;Disclosure Framework - Changes to the Disclosure Requirements for Defined Benefit Plans&#160;("ASU 2018-14")&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;In August 2018, the FASB issued ASU 2018-14. ASU 2018-14 modifies the disclosure requirements for defined benefit pension plans and other post-retirement plans. ASU 2018-14 is effective for all entities for fiscal years ending after December 15, 2020, and earlier adoption is permitted. The Company is currently evaluating the impact of adopting ASU 2018-14 on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;"&gt;ASU 2019-12, Simplifications to Accounting for Income Taxes ("ASU 2019-12")&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;In December 2019, the FASB issued ASU 2019-12. ASU 2019-12 removes certain exceptions for recognizing deferred taxes for investments, performing intra-period allocation and calculating income taxes in interim periods. The ASU also adds guidance to reduce complexity in certain areas, including deferred taxes for goodwill and allocating taxes for members of a consolidated group. ASU 2019-12 is effective for all entities for fiscal years beginning after December 15, 2020, and earlier adoption is permitted. The Company is currently evaluating the impact of adopting ASU 2019-12 on its consolidated financial statements.&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt; &lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-AA6FECD7E6169A78688350AC63F27313-0-wk-Fact-D634668AFEE6A66A0D5750AC63D87F8B">Inventories&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;The components of inventory are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:61%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Raw materials and supplies&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;77.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;70.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Work-in-process&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;114.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;89.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Finished goods&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;56.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;62.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total inventories&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;248.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;222.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-1656B389C79112900FF450AC63F2CC23-0-wk-Fact-8BE5756A0EC972C7A3A950AC63D8B41F">&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;The components of inventory are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:61%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Raw materials and supplies&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;77.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;70.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Work-in-process&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;114.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;89.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Finished goods&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;56.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;62.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total inventories&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;248.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;222.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17806105e646-wk-Fact-058BB9D5B1E9C3059D6850AC63C01902"
      unitRef="usd">77700000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
    <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17806105e665-wk-Fact-AED6E5912C9A8A64084550AC63E6756D"
      unitRef="usd">70500000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17806105e680-wk-Fact-1D02B4370A92BA0DA2F650AC63C84CE7"
      unitRef="usd">114200000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17806105e699-wk-Fact-5FF461D0DBC0E6B9D77C50AC63E44B2F"
      unitRef="usd">89700000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17806105e719-wk-Fact-36287B9BAFB1D8F6105A50AC63E3545E"
      unitRef="usd">56200000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17806105e738-wk-Fact-55AA2C10F441AA2AB7E550AC63E39FC4"
      unitRef="usd">62300000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17806105e763-wk-Fact-F091EAB5DDEA37D108C650AC63DA852F"
      unitRef="usd">248100000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17806105e782-wk-Fact-ED5377811E6E36E4601D50AC63CE5708"
      unitRef="usd">222500000</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-2075361569F8414EBE1C50AC63F22303-0-wk-Fact-E6C851553EAE049A2F2850AC63DA6421">Property, plant and equipment&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;Property, plant and equipment consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:63%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Land and improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;46.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;46.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Buildings, building improvements and leasehold improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;242.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;234.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Furniture and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;340.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;334.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Software&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;55.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;55.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Construction-in-progress&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;86.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;81.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Property, plant and equipment, gross&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;771.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;752.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accumulated depreciation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;(221.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(210.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total property, plant and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;549.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;542.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-28D8F4359059EE96455850AC63F253EE-0-wk-Fact-36098905452BF3C6323B50AC63DB590C">&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;Property, plant and equipment consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:63%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Land and improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;46.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;46.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Buildings, building improvements and leasehold improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;242.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;234.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Furniture and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;340.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;334.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Software&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;55.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;55.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Construction-in-progress&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;86.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;81.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Property, plant and equipment, gross&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;771.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;752.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accumulated depreciation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;(221.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(210.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total property, plant and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;549.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;542.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2020Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandAndLandImprovementsMember"
      decimals="-5"
      id="d17806698e646-wk-Fact-036CD9AE33310F76039950AC63CC5FFE"
      unitRef="usd">46600000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandAndLandImprovementsMember"
      decimals="-5"
      id="d17806698e665-wk-Fact-7C945696B7199C4DF21D50AC63CB9A58"
      unitRef="usd">46500000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2020Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember"
      decimals="-5"
      id="d17806698e680-wk-Fact-899A8B7428DCA941D07750AC639B11CE"
      unitRef="usd">242300000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember"
      decimals="-5"
      id="d17806698e699-wk-Fact-1BC7EB05CEDF5E833B0450AC63CAA3E5"
      unitRef="usd">234800000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2020Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember"
      decimals="-5"
      id="d17806698e719-wk-Fact-70E036CB4A200219E47250AC639A7907"
      unitRef="usd">340000000.0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember"
      decimals="-5"
      id="d17806698e738-wk-Fact-C15EE064807EB17F347650AC63CE70D3"
      unitRef="usd">334200000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2020Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerSoftwareIntangibleAssetMember"
      decimals="-5"
      id="d17806698e758-wk-Fact-0270F0B3C67F0C61F39150AC63C6A3A3"
      unitRef="usd">55600000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerSoftwareIntangibleAssetMember"
      decimals="-5"
      id="d17806698e777-wk-Fact-09C32717A638DE0F32B650AC63D3005F"
      unitRef="usd">55700000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2020Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember"
      decimals="-5"
      id="d17806698e797-wk-Fact-883FCB6A9EA4B6D5F4FB50AC63E28D68"
      unitRef="usd">86500000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember"
      decimals="-5"
      id="d17806698e816-wk-Fact-BF86A09B6F07C6F6F1AC50AC63CAD2B4"
      unitRef="usd">81500000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17806698e836-wk-Fact-8D9DD118FF47BE674B1950AC63D172EB"
      unitRef="usd">771000000.0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17806698e855-wk-Fact-8712D1FDDA51130E554050AC63D7AE36"
      unitRef="usd">752700000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17806698e875-wk-Fact-1C90626E08734D429EB250AC63D16D4F"
      unitRef="usd">221800000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17806698e895-wk-Fact-563733EFDFD672AA08D050AC63DD8913"
      unitRef="usd">210400000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17806698e921-wk-Fact-99ED5AE3E83E32B0A84150AC63E1866C"
      unitRef="usd">549200000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17806698e940-wk-Fact-1C28759FD7611ABEF76950AC6399C4F9"
      unitRef="usd">542300000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-6F7C699D521F1DE32BFD50AC63F24F35-0-wk-Fact-D5AC0C17BFBEA57BC2F350AC63DDBE52">Leases&lt;div style="line-height:120%;padding-bottom:10px;padding-top:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;The Company has operating leases for corporate offices, research and development facilities and manufacturing facilities. We determine if an arrangement is a lease at inception. Operating leases are included in right-of-use (ROU) assets and liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;ROU assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of the Company's leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company uses an implicit rate when readily determinable. At the beginning of a lease, the operating lease ROU asset also includes any concentrated lease payments expected to be paid and excludes lease incentives. The Company's lease ROU asset may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise those options. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company has lease agreements with lease and non-lease components, which are accounted for separately. The Company's leases have remaining lease terms of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt; year to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;&lt;span&gt;15&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt; years, some of which include options to extend the leases for up to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt; years, and some of which include options to terminate the leases within &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt; year.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;The components of lease expense were as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:12px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:61%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Three months ended March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating lease cost:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amortization of right-of-use assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;1.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;1.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;Supplemental balance sheet information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:39%;"/&gt;&lt;td style="width:21%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;font-style:italic;"&gt;(In millions, except lease term and discount rate)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Balance Sheet location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;25.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;24.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating lease liabilities, current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;4.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;22.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;26.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;25.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating leases:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted average remaining lease term (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;7.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted average discount rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;4.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeFinanceLeasesTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-11B2EBE071C4262D916150AC63F29E7E-0-wk-Fact-68A32D7FDF7707B2516050AC63DD4A28">Leases&lt;div style="line-height:120%;padding-bottom:10px;padding-top:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;The Company has operating leases for corporate offices, research and development facilities and manufacturing facilities. We determine if an arrangement is a lease at inception. Operating leases are included in right-of-use (ROU) assets and liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;ROU assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of the Company's leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company uses an implicit rate when readily determinable. At the beginning of a lease, the operating lease ROU asset also includes any concentrated lease payments expected to be paid and excludes lease incentives. The Company's lease ROU asset may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise those options. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company has lease agreements with lease and non-lease components, which are accounted for separately. The Company's leases have remaining lease terms of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt; year to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;&lt;span&gt;15&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt; years, some of which include options to extend the leases for up to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt; years, and some of which include options to terminate the leases within &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt; year.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;The components of lease expense were as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:12px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:61%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Three months ended March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating lease cost:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amortization of right-of-use assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;1.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;1.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;Supplemental balance sheet information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:39%;"/&gt;&lt;td style="width:21%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;font-style:italic;"&gt;(In millions, except lease term and discount rate)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Balance Sheet location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;25.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;24.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating lease liabilities, current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;4.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;22.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;26.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;25.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating leases:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted average remaining lease term (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;7.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted average discount rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;4.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeFinanceLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="FI2020Q1_srt_RangeAxis_srt_MinimumMember"
      id="d17807561e581-wk-Fact-37AFB2B597B23076BF8850AC63DDB758">P1Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="FI2020Q1_srt_RangeAxis_srt_MaximumMember"
      id="d17807561e585-wk-Fact-BA815A211DCE01E4D68C50AC63E11119">P15Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="FI2020Q1"
      id="d17807561e589-wk-Fact-4A2E4922E67FD236BC0F50AC63DD7859">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <ebs:LesseeOperatingLeaseTerminationPeriod
      contextRef="FD2020Q1YTD"
      id="d17807561e593-wk-Fact-EE2A0389DE88D9E4260150AC639AFDDA">P1Y</ebs:LesseeOperatingLeaseTerminationPeriod>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-0BE95110EF79AEF77C4050AC63F25AFD-0-wk-Fact-85CF60AD7B65262EDC2D50AC63DD6741">&lt;div style="line-height:120%;padding-bottom:10px;padding-top:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;The components of lease expense were as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:12px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:61%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Three months ended March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating lease cost:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amortization of right-of-use assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;1.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;1.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17807561e755-wk-Fact-6F92BB4D0468AAC50E749E68D01BC951"
      unitRef="usd">1100000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17807561e774-wk-Fact-0E98739DC2F88922908250AC63DDFEDA"
      unitRef="usd">600000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17807561e789-wk-Fact-7246D8D2CEBCAAA65EE49E68D02F2798"
      unitRef="usd">300000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17807561e808-wk-Fact-D8173FCEA1502854BB6050AC63E6C8E7"
      unitRef="usd">100000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:LeaseCost
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17807561e833-wk-Fact-E8BD74F647013E68DB8550AC63E5EE6C"
      unitRef="usd">1400000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17807561e852-wk-Fact-046FE3D5F4CBA2C8F46750AC63E54FDD"
      unitRef="usd">700000</us-gaap:LeaseCost>
    <ebs:ScheduleOfLeasesSupplementalBalanceSheetsTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-3E2F3FC0FE360F562DA050AC63F211C9-0-wk-Fact-4110D577A7CAAD85E63250AC63DDB272">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;Supplemental balance sheet information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:39%;"/&gt;&lt;td style="width:21%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;font-style:italic;"&gt;(In millions, except lease term and discount rate)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Balance Sheet location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;25.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;24.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating lease liabilities, current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;4.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;22.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;26.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;25.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating leases:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted average remaining lease term (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;7.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted average discount rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;4.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</ebs:ScheduleOfLeasesSupplementalBalanceSheetsTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17807561e962-wk-Fact-BA9D48416DE5C4C80B2550AC63A4901D"
      unitRef="usd">25600000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17807561e981-wk-Fact-9B3E274FAFB5587C9D0F50AC63D0EE16"
      unitRef="usd">24700000</us-gaap:OperatingLeaseRightOfUseAsset>
    <ebs:OperatingLeaseOtherLiabilityCurrent
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17807561e1057-wk-Fact-1641FA87C6F4270E2C5C50AC63AEAD79"
      unitRef="usd">4200000</ebs:OperatingLeaseOtherLiabilityCurrent>
    <ebs:OperatingLeaseOtherLiabilityCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17807561e1076-wk-Fact-C28D8134C0E5A1E1C72A50AC63CFCB90"
      unitRef="usd">3600000</ebs:OperatingLeaseOtherLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17807561e1106-wk-Fact-9AE154B09F03A838808D50AC63B0A673"
      unitRef="usd">22700000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17807561e1125-wk-Fact-BE1C9CBC7E9DCF0006B150AC63C0F998"
      unitRef="usd">22100000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17807561e1160-wk-Fact-C680541510192003638F50AC63AB0772"
      unitRef="usd">26900000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17807561e1179-wk-Fact-7D685955C9AB481E48C550AC63E0AC0A"
      unitRef="usd">25700000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="FI2020Q1"
      id="d17807561e1306-wk-Fact-F82C9BE408331B0DF4A050AC63AD3E35">P7Y8M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="FI2019Q4"
      id="d17807561e1325-wk-Fact-73755A5FA4D527DAB82A50AC63CF7D92">P8Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="FI2020Q1"
      decimals="3"
      id="d17807561e1355-wk-Fact-EACB9698BADF4861C87050AC63AFBB8B"
      unitRef="number">0.042</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="FI2019Q4"
      decimals="3"
      id="d17807561e1375-wk-Fact-CCAA4DF7F94F88577E4F50AC63DB69AD"
      unitRef="number">0.042</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-A4073591F8B0BD050E5650AC63F2672D-0-wk-Fact-3F77C3AF40CA270213F250AC63CC1B80">Intangible assets&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;The Company's intangible as&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;sets consist of products acquired via business combinations or asset acquisitions. The following tables summarize the Company's intangible assets for the periods ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt; and December 31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="15"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:30%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="12" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;March 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;(in millions)&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Estimated Life&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Additions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Accumulated Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Products&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9-22 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ededed;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ededed;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"&gt;&lt;span&gt;788.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ededed;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ededed;border-top:2px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ededed;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"&gt;&lt;span&gt;10.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ededed;border-top:2px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ededed;border-top:2px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ededed;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"&gt;&lt;span&gt;96.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ededed;border-top:2px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ededed;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ededed;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"&gt;&lt;span&gt;702.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ededed;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Customer relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"&gt;&lt;span&gt;28.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ededed;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ededed;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"&gt;&lt;span&gt;23.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ededed;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"&gt;&lt;span&gt;4.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ededed;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contract development and manufacturing&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"&gt;&lt;span&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ededed;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ededed;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"&gt;&lt;span&gt;4.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ededed;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"&gt;&lt;span&gt;1.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ededed;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;&#160;&#160;&#160;Total intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ededed;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ededed;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"&gt;&lt;span&gt;822.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ededed;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ededed;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ededed;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"&gt;&lt;span&gt;10.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ededed;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ededed;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ededed;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"&gt;&lt;span&gt;124.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ededed;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ededed;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ededed;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"&gt;&lt;span&gt;708.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ededed;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:43%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;(in millions)&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Estimated Life&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Accumulated Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Products&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9-22 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;788.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;82.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;705.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Customer relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;28.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;23.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contract development and manufacturing&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;&#160;&#160;&#160;Total intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;822.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;109.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;712.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;During the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;three months ended March 31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;, the Company achieved a sales milestone that resulted in a &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;&lt;span&gt;$10.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt; obligation related to the Company's asset acquisition of raxibacumab in October 2017. The achievement of the milestone resulted in an increase to intangible assets with a corresponding increase in accounts payable. As of March 31, 2020 there are no remaining contractual obligations for sales milestones related to the raxibacumab acquisition. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;During the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;three months ended March 31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;, the Company recorded amortization expense for intangible assets of $&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;&lt;span&gt;14.8&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt; million and $&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;&lt;span&gt;14.5&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt; million, respectively. As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;, the weighted average amortization period remaining for intangible assets was &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;&lt;span&gt;13.3&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt; years. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;In-process research and development (IPR&amp;amp;D) assets are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. There were no changes to the Company's IPR&amp;amp;D assets during the three months ended March 31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;Goodwill was $&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;&lt;span&gt;266.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt; and $&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;&lt;span&gt;266.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt; for the periods ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;December&#160;31, 2019&lt;/span&gt;, respectively. The change in the balance during the period was due to foreign currency translation adjustments.</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-1DFD16A835B068C441F350AC63F39308-0-wk-Fact-661D276D2D726CC9F65650AC63CD61F7">The following tables summarize the Company's intangible assets for the periods ended &lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt; and December 31, 2019:&lt;/span&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="15"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:30%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="12" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;March 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;(in millions)&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Estimated Life&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Additions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Accumulated Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Products&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9-22 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ededed;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ededed;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"&gt;&lt;span&gt;788.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ededed;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ededed;border-top:2px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ededed;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"&gt;&lt;span&gt;10.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ededed;border-top:2px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ededed;border-top:2px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ededed;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"&gt;&lt;span&gt;96.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ededed;border-top:2px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ededed;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ededed;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"&gt;&lt;span&gt;702.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ededed;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Customer relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"&gt;&lt;span&gt;28.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ededed;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ededed;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"&gt;&lt;span&gt;23.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ededed;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"&gt;&lt;span&gt;4.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ededed;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contract development and manufacturing&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"&gt;&lt;span&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ededed;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ededed;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"&gt;&lt;span&gt;4.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ededed;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"&gt;&lt;span&gt;1.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#ededed;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;&#160;&#160;&#160;Total intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ededed;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ededed;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"&gt;&lt;span&gt;822.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ededed;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ededed;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ededed;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"&gt;&lt;span&gt;10.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ededed;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ededed;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ededed;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"&gt;&lt;span&gt;124.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ededed;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ededed;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ededed;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"&gt;&lt;span&gt;708.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ededed;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:43%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;(in millions)&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Estimated Life&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Accumulated Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Products&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9-22 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;788.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;82.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;705.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Customer relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;28.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;23.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contract development and manufacturing&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;&#160;&#160;&#160;Total intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;822.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;109.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;712.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2020Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d17808642e785-wk-Fact-36C9590F29070154342C50AC63A9C422"
      unitRef="usd">788000000.0</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="FD2020Q1YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d17808642e799-wk-Fact-0E96CC0D766AAC2738D379EAF5925F4A"
      unitRef="usd">10000000.0</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2020Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d17808642e813-wk-Fact-8B53B38D19F00F8A42A179EAF57D9293"
      unitRef="usd">96000000.0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2020Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d17808642e828-wk-Fact-5B8E5447046B50A8018C79EAF57916A2"
      unitRef="usd">702000000.0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="FD2020Q1YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember"
      id="d17808642e843-wk-Fact-36EF03DA5E9225B8FB4A50AC639B00E3">P8Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2020Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember"
      decimals="-5"
      id="d17808642e853-wk-Fact-D745B685D5307788E0C650AC63CF39F6"
      unitRef="usd">28600000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2020Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember"
      decimals="-5"
      id="d17808642e881-wk-Fact-F18D11E6A3CC33122EF779EAF570145B"
      unitRef="usd">23800000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2020Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember"
      decimals="-5"
      id="d17808642e896-wk-Fact-7E433BF71C4E95601CB179EAF5815BCD"
      unitRef="usd">4800000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="FD2020Q1YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ebs_ContractManufacturingMember"
      id="d17808642e916-wk-Fact-F0F63A1B976F7DDFD61250AC63A510E2">P8Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2020Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ebs_ContractManufacturingMember"
      decimals="-5"
      id="d17808642e926-wk-Fact-B4421EAFAE32CD50B53050AC63A806A2"
      unitRef="usd">5500000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2020Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ebs_ContractManufacturingMember"
      decimals="-5"
      id="d17808642e954-wk-Fact-591542D989A32E9AB63679EAF56818DB"
      unitRef="usd">4200000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2020Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ebs_ContractManufacturingMember"
      decimals="-5"
      id="d17808642e969-wk-Fact-C897C42DCD82C12D57E579EAF597BE4C"
      unitRef="usd">1300000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17808642e1004-wk-Fact-B14E76E52D795D865E4E50AC63C2500D"
      unitRef="usd">822100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17808642e1018-wk-Fact-DF0E47FD6ADFFDD935F279EAF56DFF8C"
      unitRef="usd">10000000.0</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17808642e1032-wk-Fact-3B3E23D20D069491370679EAF575E3CE"
      unitRef="usd">124000000.0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17808642e1047-wk-Fact-CDEA88DDC95DCF2AE6A679EAF55DCE3A"
      unitRef="usd">708100000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d17808642e1222-wk-Fact-C816DFD13FF187EAD27350AC639B6821"
      unitRef="usd">788000000.0</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d17808642e1236-wk-Fact-2B75A1D3DDFB9991F63250AC63D37501"
      unitRef="usd">82200000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d17808642e1250-wk-Fact-775D6009C0C6B9D7783A50AC63D871E6"
      unitRef="usd">705800000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="FD2019Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember"
      id="d17808642e1266-wk-Fact-F4C912DAA2326785CB7350AC639BC0B8">P8Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember"
      decimals="-5"
      id="d17808642e1276-wk-Fact-9E0B09D1255E64FE262050AC63B448D6"
      unitRef="usd">28600000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember"
      decimals="-5"
      id="d17808642e1290-wk-Fact-6AF214D5E14C156B257150AC63C2770C"
      unitRef="usd">23000000.0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember"
      decimals="-5"
      id="d17808642e1309-wk-Fact-FEEF896011F0C19A36BE50AC63D3E54A"
      unitRef="usd">5600000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="FD2019Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ebs_ContractManufacturingMember"
      id="d17808642e1325-wk-Fact-6FC82488CF8A2E03D00150AC63CF99EF">P8Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ebs_ContractManufacturingMember"
      decimals="-5"
      id="d17808642e1335-wk-Fact-A1BBA71C4EF9D74A0CD150AC63BB3188"
      unitRef="usd">5500000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ebs_ContractManufacturingMember"
      decimals="-5"
      id="d17808642e1349-wk-Fact-4CDB900EBB638C1CE87E50AC63A376BB"
      unitRef="usd">4000000.0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ebs_ContractManufacturingMember"
      decimals="-5"
      id="d17808642e1368-wk-Fact-2CE4EDEF8AC86507F5FB50AC639B54B3"
      unitRef="usd">1500000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17808642e1399-wk-Fact-A3265C341A80D9326B9750AC63BB80DB"
      unitRef="usd">822100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17808642e1413-wk-Fact-0BEC1D62904B20F63A4050AC63B4DA1E"
      unitRef="usd">109200000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17808642e1427-wk-Fact-0003C74888027F58C28D50AC63D2FA1A"
      unitRef="usd">712900000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="FD2020Q1YTD_us-gaap_BusinessAcquisitionAxis_ebs_RaxibacumabMember"
      decimals="-5"
      id="d17808642e1445-wk-Fact-E6045948A32349B227F39E6ED8CFD926"
      unitRef="usd">10000000.0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17808642e1466-wk-Fact-20A4A30F776CD2C76C8050AC63AE3F61"
      unitRef="usd">14800000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17808642e1470-wk-Fact-BCD7D8B56A51DBB9F81E50AC63C5640D"
      unitRef="usd">14500000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="FD2020Q1YTD"
      id="d17808642e1479-wk-Fact-A07D313F8ABC2C8A3B8C50AC63CD96A5">P13Y3M18D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:Goodwill
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17808642e1492-wk-Fact-F9685A10CF0BB5F123BD9E6E56E0368A"
      unitRef="usd">266400000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17808642e1496-wk-Fact-4537F01ABBB58F8704CB9E6E57053B1F"
      unitRef="usd">266600000</us-gaap:Goodwill>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-921F791BE5207262715350AC63F3A0A9-0-wk-Fact-C951550142015FE5B17050AC63B28878">Contingent consideration&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;Contingent consideration liabilities associated with business combinations are fair value measurement items. These liabilities represent an obligation of the Company to transfer additional assets to the selling shareholders and owners if future events occur or conditions are met. These liabilities associated with business combinations are measured at fair value at inception and at each subsequent reporting date. The changes in the fair value are primarily due to the expected amount and timing of future net sales, which are inputs that have no observable market (Level 3). &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;The following table is a reconciliation of the beginning and ending balance of contingent considerations and is based on level 3 significant unobservable inputs. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:82%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;"&gt;Balance at December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;29.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Change in fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Settlements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;(0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;"&gt;Balance at March&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;29.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;The recurring Level 3 fair value measurements the Company's contingent consideration liability include the following significant unobservable inputs: &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Contingent Consideration Liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Fair Value as of March 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Valuation Technique&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Unobservable Input&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Range&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Weighted Average &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenue milestone and royalty based&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="3" style="vertical-align:middle;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;$29.1 million&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Discounted cash flow&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Discount rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.5% - 8.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.3%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Probability of payment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10.0% - 40.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;20.9%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Projected year of payment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2020 - 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-0CE743F93AE8E8D9864E50AC63F3A7AA-0-wk-Fact-1832F6C861CC9745C9B950AC63AF5197">&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;The following table is a reconciliation of the beginning and ending balance of contingent considerations and is based on level 3 significant unobservable inputs. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:82%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;"&gt;Balance at December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;29.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Change in fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Settlements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;(0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;"&gt;Balance at March&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;29.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17809027e627-wk-Fact-80A163A46A9DA636DA7850AC63D05493"
      unitRef="usd">29200000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <ebs:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17809027e642-wk-Fact-7CCC53B493852DD12C3450AC63D2A9E1"
      unitRef="usd">600000</ebs:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17809027e662-wk-Fact-4BC29C5E69D6EB3FBB9850AC63D6FCFA"
      unitRef="usd">700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17809027e688-wk-Fact-B6DD2ABD01E91975F17450AC63CFB353"
      unitRef="usd">29100000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-978BE19EDB8D9A08D318BEB4161E5BB0-0-wk-Fact-89654CF6B360AE1E2C95BEB5236F4B19">&lt;div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;The recurring Level 3 fair value measurements the Company's contingent consideration liability include the following significant unobservable inputs: &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Contingent Consideration Liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Fair Value as of March 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Valuation Technique&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Unobservable Input&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Range&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Weighted Average &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenue milestone and royalty based&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="3" style="vertical-align:middle;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;$29.1 million&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Discounted cash flow&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Discount rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.5% - 8.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.3%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Probability of payment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10.0% - 40.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;20.9%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Projected year of payment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2020 - 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueDiscountedCashFlowMember"
      decimals="-5"
      id="d17809027e755-wk-Fact-915F481F91904C5D032EB7FC4F749A15"
      unitRef="usd">29100000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="FI2020Q1_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueDiscountedCashFlowMember"
      decimals="3"
      id="d17809027e775-wk-Fact-36C5A15C332CBCAA6870B8028149D1CF"
      unitRef="number">0.043</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="FI2020Q1_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MeasurementInputTypeAxis_ebs_MeasurementInputProbabilityofPaymentMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueDiscountedCashFlowMember"
      decimals="3"
      id="d17809027e806-wk-Fact-E504EC77D17715E9D5E0B8028158BD7A"
      unitRef="number">0.209</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-1546BBF1977DE3D5DE9E50AC63F38885-0-wk-Fact-97B0473CC686F4FAD1B650AC63D0CAEA">Derivative instruments and hedging activities&lt;div style="line-height:120%;padding-bottom:12px;padding-left:24px;text-indent:-24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;"&gt;Risk management objective of using derivatives&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;The Company is exposed to certain risk arising from both its business operations and economic conditions. The Company principally manages its exposures to a wide variety of business and operational risks through management of its core business activities. The Company manages economic risks, including interest rate, liquidity, and credit risk primarily by managing the amount, sources, and duration of its assets and liabilities and the use of derivative financial instruments. Specifically, the Company has entered into interest rate swaps to manage exposures that arise from the Company's senior secured credit agreement's payments of variable interest rate debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-left:24px;text-indent:-24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;"&gt;Accounting policy for derivative instruments and hedging activities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;The Company entered into interest rate swaps in June 2019. The Company's interest rate swaps qualify for hedge accounting as cash flow hedges. All derivatives are recorded on the balance sheet at fair value.&#160;Hedge accounting provides for the matching of the timing of gain or loss recognition on these interest rate swaps with the recognition of the changes in interest expense on the Company's variable rate debt. For derivatives designated as cash flow hedges of interest rate risk, the gain or loss on the derivative is recorded in accumulated other comprehensive income and subsequently reclassified into interest expense in the same period during which the hedged transaction affects earnings. Amounts reported in accumulated other comprehensive income related to derivatives will be reclassified to interest &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;expense as interest payments are made on the Company&#x2019;s variable-rate debt. The cash flows from the designated interest rate swaps are classified as a component of operating cash flows, similar to interest expense.&#160;If current fair values of designated interest rate swaps&#160;re&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;mained static over the next&#160;twelve&#160;months, the Company would reclassify&#160;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;&lt;span&gt;$5.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;&#160;of net deferred losses from&#160;accumulated other comprehensive loss&#160;to the statement of operations over the next&#160;twelve&#160;month period. All outstanding cash flow hedges mature in October 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;, the Company had the following outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk: &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:61%;"/&gt;&lt;td style="width:19%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Number of Instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Notional&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest rate swaps&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;350.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;The table below presents the fair value of the Company&#x2019;s derivative financial instruments designated as hedges as well as their classification on the balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="18"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Asset Derivatives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Liability Derivatives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Balance Sheet Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Balance Sheet Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Balance Sheet Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Balance Sheet Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest Rate Swaps&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;Other Current Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other Current Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;Other Current Liabilities &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;4.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other Current Liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;Other Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;Other Liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;11.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other Liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;The valuation of the interest rate swaps is determined using widely accepted valuation techniques, including discounted cash flow analysis on the expected cash flows of each interest rate swap. This analysis reflects the contractual terms of the interest rate swaps, including the period to maturity, and uses observable market-based inputs, including interest rate curves and implied volatilities. The fair values of interest rate swaps are determined using the market standard methodology of netting the discounted future fixed cash payments (or receipts) and the discounted expected variable cash receipts (or payments). The variable cash payments (or receipts) are based on an expectation of future interest rates (forward curves) derived from observable market interest rate curves. To comply with the provisions of ASC 820, Fair Value Measurement, we incorporate credit valuation adjustments in the fair value measurements to appropriately reflect both our own nonperformance risk and the respective counterparty&#x2019;s nonperformance risk. These credit valuation adjustments were concluded to not be significant inputs for the fair value calculations for the periods presented. In adjusting the fair value of our derivative contracts for the effect of nonperformance risk, we have considered the impact of netting and any applicable credit enhancements, such as the posting of collateral, thresholds, mutual puts and guarantees. The valuation of interest rate swaps fall into Level 2 in the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt; The table below presents the effect of cash flow hedge accounting on accumulated other comprehensive income.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="15"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:32%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:23%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="2" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Hedging derivatives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Cumulative Amount of Gain/(Loss) Recognized in OCI on Derivative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="2" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Location of Gain or (Loss) Reclassified from Accumulated OCI into Income &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Amount of Gain/(Loss) Reclassified from Accumulated OCI into Income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Three months ended March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest Rate Swaps&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;(16.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths
      contextRef="FD2020Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember"
      decimals="-5"
      id="d17810139e587-wk-Fact-8F6C0BDCA4D514F2C1F650AC63D3D1F3"
      unitRef="usd">5000000.0</us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths>
    <us-gaap:ScheduleOfDerivativeInstrumentsTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-F14FB17FB63549E0C71150AC63F3BCCE-0-wk-Fact-11DC88E0ECE24805BC9850AC63CE7769">&lt;div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;, the Company had the following outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk: &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:61%;"/&gt;&lt;td style="width:19%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Number of Instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Notional&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest rate swaps&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;350.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsTextBlock>
    <us-gaap:NumberOfInterestRateDerivativesHeld
      contextRef="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="INF"
      id="d17810139e653-wk-Fact-62569FB6033E64FC40EB50AC63AA54AE"
      unitRef="instrument">7</us-gaap:NumberOfInterestRateDerivativesHeld>
    <ebs:DerivativeNotionalAmount1
      contextRef="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="INF"
      id="d17810139e668-wk-Fact-307065E3EB369D30581A50AC63AD2129"
      unitRef="usd">350000000.0</ebs:DerivativeNotionalAmount1>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-05F838EF9AA27860505450AC63F3C48C-0-wk-Fact-3F4CF8F35375703CEB0F50AC63D2B71C">&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;The table below presents the fair value of the Company&#x2019;s derivative financial instruments designated as hedges as well as their classification on the balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="18"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Asset Derivatives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Liability Derivatives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Balance Sheet Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Balance Sheet Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Balance Sheet Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Balance Sheet Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest Rate Swaps&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;Other Current Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other Current Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;Other Current Liabilities &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;4.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other Current Liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;Other Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;Other Liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;11.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other Liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d17810139e1003-wk-Fact-0C614DAF7903E264A50E50AC63BBBA6C"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d17810139e1022-wk-Fact-81535FF0AE52A5ED3C0650AC63BB1401"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d17810139e1042-wk-Fact-218EFC9D09A094D2512650AC63BB9C1C"
      unitRef="usd">4800000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d17810139e1066-wk-Fact-453E7082B4615A2F3A999E771F45C181"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d17810139e1091-wk-Fact-B85ACD00501E1A46D4B69E77785BC5F6"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d17810139e1110-wk-Fact-1C3CC075FBEC951196B79E7780CC38CE"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d17810139e1130-wk-Fact-FE62A6A0E35D50E1C11B9E7789F7E6D7"
      unitRef="usd">11200000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d17810139e1154-wk-Fact-3A6359E6546F2C48391A50AC63BB96C2"
      unitRef="usd">2000000.0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-FA5CF837AAD03124170650AC63F3A957-0-wk-Fact-A256EAFD8C0B9A64447C50AC63D13D67">The table below presents the effect of cash flow hedge accounting on accumulated other comprehensive income.&lt;div style="line-height:120%;padding-bottom:12px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="15"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:32%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:23%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="2" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Hedging derivatives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Cumulative Amount of Gain/(Loss) Recognized in OCI on Derivative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="2" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Location of Gain or (Loss) Reclassified from Accumulated OCI into Income &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Amount of Gain/(Loss) Reclassified from Accumulated OCI into Income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Three months ended March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest Rate Swaps&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;(16.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax
      contextRef="FD2020Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember"
      decimals="-5"
      id="d17810139e1437-wk-Fact-F5994A5369014879B6A850AC63A77C82"
      unitRef="usd">-16000000.0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax
      contextRef="FD2019Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember"
      decimals="-5"
      id="d17810139e1452-wk-Fact-48C48B58498F43869E1E50AC63A809D2"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="FD2020Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_InterestExpenseMember"
      decimals="-5"
      id="d17810139e1476-wk-Fact-C9A43DC2B370047B4DB150AC63AE2650"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="FD2019Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_InterestExpenseMember"
      decimals="-5"
      id="d17810139e1491-wk-Fact-8AB5B04CCCE4C903B56150AC63A1392B"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-CB78BC4A13F7DC05894350AC63F32806-0-wk-Fact-B4CFFE235F9BC3D32AC250AC63BAA09C">Debt&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;The components of debt are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:21%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:21%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Senior secured credit agreement - Term loan due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;433.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;435.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Senior secured credit agreement - Revolver loan due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;353.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;373.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.875% Convertible Senior Notes due 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;10.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;3.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;799.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;822.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current portion of long-term debt, net of debt issuance costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;(26.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(12.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;(10.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(11.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current portion of debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;762.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;798.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:24px;font-size:11pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:11pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:24px;text-indent:-24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;"&gt;Senior secured credit agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;In October 2018, the Company entered into a senior secured credit agreement with multiple lending institutions (the "Credit Agreement"). The terms of the credit agreement include (i) a revolving credit facility (the "Revolving Credit Facility") of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;&lt;span&gt;$600 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt; with a maturity date of October 13, 2023, and (ii) a term loan with a principal amount of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;&lt;span&gt;$450 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt; (the "Term Loan Facility," and together with the Revolving Credit Facility, the "Senior Secured Credit Facilities"). The Company may request incremental term loan facilities or increases in the Revolving Credit Facility (each an "Incremental Loan") as long as requirements relating to net leverage ratio will be maintained on a pro forma basis.  &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;Borrowings under the Revolving Credit Facility and the Term Loan Facility will bear interest at a rate per annum equal to (a) a eurocurrency rate plus a margin ranging from &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;&lt;span&gt;1.25%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt; to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;&lt;span&gt;2.00%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt; per annum, depending on the Company's consolidated net leverage ratio or (b) a base rate (which is the highest of the prime rate, the federal funds rate plus &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;&lt;span&gt;0.50%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;, and a eurocurrency rate for an interest period of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;one month&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt; plus &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;&lt;span&gt;1%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt; plus a margin ranging from &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;&lt;span&gt;0.25%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt; to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;&lt;span&gt;1.00%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;, depending on the Company's consolidated net leverage ratio. The Company is required to make quarterly payments under the Credit Agreement for accrued and unpaid interest on the outstanding principal balance, based on the above interest rates. In addition, the Company is required to pay commitment fees ranging from &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;&lt;span&gt;0.15%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt; to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;&lt;span&gt;0.30%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt; per annum, depending on the Company's consolidated net leverage ratio, in respect of the average daily unused commitments under the Revolving Credit Facility. The Company is to repay the outstanding principal amount of the Term Loan Facility in quarterly installments based on an annual percentage equal to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;&lt;span&gt;2.5%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt; of the original principal amount of the Term Loan Facility during each of the first two years of the Term Loan Facility, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;&lt;span&gt;5%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt; of the original principal amount of the Term Loan Facility during the third year of the Term Loan Facility and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;&lt;span&gt;7.5%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt; of the original principal amount of the Term Loan Facility during each year of the remainder of the term of the Term Loan Facility until the maturity date of the Term Loan Facility, at which time the entire unpaid principal balance of the Term Loan Facility will be due and payable. The Company has the right to prepay the Term Loan Facility without premium or penalty. The Revolving Credit Facility and the Term Loan Facility mature (unless earlier terminated) on &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;October&#160;13, 2023&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;The Credit Agreement also requires mandatory prepayments of the Term Loan Facility in the event the Company or its Subsidiaries (a) incur indebtedness not otherwise permitted under the Credit Agreement or (b) receive cash proceeds in excess of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;&lt;span&gt;$100 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt; during the term of the Credit Agreement from certain dispositions of property or from casualty events involving their property, subject to certain reinvestment rights.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;The financial covenants under the Credit Agreement currently require the quarterly presentation of a minimum consolidated 12-month rolling debt service coverage ratio of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;&lt;span&gt;2.50&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt; to 1.00, and a maximum consolidated net leverage ratio of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;&lt;span&gt;3.75&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt; to 1.00 for the quarterly filing periods from October&#160;1, 2019 through September&#160;29, 2020 and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;&lt;span&gt;3.50&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt; to 1.0, thereafter, which may be adjusted to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;&lt;span&gt;4.00&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt; to 1.00 for a four quarter period in connection with a material permitted acquisition. Negative covenants in the Credit Agreement, among other things, limit the ability of the Company to incur indebtedness and liens, dispose of assets, make investments, enter into certain merger or consolidation transactions and make restricted payments. As of the date of these financial statements, the Company is in compliance with all affirmative and negative covenants.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:24px;text-indent:-24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;"&gt;&lt;span&gt;2.875%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;"&gt; Convertible senior notes due 2021&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;On &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;January&#160;29, 2014&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;, the Company issued &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;&lt;span&gt;2.875%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt; convertible senior notes due &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;2021&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt; (the "Notes"). The Notes bear interest at a rate of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;&lt;span&gt;2.875%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt; per year, payable semi-annually in arrears on &lt;/span&gt;&lt;span style="color:#000000;font-family:Franklin Gothic Book,sans-serif;font-weight:normal;"&gt;January 15&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:Franklin Gothic Book,sans-serif;font-weight:normal;"&gt;July 15&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt; of each year. The Notes mature on &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;January&#160;15, 2021&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-23EEF1BB71CA99E2EDE650AC63F324DA-0-wk-Fact-7B6B75C1DACBFDAA2A8150AC63BA8FA7">&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;The components of debt are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:21%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:21%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Senior secured credit agreement - Term loan due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;433.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;435.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Senior secured credit agreement - Revolver loan due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;353.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;373.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.875% Convertible Senior Notes due 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;10.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;3.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;799.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;822.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current portion of long-term debt, net of debt issuance costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;(26.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(12.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;(10.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(11.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current portion of debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;762.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;798.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:LongTermDebt
      contextRef="FI2020Q1_us-gaap_CreditFacilityAxis_ebs_TermLoanFacilityMember"
      decimals="-5"
      id="d17810719e644-wk-Fact-5912A89482277888C8BC50AC63D460B0"
      unitRef="usd">433100000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="FI2019Q4_us-gaap_CreditFacilityAxis_ebs_TermLoanFacilityMember"
      decimals="-5"
      id="d17810719e663-wk-Fact-1107387FB4C7ED1C455950AC63D467EC"
      unitRef="usd">435900000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="FI2020Q1_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember"
      decimals="-5"
      id="d17810719e678-wk-Fact-DA178281F2D0D4209BAA50AC63D3A74F"
      unitRef="usd">353000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="FI2019Q4_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember"
      decimals="-5"
      id="d17810719e697-wk-Fact-4B5BB9AC92A701600B3650AC63D55EC0"
      unitRef="usd">373000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="FI2020Q1_us-gaap_DebtInstrumentAxis_ebs_ConvertibleSeniorNotesDue2021Member"
      decimals="-5"
      id="d17810719e717-wk-Fact-71C7D35E4932DC6BCEB350AC63D68F79"
      unitRef="usd">10600000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ebs_ConvertibleSeniorNotesDue2021Member"
      decimals="-5"
      id="d17810719e736-wk-Fact-95BA10BC61B0B2387ACE50AC63D21BD4"
      unitRef="usd">10600000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="FI2020Q1_us-gaap_DebtInstrumentAxis_ebs_OtherLongTermDebtFacilityMember"
      decimals="-5"
      id="d17810719e756-wk-Fact-AF6DA030B535C2F9DEFF50AC63D8000B"
      unitRef="usd">3000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ebs_OtherLongTermDebtFacilityMember"
      decimals="-5"
      id="d17810719e775-wk-Fact-D18D0B8B2B4BB80F62D250AC63D53DBF"
      unitRef="usd">3000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17810719e795-wk-Fact-DC952A83F128CB61556B50AC63D0E0E6"
      unitRef="usd">799700000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17810719e814-wk-Fact-CB38FA676D3DB1E6166550AC63D39BCD"
      unitRef="usd">822500000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17810719e834-wk-Fact-F3A5DC4CD600BAC73D4750AC63D5E58E"
      unitRef="usd">26300000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17810719e854-wk-Fact-7483437E94B0458F855C50AC63D59F31"
      unitRef="usd">12900000</us-gaap:LongTermDebtCurrent>
    <us-gaap:DeferredFinanceCostsNoncurrentNet
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17810719e875-wk-Fact-DBB6BB16D4F19C6DA67450AC63D79F3C"
      unitRef="usd">10500000</us-gaap:DeferredFinanceCostsNoncurrentNet>
    <us-gaap:DeferredFinanceCostsNoncurrentNet
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17810719e895-wk-Fact-289325CD3BAC1EE0BDF150AC63D59787"
      unitRef="usd">11200000</us-gaap:DeferredFinanceCostsNoncurrentNet>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17810719e921-wk-Fact-71761EF4F2817FB54EF079E14164F9D7"
      unitRef="usd">762900000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17810719e940-wk-Fact-64FB9723C0B0F0E7FB3A50AC639B2838"
      unitRef="usd">798400000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity
      contextRef="I2018Q4Oct31_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_DebtInstrumentAxis_ebs_CreditAgreementMember"
      decimals="INF"
      id="d17810719e959-wk-Fact-50746D18D2B78C63A2DC9E7D72FCB41B"
      unitRef="usd">600000000</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity
      contextRef="I2018Q4Oct31_us-gaap_CreditFacilityAxis_ebs_TermLoanFacilityMember_us-gaap_DebtInstrumentAxis_ebs_CreditAgreementMember"
      decimals="INF"
      id="d17810719e963-wk-Fact-2F476AE96F1BC3B0CF5C9E7D73137444"
      unitRef="usd">450000000</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="D2018Q4Oct15-Oct15_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_EurodollarMember"
      decimals="INF"
      id="d17810719e972-wk-Fact-B1A80DA1D8F5FB012B8B50AC63AF5B88"
      unitRef="number">0.0125</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="D2018Q4Oct15-Oct15_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_EurodollarMember"
      decimals="INF"
      id="d17810719e976-wk-Fact-878D5849BAB352173FFE50AC63C58FC1"
      unitRef="number">0.0200</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="D2018Q4Oct15-Oct15_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_FederalFundsEffectiveSwapRateMember"
      decimals="INF"
      id="d17810719e980-wk-Fact-A418242498E2814D5FFA50AC63B06811"
      unitRef="number">0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="D2018Q4Oct15-Oct15_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_EurodollarMember"
      decimals="INF"
      id="d17810719e988-wk-Fact-CD0508352A7FAC75A1A150AC63B22FA3"
      unitRef="number">0.01</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="D2018Q4Oct15-Oct15_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_BaseRateMember"
      decimals="INF"
      id="d17810719e993-wk-Fact-896F0DAEABA13A14AD1950AC63A9AF1D"
      unitRef="number">0.0025</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="D2018Q4Oct15-Oct15_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_BaseRateMember"
      decimals="INF"
      id="d17810719e997-wk-Fact-228202233B737C2A39B450AC63C346A1"
      unitRef="number">0.0100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="D2018Q4Oct15-Oct15_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember"
      decimals="INF"
      id="d17810719e1001-wk-Fact-CBAEA79B790E3AD038DA50AC63B3CA1F"
      unitRef="number">0.0015</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="D2018Q4Oct15-Oct15_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember"
      decimals="INF"
      id="d17810719e1005-wk-Fact-63691A5BF31915F9DC5D50AC63B0CF2F"
      unitRef="number">0.0030</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <ebs:PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears
      contextRef="D2018Q4Oct15-Oct15_us-gaap_CreditFacilityAxis_ebs_TermLoanFacilityMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember"
      decimals="INF"
      id="d17810719e1009-wk-Fact-3C4436228CA8E397623050AC63B52670"
      unitRef="number">0.025</ebs:PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears>
    <ebs:PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear
      contextRef="D2018Q4Oct15-Oct15_us-gaap_CreditFacilityAxis_ebs_TermLoanFacilityMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember"
      decimals="INF"
      id="d17810719e1013-wk-Fact-B8D1E50E35A3C0559D3A50AC63B44CC5"
      unitRef="number">0.05</ebs:PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear>
    <ebs:PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears
      contextRef="D2018Q4Oct15-Oct15_us-gaap_CreditFacilityAxis_ebs_TermLoanFacilityMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember"
      decimals="INF"
      id="d17810719e1018-wk-Fact-77E137CB099E0D4C65FE50AC63BB5176"
      unitRef="number">0.075</ebs:PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears>
    <ebs:CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight
      contextRef="D2018Q4Oct15-Oct15_us-gaap_CreditFacilityAxis_ebs_TermLoanFacilityMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember"
      decimals="INF"
      id="d17810719e1031-wk-Fact-E39DC5B95C2CE85BF13A50AC63BB99AD"
      unitRef="usd">100000000</ebs:CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight>
    <ebs:DebtInstrumentCovenantDebtServiceCoverageRatio
      contextRef="FD2020Q1YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_DebtInstrumentAxis_ebs_CreditAgreementMember"
      decimals="INF"
      id="d17810719e1041-wk-Fact-29ADE7BCD4B7A915FD159E95B7A3F9E9"
      unitRef="number">2.50</ebs:DebtInstrumentCovenantDebtServiceCoverageRatio>
    <ebs:DebtInstrumentCovenantNetLeverageRatioOne
      contextRef="FD2020Q1YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_DebtInstrumentAxis_ebs_CreditAgreementMember"
      decimals="INF"
      id="d17810719e1045-wk-Fact-99F61511D402C6FE82B89E9C4A3F4D9E"
      unitRef="number">3.75</ebs:DebtInstrumentCovenantNetLeverageRatioOne>
    <ebs:DebtInstrumentCovenantNetLeverageRatioTwo
      contextRef="FD2020Q1YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_DebtInstrumentAxis_ebs_CreditAgreementMember"
      decimals="INF"
      id="d17810719e1049-wk-Fact-028CAEC85C3F221400FD9E9E055AA24E"
      unitRef="number">3.50</ebs:DebtInstrumentCovenantNetLeverageRatioTwo>
    <ebs:DebtInstrumentCovenantNetLeverageRatioThree
      contextRef="FD2020Q1YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_DebtInstrumentAxis_ebs_CreditAgreementMember"
      decimals="INF"
      id="d17810719e1053-wk-Fact-55A77288C06E069BE0299E9EC93B07AD"
      unitRef="number">4.00</ebs:DebtInstrumentCovenantNetLeverageRatioThree>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="I2014Q1Jan29_us-gaap_DebtInstrumentAxis_ebs_ConvertibleSeniorNotesDue2021Member"
      decimals="INF"
      id="d17810719e1060-wk-Fact-1042AA2FA58C9790C9A650AC63BB086A"
      unitRef="number">0.02875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="I2014Q1Jan29_us-gaap_DebtInstrumentAxis_ebs_ConvertibleSeniorNotesDue2021Member"
      decimals="INF"
      id="d17810719e1073-wk-Fact-1042AA2FA58C9790C9A650AC63BB086A"
      unitRef="number">0.02875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="I2014Q1Jan29_us-gaap_DebtInstrumentAxis_ebs_ConvertibleSeniorNotesDue2021Member"
      decimals="INF"
      id="d17810719e1081-wk-Fact-1042AA2FA58C9790C9A650AC63BB086A"
      unitRef="number">0.02875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-99D291FDAE3D0D01DBB150AC63F48BDF-0-wk-Fact-72C8F716405B707F875850AC63A6567C">Revenue recognition&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;The Company operates as &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt; operating segment. Therefore, results of its operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. The Company's revenues disaggregated by the major sources were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:23%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Three Months Ended March 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Three Months Ended March 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;U.S.&lt;br/&gt;Government&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Non-U.S.&lt;br/&gt;Government&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;&#160;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;U.S.&lt;br/&gt;Government&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Non-U.S.&lt;br/&gt;Government&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;&#160;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product sales, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;63.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;84.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;148.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;73.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;79.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;153.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contract development and manufacturing services&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;21.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;21.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contracts and grants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;22.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;22.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;20.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;21.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;85.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;106.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;192.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;93.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;96.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;190.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;"&gt;Contract liabilities &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;When performance obligations are not transferred to a customer at the end of a reporting period, cash received associated with amounts allocated to those performance obligations is reflected as contract liabilities on the consolidated balance sheets and is deferred until control of these performance obligations is transferred to the customer. The following table presents the rollforward of the contract liability balances: &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:82%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;&lt;span&gt;88.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Deferral of revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;6.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenue recognized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;(5.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;font-weight:bold;"&gt;&lt;span&gt;89.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;"&gt;Transaction price allocated to remaining performance obligations&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;, the Company expects future revenues of approximately $&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;&lt;span&gt;555.9&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt; million associated with performance obligations that have not been satisfied. The Company expects to recognize a majority of these revenues within the next &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;&lt;span&gt;24&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt; months, with the remainder recognized thereafter. However, the amount and timing of revenue recognition for unsatisfied performance obligations can materially change due to timing of funding appropriations from the USG and the overall success of the Company's development activities associated with its PHT product candidates that are then receiving development funding support from the USG under development contracts. In addition, the amount of future revenues associated with unsatisfied performance obligations excludes the value associated with unexercised option periods in the Company's contracts. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;"&gt;Contract assets&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;The Company considers unbilled accounts receivables and deferred costs associated with revenue generating contracts, which are not included in inventory or property, plant and equipment, as contract assets. As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;, the Company had contract assets associated with deferred costs of $&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;&lt;span&gt;36.3&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt; million and $&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;&lt;span&gt;34.0&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt; million, respectively, which is reflected as a component of prepaid expenses and other current assets on the Company's consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;"&gt;Accounts receivable&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;Accounts receivable, including unbilled accounts receivable contract assets, consist of the following:&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Billed, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;119.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;227.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unbilled&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;43.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;43.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;162.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;270.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;, allowances for doubtful accounts were &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;&lt;span&gt;$0.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt; and de minimis, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="FD2020Q1YTD"
      decimals="INF"
      id="d17812012e573-wk-Fact-D886683251CE85E78A9A50AC63D47DF7"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-922B7CF6048D1330F90750AC63F45D4C-0-wk-Fact-62D8960ED38210AE73BD50AC63DD289E">The Company's revenues disaggregated by the major sources were as follows:&lt;div style="line-height:120%;padding-bottom:12px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:23%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Three Months Ended March 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Three Months Ended March 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;U.S.&lt;br/&gt;Government&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Non-U.S.&lt;br/&gt;Government&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;&#160;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;U.S.&lt;br/&gt;Government&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Non-U.S.&lt;br/&gt;Government&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;&#160;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product sales, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;63.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;84.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;148.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;73.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;79.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;153.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contract development and manufacturing services&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;21.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;21.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contracts and grants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;22.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;22.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;20.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;21.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;85.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;106.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;192.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;93.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;96.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;190.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d17812012e872-wk-Fact-2A93D1427337E33F1B6050AC63DB9F11"
      unitRef="usd">63900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d17812012e891-wk-Fact-1EE7DFA9170F861423F050AC63D42746"
      unitRef="usd">84300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d17812012e910-wk-Fact-15F576BF23B68ED3410550AC63B6D635"
      unitRef="usd">148200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d17812012e930-wk-Fact-C7031B5C198114569AF050AC63D93005"
      unitRef="usd">73300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d17812012e949-wk-Fact-92A0061DAA2D0330A1AB50AC63D5326C"
      unitRef="usd">79700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d17812012e969-wk-Fact-100EA167C32CD4E7BF7F50AC63C22D94"
      unitRef="usd">153000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d17812012e984-wk-Fact-F4349E3C85239E59E8A250AC63D7435B"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d17812012e1003-wk-Fact-769A3058C6CC8C9A649F50AC63D68A2A"
      unitRef="usd">21700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember"
      decimals="-5"
      id="d17812012e1022-wk-Fact-C945A823FC8AB77DBA5A50AC63C78AD8"
      unitRef="usd">21700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d17812012e1042-wk-Fact-28537BD2C023A388A37450AC63DBB7D3"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d17812012e1061-wk-Fact-E5ADF2BE4811BE814F1B50AC63D7E7EA"
      unitRef="usd">15900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember"
      decimals="-5"
      id="d17812012e1080-wk-Fact-86B8A67AE3A5069C980750AC63B51F29"
      unitRef="usd">15900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d17812012e1101-wk-Fact-F039F0D08AECABA0FA8150AC639BCA23"
      unitRef="usd">22000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d17812012e1120-wk-Fact-9566621BC3B9309DF83950AC63D722BF"
      unitRef="usd">600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember"
      decimals="-5"
      id="d17812012e1139-wk-Fact-3612644390F14B60C4B550AC63CA1285"
      unitRef="usd">22600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d17812012e1159-wk-Fact-929341516385840F8F8F50AC63DD8C5F"
      unitRef="usd">20400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d17812012e1178-wk-Fact-54AA0CDA9D852730D97450AC63D8DBDE"
      unitRef="usd">1300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember"
      decimals="-5"
      id="d17812012e1197-wk-Fact-8EAC98B280127C3147AA50AC63C5A1FF"
      unitRef="usd">21700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q1QTD_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d17812012e1223-wk-Fact-52DE0AEEB0FA0D4A73AA50AC63DC63D9"
      unitRef="usd">85900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q1QTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d17812012e1242-wk-Fact-786F364755748F812B4A50AC63D5E39F"
      unitRef="usd">106600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17812012e1261-wk-Fact-EE62D36AAC76E41DE0BE50AC63C826F6"
      unitRef="usd">192500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q1QTD_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d17812012e1281-wk-Fact-46F83D518EFEE9F25DD450AC63D7C496"
      unitRef="usd">93700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q1QTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d17812012e1300-wk-Fact-E06C4BDB953AACFA5A2050AC63D6FC74"
      unitRef="usd">96900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17812012e1320-wk-Fact-4783103E7C9579FDD76750AC63CB769E"
      unitRef="usd">190600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-01C8180CDD07E035067750AC63F45E5C-0-wk-Fact-DC3FA048B09E76E489F650AC63E28098">The following table presents the rollforward of the contract liability balances: &lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:82%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;&lt;span&gt;88.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Deferral of revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;6.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenue recognized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;(5.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;font-weight:bold;"&gt;&lt;span&gt;89.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17812012e1385-wk-Fact-D3C32C2B142F48414D5D50AC639BDA42"
      unitRef="usd">88900000</us-gaap:ContractWithCustomerLiability>
    <ebs:ContractWithCustomerLiabilityAdditions
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17812012e1400-wk-Fact-732738E8070B28506D9050AC639BF380"
      unitRef="usd">6400000</ebs:ContractWithCustomerLiabilityAdditions>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17812012e1420-wk-Fact-834C4BA8995E517FB93950AC63A6C2B3"
      unitRef="usd">5900000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17812012e1446-wk-Fact-93C997EAFBF67C12919D50AC63E3E7CE"
      unitRef="usd">89400000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17812012e1468-wk-Fact-3E73BA1550B73B2C3FBF50AC63A0FB58"
      unitRef="usd">555900000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="FI2020Q1_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2020-04-01"
      id="d17812012e1472-wk-Fact-CDF5120DAD5156EB949350AC63DDF1EC">P24M</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:DeferredCostsCurrent
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17812012e1492-wk-Fact-F47655CB25005B5ED86D50AC63E0A89C"
      unitRef="usd">36300000</us-gaap:DeferredCostsCurrent>
    <us-gaap:DeferredCostsCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17812012e1496-wk-Fact-879509E4A94B4F6CD9E050AC63A7AF0C"
      unitRef="usd">34000000.0</us-gaap:DeferredCostsCurrent>
    <ebs:ScheduleofAccountsReceivableNetTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-E45B9451E6D6C6BE981750AC63F49E02-0-wk-Fact-65ECEC1253F8FB2BE9AF50AC639A51E4">&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;Accounts receivable, including unbilled accounts receivable contract assets, consist of the following:&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Billed, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;119.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;227.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unbilled&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;43.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;43.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;162.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;270.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</ebs:ScheduleofAccountsReceivableNetTableTextBlock>
    <us-gaap:BilledContractReceivables
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17812012e1595-wk-Fact-E6453855F10A6EAADAA450AC63B5CFF1"
      unitRef="usd">119400000</us-gaap:BilledContractReceivables>
    <us-gaap:BilledContractReceivables
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17812012e1614-wk-Fact-9795B9FE625975243C8A50AC63B65C49"
      unitRef="usd">227300000</us-gaap:BilledContractReceivables>
    <us-gaap:UnbilledContractsReceivable
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17812012e1634-wk-Fact-E6A4AEF951DA651FEE0050AC63B6C764"
      unitRef="usd">43100000</us-gaap:UnbilledContractsReceivable>
    <us-gaap:UnbilledContractsReceivable
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17812012e1653-wk-Fact-6D73FC7678536E63D51850AC63C2848D"
      unitRef="usd">43400000</us-gaap:UnbilledContractsReceivable>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17812012e1683-wk-Fact-33FB468D40ED33E2CA7E50AC63CE721D"
      unitRef="usd">162500000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d17812012e1702-wk-Fact-BF3721EEB20B5C10A7E650AC63C709EB"
      unitRef="usd">270700000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="FI2020Q1"
      decimals="-5"
      id="d17812012e1723-wk-Fact-7A190FC9A634E8B263029EB23545D3C8"
      unitRef="usd">800000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-14155CAAEACBBB4231D250AC63F4BFCE-0-wk-Fact-9A96D2CB2BB3CB25595D50AC63A3E678">Income taxes &lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;On&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt; March&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt; 27, 2020, the President of the United States signed into law the Coronavirus Aid, Relief and Economic Security Act (the &#x201c;CARES Act&#x201d;). The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;credit&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt; refunds, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property. The Company is currently assessing the impact of the CARES Act, but we do not expect there to be a material impact to our consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;The estimated effective annual tax rate for the Company, which excludes discrete adjustments, was &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;&lt;span&gt;26%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;&lt;span&gt;27%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt; for the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;. &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;For the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;three months ended March 31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;, the Company recorded a discrete tax benefit of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;&lt;span&gt;$3.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt; and $&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;&lt;span&gt;1.8&lt;/span&gt;&lt;/span&gt; million, respectively, primarily due to activity associated with equity awards.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="FD2020Q1YTD"
      decimals="2"
      id="d17812107e584-wk-Fact-EC78297E612D9138B54350AC63A0790B"
      unitRef="number">0.26</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="FD2019Q1QTD"
      decimals="2"
      id="d17812107e588-wk-Fact-4351A20008D9B1C533E950AC63C48AD1"
      unitRef="number">0.27</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17812107e615-wk-Fact-CE29E8253C15A84470C850AC63A2E7C6"
      unitRef="usd">3200000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17812107e619-wk-Fact-0F418074BB2057CAC47A50AC63DC4159"
      unitRef="usd">1800000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-522A55D0E383DFBA2F0F50AC63F4D88B-0-wk-Fact-DF277C57F669222753D450AC63A43613">oss per share&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:24px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;The following table presents the calculation of basic and diluted net loss per share:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:63%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="2" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Numerator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;(12.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(26.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Denominator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted-average number of shares&#x2014;basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;52.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;51.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Dilutive securities&#x2014;equity awards&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted-average number of shares&#x2014;diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;52.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;51.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net loss per share - basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;(0.24&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.51&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net loss per share - diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;(0.24&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.51&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;Basic earnings (loss) per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted earnings (loss) per share is computed using the treasury method by dividing net loss by the weighted average number of shares of common stock outstanding during the period, adjusted for the potential dilutive effect of other securities if such securities were converted or exercised and are not anti-dilutive. &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"&gt;For the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;three months ended March 31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;, approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt; million and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;&lt;span&gt;3.1&lt;/span&gt;&lt;/span&gt; million stock options are not considered in the diluted net loss per share calculation because the exercise price of these options is greater than the average per share closing price during the three month period and their effect would be anti-dilutive.</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-417C8ABF4BDB3191B94150AC63F4078E-0-wk-Fact-C69B5F4D810A67B6A26F50AC639A9121">&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:24px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;The following table presents the calculation of basic and diluted net loss per share:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:63%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="2" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Numerator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;(12.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(26.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Denominator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted-average number of shares&#x2014;basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;52.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;51.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Dilutive securities&#x2014;equity awards&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted-average number of shares&#x2014;diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;52.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;51.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net loss per share - basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;(0.24&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.51&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net loss per share - diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;(0.24&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.51&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17812781e727-wk-Fact-2BE66961830A83F48E5050AC63AB2A6D"
      unitRef="usd">-12500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17812781e747-wk-Fact-68AB7F5A194EFA0424DB50AC63CA9408"
      unitRef="usd">-26000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17812781e845-wk-Fact-86AA0904084337CA20DD50AC63BB987B"
      unitRef="shares">52000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17812781e864-wk-Fact-E5106EB7EC5DD52FFE1750AC63AAA0C9"
      unitRef="shares">51200000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17812781e884-wk-Fact-0A00A9B05AB5AB9D115A50AC639B4F55"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17812781e903-wk-Fact-8D71A32FA17F83B1654250AC63A1FDB2"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17812781e923-wk-Fact-FE0D54A71F3B22F2C1A650AC63BB0266"
      unitRef="shares">52000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17812781e942-wk-Fact-025C9BBD3873347BD04350AC63AAE1F5"
      unitRef="shares">51200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2020Q1YTD"
      decimals="2"
      id="d17812781e1008-wk-Fact-92317C4056EAA9BE7F9C50AC63C0B75A"
      unitRef="usdPerShare">-0.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2019Q1QTD"
      decimals="2"
      id="d17812781e1028-wk-Fact-398962EC77284B56EAE350AC63CB3AD7"
      unitRef="usdPerShare">-0.51</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2020Q1YTD"
      decimals="2"
      id="d17812781e1050-wk-Fact-F4635BF4F58F1DABA08450AC63C76B0E"
      unitRef="usdPerShare">-0.24</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2019Q1QTD"
      decimals="2"
      id="d17812781e1070-wk-Fact-3F3AD90A570B8318774450AC63B12D21"
      unitRef="usdPerShare">-0.51</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d17812781e1094-wk-Fact-728594F63012A7BB858C50AC63DDB0E0"
      unitRef="shares">700000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d17812781e1098-wk-Fact-1D426725D1AA06B6D6E850AC63B66EC7"
      unitRef="shares">3100000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-D082AF06F0D24143945550AC63F4BA32-0-wk-Fact-B1C5473C851FE57ECBB950AC63A69D46">Share-based compensation&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;During the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;three months ended March 31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;, the Company granted stock options to purchase &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;&lt;span&gt;0.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt; shares of common stock and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;&lt;span&gt;0.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt; restricted and performance stock units under the Emergent BioSolutions Inc. Stock Incentive Plan. The stock option and restricted stock unit grants vest over &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;three&lt;/span&gt; equal annual installments beginning on the day prior to the anniversary of the grant date. The performance stock units settle in stock at the end of the three-year performance period based on the Company's results compared to the performance criteria.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="-5"
      id="d17812973e577-wk-Fact-A877B4DBC52134A5685650AC63AB1C97"
      unitRef="shares">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-5"
      id="d17812973e581-wk-Fact-FC2EDDF5201D7D3F7C5550AC63A8CC9D"
      unitRef="shares">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:LegalMattersAndContingenciesTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-C9C19D679C31075BC25350AC63F52EFA-0-wk-Fact-62DA777D0B5F6E19DFAA50AC63C92BA2">Commitments and contingencies &lt;div style="line-height:120%;padding-bottom:12px;padding-left:24px;text-indent:-24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;"&gt;ANDA Litigation - Perrigo 4mg&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;On September 14, 2018,  Adapt Pharma Inc.,  Adapt Pharma Operations Limited and Adapt Pharma Ltd. (collectively, "Adapt Pharma"), and Opiant Pharmaceuticals, Inc. ("Opiant"), received notice from Perrigo UK FINCO Limited Partnership ("Perrigo"), that Perrigo had filed an Abbreviated New Drug Application ("ANDA"), with the United States Food and Drug Administration seeking regulatory approval to market a generic version of NARCAN&#xae;(naloxone hydrochloride) Nasal Spray 4mg/spray before the expiration of U.S. Patent Nos. 9,211,253, (the "&#x2018;253 Patent"), 9,468,747 (the "&#x2018;747 Patent"), 9,561,177, (the "&#x2018;177 Patent"), 9,629,965, (the "&#x2018;965 Patent") and 9,775,838 (the "&#x2018;838 Patent"). On or about October 25, 2018, Perrigo sent a subsequent notice letter relating to U.S. Patent No. 10,085,937 (the "937 Patent"). Perrigo&#x2019;s notice letters assert that its generic product will not infringe any valid and enforceable claim of these patents.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;On October 25, 2018, Emergent BioSolutions&#x2019; Adapt Pharma subsidiaries and Opiant, (collectively, the "Plaintiffs"), filed a complaint for patent infringement of the &#x2018;253, &#x2018;747, &#x2018;177, &#x2018;965, and the &#x2018;838 Patents against Perrigo in the United States District Court for the District of New Jersey arising from Perrigo&#x2019;s ANDA filing with the FDA. Plaintiffs filed a second complaint against Perrigo on December 7, 2018, for the infringement of the &#x2018;937 Patent. On February 12, 2020, Adapt Pharma and Perrigo entered into a settlement agreement to resolve the ongoing litigation.  Under the terms of the settlement, Perrigo has received a non-exclusive license under Adapt Pharma's patents to make, have made and market its generic naloxone hydrochloride nasal spray under its own ANDA. Perrigo&#x2019;s license will be effective as of January 5, 2033 or earlier under certain circumstances including circumstances related to the outcome of the current litigation against Teva (as defined below) or litigation against future ANDA filers.  The Perrigo settlement agreement is subject to review by the U.S. Department of Justice and the Federal Trade Commission, and entry of an order dismissing the litigation by the U.S. District Court for the District of New Jersey.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:24px;text-indent:-24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;"&gt;ANDA Litigation - Teva 2mg&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;On or about February 27, 2018, Adapt Pharma Inc. and Adapt Pharma Operations Limited and Opiant received notice from Teva Pharmaceuticals Industries Ltd. and Teva Pharmaceuticals USA, Inc. (collectively "Teva"), that Teva had filed an ANDA with the FDA seeking regulatory approval to market a generic version of NARCAN&#xae; (naloxone hydrochloride) Nasal Spray 2 mg/spray before the expiration of U.S. Patent No. 9,480,644, (the "&#x2018;644 Patent"), and U.S. Patent No. 9,707,226, (the "'226 Patent"). Teva's notice letter asserts that the commercial manufacture, use or sale of its generic drug product described in its ANDA will not infringe the '644 Patent or the '226 Patent, or that the '644 Patent and '226 Patent are invalid or unenforceable. Adapt Pharma Inc. and Adapt Pharma Operations Limited and Opiant filed a complaint for patent infringement against Teva in the United States District Court for the District of New Jersey.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:24px;text-indent:-24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;"&gt;ANDA Litigation - Teva 4mg&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;On or about September 13, 2016, Adapt Pharma Inc. and Adapt Pharma Operations Limited and Opiant received notice from Teva that Teva had filed an ANDA with the FDA seeking regulatory approval to market a generic version of NARCAN&#xae; (naloxone hydrochloride) Nasal Spray 4 mg/spray before the expiration of U.S. Patent No. 9,211,253 (the "'253 Patent"). Adapt Pharma Inc. and Adapt Pharma Operations Limited and Opiant received additional notices from Teva relating to the '747, the '177, the '965, the '838, and the &#x2018;937 Patents. Teva's notice letters assert that the commercial manufacture, use or sale of its generic drug product described in its ANDA will not infringe the '253, the '747, the '177, the '965, the '838, or the &#x2018;937 Patent, or that the '253, the '747, the '177, the '965, the '838, and the &#x2018;937 Patents are invalid or unenforceable. Adapt Pharma Inc. and Adapt Pharma Operations Limited and Opiant filed a complaint for patent infringement against Teva in the United States District Court for the District of New Jersey with respect to the '253 Patent. Adapt Pharma Inc. and Adapt Pharma Operations Limited and Opiant also filed complaints for patent infringement against Teva in the United States District Court for the District of New Jersey with respect to the '747, the '177, the '965, and the '838 Patents. All five proceedings have been consolidated. As of the date of this filing, Adapt Pharma Inc., Adapt Pharma Operations Limited, and Opiant, have not filed a complaint related to the &#x2018;937 Patent. Closing arguments took place on February 26, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;In the complaints described in the paragraphs above, the Plaintiffs seek, among other relief, orders that the effective date of FDA approvals of the Teva ANDA products and the Perrigo ANDA product be a date not earlier than the expiration of the patents listed for each product, equitable relief enjoining Teva and Perrigo from making, using, offering to sell, selling, or importing the products that are the subject of Teva and Perrigo&#x2019;s respective ANDAs, until after the expiration of the patents listed for each product, and monetary relief or other relief as deemed just and proper by the court.&lt;/span&gt;&lt;/div&gt;Nalox-1 Pharmaceuticals, a non-practicing entity, filed petitions with the United States Patent and Trademark Office Patent Trial and Appeal Board (the "PTAB") requesting inter parties review ("IPR") of five of the six patents listed in the Orange Book related to NARCAN&#xae; Nasal Spray 4mg/spray. In a series of decisions, the PTAB agreed to institute a review of the '253 Patent, the '747 Patent and the '965 Patent but denied review of the '177 Patent and the '838 Patent. Nalox-1 did not request review of the '937 Patent.</us-gaap:LegalMattersAndContingenciesTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6791899360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingent consideration (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Unobservable Input Reconciliation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, beginning of period</a></td>
<td class="nump">$ 29.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue', window );">Change in fair value</a></td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Settlements</a></td>
<td class="num">(0.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, end of period</a></td>
<td class="nump">$ 29.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Change In Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6805645648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative instruments and hedging activities - Fair Value by Balance Sheet Location (Details) - Interest rate swaps - Designated as Hedging Instrument - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Other Current Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Asset Derivatives</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Asset Derivatives</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Other Current Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Liability Derivatives</a></td>
<td class="nump">4.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Other Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Liability Derivatives</a></td>
<td class="nump">$ 11.2<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118948506&amp;loc=SL51823488-111719<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118948506&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6787942064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue recognition - Contract Liabilities (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_ChangeinContractWithCustomerLiabilityRollForward', window );"><strong>Change in Contract With Customer, Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Beginning of period</a></td>
<td class="nump">$ 88.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_ContractWithCustomerLiabilityAdditions', window );">Deferral of revenue</a></td>
<td class="nump">6.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="num">(5.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">End of period</a></td>
<td class="nump">$ 89.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_ChangeinContractWithCustomerLiabilityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in Contract With Customer, Liability [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_ChangeinContractWithCustomerLiabilityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_ContractWithCustomerLiabilityAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable recorded during the current reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_ContractWithCustomerLiabilityAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6806613200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 15, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th">
<div>Oct. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jan. 29, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod', window );">Debt instrument, covenant, net leverage ratio rolling period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod', window );">Debt instrument, covenant, net leverage ratio adjustment period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="nump">0.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Eurocurrency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Eurocurrency | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Eurocurrency | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Federal Funds Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Base Rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Base Rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_ConvertibleSeniorNotesDue2021Member', window );">2.875% Convertible Senior Notes due 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.875%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Senior secured credit agreement - Revolver loan due 2023 | 2017 Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity', window );">Current borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Senior secured credit agreement - Revolver loan due 2023 | 2017 Credit Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio', window );">Debt covenant, consolidated debt service coverage ratio, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Senior secured credit agreement - Revolver loan due 2023 | 2017 Credit Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_DebtInstrumentCovenantNetLeverageRatioOne', window );">Debt instrument, covenant, net leverage ratio through June 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_DebtInstrumentCovenantNetLeverageRatioTwo', window );">Debt instrument, covenant, net leverage ratio to September 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_DebtInstrumentCovenantNetLeverageRatioThree', window );">Debt instrument, covenant, net leverage ratio from October 1, 2019 to September 29, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=ebs_TermLoanFacilityMember', window );">Senior secured credit agreement - Term loan due 2023 | 2017 Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity', window );">Current borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=ebs_TermLoanFacilityMember', window );">Senior secured credit agreement - Term loan due 2023 | Amended Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears', window );">Percentage of original principal amount required to repay in the first two years</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear', window );">Percentage of original principal amount required to repay during the third year</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears', window );">Percentage of original principal amount required to repay remaining year</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight', window );">Cash proceeds excess amount from dispositions of property or casualty events subject to certain reinvestment right</a></td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash proceeds in excess during the term of the Senior Secured Credit Facility from certain dispositions of property or from casualty events involving their property, subject to certain reinvestment rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Debt Service Coverage Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DebtInstrumentCovenantDebtServiceCoverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Net Leverage Ratio Adjustment Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DebtInstrumentCovenantNetLeverageRatioOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Net Leverage Ratio, One</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DebtInstrumentCovenantNetLeverageRatioOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Net Leverage Ratio Rolling Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DebtInstrumentCovenantNetLeverageRatioThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Net Leverage Ratio, Three</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DebtInstrumentCovenantNetLeverageRatioThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DebtInstrumentCovenantNetLeverageRatioTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Net Leverage Ratio, Two</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DebtInstrumentCovenantNetLeverageRatioTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The rate of interest that was being paid on the original debt issue that is to repay in the third year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The rate of interest that was being paid on the original debt issue that is to repay in the first two years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The rate of interest that was being paid on the original debt issue that is to repay in remaining years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_EurodollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ebs_ConvertibleSeniorNotesDue2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ebs_ConvertibleSeniorNotesDue2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ebs_CreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ebs_CreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=ebs_TermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=ebs_TermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6794000896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based compensation (Details)<br> shares in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2020 </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract', window );"><strong>Stock issued or granted during period [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock options granted (in shares)</a></td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract', window );"><strong>Stock issued or granted during period [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units granted (in shares)</a></td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Tranche One | Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract', window );"><strong>Stock issued or granted during period [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="nump">33.33%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Tranche One | Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract', window );"><strong>Stock issued or granted during period [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="nump">33.33%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Tranche Two | Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract', window );"><strong>Stock issued or granted during period [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="nump">33.33%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Tranche Two | Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract', window );"><strong>Stock issued or granted during period [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="nump">33.33%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember', window );">Tranche Three | Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract', window );"><strong>Stock issued or granted during period [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="nump">33.33%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember', window );">Tranche Three | Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract', window );"><strong>Stock issued or granted during period [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="nump">33.33%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6795331392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingent consideration<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Contingent Consideration</a></td>
<td class="text">Contingent consideration<div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Contingent consideration liabilities associated with business combinations are fair value measurement items. These liabilities represent an obligation of the Company to transfer additional assets to the selling shareholders and owners if future events occur or conditions are met. These liabilities associated with business combinations are measured at fair value at inception and at each subsequent reporting date. The changes in the fair value are primarily due to the expected amount and timing of future net sales, which are inputs that have no observable market (Level 3). </span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">The following table is a reconciliation of the beginning and ending balance of contingent considerations and is based on level 3 significant unobservable inputs. </span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:82%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;">Balance at December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>29.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Change in fair value</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Settlements</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;">Balance at March&#160;31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>29.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">The recurring Level 3 fair value measurements the Company's contingent consideration liability include the following significant unobservable inputs: </span></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:15%;"/><td style="width:17%;"/><td style="width:17%;"/><td style="width:17%;"/><td style="width:17%;"/><td style="width:17%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Contingent Consideration Liability</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Fair Value as of March 31, 2020</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Valuation Technique</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Unobservable Input</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Range</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Weighted Average </span></div></td></tr><tr><td rowspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue milestone and royalty based</span></div></td><td rowspan="3" style="vertical-align:middle;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>$29.1 million</span></span></div></td><td rowspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Discounted cash flow</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Discount rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.5% - 8.6%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4.3%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Probability of payment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.0% - 40.0%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>20.9%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Projected year of payment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020 - 2028</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022</span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6790111584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text">Inventories<div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">The components of inventory are as follows:</span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:61%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">March&#160;31, 2020</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Raw materials and supplies</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>77.7</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>70.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Work-in-process</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>114.2</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>89.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Finished goods</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>56.2</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>62.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventories</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>248.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>222.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6804933392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Apr. 24, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EMERGENT BIOSOLUTIONS INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">14-1902018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">400 Professional Drive Suite 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Gaithersburg,  <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">631-3200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, Par Value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EBS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,427,756<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001367644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6805859648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (12.5)<span></span>
</td>
<td class="num">$ (26.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive (loss) income, net of tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Unrealized losses on hedging activities, net of tax</a></td>
<td class="num">(11.2)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized losses on pension benefit obligation, net of tax</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive (loss) income, net of tax</a></td>
<td class="num">(11.3)<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (23.8)<span></span>
</td>
<td class="num">$ (25.0)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b,c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6662720512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Lease Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Operating lease cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of right-of-use assets</a></td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total operating lease cost</a></td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6792308096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Debt</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">The components of debt are as follows:</span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">March&#160;31, 2020</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Senior secured credit agreement - Term loan due 2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>433.1</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>435.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Senior secured credit agreement - Revolver loan due 2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>353.0</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>373.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.875% Convertible Senior Notes due 2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>10.6</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>10.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total debt</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>799.7</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>822.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of long-term debt, net of debt issuance costs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(26.3</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(12.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unamortized debt issuance costs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(10.5</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(11.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current portion of debt</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>762.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>798.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>139</ContextCount>
  <ElementCount>299</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>50</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="ebs-20200331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ebs-20200331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ebs-20200331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ebs-20200331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ebs-20200331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003000 - Statement - Condensed Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ebs-20200331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1003501 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ebs-20200331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1004000 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ebs-20200331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1005000 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ebs-20200331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1005501 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ebs-20200331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Business</Role>
      <ShortName>Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ebs-20200331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - Basis of Presentation and Principles of Consolidation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidation</Role>
      <ShortName>Basis of Presentation and Principles of Consolidation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ebs-20200331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2103100 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ebs-20200331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2104100 - Disclosure - Property, plant and equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/PropertyPlantAndEquipment</Role>
      <ShortName>Property, plant and equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ebs-20200331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2105100 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ebs-20200331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - Intangible assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/IntangibleAssets</Role>
      <ShortName>Intangible assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ebs-20200331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - Contingent consideration</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/ContingentConsideration</Role>
      <ShortName>Contingent consideration</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ebs-20200331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - Derivative instruments and hedging activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivities</Role>
      <ShortName>Derivative instruments and hedging activities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ebs-20200331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2109100 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ebs-20200331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Revenue recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/RevenueRecognition</Role>
      <ShortName>Revenue recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ebs-20200331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2111100 - Disclosure - Income taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/IncomeTaxes</Role>
      <ShortName>Income taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ebs-20200331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2112100 - Disclosure - Net loss per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/NetLossPerShare</Role>
      <ShortName>Net loss per share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ebs-20200331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2113100 - Disclosure - Share-based compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-based compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ebs-20200331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2114100 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ebs-20200331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Basis of Presentation and Principles of Consolidation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidationPolicies</Role>
      <ShortName>Basis of Presentation and Principles of Consolidation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ebs-20200331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Inventories</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ebs-20200331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Property, plant and equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentTables</Role>
      <ShortName>Property, plant and equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/PropertyPlantAndEquipment</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ebs-20200331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Leases</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ebs-20200331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Intangible assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/IntangibleAssetsTables</Role>
      <ShortName>Intangible assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/IntangibleAssets</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ebs-20200331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Contingent consideration (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/ContingentConsiderationTables</Role>
      <ShortName>Contingent consideration (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/ContingentConsideration</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ebs-20200331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2308301 - Disclosure - Derivative instruments and hedging activities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesTables</Role>
      <ShortName>Derivative instruments and hedging activities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivities</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ebs-20200331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2309301 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Debt</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ebs-20200331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2310301 - Disclosure - Revenue recognition (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/RevenueRecognitionTables</Role>
      <ShortName>Revenue recognition (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/RevenueRecognition</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ebs-20200331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2312301 - Disclosure - Net loss per share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/NetLossPerShareTables</Role>
      <ShortName>Net loss per share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/NetLossPerShare</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ebs-20200331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2401401 - Disclosure - Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/BusinessDetails</Role>
      <ShortName>Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Business</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ebs-20200331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2402402 - Disclosure - Basis of Presentation and Principles of Consolidation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidationDetails</Role>
      <ShortName>Basis of Presentation and Principles of Consolidation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidationPolicies</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ebs-20200331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2403402 - Disclosure - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/InventoriesDetails</Role>
      <ShortName>Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/InventoriesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ebs-20200331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2404402 - Disclosure - Property, plant and equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentDetails</Role>
      <ShortName>Property, plant and equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ebs-20200331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="ebs-20200331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2405403 - Disclosure - Leases - Components of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/LeasesComponentsOfLeaseExpenseDetails</Role>
      <ShortName>Leases - Components of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="ebs-20200331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2405404 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails</Role>
      <ShortName>Leases - Supplemental Balance Sheet Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="ebs-20200331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Intangible assets - Schedule of Finite-lived Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails</Role>
      <ShortName>Intangible assets - Schedule of Finite-lived Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="ebs-20200331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - Intangible assets - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/IntangibleAssetsNarrativeDetails</Role>
      <ShortName>Intangible assets - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="ebs-20200331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Contingent consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/ContingentConsiderationDetails</Role>
      <ShortName>Contingent consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/ContingentConsiderationTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ebs-20200331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Contingent consideration Contingent consideration - Fair Value Level 3 of Significant Unobservable Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/ContingentConsiderationContingentConsiderationFairValueLevel3OfSignificantUnobservableInputsDetails</Role>
      <ShortName>Contingent consideration Contingent consideration - Fair Value Level 3 of Significant Unobservable Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ebs-20200331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2408402 - Disclosure - Derivative instruments and hedging activities - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails</Role>
      <ShortName>Derivative instruments and hedging activities - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ebs-20200331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Derivative instruments and hedging activities - Derivative Designated as Cash Flow Hedges (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesDerivativeDesignatedAsCashFlowHedgesDetails</Role>
      <ShortName>Derivative instruments and hedging activities - Derivative Designated as Cash Flow Hedges (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ebs-20200331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Derivative instruments and hedging activities - Fair Value by Balance Sheet Location (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesFairValueByBalanceSheetLocationDetails</Role>
      <ShortName>Derivative instruments and hedging activities - Fair Value by Balance Sheet Location (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ebs-20200331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2408405 - Disclosure - Derivative instruments and hedging activities - Cash Flow Hedging on AOCI (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesCashFlowHedgingOnAociDetails</Role>
      <ShortName>Derivative instruments and hedging activities - Cash Flow Hedging on AOCI (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ebs-20200331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2409402 - Disclosure - Debt - Schedule (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/DebtScheduleDetails</Role>
      <ShortName>Debt - Schedule (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ebs-20200331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/DebtNarrativeDetails</Role>
      <ShortName>Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ebs-20200331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2410402 - Disclosure - Revenue recognition - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/RevenueRecognitionNarrativeDetails</Role>
      <ShortName>Revenue recognition - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ebs-20200331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2410403 - Disclosure - Revenue recognition - Remaining Performance Obligation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/RevenueRecognitionRemainingPerformanceObligationDetails</Role>
      <ShortName>Revenue recognition - Remaining Performance Obligation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ebs-20200331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Revenue recognition - Disaggregation of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationOfRevenueDetails</Role>
      <ShortName>Revenue recognition - Disaggregation of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ebs-20200331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2410405 - Disclosure - Revenue recognition - Contract Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/RevenueRecognitionContractLiabilitiesDetails</Role>
      <ShortName>Revenue recognition - Contract Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="ebs-20200331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2410406 - Disclosure - Revenue recognition - Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/RevenueRecognitionAccountsReceivableDetails</Role>
      <ShortName>Revenue recognition - Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ebs-20200331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2411401 - Disclosure - Income taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/IncomeTaxes</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="ebs-20200331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2412402 - Disclosure - Net loss per share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/NetLossPerShareDetails</Role>
      <ShortName>Net loss per share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/NetLossPerShareTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="ebs-20200331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2413401 - Disclosure - Share-based compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/ShareBasedCompensationDetails</Role>
      <ShortName>Share-based compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/ShareBasedCompensation</ParentRole>
      <Position>58</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="ebs-20200331x10q.htm">ebs-20200331x10q.htm</File>
    <File>a101-bardaav7909mod4.htm</File>
    <File>a102-bardaav7909mod5.htm</File>
    <File>a311-kramercertificati.htm</File>
    <File>a312-lindhalcertificat.htm</File>
    <File>a321-kramercertificati.htm</File>
    <File>a322-lindhalcertificat.htm</File>
    <File>ebs-20200331.xsd</File>
    <File>ebs-20200331_cal.xml</File>
    <File>ebs-20200331_def.xml</File>
    <File>ebs-20200331_lab.xml</File>
    <File>ebs-20200331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>chart-45f5bcfaac85917cb05.jpg</File>
    <File>chart-7be1608b6ea75fd5aa6.jpg</File>
    <File>chart-937e1a19d8725011b0d.jpg</File>
    <File>chart-93d7bf203aab502f964.jpg</File>
    <File>chart-ade9397b4ccf58cca64.jpg</File>
    <File>chart-aeca25847b2a5d44978.jpg</File>
    <File>chart-f886e6c0564f5edb9d1.jpg</File>
    <File>emergentlogo01.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6791808176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation and Principles of Consolidation (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Money market funds</a></td>
<td class="nump">$ 90.7<span></span>
</td>
<td class="nump">$ 52.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MoneyMarketFundsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MoneyMarketFundsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6796666592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6806671328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Principles of Consolidation (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">The accompanying unaudited condensed consolidated financial statements include the accounts of Emergent and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements included herein have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X issued by the SEC. Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">, as filed with the SEC.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">All adjustments contained in the accompanying unaudited condensed consolidated financial statements are of a normal recurring nature and are necessary to present fairly the financial position of the Company as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">. Interim results are not necessarily indicative of results that may be expected for any other interim period or for an entire year.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair value measurements</a></td>
<td class="text">Separate disclosure is required for assets and liabilities measured at fair value on a recurring basis from those measured at fair value on a non-recurring basis. The Company has cash held in money market accounts (level 1), contingent purchase consideration (level 3) and interest rate swaps arrangements (level 2) that are measured at fair value on a recurring basis (Note 7 and Note 8).<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently issued accounting standards</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#0094ff;font-style:italic;text-decoration:underline;">Recently Adopted</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;">ASU 2016-13,&#160;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&#160;("ASU 2016-13")</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">In June 2016, the FASB issued ASU 2016-13. ASU 2016-13 provides guidance on measurement of credit losses on financial instruments that changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, held-to-maturity debt securities and loans, and that requires entities to use a new, forward-looking &#8220;expected loss&#8221; model that is expected to generally result in the earlier recognition of allowances for losses. The guidance&#160;became effective for annual periods beginning after December 15, 2019, including interim periods within those years. The Company adopted the standard as of January 1, 2020 and has evaluated the effects of this standard and determined that the adoption did not have a material impact on the Company's consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;">ASU 2018-13,&#160;Fair Value Measurement - Disclosure Framework (Topic 820)&#160;("ASU 2018-13")</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">In August 2018, the FASB issued ASU 2018-13. ASU 2018-13 improves the disclosure requirements on fair value measurements. The updated guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Early adoption is permitted for any removed or modified disclosures. The Company adopted the standard as of January 1, 2020 which has resulted in expanded disclosures around the Company's recurring level 3 fair value measurements. The disclosures are included in note 7 of the condensed consolidated financial statements. </span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;">ASU 2018-15,&#160;Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract ("ASU 2018-15")</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">In August 2018, the FASB issued ASU 2018-15. ASU 2018-15 clarifies the accounting for implementation costs in cloud computing arrangements. ASU 2018-15 is effective for all entities for fiscal years beginning after December 15, 2019. The Company adopted the standard as of January 1, 2020 and has evaluated the effects of this standard and determined that the adoption did not have a material impact on the Company's consolidated financial statements. </span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;">ASU 2017-4,&#160;Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment ("ASU 2017-4")</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">In January 2017, the FASB issued ASU 2017-4. ASU 2017-4 simplifies the subsequent measurement of goodwill and eliminates Step 2 from the goodwill impairment test. ASU 2017-4 is effective for annual and interim goodwill tests beginning after December 15, 2019. The Company's measurement period is September 30. The Company adopted the standard as of January 1, 2020 and has evaluated the effects of this standard and determined that the adoption will not have a material impact on the Company's consolidation financial statements. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#0094ff;font-style:italic;text-decoration:underline;">Not Yet Adopted</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;">ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">In March 2020, the FASB issued Topic 848. Topic 848 provides relief for impacted areas as it relates to impending reference rate reform. ASC 848 contains optional expedients and exceptions for applying US GAAP to debt arrangements, contracts, hedging relationships, and other areas or transactions that are impacted by reference rate reform. This guidance is effective for upon issuance for all entities and elections of certain optional expedients are required to apply the provisions of the guidance. The Company continues to assess all potential impacts of the standard and will disclose the nature and reason for any elections that the Company makes. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;">ASU 2018-14,&#160;Compensation -&#160;Retirement Benefits - Defined Benefit Plans - General (Topic 715-20):&#160;Disclosure Framework - Changes to the Disclosure Requirements for Defined Benefit Plans&#160;("ASU 2018-14")</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">In August 2018, the FASB issued ASU 2018-14. ASU 2018-14 modifies the disclosure requirements for defined benefit pension plans and other post-retirement plans. ASU 2018-14 is effective for all entities for fiscal years ending after December 15, 2020, and earlier adoption is permitted. The Company is currently evaluating the impact of adopting ASU 2018-14 on its consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;">ASU 2019-12, Simplifications to Accounting for Income Taxes ("ASU 2019-12")</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">In December 2019, the FASB issued ASU 2019-12. ASU 2019-12 removes certain exceptions for recognizing deferred taxes for investments, performing intra-period allocation and calculating income taxes in interim periods. The ASU also adds guidance to reduce complexity in certain areas, including deferred taxes for goodwill and allocating taxes for members of a consolidated group. ASU 2019-12 is effective for all entities for fiscal years beginning after December 15, 2020, and earlier adoption is permitted. The Company is currently evaluating the impact of adopting ASU 2019-12 on its consolidated financial statements.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> </span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355033-122828<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355100-122828<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6795260320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income taxes</a></td>
<td class="text">Income taxes <div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">On</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> March</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> 27, 2020, the President of the United States signed into law the Coronavirus Aid, Relief and Economic Security Act (the &#8220;CARES Act&#8221;). The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">credit</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;"> refunds, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property. The Company is currently assessing the impact of the CARES Act, but we do not expect there to be a material impact to our consolidated financial statements. </span></div><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">The estimated effective annual tax rate for the Company, which excludes discrete adjustments, was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"><span>26%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"><span>27%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">. </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">three months ended March 31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">, the Company recorded a discrete tax benefit of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"><span>$3.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> and $</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"><span>1.8</span></span> million, respectively, primarily due to activity associated with equity awards.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6795318928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets</a></td>
<td class="text">The following tables summarize the Company's intangible assets for the periods ended <span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> and December 31, 2019:</span><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"/></tr><tr><td style="width:30%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="12" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">March 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">(in millions)&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Estimated Life</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Cost</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Additions</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Accumulated Amortization</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Net</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Products</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9-22 years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;">$</span></div></td><td style="vertical-align:bottom;background-color:#ededed;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"><span>788.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ededed;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;">$</span></div></td><td style="vertical-align:bottom;background-color:#ededed;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"><span>10.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ededed;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;">$</span></div></td><td style="vertical-align:bottom;background-color:#ededed;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"><span>96.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;">$</span></div></td><td style="vertical-align:bottom;background-color:#ededed;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"><span>702.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Customer relationships</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>8 years</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"><span>28.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"><span>23.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"><span>4.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contract development and manufacturing</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>8 years</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;Total intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ededed;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ededed;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"><span>822.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ededed;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ededed;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ededed;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"><span>10.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ededed;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ededed;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ededed;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"><span>124.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ededed;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ededed;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ededed;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;"><span>708.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ededed;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:43%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">(in millions)&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Estimated Life</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Cost</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Accumulated Amortization</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Net</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Products</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9-22 years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>788.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>82.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>705.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Customer relationships</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>8 years</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>28.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>23.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contract development and manufacturing</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>8 years</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;Total intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>822.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>109.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>712.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6797048608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Schedule (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 29, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 799.7<span></span>
</td>
<td class="nump">$ 822.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt, net of debt issuance costs</a></td>
<td class="num">(26.3)<span></span>
</td>
<td class="num">(12.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNoncurrentNet', window );">Unamortized debt issuance costs</a></td>
<td class="num">(10.5)<span></span>
</td>
<td class="num">(11.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-current portion of debt</a></td>
<td class="nump">762.9<span></span>
</td>
<td class="nump">798.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_ConvertibleSeniorNotesDue2021Member', window );">2.875% Convertible Senior Notes due 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 10.6<span></span>
</td>
<td class="nump">10.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated percentage</a></td>
<td class="nump">2.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.875%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_OtherLongTermDebtFacilityMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=ebs_TermLoanFacilityMember', window );">Senior secured credit agreement - Term loan due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">433.1<span></span>
</td>
<td class="nump">435.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Senior secured credit agreement - Revolver loan due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 353.0<span></span>
</td>
<td class="nump">$ 373.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNoncurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNoncurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ebs_ConvertibleSeniorNotesDue2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ebs_ConvertibleSeniorNotesDue2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ebs_OtherLongTermDebtFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ebs_OtherLongTermDebtFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=ebs_TermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=ebs_TermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6805524992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets - Schedule of Finite-lived Intangible Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="nump">$ 822.1<span></span>
</td>
<td class="nump">$ 822.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Finite-lived intangible assets acquired</a></td>
<td class="nump">10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="nump">124.0<span></span>
</td>
<td class="nump">109.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">$ 708.1<span></span>
</td>
<td class="nump">$ 712.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Amortization period of intangible asset</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">9 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Amortization period of intangible asset</a></td>
<td class="text">22 years<span></span>
</td>
<td class="text">22 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ProductMember', window );">Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="nump">$ 788.0<span></span>
</td>
<td class="nump">$ 788.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Finite-lived intangible assets acquired</a></td>
<td class="nump">10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="nump">96.0<span></span>
</td>
<td class="nump">82.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">$ 702.0<span></span>
</td>
<td class="nump">$ 705.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Amortization period of intangible asset</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">8 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="nump">$ 28.6<span></span>
</td>
<td class="nump">$ 28.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="nump">23.8<span></span>
</td>
<td class="nump">23.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">$ 4.8<span></span>
</td>
<td class="nump">$ 5.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ebs_ContractManufacturingMember', window );">Contract development and manufacturing services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Amortization period of intangible asset</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">8 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="nump">$ 5.5<span></span>
</td>
<td class="nump">$ 5.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="nump">4.2<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ebs_ContractManufacturingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ebs_ContractManufacturingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6791786640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative instruments and hedging activities - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths', window );">Net deferred losses from accumulated other comprehensive loss</a></td>
<td class="nump">$ 5.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated net amount of existing gains or losses on cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=112277219&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6791985920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingent consideration (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Reconciliation of Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Level 3)</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">The following table is a reconciliation of the beginning and ending balance of contingent considerations and is based on level 3 significant unobservable inputs. </span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:82%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;">Balance at December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>29.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Change in fair value</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Settlements</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;">Balance at March&#160;31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>29.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Fair Value Measurement Inputs and Valuation Techniques</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">The recurring Level 3 fair value measurements the Company's contingent consideration liability include the following significant unobservable inputs: </span></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:15%;"/><td style="width:17%;"/><td style="width:17%;"/><td style="width:17%;"/><td style="width:17%;"/><td style="width:17%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Contingent Consideration Liability</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Fair Value as of March 31, 2020</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Valuation Technique</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Unobservable Input</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Range</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Weighted Average </span></div></td></tr><tr><td rowspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue milestone and royalty based</span></div></td><td rowspan="3" style="vertical-align:middle;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>$29.1 million</span></span></div></td><td rowspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Discounted cash flow</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Discount rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.5% - 8.6%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4.3%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Probability of payment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.0% - 40.0%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>20.9%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Projected year of payment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020 - 2028</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022</span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6794774032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventories</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">The components of inventory are as follows:</span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:61%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">March&#160;31, 2020</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Raw materials and supplies</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>77.7</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>70.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Work-in-process</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>114.2</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>89.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Finished goods</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>56.2</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>62.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventories</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>248.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>222.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>74
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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MZP^_B[#KC=W9?VQ\%I0M_+H+^0502P,$%     @ #Y*>4)E<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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MLT\\UTKY*AP3^O\BG'WBN5;^.P8P016<?>*Y5E-?!?S=AU1P]HGG6GEO\F;
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MYZI5R"F4M57._OW:PB%0.M4/TI?[?I[KJ:4U:QE_$P4ATGNO:"TV?B%ELP9
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ME9W)#I:N<Y;YX7%3R&/;7R;==3T>,8PWK;I.QR?^XPQG\R]02P,$%     @
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M92K65$][O>&D'V\R?[I.B_]02P,$%     @ #Y*>4*A\'@/L 0  YP0  !@
M  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q]5-N.FS 0_16+#UASW6XC0%JH
MJE9JI6BKML\.#!>MC:GMA.W?UQ?"DH3F!7O&9\Z<8VRG$Q>OL@-0Z(W1069>
MI]2XPUA6'3 B'_@(@UYIN&!$Z5"T6(X"2&V+&,6A[S]B1OK!RU.;VXL\Y4=%
M^P'V LDC8T3\+8#R*?,"[YQXZ=M.F03.TY&T\ /4SW$O=(07EKIG,,B>#TA
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M60(*C3+3#WHNW-US@>+C_*S@Y6W+_P%02P,$%     @ #Y*>4'SS/3:?!
M8A<  !@   !X;"]W;W)K<VAE971S+W-H965T-RYX;6R%F%N/HT80A?\*XMU
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MCR\;^U\;XP&E)#<X0BU^L,504/MPO,>SG<9L,KSIYQ_$EF]<_ )02P,$%
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MN]\8XP%326YP@#K\7JNAH/'A^![/=AZRV?!F6/X/6S]Q^0=02P,$%     @
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M/Y]XR:W6#KR5W9WWTOLN7A<"6A>F;_S<S&]Y7C@]+&U*UG]%]1-02P,$%
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MX\O&_M?&>$ IR0V.4(L?;#$4U#X<[_!LIS&;#&_Z^0>QY1L7?P%02P,$%
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M^U\C.O!2=E=^A%K_P19#0>W"\;,_FVG,)L-A/_\@MGSCXB]02P,$%     @
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M,.G_1;)53S68)DZ3)24.79SDE7<9V#L>W^0??)KV[\(TLK/DC,Z_;.Q_C>C
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ML,50T(1XO,>SF\9L,H+MYQ_$EF]<_@)02P,$%     @ #Y*>4..W=KJU 0
MT@,  !D   !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL?5/;;IPP$/T5RQ\0
MLX8TVQ4@95-5K91(JU1MG[TP@!5?J&V6Y.]K&Y;2%N7%]HSGG#DS'N>C-B^V
M W#H50IE"]PYUQ\(L54'DMD;W8/R-XTVDCEOFI;8W@"K(T@*0I/D Y&,*USF
MT7<R9:X')[B"DT%VD)*9MR,(/19XAZ^.9]YV+CA(F?>LA6_@OO<GXRVRL-1<
M@K)<*V2@*?#][G#,0GP,^,%AM*LS"I6<M7X)QM>ZP$D0! (J%QB8WR[P $($
M(B_CU\R)EY0!N#Y?V3_'VGTM9V;A08N?O'9=@?<8U="P0;AG/7Z!N9Y;C.;B
M'^$"PH<')3Y'I86-*ZH&Z[2<6;P4R5ZGG:NXC]-->H5M ^@,H M@'P%D2A25
M?V*.E;G1(S)3[WL6GGAWH+XW57#&5L0[+]YZ[Z6DZ3XGET TQQRG&+J*V2T1
MQ+,O*>A6BB/]#TZWX>FFPC3"T[\4?MPFR#8)LDB0O5OB1DR6_).$K'HJP;1Q
MFBRJ]*#B)*^\R\#>T_@F?\*G:7]BIN7*HK-V_F5C_QNM'7@IR8T?H<Y_L,40
MT+APO/-G,XW99#C=SS^(+-^X_ U02P,$%     @ #Y*>4,;1[3VS 0  T@,
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M_-E,8S89#OOY!['E&Q>O4$L#!!0    (  ^2GE!/<4X2M0$  -(#   9
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M&GM&_4FJI#1@2XGN;,.-?2J6@$-EW'1OYVJZ,%-@9#^_!61YD/(_4$L#!!0
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MVOF'C>UOM';@4TFN_ 1U_G\MAH#&A>,W?S;3E$V&T_W\@<CRB\M_4$L#!!0
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M.O^RL?\5H@.?RN;&CU#C/]AL**A<.-[ZLQG';#0<=M,/8O,WSO\"4$L#!!0
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MP(E/" 14UBLPMUSA"83P0BZ-7XLF7D-ZXG;_KOXIU.YJN3 #3TK\Y+7M"GS
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MO=OK\2V/@57=-*9D_J_(/P!02P,$%     @ #Y*>4 &1??7- 0  G 0  !D
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MCH:;5"EEP96R>7 --^ZIF ,!E?7;H]OK<6#&P*IN>@O(_"#E?P%02P,$%
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MOVSL?X7HP*>2W/@1:OP'FPT%E0O'O3^;<<Q&PV$W_2 V?^/\+U!+ P04
M"  /DIY0GM9U*=$!  "<!   &0   'AL+W=O<FMS:&5E=',O<VAE970S,BYX
M;6QU5.MNVR 4?A7$ Y0$.TX4V9::3E,G;5+4:MMO8A]?5# NX+A[^P)V72]C
M?PSG\%W.P4 Z2O6B&P"#W@3O=(8;8_HC(;IH0#!])WOH[$HEE6#&AJHFNE?
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M[NU<31=F"HSLY[> + ]2_@Y02P,$%     @ #Y*>4$Y;QCZX 0  T@,  !D
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M^ '/=AJSR?"FGW\06[YQ\0=02P,$%     @ #Y*>4 =I.</9 0  F00  !D
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M_LLOG"NF&0-/[YM,7^_Z3L$NRC03W1;M':?M*%YW]S>_OT3N_@%02P,$%
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M:=QT:>=J:$_#PLAV;+UTZO_Y/U!+ P04    "  /DIY0=347?0@"  !U!0
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MOME3Z,RY FWH>WK3%?IB&CH,SLHT%[HMNM.YZRC>]#</&:Z__"]02P,$%
M  @ #Y*>4*0*"66- P  G1   !D   !X;"]W;W)K<VAE971S+W-H965T-#$N
M>&ULE5AM;YLP$/XKB!\ ^,Q;JB12FVG:I$VJ-FW[3!,G006<@=-T_W[&N"FV
MCR3]DH#SW-USQ]V#G?F)M\_=GC'AO=95TRW\O1"'NS#LUGM6%UW #ZR1OVQY
M6Q="WK:[L#NTK-@HH[H*(8K2L"[*QE_.U=ICNYSSHZC*ACVV7G>LZZ+]]\ J
M?EKXQ'];^%'N]J)?")?S0[%C/YGX=7ALY5UX]K(I:]9T)6^\EFT7_CVY6U':
M&RC$[Y*=NM&UUZ?RQ/ES?_-UL_"CGA&KV%KT+@KY]<)6K*IZ3Y+'7^W4/\?L
M#<?7;]X_J^1E,D]%QU:\^E-NQ'[AY[ZW8=OB6(D?_/2%Z802W]/9?V,OK)+P
MGHF,L>95ISZ]];$3O-9>))6Z>!V^RT9]G[3_-S/< +0!G UD[$L&5!O0=X-4
M)3\P4ZE^*D2QG+?\Y+7#TSH4?5.0.RJ+N>X75>W4;S+;3JZ^+&D<S<.7WI'&
M/ P8&&&(B5BY"!J_8T+)X$P#,!H/X#@ *X2+2'(\ D43I<J>&A0!=Q"C#F+E
M(#8<4*M2 R95F$9A<H# KM8UE$$F0<DD")G8(C-@DE$8$N$Q4C1&BL1(K!BI
M&P,L'JL!DQD\9L%$[3.42N9027.+2>84-8MRI_0(BD PP[GD*)?<+0N9<#!#
M'<R03DQQ!R3"AS9"'DUF3RT&RNW!O0PRR4PH"'%=P$0S$W3Z[PE\H"3X>!-Z
M2TDPT,PNR66020:7"H)H13(Q>P0?<)+<KE<$GU^"#;"M6!HT&T]$[G3)99!)
M!I]@XHZPJU@:=(MD$7PX"3*=CFAIT#C,++53SAW5RF%*M @^Z&1V7;8TQBAM
M9+_[-,@4MR28> * BP8@HYY,O:3Q40=R^YP"/NH -\PI!J(6:'4%9)+!10,^
ML"D ?-3AEFT!N&]\R .[Y:ZA3#JX; "V,;#[7X/&O0TTL(<>W/T#T DRN "!
M*T!._VO,..G8I>*"DLG"X/H#KOX0.J$M@&L+Y!_H?EP1P%4$I/L1D-O]ET'F
MAA@7!!K=WOT4%P2*O/N=[M<@\^E9/;FZ C+)X-)",6FQ>U^#,J/?;+W5H''K
MQQ-4)@X;[A["Z7R-&6=, FHSP4!V6<+18:]F[4Z=BSMOS8^-.I2/5L]G[WM0
MA\5W^'!P_UZTN[+IO"<NY)%3'0RWG LFN42!K,>>%9OS3<6VHK_,Y'4[')B'
M&\$/^L^ \/R/Q/(_4$L#!!0    (  ^2GE#3V-[?, (  ) &   9    >&PO
M=V]R:W-H965T<R]S:&5E=#0R+GAM;(U5VXZ;,!#]%<0'Q%R=BP!IDZAJI5:*
MMNKVV2&3@-9@:CMA^_?UA:6$N*N^@#T^Y\P9VPQ9S_BKJ "D]];05N1^)66W
M04B4%31$+%@'K5HY,]X0J:;\@D3'@9P,J:$H"@*,&E*W?I&9V($7&;M*6K=P
MX)ZX-@WAO[= 69_[H?\>>*XOE=0!5&0=N<!WD#^Z U<S-*J<Z@9:4;/6XW#.
M_:=PLU]KO &\U-"+R=C3E1P9>]63+Z?<#[0AH%!*K4#4ZP8[H%0+*1N_!DU_
M3*F)T_&[^B=3NZKE2 3L&/U9GV25^RO?.\&97*E\9OUG&.I)?6\H_BO<@"JX
M=J)RE(P*\_3*JY"L&524E8:\V7?=FG=O5W RT-R$:"!$(R'"'Q+B@1"/A/#C
M#,E 2&8$9$LQ>[,GDA099[W'[>EV1%^B<).HW2]UT&RV65/;(U3T5L1IE*&;
M%AHP6XN))IAP1""E/J:(7"FVT0-]EF#WB @#?(_9/V+2E=M%["PT-OSXKM#8
M+9 X!1(CD-P))+.=LAAL,*TM)%FL9M4Z0:G;2NJTDCJLI#,K+@QV)\'.)/A!
M8!G,<N"'2B*,%[--V;M1__"R='I9.HI9N@563H'5_Y_^VBFP=CB8'>S68M;3
M@PUF.=#DNVR 7TS/$U[)KJW4MWL2'=OJ4Z2_ZUE\&VYVMCO^E;&]^AOAE[H5
MWI%)U37,MWUF3()R&"S4K:C4[V&<4#A+/5RJ,;=-TDXDZX;^C\:?4/$'4$L#
M!!0    (  ^2GE#M'.S+\0$   8%   9    >&PO=V]R:W-H965T<R]S:&5E
M=#0S+GAM;'54;6^;,!#^*XCOP\006") :EI5F[1)4:=NGQUR 50;,]L)W;^?
M7RBCU/N"?>?GGN?N\+D8N7B1+8 *7AGM91FV2@U[A&3= B,RX@/T^N3"!2-*
MFZ)!<A! SC:(483C.$.,='U8%=9W%%7!KXIV/1Q%(*^,$?'G )2/9;@)WQQ/
M7=,JXT!5,9 &?H!Z'HY"6VAF.7<,>MGQ/A!P*<.[S?Z0&[P%_.Q@E(M]8"HY
M<?YBC*_G,HQ-0D"A5H:!Z.4&]T"I(=)I_)XXPUG2!"[W;^R/MG9=RXE(N.?T
M5W=6;1E^#H,S7,B5JB<^?H&IGFT83,5_@QM0#3>9:(V:4VF_07V5BK.)1:?"
MR*M;N]ZNHSM)=U.8/P!/ 7@.P*X6)V0S?R"*5(7@8R!<[P=B?O%FCW5O:N.T
MK;!G.GFIO;<JV>X*=#-$$^;@,'B!V<P(I-EG">R3.. /X4D6^PD2;XZ))4C>
M$?PG@]1+D%J"]!T!7A7I,)G%]!:#=Q'VJVR]*EN/2K)2<9A\H1)'F5\D\XID
M'I%T)9)]$/D41[E?)?>JY!Z5[4HE]S5L_5O0XAXR$(V=0!G4_-K;Z5]XYR&_
MP_8>_X.[%^([$4W7R^#$E9X&>V<OG"O0N<21[FNK'Z79H'!19IOKO7"CZ0S%
MA^G50?/35_T%4$L#!!0    (  ^2GE U-4R_@0(  &<*   9    >&PO=V]R
M:W-H965T<R]S:&5E=#0T+GAM;)56VXZ;,!3\%<0'Q-A<LR)(W515*[52M%7;
M9R=Q EK U';"]N]K&X(">UB1/,07YLPY8SS8:<O%J\P94\Y;5=9RX^9*-4\(
MR4/.*BI7O&&U?G+BHJ)*#\49R48P>K1!58F(YT6HHD7M9JF=VXDLY1=5%C7;
M"4=>JHJ*?\^LY.W&Q>YMXJ4XY\I,H"QMZ)G]9.I7LQ-ZA :68U&Q6A:\=@0[
M;=Q/^&E+ A-@$;\+ULJ[OF.D[#E_-8-OQXWKF8I8R0[*4%#=7-F6E:5ATG7\
M[4G=(:<)O._?V+]8\5K,GDJVY>6?XJCRC9NXSI&=Z*54+[S]RGI!H>OTZK^S
M*RLUW%2B<QQX*>V_<[A(Q:N>19=2T;>N+6K;MCW_+0P.('T &0((_C# [P/\
M20#J*K-2/U-%LU3PUA'=VVJHV13XR=>+>3"3=NWL,ZU6ZMEKYD=1BJZ&J,<\
M=Q@RPGACS!;"Q ,&Z1J&0@A8"+$$_H@@@0E\D,"W!,&(8#U1TF$BBZDMAJQ7
M>"(%!!&XE  L)7A?2NS!!"%($"Y?C @DB!8L1O3Q8HRRQ&"6&- Y0Y" !,ER
MG6N08 U40"8Z.PS&=T*]E4=". _V8)]X0"9_AF+&:GBY6@R;!),%>GO05' 2
MKD>_F<2PN3#@KCB8H8!-@8,'Y,.VP.$2^2$H/YA[6;"!,."@>&[+P.[ \0."
M87_@9(G@!!(\XT,,^PA#1HIFOM^P0XBW7"Z!'4+P KD]:")W9B^2F<,&\M'<
M<04[@O@/R(4=0:!SXIW< ))+O*E_T=V);ZY@/Z@X%[5T]ESIRX,]XD^<*Z8Y
MO96V2*YO?<.@9"=ENK'NB^[JTPT4;_IK'1KNEME_4$L#!!0    (  ^2GE#!
MXH=:QP$  !,$   9    >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;'54VVZ<
M,!#]%<L?$'-9DLT*D+*IHE9JI56JML]>&"Z*+\0V2_KW]86E-*$O>&9\YLP9
MCTT^2?6B.P"#WC@3NL"=,<.!$%UUP*F^D0,(N]-(Q:FQKFJ)'A30VB=Q1I(H
MNB6<]@*7N8^=5)G+T;!>P$DA/7).U>\C,#D5.,;7P'/?=L8%2)D/M(7O8'X,
M)V4]LK#4/0>A>RF0@J; #_'AF#F\!_SL8=(K&[E.SE*^..=+7>#("0(&E7$,
MU"X7> 3&')&5\3ISXJ6D2US;5_8GW[OMY4PU/$KVJZ]-5^ ]1C4T=&3F64Z?
M8>XGPVAN_BM<@%FX4V)K5))I_T75J(WD,XN5PNE;6'OAUVGFOZ9M)R1S0K(D
M)*&74,@K_T0-+7,E)Z3"V0_4C3@^)/9L*A?T1^'WK'AMHY<RO=OGY.*(9LPQ
M8)(5)EX0Q+(O)9*M$L?D0WIZ&VT3I)L:4T^P^T?C_3;!;I-@YPG2-<'^/PJR
M38+LHX)]_.Z4 N;>8X3'9.]*D-50.*C67T>-*CD*_Q16T>7&/R1^J'_AX;E\
MHZKMA49G:>S5\ -LI#1@A40W5DEG7^CB,&B,,^^LK<(]#8Z1P_P$R?(?*/\
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M(:&$\2+0EHAI2X3QHA%MB3 X!,"AWN_+&RCBYA&FBT!;HKA?!XF8M3[""$8
M0>K_]($B9K<780 C &#4?Y?A1.=S13"K>7#V#J5YS_8M*;=I47E/QEJ3MR]-
M-L987:<-K^HIN-/)^G22Z8UM#B?U<7E\OW4\L6;OWMT%IQ>(RW]02P,$%
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M=J_"6PV&D=TPAM X"\M_4$L#!!0    (  ^2GE >U,-]H $  )D#   9
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M81.B]W$)V)PM@L'P<'H4W$6S*H?9F^Q@N01\N"NSV<^PIS /_APF512\ZO<
MYX,5\ KB3XWA\W >IP_!W7HYS9(&K-[<U;]2"PBN/LT>PQ0XGX]0WOWUK@V+
M+ZH\1Q)GNJ:YX1"K!N/\:Y.7:J("]@0\#S$1F$RHAMS #H#B %$>LKP!N+=A
M#GLXG\TB> J>F?/S+6/=+<,D"=Y4!=!+T;:^JV64/^#&OLNSY_(1<&2Y"M/&
MS&K(QPB&W/R,>[IW)&B"]U4)F)O2\1W&J<B?H[8A $ YX. -B*%/P1^CQE1]
MP)/1R>3D^+B!6W)BUW&!6/S7"+"KC<%WNX-A=S1HB#+@ZG/B[-=)^-#*]NT9
MKN'+!H0W"@UY6T20]_T_-59VD0% T@+.'3X561+/"0G>A$D([ 1/)RH+D.X?
M[RZ#PU='P:L 0/UCG"3 #QO#7T8S)<X'3:8A8 R+ H;\IO%S6#P&<)S!##]$
M_U7%3V$"SS<FN8U 0L4S7"4^V@#U;(;"I0CR:!;!&-,DZ@1IU*".F_0)1L_R
MN$EG*+6645""O-DRR(<\6H7Q/(@^K1"(!6T@0PX>S)SM-OA.ADQW\S/ TX%O
ME>M.L$I0(N/8")<5GG;+GH @'F)8K0S9\E1WE6<SE'LH=\)\QH"?1T]1DM'H
M]5>^R[+Y,QQZ\\ 7$6QA3K#:,.5[ LDF4/A_4SB3Q.$T3D ABIJ(HP]\%:[Q
MH#R_@\9FSJBYARE 4QT%,>6L+JQE [/F<C8?[(8'@=R0^^-3,R"E>!XI+0G@
MAP)ORXIXV;L^:QV36I-'AJ:D2]NKWG4&AL]6N&QX@)C[8Y8 '(JO"<_+=>.L
M@=YD)P7+ B7?@6$^H<#_-AB,>WV1!4%8E8] X7^/YK"/3'T;%P7B VA-F1$A
M+0I%ZS2@JOCG&8]Z8R(G^-!WI_PV& ][(_YQT)NH'ZU5=) B5Q')]J1Q0/>@
M<145J,VRJA!1IP L&/2&\(D7[+7"0-LC:P*. /E5%WCX+%S%<"0>:JF654)"
M0!@9B.8\>@3:084CR0H_B=]&)1B+2&=AGL)66C"@\!SS5EPAD.WRYF[2[!#T
M0\#EQZ@$.R(Y NGV*GC= KD&QFD<(*5CGB5)F!=&P6SH'XT!&CBS27MI>UMP
M^ 5O9KNI32[^[[MI]^V]=NQ]=?MVO:_MN%>7KC;/XL4O,L-0;A;(*M^OA)7;
M>I/:B%&>.IMU*<LUTM2E;D%4IY5'&#+IY/)S@TOSR@ :2A@VU3!@*+@)T!#F
M%<B" I0PIK^9$@^6GD _+,.T6L /8!?!R&C(QK/FW+<[JAIW8 X0)P31&*'&
MCL^'\V6<DF<".6-3NT:A]'=V"<#:X[H:Y(=2UH!&TVP%'6F19TOUK.><6/(=
MRA!',#DJCPVXDM$&FJN:RS^,_.AEL++HK<_1HJ?1(LLC/,6G&%T7 ?RO+ V5
M@(TZ[Q0 OX@;X[X#10"Y?]OWQ YL*51_\$U8Q+,=&<AEG%2E4/SVI\4BK) P
M4;2!Q*KH8/6ZMBRHA=SM5;2R68M.O.=Q\7ETHUYG(GQ WYSOF>ULZ<*1XW+>
M.QIV>J36@=H]L>\]6L0A'HRB%:UC O(UZ.8:T#A^2$7_G*T#]$X62>A30C^F
MP,@3$C X/@J -'B,YN2,((>)J]/"?#L-@;2&-"2$$633)'YPE77/4#:][KA[
MCU"KJ5Y?[N2;2I"#"?>/654 QK4Q"H,1[2>_XWEL?RV/6"$M,^1CK?CP0NB@
MO^$ZR9YW=G/0&PMZ@QCL',:<KBUY8O;6P&?DEGSP31W]IZHH>5FPT3P"@3M#
M5WZJ&"Q\BY_)0;+WQ,0CN],0H8'H"'!A@=DBD"XCP)E9S,^0#+:D[#8)/%>Z
MYR).0?/&I:&EXK&]Y;E-HNF"_:QP((LP5GHHFJ2;+&@O%_*/3%J9!4-2&6C+
M.[D=C(MH#^^07R]1K@K[?':QTGU(]C(LL5!;2=,X?0*]9<M['RI0[4(B<=(=
MVQU7!@BMJ]YK9L^*#=)M6C&ZP**YZ'>@,6?)$^$IH"/P>!#,7B?)!Q#6LWA%
MAO1:>$CZN:^#:K@$$@_3#>_9JT5SB Q:H@)C^ 35B@@ZRF=Q0;_RU]G*RQ[O
MD=K((1"0='L,DP6^%"U72;:.X#?4&MG25J#T>HU\5*@WN/68=SJNJ\4BFI&<
MC%3@!<,5P4Q(.$MIT$[#?4SXEF_V&0M31C.0^,S+1[K8^4WTWDPC$(7H+"&J
M(;_]YPT8(6VU#757K58)R3U OWE<S$"H5#DCD2(BV#VG!, )^DF-T&7..BM0
ML<PE]@7;./N_U\[\G45;B\,#3[.T2RNW&$4ZWY'\=V=854IK!_#*F@'*3>N6
MI76L1>"L)9ZQ"Q:)$_GE6+B3WF.$G^M[O6*"WU$9HK76OQ1_J8G#VA&\#<[)
M#^B<O$E!)_,Z)[6CQC^.Y;IDH\-5?-]Z]&?MM;QJ\5HJUZ%E B(FV)&N1I:!
M>F?;<S>*Y1S"8_3IJ/4T_G8+5G  UM!SF,\;FO:5<&S%K!&-"\VR-X9'-[ZY
MBRWGUV9;X+;1JV7!;:?G-IS)IK%W>JY]W<T(K'_=OIRE+T"6^SBO';/=CU:M
MQEM;D/]]_A"FHNIWK(TH,^$#QA2!6RL^>,W<&(C;VN?V:0-['AIXJGZA_ +<
MU)LXN\N2BEVM0$R]X! ERX$D$QQ@B.= /7T M 6('3PDV92B"XLH*&8QV)
M[!F_ =)H1EH)JB^D.I-*!Z0 C)U7L43U+ 06M,I6E9B=,"J&Q18 B(S]CVGV
M1)Y*& 5, % ):>'"N4%'*R+E8)78AMY&^0A8%$I:4CB;Q7,2?1TPJ9)X2BD:
M]$8:EE4>)@GH]3.TA7&AJVJ:Q#.PL,.D?(21@*5@M./@P_?W1><@B$+TO@;_
M_G]/A\/^M_ E?1I\>]0#:S]2*1@()0L,"%#8&*@&Y*2*/Z'F *(6=#$8 :0/
MI96@A 7,C9:(DQT\F"1[X,^WX=SZOW?5+,'L!MS"U2=@/<A"<(T7;V[?71T<
M?0O*IV2/@+#'0%A6%3AE1++Z\.#JYA*? N1YBA+9JO62['V6PQO%MP# JHQ>
M1XP"LS4L-X\Z^WBS86&7/[X'W'%A!)H#'KKX_IS#+Z/4/5OUU P#$4CQL(TG
M/-D475'(4,-5!*<_*WAE\[QZZ,*J8N H@)=3H!_6IV70(\81VD \K1 ?@J*:
M8J"C1#*3""VN):MR%0MPUQ\F14:;*)\SWP(9"]F!#-@%J% !Z\H#C$WB'+,X
M!UF+4R+U@'$Y _4)!&GP@&F9*0,304[N-CR2K'I E(S6-&R:P>\K)#&V31'+
MKB_/D6 )O'R*-,*:5_ZQ=]>S1V=*_WCWW==$UZ79W-=%D&!24P$[JL#^64:Y
M.@>TA9UG@^<8YK&AMZ@X7(1Z*3YHHP= - Q22E\C,B^#P@,\!])?%QXL >I)
MJCF2S)\%#X HSTZ.A]\&YQ?G/P[[_3Y\,9@<?QL<4L;5*OL4'/*S<7BDWNH$
M;X%XC@B'@%2!%0"#?$BB[CP#_E*H%P77@./-6/A8\,9=2B99O%Q6AM\^P&$"
M /4@0H'T FC!!;*J>81V*VE/90:V#,J_QQB.&8CO9WI2OZYH.?U6[Q1XQ/UC
M'G[2.ST'H8;_+[L+SN=%ED^CN;W!MKT0=EQGH)OC25\"!<'K)F0$.SH\@/T>
MP%CJ8%5XJ6)>O'I<)^&G6$@V*\IN]&G%]I']*Z* K%- 8G;TYQ LTRP/U88N
M0-C"%.YQ=4"P@=BV]@3KZNK]J VJ5:Z(?+5-P2-^2XO4T\9/61DOU*SWZ]5C
M!N:* B-.2G,&]^OA(+1GSO#;;>C17$4I,RS@2]!V+HE5&11^=WY[<?Y.+0>T
M^NP3IGU^?P'*RKNP0$5@E8=K7L<BS@'-TBB: ]XN\HAVOA3!BI/I]WWL L'P
M/?.*BS -YZ$Y7L/S2Q2#BGY_3K/G%-E,45&>!0JY58R[0=9"A -<$60 J =%
MR;.AR(X!C3*0^C#C:WA[)MF$@$)/**"*-3R\!(K 3-Z"\-P^HMN[R[<:SV\C
MH;B[GX%A7J+A6(9+Q>7?9O3GCW%IG]0RFJ/\#)180!GJ@H(\QDO8!&XN!7F2
MDPN])K]G(J(#L"(6R(B1Q9;B5<)'"UC3-V")3RM0[HH09"#\R0 >8(BN9TGV
M&'U:)^J'/]_"?__1"9; 9L$J"1Y")I_[[A#6\RD&*-Q;XDV# Z@GGH)H7H93
M0_8_9FD&$Z2:.!@U%A7J.(_P;!HL]2-(A/$TFZ]M^;D1A0T6B"RP23I.'T-&
M.1X:%V3HFE=8Q$F#5=T@SXR"[T"EK!(XS)N4])(44>+P>USSD7V*JRQ9[[O^
M!HI[=K1U!V_.[]72WV0E++58XJYB.B08?E6&XIPX/.^\Z5QT+CM7G>O.=T?=
M0[03TLC9QJ/U_)?>QU265V-Q-]_=_-E(P/\9N .%*;U<:3MH-B12BR!$5!.[
M]%,O4%'B"Z-B:>SZ\^2L?]8N!:<L!5E3P1C1$^P!=A?;&JC6/D ,(YV+U@*O
MD:*:1I]*$7AB3O$DMK39*/.4^(?=5PDYVGBSAHFB5R %DEU2NM4L3I*JD'EF
M,(8:6)2YN^](^T2V@6^SEHG#"C04;MRA^([ =@#)(<A-9NP*XV*'=^_NCN#=
M&!\&K0KU;1(2\%3M)'&R:12AHQ[@1=8%)HS:/D"MCQ#$>*,N%M[GV31^ $8G
M9T4G8&OHMN8>5F76C=.? #P(W,8Y:1T>%2W0G #>>!(PZT*9>##;' ATB4[N
M!&RL.4#OIJ2]H/Y,^]F@1!<QV*I@:HDRG4</*%91B"$!=,">+E&%C0NCY%N*
MO)6L96G=TVH-RM]&8X!QJ8Q8G:Y8H(8D*47<!!0X ]61G'D^RT10E2*_9+TP
MNNV9@83F*QP0, @2>6SU+9<8'('_/21*Y3 ?F@M' 6;/1P@#8_H7%9C,>CQ
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ME"A9*%F+*:E&!RTTUGX,6^T@'O,C)2BK\$W0XU++>"GJ8*%]EVK"F!!U3B8
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M]9RP398$!DGQ:($%#/SJK-^;8&0N4:+EU7C8&^IOW*HJC[V!N9;YG",#+=B
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MT-H;.4#]:P2C;A@N:'0.!H4:5@#_M!V0_2RL]Z1WQJMO+!M _I<(-XYR#Y@
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M3*_?06K]I#\U?7K31KXZ?K>K9W%:>E+%I"!NSPS_N\T>FZ ;W.M[M#":@18
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M NH ]LOZ3;A&K0:W+5%,M,^1$E7V;00&;[:F2T#@7(AD$W7M@XE?2+39--7
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MT)/OL%N,E]:@PJOG9@V75O7W)BZ'#C]=O"$]-2C8N2VTFW@4R7W!9#U_Z:1
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MQ4LX;"]E7=Y9$3Z.*ZQY$=9*MEU=?\"V?_1'(_LWC<(YGM_6>O<_4$L#!!0
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MR-=;@-["UUN WG*%9VWTL,W76X#>PM=;@-["UUN WL+76X#>PM=;@-["UUN
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MF0$  &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ #Y*>4)E<G",0!@
MG"<  !,              ( !MP(  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"
M% ,4    "  /DIY0*1%F034#   Z#P  &               @ 'X"   >&PO
M=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ #Y*>4$3F!]Y]!
MN!8  !@              ( !8PP  'AL+W=O<FMS:&5E=',O<VAE970R+GAM
M;%!+ 0(4 Q0    (  ^2GE#Q75F"4 (  $T(   8              "  181
M  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    "  /DIY0T9F!
M%M\#  #/$0  &               @ &<$P  >&PO=V]R:W-H965T<R]S:&5E
M=#0N>&UL4$L! A0#%     @ #Y*>4&\ **E; @  6@<  !@
M ( !L1<  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    (  ^2
MGE"H?!X#[ $  .<$   8              "  4(:  !X;"]W;W)K<VAE971S
M+W-H965T-BYX;6Q02P$"% ,4    "  /DIY0?/,]-I\$  !B%P  &
M        @ %D'   >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%
M  @ #Y*>4'=S6^JD P  BA   !@              ( !.2$  'AL+W=O<FMS
M:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    (  ^2GE"GCA$^P0$  $\$   8
M              "  1,E  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"
M% ,4    "  /DIY0%!!(:[ !  #2 P  &0              @ $*)P  >&PO
M=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    (  ^2GE"SU#\%M0$
M -(#   9              "  ?$H  !X;"]W;W)K<VAE971S+W-H965T,3$N
M>&UL4$L! A0#%     @ #Y*>4*;XH>>U 0  T ,  !D              ( !
MW2H  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    "  /DIY0
MT/B[H;0!  #2 P  &0              @ ')+   >&PO=V]R:W-H965T<R]S
M:&5E=#$S+GAM;%!+ 0(4 Q0    (  ^2GE#9C(&8OP$  #<$   9
M      "  ;0N  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%
M  @ #Y*>4+3CM &X 0  T@,  !D              ( !JC   'AL+W=O<FMS
M:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    "  /DIY0&*T38;4!  #2 P
M&0              @ &9,@  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+
M 0(4 Q0    (  ^2GE"205"^MP$  -(#   9              "  84T  !X
M;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ #Y*>4.W6? :T
M 0  T@,  !D              ( !<S8  'AL+W=O<FMS:&5E=',O<VAE970Q
M."YX;6Q02P$"% ,4    "  /DIY0>59\GK0!  #2 P  &0
M@ %>.   >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    (  ^2
MGE!.X<2$M0$  -(#   9              "  4DZ  !X;"]W;W)K<VAE971S
M+W-H965T,C N>&UL4$L! A0#%     @ #Y*>4..W=KJU 0  T@,  !D
M         ( !-3P  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4
M    "  /DIY0QM'M/;,!  #2 P  &0              @ $A/@  >&PO=V]R
M:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    (  ^2GE!/<4X2M0$  -(#
M   9              "  0M   !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL
M4$L! A0#%     @ #Y*>4%&F@W'3 0  G 0  !D              ( !]T$
M 'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    "  /DIY0P36T
MG;@!  #1 P  &0              @ $!1   >&PO=V]R:W-H965T<R]S:&5E
M=#(U+GAM;%!+ 0(4 Q0    (  ^2GE#5H2NKN $  -(#   9
M  "  ?!%  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @
M#Y*>4#(CU9K% 0  -P0  !D              ( !WT<  'AL+W=O<FMS:&5E
M=',O<VAE970R-RYX;6Q02P$"% ,4    "  /DIY0!>**3K<!  #2 P  &0
M            @ ';20  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4
M Q0    (  ^2GE"WSPD9PP$  #<$   9              "  <E+  !X;"]W
M;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ #Y*>4 &1??7- 0
MG 0  !D              ( !PTT  'AL+W=O<FMS:&5E=',O<VAE970S,"YX
M;6Q02P$"% ,4    "  /DIY0PX+VG+<!  #2 P  &0              @ ''
M3P  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    (  ^2GE">
MUG4IT0$  )P$   9              "  ;51  !X;"]W;W)K<VAE971S+W-H
M965T,S(N>&UL4$L! A0#%     @ #Y*>4$Y;QCZX 0  T@,  !D
M     ( !O5,  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4
M"  /DIY0!VDYP]D!  "9!   &0              @ &L50  >&PO=V]R:W-H
M965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    (  ^2GE#P'G"+LP$  -(#   9
M              "  ;Q7  !X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L!
M A0#%     @ #Y*>4"LV-?[^ 0  =@4  !D              ( !IED  'AL
M+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    "  /DIY0E< O_Z8"
M  !0"@  &0              @ ';6P  >&PO=V]R:W-H965T<R]S:&5E=#,W
M+GAM;%!+ 0(4 Q0    (  ^2GE 03X]:_P$   L&   9              "
M ;A>  !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ #Y*>
M4'4U%WT( @  =04  !D              ( ![F   'AL+W=O<FMS:&5E=',O
M<VAE970S.2YX;6Q02P$"% ,4    "  /DIY0I,-'?B\"   *!P  &0
M        @ $M8P  >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0
M   (  ^2GE"D"@EEC0,  )T0   9              "  9-E  !X;"]W;W)K
M<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ #Y*>4-/8WM\P @  D 8
M !D              ( !5VD  'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q0
M2P$"% ,4    "  /DIY0[1SLR_$!   &!0  &0              @ &^:P
M>&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    (  ^2GE U-4R_
M@0(  &<*   9              "  >9M  !X;"]W;W)K<VAE971S+W-H965T
M-#0N>&UL4$L! A0#%     @ #Y*>4,'BAUK' 0  $P0  !D
M ( !GG   'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    "  /
MDIY06E-#R:T!  ## P  &0              @ &<<@  >&PO=V]R:W-H965T
M<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    (  ^2GE#,+!O&)0(  #0'   9
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M970U,2YX;6Q02P$"% ,4    "  /DIY0'M3#?: !  "9 P  &0
M    @ $C@@  >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    (
M  ^2GE#>UKV&>@,  %00   9              "  ?J#  !X;"]W;W)K<VAE
M971S+W-H965T-3,N>&UL4$L! A0#%     @ #Y*>4"9Q;$KY 0  ( 4  !D
M             ( !JX<  'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"
M% ,4    "  /DIY06N#2#?X!  !S!0  &0              @ ';B0  >&PO
M=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    (  ^2GE"4N.8$[P$
M .P$   9              "  1",  !X;"]W;W)K<VAE971S+W-H965T-38N
M>&UL4$L! A0#%     @ #Y*>4)\3=5AJ @  [0<  !D              ( !
M-HX  'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4    "  /DIY0
MI :ROJ,"  !>"P  &0              @ '7D   >&PO=V]R:W-H965T<R]S
M:&5E=#4X+GAM;%!+ 0(4 Q0    (  ^2GE ,S*PG;$H  /LO 0 4
M      "  ;&3  !X;"]S:&%R9613=')I;F=S+GAM;%!+ 0(4 Q0    (  ^2
MGE!5N_=H8P(  #X-   -              "  4_>  !X;"]S='EL97,N>&UL
M4$L! A0#%     @ #Y*>4+[CX.J"!   ,28   \              ( !W>
M 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (  ^2GE U TT!"0(  #,C   :
M              "  8SE  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+
M 0(4 Q0    (  ^2GE";Z.7DWP$  - B   3              "  <WG  !;
H0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !# $, 1Q(  -WI      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6791806160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net loss per share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net loss per share</a></td>
<td class="text">oss per share<div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:24px;text-indent:0px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">The following table presents the calculation of basic and diluted net loss per share:</span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td rowspan="2" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Three Months Ended March 31,</span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2020</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Numerator:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(12.5</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(26.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Denominator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average number of shares&#8212;basic</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>52.0</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>51.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dilutive securities&#8212;equity awards</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average number of shares&#8212;diluted</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>52.0</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>51.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net loss per share - basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(0.24</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.51</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net loss per share - diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(0.24</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.51</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Basic earnings (loss) per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted earnings (loss) per share is computed using the treasury method by dividing net loss by the weighted average number of shares of common stock outstanding during the period, adjusted for the potential dilutive effect of other securities if such securities were converted or exercised and are not anti-dilutive. </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">three months ended March 31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">, approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"><span>0.7</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> million and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"><span>3.1</span></span> million stock options are not considered in the diluted net loss per share calculation because the exercise price of these options is greater than the average per share closing price during the three month period and their effect would be anti-dilutive.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6805641520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Supplemental Balance Sheet Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 25.6<span></span>
</td>
<td class="nump">$ 24.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_OperatingLeaseOtherLiabilityCurrent', window );">Operating lease liabilities, current portion</a></td>
<td class="nump">4.2<span></span>
</td>
<td class="nump">3.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">22.7<span></span>
</td>
<td class="nump">22.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 26.9<span></span>
</td>
<td class="nump">$ 25.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Operating leases:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (years)</a></td>
<td class="text">7 years 8 months 12 days<span></span>
</td>
<td class="text">8 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DirectFinancingLeaseLeaseIncomeAbstract', window );"><strong>Operating leases:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">4.20%<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_OperatingLeaseOtherLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Other Liability, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_OperatingLeaseOtherLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DirectFinancingLeaseLeaseIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DirectFinancingLeaseLeaseIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6806225072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Contingent consideration Contingent consideration - Fair Value Level 3 of Significant Unobservable Inputs (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value, measurement with unobservable inputs reconciliation, recurring basis, liability value</a></td>
<td class="nump">$ 29.1<span></span>
</td>
<td class="nump">$ 29.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember', window );">Discounted cash flow | Fair Value, Inputs, Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value, measurement with unobservable inputs reconciliation, recurring basis, liability value</a></td>
<td class="nump">$ 29.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember', window );">Discounted cash flow | Fair Value, Inputs, Level 3 | Fair Value, Recurring | Discount rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business combination, contingent consideration, liability, measurement input</a></td>
<td class="nump">0.025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember', window );">Discounted cash flow | Fair Value, Inputs, Level 3 | Fair Value, Recurring | Discount rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business combination, contingent consideration, liability, measurement input</a></td>
<td class="nump">0.086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember', window );">Discounted cash flow | Fair Value, Inputs, Level 3 | Fair Value, Recurring | Discount rate | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business combination, contingent consideration, liability, measurement input</a></td>
<td class="nump">0.043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember', window );">Discounted cash flow | Fair Value, Inputs, Level 3 | Fair Value, Recurring | Probability of payment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business combination, contingent consideration, liability, measurement input</a></td>
<td class="nump">0.100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember', window );">Discounted cash flow | Fair Value, Inputs, Level 3 | Fair Value, Recurring | Probability of payment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business combination, contingent consideration, liability, measurement input</a></td>
<td class="nump">0.400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember', window );">Discounted cash flow | Fair Value, Inputs, Level 3 | Fair Value, Recurring | Probability of payment | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business combination, contingent consideration, liability, measurement input</a></td>
<td class="nump">0.209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=ebs_MeasurementInputProbabilityofPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=ebs_MeasurementInputProbabilityofPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6792882048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative instruments and hedging activities - Cash Flow Hedging on AOCI (Details) - Interest rate swaps - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax', window );">Cumulative Amount of Gain/(Loss) Recognized in OCI on Derivative</a></td>
<td class="num">$ (16.0)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Amount of Gain/(Loss) Reclassified from Accumulated OCI into Income</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6794216688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenue recognition - Accounts Receivable (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BilledContractReceivables', window );">Billed, net</a></td>
<td class="nump">$ 119.4<span></span>
</td>
<td class="nump">$ 227.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnbilledContractsReceivable', window );">Unbilled</a></td>
<td class="nump">43.1<span></span>
</td>
<td class="nump">43.4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Total, net</a></td>
<td class="nump">162.5<span></span>
</td>
<td class="nump">270.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for doubtful accounts receivable</a></td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=119407570&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=119407570&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118955202&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BilledContractReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts due for billed services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the Company and, at a minimum, one other party. An example would be amounts billed to customers under contracts or programs but not paid as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BilledContractReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnbilledContractsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118261985&amp;loc=d3e55302-109406<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(c)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnbilledContractsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6791798384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue recognition - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation, amount</a></td>
<td class="nump">$ 555.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCurrent', window );">Deferred costs, current</a></td>
<td class="nump">$ 36.3<span></span>
</td>
<td class="nump">$ 34.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6797092272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative instruments and hedging activities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Instruments and Hedging Activities Disclosure</a></td>
<td class="text">Derivative instruments and hedging activities<div style="line-height:120%;padding-bottom:12px;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Risk management objective of using derivatives</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">The Company is exposed to certain risk arising from both its business operations and economic conditions. The Company principally manages its exposures to a wide variety of business and operational risks through management of its core business activities. The Company manages economic risks, including interest rate, liquidity, and credit risk primarily by managing the amount, sources, and duration of its assets and liabilities and the use of derivative financial instruments. Specifically, the Company has entered into interest rate swaps to manage exposures that arise from the Company's senior secured credit agreement's payments of variable interest rate debt.</span></div><div style="line-height:120%;padding-bottom:12px;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Accounting policy for derivative instruments and hedging activities</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">The Company entered into interest rate swaps in June 2019. The Company's interest rate swaps qualify for hedge accounting as cash flow hedges. All derivatives are recorded on the balance sheet at fair value.&#160;Hedge accounting provides for the matching of the timing of gain or loss recognition on these interest rate swaps with the recognition of the changes in interest expense on the Company's variable rate debt. For derivatives designated as cash flow hedges of interest rate risk, the gain or loss on the derivative is recorded in accumulated other comprehensive income and subsequently reclassified into interest expense in the same period during which the hedged transaction affects earnings. Amounts reported in accumulated other comprehensive income related to derivatives will be reclassified to interest </span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">expense as interest payments are made on the Company&#8217;s variable-rate debt. The cash flows from the designated interest rate swaps are classified as a component of operating cash flows, similar to interest expense.&#160;If current fair values of designated interest rate swaps&#160;re</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">mained static over the next&#160;twelve&#160;months, the Company would reclassify&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"><span>$5.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:normal;">&#160;of net deferred losses from&#160;accumulated other comprehensive loss&#160;to the statement of operations over the next&#160;twelve&#160;month period. All outstanding cash flow hedges mature in October 2023.</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">, the Company had the following outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk: </span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:61%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Number of Instruments</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Notional</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest rate swaps</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>7</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>350.0</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">The table below presents the fair value of the Company&#8217;s derivative financial instruments designated as hedges as well as their classification on the balance sheet.</span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"/></tr><tr><td style="width:11%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td colspan="9" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Asset Derivatives</span></div></td><td colspan="9" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Liability Derivatives</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;</span></div></td><td colspan="4" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">March&#160;31, 2020</span></div></td><td colspan="4" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">December&#160;31, 2019</span></div></td><td colspan="4" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">March&#160;31, 2020</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;</span></div></td><td style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Balance Sheet Location</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Fair Value</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Balance Sheet Location</span></div></td><td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Fair Value</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Balance Sheet Location</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Fair Value</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Balance Sheet Location</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Fair Value</span></div></td></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest Rate Swaps</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">Other Current Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other Current Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">Other Current Liabilities </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>4.8</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other Current Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">Other Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">Other Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>11.2</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">The valuation of the interest rate swaps is determined using widely accepted valuation techniques, including discounted cash flow analysis on the expected cash flows of each interest rate swap. This analysis reflects the contractual terms of the interest rate swaps, including the period to maturity, and uses observable market-based inputs, including interest rate curves and implied volatilities. The fair values of interest rate swaps are determined using the market standard methodology of netting the discounted future fixed cash payments (or receipts) and the discounted expected variable cash receipts (or payments). The variable cash payments (or receipts) are based on an expectation of future interest rates (forward curves) derived from observable market interest rate curves. To comply with the provisions of ASC 820, Fair Value Measurement, we incorporate credit valuation adjustments in the fair value measurements to appropriately reflect both our own nonperformance risk and the respective counterparty&#8217;s nonperformance risk. These credit valuation adjustments were concluded to not be significant inputs for the fair value calculations for the periods presented. In adjusting the fair value of our derivative contracts for the effect of nonperformance risk, we have considered the impact of netting and any applicable credit enhancements, such as the posting of collateral, thresholds, mutual puts and guarantees. The valuation of interest rate swaps fall into Level 2 in the fair value hierarchy.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> The table below presents the effect of cash flow hedge accounting on accumulated other comprehensive income.</span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"/></tr><tr><td style="width:32%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td rowspan="2" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Hedging derivatives</span></div></td><td colspan="6" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Cumulative Amount of Gain/(Loss) Recognized in OCI on Derivative</span></div></td><td rowspan="2" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Location of Gain or (Loss) Reclassified from Accumulated OCI into Income </span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Amount of Gain/(Loss) Reclassified from Accumulated OCI into Income</span></div></td></tr><tr><td colspan="6" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">March 31,</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Three months ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2020</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2019</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2020</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2019</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest Rate Swaps</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(16.0</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest expense</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI http://asc.fasb.org/topic&amp;trid=2229140<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6662150944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract', window );"><strong>Property Plant and Equipment Income Statement Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, plant and equipment</a></td>
<td class="text">Property, plant and equipment<div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Property, plant and equipment consisted of the following:</span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">March&#160;31, 2020</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Land and improvements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>46.6</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>46.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Buildings, building improvements and leasehold improvements</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>242.3</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>234.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Furniture and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>340.0</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>334.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Software</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>55.6</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>55.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Construction-in-progress</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>86.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>81.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment, gross</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>771.0</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>752.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accumulated depreciation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(221.8</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(210.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total property, plant and equipment, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>549.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>542.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6795217856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative instruments and hedging activities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock', window );">Schedule of Derivative Instruments</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">, the Company had the following outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk: </span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:61%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Number of Instruments</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Notional</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest rate swaps</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>7</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>350.0</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">The table below presents the fair value of the Company&#8217;s derivative financial instruments designated as hedges as well as their classification on the balance sheet.</span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"/></tr><tr><td style="width:11%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td colspan="9" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Asset Derivatives</span></div></td><td colspan="9" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Liability Derivatives</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;</span></div></td><td colspan="4" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">March&#160;31, 2020</span></div></td><td colspan="4" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">December&#160;31, 2019</span></div></td><td colspan="4" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">March&#160;31, 2020</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;</span></div></td><td style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Balance Sheet Location</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Fair Value</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Balance Sheet Location</span></div></td><td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Fair Value</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Balance Sheet Location</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Fair Value</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Balance Sheet Location</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Fair Value</span></div></td></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest Rate Swaps</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">Other Current Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other Current Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">Other Current Liabilities </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>4.8</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other Current Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">Other Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">Other Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>11.2</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Derivative Instruments, Gain (Loss)</a></td>
<td class="text">The table below presents the effect of cash flow hedge accounting on accumulated other comprehensive income.<div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"/></tr><tr><td style="width:32%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td rowspan="2" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Hedging derivatives</span></div></td><td colspan="6" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Cumulative Amount of Gain/(Loss) Recognized in OCI on Derivative</span></div></td><td rowspan="2" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Location of Gain or (Loss) Reclassified from Accumulated OCI into Income </span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Amount of Gain/(Loss) Reclassified from Accumulated OCI into Income</span></div></td></tr><tr><td colspan="6" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">March 31,</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Three months ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2020</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2019</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2020</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2019</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest Rate Swaps</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(16.0</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest expense</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624181-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5618551-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5580258-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41620-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41638-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41678-113959<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41641-113959<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6785950416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>$0.001 Par Value Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Retained Earnings</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 1,010.9<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 688.6<span></span>
</td>
<td class="num">$ (39.6)<span></span>
</td>
<td class="num">$ (5.5)<span></span>
</td>
<td class="nump">$ 367.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Employee equity plans activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Employee equity plans activity</a></td>
<td class="nump">1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="num">(26.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2019</a></td>
<td class="nump">$ 987.5<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">690.2<span></span>
</td>
<td class="num">$ (39.6)<span></span>
</td>
<td class="num">(4.5)<span></span>
</td>
<td class="nump">341.3<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">53,000,000.0<span></span>
</td>
<td class="nump">53,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 1,088.5<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">716.1<span></span>
</td>
<td class="num">$ (39.6)<span></span>
</td>
<td class="num">(9.9)<span></span>
</td>
<td class="nump">421.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Employee equity plans activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Employee equity plans activity</a></td>
<td class="nump">10.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="num">(12.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income</a></td>
<td class="num">$ (11.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance (in shares) at Mar. 31, 2020</a></td>
<td class="nump">53,500,000.0<span></span>
</td>
<td class="nump">53,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2020</a></td>
<td class="nump">$ 1,074.8<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 726.2<span></span>
</td>
<td class="num">$ (39.6)<span></span>
</td>
<td class="num">$ (21.2)<span></span>
</td>
<td class="nump">$ 409.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6791790080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2020 </div>
<div>category </div>
<div>segment </div>
<div>product</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_NumberOfCategoriesOfPublicHealthThreats', window );">Number of categories of public health threats | category</a></td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_NumberOfRevenueGeneratingProducts', window );">Number of revenue generating products | product</a></td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_NumberOfCategoriesOfPublicHealthThreats">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to the number of categories of public health threats.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_NumberOfCategoriesOfPublicHealthThreats</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_NumberOfRevenueGeneratingProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to the number of revenue generating products.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_NumberOfRevenueGeneratingProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6805285424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, renewal term</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_LesseeOperatingLeaseTerminationPeriod', window );">Operating lease, termination period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease, term of contract</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease, term of contract</a></td>
<td class="text">15 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_LesseeOperatingLeaseTerminationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Termination Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_LesseeOperatingLeaseTerminationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6804880752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 192.5<span></span>
</td>
<td class="nump">$ 190.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of product sales and contract development and manufacturing services</a></td>
<td class="nump">76.9<span></span>
</td>
<td class="nump">91.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">42.7<span></span>
</td>
<td class="nump">46.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">69.7<span></span>
</td>
<td class="nump">65.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">14.8<span></span>
</td>
<td class="nump">14.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">204.1<span></span>
</td>
<td class="nump">217.8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(11.6)<span></span>
</td>
<td class="num">(27.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (expense) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(8.6)<span></span>
</td>
<td class="num">(9.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(1.1)<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense, net</a></td>
<td class="num">(9.7)<span></span>
</td>
<td class="num">(10.6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Loss before provision for income taxes</a></td>
<td class="num">(21.3)<span></span>
</td>
<td class="num">(37.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">8.8<span></span>
</td>
<td class="nump">11.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (12.5)<span></span>
</td>
<td class="num">$ (26.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per common share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.51)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.51)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Shares used in computing loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">52.0<span></span>
</td>
<td class="nump">51.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">52.0<span></span>
</td>
<td class="nump">51.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 148.2<span></span>
</td>
<td class="nump">$ 153.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractManufacturingMember', window );">Contract development and manufacturing services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">21.7<span></span>
</td>
<td class="nump">15.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember', window );">Contracts and grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 22.6<span></span>
</td>
<td class="nump">$ 21.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_ContractManufacturingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_ContractManufacturingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
